<SEC-DOCUMENT>0001493152-23-009812.txt : 20230330
<SEC-HEADER>0001493152-23-009812.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230330170109
ACCESSION NUMBER:		0001493152-23-009812
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GT Biopharma, Inc.
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40023
		FILM NUMBER:		23781544

	BUSINESS ADDRESS:	
		STREET 1:		8000 MARINA BLVD
		STREET 2:		SUITE 100
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(800) 304-9888

	MAIL ADDRESS:	
		STREET 1:		8000 MARINA BLVD
		STREET 2:		SUITE 100
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19940916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:GTBP="http://gtbiopharma.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_GTBP_gtbiopharma.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000109657 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DTradingSymbol_GTBP -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Sqft_0_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0000109657</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">GTBP</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" id="xdx2ixbrl0067" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0070" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0100" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:CommonStockIssuable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0146" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0165" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0166" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0229" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants" contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0433" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0446" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:FairValueOfCommonStockIssuedToNoteholderAsSettlement" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ConvertibleNotesPayableIssuedForConsultingServices" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:IncreaseDecreaseInDeposit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:CancellationOfCommonStockUponSettlementWithFormerOfficer" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:RightofuseAssetsExchangedForLeaseLiabilities" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:CommonStockIssuedUponSettlementOfVendorPayable" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:AccountsPayableReclassifiedToConvertibleNotes" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfDerivativeLiability" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2021-01-012021-12-31_us-gaap_ShortTermInvestmentsMember" id="xdx2ixbrl0666" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0674" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0684" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0685" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0689" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0694" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0695" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0699" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0700" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0704" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0705" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0710" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl0831" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl0832" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0845" name="us-gaap:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">http://fasb.org/us-gaap/2022#DerivativeGainLossOnDerivativeNet</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0846" name="us-gaap:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">http://fasb.org/us-gaap/2022#DerivativeGainLossOnDerivativeNet</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0853" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0854" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfWarrants" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0856" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0991" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1001" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1003" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1005" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1007" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1009" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1011" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31" id="xdx2ixbrl1037" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" id="xdx2ixbrl1039" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1045" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1047" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1049" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1051" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1065" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1067" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gtbp-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-032023-01-04_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-03</xbrli:startDate>
        <xbrli:endDate>2023-01-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_OptionsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OptionsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-05_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-232022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PaymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-23</xbrli:startDate>
        <xbrli:endDate>2022-08-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PaymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-01_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PaymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-03_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PaymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesPayableIssuedForCashMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForCashMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-01_custom_NotesPayableIssuedForCashMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForCashMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_NotesPayableIssuedForCashMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForCashMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForCashMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForCashMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForSettlementAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:FiscalTwentyNinteenandTwentyTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForSettlementAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForSettlementAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-23_custom_NotesPayableIssuedForForbearanceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForForbearanceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesPayableIssuedForForbearanceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForForbearanceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_NotesPayableIssuedForForbearanceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForForbearanceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForForbearanceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForForbearanceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesPayableIssuedForConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-31_custom_NotesPayableIssuedForConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotesPayableIssuedForConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:JanuaryTwentyTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:JanuaryTwentyTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:JanuaryTwentyTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember15065312">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertibleNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:ConvertibleNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccountingStandardsUpdate202006Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AccountingStandardsUpdate202006Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccountingStandardsUpdate202006Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-082021-02-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-08</xbrli:startDate>
        <xbrli:endDate>2021-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-10_custom_OwnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OwnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_us-gaap_CommonStockMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:NoteHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:NoteHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:NoteHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-10_us-gaap_CommonStockMember_custom_NoteHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:NoteHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:NoteHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-132021-02-16_custom_EmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-13</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012021-02-28_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2021-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-282022-04-29_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-28</xbrli:startDate>
        <xbrli:endDate>2022-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesJOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesJPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesJPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012021-02-28_custom_SeriesJPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2021-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesJPreferredStockMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesJOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_SeriesKPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesKPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesKPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantEmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-14</xbrli:startDate>
        <xbrli:endDate>2022-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantEmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantEmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-14</xbrli:startDate>
        <xbrli:endDate>2022-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantEmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-14</xbrli:startDate>
        <xbrli:endDate>2022-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwoEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:TwoEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:TwoEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-142022-07-15_custom_TwoEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:TwoEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-14</xbrli:startDate>
        <xbrli:endDate>2022-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-19_us-gaap_LeaseAgreementsMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-182021-11-19_us-gaap_LeaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-18</xbrli:startDate>
        <xbrli:endDate>2021-11-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-19_us-gaap_LeaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-072022-02-08_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-07</xbrli:startDate>
        <xbrli:endDate>2022-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-012022-03-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-01</xbrli:startDate>
        <xbrli:endDate>2022-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-052021-08-06_custom_SheffieldPropertiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:SheffieldPropertiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-05</xbrli:startDate>
        <xbrli:endDate>2021-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ScientificResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ScientificResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ScientificResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ScientificResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-25</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-252021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-25</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-252021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-25</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-032023-01-04_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_InstitutionalInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GTBP:InstitutionalInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-03</xbrli:startDate>
        <xbrli:endDate>2023-01-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GTBP:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GTBP:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GTBP:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GTBP:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-132023-03-14_us-gaap_SubsequentEventMember_custom_ResearchAndDevelopmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-13</xbrli:startDate>
        <xbrli:endDate>2023-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_905_edei--DocumentType_c20220101__20221231_zJotKxZk1qd1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
    One)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--DocumentAnnualReport_c20220101__20221231_zFJt5qthx9Kd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the fiscal year ended: <span id="xdx_906_edei--DocumentPeriodEndDate_c20220101__20221231_zPN0l4ENangl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_906_edei--CurrentFiscalYearEndDate_c20220101__20221231_zf2CLm01EIQh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90B_edei--DocumentFiscalYearFocus_c20220101__20221231_zB9uMZxmPWCi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--DocumentTransitionReport_c20220101__20221231_zJv4Z8X1Jcwc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the transition period from _____________ to _____________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <span id="xdx_90A_edei--EntityFileNumber_c20220101__20221231_z0PCD6X9TGTk"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-40023</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20220101__20221231_zodK2chImGxb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">GT
BIOPHARMA, INC</ix:nonNumeric></span>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20220101__20221231_zI2PQITpwICd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20220101__20221231_zM6SDpWgCSM5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">94-1620407</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityAddressAddressLine1_c20220101__20221231_zijZOBrrRS02"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">8000
Marina Blvd</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityAddressAddressLine2_c20220101__20221231_z7W33K4ThHt5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Suite
100</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_903_edei--EntityAddressCityOrTown_c20220101__20221231_zF3RMkSHV6J7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Brisbane</ix:nonNumeric></span>,
<span id="xdx_904_edei--EntityAddressStateOrProvince_c20220101__20221231_zZtTtdle3mKg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20220101__20221231_z6izY36c2tP4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">94005</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_90B_edei--CityAreaCode_c20220101__20221231_zCCivOsuwSf5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">(415)</ix:nonNumeric></span>
<span id="xdx_90D_edei--LocalPhoneNumber_c20220101__20221231_zY1eDSAm5Y28"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">919-4040</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Securities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchanges
    on which Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20220101__20221231_zS4j9NrJLynf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common
    Stock, $0.001 Par Value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SecurityExchangeName_c20220101__20221231_zeakXzx7LLV1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_906_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_z0N96RyXapxd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_90A_edei--EntityVoluntaryFilers_c20220101__20221231_zxS9UhfY0Tm7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_904_edei--EntityCurrentReportingStatus_c20220101__20221231_zbGfiHJ6oT0l"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post
such files). <span id="xdx_90C_edei--EntityInteractiveDataCurrent_c20220101__20221231_znyvKcxqNWOc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityFilerCategory_c20220101__20221231_ziuYah91Xbbi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntitySmallBusiness_c20220101__20221231_z9gTAP3dQ7Ta"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20220101__20221231_zLcY2W4qFadl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_90B_edei--EntityShellCompany_c20220101__20221231_zjLMgij4EJM"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the registrant&#8217;s common stock, $0.001 par value per share, held by non-affiliates on June 30, 2022 was
approximately $<span id="xdx_909_edei--EntityPublicFloat_iI_pn5n6_c20220630_zogtQVAWNc0l"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">89.8</ix:nonFraction></span> million. As of March 30, 2023, there were <span id="xdx_904_edei--EntityCommonStockSharesOutstanding_iI_pid_c20230330_zKN0TsL6tzRk"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,809,271</ix:nonFraction></span> shares of the registrant&#8217;s common stock, $0.001 par value,
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DOCUMENTS
INCORPORATED BY REFERENCE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--DocumentsIncorporatedByReferenceTextBlock_c20220101__20221231_zSDveHTNUhhe" title="Documents Incorporated by Reference"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock">In
Part III, portions of the registrant&#8217;s 2023 Proxy Statement to be filed with the Securities and Exchange Commission within 120
days of the Registrant&#8217;s fiscal year end.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Table
of Contents</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_001">PART I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_003">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_004">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_005">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_006">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_007">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_008">PART II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_009">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_010">[Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_011">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_012">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_013">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_014">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_015">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_016">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_017">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_018">PART III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_019">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_020">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_021">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_022">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_023">Principal Accounting Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_024">PART IV</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_025">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eds_026">Form 10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business involves significant risks. Below is a summary of the material risks that our business faces, which makes an investment in our
securities speculative and risky. This summary does not address all these risks. These risks are more fully described below under the
heading &#8220;Risk Factors&#8221; in Part I, Item 1A of this annual report on Form 10-K. Before making investment decisions regarding
our securities, you should carefully consider these risks. The occurrence of any of the events or developments described below could
have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such event,
the market price of our securities could decline, and you could lose all or part of your investment. In addition, there are also additional
risks not described below that are either not presently known to us or that we currently deem immaterial, and these additional risks
could also materially impair our business, operations or market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business is at an early stage of development and we may not develop therapeutic products that can be commercialized.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a history of operating losses and we expect to continue to incur losses for the foreseeable future and we may never generate
    revenue or achieve profitability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to meet our obligations under our license agreements, we may lose our rights to key technologies on which our business depends.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    reliance on the activities of our non-employee consultants, research institutions and scientific contractors, whose activities are
    not wholly within our control, may lead to delays in development of our proposed products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited clinical testing and regulatory capabilities, and human clinical trials are subject to extensive regulatory requirements,
    very expensive, time-consuming and difficult to design and implement. Our products may fail to achieve necessary safety and efficacy
    endpoints during clinical trials, which may limit our ability to generate revenues from therapeutic products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to extensive regulation, which can be costly and time consuming and can subject us to unanticipated delays. Even if we
    obtain regulatory approval for some of our products, those products may still face regulatory difficulties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
    limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if
    any.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently lack manufacturing capabilities to produce our therapeutic product candidates at commercial-scale quantities and do not
    have an alternate manufacturing supply, which could negatively impact our ability to meet any future demand for the product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on third parties to conduct preclinical and clinical trials of our product candidates. If these third parties do not successfully
    carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize
    our product candidates and our business could be substantially harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epidemic
    or pandemic outbreaks such as COVID-19 (coronavirus), natural disasters, whether or not caused by climate change, unusual weather
    conditions, terrorist acts and political events, could disrupt business and result in halting our clinical trials and otherwise adversely
    affect our financial performance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    has been a limited public market for our common stock , and we do not know whether one will develop to provide you adequate liquidity.
    Furthermore, the trading price for our common stock, should an active trading market develop, may be volatile and could be subject
    to wide fluctuations in per-share price.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    our common stock may be deemed a &#8220;penny&#8221; stock, an investment in our common stock should be considered high-risk and
    subject to marketability restrictions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTICE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K, including any documents which may be incorporated by reference into this Annual Report, contains &#8220;Forward-Looking
Statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. All statements other than statements of historical fact are &#8220;Forward-Looking Statements&#8221; for purposes
of these provisions, including our plans of operation, any projections of revenues or other financial items, any statements of the plans
and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding
future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. All Forward-Looking Statements
included in this document are made as of the date hereof and are based on information available to us as of such date. We assume no obligation
to update any Forward-Looking Statement. In some cases, Forward-Looking Statements can be identified by the use of terminology such as
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221;
&#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; or the negative thereof or other
comparable terminology. Although we believe that the expectations reflected in the Forward-Looking Statements contained herein are reasonable,
there can be no assurance that such expectations or any of the Forward-Looking Statements will prove to be correct, and actual results
could differ materially from those projected or assumed in the Forward-Looking Statements. Future financial condition and results of
operations, as well as any Forward-Looking Statements are subject to inherent risks and uncertainties, including any other factors referred
to in our press releases and reports filed with the Securities and Exchange Commission. All subsequent Forward-Looking Statements attributable
to the company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Additional factors
that may have a direct bearing on our operating results are described under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report
on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Introductory
Comment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Annual Report on Form 10-K, the terms &#8220;GT Biopharma,&#8221; &#8220;GTBP,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221;
&#8220;the company&#8221; and &#8220;our company&#8221; refer to GT Biopharma, Inc., a Delaware corporation formerly known as DDI Pharmaceuticals,
Inc., Diagnostic Data, Inc. and Oxis International, Inc., together with our subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_002"></span>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based
on our proprietary Tri-specific Killer Engager (TriKE<sup>&#174;</sup>) fusion protein immune cell engager technology platform. Our TriKE<sup>&#174;
</sup>platform generates proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient&#8217;s own
natural killer cells, or NK cells. Once bound to an NK cell, our moieties are designed to enhance the NK cell, and precisely direct it
to one or more specifically targeted proteins expressed on a specific type of cancer cell or virus infected cell, resulting in the targeted
cell&#8217;s death. TriKE<sup>&#174;</sup>s can be designed to target any number of tumor antigens on hematologic malignancies or solid
tumors and do not require patient-specific customization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using our TriKE<sup>&#174;</sup> platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic
malignancies, and solid tumors. The platform is scalable, and we are putting processes in place to be able to produce investigational
new drug (IND) ready moieties in a timely manner after a specific TriKE<sup>&#174;</sup> conceptual design. Specific drug candidates can
then be advanced into the clinic on our own or through potential collaborations with partnering companies. We believe our TriKE<sup>&#174;</sup>s
may have the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also using our TriKE<sup>&#174;</sup> platform to develop therapeutics useful for the treatment of infectious disease such as for
the treatment of patients infected by the human immunodeficiency virus (HIV). While the use of anti-retroviral drugs has
substantially improved the health and increased the longevity of individuals infected with HIV, these drugs are designed to suppress
virus replication to help modulate progression to acquired immunodeficiency syndrome (AIDS) and to limit further transmission of the
virus. Despite the use of anti-retroviral drugs, infected individuals retain reservoirs of latent HIV-infected cells that, upon
cessation of anti-retroviral drug therapy, can reactivate and re-establish an active HIV infection. For a curative therapy,
destruction of these latent HIV infected cells must take place. The HIV-TriKE<sup>&#174;</sup> contains the antigen binding fragment
(Fab) from a broadly neutralizing antibody targeting the HIV-Env protein or a protein that binds infected CD4+ T cells. The HIV-TriKE<sup>&#174;</sup> is designed to target HIV
while redirecting NK cell killing specifically to actively replicating HIV infected cells. The HIV-TriKE<sup>&#174;</sup> induced NK
cell proliferation and demonstrated the ability in vitro to reactivate and kill HIV-infected T-cells. These findings indicate a
potential role for the HIV-TriKE<sup>&#174;</sup> in the reactivation and elimination of the latently infected HIV reservoir cells by
harnessing the NK cell&#8217;s ability to mediate the antibody-directed cellular cytotoxicity (ADCC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
initial work has been conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by
Dr. Jeffrey Miller, the Deputy Director. Dr. Miller is a recognized key opinion leader in the field of NK cell and IL-15 biology and
their therapeutic potential. We have exclusive rights to the TriKE<sup>&#174;</sup> platform and are generating additional intellectual
property for specific moieties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Immuno-Oncology
Platform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tri-specific
Killer Engagers (TriKE<sup>&#174;</sup>s)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
generation of chimeric antigen receptor, or CAR, expressing T cells from monoclonal antibodies has represented an important step forward
in cancer therapy. These therapies involve the genetic engineering of T cells to express either CARs, or T cell receptors, or TCRs, and
are designed such that the modified T cells can recognize and destroy cancer cells. While a great deal of interest has recently been
placed upon chimeric antigen receptor T, or CAR-T, therapy, it has certain limitations for broad potential applicability because it can
require an individual approach that is expensive, time consuming, and may be difficult to apply on a large scale. NK cells represent
an important immunotherapeutic target as they are involved in tumor immune-surveillance, can mediate antibody-dependent cell-mediated
cytotoxicity (ADCC), contain pre-made granules with perforin and granzyme B and can quickly secrete inflammatory cytokines, and unlike
T cells they do not require antigen priming and can kill cells in the absence of major histocompatibility complex (MHC) presentation
of antigens. Unlike full-length antibodies, TriKE<sup>&#174;</sup> constructs are composed of a single-chain fusion protein that binds
the CD16 receptor of NK cells directly producing a potent and lasting cytotoxic killing response, interleukin 15 (IL-15) to promote NK
cell activation, persistence and proliferation, and a cancer cell targeting moiety. An additional benefit of TriKE<sup>&#174; </sup>may
have been its attractive biodistribution, as a consequence of their smaller size, which we expect to be important in the treatment of
solid tumors. In addition to these advantages, TriKE<sup>&#174;</sup> is designed to be non-immunogenic, have appropriate clearance properties,
and can be engineered to target a variety of tumor antigens.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there is a continued unmet medical need for targeted immuno-oncology therapies that can have the potential to be dosed in a patient-friendly
outpatient setting, can be used on a stand-alone basis, augment the current monoclonal antibody therapeutics, or be used in conjunction
with more traditional cancer therapy. We believe our TriKE<sup>&#174;</sup> constructs have this potential and therefore we have generated,
and intend to continue to generate, a pipeline of product candidates to be advanced into the clinic on our own or through potential collaborations
with larger companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-3550
TriKE<sup>&#174;</sup> and Phase 1 Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Phase 1 Clinical Trial</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3550
is the Company&#8217;s first-generation TriKE<sup>&#174;</sup> product candidate which is a single-chain, tri-specific recombinant fusion
protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified
form of IL-15, all connected by small peptide linkers. The GTB-3550 Phase 1 clinical trial for treatment of patients with CD33-expressing, high risk myelodysplastic syndromes
and refractory/relapsed acute myeloid leukemia opened for patient enrollment in September 2019 and completed enrollment in September
2021. The clinical trial was conducted at the University of Minnesota&#8217;s Masonic Cancer Center in Minneapolis, Minnesota under the
direction of Dr. Erica Warlick and Dr. Mark Juckett.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Background
and Select Non-Clinical Data</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with our research agreement with the Masonic Cancer Center at the University of Minnesota, the exploration of targeting NK
cells to a variety of tumors initially focused on novel bi-specific killer engagers, or BiKEs, composed of the variable portions of antibodies
targeting the CD16 activating receptor on NK cells and CD33 (AML and MDS; see figure below), B7H3 (solid tumors &#8211; breast, lung,
colon, prostate), Her2 (Breast, Gastric), or CD19/CD22 (B cell lymphomas) on the tumor cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt="" style="height: 214px; width: 442px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequently,
a tri-specific (TriKE<sup>&#174;</sup>) construct that replaced the linker molecule between the CD16 scFv and the CD33 scFv with a modified
IL-15 molecule, containing flanking sequences, was generated, and tested. Data indicates that the CD16 x IL-15 x CD33 potently induce
proliferation of healthy donor NK cells, possibly greater than that induced by exogenous IL-15, which is absent in the BiKE platform.
Targeted delivery of the IL-15 through the TriKE<sup>&#174;</sup> also resulted in specific expansion of the NK cells without inducing
T cell expansion on post-transplant patient samples.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
compared to the CD16 x CD33 BiKE, the CD16 x IL-15 x CD33 TriKE<sup>&#174;</sup> is also capable of potently restoring killing capacity
of post-transplant NK cells against CD33-expressing HL-60 targets and primary AML blasts. These results demonstrated the ability to functionally
incorporate an IL-15 cytokine into the BiKE platform and also demonstrated the possibility of targeting a variety of cytokines directly
to NK cells while reducing off-target effects and the amount of cytokines needed to obtain biologically relevant function.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
figure below is a schematic of a BiKE construct (top) and a TriKE<sup>&#174;</sup> construct (bottom), which has the modified IL-15 linker
between the CD16 scFv and the CD33 scFv components.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt="" style="height: 123px; width: 326px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CD33 -targeting TriKE<sup>&#174;</sup> constructs was tested against
three separate human tumor cell lines to evaluate specificity: CD33+ HL-60 (promyelocitic leukemia) cells, CD33, Raji (Burkitt&#8217;s
lymphoma), and CD33- HT29 (colorectal adenocarcinoma). TriKE<sup>&#174; </sup> (GTB-3550) activity was only seen against the CD33+ HL-60
cells containing a Luc reporter to allow for in vivo imaging of the tumors, were used to show in vivo efficacy of BiKE (1633) and TriKE<sup>&#174;
</sup>(GTB-3550) against relevant human tumor targets (HL-60-luc) over an extended period of time. The system consisted of initial conditioning
of mice using radiation (250-275 cGy), followed by injection of the tumor cells (I.V. for HL-60-luc, a three-day growth phase, injection
of human NK cells, and repeated injection of the drugs of interest, BiKE and TriKE<sup>&#174;</sup> (three to five times a week). Imaging
was carried out at Day 7, 14, and 21, and extended as needed. Subsequent studies were also carried out to evaluate other TriKEs expressing
targeting arms against other tumor antigens (B7H3 and HER2 for instance).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
figure below shows the results (tumor burden and mortality) when dosing NK cells alone (top panel), the BiKE version (lacking IL-15)
of GTB-3550 (middle panel; called 1633), and the TriKE<sup>&#174;</sup>, GTB-3550 (bottom panel; then called 161533) in the above human
tumor model, HL-60-luc. In the NK-cell-only arm, two out of the five mice were dead by Day 21 with two of the surviving mice having extensive
tumor burden as depicted by the colored images. In contrast, all five mice in each of the BiKE and TriKE<sup>&#174;</sup> arms survived.
In addition, the tumor burden in the TriKE<sup>&#174;</sup>-treated mice was significantly less than in the BiKE-treated mice, demonstrating
the improved efficacy from NK cells in the TriKE<sup>&#174;</sup>-treated mice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt="" style="height: 286px; width: 380px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on these results, and others, the IND for GTB-3550 was filed in June 2017 by the University of Minnesota. The FDA requested that additional
preclinical toxicology, additional information and clarifications on manufacturing, and clinical development plans. The requested additional
information and clarifications were completed and incorporated into the IND in eCTD format. We filed the IND amendment in June 2018 and
announced on November 1, 2018, that the FDA granted approval of the IND and the Company was authorized to initiate a first-in-human Phase
1 study with GTB-3550 in AML, MDS, and severe mastocytosis. The Phase 1 clinical trial was initiated in September 2019 and closed in
September 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Targeting
Solid Tumors and Other Potentially Attractive Characteristics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
full-length antibodies, TriKE<sup>&#174;</sup> is composed of a single-chain fusion protein that binds the CD16 receptor of NK cells directly
producing a potentially more potent and lasting response as demonstrated by preclinical studies. An additional benefit due to the smaller
size of TriKE<sup>&#174;</sup> is enhanced biodistribution which we expect to be important in the treatment of solid tumors. In addition
to these potential advantages, TriKE<sup>&#174;</sup> is designed to be non-immunogenic, have appropriate clearance properties and can
be engineered quickly to target a variety of tumor antigens. We believe these attributes make them an ideal pharmaceutical platform for
potentiated NK cell-based immunotherapies and have the potential to overcome some of the limitations of CAR-T therapy and other antibody
therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examples
of our earlier stage solid tumor targeting product candidates are focused on CD33, B7-H3, Her2, CD19, CLEC12A, CD22, and CD133
alone and in combination. We believe these constructs have the potential to target prostate, breast, colon, ovarian, liver, and head
and neck cancers. Depending on the availability of drug supply, we hope to initiate human clinical testing for certain of our solid tumor
product candidates in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Efficient
Advancement of Potential Future Product Candidates &#8211; Production and Scale Up</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using our TriKE<sup>&#174;</sup> platform with the intent to bring to market multiple immuno-oncology products that can treat a range
of hematologic malignancies and solid tumors. The platforms are scalable, and we are currently working with a third-party product manufacturer
investigating the optimal GMP production expression system for TriKE<sup>&#174;</sup> constructs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe TriKE<sup>&#174;</sup>s will have the ability, if approved for marketing, to be used as both monotherapy and in combination with
standard-of-care therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Immuno-Oncology
Product Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>GTB-3550</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3550
was our first TriKE<sup>&#174;</sup> product candidate. It reflected our first-generation TriKE<sup>&#174;</sup> platform. It is a single-chain,
tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and
anti-CD33 antibodies and a modified form of IL-15. We studied this anti-CD16-IL-15-anti-CD33 TriKE<sup>&#174; </sup>in CD33 positive leukemias,
a marker expressed on tumor cells in acute myelogenous leukemia, or AML, myelodysplastic syndrome, or MDS. CD33 is primarily a myeloid
differentiation antigen with endocytic properties broadly expressed on AML blasts and, possibly, some leukemic stem cells. CD33 or Siglec-3
(sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC3, gp67, p67) is a transmembrane receptor expressed on cells of myeloid lineage.
It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. The anti-CD33 antibody fragment used for
these studies was derived from the M195 humanized anti-CD33 scFV and has been used in multiple human clinical studies. It has been exploited
as target for therapeutic antibodies for many years. We believe the recent approval of the antibody-drug conjugate gemtuzumab validates
this targeted approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3550
is being replaced by a more potent next-generation camelid nanobody TriKE<sup>&#174;</sup>, GTB-3650, targeting relapsed/refractory
Acute Myeloid Leukemia (AML) and high-risk Myelodysplastic Syndromes (MDS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>About
High-Risk Myelodysplastic Syndromes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myelodysplastic
Syndromes is a rare form of bone marrow-related cancer caused by irregular blood cell production within the bone marrow. As a result
of this irregular production, MDS patients do not have sufficient normal red blood cells, white blood cells and/or platelets in circulation.
High-risk MDS is associated with poor prognosis, diminished quality of life, and a higher chance of transformation to acute myeloid leukemia.
The goals of therapy are to reduce disease associated symptoms and the risk of disease progression and death, thereby improving both
quality and quantity of life. United States incidence of MDS is estimated to be 10,000 cases per year, although the condition is thought
to be under diagnosed. The prevalence has been estimated to be from 60,000 to 170,000 in the United States. Approximately 40% of patients
with High-Risk MDS transform to AML, another aggressive cancer with poor outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>About
Acute Myeloid Leukemia</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acute
myeloid leukemia is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells,
or platelets. The median age at the time of diagnosis is 65&#8211;69 years. AML is an aggressive disease and is fatal without anti-leukemic
treatment. Among patients treated with chemotherapy, 65% to 80% achieve complete remission. Despite a plethora of novel agents that have
been approved by the U.S. Food and Drug Administration since 2017 for treatment of AML, once complete remission (CR) is achieved, approximately
50% of patients age &lt; 60 years of age and up to 90% of patients &#8805; 60 years of age will relapse, despite consolidation strategies.
Furthermore, while 10&#8211;40% of younger AML patients are primarily refractory to AML induction therapy, the number is considerably
higher for patients above 60 years (40&#8211;60%). The vast majority of fit AML patients will undergo hematopoietic stem cell transplantation
(HSCT) after achieving a CR. However, 40% of these patients relapse after HSCT. Thus, refractory or relapsed (r/r) AML is a very common
scenario in AML and despite recent advances and new targeted therapies, the management of AML remains a challenge, particularly in older
adults ineligible for intensive therapies. According to the National Cancer Institute (NCI), the five-year survival rate is about 35%
in people under 60 years old, and 10% in people over 60 years old. Older people whose health is too poor for intensive chemotherapy have
a typical survival of five to ten months. AML accounts for approximately 1.8% of cancer deaths in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>About
GTB-3550 TriKE<sup>&#174;</sup> Clinical Trial</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
opened our GTB-3550 Phase 1 clinical trial in September 2019 and enrolled our first patient in January 2020. Patients with CD33+ malignancies
(primary induction failure or relapsed AML with failure of one reinduction attempt or high-risk MDS progressed on two lines of therapy)
age 18 and older were eligible (ClinicalTrials.gov Identifier NCT03214666). The primary endpoint is to identify the maximum tolerated
dose (MTD) of GTB-3550 TriKE<sup>&#174;</sup>. Correlative objectives include the number, phenotype, activation status and function of
NK cells and T cells. From January, 2020 until September, 2021 twelve patients received escalating doses of GTB-3550 in the Phase 1 trial.
The results of this trial were presented at several conferences in 2021. To summarize, the therapy was overall well tolerated and safe.
There were no serious cases of cytokine release syndrome observed. Four of twelve patients had transient reductions in bone marrow leukemic
blast cells. Correlative studies showed activation, proliferation, and persistence of functionally active endogenous NK cells. The results
of our first generation GTB-3550 Phase 1 clinical trial support our plans to advance the next generation camelid nanobody into the clinic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Next Generation of Camelid Nanobody TriKE<sup>&#174;</sup>s</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to be a leader in immuno-oncology therapies targeting a broad range of indications including hematological malignancies and solid
tumors. A key element of our strategy includes introducing a next-generation camelid nanobody platform. Camelid antibodies (often referred
as nanobodies) are smaller than human immunoglobulin and consist of two heavy chains. These nanobodies have the potential to have greater
affinity to target antigens, potentially resulting in greater potency. GT Biopharma is utilizing this camelid antibody structure for
all its new TriKE<sup>&#174;</sup> product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Generation
of humanized single-domain antibody targeting CD16 for incorporation into the TriKE<sup>&#174;</sup> platform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
develop second generation TriKE<sup>&#174;</sup>s, we designed a new humanized CD16 engager derived from a single-domain antibody. While
scFvs consist of a heavy and a light variable chain joined by a linker, single-domain antibodies consist of a single variable heavy chain
capable of engaging without the need of a light chain counterpart (see figure below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt="" style="height: 234px; width: 473px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
single-domain antibodies are thought to have certain attractive features for antibody engineering, including physical stability, ability
to bind deep grooves, and increased production yields, amongst others. Pre-clinical studies demonstrated increased NK cell activation
against CD33+ targets including NK cell degranulation (% CD107a+) and IFNg with the single-domain CD16 TriKE<sup>&#174;</sup> (cam 16-wt15-33;
GTB-3650) compared to the original TriKE<sup>&#174;</sup> (scFv16-m 15-33; GTB-3550) (see figure below). These data were published by
Felices M et al (2020) in Cancer Immunol Res.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CD33+
HL60 Targets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_005.jpg" alt="" style="height: 201px; width: 589px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-3650</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3650
is a CD33 targeted TriKE<sup>&#174;</sup> which targets CD33 on the surface of myeloid leukemias. We are advancing GTB-3650 through
preclinical studies and anticipate filing an Investigational New Drug (IND) application in the first half of 2023. We further
anticipate starting a study targeting patients with relapsed/refractory AML and high grade MDS by the end of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-5550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-5550
is a B7-H3 targeted TriKE<sup>&#174;</sup> which targets B7-H3 on the surface of advanced solid tumors. We are advancing GTB-5550
through preclinical studies and have initiated a GMP manufacturing campaign in anticipation of filing an IND in the late second half
of 2023 and starting a study targeting patients with B7-H3 positive solid tumors in the first half of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Oncology
Markets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Acute
Myeloid Leukemia and Myelodysplastic Syndromes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AML
is a heterogeneous hematologic stem cell malignancy in adults with incidence rate of 4.3% per 100,000 populations. The median age at
the time of diagnosis is 68 years. AML is an aggressive disease and is fatal without anti-leukemic treatment. AML is the most common
form of adult leukemia in the U.S. These patients will require frontline therapy, usually chemotherapy including cytarabine and an anthracycline,
a therapy that has not changed in over 40 years. Myelodysplastic syndromes are a heterogeneous group of myeloid neoplasms characterized
by dysplastic features of erythroid/myeloid/megakaryocytic lineages, progressive bone marrow failure, a varying percentage of blast cells,
and enhanced risk to evolve into acute myeloid leukemia. It is estimated that over 10,000 new cases of MDS are diagnosed each year and
there are minimal treatment options; other estimates have put this number higher. In addition, the incidence of MDS is rising for unknown
reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">B7-H3
Positive Solid Tumors</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
B7-H3 protein, which functions as a checkpoint inhibitor, has been identified in many of the most common solid tumor cancers, including
but not limited to bladder, breast, cervical, colorectal, endometrial, esophageal, gastric, glioma, kidney, liver, lung, pancreatic,
prostate, head and neck cancer, and melanoma. In recent studies, B7-H3 has been identified as a critical promoter of tumor cell proliferation,
migration, invasion, epithelial-to-mesenchymal transition, cancer stemness and drug resistance. Because this protein does not seem to
be expressed in normal cells, this makes it an attractive target for therapeutic intervention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of any of our product
candidates. We rely on a third-party contract manufacturing operation to produce and/or test our compounds and expect to continue to
do so to meet the preclinical and clinical requirements of our potential product candidates as well as for our future commercial needs.
We do not have long-term commitments with a third-party product manufacturer. We require in our manufacturing and processing agreements
that third-party product manufacturers produce intermediates, active pharmaceutical ingredients, or API, and finished products in accordance
with the FDA&#8217;s current Good Manufacturing Practices (cGMP), and all other applicable laws and regulations. We maintain confidentiality
agreements with potential and existing manufacturers to protect our proprietary rights related to our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patents
and Trademarks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Immuno-oncology
platform</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TriKE<sup>&#174;
</sup>Patents</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2021, two patents were issued by the US Patent Office covering our pipeline of clinical and non-clinical product candidates
consisting of tri-specific killer engagers, or TriKE<sup>&#174;</sup>s, designed to target natural killer, or NK, cells and tumor or virus
infected cells forming an immune synapse between the NK cell and the tumor cell thereby inducing NK cell activation at that site. The
patents broadly include TriKE<sup>&#174;</sup>s that target the CD16 receptor, which includes the more potent camelid nanobody sequence,
an IL-15 activating domain, and any targeting domain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>University
of Minnesota License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016
Exclusive Patent License Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (&#8220;UofMN&#8221;) to further
develop and commercialize cancer therapies using TriKE<sup>&#174; </sup>technology developed by researchers at the UofMN to target NK
cells to cancer. Under the terms of the 2016 agreement, we received exclusive rights to conduct research and to develop, make, use, sell,
and import TriKE<sup>&#174;</sup> technology worldwide for the treatment of any disease, state or condition in humans. We are responsible
for obtaining all permits, licenses, authorizations, registrations and regulatory approvals required or granted by any governmental authority
anywhere in the world that is responsible for the regulation of products such as the TriKE<sup>&#174;</sup> technology, including without
limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union. Under the agreement, the University
of Minnesota received an upfront payment of $200,000, annual license maintenance fees of $100,000 beginning in 2021, 4% royalty fees
(not to exceed 6% under subsequent license agreements or amendments to this agreement), upon sale of a licensed product or a minimum
annual royalty payment ranging from $250,000 to $5.0 million. The agreement also includes certain milestone payments totaling $3.1 million,
and one-time sales milestone payments of $1.0 million upon reaching $250 million in gross sales and $5.0 million upon reaching $500 million
in cumulative gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021
Exclusive License Agreement&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 26, 2021, we entered into an agreement with the UofMN specific to the B7H3 targeted TriKE<sup>&#174;</sup>. Under the agreement,
the UofMN received an upfront license fee of $20,000, and will receive annual license maintenance fees of $5,000 beginning in 2022, 2.5%
to 5% royalty fees or minimum annual royalty payments of $250,000 beginning in the first year after the first commercial sale of licensed
product, and $2.0 million beginning in the fifth year after the first commercial sale of licensed product. The agreement also includes
certain milestone payments totaling $3.1 million and one-time sales milestone payments of $1.0 million upon reaching $250 million in
gross sales, and $5.0 million upon reaching $500 million in cumulative gross sales of licensed products. There is no double payment intended;
if one of the milestone payments has been paid under the 2016 agreement, no further payment is due for the corresponding milestone above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees and Human Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the date of this Annual Report, we have 2 full-time employees and eight consultants to carry on our operations. Many of our activities are outsourced to consultants who provide
services to us on a project basis. As business activities require and capital resources permit, we will hire additional employees to
fulfill our Company&#8217;s needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form
and Year of Organization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
1965, the corporate predecessor of GT Biopharma, Diagnostic Data, Inc., was incorporated in the State of California. Diagnostic Data
changed its incorporation to the State of Delaware in 1972, and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI Pharmaceuticals
merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. On July 17, 2017, we
amended our Certificate of Incorporation for the purpose of changing our name from Oxis International, Inc. to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Available Information </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We post our annual report on Form 10-K, quarterly reports on Form 10-Q,
current reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange
Act, free of charge, on the Investors section of our public website (www.gtbiopharma.com) as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the SEC&#160;. In addition, you can read our SEC filings over the Internet at the SEC&#8217;s
website at www.sec.gov. The contents of these websites are not incorporated into this annual report on Form 10-K. Further, our references
to the URLs for these websites are intended to be inactive textual references only.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_003"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below in addition
to the other information contained in this Annual Report on Form 10-K before deciding whether to invest in shares of our common stock.
If any of the following risks actually occur, our business, financial condition or operating results could be harmed. In that case, the
trading price of our common stock could decline and you may lose part or all of your investment. In the opinion of management, the risks
discussed below represent the material risks known to the company. Additional risks and uncertainties not currently known to us or that
we currently deem immaterial may also impair our business, financial condition and operating results and adversely affect the market
price of our common stock.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is at an early stage of development and we may not develop therapeutic products that can be commercialized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is at an early stage of development. We do not have immune-oncology products in late stage clinical trials. We are still in
the early stages of identifying and conducting research on potential therapeutic products. Our potential therapeutic products will require
significant research and development and pre-clinical and clinical testing prior to regulatory approval in the United States and other
countries. We may not be able to obtain regulatory approvals, enter clinical trials for any of our product candidates, or commercialize
any products. Our product candidates may prove to have undesirable and unintended side effects or other characteristics adversely affecting
their safety, efficacy or cost effectiveness that could prevent or limit their use. Any product using any of our technology may fail
to provide the intended therapeutic benefits or achieve therapeutic benefits equal to or better than the standard of treatment at the
time of testing or production.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a history of operating losses and we expect to continue to incur losses for the foreseeable future and we may never generate revenue
or achieve profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company reported a net loss of $20.9 million and as of December 31, 2022 and had an
accumulated deficit of $674.5 million. We have not generated any revenue to date and are not profitable, and have incurred losses in
each year since our inception. We do not expect to generate any product sales or royalty revenues for the foreseeable future. We
expect to incur significant additional operating losses for the foreseeable future as we expand research and development and
clinical trial efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to achieve long-term profitability is dependent upon obtaining regulatory approvals for our products and successfully commercializing
our products alone or with third parties. However, our operations may not be profitable even if any of our products under development
are successfully developed and produced and thereafter commercialized. Even if we achieve profitability in the future, we may not be
able to sustain profitability in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we succeed in commercializing one or more of our product candidates, we expect to continue to incur substantial research and development
and other expenditures to develop and market additional product candidates. The size of our future net losses will depend, in part, on
the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and
will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need additional capital to conduct our operations and develop our products, and our ability to obtain the necessary funding is uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have used a significant amount of cash since inception to finance the continued development and testing of our product candidates, and
we expect to need substantial additional capital resources to develop our product candidates going forward and launch and commercialize
any product candidates for which we receive regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be successful in generating and/or maintaining operating cash flow, and the timing of our capital expenditures and other expenditures
may not result in cash sufficient to sustain our operations through the commercialization of our product candidates. If financing is
not sufficient and additional financing is not available or available only on terms that are detrimental to our long-term survival, it
could have a material adverse effect on our ability to continue to function. The timing and degree of any future capital requirements
will depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of the assumptions underlying our estimates for capital needs in 2023 and beyond;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scientific
    and clinical progress in our research and development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    magnitude and scope of our research and development programs and our ability to establish, enforce and maintain strategic arrangements
    for research, development, clinical testing, manufacturing and marketing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    progress with pre-clinical development and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    time and costs involved in obtaining regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and type of product candidates that we pursue.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
financing through strategic collaborations, public or private equity or debt financings or other financing sources may not be available
on acceptable terms, or at all. Additional equity financing could result in significant dilution to our stockholders, and any debt financings
will likely involve covenants restricting our business activities. Further, if we obtain additional funds through arrangements with collaborative
partners, these arrangements may require us to relinquish rights to some of our technologies, product candidates or products that we
would otherwise seek to develop and commercialize on our own.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
sufficient capital is not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or product
development initiatives, any of which could have a material adverse effect on our financial condition or business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
research and development costs could exceed our projections requiring us to significantly modify our planned operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
currently projected expenditures for 2023 include approximately $10.2 million for research and development. The actual cost
of our programs could differ significantly from our current projections if we change our planned development process. In the event that
actual costs of our clinical program, or any of our other ongoing research activities, are significantly higher than our current estimates,
we may be required to significantly modify our planned level of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development of any product candidate is highly uncertain. It is difficult to reasonably estimate or know the nature, timing
and costs of the efforts necessary to complete the development of, or the period in which material net cash inflows are expected to commence
from any product candidate, due to the numerous risks and uncertainties associated with developing drugs. Any failure to complete any
stage of the development of products in a timely manner could have a material adverse effect on our operations, financial position and
liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
previously identified material weaknesses in our internal controls over financial reporting. While we have worked to remedy these weaknesses,
if we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our
financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which
would harm our business and the trading price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure
controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered
in their implementation, could cause us to fail to meet our reporting obligations. Ineffective internal control could also cause investors
to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
previously identified material weaknesses in our internal control over financial reporting as a company, which resulted in unauthorized
transactions involving our assets and common stock. As defined in Regulation 12b-2 under the Securities Exchange Act of 1934, or the
Exchange Act, a &#8220;material weakness&#8221; is a deficiency, or combination of deficiencies, in internal control over financial reporting,
such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will
not be prevented, or detected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have taken measures to mitigate the issues identified and implement a functional system of internal controls over financial reporting.
However, such controls may become inadequate due to changes in conditions, or the degree of compliance with such policies or procedures
may deteriorate, which could result in the discovery of additional material weaknesses and deficiencies. In any event, the process of
determining whether our existing internal control over financial reporting is compliant with Section 404 of the Sarbanes-Oxley Act, or
Section 404, and sufficiently effective requires the investment of substantial time and resources, including by certain members of our
senior management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required, pursuant to Section 404, to furnish a report by management on, among other things, the effectiveness of our internal control
over financial reporting. However, for as long as we are a &#8220;smaller reporting company,&#8221; our independent registered public
accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section
404. While we could be a smaller reporting company for an indefinite amount of time, and thus relieved of the above-mentioned attestation
requirement, an independent assessment of the effectiveness of our internal control over financial reporting could detect problems that
our management&#8217;s assessment might not. Such undetected material weaknesses in our internal control over financial reporting could
lead to financial statement restatements and require us to incur the expense of remediation.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
intellectual property may be compromised.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
of our value going forward depends on the intellectual property rights that we have been and are acquiring. There may have been many
persons involved in the development of our intellectual property, and we may not be successful in obtaining the necessary rights from
all of them. It is possible that in the future, third parties may challenge our intellectual property rights. We may not be successful
in protecting our intellectual property rights. In either event, we may lose the value of our intellectual property, and if so, our business
prospects may suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be
able to compete effectively in our market and our business would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related
to our technologies. Any disclosure to or misappropriation by third parties of our trade secret or other confidential information could
enable competitors to quickly duplicate or surpass our technological achievements, thus eroding any competitive advantage we may derive
from this information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain.
The patent applications we own or license may fail to result in issued patents in the United States or in foreign countries. Third parties
may challenge the validity, enforceability or scope of any issued patents we own or license or any applications that may be issued as
patents in the future, which may result in those patents being narrowed, invalidated or held unenforceable. Even if they are unchallenged,
our patents and patent applications may not adequately protect our intellectual property or prevent others from developing similar products
that do not fall within the scope of our patents. If the breadth or strength of protection provided by the patents we hold or pursue
is threatened, our ability to commercialize any product candidates with technology protected by those patents could be threatened. Further,
if we encounter delays in our clinical trials, the time during which we would have patent protection for any covered product candidates
that obtain regulatory approval would be reduced. Since patent applications in the United States and most other countries are confidential
for a period of time after filing, we cannot be certain at the time of filing that we are the first to file any patent application related
to our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect
proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery
platform and drug development processes that involve proprietary know-how, information or technology that is not covered by patents or
not amenable to patent protection. Although we require all of our employees and certain consultants and advisors to assign inventions
to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information
or technology to enter into confidentiality agreements, our trade secrets and other proprietary information may be disclosed or competitors
may otherwise gain access to such information or independently develop substantially equivalent information. Further, the laws of some
foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result,
we may encounter significant difficulty in protecting and defending our intellectual property both in the United States and abroad. If
we are unable to prevent material disclosure of the trade secret intellectual property related to our technologies to third parties,
we may not be able to establish or maintain the competitive advantage that we believe is provided by such intellectual property, which
could materially adversely affect our market position and business and operational results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Claims
that we infringe the intellectual property rights of others may prevent or delay our drug discovery and development efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research, development and commercialization activities, as well as any product candidates or products resulting from those activities,
may infringe or be accused of infringing a patent or other form of intellectual property under which we do not hold a license or other
rights. Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents
of which we are currently unaware, with claims that cover the use or manufacture of our product candidates or the practice of our related
methods. Because patent applications can take many years to issue, there may be currently pending patent applications that may later
result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim
that use of our technologies infringes one or more claims of these patents. If our activities or product candidates infringe the patents
or other intellectual property rights of third parties, the holders of such intellectual property rights may be able to block our ability
to commercialize such product candidates or practice our methods unless we obtain a license under the intellectual property rights or
until any applicable patents expire or are determined to be invalid or unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defense
of any intellectual property infringement claims against us, regardless of their merit, would involve substantial litigation expense
and would be a significant diversion of employee resources from our business. In the event of a successful claim of infringement against
us, we may have to pay substantial damages, obtain one or more licenses from third parties, limit our business to avoid the infringing
activities, pay royalties and/or redesign our infringing product candidates or methods, any or all of which may be impossible or require
substantial time and monetary expenditure. Further, if we were to seek a license from the third-party holder of any applicable intellectual
property rights, we may not be able to obtain the applicable license rights when needed or on commercially reasonable terms, or at all.
The occurrence of any of the above events could prevent us from continuing to develop and commercialize one or more of our product candidates
and our business could materially suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may desire, or be forced, to seek additional licenses to use intellectual property owned by third parties, and such licenses may not
be available on commercially reasonable terms or at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
third party may hold intellectual property, including patent rights, that are important or necessary to the development of our product
candidates, in which case we would need to obtain a license from that third party or develop a different formulation of the product that
does not infringe upon the applicable intellectual property, which may not be possible. Additionally, we may identify product candidates
that we believe are promising and whose development and other intellectual property rights are held by third parties. In such a case,
we may desire to seek a license to pursue the development of those product candidates. Any license that we may desire to obtain or that
we may be forced to pursue may not be available when needed on commercially reasonable terms or at all. Any inability to secure a license
that we need or desire could have a material adverse effect on our business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
patent protection covering some of our product candidates may be dependent on third parties, who may not effectively maintain that protection.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we expect that we will generally seek to gain the right to fully prosecute any patents covering product candidates we may in-license
from third-party owners, there may be instances when platform technology patents that cover our product candidates remain controlled
by our licensors. If any of our current or future licensing partners that retain the right to prosecute patents covering the product
candidates we license from them fail to appropriately maintain that patent protection, we may not be able to prevent competitors from
developing and selling competing products or practicing competing methods and our ability to generate revenue from any commercialization
of the affected product candidates may suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming
and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents or the patents of our current or potential licensors. To attempt to stop infringement or unauthorized use, we
may need to enforce one or more of our patents, which can be expensive and time-consuming and distract management. If we pursue any litigation,
a court may decide that a patent of ours or our licensor&#8217;s is not valid or is unenforceable, or may refuse to stop the other party
from using the relevant technology on the grounds that our patents do not cover the technology in question. Further, the legal systems
of certain countries, particularly certain developing countries, do not favor the enforcement of patents, which could reduce the likelihood
of success of any infringement proceeding we pursue in any such jurisdiction. An adverse result in any infringement litigation or defense
proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could
put our patent applications at risk of not issuing, which could limit our ability to exclude competitors from directly competing with
us in the applicable jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interference
proceedings provoked by third parties or brought by the U.S. PTO may be necessary to determine the priority of inventions with respect
to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to use it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms, or at all. Litigation or interference proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unsuccessful in obtaining or maintaining patent protection for intellectual property in development, our business and competitive
position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking patent protection for some of our technology and product candidates. Patent prosecution is a challenging process and is not
assured of success. If we are unable to secure patent protection for our technology and product candidates, our business may be adversely
impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, issued patents and pending international applications require regular maintenance. Failure to maintain our portfolio may result
in loss of rights that may adversely impact our intellectual property rights, for example by rendering issued patents unenforceable or
by prematurely terminating pending international applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how,
technology and other proprietary information, to maintain our competitive position. We currently, and expect in the future to continue
to, seek to protect these trade secrets, in part, by entering into confidentiality agreements with parties who have access to them, such
as our employees, collaborators, contract manufacturers, consultants, advisors and other third parties. Despite these efforts, any of
these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able
to obtain adequate remedies for any such disclosure. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret
is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United
States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently
developed by a competitor, we would have no right to prevent them, or those to whom they disclose the trade secrets, from using that
technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor,
our competitive position would be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to meet our obligations under our license agreements, we may lose our rights to key technologies on which our business depends.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends in part on licenses from third parties. These third-party license agreements impose obligations on us, such as payment
obligations and obligations to diligently pursue development of commercial products under the licensed patents. If a licensor believes
that we have failed to meet our obligations under a license agreement, the licensor could seek to limit or terminate our license rights,
which could lead to costly and time-consuming litigation and, potentially, a loss of the licensed rights. During the period of any such
litigation, our ability to carry out the development and commercialization of potential products could be significantly and negatively
affected. If our license rights were restricted or ultimately lost, our ability to continue our business based on the affected technology
platform could be severely adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will have to hire additional employees to carry on our business operations. If we are unable to hire qualified personnel, we may not
be able to implement our business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We currently have two
full-time employees and eight consultants to carry on our operations. Our interim Chief Executive Officer and Executive Chairman of
the Board provides his services through a consulting arrangement. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loss of the services of any of our employees or consultants could delay our product development programs and our research and
development efforts. In order to develop our business in accordance with our business strategy, we will have to hire additional
qualified personnel, including in the areas of manufacturing, clinical trials management, regulatory affairs, finance, discovery
biology, and business development. We will need to raise sufficient funds to hire and retain the necessary employees and
consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
there is intense competition for a limited number of qualified personnel among biopharmaceutical, biotechnology, pharmaceutical and other
businesses. Many of the other pharmaceutical companies against which we compete for qualified personnel have greater financial and other
resources, different risk profiles, longer histories in the industry and greater ability to provide valuable cash or stock incentives
to potential recruits than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of
these characteristics may be more appealing to high quality candidates than what we are able to offer as an early-stage company. If we
are unable to continue to attract and retain high quality personnel, the rate and success at which we can develop and commercialize product
candidates will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on key personnel for our continued operations and future success, and a loss of certain key personnel could significantly hinder
our ability to move forward with our business plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the specialized nature of our business, we are highly dependent on our ability to identify, hire, train and retain highly qualified
scientific and technical personnel for the research and development activities we conduct or sponsor. The loss of one or more key executive
officers, scientific or operational team members would be significantly detrimental to us. In addition, recruiting and retaining qualified
scientific personnel to perform research and development work is critical to our success. Our anticipated growth and expansion into areas
and activities requiring additional expertise, such as discovery biology, clinical testing, regulatory compliance, manufacturing and
compliance, will require the addition of new management personnel and the development of additional expertise by existing management
personnel. There is intense competition for qualified personnel in the areas of our present and planned activities. Accordingly, we may
not be able to continue to attract and retain the qualified personnel, which would adversely affect the development of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming
ownership of what we regard as our own intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors
or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in
their work for us, with contractual provisions and other procedures, we may be subject to claims that these employees or we have used
or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employers.
Litigation may be necessary to defend against any such claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property
to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party
who in fact contributes to the development of intellectual property that we regard as our own. Further, the terms of such assignment
agreements may be breached and we may not be able to successfully enforce their terms, which may force us to bring claims against third
parties, or defend claims they may bring against us, to determine the ownership of intellectual property rights we may regard and treat
as our own.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could cause our business to suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
regulations of governmental authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency, or EMA,
to provide accurate information to the FDA or EMA, to comply with manufacturing standards we have established, to comply with federal,
state and international healthcare fraud and abuse laws and regulations as they may become applicable to our operations, to report financial
information or data accurately or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use
of information obtained during clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is
not always possible to identify and deter employee misconduct, and the precautions we currently take and the procedures we may establish
in the future as our operations and employee base expand to detect and prevent this type of activity may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from
a failure by our employees to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful
in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations,
including the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on the activities of our non-employee consultants, research institutions and scientific contractors, whose activities are not
wholly within our control, may lead to delays in development of our proposed products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely extensively upon and have relationships with scientific consultants at academic and other institutions, some of whom conduct research
at our request, and other consultants with expertise in clinical development strategy or other matters. These consultants are not our
employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to
us. We have limited control over the activities of these consultants and, except as otherwise required by our collaboration and consulting
agreements to the extent they exist, can expect only limited amounts of their time to be dedicated to our activities. These research
facilities may have commitments to other commercial and non-commercial entities. We have limited control over the operations of these
laboratories and can expect only limited amounts of time to be dedicated to our research goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
may take longer to complete our clinical trials than we project, or we may not be able to complete them at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
budgeting and planning purposes, we have projected the date for the commencement, continuation and completion of our various clinical
trials. However, a number of factors, including scheduling conflicts with participating clinicians and clinical institutions, and difficulties
in identifying and enrolling patients who meet trial eligibility criteria, may cause significant delays. We may not commence or complete
clinical trials involving any of our products as projected or may not conduct them successfully.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to rely on medical institutions, academic institutions or clinical research organizations to conduct, supervise or monitor some
or all aspects of clinical trials involving our products. We will have less control over the timing and other aspects of these clinical
trials than if we conducted them entirely on our own. If we fail to commence or complete, or experience delays in, any of our planned
clinical trials, our stock price and our ability to conduct our business as currently planned could be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
drug development is costly, time-consuming and uncertain, and we may suffer setbacks in our clinical development program that could harm
our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
drug development for our product candidates is costly, time-consuming and uncertain. Our product candidates are in various stages of
development and while we expect that clinical trials for these product candidates will continue for several years, such trials may take
significantly longer than expected to complete. In addition, we, the FDA, an institutional review board, or IRB, or other regulatory
authorities, including state and local agencies and counterpart agencies in foreign countries, may suspend, delay, require modifications
to or terminate our clinical trials at any time, for various reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discovery
    of safety or tolerability concerns, such as serious or unexpected toxicities or side effects or exposure to otherwise unacceptable
    health risks, with respect to study participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of effectiveness of any product candidate during clinical trials or the failure of our product candidates to meet specified endpoints;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in subject recruitment and enrollment in clinical trials or inability to enroll a sufficient number of patients in clinical trials
    to ensure adequate statistical ability to detect statistically significant treatment effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in retaining subjects and volunteers in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in obtaining the Institutional Review Board&#8217;s (&#8220;IRB&#8221;) approval for studies to be conducted at each clinical trial
    site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequacy
    of or changes in our manufacturing process or the product formulation or method of delivery;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective contract research
    organizations, (&#8220;CROs&#8221;), clinical trial sites and other third-party contractors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to add a sufficient number of clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty
    regarding proper formulation and dosing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us, our employees, our CROs or their employees or other third-party contractors to comply with contractual and applicable regulatory
    requirements or to perform their services in a timely or acceptable manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scheduling
    conflicts with participating clinicians and clinical institutions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to design appropriate clinical trial protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of medical investigators to follow our clinical protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in maintaining contact with subjects during or after treatment, which may result in incomplete data; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws, regulations and regulatory policies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we experience delays or difficulties in the enrollment of patients in clinical trials, those clinical trials could take longer than expected
to complete and our receipt of necessary regulatory approvals could be delayed or prevented.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient
number of eligible patients to participate in these trials as required by U.S. Food and Drug Administration, or the FDA, or similar regulatory
authorities outside the United States. In particular, because we are focused on patients with molecularly defined cancers, our pool of
suitable patients may be smaller and more selective and our ability to enroll a sufficient number of suitable patients may be limited
or take longer than anticipated. In addition, some of our competitors have ongoing clinical trials for product candidates that treat
the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll
in clinical trials of our competitors&#8217; product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
enrollment for any of our clinical trials may also be affected by other factors, including without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    severity of the disease under investigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    frequency of the molecular alteration we are seeking to target in the applicable trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    eligibility criteria for the study in question;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    perceived risks and benefits of the product candidate under study;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent of the efforts to facilitate timely enrollment in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patient referral practices of physicians;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to monitor patients adequately during and after treatment; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proximity and availability of clinical trial sites for prospective patients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to
abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for
our product candidates, and we may not have or be able to obtain sufficient cash to fund such increased costs when needed, which could
result in the further delay or termination of the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consistent
with our general product development strategy, we intend to design future trials for our product candidates to include some patients
with the applicable clinical characteristics, stage of therapy, molecular alterations, biomarkers, and/or cell surface antigens that
determine therapeutic options, or are indicators of the disease, with a view to assessing possible early evidence of potential therapeutic
effect. If we are unable to locate and include such patients in those trials, then our ability to make those early assessments and to
seek participation in FDA expedited review and approval programs, including breakthrough therapy and fast track designation, or otherwise
to seek to accelerate clinical development and regulatory timelines, could be compromised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited clinical testing and regulatory capabilities, and human clinical trials are subject to extensive regulatory
requirements, which are very expensive, time-consuming and difficult to design and implement. Our products may fail to achieve
necessary safety and efficacy endpoints during clinical trials, which may limit our ability to generate revenues from therapeutic
products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that we will be able to invest or develop resources for clinical trials successfully or as expediently as necessary.
In particular, human clinical trials can be very expensive and difficult to design and implement, in part because they are subject to
rigorous regulatory requirements. The clinical trial process is time consuming. We estimate that clinical trials of our product candidates
will take at least several years to complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems
that cause us to abandon or repeat clinical trials. The commencement and completion of clinical trials may be affected by several factors,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    safety issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination
    of dosing issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to demonstrate effectiveness during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of patient recruitment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to monitor patients adequately during or after treatment; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of medical investigators to follow our clinical protocols.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we or the FDA, may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable
health risks or if the FDA finds deficiencies in our investigational new drug application, or IND, submissions or the conduct of these
trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to extensive regulation, which can be costly and time consuming and can subject us to unanticipated delays. even if we obtain
regulatory approval for some of our products, those products may still face regulatory difficulties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our potential products, processing and manufacturing activities, are subject to comprehensive regulation by the FDA in the United
States and by comparable authorities in other countries. The process of obtaining FDA and other required regulatory approvals, including
foreign approvals, is expensive and often takes many years and can vary substantially based upon the type, complexity and novelty of
the products involved. In addition, regulatory agencies may lack experience with our technologies and products, which may lengthen the
regulatory review process, increase our development costs and delay or prevent their commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we violate regulatory requirements at any stage, whether before or after we obtain marketing approval, the FDA may take enforcement action(s)
against us, which could include issuing a warning or untitled letter, placing a clinical hold on an ongoing clinical trial, product seizure,
enjoining our operations, refusal to consider our applications for pre-market approval, refusal of an investigational new drug application,
fines, or even civil or criminal liability, any of which could materially harm our reputation and financial results. Additionally, we
may not be able to obtain the labeling claims necessary or desirable for the promotion of our products. We may also be required to undertake
post marketing trials to provide additional evidence of safety and effectiveness. In addition, if we or others identify side effects
after any of our adoptive therapies are on the market, or if manufacturing problems occur, regulators may withdraw their approval and
reformulations, additional clinical trials, changes in labeling of our products, and additional marketing applications may be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the following factors, among others, could cause regulatory approval for our product candidates to be delayed, limited or denied:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product candidates require significant clinical testing to demonstrate safety and effectiveness before applications for marketing
    approval can be filed with the FDA and other regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">data
    obtained from pre-clinical and nonclinical animal testing and clinical trials can be interpreted in different ways, and regulatory
    authorities may not agree with our respective interpretations or may require us to conduct additional testing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or inconclusive results or the occurrence of serious or unexpected adverse events during a clinical trial could cause us to delay
    or terminate development efforts for a product candidate; and/or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    and other regulatory authorities may require expansion of the size and scope of the clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
difficulties or failures that we encounter in securing regulatory approval for our product candidates would likely have a substantial
adverse impact on our ability to generate product sales, and could make a search for a collaborative partner more difficult.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
regulatory approval even after clinical trials that are believed to be successful is an uncertain process.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we complete our planned clinical trials and believe the results were successful, obtaining regulatory approval is a lengthy, expensive
and uncertain process, and the FDA or other regulatory agencies may delay, limit or deny approval of any of our applications for pre-market
approval for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to demonstrate to the FDA&#8217;s satisfaction that our product candidates are safe and effective for any indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials may not meet the level of statistical significance or clinical significance required by the FDA for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may not find the data from pre-clinical studies and clinical trials sufficient to demonstrate that the clinical and other benefits
    of our product candidates outweigh their safety risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with our interpretation of data from pre-clinical studies or clinical trials, or may not accept data generated at
    our clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from pre-clinical studies and clinical trials of our product candidates may not be sufficient to support the submission
    of applications for regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may have difficulties scheduling an advisory committee meeting in a timely manner, or the advisory committee may recommend against
    approval of our application or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or
    clinical trials, limitations on approved labeling, or distribution and use restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may require development of a risk evaluation and mitigation strategy as a condition of approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we enter into
    agreements for clinical and commercial supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may change their approval policies or adopt new regulations that adversely affect our applications for pre-market approval; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may require simultaneous approval for both adults and for children and adolescents delaying needed approvals, or we may have
    successful clinical trial results for adults but not children and adolescents, or vice versa.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can submit an application for regulatory approval in the United States, we must conduct a pivotal, registrational trial. We will also
need to agree on a protocol with the FDA for a clinical trial before commencing the trial. Registrational clinical trials frequently
produce unsatisfactory results even though prior clinical trials were successful. Therefore, even if the results of our early phase trials
are successful, the results of the additional trials that we conduct may or may not be successful. Further, our product candidates may
not be approved even if they achieve their primary endpoints in registrational clinical trials. The FDA or other foreign regulatory authorities
may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. Any of these regulatory
authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on
a protocol for a clinical trial. The FDA or other regulatory agencies may require that we conduct additional clinical, nonclinical, manufacturing
validation or drug product quality studies and submit those data before considering or reconsidering the application. Depending on the
extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us
to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be
considered sufficient by the FDA or other regulatory agencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA or other regulatory agencies may also approve a product candidate for fewer or more limited indications than we request,
may impose significant limitations related to use restrictions for certain age groups, warnings, precautions or contraindications or
may grant approval contingent on the performance of costly post-marketing clinical trials or risk mitigation requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will continue to be subject to extensive FDA regulation following any product approvals, and if we fail to comply with these regulations,
we may suffer a significant setback in our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are successful in obtaining regulatory approval of our product candidates, we will continue to be subject to the requirements of
and review by, the FDA and comparable regulatory authorities in the areas of manufacturing processes, post-approval clinical data, adverse
event reporting, labeling, advertising and promotional activities, among other things. In addition, any marketing approval we receive
may be limited in terms of the approved product indication or require costly post-marketing testing and surveillance. Discovery after
approval of previously unknown problems with a product, manufacturer or manufacturing process, or a failure to comply with regulatory
requirements, may result in enforcement actions such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters or other actions requiring changes in product manufacturing processes or restrictions on product marketing or distribution;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls or seizures or the temporary or permanent withdrawal of a product from the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspending
    any ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary
    or permanent injunctions against our production operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of our applications for pre-market approval or an investigational new drug application; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenue, the imposition of civil penalties or criminal prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of these actions would likely cause a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Many
of our business practices are subject to scrutiny and potential investigation by regulatory and government enforcement authorities, as
well as to lawsuits brought by private citizens under federal and state laws. We could become subject to investigations, and our failure
to comply with applicable law or an adverse decision in lawsuits may result in adverse consequences to us. If we fail to comply with
U.S. healthcare laws, we could face substantial penalties and financial exposure, and our business, operations and financial condition
could be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
payment is not yet available from third-party payors (government or commercial) for our product, our goal is to obtain such coverage
as soon as possible after product approval and commercial launch in the U.S. If this occurs, the availability of such payment would mean
that many healthcare laws would place limitations and requirements on the manner in which we conduct our business (including our sales
and promotional activities and interactions with healthcare professionals and facilities) and could result in liability and exposure
to us. In some instances, our interactions with healthcare professionals and facilities that occurred prior to commercialization could
have implications at a later date. The laws that may affect our ability to operate include, among others: (i) the federal healthcare
programs Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering
or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase,
order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as Medicare or Medicaid;
(ii) federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be
presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, and which may apply
to entities like us under theories of &#8220;implied certification&#8221; where the government and qui tam relators may allege that device
companies are liable where a product that was paid for by the government in whole or in part was promoted &#8220;off-label,&#8221; lacked
necessary approval, or failed to comply with good manufacturing practices or other laws; (iii) transparency laws and related reporting
and/or disclosures such as the Sunshine Act; and/or (iv) state law equivalents of each of the above federal laws, such as anti-kickback
and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, many of
which differ from their federal counterparts in significant ways, thus complicating compliance efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us,
we may be subject to penalties, including civil and criminal penalties, exclusion from participation in government healthcare programs,
damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of
our operations could adversely affect our ability to operate our business and our financial results. The risk of our being found in violation
of these laws is increased by the fact that their provisions are open to a variety of evolving interpretations and enforcement discretion.
Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal
expenses and divert our management&#8217;s attention from the operation of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
federal and state government agencies have heightened civil and criminal enforcement efforts. There are numerous ongoing investigations
of healthcare pharmaceutical companies and others in the healthcare space, as well as their executives and managers. In addition, amendments
to the Federal False Claims Act, have made it easier for private parties to bring qui tam (whistleblower) lawsuits against companies
under which the whistleblower may be entitled to receive a percentage of any money paid to the government. In addition, the Affordable
Care Act amended the federal civil False Claims Act to provide that a claim that includes items or services resulting from a violation
of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Penalties
include substantial fines for each false claim, plus three times the amount of damages that the federal government sustained because
of the act of that person or entity and/or exclusion from the Medicare program. In addition, a majority of states have adopted similar
state whistleblower and false-claims provision. There can be no assurance that our activities will not come under the scrutiny of regulators
and other government authorities or that our practices will not be found to violate applicable laws, rules and regulations or prompt
lawsuits by private citizen &#8220;relators&#8221; under federal or state false claims laws. Any future investigations of our business
or executives, or enforcement action or prosecution, could cause us to incur substantial costs, and result in significant liabilities
or penalties, as well as damage to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Laws
impacting the U.S. healthcare system are subject to a great deal of uncertainty, which may result in adverse consequences to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been a number of legislative and regulatory proposals to change the healthcare system, reduce the costs of healthcare and change
medical reimbursement policies. Doctors, clinics, hospitals and other users of our products may decline to purchase our products to the
extent there is uncertainty regarding coverage from government or commercial payors. Further proposed legislation, regulation and policy
changes affecting third-party reimbursement are likely. Among other things, Congress has in the past proposed changes to and the repeal
of the Patient Protection and Affordable Care and Health Care and Education Affordability Reconciliation Act of 2010 (collectively, the
&#8220;Affordable Care Act&#8221;), and lawsuits have been brought challenging aspects of the law at various points. There have been
repeated recent attempts by Congress to repeal or replace the Affordable Care Act. At this time, it remains unclear whether there will
be any changes made to or any repeal or replacement of the Affordable Care Act, with respect to certain of its provisions or in its entirety.
We are unable to predict what legislation or regulation, if any, relating to the health care industry or third-party coverage and reimbursement
may be enacted in the future at the state or federal level, or what effect such legislation or regulation may have on us. Denial of coverage
and reimbursement of our products, or the revocation or changes to coverage and reimbursement policies, could have a material adverse
effect on our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in our efforts to build a pipeline of product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key element of our strategy is to use and expand our product platform to build a pipeline of product candidates and progress those product
candidates through clinical development for the treatment of a variety of different types of cancer. Even if we are successful in building
a product pipeline, the potential product candidates that we identify may not be suitable for clinical development for a number of reasons,
including causing harmful side effects or demonstrating other characteristics that indicate a low likelihood of receiving marketing approval
or achieving market acceptance. If our methods of identifying potential product candidates fail to produce a pipeline of potentially
viable product candidates, then our success as a business will be dependent on the success of fewer potential product candidates, which
introduces risks to our business model and potential limitations to any success we may achieve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused
by such products, a number of potentially significant negative consequences could result, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw approvals of such product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the product&#8217;s label;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a medication guide for distribution to patients that outlines the risks of such side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and
could significantly harm our business, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may expend our limited resources to pursue a particular product candidate or indication that does not produce any commercially viable
products and may fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater
likelihood of success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we must focus our efforts on particular research programs and product candidates
for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications
that later prove to have greater commercial potential. Further, our resource allocation decisions may result in our use of funds for
research and development programs and product candidates for specific indications that may not yield any commercially viable products.
If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable
rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been
more advantageous for us to retain sole development and commercialization rights to such product candidate. Any such failure to improperly
assess potential product candidates could result in missed opportunities and/or our focus on product candidates with low market potential,
which would harm our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
products may be expensive to manufacture, and they may not be profitable if we are unable to control the costs to manufacture them.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products may be significantly more expensive to manufacture than we expect or than other therapeutic products currently on the market
today. We hope to substantially reduce manufacturing costs through process improvements, development of new methods, increases in manufacturing
scale and outsourcing to experienced manufacturers. If we are not able to make these, or other improvements, and depending on the pricing
of the product, our profit margins may be significantly less than that of other therapeutic products on the market today. In addition,
we may not be able to charge a high enough price for any product we develop, even if they are safe and effective, to make a profit. If
we are unable to realize significant profits from our potential product candidates, our business would be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently lack manufacturing capabilities to produce our therapeutic product candidates at commercial-scale quantities and do not have
an alternate manufacturing supply, which could negatively impact our ability to meet any future demand for the product.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that we would need to significantly expand our manufacturing capabilities to meet potential demand for our therapeutic product
candidates, if approved. Such expansion would require additional regulatory approvals. Even if we increase our manufacturing capabilities,
it is possible that we may still lack sufficient capacity to meet demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any alternate supply for our products. If the facilities where our products are currently being manufactured or
equipment were significantly damaged or destroyed, or if there were other disruptions, delays or difficulties affecting manufacturing
capacity or availability of drug supply, including, but not limited to, if such facilities are deemed not in compliance with current
Good Manufacturing Practice, or GMP, requirements, future clinical studies and commercial production for our products would likely be
significantly disrupted and delayed. It would be both time-consuming and expensive to replace this capacity with third parties, particularly
since any new facility would need to comply with the regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ultimately,
if we are unable to supply our products to meet commercial demand, whether because of processing constraints or other disruptions, delays
or difficulties that we experience, our production costs could dramatically increase and sales of our products and their long-term commercial
prospects could be significantly damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
be successful, our proposed products must be accepted by the healthcare community, which can be very slow to adopt or unreceptive to
new technologies and products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proposed products and those developed by our collaborative partners, if approved for marketing, may not achieve market acceptance since
hospitals, physicians, patients or the medical community in general may decide not to accept and use these products. The products that
we are attempting to develop represent substantial departures from established treatment methods and will compete with a number of more
conventional therapies manufactured and marketed by major pharmaceutical companies. The degree of market acceptance of any of our developed
products will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    establishment and demonstration to the medical community of the clinical efficacy and safety of our proposed products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to create products that are superior to alternatives currently on the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish in the medical community the potential advantage of our treatments over alternative treatment methods; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reimbursement
    policies of government and third-party payers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the healthcare community does not accept our products for any of these reasons, or for any other reason, our business would be materially
harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is based on novel technologies that are inherently expensive and risky and may not be understood by or accepted in the marketplace,
which could adversely affect our future value.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical development, commercialization and marketing of immuno-oncology therapies are at an early-stage, substantially research-oriented,
and financially speculative. To date, very few companies have been successful in their efforts to develop and commercialize an immuno-oncology
therapeutic product. In general, such products may be susceptible to various risks, including undesirable and unintended side effects,
unintended immune system responses, inadequate therapeutic efficacy, or other characteristics that may prevent or limit their approval
or commercial use. Furthermore, the number of people who may use such therapies is difficult to forecast with accuracy. Our future success
is dependent on the establishment of a significant market for such therapies and our ability to capture a share of this market with our
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development efforts with our therapeutic product candidates are susceptible to the same risks of failure inherent in the development
and commercialization of therapeutic products based on new technologies. The novel nature of immuno-oncology therapeutics creates significant
challenges in the areas of product development and optimization, manufacturing, government regulation, third-party reimbursement and
market acceptance. For example, the FDA has relatively limited experience regulating such therapies, and there are few approved treatments
using such therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
competition includes fully integrated biotechnology and pharmaceutical companies that have significant advantages over us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for therapeutic immuno-oncology products is highly competitive. We expect that our most significant competitors will be fully
integrated and more established pharmaceutical and biotechnology companies or institutions, including major multinational pharmaceutical
companies, biotechnology companies and universities and other research institutions. These companies are developing similar products,
and they have significantly greater capital resources and research and development, manufacturing, testing, regulatory compliance, and
marketing capabilities. Many of these potential competitors may be further along in the process of product development and also operate
large, company-funded research and development programs. As a result, our competitors may develop more competitive or affordable products,
or achieve earlier patent protection or product commercialization than we are able to achieve. Competitive products may render any products
or product candidates that we develop obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have substantially greater financial, technical and other resources than we do, such as larger research and development
staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical
industries may result in even more resources being concentrated in certain of our competitors. As a result, these companies may be able
to obtain regulatory approval more rapidly than we can and may be more effective in selling and marketing their products. Smaller or
early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established
companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability
of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing drug products that are
more effective or less costly to produce or purchase on the market than any product candidate we are currently developing or that we
may seek to develop in the future. If approved, our product candidates will face competition from commercially available drugs as well
as drugs that are in the development pipelines of our competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Established
pharmaceutical companies may invest heavily to accelerate discovery and development of or in-license novel compounds that could make
our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling
advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful.
Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA, EMA or other regulatory approval, or discovering,
developing and commercializing medicines before we do, which would have a material adverse impact on our business and ability to achieve
profitability from future sales of our approved product candidates, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
competitors develop and market products that are more effective, safer or less expensive than our product candidates or offer other advantages,
our commercial prospects will be limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
therapeutic immuno-oncology (IO) development programs face, and will continue to face, intense competition from pharmaceutical, biopharmaceutical
and biotechnology companies, as well as numerous academic and research institutions and governmental agencies engaged in drug discovery
activities or funding, both in the United States and abroad. Some of these competitors are pursuing the development of drugs and other
therapies that target the same diseases and conditions that we are targeting with our product candidates. According to Global Data, Thematic
Research: Immuno-Oncology (March 2021), as of December 2020, there are 4,822 industry-sponsored clinical trials for immuno-oncology with
422 drugs in development. Phase 2 trials constitute the majority of the IO pipeline, followed by early-stage molecules in Phase 1/2 and
Phase 1. For late-stage pipeline products, 484 clinical trials are ongoing in Phase 3, and 51 are in Phase 2/3 development. There are
currently 22 marketed immuno-oncology agents. Cancer vaccine products lead the category with 9 products followed by checkpoint modulators
with 8 approved drugs. The indications with the most marketed IO agents in the United States are metastatic melanoma and non-small cell
lung cancer, with 6 approved products each. The market value of bispecific antibodies, cancer vaccines, checkpoint modulators, cell therapies,
and oncolytic viruses globally has increased sharply in the past 10 years with nearly $29 billion in 2019 compared to $370 million in
2010&#160;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a general matter, we also face competition from many companies that are researching and developing cell therapies. Many of these companies
have financial and other resources substantially greater than ours. In addition, many of these competitors have significantly greater
experience in testing pharmaceutical and other therapeutic products, obtaining FDA and other regulatory approvals, and marketing and
selling. If we obtain regulatory approval for any of our product candidates, we also will be competing with respect to manufacturing
efficiency and marketing capabilities, areas in which we have limited or no commercial-scale experience. Mergers and acquisitions in
the pharmaceutical and biotechnology industries may result in even more resources&#8217; being concentrated by our competitors. Competition
may increase further as a result of advances made in the commercial applicability of our technologies and greater availability of capital
for investment in these fields.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to keep up with rapid technological changes in our field or compete effectively, we will be unable to operate profitably.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are engaged in activities in the biotechnology field, which is characterized by extensive research efforts and rapid technological progress.
If we fail to anticipate or respond adequately to technological developments, our ability to operate profitably could suffer. Research
and discoveries by other biotechnology, pharmaceutical or other companies may render our technologies or potential products or services
uneconomical or result in products superior to those we develop. Similarly, any technologies, products or services we develop may not
be preferred to any existing or newly developed technologies, products or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to obtain third-party patient reimbursement or favorable product pricing, which would reduce our ability to operate profitably.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully commercialize certain of our proposed products in the human therapeutic field may depend to a significant degree
on patient reimbursement of the costs of such products and related treatments at acceptable levels from government authorities, private
health insurers and other organizations, such as health maintenance organizations. Reimbursement in the United States or foreign countries
may not be available for any products we may develop, and, if available, may be decreased in the future. Also, reimbursement amounts
may reduce the demand for, or the price of, our products with a consequent harm to our business. We cannot predict what additional regulation
or legislation relating to the healthcare industry or third-party coverage and reimbursement may be enacted in the future or what effect
such regulation or legislation may have on our business. If additional regulations are overly onerous or expensive, or if healthcare-related
legislation makes our business more expensive or burdensome than originally anticipated, we may be forced to significantly downsize our
business plans or completely abandon our business model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business may bring us into conflict with our licensees, licensors or others with whom we have contractual or other business relationships,
or with our competitors or others whose interests differ from ours. If we are unable to resolve those conflicts on terms that are satisfactory
to all parties, we may become involved in litigation brought by or against us. That litigation is likely to be expensive and may require
a significant amount of management&#8217;s time and attention, at the expense of other aspects of our business. The outcome of litigation
is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities,
or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are exposed to the risk of liability claims, for which we may not have adequate insurance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we participate in the pharmaceutical industry, we may be subject to liability claims by employees, customers, end users and third parties.
We intend to obtain proper insurance, however, there can be no assurance that any liability insurance we purchase will be adequate to
cover claims asserted against us or that we will be able to maintain such insurance in the future. We intend to adopt prudent risk-management
programs to reduce these risks and potential liabilities, however, we have not taken any steps to create these programs and have no estimate
as to the cost or time required to do so and there can be no assurance that such programs, if and when adopted, will fully protect us.
We may not be able to put risk management programs in place, or obtain insurance, if we are unable to retain the necessary expertise
and/or are unsuccessful in raising necessary capital in the future. Our failure to obtain appropriate insurance, or to adopt and implement
effective risk-management programs, as well as any adverse rulings in any legal matters, proceedings and other matters could have a material
adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
and clinical trials are conducted during the development of potential products and other treatments to determine their safety and efficacy
for use by humans. Notwithstanding these efforts, when our treatments are introduced into the marketplace, unanticipated side effects
may become evident. Manufacturing, marketing, selling and testing our product candidates under development or to be acquired or licensed,
entails a risk of product liability claims. We could be subject to product liability claims if our product candidates, processes, or
products under development fail to perform as intended. Even unsuccessful claims could result in the expenditure of funds in litigation
and the diversion of management time and resources, and could damage our reputation and impair the marketability of our product candidates
and processes. While we plan to maintain liability insurance for product liability claims, we may not be able to obtain or maintain such
insurance at a commercially reasonable cost. If a successful claim were made against us, and we lacked insurance or the amount of insurance
were inadequate to cover the costs of defending against or paying such a claim or the damages payable by us, we would experience a material
adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could be subject to product liability lawsuits based on the use of our product candidates in clinical testing or, if obtained, following
marketing approval and commercialization. If product liability lawsuits are brought against us, we may incur substantial liabilities
and may be required to cease clinical testing or limit commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be subject to product liability lawsuits if any product candidate we develop allegedly causes injury or is found to be otherwise
unsuitable for human use during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations
of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and
a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves
against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates,
if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual
outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
    of investigations by regulators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    to defend the related litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    diversion of management&#8217;s time and our resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to trial participants or patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenues from product sales; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims
could prevent or inhibit the clinical testing and commercialization of products we develop. We may wish to obtain additional such insurance
covering studies or trials in other countries should we seek to expand those clinical trials or commence new clinical trials in other
jurisdictions or increase the number of patients in any clinical trials we may pursue. We also may determine that additional types and
amounts of coverage would be desirable at later stages of clinical development of our product candidates or upon commencing commercialization
of any product candidate that obtains required approvals. However, we may not be able to obtain any such additional insurance coverage
when needed on acceptable terms or at all. If we do not obtain or retain sufficient product liability insurance, we could be responsible
for some or all of the financial costs associated with a product liability claim relating to our preclinical and clinical development
activities, in the event that any such claim results in a court judgment or settlement in an amount or of a type that is not covered,
in whole or in part, by any insurance policies we may have or that is in excess of the limits of our insurance coverage. We may not have,
or be able to obtain, sufficient capital to pay any such amounts that may not be covered by our insurance policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third parties to conduct preclinical and clinical trials of our product candidates. If these third parties do not successfully
carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize
our product candidates and our business could be substantially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely, and expect to continue to rely, upon third-party CROs to execute our preclinical and clinical trials and to monitor and manage
data produced by and relating to those trials. However, we may not be able to establish arrangements with CROs when needed or on terms
that are acceptable to us, or at all, which could negatively affect our development efforts with respect to our drug product candidates
and materially harm our business, operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will have only limited control over the activities of the clinical research organization (CRO) we will engage to conduct our clinical
trials. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol,
legal, regulatory and scientific standards, and our reliance on any CRO does not relieve us of our regulatory responsibilities. Based
on our present expectations, we, our CROs and our clinical trial sites are required to comply with good clinical practices (GCPs), for
all our product candidates in clinical development. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors,
principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in
the applicable trial may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform
additional clinical trials before approving a product candidate for marketing, which we may not have sufficient cash or other resources
to support and which would delay our ability to generate revenue from any sales of such product candidate. In addition, our clinical
trials are required to be conducted with product produced in compliance with current good manufacturing practice requirements, or cGMPs.
Our or our CROs&#8217; failure to comply with those regulations may require us to repeat clinical trials, which would also require significant
cash expenditures and delay the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreements
governing relationships with CROs generally provide those CROs with certain rights to terminate a clinical trial under specified circumstances.
If a CRO that we have engaged terminates its relationship with us during the performance of a clinical trial, we would be forced to seek
an engagement with a substitute CRO, which we may not be able to do on a timely basis or on commercially reasonable terms, if at all,
and the applicable trial would experience delays or may not be completed. In addition, our CROs are not our employees, and except for
remedies available to us under any agreements we enter with them, we are unable to control whether or not they devote sufficient time
and resources to our clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or
obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is
compromised due to a failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may
be extended, delayed or terminated and we may not be able to obtain regulatory approval for, or successfully commercialize, the affected
product candidates. As a result, our operations and the commercial prospects for the effected product candidates would be harmed, our
costs could increase and our ability to generate revenues could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
contract with third parties for the supply of product candidates for clinical testing and expect to contract with third parties for the
manufacturing of our product candidates for large-scale testing and commercial supply. This reliance on third parties increases the risk
that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could
delay, prevent or impair our development or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate continuing our engagement of third parties to provide our clinical supply as we advance our product candidates into and through
clinical development, and we depend on third parties to produce and maintain sufficient quantities of material to supply our clinical
trials. If these third parties do not produce and maintain adequate supplies of clinical material, our development efforts could be significantly
delayed, or could incur substantially higher costs. We expect in the future to use third parties for the manufacture of our product candidates
for clinical testing, as well as for commercial manufacture. We plan to enter into long-term supply agreements with several manufacturers
for commercial supplies. We may be unable to reach agreement on satisfactory terms with contract manufacturers to manufacture our product
candidates. Additionally, the facilities to manufacture our product candidates must be the subject of a satisfactory inspection before
the FDA or other regulatory authorities approve a marketing authorization for the product candidate manufactured at that facility. We
will depend on these third-party manufacturers for compliance with the FDA&#8217;s and international regulatory authority requirements
for the manufacture of our finished products. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturers for compliance with cGMPs. If our manufacturers cannot successfully manufacture material that conforms to our specifications
and the FDA and other regulatory authorities&#8217; cGMP requirements, they will not be able to secure and/or maintain regulatory approval
for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate
quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve
these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find
alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market
our product candidates, if approved, and may subject us to recalls or enforcement action for products already on the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished
product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable
of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely
be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source
of supply for our product candidates and to have any such new source approved by the FDA or any other relevant regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have no marketing and sales force. If we are unable to establish effective marketing and sales capabilities or enter into agreements
with third parties to market and sell our product candidates, we may not be able to effectively market and sell our product candidates,
if approved, or generate product revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are able
to obtain regulatory approval. To commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales,
distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and
we may not be successful in doing so. If our product candidates receive regulatory approval, we intend to establish an internal sales
and marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will
be expensive and time consuming and will require significant attention of our executive officers to manage. Any failure or delay in the
development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our
products that we obtain approval to market. With respect to the commercialization of all or certain of our product candidates, we may
choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established
distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution
systems. If we are unable to enter into such arrangements when needed on acceptable terms or at all, we may not be able to successfully
commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations.
If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third
parties, our future product revenue will suffer and we may incur significant additional losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations would suffer in the event of system failures.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While
we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial
data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and we may incur
substantial costs to attempt to recover or reproduce the data. If any disruption or security breach resulted in a loss of or damage to
our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and/or the
further development of our product candidates could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operations are vulnerable to interruption by natural disasters, power loss, terrorist activity and other events beyond our control, the
occurrence of which could materially harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Businesses
located in California have, in the past, been subject to electrical blackouts as a result of a shortage of available electrical power,
and any future blackouts could disrupt our operations. We are vulnerable to a major earthquake, wildfire and other natural disasters,
and we have not undertaken a systematic analysis of the potential consequences to our business as a result of any such natural disaster
and do not have an applicable recovery plan in place. We do not carry any business interruption insurance that would compensate us for
actual losses from interruption of our business that may occur, and any losses or damages incurred by us could cause our business to
materially suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Epidemic
or pandemic outbreaks such as COVID-19 (coronavirus), natural disasters, whether or not caused by climate change, unusual weather conditions,
terrorist acts and political events, could disrupt business and result in halting our clinical trials and otherwise adversely affect
our financial performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of one or more natural disasters, such as tornadoes, hurricanes, fires, floods and earthquakes, unusual weather conditions,
epidemic outbreaks, terrorist attacks or disruptive political events in certain regions where our operations are located could adversely
affect our business. Epidemic or pandemic outbreaks, such as COVID-19 (coronavirus) could impact our management and our ability to conduct
clinical trials. This also may affect the market conditions that would limit our ability to raise additional capital. This could have
a sustained material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
has been a limited public market for our common stock</i></b>&#160;<b><i>, and we do not know whether one will develop to provide you
adequate liquidity. Furthermore, the trading price for our common stock, should an active trading market develop, may be volatile and
could be subject to wide fluctuations in per-share price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed for trading on the Nasdaq Capital Market under the trading symbol &#8220;GTBP&#8221;; historically, however, there
has been a limited public market for our common stock. We cannot assure you that an active trading market for our common stock will develop
or be sustained. The liquidity of any market for the shares of our common stock will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    operating performance and financial condition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market for similar securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent of coverage of us by securities or industry analysts; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    interest of securities dealers in making a market in the shares of our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if an active trading market develops, the market price for our common stock may be highly volatile and could be subject to wide fluctuations.
In addition, the price of shares of our common stock could decline significantly if our future operating results fail to meet or exceed
the expectations of market analysts and investors and actual or anticipated variations in our quarterly operating results could negatively
affect our share price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
factors may also contribute to volatility of the price of our common stock and could subject our common stock to wide fluctuations. These
include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    in the financial markets and worldwide or regional economies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of innovations or new products or services by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by the government relating to regulations that govern our industry;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    sales of our common stock or other securities in the open market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in interest rates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market valuations of other comparable companies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to maintain compliance with
the continued listing requirements of The Nasdaq Capital Market.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our common stock is listed on The Nasdaq Capital Market. In order to maintain
that listing, we must satisfy minimum financial and other requirements including, without limitation, a requirement that our closing bid
price be at least $1.00 per share. On February 22, 2023, we <span style="background-color: white">received a deficiency letter from The
Nasdaq Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying us
that, for the last 30 consecutive business days, the closing bid price for our common stock had been below the minimum $1.00 per share
required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (&#8220;Rule 5550(a)(2)&#8221;).
The Nasdaq deficiency letter had no immediate effect on the listing of our common stock</span>. <span style="background-color: white">In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been given 180 calendar days, or until August 21, 2023, to regain compliance
with Rule 5550(a)(2). If at any time before August 21, 2023, the bid price of our common stock closes at $1.00 per share or more for a
minimum of 10 consecutive business days, the Staff will provide written confirmation that we have achieved compliance and the matter will
be closed. If we do not regain compliance with Rule 5550(a)(2) by August 21, 2023, we may be afforded a second 180 calendar day period
to regain compliance. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares
and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, we would
be required to provide written notice to Nasdaq of our intent to cure the deficiency during the second compliance period. </span>If we
fail to continue to meet all applicable continued listing requirements for The Nasdaq Capital Market in the future and Nasdaq determines
to delist our common stock, the delisting could adversely affect the market liquidity of our common stock, and our ability to obtain financing
to repay debt and fund our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
outstanding warrants may affect the market price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, we had approximately 32.7 million shares of common stock issued and outstanding and warrants outstanding for the
purchase of up to 2,337,274 additional shares of common stock at an average exercise price of $5.30 per share, all of which are exercisable
as of the date of this Annual Report (subject to certain beneficial ownership limitations). The amount of common stock reserved for issuance
may have an adverse impact on our ability to raise capital and may affect the price and liquidity of our common stock in the public market.
In addition, the issuance of these shares of common stock will have a dilutive effect on current stockholders&#8217; ownership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
our common stock may be deemed a &#8220;penny&#8221; stock, an investment in our common stock should be considered high-risk and subject
to marketability restrictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the trading price of our common stock has been $5.00 per share or lower, and deemed a penny stock, as defined in Rule 3a51-1 under the
Exchange Act, and subject to the penny stock rules of the Exchange Act specified in rules 15g-1 through 15g-10. Those rules require broker&#8211;dealers,
before effecting transactions in any penny stock, to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deliver
    to the customer, and obtain a written receipt for, a disclosure document;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
    certain price information about the stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
    the amount of compensation received by the broker&#8211;dealer or any associated person of the broker&#8211;dealer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">send
    monthly statements to customers with market and price information about the penny stock; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    some circumstances, approve the purchaser&#8217;s account under certain standards and deliver written statements to the customer
    with information specified in the rules.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consequently,
the penny stock rules may restrict the ability or willingness of broker&#8211;dealers to sell the common stock and may affect the ability
of holders to sell their common stock in the secondary market and the price at which such holders can sell any such securities. These
additional procedures could also limit our ability to raise additional capital</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
Industry Regulatory Authority (&#8220;FINRA&#8221;) sales practice requirements may also limit a stockholder&#8217;s ability to buy and
sell our common stock, which could depress the price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the &#8220;penny stock&#8221; rules described above, FINRA has adopted rules that require a broker-dealer to have reasonable
grounds for believing that the investment is suitable for that customer before recommending an investment to a customer. Prior to recommending
speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information
about the customer&#8217;s financial status, tax status, investment objectives and other information. Under interpretations of these
rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some
customers. Thus, the FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock,
which may limit your ability to buy and sell our shares of common stock, have an adverse effect on the market for our shares of common
stock, and thereby depress our price per share of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion
regarding our stock, our stock price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock may be influenced by the research and reports that industry or securities analysts publish about
us or our business. We currently have research coverage by one securities analyst, and we may never obtain research coverage by additional
analysts. If no or few securities or industry analysts commence coverage of us, the trading price for our common stock may be negatively
affected. In the event that we receive additional securities or industry analyst coverage, if any of the analysts who cover us issue
an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our operating
results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage
of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock
price or trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions may limit the ability of another party to acquire us, which could cause our stock price to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware
law and our charter, bylaws, and other governing documents contain provisions that could discourage, delay or prevent a third party from
acquiring us, even if doing so may be beneficial to our stockholders, which could cause our stock price to decline. In addition, these
provisions could limit the price investors would be willing to pay in the future for shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not currently or for the foreseeable future intend to pay dividends on our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable
future. As a result, any return on your investment in our common stock will be limited to the appreciation in the price of our common
stock, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_004"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_005"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the date of the issuance of this Annual Report, we sublease offices comprising of 4,500 rentable square feet at 8000 Marina Blvd, Suite
100, Brisbane, CA 94005 under a sublease that expires on June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_006"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2023, the Company received a demand letter from an attorney representing
an alleged holder of a convertible note which alleges that the Company did not deliver shares of common stock that were due on conversion
in 2022. The demand letter contends that the Company is liable for per diem liquidated damages. The Company has denied liability and will
defend any such claim vigorously if asserted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 13, 2022, the Company made a claim against Michael Handelman, its former Chief Financial Officer, asserting that he misappropriated
Company funds and shares of common stock, and failed to file the required SEC reports on Form 3 and Form 4 regarding each acquisition
and disposition of the Company&#8217;s common stock. The Company seeks monetary damages estimated at $370,000; the return of shares of
our common stock received without authorization and the disgorgement of any profits earned from the sale of those shares; a full accounting
for all sums charged on the Company&#8217;s debit card, with payment to the Company for any charges that cannot be demonstrated to have
a corporate purpose; an order directing Mr. Handelman to make all filings required by Section 16(a) of the 1934 Act; an award of all
sums and shares improperly issued to members of Mr. Handelman&#8217;s family; and an award of the Company&#8217;s attorneys&#8217; fees
and any forum and arbitration fees. As a component of Mr. Handelman&#8217;s contract with the Company, disputes shall be fully addressed
and finally resolved by binding arbitration conducted by the American Arbitration Association (AAA) in New York City, New York, in accordance
with its National Employment Dispute Resolution rules. In connection with any such arbitration, the Company shall bear all costs not
otherwise borne by a plaintiff in a court proceeding. The Company agrees that any decisions of the arbitration panel will be binding
and enforceable in any state in which the Company conducts the operation of its business. In accordance with California Labor Laws, the
Company has designated Los Angeles, California as the venue for this arbitration. The Company is waiting to receive a hearing date from
AAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 3, 2021, a complaint was filed by Sheffield Properties in the
superior Court of California. County of Ventura. The litigation arose from a commercial lease entered into by GT Biopharma for office
space in Westlake Village. In July, 2021 we entered into settlement agreement with Sheffield Properties in the amount of $100,000 that
was paid in full on August 6, 2021.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28, 2019, a complaint was filed in the Superior Court of California, County of Los Angeles, West Judicial District, Santa Monica
Courthouse, Unlimited Civil Division by Jeffrey Lion and by Daniel Vallera, as individuals. The complaint was filed against GT Biopharma,
Inc. and its subsidiary Oxis Biotech, Inc. The Plaintiffs allege breach of a license agreement between the Plaintiffs and the Company
entered into on or about September 3, 2015. The Company filed an answer to the complaint denying many allegations and asserting affirmative
defenses. The Company reached a settlement of the case and paid on March 4, 2022, $425,000 in full and final settlement of the claims.
This amount was fully accrued at December 31, 2021 and paid on March 4, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_007"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_008"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_009"></span>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on the Nasdaq Capital Market under the trading symbol &#8220;GTBP.&#8221; Until May 2009, our common stock was
traded on the OTC Bulletin Board (&#8220;OTCBB&#8221;) under the symbol &#8220;OXIS.&#8221; From May 20, 2009 until March 11, 2010, our
common stock was traded on Pink OTC Markets Inc. trading platform under the symbol &#8220;OXIS.&#8221; From January 2015 to August 2017,
our common stock was quoted on the OTCQB under the &#8220;OXIS&#8221; trading symbol. From August 2017 to February 11, 2021, our common
stock was quoted on the OTCQB under the &#8220;GTBP&#8221; trading symbol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is also quoted on several European based exchanges including Berlin (GTBP.BE), Frankfurt (GTBP.DE), the Euronext (GTBP.NX)
and Paris, (GTBP.PA). The foregoing trading prices exclude trading on these foreign stock markets.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 30, 2023, there were 46 stockholders of record, which total does not include stockholders who hold their shares in &#8220;street
name.&#8221; The transfer agent for our common stock is ComputerShare, whose address is 8742 Lucent Blvd., Suite 225, Highland Ranch,
CO 80129.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any dividends on our common stock to date and do not anticipate that we will pay dividends in the foreseeable future. Any
payment of cash dividends on our common stock in the future will be dependent upon the amount of funds legally available, our earnings,
if any, our financial condition, our anticipated capital requirements and other factors that the Board of Directors may think are relevant.
However, we currently intend for the foreseeable future to follow a policy of retaining all of our earnings, if any, to finance the development
and expansion of our business and, therefore, do not expect to pay any dividends on our common stock in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2023 Annual Meeting
of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Issuances </b>&#160;<b>of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company made the following issuances of its unregistered securities
pursuant exemptions contained in Section 4(a)(2) or 3(a)(9) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder
during the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company issued 526,857 shares of common stock in accordance with various consulting agreements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company issued 1,222,281 shares of common stock in settlement of vendors payables.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company issued 337,702 shares of common stock upon conversion of notes payable.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchases of Equity Securities</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not repurchase any shares during the fourth quarter of the fiscal year covered by this Annual Report on Form 10-K.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_010"></span>ITEM
6. [RESERVED]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_011"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Some of the statements
in this Annual Report on Form 10-K are &#8220;forward-looking statements&#8221; within the meaning of the safe harbor from liability
established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our current
beliefs, goals and expectations about matters such as our expected financial position and operating results, our business strategy and
our financing plans. The forward-looking statements in this report are not based on historical facts, but rather reflect the current
expectations of our management concerning future results and events. The forward-looking statements generally can be identified by the
use of terms such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;foresee,&#8221; &#8220;may,&#8221; &#8220;guidance,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;outlook,&#8221;
&#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;likely&#8221; or other similar words or phrases. Similarly, statements that describe
our objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results,
performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will turn
out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations
for various reasons. You should carefully review all information, including the discussion of risk factors under &#8220;Part I. Item
1A: Risk Factors&#8221; and elsewhere in this annual report. Any forward-looking statements in the Form 10-K are made only as of the
date hereof and, except as may be required by law, we do not have any obligation to publicly update any forward-looking statements contained
in this Form 10-K to reflect subsequent events or circumstances.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based
off our proprietary Tri-specific Killer Engager (TriKE<sup>&#174;</sup>) technology platform. Our TriKE<sup>&#174;</sup> platform generates
proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer cells,
or NK cells. Once bound to an NK cell, our moieties are designed to enhance the NK cell, and precisely direct it to one or more specifically-targeted
proteins expressed on a specific type of cancer cell or virus infected cell, ultimately resulting in the targeted cell&#8217;s death.
TriKE<sup>&#174;</sup> is composed of recombinant fusion proteins and interleukin 15 (IL-15), can be designed to target any number of
tumor antigens on hematologic malignancies, sarcomas or solid tumors and do not require patient-specific customization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
shown in the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $674.5 million as of
December 31, 2022. On a consolidated basis, the Company had cash and cash equivalents of $5.7 million and short-term investments of $10.8
million at December 31, 2022. We anticipate we will have to raise additional capital to fund our selling, general and administrative,
and research and development expenses until we have a marketable product. There are no assurances that we will be able to raise the funds
necessary to maintain our operations or to implement our business plan. The consolidated financial statements included in this Annual
Report on Form 10-K do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts
and classification of liabilities that might be necessary in the event we cannot continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">COVID-19</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has
continued to spread, has adversely affected workforces, customers, economies, and financial markets globally. It has also disrupted the
normal operations of many businesses. This outbreak could decrease spending, adversely affect demand for the Company&#8217;s products,
and harm the Company&#8217;s business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company believes the COVID-19 pandemic did impact its operating results. However, the Company has
not observed any impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic. At this
time, it is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects
on the Company&#8217;s business or results of operations, financial condition, or liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has been following the recommendations of health authorities to minimize exposure risk for its team members, including the temporary
closure of its corporate office and having team members work remotely. Most vendors have transitioned to electronic submission of invoices
and payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2022, the Company appointed Manu Ohri as our Chief Financial Officer and Dr. Gavin Choy ceased serving as the Acting Chief
Financial Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 2, 2022, the Company appointed Michael Breen as Interim Chief Executive Officer. Dr. Berk ceased serving as the Company&#8217;s
Interim Chief Executive Officer, but continued to serve as its President of Research &amp; Development and Chief Medical Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 9, 2022, Alan Urban joined as a member of the Company&#8217;s Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 8, 2022, Dr. Berk&#8217;s employment was terminated as the President of Research &amp; Development and Chief Medical Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 14, 2022, the Company appointed Dr. Jeffrey Miller as our consulting Chief Medical Officer and consulting Chief Scientific Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Issuance
of common stock in public offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Company completed a public offering of 4,945,000 shares of common stock for net proceeds of $24.7 million, after
deducting underwriting discounts, commissions and other direct offering expenses. As part of the offering, the Company also granted these
investors, warrants to purchase 5,192,250 shares of common stock. The warrants are fully vested, exercisable at $5.50 per share and will
expire in five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the completion of the public offering and the successful listing of its shares of common stock on the Nasdaq Capital Market,
convertible notes with an aggregate principal amount of $33.3 million and accrued interest of $5.5 million, for a total of $38.8 million,
were mandatorily converted at its stated conversion rate of $3.40 per share into 11,413,322 shares of the Company&#8217;s common stock.
The Company issued 11,086,024 shares of common stock to the note holders while the remaining 327,298 common shares, valued at $1.1 million,
were issuable at December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued the remaining 327,298 common shares. In addition, the Company also issued an additional
10,404 shares of commons stock with a fair value of $35,000 as settlement to a noteholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Cancellation
of common stock previously issued for services</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company cancelled 290,999 previously issued shares of common stock during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Issuance
of common stock as equity compensation to officers, employees and board of directors</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of employment agreements with its former CEO and its former CFO (&#8220;Officers&#8221;), the Officers received a fully vested stock
grant equal to an aggregate of 10% and 1.5% of the fully diluted shares of common stock of the Company (calculated with the inclusion
of the current stock holdings of the CEO) upon conversion of options, warrants and Convertible Notes in association with a national markets
qualified financing as consideration for entering into the Agreement (with such stock to vest and be delivered within 30 days after the
national markets qualified financing). In addition, the Company also granted similar equity compensation to members of the Company&#8217;s
board of directors wherein these directors received stock grants equal to 1% and 1.25% of the fully diluted shares of common stock of
the Company. Pursuant to the agreement, approximately 33% of the common stock to be issued vested immediately while the remaining 67%
vests over a period of two years. The Company has disputed the grants received by both executives. The disputes with the CEO were later resolved in a settlement. The disputes
with the CFO are subject to a pending arbitration, which includes a challenge to the validity of his employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Company completed its equity offering and listed its shares of common stock on the Nasdaq Capital Market. As such,
4,379,407 shares of its common stock were granted to these Officers, employees and directors, which had a fair value of $18.6 million.
Since the grant of the common stock is subject to milestone or performance conditions, the Company measured the fair value of the common
stock on the respective date of the agreement, and such awards were recorded as compensation expense as the milestone or performance
condition was met and in accordance with its vesting terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, the Company granted 378,058 shares of fully vested common stock with a fair value of $938,000 to certain officers of the Company
for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022,the Company issued 709,523 shares of common stock and recognized stock compensation expense of $2,522,000
to account the fair value of common stock that vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there were 44,818 unvested shares of common stock issued to officers, employees and directors with a fair value
of $206,035 that will be recognized as stock compensation expense in future periods pursuant to its vesting term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued 3,774,967 shares of common stock and recognized stock compensation expense of $16,983,000
to account the fair value of common stock that vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Equity
compensation to consultants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of consulting agreements with certain consultants, the Company agreed to grant these consultants common stock equal to 1% and 3%
of the fully diluted shares of common stock of the Company upon conversion of options, warrants and Convertible Notes in association
with a national markets qualified financing as consideration for entering into the Agreement (with such stock to vest and be delivered
within 30 days after the national markets qualified financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Company completed its equity offering and listed its shares of common stock on the Nasdaq Capital Market. As a
result of this offering, the Company agreed to issue to these consultants 2,850,090 shares of common stock with a grant date fair value
of $10.7 million, of which 1,934,817 shares of common stock vested immediately while the remaining 915,273, shares of common stock vests
over two years. Pursuant to current accounting guidelines, as the grant of the common stock is subject to milestone or performance conditions,
the Company measured the fair value of the common stock on the respective date of the agreement, and then such award is being recorded
as compensation expense based upon the vesting term of the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
January 2021 to June 2021, the Company granted a total of 1,275,032 shares of common stock with a fair value of $7,119,000 to consultants
for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, the Company granted 20,882 shares of fully vested common stock with a fair value of $51,787 to R&amp;D consultants for services
rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued 526,857 shares of common stock and recognized stock compensation expense of $2,092,000
to account the fair value of common stock that vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there were 46,343 unvested shares of common stock issued to consultants with a fair value of $162,664 that will
be recognized as stock compensation expense in future periods based upon their vesting term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued 3,082,406 shares of common stock and recognized stock compensation expense of $15,340,000
to account the fair value of common stock that vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Cancellation
of common stock upon settlement with a former Officer</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2022, the Company entered into a settlement agreement with its former Chief Executive Officer (&#8220;Officer&#8221;) and received
1,845,000 shares of its previously issued common stock in full and final settlement of all its claims against the Officer. The common
stock was subsequently cancelled and returned to treasury. In addition, the Company incurred legal and professional expenses of $224,243.
The legal and professional fees incurred were accounted as costs of the acquisition of the common stock and recorded as a reduction to
additional paid in capital. Both the Company and the Officer released each other from claims under the settlement agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>TriKE<sup>&#174;
</sup>Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2017, we entered into a co-development partnership agreement with Altor BioScience Corporation in which we will collaborate exclusively
in the clinical development of a novel 161533 (GTB-3550) TriKE<sup>&#174;</sup> fusion protein for cancer therapies using our TriKE<sup>&#174;
</sup>technology. The GTB-3550 Phase 1 clinical trial for treatment of patients with CD33-expressing, high risk myelodysplastic syndromes
and refractory/relapsed acute myeloid leukemia opened for patient enrollment September 2019 and completed enrollment in September 2021.
The results of our first generation GTB-3550 Phase 1 clinical trial support our plans to advance the next generation camelid nanobody
into the clinic, and as such, no further clinical development will ensue with GTB-3550.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>University
of Minnesota Scientific Research Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to a scientific research agreement with the Regents of the University of Minnesota, effective June 16, 2021. This scientific
research agreement aims to work with the Company with three major goals in mind: (1) support the Company&#8217;s TriKE<sup>&#174;</sup>
product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans; and, (3) investigation
of the patient&#8217;s native NK cell population based on insights obtained from the analysis of the human data generated during our
GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for TriKE<sup>&#174;</sup> constructs
in support of our product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> platform drug delivery changes to allow
transition to alternative drug delivery means and extended PK in humans; and, (3) gain an increased understanding of changes in the patient&#8217;s
native NK cell population as a result of TriKE<sup>&#174; </sup>therapy. Most studies will use TriKE<sup>&#174;</sup> DNA/amino acid sequences
created by us under current UMN/GTB licensing terms. The term of this agreement shall expire on June 30, 2023. The University of Minnesota
shall use reasonable efforts to complete the project for a fixed sum of $2.1 million, of which $1.7 million has been incurred and recorded
as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subcontract
Manufacturing Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development
and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work
(&#8220;SOWs&#8221;) for the research and development of products for use in clinical trials. On August 24, 2022, the Company entered
into a revised agreement with this third-party manufacturer and issued 1,222,281 shares of common stock with a fair value of $3.2 million
as part of a payment arrangement. The shares were valued at $2.66 per share based on the closing price of the Company&#8217;s common
stock on the date of the agreement. As part of the revised agreement, the Company paid to this third-party manufacturer $3.3 million
in cash on specified dates. In addition, the Company and the third-party manufacturer agreed that services to be rendered in future periods,
as specified in the agreement, will be paid or settled at the Company&#8217;s discretion, in a combination of cash and issuance of the
Company&#8217;s common stock. The agreement also amended certain agreements executed in prior years which eliminated future financial
commitments of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SOWs agreements totaled approximately $13.0 million, of which $7.5 million was incurred at that date and an additional $5.5 million
is in process. The Company was indebted $2.3 million to this third- party manufacturer as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trial Agreement </i>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, we executed clinical trial agreement with the Regents of the University of Minnesota, to commence enrollment in its first-in-human
GTB-3550 TriKE<sup>&#174;</sup> (CD16/IL-15/CD33) Phase 1, open-label, dose escalation clinical trial for the treatment of CD33-expressing,
high risk myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis. The clinical trial
was conducted at the University of Minnesota&#8217;s Masonic Cancer Center in Minneapolis, Minnesota under the direction of Dr. Erica
Warlick and Dr. Mark Juckett. The primary objective of the trial was to determine safety and tolerability as well as the maximum tolerated
dose of GTB-3550 TriKE<sup>&#174;</sup>. The hypothesis was that GTB-3550 TriKE<sup>&#174; </sup>would induce natural killer cell function
by targeting malignant cells as well as CD33+ myeloid derived suppressor cells (MDSC) which contribute to tumor induced immunosuppression.
Because CD16 is a potent activating receptor on NK cells, this single agent GTB-3550 investigational agent may induce a targeted anti-CD33+
tumor response. The phase 1 trial was completed in September 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
discussion of Patents and Licenses above under Item 1: Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Years Ended December 31, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2022 and 2021, we incurred $8.8 and $9.6 million of research and development expenses, respectively. Research
and development expenses related to our continued development and production of our most advanced TriKE&#174; product candidates GTB-3650
and GTB-5550 along with the progression on other promising product candidates, decreased over the previous year by approximately $780,000
primarily due to reduction in stock compensation to employees and consultants. We anticipate our direct clinical and preclinical expenses
to increase significantly in 2023 as we plan to advance our next generation GTB-3650
camelid nanobody product into the clinic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling,
general and administrative expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2022 and 2021, we incurred $12.4 million and $47.9 million of selling, general and administrative
expenses, respectively. The decrease in selling, general and administrative expenses is primarily attributable to reduction in
payroll and stock compensation expenses of approximately $27.0 million, reduction in marketing, promotion and investor relations expense of $3.6 million, reduction in travel expense of $484,000, and reduction in legal, professional and advisory board fees of $1.2 million
for the year ended December 31, 2022 as compared to 2021.
The Company managed to reduce expenses by better managing and controlling its payroll costs, legal and consulting expenses in 2022.
During 2021, we incurred expenses that consisted primarily of personnel costs from our executive, legal, finance, and information
technology organizations and related expenditures, as well as third party professional fees and insurance for the uplisting of our
common shares on NASDAQ. Furthermore, the increase was due to the expenses incurred in support of our planned growth and new public
company compliance initiatives in fiscal year 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income/Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income was $292,000 and $38,000 for the years ended December 31, 2022 and 2021, respectively. Interest income increased primarily due
to the interest earned on short-term investments due to higher interest rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded interest expense of $8,000 and $718,000 for the years ended December 31, 2022 and 2021, respectively. The decrease in interest
expense was due to the conversion of convertible notes payable to common shares during 2021. We did not have any outstanding convertible
notes payable as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of derivative liability was due to fair value remeasurement which resulted in a gain of $119,000 and $211,000 for
the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
unrealized loss on marketable securities was due to fair value remeasurement of our marketable securities which resulted in a loss of
$30,000 and $29,000 for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current operations have focused on business planning, raising capital, establishing an intellectual property
portfolio, hiring, and conducting preclinical studies and clinical trials. The Company does not have any product candidates approved
for sale and has not generated any revenue from product sales. The Company has sustained operating losses since inception and
expects such losses to continue over the foreseeable future. On January 4, 2023, the Company raised $6.5 million from an
institutional investor by selling 3.6 million shares of common stock, and pre-funded warrants to purchase up to 2.9 million shares
of common stock. During 2021, the Company raised $24.7 million through issuance of common stock, raised $16.4 million through the
exercise of warrants and raised $1.2 million from a series of issuances of convertible notes. The Company reported $16.5 million of
cash and short-term investments at December 31, 2022 and raised an additional $6.5 million on January 4, 2023. We anticipate that we
will need cash of approximately $15.0 million for the next twelve months for selling, general and administrative expenses and
research and development expenses. We expect the cash and short-term investments totaling $23.0 million will be sufficient to fund
operations for the following 12 months, and anticipates raising additional funds when the Company embarks on Phase 1
trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared on a going-concern basis, which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of business. Accordingly, the financial statements do not include any adjustments
that might be necessary should the Company be unable to continue in existence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred substantial losses since inception to December 31, 2022. The Company anticipates incurring additional losses until
such time, it can generate significant sales or revenue from out-licensing of its products currently in development. Substantial additional
financing will be needed by the Company to fund its operations and to commercially develop its product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include but are
not limited to public offerings of equity and/or debt securities; and payments from potential strategic research and development, licensing
and/or marketing arrangements with other pharmaceutical companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider the following accounting policies to be critical given they involve estimates and judgments made by management and are important
for our investors&#8217; understanding of our operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Basis
of Presentation and Principles of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries,
Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. Intercompany transactions and balances have been eliminated in
consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Accounting
Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates. Significant estimates include accruals for potential liabilities, assumptions used in deriving the
fair value of derivative liabilities, share-based compensation and valuation of deferred tax assets. Actual results could differ from
those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based awards to employees and nonemployees and consultants in accordance with the provisions of Accounting
Standards Codification 718, <i>Compensation-Stock Compensation</i>. Stock-based compensation cost is measured at fair value on the grant
date and that fair value is recognized as expense over the requisite service, or vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. Use of the
Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free
interest rate. The Company estimates volatility using its own historical stock price volatility. The expected term of the instrument
is estimated by using the simplified method to estimate expected term. The risk-free interest rate is estimated using comparable published
federal funds rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that inflation has not had a material adverse impact on our business or operating results during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_012"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
company qualifies as a smaller reporting company, as defined in 17 C.F.R. &#167;229.10(f) (1) and is not required to provide information
by this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_013"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see the consolidated financial statements beginning on page F-1 located in Part IV of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_014"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_015"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive officer and principal financial officer evaluated the effectiveness of our &#8220;disclosure controls and procedures&#8221;
(as such term is defined in Rules 13a-15(e) and 15d-15(e) of the United States Securities Exchange Act of 1934, as amended), as of December
31, 2022. Based on that evaluation, we have concluded that our disclosure controls and procedures were effective as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Previously
Reported Material Weaknesses in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, we identified material weaknesses in the
Control Environment and Risk Assessment components as set forth by the committee of Sponsoring Organizations of the Treadway Commission
(COSO) in Internal Control Integrated Framework.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
2022, we commenced a remediation plan with the goal of remediating the material weaknesses. In carrying out the remediation plan,
management modified existing key controls at a sufficient level of precision to identify, discuss, and address any segregation of
duties and reliance on outside consultants issues, risk of executive override and insufficient written policies and procedures for
accounting and financial reporting for the requirements and application of GAAP and SEC Guidelines. During the fourth quarter of
2022, we completed our testing of these control matrices and evaluated the effectiveness of the Company&#8217;s internal control
over financial reporting using the criteria set forth by the COSO framework. Based upon our evaluation, we concluded that our internal controls over financial reporting are operating effectively
with a significant level of precision, and that the material weaknesses reported as of December 31, 2021 were fully remediated as of December
31, 2022. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting
is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by,
or under the supervision of, a company&#8217;s principal executive and principal accounting officers and effected by a company&#8217;s
board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles
and includes those policies and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertain to the maintenance of records that in reasonable detail accurately
and fairly reflect the transactions and dispositions of the assets of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Provide
reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in
accordance with authorizations of management and directors of the company; and</p>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the consolidated financial
statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our
company have been detected. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect
to financial statement preparation and presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, our management, including our interim Chief Executive Officer and Chief Financial Officer conducted an assessment
of the effectiveness of the Company&#8217;s internal control over financial reporting. In making this assessment, we used the criteria
set forth by the COSO framework. Based upon our evaluation, we concluded that our internal controls over financial reporting were operating
effectively with a significant level of precision as of December 31, 2022. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Attestation
Report on Internal Control over Financial Reporting</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm, due to the deferral
allowed under the Jobs Act for small reporting companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than with respect to the remediation efforts discussed above, &#160;there was no change in our internal control over financial reporting
that occurred during the period covered by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting. Although we have altered some work routines due to the COVID-19 pandemic, the
changes in our work environment, including remote work arrangements, have not materially impacted our internal controls over financial
reporting and have not adversely affected the Company&#8217;s ability to maintain operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_016"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_017"></span>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_018"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_019"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information responsive to this item is incorporated herein by reference
to our definitive proxy statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after
the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_020"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2023 Annual Meeting
of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_021"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information responsive to this item is incorporated herein by reference
to our definitive proxy statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after
the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_022"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information responsive to this item is incorporated herein by reference
to our definitive proxy statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after
the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_023"></span>ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information responsive to this item is incorporated herein by reference
to our definitive proxy statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after
the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_024"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_025"></span>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements and related notes thereto are listed and included in this Annual Report beginning on
page F-1. The following documents are furnished as exhibits to this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated
    by Reference</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.25in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Herewith</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000103221002000530/dex3a.txt" style="-sec-extract: exhibit">Restated Certificate of Incorporation as filed in Delaware September 10, 1996 and as thereafter amended through March 1, 2002</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-KSB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/01/2002</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000151316011000020/ex32.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., dated February 9, 2011</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2011
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418002596/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of July 19, 2017</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/15/2018
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001479/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of February 10, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/11/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-5.htm">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective June 13, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">3.6</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222031139/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of GT Biopharma, Inc., effective November 3, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">11/09/2022</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979819000017/exhibitthreeone.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series J-1 Preferred Stock of GT Biopharma, Inc., dated April 3, 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/04/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/gtbp_ex42.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series K Preferred Stock of GT Biopharma, Inc., dated April 3, 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/16/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0">4.3</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0"><a href="ex4-3.htm">Description of the Registrant&#8217;s Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as Amended</a></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">X</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495417007377/oxis_ex103.htm" style="-sec-extract: exhibit">Exclusive License Agreement, dated July 18, 2016, between the Regents of the University of Minnesota and Oxis Biotech, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/11/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495417007377/oxis_ex104.htm" style="-sec-extract: exhibit">License Agreement, dated September 3, 2015, among Daniel A. Vallera, Jeffrey Lion and Oxis Biotech, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/11/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420005654/gtbp_ex107.htm" style="-sec-extract: exhibit">Clinical Trial Agreement, dated September 2019, between the Regents of the University of Minnesota and GT Biopharma, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/15/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-5.htm" style="-sec-extract: exhibit">Note Conversion Agreement, dated as of August 29, 2017, among GT Biopharma, Inc. and the holders of the convertible notes and debentures named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-8.htm" style="-sec-extract: exhibit">Amendment Agreement related to Note Conversion Agreement, dated October 10, 2017, among GT Biopharma, Inc. and the holders of the convertible notes and debentures named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-6.htm" style="-sec-extract: exhibit">Warrant Exercise Agreement, dated August 29, 2017, among GT Biopharma, Inc. and the warrant holders named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-9.htm" style="-sec-extract: exhibit">Amendment Agreement related to Warrant Exercise Agreement, dated October 10, 2017, among GT Biopharma, Inc. and the warrant holders named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-7.htm" style="-sec-extract: exhibit">Preferred Stock Exchange Agreement, dated as of August 29, 2017, among GT Biopharma, Inc. and the holders of preferred stock named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-10.htm" style="-sec-extract: exhibit">Amendment Agreement related to Preferred Stock Exchange Agreement, dated October 10, 2017, among GT Biopharma, Inc. and the holders of preferred stock named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979817000002/securitiespurchaseagree.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated January 9, 2017, among OXIS International, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/13/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979817000002/debenture.htm" style="-sec-extract: exhibit">Form of 10% Senior Convertible Debenture (related to Securities Purchase Agreement, dated January 9, 2017)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/13/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979817000002/warrant.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant (related to Securities Purchase Agreement, dated January 9, 2017)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/13/2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418000646/gtbp_ex101.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated January 22, 2018, among GT Biopharma, Inc. and the buyers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/23/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418000646/gtbp_ex102.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated January 22, 2018, among GT Biopharma, Inc. and the buyers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/23/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418000646/gtbp_ex103.htm" style="-sec-extract: exhibit">Form of Senior Convertible Note (related to Securities Purchase Agreement, dated January 22, 2018)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/23/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418000646/gtbp_ex104.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase Common Stock (related to Securities Purchase Agreement, dated January 22, 2018)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/23/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418008406/gtbp_ex101.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated August 2, 2018, among GT Biopharma, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/03/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418008406/gtbpex4_1.htm" style="-sec-extract: exhibit">Form of 10% Senior Convertible Debenture (related to Securities Purchase Agreement, dated August 2, 2018)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/03/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418009126/gtbp_ex1010.htm" style="-sec-extract: exhibit">Stock Pledge Agreement, dated August 2, 2018, by the Pledgors named therein for the benefit of Grushko &amp; Mittman, P.C.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/14/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418009975/gtbp_ex101.htm" style="-sec-extract: exhibit">Security Purchase Agreement, dated September 7, 2018, among GT Biopharma, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/07/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418009975/gtbp_ex41.htm" style="-sec-extract: exhibit">Form of 10% Senior Convertible Debenture (related to Securities Purchase Agreement, dated September 7, 2018)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/07/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418010637/gtbp_ex101.htm" style="-sec-extract: exhibit">Security Purchase Agreement, dated September 24, 2018, among GT Biopharma, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/28/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418010637/gtbp_ex41.htm" style="-sec-extract: exhibit">Form of 10% Senior Convertible Debenture (related to Securities Purchase Agreement, dated September 24, 2018)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/28/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495419001122/gtbp_ex101.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated February 4, 2019, among GT Biopharma, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/06/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495419001122/gtbp_ex103.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated February 4, 2019, among GT Biopharma, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/06/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495419001122/gtbp_ex41.htm" style="-sec-extract: exhibit">Form of Secured Convertible Note (related to Securities Purchase Agreement, dated February 4, 2019)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/06/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495419001122/gtbp_ex102.htm" style="-sec-extract: exhibit">Security Agreement, dated February 4, 2019, among GT Biopharma, Inc. and Alpha Capital Anstalt, as collateral agent</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/06/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979819000027/exhibittenone.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated May 22, 2019, among GT Biopharma, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/24/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979819000027/exhibittentwo.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated May 22, 2019, among GT Biopharma, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/24/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979819000027/exfourone.htm" style="-sec-extract: exhibit">Form of Convertible Note (related to Securities Purchase Agreement, dated May 22, 2019)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/24/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495419009972/gtbp_ex101.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated August 20, 2019, among GT Biopharma, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/20/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495419009972/gtbp_ex103.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated August 20, 2019, among GT Biopharma, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/20/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495419009972/gtbp_ex41.htm" style="-sec-extract: exhibit">Form of Convertible Note (related to Securities Purchase Agreement, dated August 20, 2019)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/20/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420005654/gtbp_ex101.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated January 30, 2020, among GT Biopharma, Inc. and the purchaser named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/15/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420005654/gtbp_ex102.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated January 30, 2020, among GT Biopharma, Inc. and the purchaser named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/15/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420005654/gtbp_ex103.htm" style="-sec-extract: exhibit">Form of Convertible Note (related to Securities Purchase Agreement, dated January 30, 2020)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/15/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420005654/gtbp_ex104.htm" style="-sec-extract: exhibit">Form Securities Purchase Agreement among GT Biopharma, Inc. and the purchaser named therein (executed in April/May 2020)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/15/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420005654/gtbp_ex105.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement among GT Biopharma, Inc. and the purchaser named therein (executed in April/May 2020)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/15/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420005654/gtbp_ex106.htm" style="-sec-extract: exhibit">Form of Convertible Note (related to Securities Purchase Agreement executed in April/May 2020)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/15/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420007499/gtbp_ex101.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated July 7, 2020, among GT Biopharma, Inc. and the purchaser named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/09/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420007499/gtbp_ex103.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated July 7, 2020, among GT Biopharma, Inc. and the purchaser named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/09/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420007499/gtbp_ex41.htm" style="-sec-extract: exhibit">Form of Convertible Note (related to Securities Purchase Agreement, dated July 7, 2020)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/09/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420006903/gtbp_ex101.htm" style="-sec-extract: exhibit">Form of Standstill and Forbearance Agreement, dated June 23, 2020, between the Company and certain holders of convertible notes and debentures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/23/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420006839/gtbp_ex101.htm" style="-sec-extract: exhibit">Settlement Agreement, dated June 19, 2020, among GT Biopharma, Inc., Empery Asset Master Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, Anthony Cataldo and Paul Kessler.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/19/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420006839/gtbp_ex102.htm" style="-sec-extract: exhibit">Form of Convertible Note, dated June 19, 2020 (related to Settlement Agreement, dated June 19, 2020)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/19/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420006839/gtbp_ex103.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant to Purchase Common Stock, dated June 19, 2020 (related to Settlement Agreement, dated June 19, 2020)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/19/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418001758/gtbp_ex103.htm" style="-sec-extract: exhibit">Consultant Agreement, dated February 14, 2018, among GT Biopharma, Inc., Georgetown Translational Pharmaceuticals, Inc. and Anthony J. Cataldo</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/21/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420009193/gtbp_ex1011.htm" style="-sec-extract: exhibit">Employment agreement with Anthony Cataldo++</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/14/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420010329/gtbp_ex41.htm" style="-sec-extract: exhibit">Form of Convertible Note (related to Securities Purchase Agreement, dated September 16, 2020)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/22/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420010329/gtbp_ex101.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated September 16, 2020, among GT Biopharma, Inc. and the purchasers named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/22/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420010850/gtbp_ex101.htm" style="-sec-extract: exhibit">Master Services Agreement, dated October 5, 2020, between GT Biopharma, Inc. and Cytovance Biologics, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/6/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420011842/gtbp_ex101.htm" style="-sec-extract: exhibit">Form of First Amendment and Extension of Standstill and Forbearance Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/4/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420012026/gtbp_ex41.htm" style="-sec-extract: exhibit">Form of Secured Convertible Note</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/9/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420012026/gtbp_ex101.htm" style="-sec-extract: exhibit">Securities Purchase Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/9/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420012364/gtbp_ex1019.htm" style="-sec-extract: exhibit">Settlement Agreement, dated as of November 9, 2020, by and among Adam Kasower, East Ventures, Inc., A British Virgin Islands company, SV Booth Investments III, LLC, a Delaware limited liability company and Theorem Group, LLC, a California LLC and GT Biopharma Inc., a Delaware corporation.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/13/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420012364/gtbp_ex1020.htm" style="-sec-extract: exhibit">Form of Settlement Note, dated November 9, 2020.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/13/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.57</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420012364/gtbp_ex1022.htm" style="-sec-extract: exhibit">Board Service Agreement with Bruce Wendel, dated November 11, 2020++</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/13/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420012364/gtbp_ex1023.htm" style="-sec-extract: exhibit">Board Service Agreement with Greg Berk, dated November 11, 2020++</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/13/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420012364/gtbp_ex1024.htm" style="-sec-extract: exhibit">Consultant Agreement with Michael Handelman, dated November 13, 2020++</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/13/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420013851/gtbp_ex101.htm" style="-sec-extract: exhibit">Form of Amendment to Convertible Note &amp; Standstill Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/23/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420013901/gtbp_ex101.htm" style="-sec-extract: exhibit">Settlement Agreement, dated as of December 22, 2020, by and among Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, Anthony Cataldo, Paul Kessler and GT Biopharma Inc., a Delaware corporation.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495420013901/gtbp_ex102.htm" style="-sec-extract: exhibit">Settlement Note, dated December 22, 2020, by GT Biopharma Inc. payable to Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001050/gtbp_ex101.htm" style="-sec-extract: exhibit">Form of Second Amendment and Extension of Standstill and Forbearance Agreement.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/1/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001050/gtbp_ex10-2.htm" style="-sec-extract: exhibit">Form of Amendment to Convertible Note, dated January 31, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/1/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001271/gtbp_ex1069.htm" style="-sec-extract: exhibit">Board Service Agreement with Rajesh Shrotriya, dated January 12, 2021.++</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/08/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.69</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001271/gtbp_ex1070.htm" style="-sec-extract: exhibit">Board Service Agreement with Michael Breen, dated January 12, 2021. ++</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/08/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001271/gtbp_ex1071.htm" style="-sec-extract: exhibit">Amendment
    to Settlement Note with Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/08/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.71</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001271/gtbp_ex1072.htm" style="-sec-extract: exhibit">Form
    of Securities Purchase Agreement - December 2020 / January 2021 Notes</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/08/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.69</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001271/gtbp_ex1073.htm" style="-sec-extract: exhibit">Form
    of December 2020 / January 2021 Note</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/08/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.73</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421005897/gtbp_ex101.htm" style="-sec-extract: exhibit">Amended
    and Restated Employment Agreement with Anthony Cataldo, dated April 23, 2021.++</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/17/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.71</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421005897/gtbp_ex102.htm" style="-sec-extract: exhibit">Amended
    and Restated Employment Agreement with Michael Handelman, dated April 23, 2021.++</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/17/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421005897/gtbp_ex103.htm" style="-sec-extract: exhibit">Amended
    and Restated Employment Agreement with Dr. Gregory Berk, dated April 23, 2021.++</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/17/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.73</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222007883/ex10-73.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Exclusive
    License Agreement with Regents of the University of Minnesota, dated March 26, 2021.</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;03/28/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.73<span style="font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222007883/ex10-74.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Research
    Agreement with Regents of the University of Minnesota, dated June 16, 2021.</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/28/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;10.74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.75</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222007883/ex10-75.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Sublease
    Agreement dated November, 2021, between Aimmune Therapeutics, Inc. (Sublandlord) and GT Biopharma, Inc. (Subtenant)</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/28/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif">10.75</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.76</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222007883/ex10-76.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Employment
    Agreement with Michael Breen, entered into as of December 31, 2021 with an effective date of November 8, 2021. ++</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/28/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif">10.76</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.77</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222013539/ex10-1.htm" style="-sec-extract: exhibit">Board Service Agreement with Michael Breen dated November 11, 2020++</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10-Q</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">05/16/2022</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">10.78</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222013539/ex10-2.htm" style="-sec-extract: exhibit">Employment Agreement with Manu Ohri dated May 15, 2022++</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10-Q</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">05/16/2022</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.79</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222030019/ex10-1.htm" style="-sec-extract: exhibit">Settlement and Investment Agreement dated August 24, 2022, by and between GT Biopharma, Inc. and Cytovance Biologics, Inc.**</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10-Q</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10/31/2022</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">10.80</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315223000198/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated December 2022, by and between GT Biopharma, Inc. and the purchasers named therein.</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">01/03/2023</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.81</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315223000198/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Warrant</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">01/03/2023</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.82</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315223000198/ex4-2.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">01/03/2023</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.83</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315223000198/ex4-3.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">01/03/2023</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000151316015000022/ex141.htm" style="-sec-extract: exhibit">Code
    of Ethics</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2015</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000151316015000022/ex211.htm" style="-sec-extract: exhibit">Subsidiaries
    of GT Biopharma, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2015</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Weinberg &amp; Company, P.A.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#poa_001"><span style="font-size: 10pt">Power
    of Attorney (included on signature page)</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification
    of the Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification
    of the Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification
    of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
    of 2002. *</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification
    of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
    of 2002. *</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File &#8211; The cover page interactive data file does not appear in the Interactive Data File because its
    XBRL tags are embedded within the Inline XBRL document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">++
Indicates management contract or compensatory plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
T<span style="background-color: white">his certification shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange
Act, or otherwise subject to the liability of that Section, nor shall it be deemed to be incorporated by reference into any filing under
the Securities Act or the Exchange Act.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">**The
Registrant has omitted portions of this exhibit that are both not material and the type of information that the Registrant treats as
private or confidential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eds_026"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
    Biopharma, Inc.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 30, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;
    </span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Manu Ohri</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manu
    Ohri, Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span id="poa_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Breen and Manu Ohri, and
each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution for him, and in his name in any and
all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other
documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and
each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as
fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents, and any of them or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael Breen</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman of the Board and</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
Chief Executive Officer (Principal Executive Officer)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Manu Ohri</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manu
    Ohri</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Bruce Wendel</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    Chairman of the Board</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bruce
    Wendel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Rajesh Shrotriya</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rajesh
    Shrotriya, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Alan Unban</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Urban</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements of GT Biopharma, Inc.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48px; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#fin_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm (PCAOB Firm ID: <span id="xdx_90E_edei--AuditorFirmId_c20220101__20221231_zhfj7TAJuxe4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">572</ix:nonNumeric></span>)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#fin_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#fin_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations for the year ended December 31, 2022 and 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#fin_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Stockholders&#8217; Equity for the year ended December 31, 2022 and 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#fin_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the year ended December 31, 2022 and 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#fin_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 48; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fin_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Stockholders and Board of Directors of GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brisbane,
CA</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Opinion
on the Financial Statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of GT Biopharma, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and
2021 and the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for the years then
ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the
results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in
the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis
for Opinion</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Critical
Audit Matter Description</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial
statements and (2) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters does
not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical
audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
Assessment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in note 2 to the consolidated financial statements, the Company&#8217;s consolidated financial statements have been prepared on a
going concern basis, as management believes that the Company will be able to realize its assets and discharge its liabilities in the
normal course of operations as they become due for a period of no less than 12 months from the date of issuance of these consolidated
financial statements. For the year ended December 31, 2022, the Company incurred a net loss of $20.9 million and net cash used in operating
activities was $15.2 million. Management evaluates the Company&#8217;s liquidity to determine if there is substantial doubt about the Company&#8217;s
ability to continue as a going concern. In preparing this liquidity assessment, management applies significant judgment in estimating
future cash flow requirements of the Company based on budgets and forecasts, which includes developing assumptions related to (i) estimation
of amount and timing of cash outflows and cash inflows; and (ii) determining what future expenditures are committed and what could be
considered discretionary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal considerations for our determination that performing procedures relating to the liquidity assessment is a critical audit matter
are the significant judgments made by management in estimating the future cash flow requirements of the Company based on budgets and
forecasts and in developing the related assumptions. This in turn led to a high degree of auditor judgment, subjectivity and effort in
performing procedures and evaluating audit evidence related to management&#8217;s liquidity assessment and the development of assumptions included
in the estimated future cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since December 2020.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span id="xdx_900_edei--AuditorName_c20220101__20221231_zAamJnZkB8lh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">Weinberg
    &amp; Company, P.A</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--AuditorLocation_c20220101__20221231_zIB0aWKPVQb9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Los
    Angeles, California</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fin_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
Thousands, Except Par Value and Share Data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_111_pn3n3_zvKeO2ZoDRT3" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_ztF5ThrWpTuf" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20211231_zszmpmXTR0I1" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zdXiopBTcue5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_i01B_ztLLjgokGTl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzGos_zWD88tKZKEC3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,672</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,968</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShortTermInvestments_i02I_maACzGos_ztAq9oVtraXa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,011</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzGos_zWiRRjR2reNj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsCurrent_i02TI_mtACzGos_maAzrH7_zWz1fGnEktSb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,169</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzrH7_zxDxEmHi3rpc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0067">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepositsAssetsNoncurrent_i01I_maAzrH7_zcn6nHPbQwMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0070">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Assets_i01TI_mtAzrH7_zh2imRDEkiQb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,736</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,169</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesCurrentAbstract_i01B_zYIVD3EbTB0l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_maLCzmA1_zgxrJWg22rHc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,189</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzmA1_zowx82on755l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,669</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,901</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzmA1_zUNUvX8HZ5sb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease liability, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0088">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LinesOfCreditCurrent_i02I_maLCzmA1_zWPRu6mLmpXa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0090">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLCzmA1_zmbhjEia46ah" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrent_i02TI_maLzsjz_mtLCzmA1_zlhXwgQutXel" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,259</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzsjz_zyYYieDMCUb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-current operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0100">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Liabilities_i01TI_mtLzsjz_maLASEzO3i_z2azOeWpnxd4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,002</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,259</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; Equity </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_maSEzwuq_z75DoAdNNp6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
  <td style="text-align: left">Convertible Preferred stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_zzV0J9I2VSJ9" title="Preferred stock, par value"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zMA76hBqG2t6" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_zX5l55MyWPqa" title="Preferred stock, shares authorized"><span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_zINL9wFKtd5" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized Series C - <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zN2pP6W2CeWa" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zHXihtNyPife" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zKXCZeLy5Ls3" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zQrRtxDRSsMh" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares
  issued and outstanding at December 31, 2022 and 2021, respectively</td>
  <td>&#160;&#160;</td>
  <td style="text-align: left">&#160;&#160;</td>
  <td style="text-align: right">&#160;<br />
<ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
  <td style="text-align: left"></td>
  <td>&#160;&#160;</td>
  <td style="text-align: left">&#160;&#160;</td>
  <td style="text-align: right">&#160;<br />
<ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
  <td style="text-align: left">&#160;&#160;</td>
</tr>
<tr id="xdx_403_eus-gaap--CommonStockValue_i02I_maSEzwuq_zTKPHXm50Fy1" style="vertical-align: bottom; background-color: White">
  <td>Common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_znMlsy7EOwf8" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_zBFheHLXWCz9" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zjv6smvKyGu6" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211231_zl07A5IOcok7" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zwiAoNRkjVyl" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zSOvObOKcpva" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,722,452</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zjgUCTZun44k" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zuOkjfmitsj4" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,061,989</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as
  of December 31, 2022 and 2021, respectively</td>
  <td>&#160;</td>
  <td style="text-align: left">&#160;&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td>
  <td style="text-align: left">&#160;&#160;</td>
  <td>&#160;&#160;</td>
  <td style="text-align: left">&#160;&#160;</td>
  <td style="text-align: right">&#160;<br />
<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td>
  <td style="text-align: left">&#160;&#160;</td>
</tr>
<tr id="xdx_404_ecustom--CommonStockIssuable_i02I_pn3n3_maSEzwuq_zjJvKokuEN4k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issuable, <span id="xdx_909_ecustom--CommonStockIssuableShares_iI_pid_c20221231_zH0Uw5wYA0y2" title="Common stock issuable, shares"><ix:nonFraction name="GTBP:CommonStockIssuableShares" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> shares and <span id="xdx_90D_ecustom--CommonStockIssuableShares_iI_pid_c20211231_zZf5N69WFJ4d" title="Common stock issuable, shares"><ix:nonFraction name="GTBP:CommonStockIssuableShares" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">327,298</ix:nonFraction></span> shares at December 31, 2022 and 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0146">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:CommonStockIssuable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,113</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdditionalPaidInCapital_i02I_maSEzwuq_zNme9DNqwdAc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">686,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">674,348</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzwuq_zZ70zNfwe0rg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">674,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">653,584</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquity_i02TI_mtSEzwuq_maLASEzO3i_zZu3WfuOctCi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Total Stockholders&#8217; Equity </td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,910</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzO3i_zBS0Af8avkZa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,736</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,169</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fin_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Operations </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
Thousands, Except Share Data) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_pn3n3_zyHXUyhAM8Wd" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zm5NpQhuTWJi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231_zrwNqSsxU3I2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_maOILzLy6_z9NXSnOCBQsf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0165">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0166">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpensesAbstract_iB_z2S4epQTaaE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzmE9_zgKumOAPML5j" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Research and development (including $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zqaGUzZyta4f" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_OfficersEmployeesAndDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">718</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zEoNeEVyuGv1" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_OfficersEmployeesAndDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span> of stock compensation to officers, directors and employees during the years ended December 31, 2022 and 2021, respectively)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,811</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,591</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maOEzmE9_z5iahK4Vk0k8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling, general and administrative (including $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zSsN6sEJ8LSh" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,903</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zhWfntYNkRce" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,234</ix:nonFraction></span> of stock compensation to officers, directors and employees during the years ended December 31, 2022 and 2021, respectively)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,446</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47,924</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpenses_iT_mtOEzmE9_msOILzLy6_zL7l5HXxHkXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total Operating Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,257</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iT_mtOILzLy6_maNILzFMl_zfg4xHdAS6Na" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from Operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,257</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57,515</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zy0y329ynbe7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other (Income) Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestIncomeOther_i01N_di_maNIEz7im_zadpzbEHvcU6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">292</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestExpense_i01_msNIEz7im_z9GD5aOdW4Ch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">718</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeGainLossOnDerivativeNet_i01N_di_maNIEz7im_z4eDnRFo5vIj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">211</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01N_di_maNIEz7im_zVafHi0Q3Gz5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized loss on marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_i01NT_di_mtNIEz7im_maNILzFMl_zbREBv7D2Opg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total Other (Income) Expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">373</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iT_mtNILzFMl_zoqoqEWdrZG" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,884</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,013</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_pid_zTOsqO1GZOKa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Loss Per Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.66</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.06</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_z7cERRRmqVxh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Weighted average common shares outstanding - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,868,024</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,155,624</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fin_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Stockholders&#8217; Equity </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
Thousands) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_114_pn3n3_zXxwENdI1T5f" summary="xdx: Statement - Consolidated Statements of Stockholders&apos; Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zeLHWbyimzdj" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zRDF6gsiRg27" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_custom--CommonSharesIssuableMember_zEFRvSoXkvI" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zWUMrVCSqSLb" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zKFk0gNl45o" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B7_zf7TQDXAPdC5" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Preferred Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Common Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Common Shares Issuable</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Additional</b></p>
                                               <p style="margin-top: 0; margin-bottom: 0"><b>Paid-in-</b></p></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Capital</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Deficit</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_436_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zCR7cSjbavRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Balance, December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z70vwUnJCti7" title="Beginning balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,450</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOn6WGfsvT2b" title="Beginning balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,218</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zH6Mg0C7f0E7" title="Beginning balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0229">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0220">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">566,356</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">595,797</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,433</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_zpnNEssPEH7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Extinguishment of debt discount upon adoption of ASU 2020-06</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,745</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,519</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z5m1m3spXQ57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of Preferred Series J-1 to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zP0YRfJfj2fd" title="Conversion of Preferred Series J-1 to common stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">2,354</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHN9Xe0bbss9" title="Conversion of Preferred Series J-1 to common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0240">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0242">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_zwTxykFigos8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common shares issued upon mandatory conversion of notes payable and accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIoKzypFIir5" title="Common shares issued upon mandatory conversion of notes payable and accrued interest, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">11,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_z2x51io5bjbk" title="Common shares issued upon mandatory conversion of notes payable and accrued interest, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,799</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_zbdiNh7VhQHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Common shares issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztlMV8r49Ftc" title="Common shares issued upon exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,074</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,430</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,433</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_zI1DtG0OfL8j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock in public offering, net of cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ1pTKZF3YZ7" title="Issuance of common stock in public offering, net of cost, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,945</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,674</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_zmKcAw82i0rc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for research and development agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRygCSL5OyW2" title="Issuance of common stock for research and development agreement, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,355</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IssuanceOfCommonStockAsEquityCompensationToConsultants_zIRAtU7sqMQh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Issuance of common stock as equity compensation to consultants</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesEquityCompensationToConsultants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDr1a5XxLnYa" title="Issuance of common stock for services, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesEquityCompensationToConsultants" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,082</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,340</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_z4olmx6LAb1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Issuance of common stock as </p>equity compensation to officers and board of directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFUVla8Nnzxd" title="Equity compensation to officers and board of directors, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,979</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,983</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_zRxc1cg0lX95" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fair value of vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Equity compensation to officers and board of directors, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zlkHWRWZEV19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Extinguishment of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zEv6VoNwAVac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,013</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,013</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_433_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zhdkrrrLGv33" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zA7THi9EESuc" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOY7Ch6TDhUa" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">32,062</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zwf1Ox1cpMAa" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,113</ix:nonFraction></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">674,348</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">653,584</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,910</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zq7UM6Kf7sE2" style="display: none; vertical-align: bottom; background-color: White">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zz8Muhgv4NB4" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwA2YtoWD7xi" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">32,062</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_z8kTQnds41Vg" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,113</ix:nonFraction></td><td style="text-align: left">#</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">674,348</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">653,584</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,910</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueCancellation_zvj3JeMgjyYc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cancellation of common stock previously issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesCancellation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNDNFX9ifZ7g" title="Cancellation of common stock previously issued for services, shares" style="text-align: right">(<ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCancellation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">291</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued_zFGWRjtRR1Od" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cancellation of common stock previously issued to prior CEO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbAGX4kRvuRd" title="Cancellation of common stock previously issued to prior CEO, shares" style="text-align: right">(<ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">1,845</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">222</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">224</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zVKOhqypEaoh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Common stock issued upon conversion of notes payable</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze4pmOBTMAce" title="Common stock issued upon conversion of notes payable, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">338</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zBLaWRmn2Xuh" title="Common stock issued upon conversion of notes payable, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">327</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,113</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_ztwKLUeqQk5l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Issuance of common stock as equity compensation to officers, employees,
and board of directors</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzTxxocQHnck" title="Equity compensation to officers, employees, and board of directors, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">710</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,521</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,522</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueEquityCompensationToConsultants_zXax0QwuJ4Hl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Issuance of common stock as equity compensation to consultants</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesEquityCompensationToConsultants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGGydRpV6Uug" title="Equity compensation to consultants, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesEquityCompensationToConsultants" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,091</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,092</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_zmT7iQSesrHf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value of vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Equity compensation to consultants, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,032</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,032</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_z6REmXLnSvfh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock in settlement of vendor payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXlhI489hcak" title="Issuance of common shares in settlement of vendors payable, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zmhyaQlrd1fj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,884</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,884</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_43F_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zhCaPxEyOH63" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance, December 31, 2022</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z9IVDRh2Wek1" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCUg1Rqj4ztg" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">32,723</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zmduCLtTeBNg" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="font-weight: bold; text-align: left"></td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">686,168</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">674,468</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,734</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20220101__20221231_eus-gaap--StockholdersEquity_iE_z0RxZQBKh9k4" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zzVbbxlxtIal" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYFmOphVlbW5" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">32,723</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zsXJiW6rfsTg" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">-</span></td><td style="font-weight: bold; text-align: left">#</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">686,168</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">674,468</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,734</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fin_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
Thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_112_pn3n3_zLJ2f0vPxymj" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zxqTfH8ksOj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zuTsZgZhqFeg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zZfU2CS0FBQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_i01_maNCPBUzlBl_zzcZ5ZAdhf0a" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,884</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,013</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zvRM8w61pgz5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockBasedCompensationConsultantsAndResearchAndDevelopment_i02_maNCPBUzlBl_z0EhUrLJwhz8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Stock based compensation &#8211; consultants and research and development</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="GTBP:StockBasedCompensationConsultantsAndResearchAndDevelopment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,522</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="GTBP:StockBasedCompensationConsultantsAndResearchAndDevelopment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,695</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockBasedCompensationOfficersEmployeesAndBoardOfDirectors_i02_maNCPBUzlBl_zKo4yZd9pAi9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation - officers, employees and board of directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,092</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,983</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockBasedCompensationVestedStockOptions_i02_maNCPBUzlBl_zr13WjSXqTl5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation - vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationVestedStockOptions" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,032</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationVestedStockOptions" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--FairValueOfCommonStockIssuedToNoteholderAsSettlement_i02N_di_msNCPBUzlBl_z34rjdjr3nYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fair value of common stock issued to a noteholder as settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:FairValueOfCommonStockIssuedToNoteholderAsSettlement" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ConvertibleNotesPayableIssuedForConsultingServices_i02_maNCPBUzlBl_zenQlM1EpAGa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible notes payable issued for consulting services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:ConvertibleNotesPayableIssuedForConsultingServices" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">720</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_msNCPBUzlBl_zbeeH1NAur64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">211</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzlBl_zaX36kG0epGi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msNCPBUzlBl_z3Riuh9mbib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain from extinguishment of line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--UnrealizedLossOnMarketableSecurities_i02N_di_msNCPBUzlBl_za4NoNgn4jW2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Unrealized loss on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:UnrealizedLossOnMarketableSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:UnrealizedLossOnMarketableSecurities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zBC0J2482nhl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets_i03N_di_msNCPBUzlBl_zGRUPDlCvuT7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Decrease in prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">136</ix:nonFraction></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">174</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IncreaseDecreaseInDeposit_i03N_di_msNCPBUzlBl_zDe7VX6yym9g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">(Increase) in deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GTBP:IncreaseDecreaseInDeposit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_pn3n3_maNCPBUzlBl_zIajq3H67sK7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">(Decrease) increase in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,030</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,077</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzlBl_zNWIc07msQZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Decrease in operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">86</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInInterestPayableNet_i03_maNCPBUzlBl_zu9YFWPvChe7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Increase in accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCz4rY_mtNCPBUzlBl_zvmJRmvGSVy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net Cash Used in Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15,217</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15,606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zFCOkJuSF2n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsForProceedsFromInvestments_i01N_di_msNCPBUzqGp_zHHHDLXUYJR8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Sales (purchases) of investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,145</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,040</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzqGp_maCCERCz4rY_ztsDHK1odLWg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net Cash Provided by (Used in) Investing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,145</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,040</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z82NKiwm8IB9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzKTR_zwukUAuxJLd5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--CancellationOfCommonStockUponSettlementWithFormerOfficer_i01N_di_msNCPBUzKTR_z911RjnUaoq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cancellation of common stock upon settlement with former officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GTBP:CancellationOfCommonStockUponSettlementWithFormerOfficer" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">224</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUzKTR_z1bOb24YE9Ub" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Proceeds from exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,433</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_i01_maNCPBUzKTR_zjf2VDLx5bDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,205</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzKTR_maCCERCz4rY_zWh9MpNh75G9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Cash (Used in) Provided by Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">224</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,317</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCz4rY_zwWeg6v0xfO2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net (Decrease) Increase in Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,296</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,671</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_z71q6QRJockf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Cash at Beginning of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,968</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,297</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_z8GNyAkgpL37" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Cash at End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,672</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,968</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zd8JLdtZTv0a" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CashPaidDuringYearFor_i01B_zzSvXz92SCY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid during the year for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaid_i02_zO5zy99S5AIa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxesPaidNet_i02_zSkE44Dv3cAi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zabAa2X5SuM9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RightofuseAssetsExchangedForLeaseLiabilities_i01_zsYuLSuD46y9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use assets exchanged for lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:RightofuseAssetsExchangedForLeaseLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">260</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption_i01_zSo8abRQ8EU" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Extinguishment of unamortized debt discount and adjustment to accumulated deficit
    upon adoption of ASU 2020-06</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,745</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssued1_i01_z4thRjMlpK2f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued upon conversion of notes payable and accrued interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CommonStockIssuedUponSettlementOfVendorPayable_i01_zru2B1ib8wZ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued upon settlement of vendor payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:CommonStockIssuedUponSettlementOfVendorPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,251</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccountsPayableReclassifiedToConvertibleNotes_i01_zS095fvsGjO2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable reclassified to convertible notes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:AccountsPayableReclassifiedToConvertibleNotes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">525</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ExtinguishmentOfDerivativeLiability_i01_zVY0xHpsqKRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Extinguishment of derivative liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ExtinguishmentOfDerivativeLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ConversionOfStockAmountConverted1_i01_zJAZLt6GgyZ7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Conversion of Series J Preferred Stock to Common Stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fin_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>GT
Biopharma, Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; background-color: white"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>For
the Years Ended December 31, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zlcg3HbkuYg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_825_zi81Nk93I8U3">Organization and Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
1965, the corporate predecessor of GT Biopharma Inc. (the &#8220;Company&#8221;), Diagnostic Data, Inc., was incorporated in the State of California.
Diagnostic Data changed its incorporation to the State of Delaware in 1972, and changed its name to DDI Pharmaceuticals, Inc. in 1985.
In 1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International,
Inc. In July 2017, the Company changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products
based off our proprietary Tri-specific Killer Engager (TriKE<sup>&#174;</sup>), and Tetra-specific Killer Engager (Dual Targeting TriKE<sup>&#174;</sup>Dual
Targeting TriKE<sup>&#174;</sup>) platforms. The Company&#8217;s TriKE<sup>&#174; </sup>and Dual Targeting TriKE<sup>&#174;</sup> platforms
generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer
cells (NK cells).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zL8l5PbY0r2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82C_zqg1YR3oXhrb">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_84D_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z19k8I4c2dmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zqob9Y9qTHU5">Basis
of Presentation and Principles of Consolidation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America. The consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries,
Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated
in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="GTBP:LiquidityPolicyTextBlock"><p id="xdx_84F_ecustom--LiquidityPolicyTextBlock_zDg78qWfj2Jg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zMWPnp1TEuY9">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared under the assumption that the Company will continue as a going
concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The Company recorded a net loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_zoYFhP1AV3l" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">20.9</ix:nonFraction></span>
million of which $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231_zQYfgsiL4tW1" title="Non-cash stock compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.7</ix:nonFraction></span>
million resulted from non-cash stock compensation, and used cash in operations of $<span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_z0jLxMO5fjSe" title="Cash in Operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">15.2</ix:nonFraction></span>
million for the year ended December 31, 2022. The Company had a cash and short-term investments balance of $<span id="xdx_908_ecustom--CashOnHandAndShortTermInvestment_iI_pn5n6_c20221231_z6Kl1tjczTUc" title="Cash and short term investments"><ix:nonFraction name="GTBP:CashOnHandAndShortTermInvestment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.5</ix:nonFraction></span>
million at December 31, 2022. On January 4, 2023, the Company raised an additional $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUJmTJm8h05b" title="Cash on equity issuance"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-032023-01-04_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.5</ix:nonFraction></span>
million of cash through an equity issuance (see Note 11). Management anticipates that the $<span id="xdx_90C_eus-gaap--InvestmentsAndCash_iI_pn5n6_c20221231_z7HvOH39bIM3" title="Investments and cash"><ix:nonFraction name="us-gaap:InvestmentsAndCash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">23.0</ix:nonFraction></span>
million of cash and cash equivalents and short-term investments available following the stock issuance are adequate to satisfy the
liquidity needs of the Company for at least one year from the date the Company&#8217;s 2022 consolidated financial statements are
issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has financed its operations through public and private sales of common stock, issuance of preferred stock, issuance of
convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to secure
additional financing on acceptable terms. <span style="background-color: white">In the event that the Company does not generate
sufficient cash flows from investing and financing activities, the Company will be forced to delay, reduce, or eliminate some or all
of its discretionary spending, which could adversely affect the Company&#8217;s business prospects, ability to meet long-term
liquidity needs or ability to continue operations.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="GTBP:UnusualRisksAndUncertaintiesPolicyTextBlock"><p id="xdx_84E_ecustom--UnusualRisksAndUncertaintiesPolicyTextBlock_zCnh8KI6YFS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86F_zbPGhi2mNm84" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">COVID-19</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global COVID-19 pandemic continues to present uncertainty and unforeseeable risks to GT Biopharma&#8217;s operations and business plan.
The Company has closely monitored recent developments, including the lifting of COVID-19 safety measures, the spread of new strains or
variants of the coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. Thus, the full impact of
the COVID-19 pandemic on the business and operations remains uncertain and will vary depending on the pandemic&#8217;s future impact
on the third parties with whom the Company does business, as well as any legal or regulatory consequences resulting therefrom. The Company
has been following the recommendations of health authorities to minimize exposure risk for its team members and may take further actions
that alter our operations, including any required by federal, state or local authorities, or that it determines are in the best interests
of its employees and other third parties with whom GT Biopharma does business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_847_eus-gaap--UseOfEstimates_zmffGgDs1vt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zFLvBtEPfeKk">Accounting
Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates. Significant estimates include accruals for potential liabilities,
assumptions used in deriving the fair value of derivative liabilities, share-based compensation and valuation of deferred tax assets.
Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjR4PL06PRr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Cash
Equivalents and Short-Term Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying consolidated financial statements. As of December 31, 2022, total cash and cash equivalents which consist
of cash and money market funds, amounted to approximately $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zI0liZ1AxHj5" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.7</ix:nonFraction></span>&#160;million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our businesses. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
consolidated statements of operations. As of December 31, 2022, total short-term investments amounted to approximately $<span id="xdx_901_eus-gaap--ShortTermInvestments_iI_pn5n6_c20221231_z9WB8Ry3wHBh" title="Short-term investments"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.8</ix:nonFraction></span> million.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zuyF6MoVXLOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_zB5YeCD5rWh2">Fair
Value of Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 820-10 requires entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10
defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s derivative liability of $<span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231_zoupMEcwRSUa" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,700</ix:nonFraction></span>
at December 31, 2022 and $<span id="xdx_903_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231_zvdjwnOhtTn7" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,000</ix:nonFraction></span> at December 31, 2021 was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and notes payable, approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_z81iMwHLqIv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_zodClfERMec">Derivative
Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception and on
subsequent valuation dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zvj8Qg36B8f5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically issues stock-based compensation
to officers, directors, employees and consultants for services rendered. Such issuances vest and expire according to terms established
at the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="background-color: white">Stock-based payments to officers,
directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options,
are recognized in the financial statements based on their grant date fair values in accordance with ASC 718,&#160;<i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVuOyqmgqzxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zrP9tkQS7247">Research
and Development Costs</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products comprise research and development expenses. Purchased materials that do not have an alternative
future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_845_eus-gaap--LesseeLeasesPolicyTextBlock_z5zpoPyrzbi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_864_zdZH1dcAPH6g">Leases</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
accounts for its lease<span style="background-color: white">s</span> in accordance with the guidance of ASC 842,&#160;<i>Leases</i>. The Company determines whether a contract is, or
contains, a lease at inception. Right-of-use assets represent the Company&#8217;s right to use an underlying asset during the lease term,
and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and
lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease
term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present
value of unpaid lease payments</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z4bd0h0IYdrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zWDNiQlHPtI5">Net
Loss Per Share</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEgi1z1Rmswe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following shares were excluded in the computation of the diluted net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zipYmU8WkIGg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zU9UWDlsIkZb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231_zQlvrHZC1fVc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zpx6zK8cGit3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_WarrantsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,337,274</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_custom_WarrantsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,337,274</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zTAusukgtt6b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_OptionsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,630,452</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_custom_OptionsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zoUC5MvZbyd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,967,726</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,639,774</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zCRXDR4bUjNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zF7y24q5FnX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zUUmErhmJpd2">Concentration</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal
Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20221231_z0tzcbSMKFH7" title="FDIC amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.<span style="background-color: white">
Management believes that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly,
minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zl2eOgoSa2K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zODc3uUH0vU4">Segments</span>
</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined its reporting units in accordance with  &#8220;<i>Segment Reporting</i>&#8221; (&#8220;ASC 280&#8221;). Management
evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that the Company has one consolidated operating segment. The Company&#8217;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#8217;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zS2DXMm4M17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zs67VLMvEI7e">Recently
Issued Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <i>Credit Losses &#8211; Measurement of Credit Losses on Financial
Instruments</i> (&#8220;ASC 326&#8221;). ASU 2016-13 requires entities to use a forward-looking approach based on current expected
credit losses (&#8220;CECL&#8221;) to estimate credit losses on certain types of financial instruments, including trade receivables.
This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1,
2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related
codification improvements will be material to its financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt&#8212;Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity&#8217;s Own Equity</i>. Effective January 1, 2021, the Company adopted ASU 2020-06 using
the modified retrospective approach. Adoption of the new standard resulted in a decrease to additional paid-in capital of $<span id="xdx_90A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_pn5n6_c20220101__20221231_zgHlZwJegvjl" title="Decrease to additional paid-in capital"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million
(see Note 5).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>. ASU 2021-04 provides clarification
and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options
(such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange
as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification
or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting
treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and
debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including
interim periods within those fiscal years. Effective January 1, 2022, the Company adopted ASU 2021-04 using a prospective approach. The
adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission (the &#8220;SEC&#8221;) did not or are not believed by management to have a material
impact on the Company&#8217;s present or future consolidated financial statements.</span></p>

</ix:nonNumeric><p id="xdx_854_zMZMDLpExu42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_807_eus-gaap--FairValueDisclosuresTextBlock_zAlOFwgznSlf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 <span>&#8211;</span> <span id="xdx_823_zLJ52zke3p65">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock"><p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_z5P3ACjZbzje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of financial instruments outstanding were (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z8O7MHPLJB85" style="display: none">Schedule
of Estimated Fair Value of Financial Instrument</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z0Nwf4vaguHj" title="Cost" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,866</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zxzqvnjslD7b" title="Unrealized gains" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z7w5n6zTDhad" title="Unrealized losses" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zO2MI49T56p" title="Fair value" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,836</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total</p></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231_zuPQFV0NnH08" title="Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,866</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20221231_z4YJRJdvNVdk" title="Unrealized gains" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20220101__20221231_zNlzXae6QJc2" title="Unrealized losses" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20220101__20221231_zEQ272R0XVh" title="Fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,836</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztAYkzKBPsRg" title="Cost" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,040</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zNPPfyPvHdHd" title="Unrealized gains" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z0c3DddLu0Df" title="Unrealized losses" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2021-01-012021-12-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zfz99ky0Pkdb" title="Fair value" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2021-01-012021-12-31_us-gaap_ShortTermInvestmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,011</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231_zxAaYty20ae7" title="Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,040</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231_zp3R7zxneRl6" title="Unrealized gains" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20210101__20211231_z2JoDP36MTr1" title="Unrealized losses" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20210101__20211231_z72PrVxMotCg" title="Fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,011</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AF_zEVvL7rYm0z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zRV5XjC21Sf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&#8217;s fair value hierarchy for its financial assets (cash equivalents and investments, in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zhYv3SDQBCra" style="display: none">Schedule of Fair Value Hierarchy Financial Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zVlB2J6BDbHb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zs3pIkHwJCA2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZBVLWVooYVg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgy53sOf7B63" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zCD2990X8Uig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,505</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,505</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_z2iq57rzLLBd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_custom_CorporateNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,836</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,836</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zVqoiyls41Tk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total financial assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,341</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,341</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0695">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_49A_20211231_z6u3KPsgWw72" style="border-bottom: Black 1.5pt solid; text-align: center">1</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1xzZplSugg5" style="border-bottom: Black 1.5pt solid; text-align: center">2</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjIAwY1kW568" style="border-bottom: Black 1.5pt solid; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkP0MsVY8XPj" style="border-bottom: Black 1.5pt solid; text-align: center">4</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zLzr2WdwxdJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,484</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,484</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0700">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zLGxsofpk1Fj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_custom_CorporateNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0704">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zKl8cYu3bI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,495</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,495</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AC_zJ9Et4xwZfB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zorO4p4t9P9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_822_z76ZlGsHNg9d">Accounts Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUhfGv2y8k07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z6lDKgLhjGB7" style="display: none">Schedule of Accounts Payable</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20221231_zILvVLffkSD2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31, </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20211231_zqGmjJ5QkVJd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31, </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maAPCz7ta_zHlh7QCLZok7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable to a third-party manufacturer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,283</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,335</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz7ta_zW4zfHTwGGR" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    accounts payable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">857</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,854</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz7ta_zJC8oa4mKaJ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accounts payable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,140</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,189</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_zMiltEy7cZyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 5, 2020, the Company entered into a Master
Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the
Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products
for use in clinical trials. The Company&#8217;s commitments in relation to these Statements of Work and any related Change Orders totaled
approximately $<span id="xdx_904_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20201005__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8MzGIZgAOz6" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2020-10-05_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.0</ix:nonFraction></span> million. There was no outstanding liability with this third-party product manufacturer as of December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2021, the
Company recorded research and development expenses of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWm6L3XfJMR3" title="Reserach and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.5</ix:nonFraction></span>
million  related to the services rendered by this third-party product manufacturer and paid $<span id="xdx_904_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zh1jpKpeSJHj" title="Adjustment to additional paid in capital, stock issued, issuance cost"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,500</ix:nonFraction></span>.
In addition, the Company also issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ0sgs6hSn1c" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">189,753</ix:nonFraction></span>
shares of common stock with a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmxZZWRJ6w3a" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span>
million  pursuant to this Master Services Agreement. As of December 31, 2021, the outstanding balance due to this third-party
product manufacturer amounted to $<span id="xdx_908_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwwAov8Im7xa" title="Accounts Payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.3</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 24, 2022, the Company entered into an agreement
with this third-party manufacturer and issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220823__20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zK7KCvopDJj6" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-08-232022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,222,281</ix:nonFraction></span> shares of common stock with a fair value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220823__20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z08TNV9ctPQa" title="Stock issued during period, value, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-08-232022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.2</ix:nonFraction></span> million as part of a payment
agreement. The shares were valued at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbiphK4SHLvl" title="Share issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.66</ix:nonFraction></span> per share based on the closing price of the Company&#8217;s common stock on the date of the
agreement. As part of the agreement, the Company also paid this third-party manufacturer $<span id="xdx_906_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pn5n6_c20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxD7t3wchJB" title="Notes payable, related parties"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million on September 1, 2022, $<span id="xdx_901_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pn5n6_c20220901__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0soNdamtB7h" title="Notes payable, related parties"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-09-01_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million
on October 3, 2022, and $<span id="xdx_908_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pn5n6_c20221003__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzJ8LCCdbeO7" title="Notes payable, related parties"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-10-03_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million in November 2022. In addition, the Company and the third-party manufacturer agreed that services
to be rendered in future periods, as specified in the agreement, will be paid or settled at the Company&#8217;s discretion, in a combination
of cash and issuance of the Company&#8217;s common stock. The agreement also amended certain agreements executed in prior years which
eliminated future financial commitments of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2022, the Company
recorded research and development expenses in the aggregate of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMn66qh5sDv1" title="Reserach and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction></span> million for services rendered by this third-party product manufacturer
and made additional payments of $<span id="xdx_902_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember_zS10UbSEA673" title="Accounts Payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022, the Company was indebted
$<span id="xdx_907_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCrqFFf2AuHd" title="Accounts Payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million to this third-party product manufacturer and was reported as part of accounts payable in the accompanying balance sheet.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zoh1YnyNyoxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_828_z8FeedWbIsv1">Convertible Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following activity occurred during the year
ended December 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
    Payable Issued for Cash</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Company&#8217;s financing activities, the Company issued convertible notes payable in exchange for cash. As of December 31,
2020, the outstanding balance of these notes amounted to $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zqFozVAyc7wb" title="Outstanding balance"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForCashMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">24.1</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company issued similar notes payable in
exchange for cash of $<span id="xdx_901_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20210101__20210101__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zrxr5S17gs4a" title="Proceeds from notes payable in cash"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-01-012021-01-01_custom_NotesPayableIssuedForCashMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million. On February 16, 2021, in accordance with the note agreements upon completion of an equity offering,
these notes were mandatorily converted at a conversion rate of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zT636pS5Rkg4" title="Conversion rate"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-02-16_custom_NotesPayableIssuedForCashMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></span> per share into <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zA6NRtTulYNi" title="Shares"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForCashMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,438,235</ix:nonFraction></span> shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
    Payable Issued for Settlement Agreements</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2019 and 2020, the Company issued its convertible notes payable to resolve claims and disputes pertaining to certain debt and
equity instruments issued by the Company in prior years. As of December 31, 2020, the outstanding balance of these notes payable for
settlement agreements amounted to $<span id="xdx_90B_eus-gaap--NotesPayableCurrent_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember__us-gaap--AwardDateAxis__custom--FiscalTwentyNinteenandTwentyTwentyMember_zD3ukr0MbFji" title="Outstanding balance"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2021 in accordance with the note agreements upon completion of an equity
offering, these notes were mandatorily converted at a conversion rate of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember_zO8m1AKV5d6l" title="Conversion rate"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></span> per share into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember_zo8INDS91pM8" title="Shares"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">743,529</ix:nonFraction></span> shares of the Company&#8217;s common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
    Payable Issued for Forbearance Agreements</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2020, the Company entered into Standstill and Forbearance Agreements (collectively, the &#8220;Forbearance Agreements&#8221;)
with the holders of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200623__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_ztxRkPxDaCGc" title="Forbearance Agreements"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-06-23_custom_NotesPayableIssuedForForbearanceAgreementsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.2</ix:nonFraction></span> million aggregate principal amount of the Convertible Notes (the &#8220;Default Notes&#8221;), which were in
default. As of December 31, 2020, the outstanding balance of the notes payable amounted to $<span id="xdx_90A_eus-gaap--NotesPayableCurrent_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_zpqi52SKuFW2" title="Outstanding balance"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForForbearanceAgreementsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2021 in accordance
with the note agreements upon completion of an equity offering, these notes were mandatorily converted at a conversion rate of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_z5K5NdFbsLqf" title="Conversion rate"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-02-16_custom_NotesPayableIssuedForForbearanceAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></span>
per share into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_zOZWiA8aWItc" title="Shares"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForForbearanceAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,132,059</ix:nonFraction></span> shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
    Payable issued for Consulting Agreements</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the outstanding balance of convertible notes payable issued in exchange for consulting services amounted to $<span id="xdx_909_eus-gaap--NotesPayable_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zq9MBgYR9oIl" title="Outstanding balance"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, the Company issued additional notes payable of $<span id="xdx_903_eus-gaap--NotesPayable_iI_pn5n6_c20210131__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zy4rzf83RuFg" title="Notes payable, issued"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-01-31_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million in exchange for consulting services as well as a note payable of $<span id="xdx_900_ecustom--NotesPayableForUnpaidConsultingFee_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zINSXAywSok2" title="Notes payable for unpaid consulting fee"><ix:nonFraction name="GTBP:NotesPayableForUnpaidConsultingFee" contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
million in exchange for cancellation of an unpaid consulting fee recorded and incurred in fiscal  2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2021 in accordance with the note agreements upon completion of an equity offering, these notes were mandatorily
converted at a conversion rate of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zHudqM3IXHn9" title="Conversion rate"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></span> per share into <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_z4fNr0nX4Z3h" title="Shares"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">472,059</ix:nonFraction></span> shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company accrued interest of $<span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zc3yQkwrfuZe" title="Accrued interes"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span>
million related to all outstanding convertible notes payable. In addition, during the period ended December 31, 2021, the Company
accrued interest of $<span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zm5MPJUQHOj8" title="Accrued interest"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million. As a result of the mandatory conversion of the Company&#8217;s notes payable, on February 16, 2021, total accrued interest
amounting to $<span id="xdx_908_ecustom--SharesIssuedDuringPeriodValueAccruedInterest_pn5n6_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_z9DsTt501rZ9" title="Total accrued interest"><ix:nonFraction name="GTBP:SharesIssuedDuringPeriodValueAccruedInterest" contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.5</ix:nonFraction></span>
million was converted to <span id="xdx_900_ecustom--SharesIssuedDuringPeriodSharesAccruedInterest_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zpxJMiVeDF1d" title="Number of shares issued for accrued interest"><ix:nonFraction name="GTBP:SharesIssuedDuringPeriodSharesAccruedInterest" contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,627,440</ix:nonFraction></span>
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
total, notes payable of $<span id="xdx_905_eus-gaap--NotesPayable_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zuvlxiLtgQ1k" title="Total, notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">38.8</ix:nonFraction></span> million ($<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_z6tLet9u7uMf" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">33.3</ix:nonFraction></span> million principal and accrued interest of $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zOCE8oJXlEOf" title="Accrued interest"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.5</ix:nonFraction></span> million) were mandatorily converted to <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zjE0u6UwQwM8" title="Converted shares"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2022-01-012022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,413,322</ix:nonFraction></span>
shares of common stock of which, <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zi3VDxa8rXA" title="Converted shares"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-01-012021-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,086,024</ix:nonFraction></span> shares of common stock were issued in fiscal 2021 and the
remaining <span id="xdx_90F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zR11M47JQKRg" title="Common stock shares, unissued"><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember15065312" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">327,298</ix:nonFraction></span> shares were issued in fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Adoption
of ASU 2020-06</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="background-color: white">In fiscal 2020, the Company recorded
a note/debt discount of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn5n6_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotePayableMember_zAJhhwRvtzC4" title="Debt instrument, convertible, beneficial conversion feature"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2020-01-012020-12-31_custom_ConvertibleNotePayableMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.7</ix:nonFraction></span>&#160;million to account for the beneficial conversion feature that existed on the date of issuance of certain
convertible notes payable. The debt discount was </span><span>being</span> <span style="background-color: white">amortized
to interest expense over the term of the corresponding convertible notes payable.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2021, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, <i>Debt-Debt with Conversion and
Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for
Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>. As a result of the adoption of ASU 2020-06, the Company extinguished
its previously recorded debt discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20221231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member_z4OBmMoB3scl" title="Debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2022-12-31_us-gaap_AccountingStandardsUpdate202006Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.7</ix:nonFraction></span> million by charging the opening additional paid in capital at January 1, 2021. In addition,
the Company also adjusted accumulated deficit to account for the derecognition of the $<span id="xdx_906_eus-gaap--InterestExpenseDebt_pn5n6_c20200101__20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member_z2WiKHnPFFLa" title="Interest expense due to amortization of debt discount"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2020-01-012020-12-31_us-gaap_AccountingStandardsUpdate202006Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million interest expense due to the amortization
of the debt discount that was recorded in fiscal 2020. As a result of these adjustments, the unamortized debt discount of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20211231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member_zsyBEA73pR42" title="Debt instrument, unamortized discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-12-31_us-gaap_AccountingStandardsUpdate202006Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million
was extinguished during the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DerivativesAndFairValueTextBlock"><p id="xdx_806_eus-gaap--DerivativesAndFairValueTextBlock_zFpbva4V1Woi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_829_zVr2Srjfp9i5">Derivative Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">During the year
ended December 31, 2020, the Company issued certain warrants that contained a fundamental transaction provision that could give rise to
an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with ASC 480,
the fair value of these warrants is classified as a liability in the Consolidated Balance Sheets and will be re-measured at
the end of every reporting period with the change in value reported in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuG0syJwcwxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liabilities were valued using a Binomial pricing model with the following average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_z0UziVqcKBw3" style="display: none">Schedule
of Derivative Liabilities Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zIpdXiETvf6d" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231_zRCfpTGncpsl" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5cUR9Ao3Je2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: justify">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.22</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.26</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zASm9Vf2dB6j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">109</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">129</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0NcfDqHMfvh" title="Expected life (in years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1">2.6</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_pid_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zwRU9ZyZICi7" title="Expected life (in years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1">3.6</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlDsQEUAjxIf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Fair value of warrants (in thousands)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231_zR5pR86lfrsk" title="Fair value of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210101__20211231_zZ2N533ilBTl" title="Fair value of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zM9qaQARkQXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.65pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its
common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by
the remaining contractual life of the derivative instrument. The expected dividend yield was based on the fact that the Company has not
paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2021, <span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_c20210101__20211231_zscbCzIe5ZR8" title="Warrant exercised"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,826</ix:nonFraction></span> warrants were exercised which resulted in an extinguishment of derivative liability charge of $<span id="xdx_908_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_pn4n6_c20211231_zniRJAbzohsk" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.03</ix:nonFraction></span> million. The Company
recognized a net gain of $<span id="xdx_905_eus-gaap--DerivativeGainOnDerivative_pn4n6_c20220101__20221231_zK5JdbpGRtIg" title="Net gain"><ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.12</ix:nonFraction></span> million and $<span id="xdx_90E_eus-gaap--DerivativeGainOnDerivative_pn4n6_c20210101__20211231_zsF1F9OMwKDk" title="Net gain"><ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.21</ix:nonFraction></span> million for the years ended December 31, 2022 and 2021, respectively, to account for
the <span id="xdx_907_eus-gaap--DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_iP3us-gaap--DerivativeGainOnDerivative_dxL_c20220101__20221231_zY5P46e6jWDg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23DerivativeGainLossOnDerivativeNet"><span id="xdx_90B_eus-gaap--DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_iP3us-gaap--DerivativeGainOnDerivative_dxL_c20210101__20211231_zo8iUfYNmmJi" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23DerivativeGainLossOnDerivativeNet"><span style="-sec-ix-hidden: xdx2ixbrl0845"><span style="-sec-ix-hidden: xdx2ixbrl0846">change in fair value of the derivative liability</span></span></span></span>.</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zLPhfjCHTdL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zEdDNLvpQEi" style="display: none">Schedule
of Derivative Liability Transactions</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20220101__20221231_zwhqCDktytb2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022<br />
                                            (in thousands)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20210101__20211231_zuvS276Z3CY9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021<br />
                                            (in thousands)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zeO1NaGtY4Q8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
    Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">384</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3n3_zomiiUQtoG6d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0854">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--ExtinguishmentOfWarrants_pn3n3_zZBctFgLebVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="GTBP:ExtinguishmentOfWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3n3_z7PNVM0M82Ic" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">119</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">211</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zUPudqAzKVg5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending
    Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zl2aaIOQzpXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zKQUBuy02gBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82A_z0QFMO2rDW23">Stockholders&#8217; Equity </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zd8CeVvLZQR2" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span> shares
of common stock , par value of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zKyJSga7VWla" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 10, 2021, the Company effectuated a 1:17
<span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20210208__20210210_zKbiWGmEmDxf" title="Stockholders&apos; equity, reverse stock split"><ix:nonNumeric contextRef="From2021-02-082021-02-10" name="us-gaap:StockholdersEquityReverseStockSplit">reverse stock split</ix:nonNumeric></span> of the Company&#8217;s issued and outstanding shares of common stock and all fractional shares were rounded up. All
share and per share amounts in the accompanying consolidated financial statements have been adjusted retroactively to reflect the reverse
stock split as if it had occurred at the beginning of the earliest period presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On October 10,
2022, at a special meeting of the stockholders of the Company, the stockholders ratified and approved the inclusion of discretionary votes
by brokers and other nominees holding shares for beneficial owners in the tabulation of votes on the proposal presented at the Company&#8217;s
annual meeting of stockholders to reduce the authorized number of shares of the Company&#8217;s common stock from <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20221010__srt--TitleOfIndividualAxis__custom--OwnersMember_zyWBx5RfAoEb" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-10-10_custom_OwnersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000,000</ix:nonFraction></span> shares to
<span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20221010_zdisYheuoLDh" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-10-10" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span> shares</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Common
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Issuance of common stock in public offering</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 16, 2021, the Company completed a public
offering of <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpwAkNUmmyhh" title="Common stock, capital shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-02-16_us-gaap_CommonStockMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,945,000</ix:nonFraction></span> shares of common stock for net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zcfc3cdXCT45" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-02-152021-02-16_us-gaap_CommonStockMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">24.7</ix:nonFraction></span> million, after deducting underwriting discounts, commissions and
other direct offering expenses. As part of the offering, the Company also granted these investors, warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zLiIQyznE9c5" title="Number of warrant purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-02-16_us-gaap_CommonStockMember_custom_InvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,192,250</ix:nonFraction></span> shares
of common stock. The warrants are fully vested, exercisable at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zDTAoHt2jvn5" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-02-16_us-gaap_CommonStockMember_custom_InvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></span> per share and will expire in <span id="xdx_901_ecustom--ClassOfWarrantExpireTerm_dc_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zv3UVhc6cmz3" title="Class of warrant expire term"><ix:nonNumeric contextRef="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_InvestorsMember" format="ixt-sec:durwordsen" name="GTBP:ClassOfWarrantExpireTerm">five years</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the completion of the public offering
and the successful listing of its shares of common stock on the Nasdaq Capital Market, convertible notes with an aggregate principal amount
of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_ztv1nvRA7o96" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">33.3</ix:nonFraction></span> million and accrued interest of $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zE52rCbki8I5" title="Debt instrument, increase, accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.5</ix:nonFraction></span> million, for a total of $<span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zwYC8ECGuS52" title="Debt conversion converted instrument amount"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">38.8</ix:nonFraction></span> million, were mandatorily converted at its stated conversion
rate of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zosnijamzma1" title="Debt instrument, convertible, conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></span> per share into <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zR1jxSRohmXj" title="Debt conversion, converted instrument, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,413,322</ix:nonFraction></span> shares of the Company&#8217;s common stock. The Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zspqLc9PbJUe" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,086,024</ix:nonFraction></span> shares of common stock
to these note holders while the remaining <span id="xdx_906_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zuhaSe9BwRwe" title="Remaining number of common shares"><ix:nonFraction name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">327,298</ix:nonFraction></span> common shares, valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zRWEMXTjQ15b" title="Stock issued during period, value, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million, were issuable at December 31, 2021. For financial
reporting purposes, as of December 31, 2021, the Company reported the $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMEexKEpKDY5" title="Stock issued during period, value, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million as common stock issuable to account for the estimated
balance of the converted notes payable and accrued interest that the Company had not yet issued the corresponding common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2022, the Company
issued the remaining <span id="xdx_90C_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zAHkBFRuhr23" title="Remaining number of common shares"><ix:nonFraction name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">327,298</ix:nonFraction></span> common shares issuable at December 31, 2021 valued at $<span id="xdx_90F_eus-gaap--StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_iI_pn5n6_c20221010__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zy4y5tBK1eia" title="Stock repurchase program, remaining authorized repurchase amount"><ix:nonFraction name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="AsOf2022-10-10_us-gaap_CommonStockMember_custom_NoteHolderMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million. In addition, the Company also issued
an additional <span id="xdx_907_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zHtM7NuXL5Ng" title="Additional paid in capital, common stock"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,404</ix:nonFraction></span> shares of commons stock with a fair value of $<span id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_z1vVp6xrKmV9" title="Adjustments to additional paid in capital, fair value"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span> as settlement with a noteholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<i><span style="text-decoration: underline">Cancellation of common stock previously
issued for services</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company cancelled <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpC8K3TQjYY3" title="Number of shares issued for service"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,999</ix:nonFraction></span> previously issued shares
of common stock during the year ended December 31, 2022.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Issuance of common stock as equity compensation
to officers, employees and board of directors</span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Company completed its equity offering and listed its shares of common stock on the Nasdaq Capital Market. As such,
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210213__20210216__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zOKBpO2B0xaa"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-02-132021-02-16_custom_EmploymentAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,379,407</ix:nonFraction></span> shares of its common stock were granted to these officers, employees and directors, which had a fair value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210213__20210216__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zAC0TiTiNdra"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-02-132021-02-16_custom_EmploymentAgreementsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">18.6</ix:nonFraction></span> million
at the date of Grant. Since the grant of the common stock is subject to milestone or performance conditions, such awards will be recorded
as compensation expense as the milestone or performance condition are met and in accordance with its vesting terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zxO8nyZd41wi"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_EmploymentAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,040,524</ix:nonFraction></span> shares of common stock and recognized stock compensation expense of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zy4PJYkb0Blc"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.9</ix:nonFraction></span>
million to account the fair value of common stock that vested under this award. Also in 2021, the Company cancelled&#160;<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zhTAG1wePlW9" title="Share based compensation cancelled"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-12-31_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">278,058</ix:nonFraction></span>&#160;shares
of common stock granted to a Board member in February 2021 and issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210201__20210228__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zh5XtqwoJh8"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-02-012021-02-28_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span> shares of common stock with a fair value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210201__20210228__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zY5IUBNIkUzj"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-02-012021-02-28_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,000</ix:nonFraction></span> to an
employee for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_z99BZu1zXgM9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">312,815</ix:nonFraction></span> shares of common stock and recognized stock compensation expense of $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zz3DnPpubcpl"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span>
million to account the fair value of common stock that vested. &#160;Also in 2022, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zRjWoyEuNrGh"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-12-31_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">396,708</ix:nonFraction></span> shares of common stock
with a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zXwoPxTK32Jl"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">994,000</ix:nonFraction></span> to certain officers of the Company for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there were <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zXF14PWgLZZj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-12-31_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,818</ix:nonFraction> </span>unvested shares of common stock issued to officers, employees and directors with a fair value
of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zpVWvUpmm1yh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2022-12-31_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,035</ix:nonFraction></span> that will be recognized as stock compensation expense in future periods pursuant to its vesting term.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Equity
compensation to consultants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Company completed its equity offering and listed its shares of common stock on the Nasdaq Capital Market. As such,
<span id="xdx_90F_eus-gaap--SharesIssued_iI_pid_c20210216__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zlm91lZmPGnh"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2021-02-16_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,850,090</ix:nonFraction></span> shares of its common stock were granted to consultants, which had a fair value of $<span id="xdx_90D_ecustom--CommonStockConsultantToFairValue_pn5n6_c20210215__20210216__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zNGMxFvPC2H1"><ix:nonFraction name="GTBP:CommonStockConsultantToFairValue" contextRef="From2021-02-152021-02-16_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.7</ix:nonFraction></span> million at the date of Grant. Since
the grant of the common stock is subject to milestone or performance conditions, such awards will be recorded as compensation expense
as the milestone or performance condition are met and in accordance with its vesting terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zd0kZoKGb8B1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,432,895</ix:nonFraction></span> shares of common stock and recognized stock compensation expense of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z8oK4XzitrA2"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.2</ix:nonFraction></span>
million to account the fair value of common stock that vested under this award. Also in 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_znKGIDHPI4G3"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-12-31_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">649,511</ix:nonFraction></span> shares of common
stock with a fair value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zWIanw0JMO2e"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.1</ix:nonFraction></span> million to consultants for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z6TjmqnNKap"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">370,744</ix:nonFraction></span> shares of common stock and recognized stock compensation expense of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zVSyDib7z3pi"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span>
million to account the fair value of common stock that vested under this award. Also in 2022, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zX7y68c43hp8"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-12-31_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">156,113</ix:nonFraction></span> shares of fully
vested common stock with a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zB77YaHajyGf"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">791,000</ix:nonFraction></span> to consultants for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zrvgZZ8x25Ee"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-12-31_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,343</ix:nonFraction></span> unvested shares of common stock issued to consultants with a fair value of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zAwDwiLanqf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2022-12-31_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,664</ix:nonFraction></span> that will
be recognized as stock compensation expense in future periods pursuant to its vesting term.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<ix:exclude><!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span style="text-decoration: underline">Cancellation of common stock upon settlement
with a former Officer</span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2022, the Company entered into a settlement agreement with its former Chief Executive Officer (&#8220;Officer&#8221;) and
received <span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20220428__20220429__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ztrphrX4wcU3" title="Number of shares received"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-04-282022-04-29_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,845,000</ix:nonFraction></span>
shares of its previously issued common stock in full and final settlement of all its claims against the Officer. The common stock
was subsequently cancelled and returned to treasury. In addition, the Company incurred legal and professional expenses of $<span id="xdx_908_eus-gaap--ProfessionalFees_c20220428__20220429__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zU1TVmgUCzub" title="Legal and professional expenses"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2022-04-282022-04-29_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,243</ix:nonFraction></span>.
The legal and professional fees incurred were accounted as costs of the acquisition of the common stock and recorded as
a reduction to additional paid in capital. Both the Company and the Officer released each other from claims under the settlement
agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Preferred
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">A.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Series
    C Preferred Stock</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2022 and 2021, there were <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zOzKHR6Yl3e9"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction>
</span>shares of Series C Preferred Stock, par value $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zmMwkpPgloja"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction>
</span>per share (the &#8220;Series C Preferred Stock&#8221;) issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of stock splits in previous years, the <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zXGkBLjfg6y7" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span> shares of Series C Preferred Stock are not convertible. Shares of Series C Preferred
Stock have no voting rights. Similarly, as there are no conversion rights, in the event of liquidation, the holders of the Series C Preferred
Stock shall not participate in any distribution of the assets or surplus funds of the Company. The holders of Series C Preferred Stock
also are not entitled to any dividends if and when declared by the Company&#8217;s board of directors. No dividends
to holders of the Series C Preferred Stock were issued or unpaid through December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Series
    J-1 Preferred Stock</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -34.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue its
Series J-1 Preferred Stock with a par value of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zoRxDOmjT7a4" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesJOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share. Shares of the Series J Preferred Stock were convertible at any time,
at the option of the holders, into shares of the Company&#8217;s common stock at an effective conversion price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_z56X6v6U2Lk8"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-12-31_custom_SeriesJPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></span>&#160;per
share, subject to adjustment for, among other things, stock dividends, stock splits, combinations, reclassifications of our capital
stock and mergers or consolidations, and subject to a beneficial ownership limitation which prohibits conversion if such conversion
would result in the holder (together with its affiliates) being the beneficial owner of in excess of&#160;<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zWLsw9PYqd5j"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2022-01-012022-12-31_custom_SeriesJPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>%
of the Company&#8217;s common stock. Shares of the Series J Preferred Stock had the same voting rights as shares of the
Company&#8217;s common stock, with the holders of the Series J Preferred Stock entitled to vote on an as-converted-to-common stock
basis, subject to the beneficial ownership limitation described above, together with the holders of the Company&#8217;s common stock
on all matters presented to the Company&#8217;s stockholders. The Series J Preferred Stock are not entitled to any dividends (unless
specifically declared by the Board), but would participate on an as-converted-to-common-stock basis in any dividends to the holders
of the Company&#8217;s common stock. In the event of the Company&#8217;s dissolution, liquidation or winding up, the holders of the
Series J Preferred Stock would be on parity with the holders of the Company&#8217;s common stock and would participate, on a on an
as-converted-to-common stock basis, in any distribution to holders of the Company&#8217;s common stock. As of December 31, 2020,
total Series J-1 Preferred stock issued and outstanding totaled 2,353,548 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the completion of the public offering and
the successful listing of the Company&#8217;s shares of common stock on the Nasdaq Capital Market, in February 2021, all outstanding Series
J Preferred Stock totaling <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20210201__20210228__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_z1SZHqcgqMc8" title="Common shares issued upon conversion of notes payable, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-02-012021-02-28_custom_SeriesJPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,353,548</ix:nonFraction></span> shares were mandatorily converted to <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zunYhvIJZWp4" title="Common shares issued upon conversion of notes payable, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_custom_SeriesJPreferredStockMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">692,220</ix:nonFraction></span> shares of common stock pursuant to the terms
of the conversion agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022 and 2021, there were <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zHWqyNlzDfh4" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zVL0F4id9Gii" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zYj5xapsZj3h" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zZkQlC2yv5wf" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesJOnePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_custom_SeriesJOnePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesJOnePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesJOnePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> Series J-1 Preferred Stock
issued and outstanding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Series
    K Preferred Stock</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Board designated <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210215__20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_z7ejRTICysig" title="Preferred stock shares designated"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,000</ix:nonFraction></span> shares of Series K preferred stock, par value $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zEhcGRbMnKbk" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember" decimals="INF" unitRef="USDPShares">.01</ix:nonFraction></span>. (the &#8220;Series K Preferred Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company&#8217;s common
stock at an effective conversion rate of <span id="xdx_90B_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zP97wDRlj8qc" title="Convertible shares issuable"><ix:nonFraction name="us-gaap:PreferredStockConvertibleSharesIssuable" contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares of common stock for each share of Series K Preferred Stock. Shares of the Series
K Preferred Stock have the same voting rights a shares of the Company&#8217;s common stock, with the holders of the Series K Preferred
Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders
of the Company&#8217;s common stock on all matters presented to the Company&#8217;s stockholders. The Series K Preferred Stock are not
entitled to any dividends (unless specifically declared by the Board), but will participate on an as-converted-to-common-stock basis
in any dividends to the holders of the Company&#8217;s common stock. In the event of the Company&#8217;s dissolution, liquidation or
winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company&#8217;s common stock and will
participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021, there were
<span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zgEZZNVaC3T4" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zFCEqqMKnhUe" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_z3CzNQbAehxl" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zQKKxUv9kecg" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesKPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_custom_SeriesKPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesKPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesKPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> Series K Preferred stock, issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Warrants
and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVmuTixxFRaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the years ended December 31, 2022 and 2021, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zPL1qDLeTdUk" style="display: none">Schedule of Warrant Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants outstanding at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zAidrt5agsmk" title="Warrants outstanding, beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">221,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zcGY9iwCNPcb" title="Weighted average exercise price, beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_z3EuXatLSHOl" title="Number of warrants, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,192,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20210101__20211231_z2d46zBA1gvb" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231_z3FOuNgqLgG" title="Number of warrants, forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20210101__20211231_zROGhViFSt42" title="Weighted average exercise price, forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231_zOAQSpW12wJk" title="Number of warrants, exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,074,017</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zjSQy4fHZey7" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_z1ALWcmxMJB4" title="Warrants outstanding, beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,337,274</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zHJbdLrHCZa" title="Weighted average exercise price, beginning balance" style="text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_z4oyI7zEEEc6" title="Number of warrants, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20220101__20221231_zdzHJQmsyOFl" title="Weighted average exercise price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231_zB3JqQ7hdXn6" title="Number of warrants, forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20220101__20221231_zyy8ERkDL5i2" title="Weighted average exercise price, forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231_zr1rAal3cNe8" title="Number of warrants, exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zb1oj5ephd23" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231_zs8TjyYL8tD9" title="Warrants outstanding, beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,337,274</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_z8OFkijsZDT8" title="Weighted average exercise price, beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20221231_zhXYdJr1oDH1" title="Warrants exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,337,274</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zZaOUhMxFGYk" title="Exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zEGw13l4zTt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, as part of the Company&#8217;s public offering, the Company issued warrants to investors to purchase up to an aggregate
of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210216__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_znaZytMyyWj9" title="Issued warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-02-16_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,192,250</ix:nonFraction></span> shares of common stock. The warrants have an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210216__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zfJcAWBtWWsd" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-02-16_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></span> per share, subject to adjustment in certain circumstances
and has a term of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dc_c20210216__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zcFDSKBm74uj" title="Warrant term"><ix:nonNumeric contextRef="AsOf2021-02-16_us-gaap_IPOMember" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfqLj6XNRulh" title="Common stock  exercise  warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,074,017</ix:nonFraction></span> shares of common stock upon exercise of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4xnxFEAG49e" title="Common stock  exercise  warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,074,017</ix:nonFraction></span> warrants, which resulted cash proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN8q6pmoTz46" title="Warrants  cash proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.4</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, all issued and outstanding
warrants are fully vested. <span style="background-color: white">There was <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20221231_z5b8mH6RebPd" title="Options outstanding intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> intrinsic
value of the outstanding warrants as of December 31, 2022, as the exercise price of these warrants was equal to or greater than the market
price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9N3xVDZw8b3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option transactions for the years ended December 31, 2022 and 2021 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BF_zkmuoVUXWQr" style="display: none">Schedule
of Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zvSot9rnVhHk" title="Number of options outstanding, beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zWwJMd2Jqvg8" title="Weighted-Average Exercise Price, Beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20210101__20211231_zPtEn2lmMNve" title="Number of options, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zOA5w1sNPSxk" title="Weighted-Average Exercise Price, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20210101__20211231_zq2iQDVImP56" title="Number of options, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_znWJP9XBSWu1" title="Weighted-Average Exercise Price, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20210101__20211231_z5Ra0jdk0ouj" title="Number of options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zQsqX1NCgGZa" title="Weighted-Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_z32vbvCsSZPh" title="Number of options outstanding, beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z2mT1cvUOU9b" title="Weighted-Average Exercise Price, Beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231_zOfZ1vfUgNp1" title="Number of options outstanding, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,532,952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zH5JUeKQI1Q9" title="Weighted-Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231_zZcvKcdMJeX1" title="Number of options outstanding, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">205,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zIEx8nBiVGS" title="Weighted-Average Exercise Price, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20220101__20221231_z9CTyUEVT7j8" title="Number of options outstanding, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zA1BPoS8srYj" title="Weighted-Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zNJkXaRTv711" title="Number of options outstanding outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,630,452</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zq7QYxtAaMzb" title="Weighted-Average Exercise Price, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.57</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zrF4X1nmq76b" title="Number of options outstanding, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,440,404</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zk9HfEbEkYnd" title="Weighted-Average Exercise Price, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.55</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zG8DHITmGgD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Year Ended December 31, 2022</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2022, the Company granted certain consultants, employees, officers and directors stock options to purchase an aggregate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zc9y8XUDc3f5" title="Common stock, stock option shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,532,952</ix:nonFraction></span>
shares of common stock. The stock options are exercisable at $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_z9vRzXx3AYS3" title="Stock options  exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.48</ix:nonFraction></span> per share and will expire in 10 years. A portion of the options vested
immediately with the remaining portion vesting over a period of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_zNrFdJzh91Nk" title="Vesting period"><ix:nonNumeric contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember_srt_MinimumMember" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">5 months</ix:nonNumeric></span> up to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zqpLi5KI9466" title="Vesting period"><ix:nonNumeric contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">36 months</ix:nonNumeric></span>. The fair value of the options amounted to $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zWVtr8KphqE5" title="Fair value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">3.4</ix:nonFraction></span>
million or an average of $2.22 per share and were calculated using the Black Scholes Option pricing model. Assumptions used in the model
were: expected term &#8211; <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zvLguMBScbva" title="Expected term"><ix:nonNumeric contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.27</ix:nonNumeric></span> years; expected volatility &#8211; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zr2bHm3hY3Eg" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125.53</ix:nonFraction></span>%; risk free interest rate &#8211; <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zuTk8M89qP71" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.03</ix:nonFraction></span>% and dividend yield
of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zKeVIbTIa5ji" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%. The Company  recognized the corresponding stock compensation expense of these options based upon the vesting term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded forfeitures of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_znwTXK4ACZbd" title="Forfeited"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2022-01-012022-12-31_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">205,000</ix:nonFraction></span> options to purchase common stock during 2022 due to the resignation of employees. The forfeitures
were related to shares that had not yet been vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2022, the Company
recorded total stock compensation of $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231_z5Ly2DokQ6I6" title="Share-based compensation arrangement by share-based payment award, options, vested in period, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,032,000</ix:nonFraction></span> to account the fair value of stock options that vested in fiscal 2022.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022, there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20221231_z6YmLoqjlCkl" title="Non- vested number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">275,101</ix:nonFraction></span> unvested
options with a grant date fair value of $<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_iI_c20221231_zySlCthYJeUe" title="Share based compensation unvested intrinsic value"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">645,172</ix:nonFraction></span> which will be recognized as stock compensation expense in future periods based upon the
remaining vesting term of the applicable grants. There was no intrinsic value of the outstanding options at December 31, 2022, as the
exercise price of these options is greater than or equal to the market price.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Year Ended December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 31, 2021, the Company granted two employees
a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zY3LVkNpUmlf" title="Stock option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,500</ix:nonFraction></span> stock options. The stock options are exercisable at $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zdvNobShe0v8" title="Stock options exercisable price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_TwoEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></span> per share and will expire in <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zQ3Ky9PxCoui" title="Options expiration period"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10 years</ix:nonNumeric></span>. A portion of the options
vested immediately, with the remaining portion vesting over a two-year period from the date of grant. The fair value of the options amounted
to $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zH8Dsliw3qh7" title="Fair value of options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">808,280</ix:nonFraction></span> or an average of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zGJgEH7dlNhk" title="Fair value of stock option, per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.67</ix:nonFraction></span> per share and were calculated using a Black-Scholes option pricing model. Assumptions used in the model
were: expected term &#8211; <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220714__20220715__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zHLsFeZaFhBb" title="Expected term"><ix:nonNumeric contextRef="From2022-07-142022-07-15_custom_TwoEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span> years; expected volatility &#8211; <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zalQQh5QohYf" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">129.0</ix:nonFraction></span>%; risk free interest rate &#8211; <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zWMiPsVOjATe" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.26</ix:nonFraction></span>% and dividend yield of
<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zULcgE4KZAwd" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2021, the Company
recorded stock compensation of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zD3tRNlc3qSb" title="Stock option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">251,000</ix:nonFraction></span> to account the fair value of stock options that vested in fiscal 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_zbPCxLmqGDIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note
8 &#8211; <span id="xdx_821_zBt9qWb7Y5G2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Leases</span></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 19, 2021, the Company entered into a sublease
with a third party for <span id="xdx_908_eus-gaap--AreaOfLand_iI_uSqft_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdwpnFY5S88" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2021-11-19_us-gaap_LeaseAgreementsMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">4,500</ix:nonFraction></span> square feet of office space located in Brisbane, California, with a <span id="xdx_906_eus-gaap--LesseeOperatingSubleaseOptionToExtend_c20211118__20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zCgCyzaaWIEk" title="Commencement date"><ix:nonNumeric contextRef="From2021-11-182021-11-19_us-gaap_LeaseAgreementsMember" name="us-gaap:LesseeOperatingSubleaseOptionToExtend">commencement date of January 1, 2022
and maturing on June 30, 2024.</ix:nonNumeric></span> <span style="background-color: white">Leases with an initial term of 12 months or less are not recorded
on the balance sheet. The Company accounts for the lease and non-lease components of its leases as a single lease component. Rent expense
is recognized on a straight-line basis over the lease term. As a result of this agreement, the Company recognized</span> right-of-use
(&#8220;ROU&#8221;) asset and liability of $<span id="xdx_90B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zTxl9URnVjtc" title="Operating lease, right-of-use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-11-19_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247,294</ix:nonFraction></span> <span style="background-color: white">pursuant to ASC 842<i>, Lease.</i></span> Operating
lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease
term. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the
Company&#8217;s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is
not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The
Company&#8217;s incremental borrowing rate is a hypothetical collateralized borrowing rate based on its understanding of what its credit
rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 8, 2022, the Company entered another lease
which will end on February 7, 2025. As a result, the Company <span style="background-color: white">recognized</span> additional ROU asset
and liability of $<span id="xdx_908_ecustom--AdditionalOperatingLeaseAssets_c20220207__20220208__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0EB4mXgz551" title="Additional Operating lease assets"><ix:nonFraction name="GTBP:AdditionalOperatingLeaseAssets" contextRef="From2022-02-072022-02-08_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,861</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">As a result of these lease agreements,
the Company recognized ROU asset and liability in the aggregate of $<span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20220208_zm332CEMNLxk" title="Operating lease, right-of-use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-02-08" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,155</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_z92Vm6MA67r1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">The components of rent expense and
supplemental cash flow information related to leases for the period are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">&#160;<span id="xdx_8B1_zFWXrBDT8D1h" style="display: none">Schedule of Components
Leases Rent Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Lease Costs (in thousands):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 76%; text-align: justify; padding-bottom: 1.5pt">Operating cash flows from operating leases</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeasePayments_c20220101__20221231_zDf2DayfmIDe" title="Operating cash flows from operating leases" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: justify">Other Information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Weighted-average remaining lease term (in years):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zHOIuaDSkMm4" title="Weighted average remaining lease term operating leases"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.75</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Weighted-average discount rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20221231_zlh5gotrxAuk" title="Weighted average discount rate operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zs2c3Go7FO58" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="GTBP:ScheduleOfSupplementalLeaseTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfSupplementalLeaseTableTextBlock_zQqKkypmcrnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
supplemental balance sheet information related to leases for the period is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_8BB_zL5YJSkPcp3a" style="display: none"><span>Schedule of
Supplemental Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zI2kWyxqLMk6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Operating leases (in thousands)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LongtermRightofuseAssetsNet_iI_pn3n3_zSbacztJBaqg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 76%; text-align: justify; padding-bottom: 1.5pt">Long-term right-of-use assets, net</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right"><ix:nonFraction name="GTBP:LongtermRightofuseAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLz4mp_zItWNdkXQIkf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Current portion of operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLz4mp_zoy3sdcm63Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Non-current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLz4mp_zlvj2TidPRDj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Total operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">174</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zCsp7DHArpk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhWalD4vG3Ti" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Maturities of the Company&#8217;s
lease liabilities are as follows (in thousands):</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zpkYAqAVHDL6" style="display: none">Schedule of Maturity Lease Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">Year ending</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_z5ARj7VPtFO7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzt3J_zGKx2PUnKdj5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzt3J_zk5pIjkIgFQb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLLzt3J_z7Na7aLyZ1p1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzt3J_zH17zc4DhhA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Total lease payments</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_za5mS08gj6hi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Less: Imputed interest/present value
    discount</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_zfYygSXv4mdj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Present value of lease liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">174</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Split-Segment; Name: 001 -->
</ix:nonNumeric><p id="xdx_8A1_zFcbcSxu2lrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zL5cb7TZwcS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_827_z7DFQ6mEV838">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, the Company records accruals for contingencies to the extent that our management concludes that the occurrence is
probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed
as incurred. There is no current or pending litigation of any significance with the exception of the matters that have arisen under,
and are being handled in, the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 13, 2022, the Company filed a demand for arbitration with the American Arbitration Association (AAA) against Michael Handelman, its
former Chief Financial Officer, on claims of breach of fiduciary duty and failure to comply with federal securities reporting law. The
claims are pending before an arbitrator in Los Angeles and the hearing is scheduled to begin on May 15, 2023. Mr. Handelman has not asserted
counterclaims against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28, 2019, a complaint was filed in the Superior Court of California, County of Los Angeles, West Judicial District, Santa Monica
Courthouse, Unlimited Civil Division by Jeffrey Lion and by Daniel Vallera, as individuals. The complaint was filed against GT Biopharma,
Inc. and its subsidiary Oxis Biotech, Inc. The Plaintiffs allege breach of a license agreement between the Plaintiffs and the Company
entered into on or about September 3, 2015. The Company filed an answer to the complaint denying many allegations and asserting affirmative
defenses. The Company reached a settlement of the case and paid on March 4, 2022, $<span id="xdx_905_eus-gaap--LitigationSettlementExpense_c20220301__20220304_zIxuh5yPGAW5" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2022-03-012022-03-04" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425,000</ix:nonFraction></span> in full and final settlement of the claims.
This amount was fully accrued at December 31, 2021 and was paid during fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 3, 2021, a complaint was filed by Sheffield Properties in the superior Court of California, County of Ventura. The litigation arose
from a commercial lease entered into by GT Biopharma, Inc. for office space in Westlake Village in California. In July, 2021 the Company
entered into settlement agreement with Sheffield Properties and the payment in the settlement amount of $<span id="xdx_90E_eus-gaap--LitigationSettlementExpense_pn5n6_c20210805__20210806__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SheffieldPropertiesMember_zi3UALQO0la6" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2021-08-052021-08-06_custom_SheffieldPropertiesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million was made on August
6, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Significant
Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a Scientific Research Agreement (&#8220;SRA&#8221;) with the Regents of the University of Minnesota, effective
June 16, 2021. This SRA has three major goals: (1) support the Company&#8217;s TriKE<sup>&#174;</sup>
product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans; and, (3)
investigation of the patient&#8217;s native NK cell population based on insights obtained from the analysis of the human data
generated during our GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for
TriKE<sup>&#174;</sup> constructs in support of our product development and GMP manufacturing efforts; (2) TriKE<sup>&#174; </sup>platform
drug delivery changes to allow transition to alternative drug delivery means and extended PK in humans; and, (3) gain an increased
understanding of changes in the patient&#8217;s native NK cell population as a result of TriKE<sup>&#174;</sup> therapy. Most studies
will use TriKE<sup>&#174;</sup> DNA/amino acid sequences created by us under current UMN/GTB licensing terms. The term of this
agreement shall expire on June 30, 2023. The University of Minnesota shall use reasonable efforts to complete the project for a
fixed sum of $<span id="xdx_901_ecustom--ProjectFee_pn5n6_c20220101__20221231_znX8N0UnZ7Wk" title="Project fee"><ix:nonFraction name="GTBP:ProjectFee" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million,
of which $<span id="xdx_90C_ecustom--ProjectFeeIncurred_pn5n6_c20220101__20221231_z3FC3sDrYsDk" title="Project fee incurred"><ix:nonFraction name="GTBP:ProjectFeeIncurred" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span>
million has been incurred and recorded as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recorded an expense of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zpxaZ9XbI0b1" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_ScientificResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">766,000</ix:nonFraction></span>
and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zskFIsaiqs9f" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_ScientificResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">964,000</ix:nonFraction></span>
relating to the scientific research agreement for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2016
Exclusive Patent License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (&#8220;UofMN&#8221;),
to further develop and commercialize cancer therapies using TriKE<sup>&#174;</sup> technology developed by researchers at the UofMN to
target NK cells to cancer. Under the terms of the 2016 agreement, the Company receives exclusive rights to conduct research and to develop,
make, use, sell, and import TriKE<sup>&#174;</sup> technology worldwide for the treatment of any disease, state, or condition in humans.
The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted
by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE<sup>&#174;</sup>
technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union.
Under the agreement, the UofMN received an upfront payment of $<span id="xdx_908_ecustom--ProceedsFromUpfrontAmount_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zIY1O6U800xa" title="Proceeds from upfront amount"><ix:nonFraction name="GTBP:ProceedsFromUpfrontAmount" contextRef="AsOf2022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, and an annual License Maintenance fee of $<span id="xdx_900_eus-gaap--CostMaintenance_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpevlTGwQbjl" title="Maintenance fee"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million beginning
in 2021. The agreement also includes <span id="xdx_907_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zw5GAdAFkCJ3" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction>%</span> royalty fees, (not to exceed <span id="xdx_909_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zyR5a3A0Pjlj" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% under subsequence license agreements or amendments to this agreement
or minimum annual royalty payments ranging from $<span id="xdx_904_eus-gaap--RoyaltyExpense_pn4n6_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zKIFkbspZKPk" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.25</ix:nonFraction></span> million to $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn5n6_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zPPEhNCer4Yd" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million. The agreement also includes certain performance milestone
payments totaling $<span id="xdx_90E_ecustom--PerformanceMilestonePayments_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zv7YOjA5Lo4k" title="Milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, and one-time sales milestone payments of $<span id="xdx_907_ecustom--SalesMilestonePayments_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zT8dcmHnEfKc" title="Sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million upon reaching $<span id="xdx_902_ecustom--GrossSales_pn6n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zHAvE3einS8g" title="Sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million in gross sales, and
$<span id="xdx_907_ecustom--SalesRevenue_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpaIWXZr1Gmg" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million upon reaching $<span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zgwWRPoGlIIl" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million dollars in cumulative gross sales of Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did <span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zMDxqCnMbczh" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span>t incur any research and development expense relating to the 2016 Exclusive Patent
License Agreement for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021
Patent License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE<sup>&#174;</sup>. Under the agreement, the UofMN received
an upfront license fee of $<span id="xdx_901_ecustom--UpfrontLicenseFee_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zabHXXf0dU61" title="Upfront license fee"><ix:nonFraction name="GTBP:UpfrontLicenseFee" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span>, and will receive an annual License Maintenance fee of $<span id="xdx_901_ecustom--LicenseMaintenanceFeeReceivable_iI_c20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zZcbJzB6K9S8" title="License maintenance fee, receivable"><ix:nonFraction name="GTBP:LicenseMaintenanceFeeReceivable" contextRef="AsOf2021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> beginning in 2022, <span id="xdx_906_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zTi64CfuvDfe" title="Net sales percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2021-03-252021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction>%</span> to <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zTccv5LX3Ojh" title="Net sales percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2021-03-252021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%</span> royalty
fees, or minimum annual royalty payments of $<span id="xdx_90B_eus-gaap--RoyaltyExpense_pn4n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zTDWdC6uL0O" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.25</ix:nonFraction></span> million beginning in the year after the first commercial sales of Licensed Product,
and $<span id="xdx_901_eus-gaap--CostMaintenance_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zUG4R1ersv34" title="Maintenance fee"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million beginning in the fifth year after the first commercial sale of such Licensed Product. The agreement also includes certain
performance milestone payments totaling $<span id="xdx_905_ecustom--PerformanceMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zhSqJdWZ4rA5" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z9vFpZJlPwI8" title="Sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million upon reaching $<span id="xdx_90E_ecustom--GrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8J1nnEfFa1k" title="Gross sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million
in gross sales, and $<span id="xdx_909_ecustom--SalesRevenue_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zi9U1CfAyz2" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million upon reaching $<span id="xdx_901_ecustom--CummulativeGrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zNjYVUv7Knd8" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million dollars in cumulative gross sales of Licensed Products. There is no double
payment intended; if one of the milestone payments has been paid under the 2016 agreement no further payment is due for the corresponding
milestone above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did <span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdOEvssQX5aa" title="Research and development expense"><span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zHz5gzbRA6k6" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t incur any research and development expense relating to the 2021 Patent License
Agreement for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p id="xdx_8AA_zSlMIiHsedS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Employee Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="GTBP:ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock_zJjSbKygK2t4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s future financial commitment to certain employees pursuant to their respective employment
agreements (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zasXu0L8RLFa" style="display: none">Schedule
of Company&#8217;s Future Financial Commitment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year ending</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zQONIIjZE8B5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherCommitmentDueInNextTwelveMonths_iI_pn3n3_maOCzdEO_zB66ZJtMVo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:OtherCommitmentDueInNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">432</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherCommitmentDueInSecondYear_iI_pn3n3_maOCzdEO_zWNNXeI8fjTi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherCommitmentDueInSecondYear" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherCommitment_iTI_pn3n3_mtOCzdEO_zchEAYQARl88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">486</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z5EnAi48fsQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zdbUCYALItXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_826_zGs4BOHfW4g9">Income Tax</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any income tax provision for the years ended December 31, 2022 and 2021, respectively, due to the Company&#8217;s net losses.
The Company files income tax returns in the United States (&#8220;Federal&#8221;) and California, Minnesota and Massachusetts (&#8220;State&#8221;)
jurisdictions. The Company is subject to Federal and State income tax examinations by tax authorities for all years since its inception.
At December 31, 2022, the Company had Federal and State net operating loss carry forwards available to offset future taxable income of
approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20221231_zgRke5BEOZr9" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">238</ix:nonFraction></span> million. These carry forwards will begin to expire in the year ending <span id="xdx_903_eus-gaap--OperatingLossCarryforwardsExpirationDate_c20220101__20221231_zpnmav7XqAQ4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="us-gaap:OperatingLossCarryforwardsExpirationDate">December 31, 2030</ix:nonNumeric></span>, subject to IRS limitations,
including change in ownership. The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts
the carrying amount of the deferred tax assets by a valuation allowance to the extent the future realization of the deferred tax assets
is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of our
deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or
loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the weight of available evidence,
including cumulative losses in recent years and expectations of future taxable income, the Company has determined that it was more
likely than not that its deferred tax assets would not be realized at December 31, 2022 and 2021, respectively. Accordingly, the Company has recorded a valuation allowance for <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20220101__20221231_zGJ0K1PR39J2"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20210101__20211231_zRpN296xz6cc"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></ix:nonFraction></span></span>%
of its cumulative deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes, and operating losses and tax credit carryforwards. The significant components
of net deferred income tax assets are (in thousands):</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zpsMRDz6YbBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zgUdxd1Q2Lnd" style="display: none">Schedule
of Net Deferred Income Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_496_20221231_zJFoI1d9QIrl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_491_20211231_zGGctYHlTdvl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn3n3_maDTAGzPo9_zjG3tRmkgLZ4" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Federal net operating loss carryforward</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66,741</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58,171</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTAGzPo9_zCJGaYqDJxe6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation and other items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,674</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,622</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzPo9_zQDTJK1tT7yc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Intellectual property</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41,572</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzPo9_maDTANzU5L_z2A16JeZ213e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets before valuation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,987</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127,848</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzU5L_zwiCOrrHX0Kh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,987</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127,848</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzU5L_zdxbcBSgYsF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zDM9xO4w7Lff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z7lxuxZ2xD3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income tax
provision is as follows for the year ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zC4cXtFI7ON3" style="display: none">Schedule
of Income Tax Provision</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zKRygQgZKjLg" title="Federal statutory income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zNVbotp5Aolj" title="Federal statutory income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zmZUT8NLhfdi" title="State tax, net of federal benefit"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231_zXTK0f8UVrQk" title="State tax, net of federal benefit"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance on net operating loss carryforwards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20220101__20221231_zEtbWqxdas7b" title="Change in valuation allowance on net operating loss carryforwards">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">29</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20210101__20211231_zvArZUvdEWe6" title="Change in valuation allowance on net operating loss carryforwards">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">30</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zg1lOq9En3wc" title="Effective income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zZMABh2k79r7" title="Effective income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zaJjnrNAQQ3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zev4qmpX8GH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; <span id="xdx_82F_zDvMeHszkSlc">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock
Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, GT Biopharma received gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember_zb2HwkUEJlm" title="Gross proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-032023-01-04_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_InstitutionalInvestorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.5</ix:nonFraction></span> million, before deducting placement agent fees and other offering expenses
of approximately $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ziWlbS8dWKSh" title="Placement agent fees and other offering expenses"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-01-032023-01-04_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_InstitutionalInvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span>, in relation to a purchase agreement (the &#8220;Purchase Agreement&#8221;) signed on December 30, 2022, <span style="background-color: white">between
the Company</span> and an institutional investor (the &#8220;Purchaser&#8221;) for the issuance and sale, in a registered direct offering
(the &#8220;Offering&#8221;), of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjrAIizOUfUg" title="Common stock shares issued during the period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-032023-01-04_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_InstitutionalInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,600,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBotL1Cvaqi3" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (the &#8220;Shares&#8221;),
pre-funded warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__srt--RangeAxis__srt--MaximumMember_zrNvqD7rtCJ" title="Warrants purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">2,900,000</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;Pre-Funded Warrants&#8221;), and
warrants to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_ziwF1AC09GB2" title="Warrants purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_CommonWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">6,500,000</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;Common Warrants&#8221;).
The Common Warrants have an exercise price equal to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zrHSRH5EBhli" title="Warrants exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_CommonWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USDPShares">1.00</ix:nonFraction></span>, will be exercisable commencing six months following issuance, and will have
a term of exercise equal to five years following the initial exercise date. The Pre-Funded Warrants have an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zdzuJqF92Ftg" title="Warrants exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per Share, are immediately exercisable and can be exercised at any time after their original issuance until such Pre-Funded Warrants
are exercised in full. The Shares and Common Warrants were sold at an offering price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zoiHWhKkxnE8" title="Shares and warrants sold price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_CommonWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USDPShares">1.00</ix:nonFraction></span> per Share and accompanying Common Warrant
and the Pre-Funded Warrants and Common Warrants were sold at an offering price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pip0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zUSxHzPBDTW7" title="Shares and warrants sold price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.9999</ix:nonFraction></span> per Pre-Funded Warrant and accompanying Common
Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Issuance
of Common Stock for research and development agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 14, 2023, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230313__20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentAgreementMember_ztTj4Qn3KKye" title="Common stock shares issued during the period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-03-132023-03-14_us-gaap_SubsequentEventMember_custom_ResearchAndDevelopmentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">486,819</ix:nonFraction></span> </span> shares of common stock with a fair value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230313__20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentAgreementMember_z0liH6L68MV" title="Common stock value issued during the period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-03-132023-03-14_us-gaap_SubsequentEventMember_custom_ResearchAndDevelopmentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">820,341</ix:nonFraction></span> pursuant to a payment agreement
with a third-party manufacturer (see Note 4). The shares were valued at the respective month-end closing prices of the Company&#8217;s common stock when the payment was due to the vendor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Demand
Letter</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company received a demand letter from an attorney representing an alleged holder of a convertible note which alleges
that the Company did not deliver shares of common stock that were due on conversion in 2022. The demand letter contends that the Company
is liable for per diem liquidated damages. The Company has denied liability and will defend any such claim vigorously if asserted.</span></p>

</ix:nonNumeric><p id="xdx_815_zjBe6QdkQl32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>2
<FILENAME>ex3-5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 3.5</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex3-5_001.jpg" ALT="" STYLE="height: 946px; width: 670px">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex3-5_002.jpg" ALT="" STYLE="height: 868px; width: 670px">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>3
<FILENAME>ex4-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
PURSUANT TO SECTION 12 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following is a summary of the material terms of our securities that are registered under Section 12 of the Securities Exchange Act of
1934, as amended, or the Exchange Act, and is not intended to be a complete summary of the rights and preferences of such securities.
The full text of our second amended and restated certificate of incorporation and amendments thereto, our amended and restated bylaws
and the warrant agreements are included as exhibits to the Form 10-K of which this exhibit is a part. You are encouraged to read the
applicable provisions of Delaware law, our certificate of incorporation and bylaws (as in effect from time-to-time) and the warrant agreements
in their entirety for a complete description of the rights and preferences of our securities.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 250 million shares of common stock, par value $0.001 per share, and 15 million shares of preferred
stock, par value $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to one vote for each share of common stock held of record for the election of directors and on all matters
submitted to a vote of stockholders. Holders of our common stock are entitled to receive dividends ratably, if any, as may be declared
by our board of directors (&ldquo;Board&rdquo;) out of legally available funds, subject to any preferential dividend rights of any preferred
stock then outstanding. In the event of our dissolution, liquidation or winding up, holders of our common stock are entitled to share
ratably in our net assets legally available after the payment of all of our debts and other liabilities, subject to the liquidation preferences
of any preferred stock then outstanding. Holders of our common stock have no preemptive, subscription, redemption or conversion rights.
The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the
holders of shares of any series of preferred stock currently outstanding or that we may designate and issue in the future. All outstanding
shares of our common stock are fully paid and non-assessable. Except as described below in &ldquo;Anti-Takeover Provisions Under Our
Charter and Bylaws and Delaware Law,&rdquo; holders of a majority of the outstanding shares of stock entitled to vote shall constitute
a quorum for the transaction of business, and a vote of the majority of the voting power represented at such meeting at which a quorum
is generally required to take action under our certificate of incorporation and bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants were issued in registered form and entitle the registered holder to purchase one share of our common stock at a price
equal to $5.50 per share, subject to adjustment as discussed below, terminating at 5:00 p.m., New York City time, on the fifth anniversary
of the date of issuance. The Underwriters Warrants were issued in registered form and entitle the registered holder to purchase one share
of our common stock at a price equal to $6.875 per share, subject to adjustment as discussed below, terminating at 5:00 p.m., New York
City time, on the fifth anniversary of the date of issuance. Holders of Warrants may exercise such warrants on a &ldquo;cashless&rdquo;
basis if an effective registration statement is not available with respect to the offering of shares of Common Stock upon exercise of
such Warrant. In such event, the aggregate number of shares of common stock issuable in such cashless exercise shall be equal to (x)
the difference between (i) value of the aggregate number of shares of common stock for which the Warrant is being exercised based on
the weighted average price of our common stock as determined in the formula set forth in such Warrant and (ii) the value of the aggregate
number of shares of common stock for which the Warrant is being exercised based on the exercise price then in effect, divided by (y)
the exercise price then in effect. The exercise price and number of shares of common stock issuable upon exercise of the Warrants may
be adjusted in certain circumstances, including in the event of a stock dividend, extraordinary dividend on or recapitalization, reorganization,
merger or consolidation. The Warrants may be exercised by delivery of a notice of exercise and the aggregate exercise price (assuming
no cashless exercise has been elected if an effective registration statement is not available with respect to the offering of shares
of Common Stock upon exercise of such Warrant) to us as specified in such Warrant. Holders of Warrants do not have the rights or privileges
of holders of common stock and any voting rights until they exercise their Warrants and receive shares of common stock. After the issuance
of shares of common stock upon exercise of the Warrants, each holder will be entitled to one vote for each share held of record on all
matters to be voted on by stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is authorized, without action by the stockholders, to designate and issue up to 15 million shares of preferred stock in one or
more series. In the past our Board has designated series lettered A through K and issued shares in those series. Only preferred shares
in the series designated C have shares issued and outstanding. Our Board can fix or alter the rights, preferences and privileges of the
shares of each series and any of its qualifications, limitations or restrictions, including dividend rights, conversion rights, voting
rights, terms of redemption, liquidation preferences and the number of shares constituting a class or series. The issuance of preferred
stock could, under certain circumstances, result in one or more of the following adverse effects:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreasing
    the market price of our common stock</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricting
    dividends on our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diluting
    the voting power of our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairing
    the liquidation rights of our common stock; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying
    or preventing a change in control of us without further action by our stockholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board will make any determination to issue such shares based on its judgment as to our best interests and the best interests of our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Series
C Preferred Stock</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a discussion of the terms of our Series C Preferred Stock, see Note 7 to our audited financial statements, <I>Stockholders&rsquo; Equity</I>,
incorporated in this document by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Provisions Under Our Charter and Bylaws and Delaware Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of Delaware law, our certificate of incorporation and our bylaws (each as currently in effect) contain provisions that could
have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized
below, may have the effect of discouraging coercive takeover practices and inadequate takeover bids. These provisions are also designed,
in part, to encourage persons seeking to acquire control of us to first negotiate with our Board. We believe that the benefits of increased
protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging
a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amended
and Restated Certificate of Incorporation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Undesignated
Preferred Stock</I>. Our Board has the ability to issue preferred stock with voting or other rights or preferences that could impede
the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or
delaying changes in control or management of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
Meetings of Stockholders</I>. Our bylaws provide that special meetings of our stockholders may be called only by our Chairman of the
Board, our president or our Board, thus prohibiting a stockholder from calling a special meeting. This provision might delay the ability
of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any
action, including the removal of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board
Vacancies Filled Only by Majority of Directors</I>. Vacancies and newly created seats on our Board may be filled only by a majority of
the directors then in office. Only our Board may determine the number of directors on our board. The inability of stockholders to determine
the number of directors or to fill vacancies or newly created seats on our Board makes it more difficult to change the composition of
our Board, but these provisions promote a continuity of existing management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
Cumulative Voting</I>. The Delaware General Corporation Law (&ldquo;DGCL&rdquo;) provides that stockholders are not entitled to the right
to cumulate votes in the election of directors unless our certificate of incorporation provides otherwise. Our certificate of incorporation
and bylaws do not expressly provide for cumulative voting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Directors
Removed Only by Special Meeting of Stockholders</I>. A director can be removed only by the affirmative vote of a majority of the votes
of the issued and outstanding stock entitled to vote for the election of directors of the corporation given at a special meeting of the
stockholders called and held for this purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment
of Charter Provisions</I>. In order to amend certain of the above provisions in our certificate of incorporation and our bylaws, the
Board is expressly authorized to adopt, alter or repeal the bylaws, subject to the rights of the stockholders entitled to vote. Stockholders
can vote at any stockholder meeting and repeal, alter, or amend the bylaws by the affirmative vote of a majority of the stockholders
entitled to vote in such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware
Anti-takeover Statute</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &ldquo;business
combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years after the date of the transaction in which
the person became an interest stockholder, unless the business combination is approved in a prescribed manner. A &ldquo;business combination&rdquo;
includes mergers, asset sales and other transactions in which the interested stockholder receives or could receive a financial benefit
on other than a <I>pro rata</I> basis with other stockholders. An &ldquo;interested stockholder&rdquo; is a person who, together with
affiliates and associates, owns, or within three years did own, 15% or more of the corporation&rsquo;s outstanding voting stock. This
provision has an anti-takeover effect with respect to transactions not approved in advance by our Board, including discouraging takeover
attempts that might result in a premium over the market price for the shares of our market price. With approval of our stockholders,
we could amend our amended and restated certificate of incorporation in the future to avoid the restrictions imposed by this anti-takeover
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of Delaware law and our amended and restated certificate of incorporation could have the effect of discouraging others from
attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock
that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in
our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise
deem to be in their best interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
transfer agent and registrar for our capital stock is Computershare Limited. The transfer agent&rsquo;s address is 8742 Lucent Blvd.,
Suite 225, Highland Ranch, CO 80129, and its telephone number is (303) 262-0600.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (File Nos. 333-255429, 333-252973 and 333-251311),
Form S-8 (File No. 333-266316) and Form S-3 (File No. 333-267870) of GT Biopharma, Inc. of our report dated March 30, 2023 relating to
the consolidated financial statements of GT Biopharma, Inc. as of December 31, 2022 and 2021, and for the year then ended which appears
in this Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weinberg
&amp; Company, P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michael Breen, certify that:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-K of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 30, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Executive Officer, Chairman and Director </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Manu Ohri, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-K of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 30, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Manu Ohri</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manu
    Ohri </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Principal Accounting Officer </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael Breen, Chief Executive Officer of GT
Biopharma, Inc. (the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2022 (the &ldquo;Report&rdquo;) fully complies with
the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 30, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Executive Officer, Chairman and Director </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Manu Ohri, Chief Accounting Officer of GT Biopharma,
Inc. (the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2022 (the &ldquo;Report&rdquo;) fully complies with
the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
the Company.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 30, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Manu Ohri </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manu
    Ohri</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Principal Accounting Officer </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #6 ;H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBD)Q0
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M "FL,Y'K3J2@#S6^\)V/A'7QKT)>X>2X+16N-JQ[AR0?8G/TKJ'=+R6WU%5
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M4W*PQD<$?44 6**IP:I9W,@C@NH)'(W *X.14LMY! H:6:-%9@H+, "2<8H
MGHIJL&) (XIU !2&EI#0!R/CWQC+X0MK-X;:.9[EV7+D@+@9[5R__"RM2EU2
M"6W@0Q2PHS0._P HSUP<9SGO4GQP'^@:,?\ IO)_Z#7&::O[RS;^]"/TKV<%
MA*56DIR6NIA4FXO0]LDT#3=48WES:AI9X=KG>PR",= <9QQGK63XB;1_"FE6
MZRZ:]Q#([H$#DG++\Q))R<@5T]E_QY0?]<U_E3+_ $JRU6-([^VCN$1MRB09
MP?6O&:LS9;'$+>>&9K]+%-,=IGBP&WD?(,DC=GL1GUR>*T?#%EHFOVO]HP:8
M\&W]TH>9FS@<'&>N#UZUT0T'3 &Q90#=C.$'..GY9J6PTNSTN)H[&W2!&.2J
M# )H&5[30+"RN$G@MPLJ*55B['&>O4]3Z]:TA2T4 %%%% "5FZSJZZ7 GEQF
M>ZG;R[>W4\RO_0#J3V%7YID@A>25PB("S,>@ ZFL+0+>34+A]=O$(DG7;:QL
M/]3!GC_@3=3^ H LZ1HK6LKWVH2"YU.8?O)<?*@_N(.RC]>]:^*6B@ HHHH
M**** (Y65$9F.U0,DGM7+ZEJ OW^3F)/NGU]ZZB:-9HRDBAE/4'O6/+HB&[4
MQ@+">645M1<$[R/-S&G6J04:3]3#TGS8VE9LB)C\H/K6Q'/CO6C<:=%*BA?D
M91@$5S]U(]I>/;X!*J&)[<UXV(HXBKB&X1T9Z=*M1PF&2J/8U!<>]->?-4+6
M:2Z@$J1M@G'2K"VES+]V,@>IXKBE.MS^S:U.V,H.'.F0R7<?(WK^=6K?1DNH
MS)< @D?(1U%<V%VV#@]03_.N\M1_HL7^X/Y5[*RY8><:JEJ>/1Q[QJG3G'1.
MQA1:,QO/+N1NA W9[-4VN>#M(\1K;?VA;%FMF#0NK$%<'./I5C4I9;&_LIUD
M8PS3+;R1'&/FSAA[@UJKP*ZIS<W=CPV%AATU S/^$:TC_GPB_6C_ (1G2/\
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M<Z*T\T$^H:A;2PC<XEO' Q['.#0!U]%8L.B6=Q$LL-]?R1N,JRWKD$?G3_\
MA';?_GZU'_P,D_QH U@0:*S=!##3BK222;)9$#2,6; <@9)ZUI4 0WD+W%G+
M#'(8FD0J' R5R,9KE4^'EI$B11WMR88P?+5P&*$E2Q!]]OZFNQHH Y.+P/'!
M8"W34+A61UDC(4;%90 "4Z-]WOZU+'X.'V])[B],T2X9H3 @#N$*[B1VP3\H
MXKIZ* .;L/"2:;=_:+>[<.+80#Y!UV@!OPQTJG#\/[>"(0K?7+PJ2R+( Q5S
MMW,#[[?U-=A10!Q4/PYAB\L#4)0J#;\L2@A>.A_A/R]1[TK?#Z(QQAKR24(P
M8HT8VMC& /[I.T9(Y.37:44 97AW3)-)TJ.WN)/-N"2\LF<[F/O[# _"M6BB
M@ HHHH YGQKX1@\6:8D<KR)-;%I(2A'+$8P<]JYD>!K:RTN"^F^TP^0ZJ868
M%O*+ 9/^UDD\5Z616'XGRUBD.XA)6 ;'IU_I5/%U*$-'HC*LXPBY2-B)5BC5
M%^ZH"C\*?FO'O$6LZA:>)O,ANY5>-0JL&]N1CICFO6[-VDLX78Y9D!)]\5A3
MJJIL*E6531%BBBBM38**** "BBD/0T 8'B/-_-9:*N=MXY>X(/2%,%OS.%_&
MMY%"J H  Z =JP]-!N_%>JW3<K;+':1G\-[?JP_*MWI0 M%%% !1110 4444
M )2;:=10 TBN2U?_ )#L_P#US6NN/2O(OB%XJU#3O%%UIMJ4CCDBB_>*/G&?
M0]JZL'&4JEHG'CJ'MZ7)<]$\-\Z/'_O-_.M8K\IK%\(2&7P[;.QRQSDGJ>>I
MK=Q6%56J,WHQY::B<U_PC+&T9#. [9/ X!KH;=#'!&K=54 XJ0BBB524_B%2
MP].DVX+<R/$'33?^O^'^9K7%9/B-2M@ET!D6<Z7##U53S^E23>(-/M;"&]GN
M-EO-_JW*-S^&,BH-C3HK!_X3;0O^?\?]^G_^)H_X3;0?^?\ '_?I_P#XF@#>
MHK!_X3;0?^?\?]^G_P#B:/\ A-M!_P"?\?\ ?I__ (F@#>HK!/C;0NU\/^_3
M_P"%.\.>+M+\4V[S:9*[>6VV170J5- $U\I?7[)58H3;S ,.HY7FC4X+==.'
M]H.95216Z[0[9^4'';-.N?\ D9+#_KA-_-*=K+6@L6-Z3Y:_/@=25!./TH S
MM7UM-,T_S+>W\Z1HN(PP$:Y]3^=<M=:V(XH1;W3VMPHYB0X'M@=A[=*YS5/$
ME]=1(LY4&<EXT'"1K_#^E8QB$]ZYEWDL,D]>?K0!VEFT<:YF26:9FW))]X=<
MD'ZYK2M;FS@U..8VQ8;R)8G 91VW+] :Y#1K@VLRVTD@-K(?D#DD(W_U^E=1
M%(TC(UJZAXE8*S+GCTQZX- &KH4L^G>(+JSEDD6R;,MI#"NY&!Y..X _"NP$
MJ[@F1N(R%)YQ]*\\F:&SW3QS2K?0H2)E!V[C_#Z 5I^&KF:!([V>)I!/MCDG
M>3>[%C\N!_"@H Z+0O\ CQD_Z^)?_0S6C6;H7_'C)_U\2_\ H9K2H 6DI:0T
M &:*AGN8[>,O*P51U)IT,Z3QK)&P96Z$4N97L+F5[$M)FBL'Q+KEQHDEF(8%
ME%VQ@CSGB4XV ^QY_*F,U;E[A-HMT1LYRSM@"BWO5E8QNK13@<QMU_#U%,;4
M;>.V,QE1T7@LASS2;;;4X%8A9$Z@@\CZ'J*GF5^7J3S*]KZEI94=<H0P]12?
M:(O^>J?]]"J$3#2HU@D3;:CB.51POLWI]:K_ /"(^'Y27.E6C%CN)V=<]ZHH
MU_M$7_/5/^^A4)U2Q4D->6P(Z@RK_C6?_P (9X?_ .@1:?\ ?%3KX9T55 &D
MV.!_TP7_  H #XCTH:C'8F_MQ<2KNC7S!A_8'IGVJMXE/[B#_KH*<?!^B'4H
M;[^SK82P#]T!& JGUQTS[UHWMHMW;20MC+(0">Q(ZUE6A[2#B95J?M(./<\7
M\5$?\)&_/^>*]HT__CPM_P#KFO\ *LC2O#D:1,VIVUI-.6#+M7=MPH'4C/.,
MUO*H4  <#M4T:+I[D4:+IMNX^BBBMSH"BBB@ I*6DH YCPYJEK#'<^?+B:ZO
MYW "D\!RHR>WW<<UO_VA:B5HOM$7F+C<N\9&>GYUS/AG3&ET^26.ZEB_TJ=)
MHU Q+ME<@$D9'7'':G0>%+66"*1KS$O(D=54AB"P/WAV!P#VQ0!TD6HVLRJT
M5Q$X;IAQSSC^?%.CNX9FVI(I)S@9Y./:N9_X1/3F#Q"^812*5P G<XP&Z_AZ
M\]:U+#P^EA=BXCN&8XP08UY^AQD?04 ;-%(*6@ HHHH ***2@ KBO%/P^MO$
M&OV^HL0H) N27()5>FT#C/;FNUJ&Z8+!(6. %/)IJI*G[T7J*6QR.A^(K+1+
M:RTJ]\U9Y)941@GRE0Y"L?0'BNS!KR+6+6?4?&5HEM&939Q*)\?\L_GSS^E>
MN+TK&G5=2[D949N2U0^BBBM38R/$/,%G$>4EO(D=>S+G./T%:H%97B \:=_U
M_P /\S6L.E !12T4 )12T4 -89&*BM;2"RA$5M#'#$.B1J *GHH RKK_ )&2
MP_ZX3?S6FR6-U%=WUS/=O=6DL1"V9C'R<?PD<\\TZZ_Y&.P_ZX3?S6JDEQ<O
M=7MG=R[',GFV:1,-\L87)'YY% 'FVHZ9:/91/;0D1EB-C?,RY/&,=..Q]#6+
M>Z)JUFJSM#*UL!\D@(SCU(ZULQR7UAYMO<JT)@SE).I )Z'^+!-3Z3::A=2W
M$>FP37-HJ>6#*RH<-SP3UY% &;H=K-]ICDNB(XVP%W+T/][VKL;B>QBC2\^T
M02M*QVR0$D,PP"I'J*Q;>RGDNVL-0CO8W?",RP_ZH9X;W''/L:Z&U\,I;_:3
MJT"B&-W%K;POCRX@,M( .221TH CBLDN+2\MKG4([2W>55A#$?.3AL?S]ZV_
M*-M>Z9;0VS6]HLA01 #^'D$^V3FN-T)W34?LUL@D$K!XVNK<R;3_  L0.5^M
M=WO1]1M;N26%FB!MYRKG"2''0?CW]: +6A?\>+_]?$O_ *&:TJR/#.X:1\TO
MFMY\N9",;OG/.*UZ "JFJ7O]G:;<79C:3R4+[5ZG%7*CEC66-D<95A@@]Q0Q
M.]M#S_3?%#>+(;F&6-8YH")45"<,G?\ *NHT*X_=>2QZ<BO,I()/!WC%PH_=
M1/N4?WHF[?E_*O1%DCLKBVF)/V6X;"2#H"1D _6O-2G[527HSSJ:DZO,MUN=
M&*9+$DFWS$5BIW+D9P?4>].B<2(&4Y!Z4DSJB%F.!CK7I'I''K9VVG2O8V1<
MQ*^]@S9RQ'_UJHZ[XJD\.7MO9:>L;,!YEPI&>O1?8UH6T?EPW>K-E[6,R2(,
M'>P7V]R/Y5Q?A2SN/%7B>2\G =0QN)/[N?X5^G3\!7FQC44W)[L\Q*HI-O=L
M]<M)C=6D4KQE#(@8HW49'0TZSM_LMN(LY"DXP. "<@5C>&/$#ZXD[21)#Y)$
M14'GS%'[P#V!(%= *]%'I+86BBBF,*2EHH 3%+110 4444 %%%% !2&EHH P
M/#Y$.H:W9=#%>><!_LR*&_GFBX\/2S^7%)<"2W%P9=I7:44Y)7(^\"3WI+K&
MG>+[6X/$6HPFV8]O,7YDS]1N%;X.10!RH\"VXM5@%RX"RB12$7Y"#G@=NM=4
MN<<TM% !1110 44E-9@H))X%)NP#CTK/NM5@A1@DJ/(.-H.>:N1RI,@9#E3W
MKFM9AMH=2$D3H)9!\Z#J?>N3&5Y4J7/ SJ.2BW%7-^RO%NX!(#ST(]#4&M\Z
M+>_]<6_E7'RZK=:==%+9]HFX(QG\:BN+F\N8G1[B1MP(.6XKDAF'-2LUJ=&$
MP\L32<TQAAC2V@E1%661XP[@?,X!&,FO1P>!7G,P9["*-3AU()]L5876K^S^
M<7#,/1^<UA@\5[)/G1GA<)5Y)2EI;N=O]MB%R8"WS@9JP#D5Q!N))8&G=_WC
M?,6KI]&01:?&//,[,,LY;.37;A,:Z\G&QC1J.I?38=<V$EW?V\LT@^SV[>8L
M0')DQ@$GT&>E7QP*:9%& 3@GI3@:]"YL+1113 **** "BDS10!B:K;M=Z[8Q
MI/+ WD3?/&1G^'UK.UO09QJ.A7EH\KSVDHBEF8_\LNY;US_6NBN],M;]D:ZA
M#M'G:<D$9Z]*K_\ "/:;_P ^Y_[^/_C0!Q?B'7+6_P!:E"VCM):!X4,N&CW$
M\MMQSC'6L._2;4;6&61YY0C$84G"X[@=!]!7I/\ PAVA9)_LV')ZGGG]:5?"
M6B*I5=/C /8%O\: /*?$&MZE::.]R;FZG$;*BI(21U]O85<M;^2:&SU%&N$+
MIE2['>H/49]*]'?P;H+1-'_9T05@00">_P"-<UX#T'3)])N=/U"SCDN]+NY+
M5RQ.2H.4/7NI% &5+J%V_EPBYE!VA3*APSJ.@8]\46=U>62/%#<R1HQ#?*,A
MCZUW@\(:&""-.AR/<_XTO_"(:'_T#HOS;_&@"/P?*\WAZ*25]\C22%FQC)WG
MM6Y4%G96]A;K;VL2Q0I]U%Z"K% !2&EHH Y[Q+H%EJ%M+>SVYDN8(6\L@]._
M3OCK6?HFI3ZQ8-%>^6TR .H50%XZ@#]:Z]AD$'I7'"T.C:VRQCY-V^/_ '3V
MI))$J*1T>FS?(4)]Q4>HW&Z985/"\M3(LPZS%$N/)EA:11CE2".OMS^E5U\Q
MFU"\"[O(D8)$!RQ4=_QIE&=K-Q<$-86$_E/MQ*2,@Y[?E_.MO1='M-+MRUK9
MQVSS -*L?3.*YSPQ#)J5\\\Y+8/F2$]SZ5VX%*UQ6ZE!]+C-]#=1%H6BWY6,
M#$F[!.>/4"KXZ4M%,84444 %%%% !1110 4444 %%%% !1110!FZ[IIU72Y+
M>-_+G!$D$@_@D4Y4_F*-#U5=6TR.<KY<P)CGB/6.0<,I_'^E:)&:YW5(9-"U
M-M9M$9[:4 :A"@R<#I*H]1W]1]* .CHJ&WN8[J%)H)%DAD4,CJ<A@>]34 %%
M)2,<"@!3TKGM:DO8;H 2DVLG3 Y!],UIQ:K;2R,F_:RG!#<55\07D5OIQ+ .
MSG"#WKAQ4HU*4N61$H.JN2&Y@R:U/I\+6\1 $GW6/\-9JAGDWLS%R<EC1>(+
MUX]IP!R:NP0YQ7D48SG%1ET/4RRG.G2<:L2'R/-E$C#+>M3K;9[5>BMO:K26
MOM7=3PZ2.I3A27+!6,DVO'2JUQ8B6/:>.<@^AKHC:^U026WM5RP^@G5C-<KV
M,5MPMA'Z=326&HSZ7,&B),?\2'H:O36^,\5F7EN7B95."1Q7'[)T7>&@Z5&E
M3HN,(FS/JS7T@FA)1%^YGUK7T>_NKNW>6>(+&O"E<DMCOBN6TYXD2*.=MH+!
M37=0QI'$JQC"@8&*WRYU*E24Y/0^=ITZJDY35D<WHWCB+5[W4(%TS4H?L;JA
MWP'<V<\X[=*UO[;3_GSO_P#P&:M$(H8G R>I]:=BO9-S,_MM/^?._P#_  &:
MFW.M&+3+R[BM;C=;QEPDL93=6KBD*Y[T </<^,[VWAB=;K1ISMD=C&[[9=NW
M$:?[9W>]3W/C"[@6[(^PGR)H]HW'+QMU _VQW'L>*ZO[%;?)B"(;#E?D'RGV
M]*7[)#_SRC^]O^X/O>OU]Z )5.13J0#%+0 444R9BD$C+U521^5 #NM<Q;:5
M>V'Q"O+V&'.G:A:(97!'R3(<#CW4UD6_Q"O5M+<MI:W$CQKND68("YC:3&,=
M,*:EE^(\JAI(M(:2 *S!_M !PJ*[<8[!OQ- '<TM<;<_$!+>&9ULM[1B<[/-
M )\LJ/PSNIC_ ! EBGBMGTB0W/F.D\<<F[8%8+E3CYC\PXXH [6BD!S2T %%
M%% !44EO%)(LCQJSI]TD=*EI#0!C21J^M;SG>ORAL]C@G^5.TV-4O92O&YF9
MN>I]:5@?[78=SAL>WK2Z>#]MD]58Y]J -*.&.(L8T5=QR=HQFI*** "BBB@
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M1+=);VPW0 8F8Y1S@9PO4#D8-=3YFZ%6/4J#5=DMV=G:"(LPPQ*#)';--DG
M&*IR1$*3N1W#YSS63<MUJW<3]:R[B7.>:XJTT>GAX-%.<UTWA./;ISO_ 'Y#
M7*R99@JC))P!7>:59BRL(H>ZCGZUE@H\U5R[!F,TJ:AW+HI:2EKUSQ0HHHH
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M '6YI:YOPYXGEUF9;>:T:.<0^<[+]S:3A2/KS^5=&* %HHHH **** "BBB@
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G*6BBM" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" ![ 48# 2(  A$! Q$!_\0
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M<C_C7JT4\4RAHI$D4]"K BGYH \QO/A#)Y,']GZNT<NW]\94R';U'I]*J?\
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MQ6)XB\-:;KMJQO$$4T8+1W:';)"1_$&]JS/^$_AOF,>@:7?ZH_\ ?2(QQ_\
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MAX+U*U_Y!_BO58QV6;;*/U%=?10!RITWQE JB'6].GVC_EM:$%OJ5--,OCB
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M=6M'D5!)RQP"5(!/UKB-2EN=6UB8I(^V-L(/05K:9J_VBPNK#5"-\<;,';N
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1!-M&*6B@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" $> 7P# 2(  A$! Q$!_\0
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M*6@ HHHH **** "BBB@ HHI,T +1124 +1244 +124M !1110 4444 %%%%
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M;C^M8NH?"^1+JS;2+I4C@)8M-RP<D$MZ'Z4 =1I7C;2-8U>33;25S<("?F7
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MR^NJ:AK3(@NY?/!P(E.T;?05D^+6N%A>UD$ZJF&V3')!]177V7@K5(YBUK-
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M!P<'OS64?A]I.%4-<J@V[D#\/M;<,_B:U=+T*'2)&^RS7'D\[(&?Y$R<G H
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MZ;K##'$G->WWV0A*]1WKRWX@VS,D=TP^Z^#BFW?4Y[6V/2M0_P"1'F_Z\?\
MV6N&\,:2(?"Z2Q???EF^M=U>(9/!;HO5K( '_@-><^'+O^S7AA#R?9Y<HR2=
MF'<545?2^H];7.LM+-+&QN)YG*X0DD]J\L\4>4R121D$,3R*]5U.X@N=%D0G
M*2(<UY/KAA5;:*)LJC=^E.UX,UHNTT=K\*=(V:(MUMP\LA;)':O38-LD15@.
MO2N7\)6#:3X<M")PYE;> !PH/:NJ,JQ)O9,9[CO4M);$3^)GG7QFV)X?MT Q
MB3(KS7PQ;+<^+M-20!AN!VGO7>_&J<S:=IQCX3S<'WK@M V1:@;OS&22W'[M
MAV;WHA3<YI(N+M2DSZ!M-(M=.+2VEO&DC'+%5YKFM6TFZ'C:#5;J6WBL4QAF
M8 GVQZU=T'QK;7EHO]HNEI.H&\2' ;W%<_XXOK37Y;:VT^8R^42[N/N**W2E
M&;Y]#G4XVN<CXOBBN?'4IC.Y6P:]A\,*8]"MACKUKQ5T4ZO!/#YTJ8VDL.>/
M2O7-(F-WX85;:<(6C*JX_A)K%13UCJCKQ'NM1>]C2O[^V,ZVWVB+S3_!N&:\
M%\36BQ>+;L)RKS9Q76_8+B"Z3[2LL'E.&EG=>!@\L&[YKF]=AEN_$#74:$13
M/E">OU-.=.R%A=9:'>>$=,BOM*19HE=4QP175ZM#&]I#:F-/+4YQC@8KE_!F
MK1:?FTORL+'!CD)^5O;/K6YXDU.&RMUDW!Y7X2,'J?\ "A1EHC&5[LXVRV#X
MK6XC "A3T^E:$R_Z_P#WG_G61H),_P 0K*Y:5)"X8,4'"G'2MR6/*3G_ &G_
M )FB$%/9GD9JG'ENK'=:-*DNE6Y0Y 0#]*OBLRPN8ET:,QS1J4A!)SG;QU(K
M.M]>NY+J&,F)DDYW!>V?ZU#5CTZ?P(Z6BBB@L**** "BBB@ KE_'VD'5-"!B
MBEEGAE1HT1C_ 'ADD=^*ZBDQ0!YXEGJ5EXJNWN-/:]MYIF=R80V(MG&UO7/&
M*K/I[?V+K$+:;=$75PSV3B#YAP."/X1VS7IF*,4 5M-61--M5F39(L2AESG:
M<=,UR?Q067^Q;*2%"[QW2M@5VM<-\679/#EL5<J?M(Y!]C0-.SN5+;6;8:FC
M/(!+Y2EE],UH^(KY#I\2QNH#\GGDBO)=-9WU:#+L2[@,<]14^HZG-/K+[Y28
M48QJ,\ 4DRW&[T,_Q=>+/>LL9R$&TFNL^'-M;:S9J+V9S<6YW0IN^7 KSS4E
M6.X=4;<@/!KI?#A-AIMOJ#3>2J-\H!YD/H*<6XZH;:?NGN$.HP1;+:>0+-LW
M8/<>M<GXPU&*"668R<!/EQW-<[I'B";4M:D-PHVNI9?5 .U<OJFLW5W?32^;
MA,_*O; H;5M!):FEX%U:.#Q($G8*)6X+>IKVFPMX;*U,=JB*!N*KGC)KYWAF
M2VE;4Y"/.5_W2=MWK7<:%XMN6\-RZC?2Y>U?:?\ :)Z4D^@ZKYO>1T6K:)>:
MY=RW6NL+>&SB)_='Y3WKRFR-O=>)0.1 92R@>W2NB?QO=>(;2;3;R9K?SL[9
M$Z'V-<3"6MKHLLGS1/P1[5<YN2MT*INROW/H'197FMH(HCMP.0/2M*[ MK,I
MDG!Y)[FN0\.>++"UTJTFNAY<LV5&34NI>-[>.9E?#JKCY0.U28M6=CEOB:I2
M\@:5E;S5!0'JE:_P_O6@AF@.-P164CN*XGQK>7.LZLU^'66UR$C*_P  ]"*Z
M;P/J5KY<2NRQ2$@$GN1VK133331I)6@D>CQ-<213O<X"_P ./2O-O%EQ-?\
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M?B6+Q)J44-LX:TMN01W:L+0KH)JK6[J62?Y2 ,D'L:?JIMYM3>6U3RT/) &
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M\+:-=QF*>U1EZ$%S50> ?#K#"V>0O'$K<?K7/1>"O$$41>2]2XNFN(Y2YE8
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MI![@ 'TYH"[+VG?#W1=&ODO[19_/B!V[I,BO-[^?%W=C_IJ_\Z]OE_U3?2O
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M,C/KBA:H$U<JO\<+Y7=?[(MSM&?]8:=!\;;Z8*QTFW7.>/,->;R0;X6=<[F
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M_C'?W]U%"-*MU\SOO/%3:I\7+[3I0/[+@=&&0V\UR_P^T$W6J2W$@/E6\14
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M&Q\?+^9XKK+GS?LTGV<H)MIV%^F>V:\UC\6:NFCV@NKEVD>XN!-/ J@A8^@
M/% %2/P3K=U9V;S(\-Q:V99H@1LFE$A;8WL17=:K8ZIK7AV!+*X;2[M@C.H
M.W&,K6*NM:Q/KIAM[N)[>XTLW%HK+M^;H&<^M5QJVK?V!?AKZ1-2TLCSOF5E
ME. <@^F.U '>6T;QP1I+(99%4!G(QN/KBN=^(<33^$YHD&6>6,8_X%5>'5KV
M/Q+I.;_SK+4(B2NT8#;00 !R/QK2\91^;X=F78S_ #+@)UZ]J:U8&?I5O]FL
M(QG#JF#5Z$W%PN?E4C@8K#\/S79TV,74;JZG:=XYQVS71RW]MIT.^[=8HPNX
MN?2AK6PD>(^,\-XBO-N-P7#8KU+X6V\</@RV,>,,23ZUY'XIG6;Q)J$J',4O
MS1-_>%>E?!TRKX39YFP&D.S/I4)6;.BI\$3O[B)9X6]>QKQ[XI6+O/#.0,Q*
M"2/3->P1N2_E]1C.ZN \=6T=TES&YP5C/--[&5/XD>>> U_XJI)%ZK(*^AN<
M?+UKPOX76OF^(W+#Y58$9KVR2[$<K  D#TH6Q57XV4/$R!M&F#<G8:^<GMF6
M:2'OYV*^C/$4X&EX;^,$5X9J&G-!XBV=<L)0OK1:[2+H]?0]7\":'$N@QDKQ
MNSCUKL&(0!<X&,<=JPO!EP&T6,%"C$9*GM6M>W:6MO+<3#Y8T+;>YQ5-.]C!
M'D/Q3G9M5M(F;(^8YK$\&Z>9+Z&?MO %+XZU&;5-;M[F2W>W1HR55NX]:V_!
MJ1BSLV5@6WC<!VYJ>5J3-Y?PD>O.2+=8U7GCI7 _$RV1M&5F #QN&45W#70
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M].<K;L\P.T';U]Z"3>MM0@NG*1.2P&<%2*LUAZ3?3W]TCW-OY#JC#'KTK<H
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MXRTB)&9YV7;<+;8*8)<]!CTYZUNBN;D\"://+)+<)-*[2B8%W/RL/3\JZ0#
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M!$-SN>@%9>B>%K70]0N[RWEF>6Z"^9O;()'>K^K:;'J^F3V,S,L4R[6*]<4
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J =D# 2(  A$! Q$!_\0
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M/\9/8?SKQ<#CZ]6O9NZ;^[T]#VL7@,-##N2T<=GW_P"'/1****^A/G HHHH
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MP?KB:C9DM$WRSPY^65/3Z^A[5]'6&JVNH:+#JL+,+6:$3 L,$+C/(KY>OO\
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MZXR?^@U[U77A/X9X.?\ ^]_)?J%%%%=1X@4444 %%%% !1110 4444 %%%%
M!114<<\,Q(BE1R.H5@<4KK8=F24444Q!1110 4444 %%%% !1110 4444 %%
M%% !7B'QN_Y&/1_^O9O_ $*O;Z\0^-W_ ",>C_\ 7LW_ *%77@?XZ^9SXK^$
MSS^^_P"/5?I7T)X6_P"27Z?_ -@W_P!E-?/=]_QZK]*^A/"W_)+]/_[!O_LI
MKNS+X8^IQ9=]H^=M*^Z?I78_"C_DI$?_ %[2_P A7':5]T_2NQ^%'_)2(_\
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M*!Y2'&$4C()]!CFF'5=/6YAMFOK83S*&BC,HW.#T('>NH\0N44F1ZBC(]10
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M$L0,IC& &'!&.Q!&"/7- &K1110 4444 %%%% !1110 4444 %%%% !1110
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M7M]>(?&[_D8]'_Z]F_\ 0JZ\#_'7S.?%?PF>?WW_ !ZK]*^A/"W_ "2_3_\
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M3T)#CK4UMX@TF[OA8Q7]NUX0<P+("P(ZCZCTH TZ*** "BBB@ HHHH ****
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MBL0^*M+6>827,:6T<$4ZW1<&.02%@H7U/RFF'QAHRZFMF]["BR0QS0S&0;)
M[,H _%?UJSF-ZBL^XUJQ@M'G%Q')A92B*PRYC!+J/<8-9\'C'2#:"XO;J"R#
M8V++,I)&U6)P.F-XSZ4 =!12*RNBNC!E89!!R"*6@ HHHH ***SFUW3%N[^T
M-V@N-/B$UU'@YC0@D-[C /2@#1HID,J3P1S1-NCD4.I]01D4^@ HJ 7MNU^]
MB)/])2(2LF#PI) .>G4&IZ "BH([VWEO9[1),SP*K2)@_*&SC^1J>@ HHHH
M**** "BBB@ KDM3\$6FJWFOW5W;V,\NH0+%;/-"': B,KG)]SGBNMHH X63P
M9JS6YL5NK+[)]H-SYA#>86,!C*XZ8R<Y].U7O^$1E\N51+;@O:65N,(>/(<L
M?P/:NLHH \_O/ VK7^I1SW%[;/'%/(X+%SN1I5<#9@*F N.,Y/)-;\WAZ>32
M_$=H)X@VJO(T;8.$W1JG/KRN:Z&B@#S>]T2_?4%T1+9I;.;4(;F>9K9P0!&
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M7+$LQR2223DFK=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC+'(QDGI6Q9>'+>QDTYTGE8V/G[-V/F\ULG/';M6S10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% $<\*W%O) ^=DB%&QUP1BL2Y\(V5S;PVWVJ^CMTMTM9(8YL+-$O17&/J"1@
MD'%;]% &3J?AS3M6D5[J-LK;O;IM;&P,5.5]&!12#VQ5*+P98QSEI+W4)X&N
M#<M:RS#RFE)SN( !//."<9[5T=% &#HWA.QT.[6XMIKERD+01I(Z[40L&(
9&3D=3D^];U%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #) DT# 2(  A$! Q$!_\0
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MD#WQ0M0>AZ'17+>#_'FG>-)-0BL;2_M9; HLT=Y$(V!;..,G^Z:ZF@ HHHH
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MN##\JZ^J?0E&'HOA'1O#UW-<Z=:M')*OEC=*SB--Q;8@).Q=Q)P,#-<G9_\
M)P^H_P#8 3_T:*](KS:S_P"3B-2_[ "?^C5I#/2:*** "BBB@ HHHH ****
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MDV95"I)7CHI!Z]<5W"11Q9\N-$R /E4#@<"F?9+;?$_V>+?#D1ML&4SUQZ4
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M9H5])J6B6EW* )9$^?'0L#@D>Q(S5AK&V(3$$:-&ACC=% :-2,84]OPJC?\
MV_2M)@AT'38;IHML:PRW'E!4 ZYP<]J:5W8:5W8UJ*YGP=XBU3Q+8?;[O2H;
M.TD!\ETN?,9R&*D$;1CD5TU.47%V8YP<)<K"BF32I!#)-(<)&I9CC. .37-V
M?Q"\+W][#9VVI^9<3.$1/(D&2>G5>/QH492U2",)25XJYT]%%%22%%%% !11
M10 4444 %%%% !69XB>*+PUJ<DUS<6T2VLA>>V'[V,;3ED_VAU%:=%)C6C/F
M[^VO#>/^2B^/?R?_  KUSX875E=^&IWL-9U;5HA=,#/J@(D4[5^49_A_J37(
M^*_&6K6_Q#2U_MR+3-/L=4LK9K(A5:YBE&YY69OX!]WCCUQ7;^ ?$%SXCTW5
M+F>:.XAAU2X@M;B)<)+"I&TCU SC/?%4MA-69UE%%%(#S?P#_P E,^(G_7U;
M?^@-7?:BMZVG7"Z<\*7IC/D-,"4#]MP'.*X'P#_R4SXB?]?5M_Z U>D4XNS3
M \F\3V7Q;GT&=$N=+."&(TQG2<@'^$G'Y=34GAZS^+<&A6L;W6D A2<:@7><
M DD!R,@FO5:*]7^UI>R]E[&GO?X?^#^IG[/6]V5&6].CLK,@OS!@M#POF;>J
M[NV>F?QKD["V\3@6RWJ7S(N0FRXC!)W<M,"3D%>  6Z'ID8[*Y?R[6:3S/+V
MHQW[=VW ZX[_ $KSN;Q#J(MI3%K<<D-K<2.',T:O=QB-&"1N(RI8EB=N 1D#
MG&:\IN[N:&E8>'=9T;P[IT&G2@73I'#=+LBC\I60*S@JHW%#R,Y)YZYHU7PS
M=-<7SV\$K6\U_#<R*CH\DRB(JV/,RN0Q4X;CY>.U59->U!-2N89-57R)KG#3
M1.I^PQ>;LVNK(-CXP,DL/O'L#6YX8U:]OI1%=N9=]G'<*^P+U=TSQV8(K?B>
MU("J^F>)6TBPM?M$=OY<8#+8XC92(6 !))!'F;/N@?E5[3-,U!])O['5Y9[A
M)<!"\HW,#$F\;EQ@;]X^GMBNAHH X>+0-2@N]%FM[1H[NVL[:!YGDC>%%16W
MJ5^]G+<%3SQR,',^HZ3J-UJ]K.^E6\\T88SS(RI%<*8G7:2<R*<G '*\DGV[
M&B@#BH]/N;'0KCSK5H+635(IVA=4W"#='N#+'\H (/3JHR>2:33- O(M5MDN
MM+@=4>?[7=2)&PN%<L0P;.\DDIE67 Q["NVHH \TOO!]X-$TFUATLJ\=C<0S
M+;1VYQ*_E[=WF< 84_,O(Q7>Z9'J$=L%U!K8L H58%;"C'()8G//?BKU% !1
M110!6N]0LK (;R\M[8.<*9I53=],GFBTU"ROPYL[RWN0APQAE5]OUP>*RO&6
MGV=]X4U-KNT@G,%I-)$98PVQ@APPST/O2>#-/L['PGI;6EI! T]I#)*8HPID
M8H,LV.I]ZOECR<W4TY8^SYNM[&_114%Y=P6%G-=W+[((4+R-M)P!UX'-09I7
M)Z*YO3O'OAK5K^*QL=1,UQ*=JH()!SC/)*X'XUTE5*+CHU8J4)1=I*P4445)
M(4444 %%%% ",0JEB< #)-9TNG:)KT4%Y-9V&H1D!HIGB24$=B"0:T7V[&W?
M=QSGTKYMUK7X?"$ATKPGXY@'AG4+@>8(?WUQIP)^;RQD':?4<_CR3K8?0^A[
M6_T^2[GTZTG@:>T5?-@B(S$&SM! Z=#Q7E<FFZU:_$>^6&.]>:[U=;A5:W#6
MQM3!M:7S"ORNI&T?,".@!!KIOAII_@W3K"[B\*ZDFI3L4:^NC+YDDC'."WI_
M%@?6NZH:U$GH>2_#O3M035M.!LKFS?3-!:PNY)X"@^T&;< ">'P 6R,CYNO-
M0^#K/6['XY:C#K^J1:E??V(I\^*$1#;YBX&T?C7L%>;6?_)Q&I?]@!/_ $:M
M-NX'I-%-<,8V"$!\':2,@&O)O&FD_$>]T$PSRV-W'YRGR].1UE[\_3UJZ=-3
M=F[&M*FJDK.27J>MT5XMX$T7XBV%M>K;>19AW4L-55V+<'[N,\>M>NVL-ZVC
MQPWUPAOFAVRS0+M4.1R5!IU::@[)ICK4E3=E)/T+E%<%/X)U*2P@MHI-,@,1
M!+1H^68!<2Y.?G.TYP >?O'O<MO!'V:\ANTD@$Z212&0!MQ*RN[G/JRN%^@Q
MTK(Q.CGUG3K:XG@FO(4FMX1/*A;E$)P"1[GIZU/:7<%];+<6[EHR2.5*D$'!
M!!P001T-8>N^&6U:>ZDCECB\ZV6/H06=9%<%B,''R@>N*K_\(OJ T-[>/56B
MNU)DMX_OP0/OWIC(WD#IUQCM0!T\EQ#"ZI)-&C,"RAF ) ZG\*ST\1:5*+,P
MW8F%[DVYA1I X!"DY4' R1R>*P]*\&/IM]932RV]TELTL2F9276W*!44$YR0
M%Y]=QHE\(7#6]A"KV0:!F_TGRV$L(,WF?NR#W'&#^HX(!T=SJUA9WD-I<7"I
M/+C:I!QR<#)Q@9/ SC)X%1V^O:9=6MQ=0W:&&W&96(*[1C(.".01T(X/;-9U
M_H.H74UDBZ@)88)DG\V<?O596SP% 1@1\N&''7D]*C:#J45CJ<\IAGN9YK>?
MR8-VV0Q.&/WCP6 QM^Z,#U)H V6\1:4EW):F[!FCW;E5&.2HRR@@8+ <[1D^
MU5E\9:$UNEPMW(8W9E4_9I<DK][ VYP.YZ"JUMH.I0:E;E+U%L(+J6Y7:SAW
M$A9C&Z9VG#/][K@=.IJC?^#[VXLM/@1[:;[,UR762:6(,)6)ZISP#T[T =+=
MZUIUC9Q7<]T@@F&8W4%PPQNR-N>,<YZ <U%+XBTF!KA7O%_T=-\A"L1CCH0,
M,?F7@9/(]:R[KPWJ+>'QID6I+<AX5AE%RNQ0 N,IY8!7G!P2<],BJ2>"KJ*>
MZ/GVMQ%)N8K<!R+AF97Q(N=H *M@KTW=."" =%_PD.E^;!$UR5DG7>B/$ZG'
M.,@C@G:V <$X.,UH12QSP)-$X>.10R,IX8$9!%<C:^%+VQ>-C/"T'F1SS1HK
M%D,3O(D<6?X?F"\] OOQ-<ZH_@CX?QWMY;-.]LB!X4< @NP&W/MNQ^%.*<G9
M#C%R:BMV)\-/^1 TWZS?^C7KK*\<\!_$_1]+\,Q:9>VUX);8O@PQ^8'#,S=N
MG7'-=-_PL:_NL_V;X*UR?:N6,L8BP3T]<UT5:-3G>G4ZJV'J^TD[=?+_ #.]
MKDM$'_%R?%7'_+"R_P#0'K..M?$:\5A;^%].L\+_ ,O-WO))]-I[>]>;> =&
M\10?$>U^UVEZIMI UYO)^161MN[GH>U53H^[)MK8JEA_<FW);=[GT/1117(<
M04444 %%%% !1110 4444 %4]6U&/2-'O=2F4M%:0/,RCJ0JDX_2KE0W=K#?
M64]I<)O@GC:.1?56&"/R-)WMH-6OJ>;6FD7/Q%\ C7-9T+1)=:G1Y--\U"42
M,\QAR.3W]NG2M[X9Z\FN^$$_XEL&FSV,SV4]K;J!''(AYVCL#D'_ !KFK;P%
M\0=!M?['\/>,[:/1ERL/VJV#30(>P.#G'U'X5V_@[PK;>#O#T>EV\TEP^]I9
M[B3[TTC?>8_Y[56FMB>QOT5YWJGCW6/#NL7$&KV%B\7V*ZO8X+25FFACA^ZT
MA/&'Z< 8/K6EX>\8W$QU:'Q$+*UDTZ""ZDG@9A%Y4J%AG=R"N"">_7BDM1O0
MR? /_)3/B)_U]6W_ * U>C22)#&TDKJD:C+,QP /4FO,/AEJ%IJGC[Q]?6%Q
M'<6LUS;-'+&<JPV-TKTRZM8+VUEM;F))8)5*21N,AE/4&@%YF!K/CSPYHEHE
MS/J4,R.X0+:NLK X)R0IZ<=:=I'CGP[K-C]K@U."%-Y3;<R+$V1[$YQ63K'P
MH\+ZG:)#;V8TYU<,9;4 ,1@C:<YXY_2G:3\*_"VFV/V>XL5U!]Q;SKD O@]N
M,<5T6H<N[N=5L-R;N_R.U5E= Z,&5AD$'((IODQ!541IM4[@-HX/K]:(88K:
M"."&-8XHU"(BC 50, "D$\1"D2H0QVKAAR?05SG**8HSOS&IW_?X^]]?6F16
ML$-Q-<(F)9MH=L]0HP![ <\>Y]:>LT3MM65"W(P&&>.O\ZHRZ]ID,]W UTK3
M6BH9XT!9DWDA!@#EB1P!ST]10!HT5!;7<-W;1W$18(_3>I1LCJ"#@@\'BFS:
MC96\GES7<,;^6TN'<#Y%QEOH,CGWH LT5DP^)-,N);&*WFDF:]B$T'EPNP,9
MZ,3CY1]<5-<ZU86=\EG/,R2N <^6Q09R0"V, G:< GG% &A16;!KVG7%G-=)
M,XCA=4</$R,&;&T;2 >=RXXYR*C'B336GDAC>>1TW@>7;R,)"APP0A<.1W R
M>#Z&@#6HK 7QEH[6L5UNO/)D1Y%8V4WW$V[G(V\*-PYZ5O(ZR(KHP96&01T(
MH 6BBB@#)\4?\BEK/_7C/_Z :/"W_(HZ+_UXP?\ H H\4?\ (I:S_P!>,_\
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MR<5/1161@PHHHH **;)(D4;22.J(@+,S'  '<FN U#QAJ'BN>;1_!5ND\?\
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M!]2:LT5I*M4E%0E)M+I=V^ZXK+<****S&%%%% !1110 4444 %%%% !1110
M4444 %%%% !61XJLI-2\):O8Q/&DEQ9RQ*TK;4!*D9)["M>J.LKI[:)?+JH4
MZ<8'%R&SCR\'=G'.,9Z4GL.+LSPNQT7QQI^H:#>PZCX/,FB6C6EL&O3AD88)
M;U/TQ7L/@Z]UR^TB277Y-*DNQ,54Z9(7CV8&,DGKG/Z5Y_XD\)?#?2?#$.LZ
M;X?TR^BN)DABF:_=+=2W\3R;B%48_/ [UT?PJN-+;1]0L]+TRQLDMKK$C:?=
MFYMYF9%.Y)#U., CMBJO>Y/8[ZBBBD,\W\ _\E,^(G_7U;?^@-7I%>;^ ?\
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MA_1F,4 M[*TC)\NWB)VJ/15&3^%7J*\BMBYUK1:M!;16B7_!\W=_D6HV/-?
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M=P(R.*Y.S_Y.'U+_ + "?^C5I#/2**** "BBB@!K1HYRR*V/49I555&%  ]
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MTL0+96J7KWJVT*W3IY;3! '9>H!/4BGW$7G6TL0."Z%<^F1BI**&KJP7/,?
MOAK6K/4[#^T+*2R32M&;2S*9%/GR&7=O3!/RA5!R<')Z<5@P_"OQ#_PL2YD/
MBC7TM/[/4+JPF'FN^X?NB<YVXY_"MO2?$^LS^+[.>6^D>TOM9O=,-B57RXXX
M4)1EXW;LJ<DGG=TXI=<\3:S;^+M1F@OY(K73-2T^R%F%4I,D^-Y;(SN^88P1
MC;[T[WM_7;_-!:U_Z[_Y,L?\*NU?_HHWB?\ [_U0?X8^+!KL2)\0-<.DF F2
M0W1\X2YX '3;COG-=!X;U;7[KXB>(-/U>2!+>"V@EM;: [EC5F<9+$ EB%!/
M8=!7;TN@=;'D^J?#'Q:C6?\ 97Q UR0&X477VFZ9=L/\13'5O0'BEN/ACXL&
MLVB6_P 0-<;3"C_:9'NB)5;'R[ .",]<UZO10!XQ/\-/B"/M7D>.]2.+M1;[
M[UQNM_XF;CA^F .*AO\ X:_$M5N?[/\ '%ZY%SB 3W\@S!@\M@</G' XKVVO
M/?'NLZM!K!L-.U&2P6UT:ZU3?$JDR21E0J-N!^3DY ZYZTF[#2N<OX=^'_CN
MZU+4;;7?&&OVD-NL/V>X@N]R3L5S)C)S@'@9 KHO^%7:O_T4;Q/_ -_ZTO%6
MN:\OPQ.LZ,MO#>/8"YEEE)_<+Y6]BHP<MG@ \<Y/2NHT6:2YT+3IYG+RR6T;
MNQZDE02:JV_D+HF>:P_#'Q8=:N4G^(&N#2Q&IMY$NB96?^(,.@'I@T7GPQ\6
M+JE@MG\0-<:P8O\ ;'ENF$BC'R[ .#SUS7K%%(#R<?#'Q9_;S(?B!KG]D?9\
MB073>=YV>F.FW'?.<U13X:?$'['$7\=ZD+HWNV11>OL%K_>!QGS/;I[U[-10
M!XA)\-OB:(D\OQQ>&3,VX-?R8P!^ZQQW.=WIVS4WA/X?^.=0M;S_ (23QAX@
MT^YAN#'$(+O>DJ #YP<YP3GKBO9IFD6"1HD#R!240G 8XX&>U<=\/]5UO4I?
M$4>O30O=6FI&$)!_JXE\M#L4D9(&>IZT 9?_  J[5_\ HHWB?_O_ %0L/ACX
ML:\OAJ'Q UQ+59 +-H;HEV3')<'@'Z5ZO10!Y1<?#'Q8-8LTMOB!KC:85?[5
M))=$2JV/EV <$9ZYIA^&7C#^U[E1X_UK^SA;YMW^UMYK3>C#H%]QS7K5% 'C
M,?PT^(!MM-,OCO4A.WF?;PMZY5/[GE\<YXSG%4I?AM\4A;1F+QO<F;[/EU:_
MDVB;?T!Q]W9SGKGVKW.N(^).K:_I&EVD^D/!!;&ZA6ZN&.9,-*BA$7&.<G)/
M8>] ')^%?A[XPU+0H[G7_&?B33=0+N'MTNMP !X.<GJ*V_\ A5VK_P#11O$_
M_?\ JOJ'B;68_&%S/'?2+:6FN6FDBQ"KY<D<L8+,>-V_+9!S@ =*]0HZ7#K8
M\HT[X8^+&GO1J7Q UR.)9R+0P718M%V+YZ-[#BD'PQ\6_P!O%#\0-<_LC[/D
M2?:F\[SL],=-N.^<YKUBB@#Q]OAGXX_XF^WQ[JWR ?V9F\;]X<'/F\?+SCIF
MF'X9^//,M@/'FJ;#9EIS]L?(N<<*O',>>YYQ7L=!Z<<T >&CX;_%$!"_C:[/
M^K+A;^3..?,QQU'&WU[XKT?X;P:[;>!K&+Q(;@ZJK2>:;F3>^-[;<G)_AQ7(
M77BSQ58VGC9[^:"*\LY+*.UC@^>.U$Q R"1\S ,"2>,CTI5UO79=:'A(:U=*
M$U2X@_M$*GGF)+83*I.W;G<V"<=!2N.QZS16!X(U>YU[P5I&J7FW[3<6X:4J
M,!FZ$@=LXS^-;]4U804444@"BBB@ HHHH QO%VE3ZYX0U?2[8J)[NTDBC+'
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MN(;^Y2V:"*9RIV( 0-S#@].U8":1:6GP8\%7L-@B7IUF&1YEBQ)GS'R2<9Z
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J?]>3UN:!_P BYI?_ %Z1?^@"EO?Y?JP[?UV1HT444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex3-5_001.jpg
<TEXT>
begin 644 ex3-5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" H(!QH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **I:EK&EZ-"DVJ:E9V,3MM1[J=8@QZX!8C)K,_P"$[\'_ /0U
MZ'_X,8?_ (J@#H**Y_\ X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_
M (J@#H**Y_\ X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (J@#H**
MQ+?QEX7NI/+M_$FCS28SMCOHF./H&K4@O;6Z -O<PS9&1Y<@;^5 $]%%% !1
M110 4444 %%%% !1110 4444 %%%% !139)8X8FDE=8XU&69C@ >YKS7Q/\
M'+PCH :*SN&UBZ'1+,@QCZR'C'TS]* /3**^4];^/WC/4;K?ILMMI4 ^['%"
MLK$?[32 Y_ "OJB!B\$;,<DJ"3^% $E%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!2U+1]+UF%(=4TVSOHD;<B74"RA3TR P
M.#7)Z[\(?!>N6+6XT6WL)<'9/9((F0^N!PWT(-=S10!\*^)-"N/#/B._T6Z8
M-+:2F,N!@..H;';((/XUE5Z5\=X(X?BK?.@P9H(7?W.P+_)17FM 'JFC_ #Q
MAJ<$,]Q)I]C%(H;$TQ=P#[("/UKI4_9GNBOS^*(5;T6R)'_H8KWS3/\ D%6?
M_7!/_015J@#YUN/V:=06,FV\2VTCXX66U9!GZAF_E7$Z]\'?&WAM?M)T[[9%
M'\WG:>YEV\]=N _OG%?8%% 'Q)IOCSQ?H<W^A^(-2B*?*8I)F=1_P!\C/X5Z
M5X;_ &C-5M72+Q'IT-[#T,]K^[E'OM^ZWT^6O5?'GPIT'QO!).T2V6K8.R]A
M7!8_]-!_&/U]#7RKXF\+ZKX1UF32]7M_*G4;E93E)%[,I[B@#[+\,^+=$\7Z
M=]MT6^2X0<2)]V2,^C*>1_(]LUMU\)Z#K^I^&=7BU/2;I[>ZCXW+T9>ZL.X/
MH:^N?AS\0K'Q]HGGQA8-0@PMW:Y^Z?[R^JGM^5 '9T444 %%%% !1110 444
M4 %%%% 'GGBGX4Q>,=8GN=8\2ZR;!RIBL()%2.+ ]""#SDYQGMGBOG_XJ?#U
M/A_KUO;VMS)<6%W$9('EQO4@X96Q@'J#D =?:OL.OG_]II1N\+MCDBZ&?^_-
M '@%??5M_P >L/\ N#^5? M??5M_QZP_[@_E0!+1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)0 44C,$4LQP ,DUP'_"[?AY_P!##_Y)7'_QN@#T"BO/_P#A=OP\_P"AA_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!\G?'S_DJ5Q_UZP_^@UYC7IWQ\_Y*E<?]>L/_ *#7F- 'WKIG_(*L_P#K
M@G_H(JU573/^059_]<$_]!%6J "BBB@ HHHH \\^.,HC^$FL*<?O&@4?]_D/
M]*^0Z^F?VCM5^S>#M.TQ9 LEY>;V7NR1J<_^/,E?,U ';?"*#[1\5= 3&<3L
M_P#WRC-_2OLFOES]GC2#>^/I]19 8]/M&(8_PN_RC'_ =]?4= 'RO^T%K!O_
M (B+IZR$Q:=:I&4[!W^<G\0R?E7,^!OB3JWP_2^72;/3YFO"AE>Z1V.$S@#:
MZ@?>-/\ BU-Y_P 5/$#\\7 3G_911_2O4?V:+L-9^(K,J 4D@E!SUW!P?RVC
M\Z .:_X:.\8?] W0_P#OQ-_\=H_X:.\8?] W0_\ OQ-_\=KZ?HH ^8/^&CO&
M'_0-T/\ [\3?_':\V\4>(KOQ9XCN]<OHH(KFZVETMU*H-J!1@$D]%'?K7W11
M0!\ 5]R>#;Q]0\$:#>2G,DVGP.Y_VC&N?US6W10 5X=^TK_R -"_Z^I/_017
MN->'?M*_\@#0O^OJ3_T$4 ?.-??5M_QZP_[@_E7P+7WU;?\ 'K#_ +@_E0!+
M535-,M-9TJZTV_B\VUNHS%*F<94CU'0^]6Z* /#4_9JTQ=4\U_$5TUANSY'V
M=1)CT,F['_CM>TZ?86NE:=;:?91"&UMHUBBC'\*@8 J=W2*-I)&5$499F. !
MZDUY/XO^/?A[0R]MHB?VQ>#C?&VV!?\ @?\ %_P$$>] 'K5<3XL^*/A#PU!/
M;WFJ1W%T%9?LMI^]DSCH<<+_ ,"(KP[^T/BE\7F:*W\Y-,<[7$.;>U Y!!;J
M_P!,M]*[/P_^SKIUG;_:?$>I27DRH6-M:_NX@<="Q^9AGTVT ?.E?1W[-7_(
M UW_ *^H_P#T$U\XU]'?LU?\@#7?^OJ/_P!!- 'N-%%% 'GGQI\-'Q'\.KQH
M8]UUIY%Y%UR0OWQQ_L%N/4"OD.OOUT62-HW4,C AE(X(/:OB+QQX=;PKXSU3
M1]I$4$Q,).>8V^9/K\I'XYH ^G/@MXD_X2'X<622ONNM.)LY?HN-A_[X*\^H
M->AU\O?L]^)/[+\9SZ+,Y$&J180$G'FIEA^:[A^5?4-  3@9-?&'Q/\ $T7B
MOQ_J6HVVTVJL((&4#YT3@-D=<G)^A%?1WQE\6?\ "+^ ;I89"M]J.;2#!P1N
M'SL,=,+GGU(KRWX<?"U=?^%NNZE<0*;[4(RFG%ARGEG((.,C<XP?9?>@#R#2
M-4N-%UFSU2T;;<6DRS)SC)4YP?8]#7W-I.IV^LZ/9ZG:-NM[N%)HS[,,U\&L
MI5BK @@X(/:OIO\ 9Y\3'4O"=UH4\F9],EW1 _\ /%\D?DP;\"* /8Z\<_:&
M\2G3?"5KH<$FV;4Y<R 9SY*8)_-BGX U['7RKXTFE^)OQQ72;>0FU6X%A$R_
MPQQY,C#KW\PCVQ0!Z]\"_#7]A?#V&\E7%SJC_:FSU"8Q&/I@;O\ @5>F5'!#
M';6\<$*!(HU"(HZ  8 J2@ KRKQW\#M,\8:Y)K%KJ<FF7DY!N!Y(FCD(&-P7
M<I!/&><<=,DFO5:* ..^'_PYTOX?V$\5G+)<W=R09[J4 %L=  .@&3Q[]:[&
MN3\7_$?PUX*C*ZI>AKO;N2S@&^5O3C^$''5B!7B6L?&KQGXQO_[,\)V#V:R<
M*MLGG7##.,EL84<CH!CUH ^A=;\2:+X<MOM&L:G;649^[YK@,W^ZO5OP%?*7
MQ>\6Z5XR\:KJ.CF5K6.U2#?)'LWL&8D@=<?,!S@\5V.A? 'Q%KMU_:/BW5?L
MIE(:1=_GW#_[S$X!Z<Y;Z5QWQ<\(Z7X*\66NE:2)O(^P1RNTS[F=RS@L>W.T
M<  4 9_PM_Y*?X>_Z_%_D:^T:^+OA;_R4_P]_P!?B_R-?:- !7G?QR_Y)+JW
M^_!_Z.2O1*\[^.7_ "275O\ ?@_]')0!\B5]>? ^*./X1Z.Z(%:5IW<C^(^<
MXS^0 _"OD.OK_P""7_)(="_[>/\ THDH ] HHHH *^-_B]K!UKXGZU()"\5M
M+]DC!_A$8VL!_P "#'\:^R*^%/$LWVCQ5K$W/[R]F?GKRY- '4^"_BUKG@71
M9-+TJQTN2&2=IW>YCD9V8@#LX&,*.U='_P -'>,/^@;H?_?B;_X[7HO[/%V)
M_AS/#M -OJ$B=>H*HV?_ !XC\*]:H ^8/^&CO&'_ $#=#_[\3?\ QVC_ (:.
M\8?] W0_^_$W_P =KZ?HH ^"]5U"75]7O=2G2-)KR>2X=8P0JL[%B "2<9/'
M)J*TNI+*]@NX2!+!(LB9]5.1_*OOFB@!$8.BNO1AD4M%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.N1]/V]O#:6T=O;Q)%#$H1(T& JC@ "@"2BBB@ HHHH **** "BBB@ HHHH
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M>,$H%*A0 2N!G!R3SS7"Z'X;^# \,65[<:G8K?+ LDDQU1XIUDQDD1AQ@@]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9S6O10  8&!THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS>6.,#"D$9Y^8\#'-=C$SO"C2)L<J"R9SM/<9I+57!Z#Z*** "BBB@ HHHH
M***CGGBMH))YY%CBC4L[N<!0.I)H DHKSR/XE:EK9DD\'>#[W7+..0QF\ENH
M[2)R.NPODMS["EN?BUINB(\7BG2=2T*\";HXIXO-2<XZ1R1Y!YXR<4 >A45#
M9W'VJR@N-NWS8U?;G.,C.*FIM6=A)W5T%%%%(84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/UZU?T+P?J^J>/!XW\4PVMI=PP""RT^WD\WR5P<EWQAF^9AQQS3BE&5E\/\
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MQJ$9[3#7DX'JX9D4'N5&?3'6L[>[)=?TMT&WJNWZW./_ &;0 WB< 8 D@_\
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M-A-,%42\9^8D97!W=L]*Y#P;\1/B?XPORMIH>@FQ@N1!=W'S*(_[V/WI)X]
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M:5^@[:7/4**\DT?XKZYIGB6U\/\ Q T"/2KF\($%S;MF(DG !^9AC/&0QQW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5P7QEU,Z9\+=793A[A5ME]
M][ '_P =S78ZM?MI>DW5\EG<7CP1EUM[9-TDI'\*CN37S[\0?%'C'QYI-GIQ
M^'&NV4,%TMQ)^ZFD\T $;?\ 5#'7KS4R7-[OI^947;WCVOP%IG]C^ =#L2NU
MH[.,N/\ :8;F_4FNCK@?!/C?Q#XCU,V5_P" [_0[.*+/VFZD8#(X"A6C7/X=
M*[>^O8-.L+B]NI!';V\;22.>BJ!DFM*CU<F9P6BB3T5YK\,-7\6^*Y[[Q'JU
MZT6A32.NG6'D1KE<\,6"[L#IUY.:]*I-6W'?L%%%%(9S_B#QEI/AO5-(TZ_,
MQN=5G\BW6)-V#D#+<\#) []:U]1O(].TR[O93B.WA>5C[*"?Z5Y/\3=#\7'X
M@:)XIT71X]5L]+B&+<2?-OR2WRY!Z$8QGD=*BO\ 7OB)\1=*ET.T\&R>'K6Z
M!AN[S4)&R(R/FVJRJ>>G /X=1.LH66^O_ *T4E?;3_@EWX V<A\(:CK,_,^I
MW\DI;'4#C_T(M7)^*=2\23?''5-5\,:9:ZA/H5FL;BY<*D:%,LW+KD_,PX/X
M5ZE-GX9_#^TM-'T:^UM[0+"EO:(2\C')+M@$@9R20#U%>1>%/$OB[PWKWB+5
MI_AMKE]+K4_FLIAE01+ECM_U1W?>QGCI5R:<_=Z+3[DE^I*OR^]U?ZW9T'PV
MTVV\4?"[7I_%=^\%MK>HLSS-.(\'*XVEL@?,, '.< <UZ9K;6OA#X=WWV-?+
MM].T]E@7.2-J849[G.*\:U_4?$?CL:!X=3X=:IH&EPZA&\A6"3R@F<'CRE"@
M!B<UU'QCUWQ#=Z=>^$M&\(ZQ=Q3QQ[]1@@=X\9#%5"J<],'D8]*536#2TOI]
MR2_S'#22OTU^]_\ #'E^D^-O$7A7X6G1K'0=1L/[0G+Q:V"Z!RQ'"?)@DJN,
MAL]Z^G-.TN)K+2Y]1ABNM2M;=5%U-&K2JQ4!B&QD9/7%>5>$]1O_ ! OAWPQ
MK/POU"&QTSRV2]O))$2)HUQOP8U#$_W<]^^*]9UW4Y=&T.[U"#3[G4)8$W):
MVJ[I)3G  '_Z^/6KFTDWY_@E9$13;2_K5W/%_BQK-VOQ?\.1V&D7.L2Z3"+L
MV=L&+,Q;/\*L1C:IZ5M_"_Q5KGC;QUXEOM16YM-/@AC@72Y7+) ^2"""!\WR
MMG@'G!Z"N.T_Q-XPL_B5J7C&;X;Z[.]W;BWBMO*E40J H^]Y1S]WT'4U[)X
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M+_@MEWUBO7^OP,W0;W_A/_B?X453OL] TF*YF/7]\R*<9^I3_ODU[U7C_P
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M2&! '4YQT4UZ!807%MI]O#=W;7=PB!9;AD5#(W=MJ@ ?05"U5RGH[%FBBB@
MKPK4O#?Q#\">.M:U[PI8V^K66JR-+(C@,5R2V"NY6R"3C:2#WKT7XH+K$OP^
MU*WT*WN)[^<)"JVX)<*S@,1CVS7GV@^*OB'X"T:V\/ZCX O-66V7R[>YLY&8
M%!T#%$<=^/N\=J2WNM_SO_2&]K='^A9TCX@:9XY\36'AOQMX0ET_4HIA/9K.
M7V^8 <;E(4CCIG(-:GQ]O)$\!6^F0+NGU*^B@5!U;&6_F%_.H_#_ (6\3^*/
M']MXU\76,&EI81^79:?&X=SUY<C_ 'B?7IP._(>//$/BCQ+XKT6ZA^'VOBQT
M6[,RHUO)FYPRD$XC(7[O^UUIM)\L7IKK]_YZ"6EY+MIZV_*X[PW<>+M1^+?A
M?0O$-E!IW]AVK.EM:2941B,@,V'8$GY1U_#FNXURWT+P-X4\9>*M!N_-OKYF
M\V83B41SD[0JXZ89B<'D'\!6#/\ $[Q1))/<Q?"#5HKZ6$P_:@DAD"\X!/D9
M(!.<9JUX)^']QJ/P-NM U**>QOM1DDF87,;*\<@<;"RG!_@4_0T2O*#_ *O=
MZ_@.-HR7;3\%_F=)\'M @T7X=Z?.J?Z7J*?:[B4\LY;D9/L,?K76ZUH>F^(M
M,?3=6M5N;-V5FB9B 2I!'((/45X[H7BCXC_#[2X= U+P-=:W%:@QVUS9,Q'E
MCH"41^/3(!Q]*Z'2W^(OC'Q'IU_J%LWA;0[.03-:K-NFNC_=;I\N.""!]">E
MRM*6FQ"O%:[E_P",=]'HOPGU*&!5C$RQVD2+P &(! _X"#7G&G_%S7/ G@S3
M=*F\!W=F(81%#=7KO''*W4MM,8SG). WXU;^+NM>)?%-PNA67@?77L+"^\QK
MD6TC"Z"@K\H"$!3DX.3D8XKT.TCN?B9X"OK/Q%X9FT,39C@AN'WN,#Y9 "JE
M2&[$=O0UFK\LI?U;^FS1I*48OH5?AMX1OK2]O_&.NWMO=ZSK**V;;F**+@@*
M>_ 7\AUZUY_XIU+Q)-\<=4U7PQIEKJ$^A6:QN+EPJ1H4RS<NN3\S#@_A5WP+
MXK\:>"O#5QH=]X$UO4EL'9;::*-QNRW"X*$E?O'<N<#''>L?PIXE\7>&]>\1
M:M/\-M<OI=:G\UE,,J")<L=O^J.[[V,\=*J5G+W7HD[?=I^;N2OA:ENVK_?K
M^2.@^&VFVWBCX7:]/XKOW@MM;U%F>9IQ'@Y7&TMD#YA@ YS@#FN[U_X;Z?KE
MKX;L5NI;;3M$E61;=5W><J@ *23QTZ\]3ZY'E>OZCXC\=C0/#J?#K5- TN'4
M(WD*P2>4$S@\>4H4 ,3FO8O&GBB_\*Z9!-IOAO4-=GE?8(;-6(0 =6*JQ'MQ
M3;LE+;56^25F)7;MOH_Q>IP][C6_VEK&$/NCT;3C(R]@Q!_^.+7;'P3 _P 2
M!XQENW>5+,6L5ML&U#SEMV>>"1C%>-:#XE\8:3X]USQ1+\-];N9M5"HD1BE0
M0*,<;O*.>B]ATKU+QQXO\1:-X7M&TKPKJ-WJ]_ =R6R-,MD^T9W%5.X@GC@
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M\'WVL?\ "*Z;X%U/X6:K=6+3#SKBY:2!,F3?O.8P!CTW<XQWIM\\FUY+_/\
M(GX8J_>_^1ZKX&L&U+X?^'IM?4:C>K"ER);U!(ZN<E6RPSN (&>M=?3(HDAB
M2*) D:*%55&  .@%/IR=VVA15DDPJAK>G?VQH6H:9YIB^UV\D'F ?=W*1G]:
MOUY/\9-)\6Z[>^'['PU:3R)$\EU(ZMMC$B;2@9B< ]<9[FLW9Z/J:1NG==#E
MM#E^*?PML3I2>&8M8TB&1F5K=3(Q#?W2AW 9Y^93^5=K\._%'ASQ_KMWK?\
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MESJ $ 'W@N,'\,E?RKJ?BYJ)TCX4ZN2W[R:%;4'U+D*?T)JEX1\#:Q<^)?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L3Q5X=7Q5HW]D
MS7<EO:R2HUR(QS-&IR8\YX!XYK;HH BM[>&TMHK:WC6*&) D:*,!5 P *EHH
MHW#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH Y_2/"EOIGB+5M>FG:ZU'4' \UUQY,( VQ*,]!C)/<UT%%%'2
MP=;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %8<_C/PK:W$EO<>)=&AFC8J\<E_$K*1U!!
M;(-;9 92#T(P:^>[/X>>%=3^.FH:!%I1&CV%D))H1<2_-*0ISNW;OXQQG'%"
MNY6]?P&[*+9[GIOB+1-8D:/2]9T^^=.66UNDE*_4*3Z&G:GKNCZ+Y?\ :NJV
M-AYN?+^U7"1;\=<;B,UX[\2OA;H/A7PM)XF\+1SZ5J&FNDH:.XD8,"P'\1)!
M&>U,^)=MHVO?"&R\:ZEIZOKL]G;Q13>:ZA2S9.%!"GJYY%)OW;KH_P P2U2?
M7]#U7_A._!__ $->A_\ @QA_^*JWI_B?P_J]S]FTW7-,O;C:6\JVNXY&P.IP
MI)Q7AFC:!\,6O/"F@'2(-9U74[<&\N;75)"L#A,G<$?&<YXXP!74?"[P)+X?
M^(7BJ_.D2Z?IT;&UL%D+$/&6R2I8DL,*O//7'8U?+JT_/\/^"1?2Z\OQ/1;C
MQGX6M+A[>Y\2Z/#-&=KQR7T2LI]""V15O3->T?6O,_LK5K&_\K'F?9;A)=F>
MF=I..AKP7XA> ?#5O\2_"N@:/IBVYU"8RWP$TC;T+C/5CMX#],5[9X:\%^'O
M!\<Z:#IJ6@G(,I\QW9L=.7)./;I2CK'F?]6*EI*R-N::*WA>:>5(HD4L[NP5
M5 ZDD]!6&/'7A D >*M#)/0#4(O_ (JKVNZ3INMZ+<Z?K$(ET^5<S(79 0#N
MZJ01T]:^4M:\)V>KZ=XC\5^';+[#X>TV5(+6/<[F?Y@K/ER3WS^('K4IZZ[%
M6TT/KW(QG(QUS6"WCGPBCE6\4Z(K*<$'4(@0?^^J/#EQ!XE\!Z;+<H)(;ZP0
M3)GKN3##(_$5X9H?A'P4OCCQR^JZ<IT/0E!BB\^7Y".O(;+$E2,'/6G)<LW%
M]+_@3'6*DO+\3W^[\1Z'I]K;W5[K.G6UM<#=!--=(B2C&<J2<'CTIMGXH\/Z
MBLS6.NZ9="!/,F,%W&_EK_>;!X'N:\4GUWP?\0?A_K.OZCX7CLY= MA;640O
M9-HW#]V $V#[V!C!KI/AC\.] 3X7))K%@KOJT FO'>1T)B#;T&01M  !XQGO
M3:^)]OUV_#5BOMY_IO\ \ [T>.O"!( \5:&2>@&H1?\ Q5;^<C(Z5\@ZUX3L
M]7T[Q'XK\.V7V'P]ILJ06L>YW,_S!6?+DGOG\0/6OJ/PIJ"ZWX,TF^;D7-E&
MSC/<J,C\\T6O&_7_ #5T#TE;^M-QLWC7PI;S/#-XGT6.6-BKH]_$&4CJ""W!
MJ>P\4>']5N/L^G:[IEY/C/EV]W'(V/7"DFO#IOAWX5N_CK#X;L]+":3;6)GN
MX!<2G>Y!(^8MN'WDZ$4_XL>"/ GA30XFT%&LO$1GC^RP07<DDC\C.59F( Z@
MC'.*2V3?7_.Q36K2Z?Y7/>-1U;3='MQ<:GJ%I8PLVT27,RQ*3Z98@9K+_P"$
M[\'_ /0UZ'_X,8?_ (JN3\=>'].O_A8FI^*[,7>J:9IA=6:9TVSLB@_=8 Y8
M#KFO*_#VF_#JS\(>'#JFF0:WKVJ70AEAM]2='@5G(!=4?C QQ@9-.SYG'L[?
M?_PQ-URJ7?\ 34^A[/Q=X:U"[CM;+Q%I-S<R'"0PWL;NQ]@&R:V:\7\-?#=-
M%^.4UWIVB2V6A6%H&MY69W221UVG#,22>6XSQCW%>T4:63[CUNT%%%%( HHH
MH R]1\2Z#H\ZP:IK>FV,S+N$=U=)$Q'KAB#BH;;QCX8O;A+>T\1Z1/._"QQ7
MT3,WT ;)KR/XT>%M%NO%_AM(+$_VKK5\J7,PE?+Q+M3&W.!P1R .E=5JGP*\
M#76F3PV.F265T4/E7"74KE&QQPS$$?A23]WF?G^ VO>Y4>F54U#5=.TF#S]2
MO[6RAZ>9<S+&OYL17A?A/XI7^@?"2X^U$WNK6UZ=.L!(2WF$@$9[D+D_H*ZG
M1?@[9:M"-6\>SW.M:S<J&D5YW2.#OL781TSZX]!5-:Z;?TQ;:/?_ "T/3K*_
ML]2MEN;"[@NK=ONRP2!U/T(XJQ7@5YI!^$GQ:T$:%/.NBZY((9;)I"P!W!3U
MZX+*03SU&:]]HM>*DOZL+5.S"H;J[MK&UDNKRXBM[>(;I)9G"(@]23P*FKG_
M !OIND:EX0U%-<MOM%A!$UP\?F,G* L.5(/:HD[)LJ*N[$]IXO\ #.H74=K9
M>(M)N;B0X2*&]C=V/7@!LFHW\;>$XY6B?Q/HJR*VTH;^($'IC&[K7BOP;T[P
M!:^'3JVOW^CQZQ++*B"[OU1XHB N A88)^;YL9YZTSPSX.\':Y\;;RSTFRM[
MCP_IMHLJB.Y::*67Y>=Q8[AECQG'R]*TY?>4?Z[_ ->9-_=;_KM_7D>Y7OBW
MPWIMTUK?>(-*M;A,;HI[V-'7/(R"<U7_ .$[\'_]#7H?_@QA_P#BJ\9^+'A3
MPI9?$#PY;I;P61U2Z>XU.XFNG52A<9SN;" _/TQ5JR\+?#GQ)=^*=/\ #OA4
MW,FDVNZWNHM2FD2XE*G 4!\=1P<G-0G[O-Z_@4U[UO3\3VJV\0Z)>V,]]::Q
MI\]G;_ZZXBN4:./C/S,#@<>M4?\ A._!_P#T->A_^#&'_P"*KB_AI\/K=?A,
M-&\3:;(!?S-<W%M*S1N,$;,[2"#A5../>N,^%GPZ\*^++OQ-?:AI8FTZ&^,%
MC&+B5?+0$GJ&!/!7J35M>\X]E?\ +]62G[M_.W]?<>\Z;K.EZS&TFEZE9WR*
M<,UK.LH!]"5)J'4?$N@Z/.L&J:WIMC,R[A'=721,1ZX8@XKPZXT'0]"^-7AN
MS^'\S+-N/]I0P3M+''&"-P9B2>5W9!/]WI5[X_>'- M[>SU2.TCCUK4[U(I+
MIYW "*F"2I;:!PO.*GI%KJ[?C8I;M/HKGJ__  G?@_\ Z&O0_P#P8P__ !56
MK7Q1X>OH;B:SUW3+B*V3?.\-W&ZQ+ZL0?E'N:\@TOPO\*M6\;+X8TS0(]1V6
M1N)-0M]4E>/<,#;\LF#UZYXSC%7/A7\-8F\+^(+;Q-HLL%OJ-X%%I,[QMY<1
MRO((;&XG!SSC/(-.V_I^MO\ ,7]?A<])_P"$[\'_ /0UZ'_X,8?_ (JM'3=<
MTC60YTO5;&^"<,;6X27;]=I.*\&^%OP[\*^+-4\47-]I?G:;;WWD6,8N)5"*
M"QZJP)XV]2:DUSP]HGA?XO\ A:Q\![X;]IO]/MX9WE5(]PSN+$D97?D9Z <4
M15W%=_U5P>G-Y?H>XZEXCT/1IEAU36M.L977<J75TD3,/4!B.*FBUG2Y]+.J
M0ZE9R:> 6-VDZF( <$[P<<8]:\P^,WPWT_6?#^H^(["T/]N0*LLD@D<^;&@P
M5VYV\+SP,\5RI\9:3J_PET?P5X=TN.XU?4H_LS62Y*V[!LM(QSG)/S#GW/2I
M5VGWT_$;LFNW^1[CI_B?P_J]S]FTW7-,O;C:6\JVNXY&P.IPI)Q6K7#?#[X8
MZ/X&LHIDB6?66CVW%ZQ))SR54$X4=N.3CFNYJFDMB4VPHHKR?QIK.L>+O',?
MP_\ #M[)8PQ1B;5KV+AT0X.Q3VX(^I([ TM;V6Y72[/0KOQ3X>T^[^R7NO:7
M;7/'[F:\C1^N/NDYJY#J5A<7$MO#>VTLT2!Y(TE5F13T) .0#@X-<!'\"? 2
M6 MVTVXDFVX-RUW)YA/K@';G_@.*S/A=\+)_#47B:#7( UMJ#&UB3S06DMQN
M&24/R[@1WS]*%U0NQWI\=>$%)!\5:&"."#J$7_Q5)_PG?@__ *&O0_\ P8P_
M_%5X+!X:\ 0?%KQ%8ZI':6F@:9;8CMYK]T,LP"YVL7#,<[N :FU7P5H?B?X8
MVFN^#/!ES;W]S?>0$6ZEG9(PQ4L06Q@D#)QQSS@9H6J37E^+L.VMOZVN>_7/
MBGP]906\]WKVEP0W*[X));R-5E7U4DX8>XJL/'7A G \5:&2?^HA%_\ %5Y=
M\8_"/A_2/AQ:WTEB&U>VAMM.MI_-<;57K\H;:> W4'K6M;?"+X=Z;X2M+O7[
M&*"5;5#<W<M]+&-^T;C]_;USQC\*;MJ^B=OZ^0NWFCUB.1)8UDC=71AD,IR#
M^-8DWC7PI;SR0S^)]%BEC8HZ/?Q*RL."""W!KS#X)S7.F^&O%5U;O<SZ#;3N
MVF^8"6<*&)('N-F<=\UQMIX.T@?!/5O&6NZ=))K%U*\EK,\LB;=[!5(4, 1D
MD\@YI2TUZ63^_H-*^G6[7W'OW_"=^#_^AKT/_P &,/\ \56G_;&F?V5_:G]H
MV?\ 9VW?]K\]?*V],[\XQ^-?/FN_#KP_I7P.L];CTAY->N(;<^>)I2=TC#^
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M@^P%3>RYGM^A5M>5;GIU]J%EI=JUUJ%Y;VELI ::XE6-!GIDD@5D?\)WX/\
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M[!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%/U7X">&=:U:ZU*]U777N+F5I7/VB,X)/09C)P.@YZ"A:<OE_G?\0;NY/O\
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M@'U./6MS6_@9X,UO5FU!HKRS>1R\L5I*%CD)ZY!4X_X#CK78^'/"NB^$]/\
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M66:;5KM!UBGN%"GZ[$4_K4QO9WZ_U_P1NVENA6\-R+X_^--UXIM%+Z+HMO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N(\5_%'1?#.I+I,4%WJVLMTL;"/S'7C/S>G'89/M6SXUUT^&?!F
MJZNI42VUNQBW=/,/"_\ CQ%<K\&O#4.G>$(==N5\[5]8S=7%S(,N0Q) SZ8Y
M^IH2O?LOU&]$O,P9_CQ=Z3D^(? 6KZ6KJ?),C'YV]/G1./<9^E>BV'BZQE\$
MVGBC5"FF6L]NL[B:3(CW=!G S[<9/I4_BKPMIWC'0I-(U/S1;.Z.3"P5@5.1
M@D''I]":\MU>SA\9?&#3_!3*1X>\.VJS26V?ED8*N ?4?,@^F[UH6ON]?T2N
MQ;>]T7_#(T;KXVSS W.@^!];U32U)WWWEM&F >HPC CKU(KJ_#OQ'TCQ5X8O
M=8TB&ZN);.,M-IZ1YN V"0H4=<XX(ZUUL44<$2111K'&@"JBC 4#L!7C'@*T
M2V^/_C!-,4)IJ0_O53A!(2AQ_P!];_UIJS;CY/\  'HN;T_$1?CKKLFJ2:7'
M\-M2?4(UWO:B=S*J\<E/)R!R/SK6TCXTJ^N6NE>)_"^I>'9KMPD#W.XJQ/ S
MN1"!G R >O.*Y#PKX\\-:5\6?&6N:_J7V9I9?LUJ?)DDW(K8/W%..$7\ZT?$
M.II\9O$^C:9X=MIWT;3;G[1>:G+$43M\JYYZ=N#DCC S1#7E\]_+^D*>G-Y;
M?UZGHWC[QG=>"]+BO+7P]>ZQN+&3R,JD"*,EG<*VT?AV/-4OAQ\0;KQ_97MZ
M_A^33K6!E2.4W'FB9N=P'R+TX]>M=M-#'/ \$J!XI%*,IZ$$8(KYILCXM\&>
M*M=^''AM"S:E.&M9V/-O$1DR _[F 3VV\<U,=W'J]BGLGVW.]TCXSZKKOBJ3
M1-/\"W<IBN?)GE%W_J5W8+.!'M7H>"W;&:]=KG/!7@ZP\%:!'IUF \K?/<W!
M'S32=V/]!VKHZIV2L3>[N%175U!96LMU=3)#!$I>221MJJHZDDU+7C_Q2N)_
M$_COPY\/XY7BL[HBZOMAP709(7\D8_4CTI:MI+=E:6;>R+=_\:A/+*OA3PEK
M'B&&%]LES!&Z1=.<$(Q].H%=%X&^)6C^.?/M[>.:SU*V&9[*X&'49P2#W /'
M8CN!75V%A::78PV5C;QV]M"H6.*-<*H^E>.W-HD7[4-F=+4(6L3+?B/@$E'&
M3]?W?Z4XVYN7O?\ !7)=^5R[%_Q5\9]2\,Z])IQ\"ZC+"9S!;7$TK0BY8<?N
MQY;!@3TP3G(J(_&#Q> 2?A/K@ ZDM+_\8K&^,GB:QTSXH^%/[06:2STL"\FC
MA +$E^, D#^ =ZZ7X>_$&]^(?C+7A$&3PY!;(L-O+$JR!FX)9E)Y.&XR1@#I
MS4P3E'3?7\/\RIM*7EI^)O?#?Q_-\0=-O;YM&_LZ*WF$*YN/-\QL9/\  N,9
M'KUKMJS-"\/Z5X9TQ=.T>S2TM%8L(U).2>I))))^IK3JG;H2K]0KR76/C-J-
MIXFU;2-'\$WNLQZ;)Y<UQ;3,<<<E@L3;>01R>U>M5Y-!X:N_AQ\/?&VJ7][!
M/J%^9I_,B!"C=D(.>^6S^..>M1)VN^R_$N*O9=W^!E6OQZUJ^T^34+/X<ZA<
M646?,N8;EWC3 R<L(<# ZUUVF?$F[U/X;-XMM_#%W/,TC1Q:?:2&9WPVW<6"
M @9SGY3C%9?@?PQ=77P CT>UDCAN]2LY65Y,A09"<9P,]"*VWL?^%>_!NXM!
M,CRZ=ITG[Q1@-*03D?\  FJZGN*7E:WZ_P"1,/><?.__  /\_D8'@[XPZMXP
MO_+MO UXMBF[S[R*Z,BQ[5SMYC4%NGRYSS5*/XW:Y-XACT2/X=:@M]*<QP37
M+1RE">'*F+@=R<X'K7+?#;QOXC\)^#H+"Q^'.KZI#)(\XO(O,"R[NXQ$PQ@
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MKBXMFVSQ0W#N\1Z88"'*G@]?2MWP]\8EO_$-MH?B+PUJ'AV\NSBV^U;BLA/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%V49>K_-(4E=RCZ+\FSY[^*?P_TYOB-H4$-[J5Q?>(+QC<F:57$4>Y1A/ER
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M.=;_ &A/"VF@*T6FVK7;CT8[C_[*E>L265K+=Q7<EM"]S""L4S1@N@/4*W4
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MXB@MXFF5H%3:3\HVY P,]>K4[P9X&/B7X"ZH&0-?ZA<R7L#$<[X^%'X[6'_
MJY;P_P"(+CQSJ?@#PQ<B0OI5RWGYZ.B$,I^H52/_ -=4HW<:<MU;[GO^7XB<
MK7FMG?\ #8Z'X@?"7P]X2^&S:FEYJIN[=4"Q-.IB>9V 9BNWCCC@CA15>R^%
M7@B ^%]-UF_UY-:URW$HBMFB\N,[=QSE,@=N]=G\=6.H6OAKPTCE6U34T#;>
MNT?+_-Q^54O#7P?_ .$.^*":Q;-*V@V5HTJ3W,R-(TI4J1A0,  D]/QI1=VW
M+:_Y+_AAR3226]OS=O\ ,I_!WPA%H_Q,\526\5U]BTTFR@DN1\S$L"22  3A
M0>!T8>M>ZUS'@7QG#XYT.;5;>RDM84N7@02,&+A<8;IQD'IV]36YJ&J:?I%M
M]IU*^MK*WW!?-N9EC7)Z#+$#-#NDD^B7]?B+1MM=_P"OR+=%16MU;WMK'<VD
M\5Q;RKNCEB<.CCU!'!%2TAA113)IH[>"2>9UCBC4N[L<!0!DDT/0#P[XZ^%M
M#"C6KF]U2?7+UTMK"Q2=?*SP#A2A('<X/)(]:J_!&RN_"7Q"U_PKJ) N3:13
M,%.5W#!Q^4GZ5D2^,-9\0?$K_A,+?P=JVOZ58EH=,2!)!&A'&\D1L"QY..V1
MZ59TWQ1J-W\?-&UG5/#=YH!OX_LC0W0;,GRE0P+(N>=HZ=J=+1I=[_EI_F%5
MZ/RM^>O^1]&4454@U33[J^GL;>_M9;NWP9H(YE:2//3<H.1^-("W7SKX]^'^
MF:C\:=)TD7VIS2:QON;UI)58Q)\Q C.W@ *0,YP,5]%5Y!HN=;_:0UN[(S%I
M%BL"'T8A1_[,]$4G-?/\O^&&W:#^7Y_\.9GB#X)V_A+0[S7?"6O:O;:E8Q-.
M/,F7#JOS%<JJ^G?(XZ5Z/\-_$TWBWP)IVK70 NG5HY]HP"ZDJ3CMG&?QJK\5
MO$5MX?\  &I^9(!=7L+6MM$/O.[C;P.^ 23]*L_#309?#?P]TC3IT*7"Q>;,
MIZJ[DL1^&<?A3B[J5]M/OUO^ I)>[WU^[_ASK**J0:II]U?3V-O?VLMW;X,T
M$<RM)'GIN4'(_&K=( HHHH @O6N$L;A[.-9+I8V,*.<!GQP">PSBO+= ^$<>
MNQR:U\1EEU'6[HDM!]I98[9<\(OEL/T./YGTW5=6T_1-.EU#4[N*UM8AEY96
MP![>Y]AS7D%YXF\5_%JZETOPA'+I'AQ6*7&K3 J\PZ$+^O Y]2.E);Z;_D/I
MKL4OA[9V>B?'35](\+7,DN@K;$W""0NB.,<9[D,2 >O)%=1\3->U._U[2? .
M@W+6M[JOSW=RA^:& 9S@CH2 WY8[UUO@[P3H_@C218Z7"=SX,]P_,DS>K'^0
MZ"O/= D%]^TQX@>[8>9:6(2V4^FV/./P9OSJK)N,'K9/YVU_KR)O92FM+V_'
M3_@^I0^(GPC\+^&OA[<ZKI$4]MJ5@$D%TUPY,IW '()P#SD;0.<5Z9X1U+4=
M2^&NEZC@3ZE)IZNHD; DDV\9/N0/SKC_ (XZD;O1=/\ "%@?-U36+J-1"G41
M@YR?0;L?D?2N_6;2_!WA:W6^NX;2PL+=(C+(<#"@ ?4G'0<FE>\)7?7]-?S*
MM[T4ET_73\F>?Z!\(X]=CDUKXC++J.MW1):#[2RQVRYX1?+8?H<?S.!\/;.S
MT3XZ:OI'A:YDET%;8FX02%T1QCC/<AB0#UY(J[>>)O%?Q:NI=+\(1RZ1X<5B
MEQJTP*O,.A"_KP.?4CI7I'@[P3H_@C218Z7"=SX,]P_,DS>K'^0Z"JCH^;9=
MOZ_X<F6JMN^YA^/O#WB7Q;JVFZ):7#67AJ16?4KF&4+*^#Q&!UP1[8]>F#P_
MQ0^&O@3PIX&GO[.%K#4T*BU?[5([3/D<;68CID\ 8ZUW'C?XI:=X7F&E:;"V
MK^()#MCL;?+;2?[Y&<?0<_3K6%X<^&FK>(=8C\4?$:X%W>#YK;3%_P!3;CKA
MAT_X"/3DFH2NM-%W_K_ABF[/7[CN? ,]_<^ =#FU-G:\>T1I&?[S<<$^Y&*Z
M.@  8' K/OM>T?3+N&TO]6L;2YFQY4,]PD;R9.!M!.3SQQ5R?-*_<B*M&QH4
M445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &%XMT34O$&A/I^EZ[/HL[N"UU!'N?:.JC#*1GCD$'BO,;'X%:
M]ICSO8?$K4K5KA_,F,$#QF5O[S8FY/)Y->UT4DK.XV[Z%+2+!]+TBUL9+RXO
M'@C"-<W+[I)2/XF/<UR'C/P+XB\3ZM'=:=XZU#1+5(P@M;6-@"W=BRR+G/'7
MIBN\HIO5W8EHK(\4L?@5KVF/.UA\2=2M&N'WS&WMWC,C>K8FY/)Y-=UKO@W6
M-2\)V&B:=XPU+3I[;;YNH<R37  _B8,I&3SU]N:[&BCI8.MSQ.W^!&N6FH3Z
MA;_$C48;VX&)KF.W=9)/]YA-D]!UK0T[X,:G'XFTK6-:\<7NLC3IA-'#=0.W
M0YP&:5MO(';M7KE%-.S37035TTSR?QC\(-9\8ZQ-=W7CJZ2T,OF6]F;0M';^
MFT"0#('\6,U7_P"%0>+_ /HK.N?E+_\ 'Z]@HJ4K*Q3=W<X/PA\.[KPAX3U;
M2K7Q \FH7\CRC43;8:-BH .TL=Q!!/)[UQ]K\"M>L;NYN[3XDZE;W-R=T\T-
MNZ/*>N6(FRW4]:]LHIO5W%TL>>>'?A+I^F:I#J^NZM?^(M4AQY4VH.62,CNJ
MDGGZDXKT.BBG<5@IDJN\+K&_EN5(5\9VGL<=Z?12>HSQG5/@GXCUJ*2'4_B9
MJ5W!(V]H9K9VC)SG[GG;1@],#BMOPI\,-=\/:S:7=[\0-8U&SMAA;$ETC;C
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M%889&'^L,9D(8CJ.G/>J6D?!+5=.\3QZY/X_U*>XW*;ATB:.6=1CY&D,I)'
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M)*1_$Q[FKM%%-N[N)*P5Y!KGP8US6_%$FO2?$"\BNP[&W9+0AK="3A$(E&
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MEC62-U*NCC(8'J".XI8XXX8DBB14C0!511@*!T ':DM'<;U5AU%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(2"RQ2?98F[8W8_E&/SK>\5_%;3O <=MI&M+>7FM-9J\DEI HCWD8S\S# +
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M=QK;Z?!# CRH?E7H7X/'8G[QK?\ B@Z>"/BGX<\;PP2)!=+B[C1 &;:,-D9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!"?2@$]\4'OWJ/&3]PCWH D) HR*0$@'G.*%?/M0 [-%,R/
M[PH([@T .SS29;/.,49.WJ*;Q_=)H ?N%+G-,5O133Q0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !112$#'/:@ W#..]!('6@-GM32%SR1GM0
M ^BFC/=@:"<?PF@!=PSBC(I-V.3P/>HVFB_YZH/QH FS151[^V3A[J)3[L*D
MBFAE7<DBO]#0!-D9Q1N&<>V::K;@>,#WIBJ,L54J<=30!*&!&>U(7 .#3 "
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBN8\>:E>:3X4U"\L03-% [\*
M&Z#CB@#IZ*\I^''Q/CUN-++6'$%V%PK2E8P0%&>/KFO4D8GC.<=^QH DHIA+
M+SGBEP%(([T .HHHH **9@G<&Z9XH !7"\4 /HJ/YLX)&*;-+'$NZ1UC YW,
M<"@":BJD=[;R_<NH7;L585*K KC!4#DYH FHJ G'52P_AQZ5'=70L8GN+AP(
M%4L['@(H&2Q/8 4 6Z*\MUKXA7][?M8>$();ULD/<VR+.D9'/.,XR <5A:A#
M\1M )U>2Y6\$0\R98;'G8OS$=..F,T >WTA&:Y#P3XSM_%FF([.L=W$JB>%F
M7>&()Q@=.E=7)(L,;S2NJ1(I9BQP !R3F@!Q8YPM9FL:[8Z-&9+MB%49)"EL
M#!/;Z5Q&O>-;_6;]]&\,QNS!BKW2H)8U(^89QGJ 16EIO@&S$D=UJ W7 (8$
M,R\@Y'% %:X^)L,[;=%A2Y;MYJLG^>,U%]O\=:N,Q6%O I[QW1']?>O0(+:*
MUBVQC]:G7[N: ///^$6\3WD.9M<U*"5OO)'=\*?;FF6O@'66<^?XIUD#VN<_
MUKT4D]V 'O1O!'R_-]* .#?X;32 [O%&L$GN9>E4+KX<ZU I^P^+]=W=E^U;
M1_/Z5Z6#GKQCUJ.>>*%#)-(L<8ZLQP* /'Y/#GQ(TI_/M]2O+Q$Z)<:@<-VY
M^;W_ $IVC_%N]TZ_33/$UK#!([A5:,M(220!SS[UVFL?$7P_I2.(M3M+B=>E
MO%.A=NG09]\UYC]@\2_$WQ%;W%[:3V>EV\R2@3VY7=L;LP'=6- 'LE]KVGZ?
MHIU:>XE%H5W;@I)QD#I]37DWA31+SXB>(9M?UF1SIL#M%#$7WJ61PRDJV<'#
M&G_$N5K_ %72?!FEHSP/YT<T:C>> KCGJ.AKU[1[)--T>UMT!&U%##T.T _R
MH L)&EI:K#:1(@ Q&BC:O_UJD!WQ9C #9PV.,>M/)/&SI67XDUJVT#1IK^YD
M5 H(0LP&6VD@<_2@#Q[QGKEGX3^(T.IO(V3*[2':?FPB@9QU^]77> /BDGC/
M5I;,PQQ[(V92H;D J!U_WJX;PKX:N?B+XJN/$VIQL+0NLD)*E00593@KP>5%
M=#K.D6^C_%.QEM!A?[/CB^\3SYA]?I0![!CAO2N<\7>(/[#L45/];,ZQIUZM
MD#I]*WY62.(23,%5?O,3@"O.?#5P?%OC&YU253Y=J)+16Z ['!'(X_BH W/#
MOAN12FJZD2^H/\S!B'P1D=>O3%=6$8-G QC!':IJ* (T1%&$  [#'%.YQSQ]
M*,-N)SQZ4O44 (O?G-.J(L%/4)G^]WI<G'/S#VH D/ YI,YZ4S.#]QJ@N+ZR
MLU+W%S%".YD<#^= %KZU&QR^ >W3M7':O\1=,LR5T]#J<P_@M)%<]!CC_/2N
M.:Y^('C622%4DTNP9R0MW9=5ZCG'H<?A0!T7C[XA0>'$DTNU<R:I("BJP8 ,
M0&'S#V-4/AEX.GMI)_$NLQ)]ONY&EC.5<B.0!L9ZCDGBM?PC\,=(\-.+DKYM
M[P6D21L'!.."?0UW:C"X[#@4 ! ;!/44*",Y]:=10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]I$"F)'NW13+,RC>S 'DD=3S70HX4#<2R9P&;KFI=G4KP6Y.:0-A=V1[GVH
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M,^E=XOR#:&&>N/:@"*WC@AB5+9%4#H N*L*"P^=12JP(R&!]Q2;$8Y[_ %H
M50H)VC%.IJYR0>@Z4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7C3POX<OK>4SHSW;?=BCGPS'(S@#VKS:7PGXJ\/I;WR1R7>GQ7"R?9H+=VE
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M.!G\:ZV-DDP\;JZ$9RIR* )1G'-+29Y.>E+D8SF@ HI RGHP/XTM !11FB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&^UC(X_V:[&@ I&'!QUQ2TQ^<8/3F@#PKQX5U/XLZ'9/SM6Y5L^RD_TKW2#
M@C Z!0*\$P+O]H*!).BS707M_P LFKWN,# V],4 24444 %%%% #3AL@'!%&
M.,$Y^M!&>AYJA>:I;6.%:1=YX W"@"\O.0!C%8NH:I.9/LUE&'<]6+;2!T_P
MHECN=6"/G;  =P(P6STP?PK4MH!;Q[!C;Z=Z ,RPT6)I%N+Q1//US( 2GK@U
MJ!$EA>)HU$9!&/TIY5_X2,#I2L3@8Y]<4 >5>-?A[+;>9K7APF&_&6W1;8SD
MX'7([9JYX&\5V7CBPDTW5+>-[JWW)(KJ7R%VJ221CJQKTG.,#82._%>)ZC;#
MPQ\9(C;D+'<VB @\\O+SU^E '9W/PI\,7<CR#3+1?[N(%K4MO!7AJRLFM8M*
ML\N"I;R #R,5T:LQD8-QC[N>]#EF&%*AAS@T >,,]S\+?&R)([+X?U"0[?F^
M6%8U_A1<GEG]*]BMKR*[MH[B%LPR*"K8QG(STJCK>A6GB/2)K*]4E9%P0#M(
MY!_I7FNCSZO\.=8;3;R-YM%E)=+A(CL1F8 *7; R%7)% 'KI)4$,-H/1A2@%
ML 'CUJE9ZK9:C"DEC<PW41^\89 ^WTR0?8_E5H$A^H$>/UH FP"-O2H9XHY(
M_*F 9#ZC-2Y#*-W!]Z494<\T <1K_P .M-U!&GL0ME='GSH(P&)X Y_"N1&H
M^./ 4N+FV.HZ9G_7W%V,KG@#:"3T7/XU[&6./E'_ -:HWC5P05!)&.: .8\.
M?$'1?$*!8K@B?^*,1/@<G')'M74@# ?>=I' KC==^&^DZS*9]DD=UUWB0JN<
M =!["L#[!XM\&$_9<7MGG(CM[=I'QTZX]%% 'J0&TCY0OT[TN9,\*,?6N$TK
MXE:=,5@U.VN--E;@_;2L/\SZ8_.NSL]0M+^$/97<$RGO'('[>U %G[PX.#[4
M\=*:!\O/6G=J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFZF][ %_X][QB<<_PA5'MW]:Y+6-"\+>,KLVFL:;-H^LD';,Z*A<X&-N22>
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M*>A8C+#!],U#'+!<()(G$BGNC C]*E50#D?D: 'T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(S!%+,0J@9)
M)P *6O(_%_C._P#%.L?\(AX2;<TF$N[M<XC1L!B"#QP^>AZ4 ,\:?%"]N-:'
MAGP?#]IOF)62=2-J8Y/52/X6[U!IW@;2?!<Y\1>*=0;5=3/"0^62=_4 *&;/
MW?3O5ZQT;3OA^R:?H-N-0\4W2 R/, ^TXRS,0%."-^*ZWP_X3:&0:IKKK>:J
M[!R3\R0D8QY>1E1QGJ>IH R8M'U?QG%#/?2-I6F*28[.->77L2RE2O0'&/:N
MH_XDOANV Q%#@8 'S2-_4]*@OM<N+F5[31(TN)URLDC E(S[X(/K6+=R^'O#
M:6MUXNU&VDU$$,))OF"MS]S(R!P?UH TSJFL:QE=.M_L=MWNI""<?[C >A[U
MFZM;Z5H^G/J.K75QJ4F[8/LX?EL9QM0G'?\ .LKQ]XD:.?1D&LKI^A7RRF2\
M@=D<;0F!GD<DXZ=ZW?!=QIUU!]GTVUN)K*'YX[^?:WG/P-P(ZDC!Z"@"EX1\
M;IXEU*XMM(T():6NU9+AY/+8;@3]PH#V/>L_QQXRUK1_%*+I++-96,"W%];D
M*"4+,O#$$]<=*L:7:OX;^+%U:1>8;368_-49X0Q1@'/3J6/K5>^\$7>N?$S4
M+FZDO;73)-/6,R6[A1*PE8[3D'/!!H S_BIK4-UH6AZM;M+-8&[C,@@D8;@'
MY&5Y[$5C:-KUM<?$[0YM.M+VPL9$V2M<R2;9,1N<8<#IP<]ZZV3X97%OI9T:
MQOU&E)=PW,*3,2Z;"6(X7'))/2NHU7PO8ZS9:;#=RR"2P \MHR!SMVGJ#0!Q
M'B5;[P5KTRZ<AEM/$<BV@R^W[--(!&A&<[L<GL/YUM67@/\ LV[T6Z@G>/[(
M9I[DF0XEEDC*G.6Z;CGN*Z'Q%X>M?$1TXSSR1_8;V*\3RV W-&<@'(/%:EW;
MQW=B]LTC*KKC<IP1B@#Q*UB=[O4E\3ZA=V6LR2>5:W\>]X0"HQ\JD)][GKVK
MV;1;>>+1;:*[NUO'"#]]Y84.,<' )K@)_"_BZ[TC_A%YQI,^FQPE4NIXY&DS
MR,[LXW?,><5Z/IUJ;+3+2T8@F"%(R1T. !_2@""_T73]1MVAN+==K<$I\C?F
M.:Q7T'^R-O\ 9VL_8]V<I/\ O-^.F"[<8S^M=#J-XNGZ=<7CJ66%"Y [XKSK
MPYH\OQ MY/$&MW5Q&KN\=M;V[X2,*2A.&#8)VJ>#UH ZF+7[JP=(=4@+*PR+
MF,[E(]<*,#H>]:,D.E:];G/E2Y_B4X=?Q'(Z5QWAS51I,VN:+JEVESIFG;V6
M68EG6,%5"N>GOP.]5-*U;0-=OY'\/WLVG:BW*6NX*DH7CHHR>GKWH V;JWUC
MPI#.]M#_ &MI>XR&!R%:,'C )W%L8%<;JW@*SUV]3Q!X(OC8ZA 0[VQ0C>PQ
M@$,PV_=].]>DV&NR6Y2UUI!;7&,+)C"2'VY)[$TW4M!^S-<:IHD<<.HE=S#&
M%F(' ;')/ '6@#DO#OQ46/4H_#WBBU-AJD?[II&;*2LH(+9"A0"5)ZUZ<"&&
M001ZBO*/$&@Z9\3-+\FZC73O$MN?*Z!267&[LQV_>QSFJ_@GQOJOAW5X_"/C
M,;;AB%M;ML_OLD<$DDDY;'0=* /8**16#*&!R",@TM !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (3
MCIR:,G/3BFL!OS@YQUKFO&&C:AK_ (?DMM.N889RC -(3C)Z= : .GW#=CO2
MU\\GX-^.<DC7--^;YOO2\?\ CM)_PIKQW_T'=,_[ZE_^)H ^AZ*^>/\ A37C
MO_H.Z9_WU+_\31_PIKQW_P!!W3/^^I?_ (F@#Z'HKYX_X4UX[_Z#NF?]]2__
M !-'_"FO'?\ T'=,_P"^I?\ XF@#Z'HKYX_X4UX[_P"@[IG_ 'U+_P#$T?\
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M569R, <9)YZ8H ^K=Y Z?3WISOLQGH37SVOP8\<[V(UW3-SG<<M+_P#$T?\
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MUF8 #83UZ=!7@TGP5\:N6W:U8'?R0&E_^)JM)\#/$<P_>>(=,,@])Y./K\M
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MM_S##RG@_P# : /H('<05.13?,'F[/;.:^?O^%.^-Q&P&LV&<>LO_P 32O\
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M /019;!'OF@ _P"$4-P^_4-1DNF;_6?)Y>[_ +Y(QQQQ4G_"$^'_ /GRD_\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AR>*C*$ JJX'J*EHH
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MTYX[5H^)_ C:Q!ISP2QBXLX3&I9CCDC/0>E4M:T.32/ <UC*GFWDHE2-H02
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M9#!"6+>_;UKTFV4K;1J<?*H'';B@!?*&,]&]:1T.S!<C_:J6F2$K&2,<<\T
M>2?%[PM91:3-KMJ1:WT"-(&C3DE5 '/X5TWPQN[Z_P#!5F]^[S/Y46PNV<KY
M:\US7BBSU?Q[J]O8)!);V$$@+O-$RAE8 '# 'T->C:)I::/I%M9QD P1I%DG
M@[5 R/RH UL#THP/2EHH 3 ]*,#TI:* &D'(Q^-(=WF 8RN.3FGT4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!E^(=<MO#NB7.J7; 10+N()
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %9NO:K%HFB7>H39VPQLV!W.#@5I5Y3\9]79X-*\,
M0AO-U.X7)5L8577/Z-ZT 9OPXF,>G^(/'M_:SDW%S(T,93YS&2K+M'<?,>]>
M@>"-,EM-,EOKB2<W%\V^19@ 5VDJ./IBLB\T^&.PT/P=$F$$,:7!1MI"!<9.
M.O*^M=ZBA$5%& !B@#F-9D?5?$UKHZQ.8H%\^X)'RLK @#/U%=37*27T>G_$
M%EN1L2[M4BBD)X+*6)'Y5U= &3KNA1:[!'#-<2Q(A.1'CYLXZY^E9<-E:>'[
M:'P[X?MUAD==Q(Z(F<%OJ"1VQ70WUY%86<EQ,X5%'4GU.!_.N4MK*^B@_P"$
MFRWVUD+2PGG,8Y*CL,[1R!0!TNGZ:FF:8;:$_,=SD^KGDG\Z\OU*6^L=3N8I
MM*OGN+FW-O'-'"2)')R.?P[5ZKI]]'J%HD\?&X<K_=/<5POC36M9G\0VNC>'
MI88YXD%S/-)"LGEJ&*G ;'.2IX.: +OA?4TT'0;6TU*.2.Z9VWQXP8\MD;@<
M8R#72ZG!9:A8H\MPL:YW13AA\IQU':N8T672?&FGQZA=[EN[=C'+\Q3<P.W/
M;.=M<AK'Q&TJZ\33:)+"\+6%PUN(1,0) I(W;MN!G.,>U 'HK^%PL?G6UW)]
MM88>Y;&Z0>AX].*QV^'4%]*TE\R(2<$PG.\>K9'7Z5(-;ET[1[&UM+^*X=UD
MD:YX;;ALA2.>N<9SVK9A\0;/#)U6YB(,: LH/WN!ST]Z )+'PMI5B%VVZNZC
M =NM1>(/#PU+3_+LMD-RAS&Y) ![^O;-&G:]/J-O>QFU6"Z@3@>:'4DKD?-C
M'I7.V_C#^QKVYDUW488[=!N<+ABI)QP%R3SZ4 9C2FRAGM(TG,$/[N[61<+!
MD9P/^ G/-.M_#$NKVK0:=#<:=:P@3PR.FWSW?[Q[@CC(QZUF3?%/X?7.NB9W
MG)>5=[[90C=.679@_C70ZEXQANIT_LK5(8K98T:W 3/F9Z@CC;@>M !;R7@V
M17W]M74X.8H+B!1&6[$XYQV_&NJT/3)[:6XOKO8MQ<JBM'&3M55S@<C/0U0\
M1ZU?:=H-M<VEK#-J$THA4&1 %)#8.X\8R!4\?B&=O"G]IM;?Z2I$;QAP?FW!
M2<XZ<DT .U'PK:7<LD\5Q+9RMR9(L9!]>:R]-\ :*FKR:U<7#:C<MMS)*1QM
M! Z8_P BFKJ]QJ>DZC9W-[%'(@8+<Y" \#H,CU]:Y>W^(>A^&KRXMI[AI9[I
MHHDM%9F"GH6W@$<[L^W2@#LO$NL6FH>'M9LK5P]PD+#:2,-R!Q@YKC++5[!-
M9M]6TV4+<72[9HHB" 4 0!N<@G!QZUW6E>'[)+J:],BOYR?ZHG[@)!P>>:Q-
M(3PAI&NQZ58P,9,LPD;<XW'YNI&.I]: .XM9#=6$,LL91I(U9D88*DCI7+W6
MGP6TUSH=ZH;2]00K"#]V(D;2N?4EB>]=@..!TK)\01V;:7(]U(L9B!DC8G!#
M*,CZ\]J ,_PYX8DTG1IM(OI5NK+>1 C'[D8QM7H.@ KIJR/#=^^HZ/',[!B/
ME#?W@ .?QK7H YK52=$UE=7&3!,!'<*.N!PN/Q;UIWC&S$FCC4HUD>737%XJ
MQ#+2; 3M [YJ7QGC_A%KLG&08\?]_%K5M 'L8PXW K@AN<T >+_%.!I=*T?Q
MSIHF@NK;'GL%^8;BB8/7'4BO7/#>K)KGAVQU*,DK<1!^<9Y]<5S26=K=V^L>
M%;P*P;,L:-SDL2_'TP*Q?@OJ$D.GZCX<NV*W6G7#((R<X0*@SGIU/K0!ZI11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !0>G%%% '*>/])_MKPK/8A S.Z-
MV[,#6;\)=8&J^";=G?=.'D+9STWG'-=O(NY2IP2>E>,>!&_X0OQY=^')6*6S
M1Q+ 7/5W()Y.,]>PH ]MHJ,NP ;AE_V>:0.Q8GC:>%]<T +*@D&QAE3UKQ3X
M.E=)\6ZIH[-@1VP=5]V<?XU[;AB.2*\.TOR=*^.5Y"A8+)!;H,GU9: /<A@'
MZTM-'7CI3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O#[MG\5?
M'Q+>:.5K/2TW#T1C&C#U[K7M[,J*68A0.I)Z5X7\*(-U]XQUN0,\\('DR,2%
M;Y9 1GIV H ]!\.F75/&FL:G(L)BMRUC&R9SE'SS^#5V3,J(78X51DD]A7*?
M#[37LM ENY8]DNI7#7S@/N&9%4GG\*O>,;LV>@MPY6:187* DJK9!( ZT <C
MXG\4Z!K5V=.OH+B.R21HEU:,*%AE4_, Q)P> .G\5;_A?7+]+U]!UW:=0B4M
M',F=LZ\98$G)P6 Z"N%%UHCZ3:Z7=NPA%_-YF^,JVW:,,1U&2.M=4--N/$'A
M'2]8LY%_M:U/G1NI&)=K,?+/8 D 9P<4 +X_N;NYEM[&SLQ=QPGS+N':69E.
M-NT9[$9.?2NI?7K)=!?6"Q^S+&9.V< $X^O%<KX)UI==UW5FN(_*NXHTBGA8
MY(8%@Q' XSFG1^%-4M/$8MXBLF@-*MSL9@#&XP-F.K#&3Z>U "Z5K%U%XH@:
M.Q>#3-44F-77!4HI8L,''S$CUJ'5O"OB!-:O+W2IK(?;I"C-(7W(AY[#U ]:
MV]6VR^*M%@A 'V<3%P. H*#'\JXSQMKVO:IKMUINB71L[;3[5KMI?+5A,ZMM
MV D< A@<@GITH O6O@O6;&W#--%(7;YT!8C.>&Z>^:\FM;.V?Q]XEMM1L[6_
M=9Y5,EPI8@[A\PZ?Y->P1^*M3N[.U>*62W 0+\D E$[8 8$X^7!'Z^U>/V3R
MS?$+Q')*GERO/*SIG.T[AD4 :,FBK;6+V^EW;V"LP8^6VT#!SZ>YJ!HO$4T!
MMCXRO6BQM\O[1QCT^[2ZXTK+%:BW,T4AW2LLA4JHQGI[9JI#XF.D2%-!LEM8
MMOE^=*_F[L=\.#CM0!?TJ#5M+ @;Q+=-:%2I@\[Y3GVV^YJ9O#^E378NKFUC
MNI._GJ"#]?SK>M=8T[Q/\/[BXUF%%O8SY=O/$V&DD.[:=BXP 0!W%9%I%-'9
MPI*<NJ*&/J<=: +OD:+C'_"+:'C_ *X-_P#%5G2:'I;7+3VUE#9%A@I:KM7]
M<U:VM52\U&WL&C6Y:13(2%VH2./4]J ':K:ZEJ&GQ6,&L7,%NG\ DP._M[UE
MW#^(-+M1&WB^_6(#:(UN.W3^[6[>V.M6GA>YUTV$1MXB2O\ I ^= I)?I[8Q
M7ED]W/J-XLTLQ%P^XENJ[<<#TZ<4 =-:1)J%ZMI>:S<7<6WB%Y RD9],>]/\
M3V&GV<>DPV6FV=M)]I4>?&A$A^=.I]JHZ):W$3VFH26]RMN(@680,5ZYSNK0
M\6LV[2I%&[_2%*CIGYTH ]KM+&^T>WOM3NY1]F2W)+*3E^1SS7%33Q6>EE(=
M0CBF%U%(KQ-C?\^<=/?!KT'0-4U"]O7M+U";7ROF1XP%3D<;L?-6?'J7@B[\
M6RVIA<7BX7S'5UBR5' ;[N?ZT =E;:BB:#;W]W(J@P([MGCD"N.NF;6O$L1\
M0VD4>DL,6B2*?F/ ^?.1G=G&.U:_BNTCD@TBR#%+)I]DF#QL"'&3VZ"M7Q!
MC^'+XB'S'CMI&C4#G<%.,?C0!E2P_P#"*S136CNVG2L=\1^[$,<;0,8[#FNI
M=UC1G<A54$L3V%><2Z3>>*O!-N=7CDM(8;>-4@#'<2 OS$C!Y]#TQ5K[1/XF
MT>Q O_*L(3YUW.%&)0I.4'3JN1D'C% %'5?&(UGQ*=-6TF_L:S.;NXVC!SD+
M@YQ]X#J.]>EQLK(&3&T],5XQK$]U%XBT_6[C3O*\.VKM"Y5^9AMV(2 ,CDJ>
M]>SH5*@KT[8H Y76K2WM/&.D:IY2F9_-1F ^8C9@?SKB+K/@[XY0R[2+36H=
MK%/NB1Y1UZ<X3WKT#QM:SS>'I)K.00WD+H8I2 =HWKNX/'(R*\[^+TTZ>'/#
MWB0,KO!=QL5&!N(60]?_ *U 'LP((!!R#2U4TN8W&DV<Q&#) C8],J#5N@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BB@C(Q0!"Q\O,C'@'BO+OBQX?EA:T\
M46(Q<64HN)BN 2D:YY)/MV%>IM'O&&^[4%[81:A9W%K<#=%/&8V ]",&@#"\
M&^(H=?\ #%E>PR;Y%AC$Z\\.5!(R0,UTH0*1SQV%>#BYN/A/XSN6N8Y9=%NI
M99E$2ERHY5 2VU1VKVS3M2M-5B%S:3QRQ'IL<-C'T)H N $/G/%>%ZT$B^/D
M 0\L]H#Q[K7N;< X!)/->&26O]K?'QYX)4*6ZVLI^;J RYQC/- 'NJC'>G4Q
M.">O/(I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXX)[5)3%Z\CKT]J?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG;MI6NZSIEK"\&E^8\MM&ZD97Y &&>HZCK0!TNJ>%FN9UE@FA **D@F3>0%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/UW5H-!T&^U6Y_U5I
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M%W;3W V=?<5M+^,^UG]VEOT,H_POFOOO_P .>GWMY!I]C/>7,@C@@C:21V.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML(M2L9+6;[CX/X@Y'ZBN&U+PS'JVHQ0WE[/INI)'Y*7L('^D0YSL)88R6.<
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M8Q^-/.K>(7^0>'!&6Z,;Z,X_"@#6TW38-+M1! ..K,>K'UHO=4L--V?;+N"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOJ6KWFG376-4G^T2P2.ICC?G)0  C.>Y/:KDTY2[/_/_ "_(RBFHQONO\O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK Q#D$4+7\?PM_F)Z?UZ_P"1Z'17(W?Q0\$V.L?V5<>(K1+L':P&XHIYR&D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4'D8-%% 'DW@#P[:V7Q3\5HKR/!I+*EA"Q^6W%P/,DVC
MMSQ]*T[Q(KSX]6<.H /';:,TUA&XRHE,F'89_BVUUNF>&K/2M?UC68)9VN=5
M:)IU=@47RUVC:  1QUR34'B;P;I7BM;=[W[1!=VI)MKVSF,4\!/4JP_D<BFG
M;E\E^C!Z\WG_ , YKQ[%#%X]\#75HJ#5'U!HF*X#O;[#OSZ@?IFI?#OR_&?Q
MD#P6M+,@'N-IYK7\/^ =+T#4/[2:[U+5=2"&-;W5+HSRHIZJI. !]!FD\1^
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MF/!NF+X4O?#HEO#:WJ.L\TEP9)F+C!;>^>>GMQTI?9MY)?E_D5?WK]+W_/\
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M9S\QSDFB.EO),'K?SM^%CE?#D$=K\7?&$<"B..6VM)G5> 7(8%L>IJ7X2?\
M(C#_ *_KO_T<]=':^'[2T\2:AKL<DQNK^***5&8; (\XVC&<\G.2:7P[X?M/
M#.D_V=92320^;)+NF8%LNQ8] .,FE'1?)+\6_P @EJ_G^EC5HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex3-5_002.jpg
<TEXT>
begin 644 ex3-5_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ER!TH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"3D#
MUH'(H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHH)P* "BF@DTZ@ HHHH **** "BBB@ HHHH ***;N.<&@!U%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8Q#%05)89!(.#WKSXCQ#JGQJU:?PO<165XUO',PO1M!BV1$HP )!R5X'H>:
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MI(W!@#D@>F5&,]6%>>^.-"^(S>'Y+G7=0L;W3+?RWFMK=L$A<9;E!SW.#U/
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MO*SK((0B1.O5AD#!'K7FVMW>H?%CQ%;:=I$,D'ARSD\R2_E1MLY!P2!P".,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#BOB7X-O?&NAVEC8W%O!)#<B8M.6 (VL,< ^M4+G1_
MB?<V;VW]MZ%$KILWQQR!A[@[>#7HE% '"Z-\-[73/ =[H$TYGN;]6>ZN,XW2
M$#H>NT$#]3WKFHO"GQ*CT8^%H]0TM-,^S%!>9.3EN8_[V<$_PXQQFO7SR*;M
MQ0!Y_J7POM[GP#9^'[6Z,%U9'SH;@94--C[S8YP?;IUK/_X1/QGXIU2V'BV[
MM+>PT^Y+H+,[7G(QAA@\*??!]J]2IN#0!Y8W@[QAX<\8:C>>%);#[%J\OF3-
M='<82,G)'!Y9FQMSVS4OA[X67<&@>(]+UR]@<:P\;[[3=\C*Q;.& _BP<=\5
MZ=@TX=* /);#1?BCX;@LM&T^YTN[L4&T7+_\L%S@ YP2 /0&K^E_#2\L_!FO
M65Q>V\^MZP6::[(.W).1DXR1U/3J37I1&: ,"@#QS7_#-IH7ACPAI-]K45IK
M]G._]GR+'(\,K&12RG:N0.4Y/OZ\9?B=-;3XA^$%\1:KI5Q>1ZA#LM[)'#(A
ME4[FR, 9 Q_]8U[)KWA_3?$NFFPU2W$T!8,.<,K#NI'(/4<>IK,T'P!X<\-W
M1NM/T\"X_AFE8R.G!'REN1P3TH S_"W@R^T+QMXAUN>XMW@U-V:)(RVY<N6^
M;(Q^56/#/A6]T?Q=XCUBYF@>+5'C:)$8LRA<_>RH'<=/_KUUP&#FEH Y'XB>
M$KCQEX973+9X$F2X69'F=E5<!@3P#GAB,>^<\5FQ:9\3H84B35O#VU%"C,,G
M;\*] HH \\U[PCXK\4>"[G2=6O\ 2FO7N4DCDA5UC"#L>,YSFM#Q)X0OM8^'
M=KX=MY[=;F*&&)Y'=@GR+@GA23R/:NSHH YS7/#']M^!YM FD =[58U8,0HD
M0 J3QG&Y1^&:S? '@4^$]#N;:_DBNKV[<M/(I+*PZ ?,,].M=K10!Y1!X.\:
M^$)9=-\)WEE)H]U<,ZO=9+VP('7U'^[GUP,TM_\ ##6[[X?+HDNL03ZD^I?;
MYIYBVP?(5VKP3Z'H.IKU4B@ B@#SGQ%X*UZ+7=/\2>&[FU&HV=D8)(IV.V8A
M< *,8YR>I SBF:'X,\1:AXKM?$WC"[M));:("&T@!(B;^0P>>"<FO2C32IQQ
M_P#6H \"\+CQ5_PG/C%O"S60D^WN+@70[>9*5(_'^8KM=,^&!NM*UA_$=Z;G
M5-91#/)&O_'NRG("GOT7\L9YKLM(\,Z7H=S?W-A;".>_F:>XD8EF=B2<9/;)
M/'N:U@"!0!Y*WA;XE-I;^&H]3TZ+3(X!&EX"0[K_ '<C+9QU.,>]>E:%I3:+
MHMIIQNYKLV\83SICEFQ6A@TZ@#DK[PG=7?Q*L?$PN(%M;:Q^SF(@ER^]CD=@
M,-US^%<]+X&\66/CS5?$FAZCI4?VX;-ER'8A?E/0+C.5%>G44 >7:AX!\6^*
MK^R7Q3K5BVF0-O>"Q5U+G\1C\>WI79>(;'Q!.-/3P]>6=HD,H:<3*?G08PHP
M.G7]*WZ* (IH([BWD@F4/'(I1U/1@1@BN7UOX?:%J.C:A;6VEV<5W<1L8I64
M@)+L*HW'IFNMHH XOPY\.=(TOPW;Z?J-A8W5T$(FE6(@.2,'KSTXSQ^%9WB?
MX766J:KI%YI5G8VRVL@-RI+(944*$ (!Z!:]%HH XSQMX&/B.+3+G39XK34=
M+F$MIO7]UU4D,![J#GVQWK$TOPCXI\0>(=.UGQE/;0C3)"]O:VO5G# AFP2,
M<9]>W%>G4W![<"@#B_$7@W4-8\>:#KL-W EGIV#)$[-N8AB<J ,=ZW?%.C-K
M_AF_TM-FZYCV+O8J <@C) )[>E;-% 'FFC>&_B/H6D6VEV6K: +:V39&'BD8
MXSGDX]ZZ?P];>+XKJ8^(KW2[B I^[%FC*P;/?(Z8KI** .,\=>$M2\2W6B7&
MFW=O;R:?<&5C-GD';TP#Z'K70ZKH.EZVBKJ5C#=!4:-?-&<*Q4L/Q*+^5:5%
M 'G>M?#"TN_%^C:OIUK906UK*)+J(EE,I!4J0 "#C'0XST[U>TCP5<6_C[4O
M$6I?8)8Y$$5DD2'="@X&01C.W XKMJ* .4\:>#(/$_AJ73[9(;>Y4J]O)C:$
M8$GD@9QR>!WK4T73+F'0+.TUC[-=7D4/E2.BY1@#VW#/9?Q%:]% #0@  ' '
M0#M7%_#WP=J/A7P[=:5JEW!<+)*QC,&<*A&".0.<Y-=M10!Y1:>%_B'X:B&C
M:%?:<^DR32^5)*27M(R20#G!/7^$'G-;5K\-T@^'VI^');S[1<7Q:9KAEV?O
M<AER1DE0Z@_0FN[P:<.E 'E,GAKXCZI;-X<U/5+"/2C$L<M[&,R2IT91WSCK
MD 'UJ76?AMK/]K>';[0;^QC;1K*.W1KI6&]ES\Q501SG/7K7J!'.:![T >9Z
MSX4^(GB*Q.G:AKND0V<CCSOLJ2*[+W'3GUQ["NXT?0++1=$M=*@C#P6Z; 9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%)D>M&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW
M#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH
M 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-
M&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6B
MDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&X>
MAH 6BDW#T-&X>AH 6BDW#T-&X>AH 6BDW#T-&10 M% P:* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:33CTIE(:"BBB@844
M44 %%%% !1110 4444 %%%% !1110 44QWV(6; 4#))["N0;QW+]AGU:#1I;
MC1(7=#=QS NVPD%A'CIN!&<^]*X'945G/K5G%I,&HS2"*&81[=W4ER H^I+
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M !1110 4\'-,I5H$.HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME!1?4@L#[=*2T=P>QB?$N5-0M/!%QI]_=0V=S?0JB(5 49&&Y!^8>^1[5O\
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MM8U*&(ZGJ.RUO0B*MO!@$D \#T&[-=9X \22ZVFKV4]W'=OIUZT*7*$'SHR
M58XXSR1D8'%87Q4T74]2@T3Q!I&GRWTMA,)7M1"2[*<<;",Y]L9KM/#$TE_I
M_P!N.CMI*38VVTT0248ZE@.GL*E?#_7384M]#>'2B@=**8PHHHH **** "BB
MB@ HHHH **** "BBB@ I5ZTE*O6@&.HHHIDA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 AZ4G:E/2D[4AH2BBB@84444 %%%% !1110
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ML(7*/?B(- ".#SG/7CI6['J%J]A%>^:JV\J*ZNW'#8Q_.A=QZ%H#%)MZ9_\
MU4N1B@L "2< 4KV ,<FCOGOZTR&>*X@2:)P\4BAE8="#WI^1ZTQ:"T444#"B
MBB@ HHHH **** "BBB@ HHHH **** "E7K24J]: 8ZBBBF2%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'I2=J4
M]*3M2&A****!A1110 4444 %%%% !1110 456O[ZWTZSDNKIV2&,99E1F('T
M4$US4'Q+\(W$9DBUE7C#!&E$,FQ3Z%MN!23N!UU%59-0M(=/>_>XC^R1QF5I
M@<J% R3QUI;#4+74[&*\LIEFMI5W1R+T855@N6:*CEF2&)Y9&"QHNYF/0"J^
MEZI9:UI\5]I]PL]K)G;(O0X.#_*D!<HJAJ6LZ?I!MAJ%W'!]JF6W@W9^>1NB
MC'KBK] !1110 4444 %(>E*>E4[_ %&UTNSDO+Z=(+>(99W.,?XGVI/9AU.:
M\,2^(+^_N3K]H8S9SR>1(4VAU/"[<=1@GFNQK,T?7],UZ!Y],NUN(XWV/A2I
M5O0@@$5IU3$G?4**CDD$:EW8*B\EF. !ZU@P^-_#MQ.88M30X<H9-CB,$=?W
MA7;^M3N/8Z*BHK:XAN[:.XMY%DAD&Y'7HP]:EIV"X4444 %%%% !1110 44T
ML%(RP&>F:I6NLZ?>ZG>Z=;7:27ED5%Q$,YCW#*Y^H]*-Q;%^B@=**!A1110
M4444 %%%% !1110 4444 %%%% !2KUI*5>M ,=1113)"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!#TI.U*>E)VI#0E%%% PHHHH ***
M* "BBB@ HHHH BN>;67/]P_RKQGX0Z?#J/@OQ5931J\<M]*NTC(SL6O9;M@M
MG,20/D/)/M7BWPDU>STKP7XJO9YU2*.]E?)/^RN,?6I6TO0KMZE+P+KUS%\-
M/%VDW$/VZ/2RZ"*2;83$V0P#8.,;216QH_C^[\/Z3X2L++P_;QZ;J:)%!-->
MD^6Q.,-A/?K63X6T2?3_ (2^+M:O(FA;5@\B!^NP9VG\2QINKZ6VH_L^:3?6
MK'S]-1)T9.V#@_D":N\;W?2U_NU,[=.]ST_5=8U7R->B;3+22TM(3Y;?:64S
M$KD@_)\O![9KC?"?C6UT7P/X6L]+TR.%]3GFCAAN+O"H%8[BTFWJ2>!CO77+
M),WPYN;V]Q'<W5HT\V3]TL,X_#./PKRC2_#]AXH^$>A:?]H6WU6+[5<6DI/&
M5?YD/ID$'\*$K7OTM^MQIW2?<Z_QQKR7A\)RZCH99)=50(#<['AE5L D!2&'
M)/4=!6_J7CV>+4=4@TG3XKV#2(O,OG:8HPQR5C 4[F ]<#WKS+4=1OKSPGX#
MDU60&=-81-['[Z*V-QK;LT;1I_B1'>Y$DD3SQ[CRZ,O!%#T6GG^G^8TM5?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:RS_ .K1@6)_(''XT; ;M%-21)$5T961@&5@<@CVIU PHHHH **** "BBB@
MI5ZTE*O6@&.HHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9;V^I_8A?6\2S%HW0C.&;'# Y!P"/>L/1_B]<:E9:3>RZ'Y=K<SRPW4ZS96
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLKZVN3$<.(9E?:?0X/%3M-$DBHTJ*[@E5+ %L=<#\13\Q/6XU8(T=I5C197
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M2,X.*ZGQ9?VE_P" /$;VDZ3)'97,;,AR P0Y%<YK6O\ Q)NK:2#2?!RV;LQ
MGEO8I&V8(&%! #<@YR0,'K26FAZIH_PNDT"/1;^ZU"_M)O.*2P;8II 00Q+C
MC)_A#4 >._#73;W5?%HM].U&6PNQ;R/%/%CA@. 1W'J*HR7$EMXP1/%XNM32
MSE,-S'+<.6*@D85CSC)R,8S^-=SX!\&^,O"'BN#5+GPU-/ J-&ZQ7,.X*W<
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M9H ^8_BJ2WQ$U/G/S ?ZD1]O;[W^]U/X5](Z%M'A:Q"X ^RK@* ,?+Z *!^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 .,[0/X5)PQYZ@<$@'HEK*T]G#*V SQJQQTY&35BFHBQQK&@VJH  '84Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRJ"2P';(%9GQ#T:6P\1Z%>Z=JUPWB:ZNU4)YYVE/9?X5%3>$M/>\^*UUJ/\
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MJ,X7&XCCL:]$\#P1/X%\.R21H\D5A%L=AEER@!P>V17GO[00_P!$T ^LD_\
M)* (_A]HFK^+?!]QJ*>*=6LKXW<JLT=P2LK;$VEA[>HY_*LS3?B'XJ\#^)/[
M%\42-=6Z2#S7GR[JA89=6'+<9P.E=E\"O^1 G_Z_Y/\ T!*\Y^-T6SQ\9/-C
M8O;1_(.67 [Y''M0!]'6UU!>6L5S;2K+!*@>.1#D,I&014I8 $D\"N%^$,TD
M_P -M,::1I&4R*"S$D*'8 #/;  K2^(E[<:=X UFYM9/+E6# ;:&X9@IZ\="
M: /,O%7Q(U[Q+XF'ASP@TL*N_D^9'\LDC*<E@W50-IZ=LYKJM+^$-I'"UYJ6
MJW\^MR?O/MJ3%6BE_O#UYYYKRGX/I$WQ-TPO(RN!,8P$R';RFX)[<%CGGICO
MFOJ%2-HH \9&G^+=*^)&CZ3JM]>ZII)=FMIFF89')WM@\NN['/M[5A_%BYU3
MPMXIL1I>N:@B/:':&OG>126^;J<@':OL2OM7O=Q9VMS/!-<6\,LD#;H7= S1
MMZJ3T/TKP3X]G/BC3>>/LG3R /XS_P M.K?[IX7J/O&@#;\-Z!%>> +'7-1\
M7ZQIRQ-Y@E><HD!.4(3/&#OZ_AWK5\*:-KOA_P"(=SIMYJUY?Z?-;O<PLTKD
M'<3EF . V>Y[]*\WU#6-8C^$=EI<6DS0:9).&EO08RDO.0N%4$?,%.2<G&">
M:^DX(804G\I/.\L)YFT;MO7&?3VH \ ^*TE[X1\16-AH^J:C#;&#[9L-T[8F
M:23+C)X)Y_,^M=7X3\)ZIKO@FTU:'Q;K-K?7GF32,)SM=_NKN^FP<]3GV%<I
M\?.?&>G_ /8/7_T9)5[0?BHWA+P'I^GR:',;D1'[+*\F(IE+/E^G9L#'?/44
M 5O /Q+UZT\46NA:M<2:A;7%R+8/*<R(S-@-N/) /;TKN/&.DZUKOQ&TBRT_
M4KW3[2*S:6:>W8C9EB.W0D #\*X#X5^!I]?UFW\3SW,45I;7/G"*)LNTBMD
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MWJO)NVR,"RA,C.-H(.2?2O2_@MXBDU?PFVG7#*9M.81(<@$ICY> !@#IGO0
M_P 8:3K6O?$K2[33]3OM/M(; R2SV[$;"78$#L&. /PKS3XAKK'@C7[32[/Q
M'JD\*Q"\0R3$%)&:0$C'?[W/^T:^D\=3BOG;X[C'CJU_[!T?_HR2@#I]/\%Z
MSX@\ 6NJV'B74X[^YC6Z-O)<$QR3JV0Q.<@_*,'L0*-=%PWPLMO$UOK%Y%K"
MVL,,\QO64'& Z8S@MG/XUW?PW_Y)QH?_ %[C^9K.^+B+_P *ZU#S! 1E"OG,
MP^;/&-IY;TSQZT >:?":6]\2Z\;74M8U,QV5KBW2.]9"@.!@8.<84<#CCFO0
MOB1X_3P3I]M9V#1S:K(.$F)8I'M(\PGN<XZ]>:X'X"RR+XCU&)7(C>W4LN1\
MV"<9^4GU[CZ'MS'Q5FEE^).KB21G$3HB!B3M78#@>G))X]: /1? _A&\\;:$
M-3\8:CJ-[;S.6M;62=U5?^F@Y[C(%9_BM=8^$NJ:?<Z-J-S/HLK/BRN)2T:L
M225QZ8(^;K7J?@B&"+P5HZ6S;HA;*$;>'_7 S^5<+\>8H#X;T]W<B9+@^6/,
MQGCGC'/'N,>] '4:/?V?Q+\$13N\MN9&Q,EO,5:*5>@R.W1@#ZBO!+OQ-XMT
M769KH:SJ>//,*RRRL1+Y3=".A W<C_:]Z[_]GZ>4_P!NP&1S"ODNL98[58[P
M2!ZD <^PK5T?PCIWCCP?K-M=S237"ZM<-;7SKB2-_E]SE>Q!/( Z$# !U?A;
MQ!IWQ!\'E970O-#Y-[!&Q4HQ&"!W'L:YSP_H\LGQ,\16%QK&K3Q6<4#0$WKA
M@K@OM)!^8#/>O'-&U35?A_XP61UGBDMY MS;D[?-CSRO.1@]O3J*]H\":S9>
M(/B3XGU33WWVUQ:VC*2,'.S!!]P01^% 'IB^_6EH%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%(>E4[_3+35+<07UNDT08-M?IGUH ^5(9$A^)B22.J(FL
M!F9C@*!-R2>PKTGXS^"&E4>*=.C>3@"\2-00J8_UG'/U_/(Q7HY^'GA$G)\/
M6)).23'UK:LM+LM-L_L=I;1Q6V23&HX.>O6@#R3X+>.%EMQX8OY8T:(9LW=C
MND!.2G.1QVY]@*Q/CY,I\5Z;#B3>MD&),GR8+N!A<<'@Y.>>/2O74^'WA)&#
MIH%DC@Y#*F"#3I? /A29M\NA6<C 8!9<X'I0!P7@Z+1-=^#,FBZCJ]K:)*_E
MO(9U4Q."'3.Y5[IG'.0#\WIN7OCR*_\ $^B>'/#-VMW+]I4WTL:C:(4^\ Q.
M#P.V<CH<UO#X?>$MNW^P++;G.WR^,U:TWP?X=T>]6\T[1[6WN%!"R1IA@#P:
M ."\*_$&SM/'OB+0=5/D>=J<OV:9G)C!!V;#DG;G;G/3)/ XJ7XP^%-%;PK/
MK*Q6]IJ$,B8D4;3-DD%.H!)W%LX)^7\NMF\ >&[V[O+R\TY;JYNI#(\L_P S
M*2,87T [54T[X8^&=.NUN3!<73+RJW<YE13D$, >] &;\%M.N+#P''+<&0+<
MRM+$C,"H3L1CD9[Y/:I/C5_R3>Z_Z[Q?^A5WRHB((T4*JC@*, 5DZCX5T/6)
MVFU'3(+F1@-QD!.<#B@#R+]GZ:)-1UR)I$$KQQ%4+#+ %\X'?&1^=>[GI7-P
M>!/"]I.LUOH=I%*IR&1,$'KVK;O+*WU"T>UNXEF@?&]&Z'!S_,"@#RZ+3K3X
MG^-M1OQJ-['IFEQBV@:W?R9/-/WF'!.T@'K@^U4/B!\*[&S\+W>JVE_J$]U9
MIO)OKG>/+'4#Y<Y].U>DVG@SP[I\Z3V>CVT,L;AU9 00PY!^M7]4T33=:A6'
M4K.*ZC4Y5902 >] 'AWP/\4_8-9G\/W#X@O?WL'M*!@C '5E [X^3WKZ![5S
M*?#_ ,)12!TT"R5AT94P16W=:;:7E@;&X@62U(53$>A (('Z"@#Y5\=D#XC:
MWS_R_O\ ^A5]9Q31SPI-%(DD4BAD=&!# \@@]Q7-GX?>$I'+/X?LF)Y+%,DU
MKZ;H^GZ-;&WTZUCMH2<[(^!G&/Y #\* /*?V@IE73M#A,CAGEF8((E*L $R2
MQ.01D8 &#DYQ@9@^$4^D7'@77--U'4+>WBFW1SAI@C)&X*;OF4 ?>X.6Y]._
MIEQX'\,WTK2W6BVLSLQ8F12>2<D\U%_PK[PDJD+X?L@&X($?7O0!QVJ^+[30
MM TOPCX7U./4=; AM(WA4%<8 W;L[02.G)P>M9G[0)_T/00?^>D_N.B5Z1:>
M!O#%C=Q7=KH=G%<1,'CD2/E2.].N_!/AJ^N9)KO1K6:1V+LTBYR3R30!P?P6
MUK2M/\#30WNIV5M*;V1@DTZHV-J<X)'%>>>+FO/B-\1;L>'K-KO8GEH8VX=$
M&-Q+8 !]Z]X/P[\'X_Y%VP_[]UKZ9HNFZ-;^1IMC#:QY)VQ(!UZT 0>&]!@\
M-^'K/2;?YDMXPK.!C>W=L9.,G)Q[U-K.E0:YHUWIERN8;E"A)&0#V/4=#@_A
M6C10!\I:3+<_#?XCP3ZG9S,;*5PR# 9XV5DW+V/#9QGMC(KZ<L]9TR_MQ/;:
MA:RQ[E4M'.K89NBG!ZGTINK:#I6N(L>J:?!=HC!E\Q,X/(SG\3^=<I;?"'PI
M:W"2QP79"R"3RFN&V$@Y ([B@#5T_P :6&M>(AI6DQRWD*+)]HOHT/DQNIQL
M#8PQ/7TQC&<UY#\>IE;Q=I\($F]+(,<R93!=L87'!^4Y.>>/3GWC3](T_3-/
M%C8V<5M:\_NHUP.>3_,UD2> ?"DS;I=!LY& QEDR?I_GUH X7PG#H>O?!@Z-
MJ&L6MFDC;'D,RJ8Y 0RY#!>ZYQSD _-Z;=YX\BU+Q9H_AWPS="[<7 -_*BC:
M(D^\%8D ],\9XZ&MX?#[PEM*?\(_9;3SC9QFK6G^#?#FDW0NM/T>UMIPI421
MI@X/!% 'BOQ[_P"1RT_I_P @]<_]_)*ZC3?"MMXU^".F6D4@-[:([PE"I(E!
M;]VW/&01D9'\)[5W4O@+PI.X:70K21AP"Z9/ZU=TOPUHNARM+I>FP6KLNTF)
M2,@D$_R'Y4 ?.7@#Q5<^!/%IBOHFBMI7$%['+N!B&>7P,\KUZ<CCO7U%%-%<
M0I-#(DD4BAD=&!5@>A!'45B:AX/\.ZO>O=:AHUI<7! !DDCR2![U=T[1=.TB
MV>VL+2.WA<_,B< \8_E0!X/\>_\ D>;'_L&Q_P#HR6O6OA=-%+\.-&$<B.4B
M*/M8':VX\'T/(JU+X!\*SMOFT*SD;&,LN<#TJ[I7AK1=#E,FF:=!:.PVDQ+C
M(_R!0!@?%J98?ASJ1:1XPVU 4B5\DL !R1@>XY'45Y?\""!XKO1G!^S=,C_X
MH'_QUOP[^VZEX5T36)VGU'3(+J1L F09SCI5./P!X3A??%H5FC<_,B8Z^] '
M!_'Z6,:-HT9D42//(54GD@ 9(^4],C^(=>C=5G^!:1S>$M0BD59%:?:Z$ @C
M!X(W'CZJOX]N[N_!7AK4)!)=Z-:SNH"YD7.   /T I+3P7X;T^XCFL]&MH)$
M=9%9%(P0<@\>E %SP_HT7A[0K73(9"X@C"ESD;CW."3CZ5\Z_&.99?B3?QJ)
M-T4<2L6EW GRU/RC'RCGISSD]^/I>XMX;NWDMIXP\4B[70]"#VK!?X?>$Y&+
M2:!9.Q[M'DF@"EHND6_B'X5VFEW&#%<V>S=UVMS@\.V<$ XW=NW0>"Z!=S_#
MCXA13:I93,;1V22/@,492NX=CP<@9P>F:^FM*T+2]#1TTRQBM5DQO6,8!QG'
M\S^=)JOA_2-<C5-3TZWN@IW 2IG!QCK]* )X-8TRZA\ZWU&SEBWB/?'.K+N/
M\.0>OM6+IGC2PUSQ$=-TB*:\MHXY&GOT0B!)%*@1AB/F;!SQQC&,YXR+/X0^
M$[*9)(X;IE5@_EO<$HQ]QWKK[+2=/T[3O[.LK2*"SP1Y,8PO/7\Z //O$ZVW
MCWX@V7A:.\G2TTI)+N_\L[#YF L>QL$[@7SV&"><TNM_![3KS2YUAU35I[I8
MV-O]LO-\:R8X+?+G'TKJU\"^%UE:5=$M5D;@N%.3^-;%YIMGJ%F;.[MTFMSC
M,;=..E 'S+\+?%/_  C'BV'SG*V5YB&?/;^ZW ).#V'K7U*.]<P/A[X1!S_P
MCUB#G.?+K<@T^TMM/^P0P*EJ$*B,9Q@YR/U/YT ?._QO_P"2AG_KTB_K7M_P
M^FBF^'^@F*1'"V4:,58'#!0"#[@TDO@#PI,V^70K.1L8RZY/TK0TKP[I&B;S
MIFGPVN\;6$0QD=: *'Q!G2#P!K,KB1E%N>(I-C=1T;!Q7@GP>NK:U^(5JUS/
M%"'B>-3*^W+'& /E.2?JOU_A/T5J7AS1]:E#ZE80W+!-F9 3\N2<>G>L\?#W
MPBA#+X?L0PY!$?2@#$?7?"7@JZUK5GUR*<ZE,)6MH&65Q(JG*C:>_;=@#UK:
M\!W^JZIX0L]1UD 75T7F 7&!&S$I@=AM(ZG/K2?\*\\($Y/AZQR?^F==!:VL
M-E:16UM$L4$*!(XUX"J!@ 4 8GC?PVGBKPK=Z:P!EQYD#8SMD7IW'7D<^M>'
M?"_4(_!7CV2#Q!%-8-=6[6X:9"H1BZD%O]D[2,C(R?3D?2G:L37O"NB^(TQJ
MNGPW#!&1)&'SIG^Z>Q[T 'B3Q'IOAG19-1U&?;%MPBK@M(<<*H[G]/<5\\_"
MSPA)XE\3Q7$\#-IMF1),Y7Y68<JF<CGOQG%>SVOPG\*P7*32VUS=J@.(;J<R
M)R,?=-=A:65KI]O':VD$<$,:A42-<  # 'Y"@#R?X_2HNC:/&SH)'GD*J3\S
M  9P-IZ9'\2_1OX9_@6D<WA+4(G59%:?:R, 01@]1N/'U5?Q[=[J'@_P]J]T
M]UJ&D6US.QR7D4D] /Z4RT\%^&]/GCFL]&MH)$=9%9%(P5.0>/2@"[X>T6+P
M]H=IID+F18$"ESD;CW."3CZ5J=J:.OO1(BR1LCC*L""/4&@#YX^.\ZMXOLX<
M2;TLU8DR97!9L87'!XY.>>/3GU'X3D'X>:=\W3(/(//X,W_LOT%:;^ /"DS[
MI=!LW;'5DR:F@\&^';2WEM[?2;>*&48D1 0&&<\_B!0!@_#^\%QKWC&*2:,S
M+K$F$& VP?*#@=N,9J7XE>!AXQT(?94A35+;YH)''WUYRF>V??//U)K5C\#>
M&8)6EBT6U20MN+*""3[^M=&.@S0!\^_!"TN;#X@:I:7<+PSQ6#J\;C!4B2.H
MOC1X/DTS7?[>M(7-G=D&9E7Y4E]SDGGZ 5[K'HMC#KL^LI HOIH5A:3OL!)Q
M^>/R'I5V2&.9-DL:NI[,N1^5 '"?"[QGINL>$M/L'EBM;VSC2S\B29=TNQ
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M\K:?,8( T9/U![\&NVD\ >$Y7W2Z#9NY_B9,GBM'2O#ND:'O_LS3X;3?PWE
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M&\<J1QJZ.,%2&8$$=B.E>Y'I6?::+866K7VIV]N%N[TJ9I.[;0 !].,_4DT
M:0HIJ]_2G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(3
MB@!:*R]8U_2_#]H+G5;Z*UA9MJE\DD_0<FN7@^+'AZ:3+0:G%9[B/MSVI\@
M<9W DX)]N] '>45DZ/XCT?7X6ETO48;I1G(0X88Z_*><>]5-;\9Z)X??9J-Q
M+&0R*Q6%V50W0EL8Q]": .AHKB/^%K>$7:=8M2:5XW"JL<3$RC )*C'(&2#G
M'W3^+D^*W@QKAXO[:0!%4B0QOM8G/ XSD8Y^HH [6BHXI5FC61#E' 8'V-24
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:2S8M;: 2JH)^9FSR1G&0!P<=ZR/@T?^+AVX!P3!(.H&>!ZLOZ!OIW&]\=]
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MB@#RC4_@S%>^-Y-9AU$PV<LOVEXMNYQ-NW$#MM)R?QKU44ZB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "C%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6L,D+1/Y<D4G8]1SW&*S[WQS/<:[=Z1X<TIM5FLAFZEW[8T/.4![MG'ZCM7
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MUA1< *J$$@# QDUCZY?:GX3^#.B:/NBBEU,2&=<9<1,=X&#TSG!XZT >E_\
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MQ^RP1LP D 5E!7@\Y:0\_P!SMWN_ '2E,NK:LWFAU5+=.R$$[CVZY4=\<]*
M(O'GQ?U!IKS1-(LI;%P3"\TH*RYSCY1_#D>O-7T^(&G>'/!6EZ3JGA.\:U:
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M:7_:5Q9!1)<R2A(%8M@KGJ3C/3T/I74:TS1Z'J$B,5=;:4A@<$':>A[5Y7\
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M[!CP>_*X_&L[4_B=>:+IJ7^H^#]4MX&."SLHVG. #Z9[5M^%[2TN/ ^C&Y1
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M;ID]2 >=_!N_-]\1-=N%FDA2ZCDF^RG/S9DSD]LKN(_X$:]WZ=!7A_PJ+?\
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MXE>7 V*$ZC)XY]0>E2:/\59)/%0T/7=$GTN6XE"V_F=0#]W>#W/J.*Y'2?\
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MH5KXD;PX#H4K'=(LX,BH>$)'0?/D$GU%=3>^,;*V\))XBAMKNZM7@,P$,9)
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MB/3WX[^B@#D? ND>(?#VBV^D:LNFR06RE89K29RQYR RL@'<\Y_"NM'2EHH
MS-:&K-:^7I-O92O(K*YNKAH@N1P1M1\_0XKS7P?X%\>>#KN^FM;CP_<"^PTP
MDDE'S#=M(Q'@<ODC!Z=J]=HH \M\3>$?B#XNVV-]J>C66E.RB:&U:1V*Y!S\
MR#<01D#*_P!:ZK1O#4_A7P='HVD>5>2H#EKJ0Q*Q;ECPK$=>!S]:ZBB@#R_X
M<> _$G@NYNX[U],NK*\VB14N9,QXSDA3'AB<@=1TJK'X+\1>!/%USKGA>UBU
M73[P%)=/>?RI%W$MD$X3 (&#UPV,=Z]:HH \[L/"&MZ]XMLO$_BAK>W6S.ZT
MTR']YY7&1N?@;@V#QD'':N-^,ZW3^/\ 05LG5+HVZ^6S2! &\QL9)( _.O=J
M\D\<>#/%WB/Q;!JUG'9PK8?+;,)N74'<"<]#R1^% %_6['QUXST270KK3;'2
M$\Q!/>&\\Q;E 3NV($) ) ;YB#T'K1XT^'^JZUX8TWPYHRZ;!96+)(LL\\BL
MS!6!&T(V/O9SN_"O0K/[7]E0WHA6X.=XA)*=>V1GI5H=* ."7P[XF'PZ_P"$
M8\C2?--H;/SOMDFW85QOQY/7/\/ZUD>'/AYXBT[P7JOA?4+C3VM[T,R7$,\C
MM$2!A0A0#&023N[]#7JE% 'CNA>$_B1::'>>%FN],MM,561+ILNSAP25CQ_#
MG@E@#\QQFI_ /@KQOX1-ROVC3FM5E++;-.X$[8*CYMAV)\Q;[I)*@8 YKUNB
M@#RGX>?#[Q)X+UFYN;DZ5<PW:JDACN) R#=DD Q\GVR/K5OXF>!_$/C>:TBL
MSID%M9LQCDFN)/,DW!<Y41X7!![G(]*]+HH X;6-%\5:EX&_L"&#2(9WA6W>
M5KMV547;@@&'DG#<<8XP3VC\#^'O$WA#PR^E/;Z3<NCM)$XO)%#%B,@_NC@8
MSSS_ %KO:* /*? _@#Q/X8U34I[^32KA-179-)#.ZLG))*IY0!//3('O5'PW
MX-^(?A&[N=&TNZTPZ7<DS&\E!(0YV\*/F$A4*<<KP.>M>R44 >.>#?AUXQ\-
M^+)[AM4LTLIF5KB9"S-,N_>0J8 #';M)/0.<9H6Y\=:)\2H!>WJSV6H:@(5M
MP 2\/3S @)**!W)X/7->PGTK$MO#%M%K[ZU<3S7=[EUA:5LK C'[J#MZ4 ;@
M&!7/>,M/UC5]!GTW28K$FYC9))+N>2/R^1@@(IW=^X[=>170KTI: /./A]X3
M\3^"]/N;*:/2+F*0M(CI=RJP?:=H(,>,%L9(Q@9//2LS1_A_XITOXAW/BLKH
MS_:))7-N+R4;=_\ M>5SC/H/PKUJB@#RSQ?X#\2^)?&=GKB1Z*L-DJQQPSW,
MK>8JNS MB,8/S= 3@CO5[X@^!+[QAHMK?1"&T\060+(L,I:.3G.W>54YX!!(
M&#D<9R/1:* /'M-\,_$3Q/:+IGBF[6PTD%%G5'4SS*HZ KD8/&22/H>AZCXB
MZ5XGN]#M+;PC((=K[)H8V6/,9  QG@ >Q'XUW-% %;3H[F'3+2*]D66[2%%F
MD7HSA1N(X'4Y[57UK2TUG1;_ $V1E5+J!XMS('V$C ;'L<'\.U:--(S0!YC\
M&IKFSTW5?#U[Y4<^FW3*(LC?@\L3@G(SZ5K?$_P3<>,]#MX[%XUO;60O'YKE
M48$?,#@'G@8J_K/A#[1K*:_HTZ6.LQQLGF,FZ.8$8&\?UKJEZ4 >82^%?'.I
M^!IM$OYM(+7%O# D?FNBVJQX(/"-O=NC<@#8,9R:TO WAOQ+X.\,RZ4\&DW+
MAVEB=;R10S,1D']T=H !.1GG QWKOJ* /+/AYX"\3>"]5N9;F33+FTN\+(B7
M4@,8SU"F/#'''4?6LO7?AYXI\.^);G7?!%R&BNGW/:;U1E).2,$!2F>G((SC
M'>O9Z* .!\)^%/$)UE=;\97L%Y>0*?[/CA8[;;?_ *S/RCG 4#D\9]C7?444
M %%%% '$?$/X?0>-K",Q2Q6NHP$F.=H\[Q@X0D'@$X.<'&.G-<5X<TOXK^%A
M_8UG9V,]D)=J7%Q('CC'J/F#;>^-N?05[910!Q&D>%-6N]7_ +8\7W4-S>Q/
MBVM[*1_LR+M')1@"6SN/4]:Y#2_!OB?P5\1KS4]*TB+5;&\1U1Q<+ L0D<,0
MP.3\NWL#D>_%>S44 >9>&/A?-;>);CQ'XFN;>^U"27S8XX@Q6)PP*ON^7)&,
M8VU#\2/AWK?C37[2ZM9-.AM+:(1@33.'?G)R A ].I_"O4Z0]* *L:6VEZ<L
M:*(K2UB"J!D[41?Z 5\X>&)]3U[XHWNM:?:Q:Q<6S2W:V\KB+SDR(UP2, C>
MI&<?=/?%>Z^-+77;W0I++01 );E6CDEDD*-&OJO8YY'XUQ_PP\%>(O!FHW*W
MD%FUK=@&2429>/:. H'7)<_]\'VR *WPZU'QCXDC\0>+FCMH1M\O2H',F%'\
M+OP <XSMSGU%:/Q6\$WGB[1H)=,$9OK,EEC8 &92/NACT_'CZ5Z'10!Y%>^$
M/%WC3P[H^C:C;VV@V-@%CF#7'GR3;455<*JX]>"XZGT&>T?PHFF>!K[0-!M[
M='N+=XOWLC(C,Z[6<G#$''.,'ICCK74T4 >=?##X?7G@N._DU)[26[N"JI);
M.[83N#N4=^>E3_%7P;=>+?#T7]G+YE_:.7BC+A0X/##GC/ QR*[ZB@#P.?X7
M>,+OX>007-PTEW:SYM=*\U0L<9W;OFZ,Y8@C)P #SDX'4?#_ , ^(M(TEEU.
M]CLI5MYELTA)=H))1@R.,A6*XX'(Y/(KU2B@#PKP'\,?%5E?W,FH/'IEM,0D
MSJZM<,F<_NRN0N>A).?:G:W\,_%>J?$V]U)/(DM&F6:*\NB NW:N%"J2Q*]!
MG&=F3UKW.B@#R7Q[\)[K6]+T^72[M9]1LXWCF:Z8[KI3E^#T!W9P#Q\W48I=
M9\'>*OB#::7!JL=OH-C: AX?.^T2LP& ^ H'M][O7K-% '*:WX5_XH2\\.^'
MK:UMTG1HT6:1E1 QR3D!B3[?J*QOAS\/+WP=I.J)=W<7]H7I"K);L72-57Y2
M RJ=VYF)[=*]$HH \0\-_!_7[?Q%/>:EJD,-N)LLT.6DN5#JQ]-@89&0<CD8
MP>?;47:@4=!P.<TZB@ IDLBQ1M)(RK&@+,S'  '4DTK5S_B+2M7UE5L+>[AM
M=-FP+J52WGLG.Y%XP >!G.<9H X#X:V,?B+QWK_C&6 H%F,5LN"5R<@LK\ \
M#&,?Q4V"Z\=:+\288[^]2:RU&_,0MP 2\(X\T("2B@>IZ]<UZOINFVNDZ?#8
MV,"PVT2[41>@%9UEX9MH-?EUJXGGN[X[UB:9LB!&8G8@[#!Q0!N5YCX_\&^(
M[GQ78^+?#4T#WEG$L?V9SM9L$]">""';.2N ."2>/3Z* /%/%GP]\?>)YK#4
MKN_TPWD1""&W9XQ "P^8-C/NWICC->LZ);ZE;:5$FL745S?DL\KPJ5123G:N
M>2JYP">2!6E10!S'CCPA!XS\/OI\CB*XC;S+>8C.U\=#WP<\X]O3%>=Z)X>^
M*C69\/SW,5AIRQM$;N20.^PNN=A4D[L XR!P3D@XQ[710!R.J^ --U'P0OAE
M6:**- (I]@+AQ_$>F<GKTSZUS&@6GQ%\-:.OAF+2;*Z\O*P:J;S]U$K<\J1O
M;:21P!T'ID^JT4 <5X1\'7?@[1[^2*6WU'6KZ43S2REH49O[I(#' )<@A><]
M!7.>!OA_XF\)^*;K5IO[)FAO 8Y$2ZD#1JSAB1F+YB .!D?45ZQ2''&: /'_
M (^[O[%T8+@?Z4V/^^:T;%O']_X4CT :78QN]BJ)K)O\QLI48^4*S%MIVD]"
M02#@BIOB;X2\1>,);.TL8[1+2V<2I,\N&W'@@K[=>*['PPFK0Z%:0ZRL NXX
M41O*<MG"@'<<8W9!SCCTH S/#O@BST;P/_PCDX2831,+F11@.[#EAG/(XP<?
MP@XKC_#^@>,_AQ<7=II>E0^(-,N6WQ[;H0O$0>-P?@$@G(&?KVKURB@#@_"_
M@G4[#Q#>>)]?O+6\UFY0HJ0(RQPCH K'DC;@<KQ[U@2^ /%<OQ*'C#;HVX.K
M_93>2]H]GW_)]L]*];HH XOXB^#[WQMX7AL+>>"VO(9DG D+&-CM*E=P&0,,
M3G;V' [<C=^$_B1XK\(C2]7N],M4C*[8VR9)MIX,C+D =QCOC(%>Q44 >;>%
M/!.OKX%N="\17L?D36ODP6T+$M#DEOF<C[P)VX ( 48)JI\/O!_C/PNLEC/<
MZ<FG17#S[8RQ>Y<Q@ ;L?+'[XW93H017JE% 'D]EX#\767Q&F\6J=((F=V>T
M%[* VY"N"WE<X.#T[59\8?#_ %5_%$'B_P ,O"-1A(>6TE;:)2HZ*1CKT()'
MKFO3Z* /,=4\/>+/B$UO#K=K;Z#I-O('DM?-%Q).XP0?EP N"1U!!SP<BKWQ
M$\&ZQXJT2TT324TZWM+:5)5EGG<,-JLNW:(SQAASG\*] HH X&W\/>)H?AVW
MAC[/I+2FT:S$WVR3;L92"_\ JN#DCC]:/AOX4USP;82:=?1:5)!)(9&N+::3
MS"<< JR 'ZY'':N^HH C=%=2C*&5A@@C((KRB+P7XC\">*[K6?#%K%JVG7@*
M26#3B&1<Y;()^7 (&#R<'&.]>MT4 >=Z?X0UK7?%MIXI\4/;0_9?FM-,A)D\
MKC(W/Q\P;!XR#BLWQU\/O$OBWQ1:ZG VDV\5F!'&KW,A:10Y8$XC^4D'IS]3
M7JU% &3=W4UMX>N+G5)[;395A?S)HY#*D)Y 8%E4MVXP.>*\-T+2_B3%9PZI
MHF+ZQN[DW.',69MK JS[R#SC(&<C':O<?%&A1^)?#MYI$LS0I<J%,BKDC#!N
MGX5YYI?A?XD^%X5L-+UBQNK(8"><N[REW 8 /(X8L<?W?7% $6F>*?B#IFK:
M/IGBG2[=+2_E%H)@5\QF(^\2KD9[]!GVJ'PWX,^(/@Z^N=)T>ZTQ]+NB91=3
MY(3^$':.0^T XY7@<UV.E^$M2GU6WU3Q1J:ZA=6S;H+>%-L$+] Z@\YQ^M=D
M."* /&O"_P .O&_ASQ5>WD.IV/DS -+,SM^_R^[ 7;\K$J 2<X$AQDU=L?A_
MXJLOB-+XN"Z*[222/]E^V2C&]2N-_E=L^E>M44 >6^-_ GB/Q3XJL]5BBT98
M+(;(XI[B5O-4,2-P$8V]>@)^M:/CSPSXF\9^'K?3$ATFU82+/(YO)& 9=P"C
M]T,C!!R<<Y&.]>@T4 >87?A/QO<_#^'PHDFCQX41S7AO9F:1 V[ 'E#&>!U/
M&1WI_A3PGXK\'Z/)8Z;:Z$99(R9)Y+R9B\O9\>4/E _AS_P*O3** .(L?"6I
MZIHFN6?BQ[%Y]4E#%K -M0+&J*0''!^7-<-IO@WXG^&+A]&T;4+=M-E#%+EI
M!Y<))ZX(+!L*. &7YC]1[A10!Q>E^ K=O"M[IVNM]KO=4P^HW$;GYY!]TJ<#
M&W@CCKZUP_A?PI\2_"&H3Z;IATU[&0;Q-<R%X%/7@##@]C\N,_G7ME% 'C_A
M'X=^+=*\<W^O7EWID)F>0NT:O*)/,(=MBG;@9)&2<@@\$<UZ\!CBG44 >6>-
M_!OB?_A,8/&'AB6"6ZA1$-K(=K''RD#/RD$$YY!QTYK(\4?#SQ[K^K6&L3ZA
MI<E[$539 SQI!ANH)&2.Y[Y)P*]JHH \D\9_#_QAXNL=,MKB[TEI;+S'>X::
M13(TA!*A!&=JKC:#DD@ G'2M[Q%X=\2Z[X"_X1U;?28I7CCC>4WDA"A&0@@>
M5SG:<CC''7MWM% 'GOA_P+=Q^"I/"GB"UTYK(J2)K*XD+L^<AB&0 $=<Y//:
MN6\*>%_B=X2NY]*L#IC6+?.)KB1G@!ZG8!AP3GGY<9'XGVNB@#R#P3\/?%>B
M^-;[7+VZTV#SV=9"BM+YN]E<[!\NT=0"3D$'Y3D&O70,4ZB@#RKQW\.M6NM=
M7Q/X4NEM]31<R19V%R!P5.,9/<-QZFG:%X5\::]>6EQXVNH6TV+;(-/5P'\U
M!M5FVJ1S@L<-W[=!ZG10!P6L>&_$&O>*],OM0M=+;2]/<O%;I?2ABY88D;]U
M@D <+Q@_Q8-9?CCX>ZYK/BNUUSPY)IVG3P+DW#3.LDC^I4(1Q]>>]>HT4 <A
MKFF^)M:\%2:5)%I0U"[A:&XD%S(L:_[2_NR3GT.,>IKFM!\!>)]*\!ZIX8N?
M['N5NBSPR/=3,J$[!MV^6/E^5FR#U/2O5** /+;:U\?/H,_A+4]!L;R-X'ME
MU5KP+$%V?*2FTL2#T^4<XZ=:T(_AR5^%3>%&F7[64,GF"0^7Y^=P.=N=FX#M
MG%>A44 >;> _#GC/PYI:V5W+IOV6S$RVULKL//9G)W.^T[5[C"YP>0#53PAX
M"\4>&_&6H:Y+)IDD-Z)=UNEU*,%FWJ?]7@X/&?0D^U>J44 >2VG@#Q7:_$A_
M&&W1G9I'?[+]LEQ\R%,;O)]\]*G\<>!/$GBWQ%8ZC''HJ060VI'/<RGSEW9&
MX",;?H"?K7J=(>E 'E7Q0_M75-,T71H[NWMM9N[CG3K>4R),,\,795.T8SRH
M!)(&<5BV47QCTNX?98Q7>UU&]VAVNJA@ ,,IV_-G!QC Z<@]?XY\ 7_B36;+
M7-)U;[%J-I&(HRP(4#+'=D9(/S8JO9:;\49T^S7>KZ;;PA AF$6Z0C)!((_B
MP <G^\/0T :GP_\ $^L:_%JEKKUG#:ZAITXBD6(Y!R"<8R1D8[$YKL9(UEC9
M'&58$$>U9'ASPY;^'K655FDN;NX?S+F[E/[R9_4UMT >+Z3X,\<^$?$^H0>'
MX-.73=3ES]J+%A;1AGVC!(;< >P8=.>M+HGP[\96?Q'N-:?5(=D;$&]N$RUT
M&C(SY2$< XX+#L1G&*]GHH \DU?X?^*M4^(%IXIQHR&VDB<6_P!KE^;R_?RN
M,X]#CWK0^(/@SQ+XVCTZ.*/2+=;5O,)DNI&W,57<N!%T!! .>1SQTKTNB@#S
MSQ+X#O/%?@RWL+VVT^UU:P 2R>WN':%5PH.24! (!XP<87GK7/:-H/Q2;PS>
M>'ICI<5H8WMA)?.S.Z.I7Y"F>!_M 'GO7LE% 'F7PT\":UX:TNZ@U>6R^S7A
MW26:QF1N5Q@N<*,>@##WKG?^$ \=>"=9E/@^[2YTVXEXC>0 JN.#(K8&1D\J
M>=N<#I7M]% '"^&/"^OZ2MWK&KW%IJGB611;Q2M.R1" $';D1Y!SDGY3T ]:
MPO ?P_\ $OA'Q-=:G.=)GANP4D"7,@:-2X8D9B^8\=.,^HKU>B@ KDOB'X4N
M/&/A=M-M+B*"X699D:4':Q (P2,D=>N#TKK:* /'7\)_$?Q%X/DT'4[O3+2W
MBVH@?)>XV,,;BH("8Y! SE5&!DFK&@^#/'%EX(NM$N+C3FCNK:2WC@DG<>2'
M'WRP1LD= HP,=Z]:HH \Y^'OA'Q+X(TJ]L9(])N?.D,R.MW(OS;0 I'E=..O
MZ51\(^!/$WAKQ??ZW)%HLZWSMO47,H>)6?<=I\O!^A'.!R._JE% 'B_B'X>>
M)- \8#Q%X(B1D9PS6WG8;<<[@0V%*'TR3S4?BKX?>/\ Q=JFGW.I2Z'OB4J&
MMWD54&=WS97)R>.,_A7ME% %6QCNHK9$O;B.XN!G=+'$8U;D]%+-CC'?_"K5
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%<9\2M4U_1?#$^H:+<6UO'!&6FDDCWR!BZ!0
M@)VC@ODD'H..<@ [.BN2^&^JWVM>#+6^U*Y>XNI"=TC@#/T 10!^?U-=;0 4
M444 %%%% !115/5%O)-+O(]/D6.]:!Q;NW19-IVD\'@'':@"Y17+>"+?Q1;Z
M9<_\)3?BZNS.50*BJ%0<9!4#(/7D5U H 6BLS7]<M?#NDR:C>;VB0JH2, N[
M$@ *,C)Y_2K\$HF@CE 8!U# ,,$9]: )**** "BBB@ HHHH ***HZOJ,6CZ5
M=ZE<!S!:Q-*ZI@DA1DX]Z +U%>56U[XT\5^$KGQ1I&MM:O.6-GI45K&P54<I
MM+ODL2 #G@9SQC ':>#[CQ'<>'XY/$\%O!?[B-D((.P  %^2-Q.3Q@=.* .A
MHK(U;Q#::/=Z=:W"RR3W]PMO"D*[B"?XB,YVCN>U<'\7?$OB7PO;V5SI>IPV
M]O-*4"); R<+D[F8L"/HH^M 'J=%9?AR[GOO#.DW=S)YD\]G#)*^ -S,@)./
MJ:U* "BBB@ HIF2#STKSK6?B%JEWXB;P]X-TZ&^O[=_]*FNO]3&F0,C:P) +
M#)[8Z&@#TBBN!_X1_P"(-O\ Z1'XUM[J5/G6UFTU%CD(_@+*=P!Z9'-)X*\2
M>)=5\6ZYI?B*&UMY=/CC58K53L8DL=^223D8QTXQQF@#OZ*04M !1110 444
M4 %%%% !112'K0 M%>.^,/%'B_2O'^F:5_:L%K:W;%E2UME;]WYK!=QD/+%0
M,X*CT]_8%.1UH =15/5M2M]'TJZU&[;;!;1M*^,9( S@9QDGH!ZUYYH_B'QI
M\0+9KO2#9:!I+-MCN73[1.2O7 )"D$\=!C]: /3Z*\RUB[^(/@[3);EKNT\0
MV:@M+,;?R;B+((^4*=I48!R03R:Z_P 'ZM+KGA/3=1FE$DD\67<1[-Q!P?ER
M<=/7\NE &]1110 4444 %%%% !1110 4444 %%':HI)5AB:22141%RSL< #U
M)[4 2T5E>']<M_$>BP:I:1SQV\V=BSIM8@'&<9/!ZCFL#P[9^-(O%NJ2:YJ:
M2Z0 3:0QQI@AG.W+ !@RJHR.0=PYXH [2B@44 %%%% !11574$OGM&73Y[>"
MXR,/<0M*@'?Y0RG]: +5%>.:;XR\<:MX\U+PJEQI4#QRLQN?LY;RD3:/D4.1
M\W!PQ)&YN1@ >MV8NEM8UO989+@?ZQX8S&C'V4LQ'YF@"Q1110 4444 %%%%
M !1110 445G:]K$/A_0KS5;A'>*UC+LJ=3VQ0!HT5Y2+CQUK_@Q_$VD:XZW-
MT1):Z7!:Q;43<59=S@DGH<Y['CD8[KPO/KMSH$$OB*"WM]1;):.#.%7MG)//
MK@T ;E%9#^(;-?$L>@JLSWCP&<E%#)&N>C'.03V&*\P\=^+_ !7H/Q#TS2X=
M6A6TN1$_EP6H4;&F9<,7+$G"X)! ] * /9J*0=*6@ HHHH **@O+J&QLI[NY
MD$<$$;22.1D*JC)/'L*\OT'5/'/Q"$^IV.JP>']*5V2W$=LL[2X/\6X]1TR,
M?2@#U>BO*K?Q1XYT_P"(FE^'-7AM);-\J;J"W8?:8\<2'YCM88Y P 6/48KT
M#7]=M/#FDRZC>^8T2,JA(@&=V8X 49&3ST] : -6BHHI!+$C@,H8!L'J,^M2
MT %%,=U12[,%4<DDX %9F@Z]:^(K![RS2985F:$&5=NXKU*\G(]#0!K44@Z"
MEH **** "BBL[7M8AT#0KS5;A'>*UC+LJ=3[4 :-%>4BX\=:_P"#'\3:1KCI
M<W1$EKI<%K%M1-Q5EWN"2>ASGL>.1CM_#LWB.Z\,))K<=G:ZPZMA41F1/[I9
M=W)]0&^F* -^BO&M;\>>-=.^(7_",6TND3S2K'%&S6SQQ[G&[=C>QSSCJ1QT
MKHKJX^*>GZ9%)%!X>U"5(AYB*DHD9@<<?,%8D8)/RCDC'&2 >AT5Y[X.^*$7
MB+77T+4M-DTS5%!"QLVX2,H)<=!M( R.O'?U]!7I0 M%(:\V^+.O^)O#>DQW
MNE7MO:VAEBC#"+?,SD2%@2V5"X5/X<DGJ.A /2J*Q_"MQ<W?A?3KB\N6N;B2
M$-)*R*I<GOA20/PK8H **** "BBB@ HHHH **** "BBB@ HHHH **9,)#!((
M6192IV,ZEE#8X) (R/;(KR/PYXI\57?Q?N=#OM3CGL+9Y1+'%"D2<(<8!R_7
M'\1/X4 >OT444 %%%% !1110 44AXKQOXG^+_%GAKQ+8VUEJT$-M<*76.*U
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M;;I"2KGEF)7;P.-N?>@#TJBL/P;?W.J>#=)OKR4RW,]LCRR$ ;F(Y.!P*W*
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MFWW&!6_^T'_K/#V,?=N,\>\= '6:IXD\0>$/AW+J>K/9W>H,$2V%M#)Y: X
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M2..8P+/+:SV[LS @9"YP>#GG&".1QUJ^"_$'B+QCX/EU&'4;2"]68QA9++Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'/%=52$>^* .6\8>"=/\7OI[78 :TG5V(&#)'GYHRPY (]#UYKJ1THVTHX%
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M@@ 9XP 2,8Z&LR+X-Q7&A1V.L^(=3O)8EQ 1,1'!CC"(<@<8'X<8KU+'%&*
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MM274Y&9GFV0D$L,'Y2F._I76ZWHEAX@TN;3M2@6:WE'(/53V(/8CUK1I",T
M>.P_ FW2\N(FUZ\&E2%66",!7+J,*6/W3C+XXXS79>+?!]KJW@7^P;>Z33H(
MA&(Y,E(U"L/O*I ;//7N0>H%=AM]*K7^G6FJ6IM;V!)X"ZN8W&02K!ER._('
M'2@#@_@]8O9Z!?M%-/)IDMVQL///S",<9V]%R>>.M>B2(LL;1NH9&&&4C((]
M*;##';Q+%"BQQH,*B* %'H *DH \H3X-?8O$C:AI/B*^TVTF#"5+8^7+@DG:
MK+@!<A>"#TJ]I?PAL+'Q&^KS:UJUS*>0QN624DJ0Q:1<-W[$>^:]("XH"XH
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MC+;VLDI$2.4"[RHP"^-PSZ&N](S0!B@#@]4^%]MJ_B*'7KK7=2-_ Z/$ZK"
MA0Y7C9@X/KG/>KOB3P&?%-G'9ZCXAU3[,H4M%$(D#L!]YL)SSSCH#T KL**
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M7PJ?#HU_4/L)B\C'EP[O**X*9V>_7K[U3T;X9:?HNDWND)J5]/IEZ&\ZVEV
M$D ;@P4,,8'0XKN:0C- 'ENF_!N&S%Y93>(=4DT:4[DLDF**S%<$R <,<[2.
M!]T9S6IX.^%MAX3U1KZ._O+DH[&&)WVHF5*[BHP&;:SC)X^;I7?;?0XHQ0!Y
MR/A'IB>(KJ^AU&^M[*[):>QMG\J-P6SL.W'R8XQ5WQ3\.H?%?BZPUBYOWA@M
M8 @BC4;F8.6!R<C'/3%=SMH QWH  H'3@4M%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M],#IQDY]J ._HK$\-^);3Q-;7%S9*YAAG>%9.JR '[RGT-;= !1110 4444
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M2%8F/S0LSEBC#M@L0/;!R002 =/1110!X)X7_P"*&^-EYHH_=V5Y(8XX8OG
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M>GU%>5ZG_P G+)C_ )[P_P#I.M:?CF6YO/C5X>L/[22QCC@$D,DJJRQNQ?\
MA)&=Q15Z_3F@#HY?BK#INJ0VNO:%J&E0RHA%Q)AU#,>AQV YSG/M6GXO^(ND
M^#@([J.XN+EONQ1QD+G /+GCH>V:Q=>^&.J^)K2"UU7Q?-/%#(TB@V2@Y/J=
MW;H*Y;XQ6Z6G@CPM;1W@O8XAL6Y!R)@(U&_.3UZ]30!U&I?&C1[...>VTW4+
MBU=0?M!CV)N.WY0>02 6S[ICG.1WVEZG:ZQIEOJ-E)YEO<('1L8X]Q]:X3Q-
M;PCX"@"&,!=,MW4!1PQ"9(]^3S[U-\&0W_"O(=\$T7[]\&5B0XX^9<@84].,
M]#0!Z&*Y?X@>(CX7\'WFH(I:=@(8>. [9P3@@UTXZ5P'QELKB\^'MR;>/?Y$
MR32#<!A!G)Y^HXH R/@=H/D:!=Z_=1NUY?S%4ED(;=&O\0/49<MG)YVCTKU.
M:*.>%X98UDCD!5T< A@>H(/4$5P?P<U&.^^'5G%&K@V<DENY8#EL[^.>F''7
M'(-=\3D>U '(^$O"\/@K^W")8H]-N+G[1#R1Y,>WH22>GKFJ#_$MKBRN-0T;
MP[J.I:? X0W2X17P2&*CDL!\I&!SDCC%-^+FHM!\/M3CM+E5EWQQ3*A!(5SR
M&'8$&KGPI>%_AIHS0Q-&H64%6?=\PE<$YQW.3CMG'- &IH/C+1O$EC<75C/)
M_HJ[KF&2,B2+KPP&>?E/ STKG9?C%X=BUZ73/)OF\M6'F"'EY!T14ZDGH,XY
MQ]:XKPV[^'OV@+W2[%V^RW<DB2K(<Y!C\W([9W#CV)IFB1I)^T?=AT5@+FX(
M##/(C8@T =WH?Q7TS6/$::++87EA<2DK%]I7&XY.T$8R,K@_CCWKI=?\26^@
MM:0-#-=7MZS):VL(&Z5E&3R3@#IS[]Z\H^+L>WXD^'FBMI996B7*0$K))^\(
MX(!.?SKIOB;X7U^\U32_$GAK?+J&GAE:(2#[O4%5. ?X@><G(P.* -FQ\?--
MX@TK0;[0KW3]2O0[,DQ4QHJHS95@?F^Z!C Z_G=\1^,K/0+J#3XX9K[5;GB"
MRM\;F/;<3]T'U-<)X6\=V?B/Q5IUKXJL3INOZ>6%K,V461W4JT;*?ND@@@'J
M0.<X!H:7'J.M?&3Q+'%KHL+J-9(H7:%9&* X 4$C[HYR/2@#MM'^)=G?^)9-
M!U#3;S2[UIGCMQ.N1*%. <]B<'ID<=:;K_Q7T'0-9ATR9+IY&8>;((RJQKE@
M3S@G! Z#&#U.,5E:S\,;G4-3M=9U?QBYDLDC42-;+& JXZG?P2<DGU)KE/BL
M%E^,&@JRAE:*V!!&0?W[T =C-\9='@U6"UN=/U"VM99 HNIX]@VX.7QR2 =O
MX$GM@WOB5XTO/#.BR#3[*>26:$D78("6^X[5/(.XY[5A?'R*)?"6FL(U!6]"
M@@#(7RWX^G X]J3QZ''P+M-\$T#^7;;HIV+.AR.&) )/X"@#1^$/B$7?A73]
M-EM;]IPUPS7DB9BD;S"Q^?.2?G';KGT->E5P_P (/^27Z/\ 6?\ ]'25W% !
M7%7'Q!2:^O;/0-(N]9>S!$TL#*L08#@!CUYR#CI[UN>++N>Q\(:S=VLK13P6
M4TD;KU5@A((S7G_P&:)O"FH!(RL@N\.Q?(8[1C QQQCUH Z[POX]TKQ/*;.-
M;BSU-$W265RA5UP 21QR/F SQGT%>?\ QRUU+C3+?1OL=['+%=K*)WC B==C
MCY6R>>>A]#5+Q^[>'/C;IFHZ>S">[2"24.25)9C$1CTVHOXUT7QZ_P"1*L/^
MPBG_ *+DH Z?P[XCTOQ?"=/?2+T1PPJ[#4+,+&V,8QG()[UUPJ*T ^Q0?]<U
M_E4U &)XIUY_#NC-?1:?-?RAL+!$0O12Q+,?N@*IY]<#O7EWPO\ &MQ<:CJM
MUJ<.H74NI7T$*RQ('6'.[ ;IM4#N!C@UZSXC_P"18U;_ *\YO_0#7E?[/W_(
M/UW_ *ZP_P FH YS3=9M= ^.>LW]YYIB2XNE"1)N=V.<*!W)KTO0/BKIFN>(
MQHDMC=6%RX/EBX7!9MQP",9&4"M^)';)X/PM&DG[0VIAT5@MS=,-PS@C.#5W
MXF!X/C%X=EM1,DS01$M;1!Y"?,<=.,\#'TH ]3\1^*-.\+6"76HR.?,<1Q0Q
M+NDE8]E7//\ GVKEI?BK#INJ0VNO:%J&E0RHA%Q)AU#,>AQV YSG/M7.>.I;
MB\^-/AZP_M);*** 20R2HKK'(Q?L2,[MJKU],<UN:]\,=5\36D%KJOB^:>*&
M1I%!L@.3ZG=VZ"@#TD'W_&G5F:#;)::!I]M%=B\CBMT1;H'/G *!OR">O7J:
MTQTH X[XI(LGPWUI7AFF7RXSLB."")%(/0\ @$^P/(ZC+^"Y ^'-MGC_ $B7
MK_O5J?%-D3X;ZT7EEC'EQ@&(9;)D4 =1P3P?8GKTKAOAAX'TS7? PO+FYU%)
M99'3]S<,@0*W51V)[T 9'QA>SU'QGI']C;)M0DB7,T#JZL=Y"Y"C)(QU)Z8X
MXKV>ZU>+P[X:2_UVZ16@A3SY%_Y:28&=H[Y.<?TKQ#QEX;E^%7B'3M;T&Y5X
M92RQQ7 WLK*!N![$'KD8/;W-KXH>)WU[P=X/O2)/LMX99;B#[N]X]J]1G'5\
M>QH [ZX^)LEG;VVH3^%]532)BY-UA2RH%RK;!SS@YR1@#//2NPTK6=/UO35U
M'3KH3VC9 D (Z=>HJ-;*WU3PP+&176WN[+R6 ;Y@C)@X..N#UQ7C?P8OU:V\
M0:1J$R+I*0F9S(Y78,[3\V>!CT[T =N_Q12YL[R_T;0;[4].M)/+END947@_
M,0.20 5(XYW=L5T6C^,=(UOP\=<M9I19*VR0-$2Z-D#!5<^HZ9ZUYSX:NF7P
MWK5CX#TQFTC,IFU'4[@#]Z% (6-06(* $9 Z\XJ;X!"0Z%JI.WR_M"[<(X.<
M'.2?E/;[O([XR* -:'XU>')9[U#!?A;=0RXB!:3GYOESQCKR>@/3I6WI7Q$T
M34/"2^(;B1[*V#>7*LBD[9/[H('S?4?I7F/P8@AG\>:ZLT22 02##J#UD /7
MV.*O_%J2*#Q?X>TEV6'22!+) @*1[MY!/RJ3G\#0!;\;^/)]6\ 73/X>O;;3
MK^/9!>2.N"_F':-O7!5<Y_#GJ=[X+2;_ (>Q@7$LVVY=2)!@1_=^5>3QW[=3
MQ6G\3X8O^%9ZNOE)B.)2@V\+AE''I69\%Y-_P]B4W"2E;AQA%(\O@?*<@<]\
M\]>M 'HHJ&YN(;2WDN+B18X8U+.['  '>IATKS[XSW4]K\/+CR)"GG3)$^/X
ME.<C]* '2?$QY[&74=*\-:G?Z9%*J&Z7:@89(<JO)('R8]=QSC'/1^'/%>E>
M*[-Y]+G=C$0)HG3:\1.<*PZ9X/3-9?PQ:)_AOHS0Q&)/+;Y6?=SO;)S@=3DU
MYMX.D?0/CM?Z-9,WV.YDFCD5_F. AD![#.1U],T -\<>*8+CXG^'KMM.U*+^
MSY0LL4D $C$/D[ "=WYXKUS0M7T[Q9 -073+B)K68I$;^V"2(V 25SG P1R/
M2N#^('_)8/!7^^G_ *,KUH"@!:QO%2K)X2UE)(I9E-E,&C@.'<;#D*<'!/;@
M_0ULUC>*W2/PAK3R22PHME,6DA&74;#DJ,CD=N10!YY\ ?\ D6=5_P"OP?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M :2:\6TGPEXP\,>/]3N](TVU:+4(Y$CN'FS'"K.AWG/)(/.T]<&O:MHHQD4
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M&R27ES;%!L*E2HXY))'(YKVG:,8HVCCVH BMK6"SM8K:WB6*"% D<:# 50,
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MS(0P;G!X'RC\Z]9QQBC'- %6QN+FXLUENK-K68DYA9U<CGCE>*MCI2;1Z4M
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M@#7HI-PHS^=  3B@'(I#@XKQG7=<\367QATK15UTM:2S0,\>%A1D+_,O)Y.
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M Q)#DG?GIP!C':NG\$7-Y=>"M*N-0N1<74D.Z242*^XY/=>.E '0T4FX49H
M6BC-)NSV- "T5C:IXDM=,U73--,4MQ<W\FQ4@PQC7O(PSD(/6MC/- "T4F:
MP)Q0 9XHS6?K"73:9/\ 8KL6TX4D2&+S. .F,BO-O@MK^MZ^FKS:OJ3W:1F)
M8EDD4LA^8D[1R <CDC!P?0T >M44#I10 44A.*-PH 6BD!SVHW>QH 6BL;7_
M !);>'X[/S89KB>[G6"&W@P9&)ZD*3D@=3CI5S5=4MM'TJZU&[<+!;QF1B6
MSCH 3QDG  ]2* +M(6XSC-4]*U$:KI5M?"VGMA/&'$,Z[73/8CUKF-&T;Q3;
M^.;^\U'6&FT9C(]M;(<J-S'"L.""HP>XH [2BDW?6C<,4 +12;O8T;AZB@!:
M* <T4 %!XHKF?'?BK_A$/"\VIK;F>4N(HE'3<P."?;B@#I<\9HS7EFHZ-XZ;
MP_IFJZ%K]W?:A-*L\MO(4CB$;+NP-Q'"GC&>=W;%>C:4M^-)MAJC1-?>6//,
M0PF[OB@"]129YI<T %)GG%,EGBMX9)II%CBC4N[N<*JCDDD\ 5AZ=K,OBCPW
M_:.F>=IQD8^4]S ')4'[P&<%2.AS0!OY_P#U4M>.?!?Q-K7B"_U5-6U&>[6*
M&-HQ(1@9)Y'X8KV(''4@4 +129R:6@ HHI,\9H 6BDR*6@ HHI,XH 6BD)P,
MT;A[T +129HW"@!:*0MBC- "T4FX&C- "T4FX49H 6BDW"C<* %HI,\<C%&:
M %I <TC8[UXS\3]<\3:-XNTRSL-=,,-V"50!840;\ ,S'!^IQ0![/FEIHZTZ
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O./C=?7%E\/_+@<*MU=QP2\=4PS8]N5%>CUQ'Q7
MT)]>\!W4<*2R7%JZW,4<6,N1D$'VVLQXYX% "?"738]/^'NGLCLQN@;AMP'!
M8XQ^E=N<$8->7?!?Q3!?>'1H5U<_\3"S)"1.H4^5VQCKCG.>:]0=@J,Q. HR
M?I0!PGC/6]/^'.A7M[I]M$M[J5P9%B)P&E*@-)C\ 3CN<]ZHW&F^.?\ A'8?
M$&F^(GNM5>U5GLS"H@9#\WR+C[_3GZCO7*_&#4VU[1=*UC3H1)IEM=R1Q7?#
MI+E4.[:1TW!UP<_</K7KOAW4(+_POI]\DT;PO;*3(H"J,##<=  0?:@#F_!7
MC._\9>';F2&.T@U>VE$<L<H;RP/7CG.,].]>=^%/%7Q!\:#5[6PU"'SO+67S
M& 0QGH%3'3=C^O>M+X(Z;<GQ!KNJX'V7!@#$G+,7SQZC -4_V?\ _D+ZU_UP
MC_\ 0C0!+XK\3^/?">AZ5!JUS%!+<3S&22!@\LBAE?[W0#YBH [#%3^)-1^)
M=CIT7BK[7#!8P#<+>(J0J/M52Z]')W9_V>:L?'<JESX7+E0@FF)+8P.8^N01
MCZ@_2O0?$4D:_#G4W\Q%0Z7)M;(VG,9 QP!SGC '7H* ,?1?B18WW@"?Q)=+
M''-:*5G@5P#YG91Z;NU9?A\^+/&GAF/Q%%X@-E<-+*]I:0Q 1 !BH63N_0]:
MX+2-!OQ\#-<N5M]R7%Q'.@'!$<9&YOIQFO4?A!J*7_P[L$$D;36Q>&540+M(
M8D9P!D[2I)ZDG)Y)H I> _'&LZIJ>I>&]?AA@UNSCW1DH0)#SDL!Q@93&.H.
M:YC_ (3+QQ=?%2;P];7EIY@:2W5-F(D&W<7P>25QD9],=Z73[";4OVC+V[M=
MKP63>;*X/ 'DA,9]<GI['TJKHW'[24X[^?/Q_P!L6H V9]7\>^"O!]_=:RRW
M5X[QQ6S\R[!@ L<<>_/4U#XBU#Q/X7\+:-XKB\1W%P]S&GGV=PHV$R_O" /8
MDKGJ!@#I75_%'Q?>^$=#@;353[7>2&&.9\$1<9W8/4_7CV-<-\2O#4>G> +3
M4=1U.ZU'69KB-S+-=ET0NF9!$@PH3(&"%].<8H ZGXA:CJM_\*_[9TZ\:RCD
M@0W4'EX:1'95(!ZCD_BI-9GP:M-?;PK]IAU*W&GAI1#:/#G,OJS==N><"I==
MF@E_9[D$,D3;;6#(0KQ^^7LJJ.H/;L>3R:T_@K(B?#R!6=0S74H4$\GOQ0!G
M>#?%7B'5?B?K&EZG<&2WM/,B"6Z 1(5<@$]_H>OK5RX\6ZCXE^(DWA70[]+*
MTM(7-U=(H=Y&X!"9^Z5+ ?4'VKGO ;QK\;O$ZL4\QKBXV@XR?WC9QE2?R(]\
MU6\!SOH_QLUVPO=D#W3SE%= 68E]Z@-@D94D\$ \9Z"@#9UGQ%XK^'&KV<6I
MW7]K>'IF6%;J9,R)D@MN(Y+!0V!W_"K7Q:\4Z_H.D6L^E7D$%I>-Y:R1K^]Y
M7.<G@>Q'-1_'@A_">F0)\\SZ@NV-3\S?NW' [\D?G7/_ !1T^?2OA=X3L+G;
MY]NRH^SID1GI0!?U:[^(LGA&R\7C5[:"**!+G[) F-R,H^=NS9X;:>F[':O0
M_ 7B&;Q/X0L]3N8]EPX*287:K,#C*^Q_GGTKGM6_Y(#'_P!@2W_]%I4?P.6-
M? +E(I4+7DA8R'(<[4Y7@?+T'?D'GL #TJD/2ES2'I0!Y]XS\;WEGX@LO"WA
MM[9]8N6VRM(,BWR RGTR1DX/;'K7$?%S1M=TCPMIZ7FLS:G92WIDF,X7,<Q0
M[0AZ[<>9QT'%.U34+;1OVBI;O4/W5O)Y065U7:N84&<LIXR"/EP??K71_'EE
M?P'8E6#*VHQD$'@CRI: +=YKU[X4^#MA=V-@\5X+>...+8SB$GC)SZ9XSWQ6
M!KNH>*=!\&Z3XPB\27$DL\:--9SH/+S+\Q 7V)(&>@P!5W5/&,WA'X/:%<:/
M"5FNH5AA>9@QA^4G<> &/''&/K61\1/#:V/P[CU35=4N=1UF::.0R2W1>)&<
M?.(4&$"YZ<<#% '4>-=4U75/A.NMZ?=O8;[99+F'R\%U; *@GD<]#W!-8OP8
M35(/#4NHSZM##H4$DS/;F(9W!1EBYZ*!SQZ5;NYH'_9Y:.&2)BMBA*QE>/WN
M.BJO<'MU!R2<DU?AN#+\%M6M59?.N6NH(49@#)(T8"J,]23VH ?:^)]2\9QZ
ME?KXFM]"L8O,CM(59=Y(0Y:0]<8R>/J*M?#OXAW>L:[JNBZQ>VUX]N7:WNX8
M]J2(AP3QQC !'UK)^#[>&=1T*72M3TS3&U*WE)#742,\BL>Q8=CQC-=G)/X:
MM=9DTK1M(L!=2Z?-*US901@1K@@+N4=3CIQTH QK7Q'K/Q%\1:EIF@ZD-/T.
MRP);VWXFEW?=VD].4?D=OPKC-3M-5B^.VDV^IYU&2.XM_*?[K&)6R';;CE<%
MC].:V/@+JEI -7TF=A#?.Z2HC[074 @@?*&^7T)/7@#YLU_&YA'Q^T(SJ[)Y
MMICRV"D-YGRGD'C.,CN,\CK0![F.M.I!U-+0 5R7Q$UFYT?PG.-/8_VG>%;6
MT120[.YQE,<[@"2/I769%>6ZWI,WQ ^(4EC_ &C<VVE:(@)ELV*O]I/;)X##
MJ"!TSS0!QOCOP5)X%M/#NK:<-K6BJEU/ "&,V<E\]LY(%>Z:/JMOKFBVFJ6K
M PW,8=><X/<9]0<C\*X+6_A.E[H]S$WBGQ!<E4WI'=W7FQE@,C*XY_ BLWX'
M^)VGTVY\,W;;;BR8R0!AAO+)^9<8_A;)))S\X]* (/%WC/Q7I'Q'T[2%N(#&
MVQHK>W7"RL^Y%5RW."2,^G4<@50\0Z[\1O!-_;ZSJUW!<6UQL1K=2#&".2NT
M=/3<.M6/&+(GQ_T$RE%79"!OVXSE\?>5AG.,<9SC!4X(ZOXSLH^'%RA=06EB
MVJ2 3\XZ4 4_&WC?5$^']IXD\/W%M%:W0C#$KOE1VSN7/3@C![@BL;1I/B9X
MDT;0]4L[V 6K QR?O K2*LB_O'[DG:5XYP#_ 'JH^(-,N=)_9XTJVNE"RM.D
MVT?PB1G< ^^&&?>O1/A5_P DRT7_ *YO_P"C'H Y35/%7BJU^+&D:!<7$?V9
MWC=X;%.&#9!+%N2 .3],CFMKXT#_ (MO<_\ 7Q%_Z%7*^*GC3]H316D9 I$
M!?&,DD#JK#.<8XSGH5/(ZKXT?\DXN?\ KO%_Z%0!N?#O=_PK[1-^[=]F'WMV
M<9./O<]/P].,5T]<M\. !\/-$Q@?Z/V  ZGT51^GU+'D]30 5Q7CO6;Q8H/#
MFC R:MJ0*CRY-K6\7>0^G?FNUKR;6/ 'C.;QAJ.LZ;K=K#]MD\OS?)42Q0 #
M: <'!'W>,$XR3VH YCQ[X<LO"_B'PAINGQNL"R*SN<_O)#(NYR>FX@#IS@ =
M *]_#"OF+QKHWBK3O$NB?VSJ*76J3*OD2\$1MYS$+GN 6!Y'\6!P,5[OX=CU
M+PYX9F;Q5JJ7#6[O(;MS@",@'GCL=WJ>GTH Z?K14-M<P74 FMYHY8ST=&#
M_B*FH 0C-1+;0QW$EPL2":4!7D Y8#. 3[9-35S_ (N\6Z;X0T9[Z^;<YXA@
M4X:5NP'H/4]J .1^,MXMQH=IX<MXS/J&HW"&*-.64*>N.N.U5_BE!<:)\(;+
M3DN#NB-O:RM&2!(%0@_@2N:V?#%K&NI3>(?$6LV,VL3*8UB2X1H;:// CZ$<
M=>3GO4/Q#M?^$T^'%U+I;,XM[AY%  /F>4[HV.>G!.?04 :7PO'_ !;71._[
MIO\ T-J\ZT&9C\>M:TQTCDL[]KB&XB= PD0*6Q],@5Z#\)[N"Y^&^EK#(KM
M'BD _A;<3@_@1^=<1\,XE\0?%#Q!XC>S9$C+^4Y?(CD8XQQC.5W=10![02D<
M9=L*BC)/M7E'@.)O$'Q2\1>++52FF@?98F/(E8!02I''1 ?^!"M/7/%2^)]9
MF\,Z-J<%K9PD#4KX3B-]A)!6$G(SZG\JZ?3KS0]#LM*T>RN873*VL*PLA);:
M3N8+QSM))QU- &U%;0V[2M#&D;2N9)"HQN;@9/J< ?E7E?Q77_A)M?T+PI8
MM>>>)Y9%Y$"D8RP'(XYKK_&/C.U\,0PVT;Q2:M>.L5K!(^U0S$#>Y[(,C/\
MDBKX4M+'1H[C4M4UNVN]:O0KW<SSQL%('W(R "$]!0!VHZ4M9D>O:=_8%MK4
MMPMO97$*3*\WRX5P" 1Z\UH0S17$2RPR))&W1T8$'\10 ^@]*** /&/B1XS\
M6Z!XRT_3;2ZMDBDV31QQ*1O!D95#D^PY'2MFRG\;>'=6U#6_%%[;/HD-O)+L
M$H WMLVHH['(VC/'+>M<I\8_^2GZ!_UPA_\ 1SUZ3\3K2>]^'&LPV\32R>6C
M[5Z[5=68\^@!/X4 <;9Z]K/B#19->F\9V6CL[![>URICCC$B_P"L[DYP/QP>
MM6O _P 4+K5/"FLW>J(+B_TR,S$1)M\U.W3C.>/PI?AB?".M>$+9+G2](^W6
MJF.?SX8V=L#.\EADY&?I700:SX:TZ]UNWTW1X4@L;59+FXL($ D##[BE1\Q
M.>O>@#G?#E[XE\5^'KCQ-9^)PFH[94BTZ*-6AC"G(5D[OCOUP5K6C\83>'/A
M/:Z[JVZ?4F0H(Y6PTDI<C'/H,DCT4UQ.K?#F?2M-7Q;X#U6ZCA:$7'V??APA
M)8@,#R% 4;6ST.2:9XQUZ_\ &WP:L]6FM@)+3456Z=,;<!"N_';)=1CWH ZZ
MQL_&NM^%;/Q':>(R-3D@,L-F(E6W8-_"PQRV.Y[UH_#?QS=>)XKW3]7A6WU?
M3W$<R!2I;'!)'9MP;('2M7X?ZC'J?@32;A'B<K;JDOEH$57 PPP  ,>PKS?X
M=:?-=?&3Q+JD.UK.&YNE,@/#%Y#C!Z'IZT 3Z<7_ .&C]3V[L>7\VW=T\N/K
MCM]>/QQ5W6?%WB'1OBIIGAU]91K"YEAWE[5,D.V-@P._3/;.:H:>H_X:/U#(
M!(3(R ?^62=,J?TVGWZ@UO'$DUM\>] E5 !)):(&>,,""^UL9!&<'J.0<$8/
M- '4?%+Q'KWA*.PN]*U$+'<S>48'MT8+@=0<9YJA\89M8/@2SO([_P BTG$:
M75HL97<S L.3R!ZJ?057^/-Q"=-T>$31F5+IF=-PRH*]2/2K/Q69'^$&F/$5
M,;/;%2F-I'EG&,*HQ]% ]ATH O?"^T\1KX'M;@:E:2V[PXLK:2'"QG>=Q=A\
MQZ''UJM\+?%6N>)-=UI=5GDF2' 38@6)"#C ]"?UKI/A=(@^'.AQEU#F%V"Y
MY($AR<?B/SK@_@B\8\0^($)3S22<<;L;_P#=SC_@6/8]: -NP\3:GX_\5ZMI
M6D:K_9VD6493S[=0TLQR1O5NPXXQVJN_BSQ/X+\7V>B^(I8[[2;MECMKXQ_-
MM''..KY*@Y^O>L/X(3OIGB36=$O=D%T%XA9!OWJ2&&[&>/3.*O\ QUMWU"[\
M,V%MA[F6290@//S>6 2/3(/Y&@"?XM^,/$WAJ\L([&\MX+:Y+2(8DRY",A^8
MGMVP.H)!JOXNN_B)H.FP>*I=6MDB4!6LH5^2(/TW \/@GKVK*^.,#VUMX5MY
M""\5K(C8Z9 C!Q7;_%O_ ))5-_O6_P#Z$M %G5_'TNG_  RMO$\=D3<W,*;8
MB"%1V'7GJN<X]1BL"5O%C> KCQ+I?BJ2_O;F%9)K>.-61%P01$!RC#OCNI]J
ML>&KC1[/X(6*:K:WG]G7(:&51R_SR-\^1MPN>1Z#')ZGEM>\%ZW\,L>(O"^K
MS3Z<KJ9HW;^'^$N!A9%)9AG QD8]: /<M-9GTRT>0EG:%"S'J3M&<U;K(\,:
MQ_PD'ARPU8P^2;J(.4SG!_R*UZ &R*S1.J/L8@@-C.#ZUY'8>*/%EK\4X_"N
ML:E^X<EH9DM8U\Q<;AG(Z$*RY'.:]>->1?&NP>S71/%-M'$9["["N#%DOGYU
M+,.P*$?\#XQW &>.O%7B3P;XFTRVEUX-IMX0SO\ 8XS)$H8!B..< \5U/CS5
M-9T70M/32=1!U:>=($5H$8W.>"=N.,=>/6O.?$%G-\1=&U[Q='$\=O96Z)9I
M-(P7Y"&E90#@9 (VD'.1S6W\.M;NO'&KZ6]TC?9]!LE1C< 2F>X(VF4.1D-@
M ]30!N^+O%NI^&K;1M!BU"UEU^_P'NY@J)$,_>*],$Y _P!T]ZY7Q/XKUOP8
M;6YL?%]MK"RM&LEI(JLQ +EF!'1<@KGKT]*=\4GBTKXI>'=6U*R2YTLVRQ.)
M0"C$.^X$'.<!U/(KOKJT\"6FER:DVF:$\"Q-*-EO#EPHR0HQR<=OI0!R7Q(\
M;:W9^%M-U71;N*"PU)0$=4(F&4R>3T]L<T[3&^)&J7.BZY+>6<>ES013S1A]
MJA "<L!R2P.XX]0.U9'Q<NH;[X=>&KFWLA90RR[DM@H7R@4.%P ,?E7I?AR-
MI?AII$:*6=M(A51ZDPC% '%P>++[QEJ6IR6OB.WT32K-S#;!'4R32;'^=C_<
MP&(_W01R#1\/_B#?WOC.Y\-:KJ-OJ2%2+2[MX\!V49/([$ G)[BL3X/CP_)#
MJ6@Z]IFG-J4-P75KR*-V<'"E 2/X64=_XJ]$2;POIGBO3-.TO1]/-]<B5OM%
MI!&/(54.2649&>%QQUH [&D/2D7TIQZ4 <CX^\9P>#-#^T_NI+Z9@MM;OG]Y
M@C<3CL >OJ1ZUR>NZ5XP;P#JNLWFN,]U/9-Y]@JKY"P$9;'^T$SR*S_CPQAO
M?#%T\3/%%),7(4$=8SCY@1R >""#Z'%=YKU_::I\+=6N[*=)8)-+F*LF,?ZL
M\<8Y_P XH XOX0P7?_"O-0DM6;3Y?M+2+<A1)YN%YX;('3''I6E\)_&&L^+X
M-7_M34(WG@""-4@53&&#?-D#!R1T_P!GWJA\$_*;P)JXB202^<XD+,"&)08V
MC&1QCJ3S^54?@%-)$OB"VE"1I"8G.Y K*3O!RV,X^4<$X'/3)H V_#WBOQ!+
M\5[_ ,,7MXMW96Z-AVMPK<!2#E1@=<<\?CBLCXN[AX^\*;-V_C&S=G/F#IMY
MS].:@\.SV\O[1&HNLT+K)Y@C8%3N/EC[IP>P/0J>O.,@R_&( ^._"P8 @CH0
M"/\ 6#L58'\5/T- ':?$6Z\3Z7HS:OX?O8XX[9,W$#PJV1_>!(Z^U2_#_7+O
MQ)X'CU"ZU));V5I%D=(U'D,.BX'' PW/]ZNLGB6YMI(6R%D0H2,9 (Q7SG9Z
MEJ?P]U+Q+X1$9N!>KY5HC[F#.Y"JPY R48@G'WE4=!0!ZOX'U'6]>O-0O9]8
M-QI5O<M!;#[/&AF &&+8&1@D=.M=T 1UK'\*Z)!X>\-V6G01[/+C!?( 9G(Y
M+8 R??VK9H .U>9^(_$>LW?Q+T[PG83SZ=9R)YDUTL.78@%Q@L/NY0#CKD@U
MZ8>E>5:MKVK^*?B7+X,M;^32M,M8F:ZEMI%2>; 5AL<@E2"5X&.-V<]@"/1_
M$.M^'/B>OA*_U*35K*XRR2R)NEC+ D9(],<]@*V/&_CBZTW6;+PWX?-O)K5X
M^P^9R(-WW3Z9[X-<%=Z=INC_ !YTNVM7S$7B+O/-YK-*1SN:0.=Q./0YZ%3@
MB;Q!J=IIGQ]@U&[8"S<0E9B%*8**-P)4\#U7!]Q0 _XKZ/K^D>$;47FMS:G;
M3WGF7/G!?W<I7Y1'W"??XZ"MN[\9'P/\)-$,-JD.I7,.RWMW;/E]29"#U X_
M%AVJW\<663X?PNC*R->Q%2#P?E?!S7GGC2)X_ 7@;4K.!Q:P1R+NFVR 2%@P
M!&,-G:QP1C P<T >D:OI?CO3]'_MG3/$,E]J)A4S6;0KY1&,GRUQ][]35WPS
MXVO?%W@FXU.Q6T@U*W9UFC<,43 )&.YXP?KFNKLK^VO-!@OHIXVMI+<2"7[J
M[<=>V*\;^"NF7$>B^(M49<6TL'DQDD@DJI)]L<CGUS0 GA'Q1X]\96.I6^FW
MT?V@2!Y[B4*HB5D(18QVW%3D]B >YK1\$>/=<T[Q</"/BR599-WDQSNX++)C
M(!;^+<< >^*?\ 6C_LC6$!0R">,L!MW 8.,_+G'!ZL1UP!SFCXIT^?5_C_I,
M5F4<VYMYY.>$6-B[9QT.!W[D>M &+XI3Q WQGLK&36!+?1SQ+9W#Q#;$&P5R
M@X[\^M>I^*_%-UX(\(6[WMU#>:Q.?*1V C5G/5L#^%<C],UY[XHX_:(TWG_E
MO:_R%;7QQ5C9:#J*Q"XM+6[<3$$$9RORG_OEA^% %77]<U_P_H46L1^.+2XO
MV5C+9%5979O*^6->GRJ0?Q..IKJ(?B7:+\-4\2W#1K=LK1K"00'N .%'?&>I
M],UHZ7;^!M4T>#4HM+T%8955CF"'Y&(^Z<J.>#^5><?$R]L=5^'5C<Z1I:V5
MC'JCJJ1Q!%("D;\*  "<4 =/:6_C/7?#4OB5]9^SW,]L\EGIT*KY'EL,J'SU
M.#UZBL;]G^,BUUN7[,54O&//R</@$[<=.,@_\"^E>A>&M5LM8\!6]Q8RH4%G
ML9%V@QL%Y4A0H!!] !Z"O.?V?C#C70JR>>#"78L"I7Y\ #&<]<\^G YR >W4
M444 >=?$+QE>Z1KFE:!8W$5@]_AI+^8 K$A)&!GOQU^E-:#Q+H?BGPQ9+KMU
MJ6BSRR"661!O#A'(#N.H.> ?[OL*N^.]*T'Q7J-AX:U1[J"]:-[BTN(\!1V*
MY/!/ XQGZ5P&G2>)?A/XNT_2+FZ;4-%U!EBB#,0OW@"4!)V,"_('!!]<8 .N
M\4^,+BZ\7?\ "*Z;JMMID,<+RW]\[KN1 I+*F>C <Y[=?6N>NO'VI^$?&T&G
MW7B*VUC2Y9V\_;&#)""V,''<=0!Q5:-]-TOX[:G#XCT^UDM=1^6%[M%9$)P5
M;!!ZE=O;K7>:_P#\(7X>TUKT:%H]U-E1%!!;Q%Y&8_+C SCWP: /,_BV=9C^
M(&FVLNJ>;$VR:R78%$&YR.0.O(Z]P!6S\5K;Q1IO@B(ZMKZW<4]U'%)#! L:
ML=LC') R1\J8![Y]!5'XQ<?$W0/7R(?_ $<U=-\>)$?P-:A'5BNIH& .<'RY
M.#0!I_#.TU]/!5I//J5O/"]J/L5N8<+'Z;V')YK'\(>*O$>J_$W6-+U"X+PV
MGFQ!(4 A0JQ )SS[ ]?6NP^'<B#X?Z$A==_V-6VYYQZXKSOP(\:_&_Q,K%-[
M7%QM!QD_.V<94G\B/?- #=4\9^-D^*H\/07-H74B)(57$7SQJV3GDXZ\^X[U
M)J&N^-? ?C33X]8U--3L]4E4,B)P!D*0B]5(W \=3BJ%W_R<PI_Z;Q_^DXJY
M\>E1]4\-+(DDB'S0R1$!F&Z/@<'GTX/XT =U\1O%TGA+PL;NU ^VW+"*W,B9
M )Y)/T'/-<_XE'C#PUX5?Q)'KMS<:@T<)N;4Q(\$/'S% !@#/<=:M?%K2;&_
M\ 1S75[]D>SQ+;A\'S'VXV>N3TSVK)6+Q3KGP_L_"<4.F6SBVAAEN4O%8>5]
MT1E""0^%&<'J.* .K^'6K>(=?TMM6UB2W:TNHHVM4B0*492ZR ]SDJI].<#I
M7:UD>%]"C\,^&[+1XIGF6V3'F-P6)))/TR36O0 'I7CGQLM->719KF74K=]%
M:YB$5H(<2*VT\E^_(8_C7L9Z5YK\<?\ DGP_Z_(OY-0!;\.W&M>'/"C:QXCU
MFWN=/AL$>"WBA6/;\HP"V,EONJ/<FLWPU/XG\?Z)+K<?B!]-"W3FTMH(AL!7
MH)#U=<XR*T/%UI/>_!26&WC:23^S[=]JGG:NQB?P )_"J_P5U%+SP(ML)(C/
M:S,CJD87:#RN< 9)YYZ^M $?@GQOKEQXCNO"OB>**+58$)CD";?,/7MQC&,8
MZUSFI^,_&R?%1?#]M<V9D4B)843$7SQJV3GDXZC/N.]&H6$^K?M%(UJ4=+5H
M9I3G(4*@R"1W]JJW?'[3"_\ 7>/_ -)Q0!+XDLOB1I?@[7+K6=:C%FJQQLBD
M,TR-)M^4CE?OC/J..U;?P7M=9/A=+E]2C_LD-*$M!$-^_/)+>G? KH_BY_R2
M_6?^V/\ Z.CK/^#,B+\-[96=0SSS;03R>>U 'F/PDM_$5W=ZM;>'[JWLW>)/
M.N9EW;!DX 7U///;%=SX"\4Z]8^.+OP9XEOXKEX4/DS.<N[<-@-U;*MGGIMK
M$_9^_P"0GKG_ %QB_FU2Q%A^TI<[9(4!8;A*H)8>2O"9!PW?(QP#SS0![@H[
MTZD7I2T -D;9$[X8[03A1DGZ5Y)H>H^(_B#?^(E.L76C1V1$5M'#'LP&)Y8G
MG(,2^X#,.]>KWD_V6RGN"NX11L^,]<#->4^#Y[[XEF_U?7M3GATJWE:.'3;6
MY\E"C*=PE*X9EQM();KN[<4 :OPL\8ZEXEAU"RU5A-<6,FU;A(\!EZ<XXS^O
M6O1Z\-^"#VMOKFNQB2),$+&"RY*[\#!*[L9P/O8SC@]:]RH *X_XCZQK/A_P
MG=ZII,MM&8 N]I4+-EG51M'3N<YKL*X?XNY_X5AK/IB'_P!'1T </IEY\1O%
M_@Z*;2-0\J&-=IF:15FF<,-WS#D ?J*T_ _Q*UCQ)I=_8S-9KK5LC2I),I59
M4&<C:O\ $OY=,UTGPG>-OAUI^QHVQN#;-N <\YPJ\_7)]2:\^\':?/>?$_Q?
MJD15[2!KQ6DSD,79L;<<'I_*@!GA/Q-\0_&EIK$6G7T)EA>&<R/A"IZ!%[ -
MMR>WRG^\:Z'5?%_B/0+/0/#$MS:_\)-?S)'+<L?,$"M( "P/4G./3 K+_9[^
M]XB^EM_[5J'XBRRZ-\9M"U:X"169,&9I45UVJ^)#R#R W7J.W- '2^*!XT\%
MVSZUIVK2:O9!_-O(+J,$H.^W'W4^G2J_BOQ[K#_#BP\2Z+/;01W.V*;]V3(D
MIW!PN> H(X/7O79>/Y$7X?:XQD5=UG(%).,DC@5XDVF7-A\!&GG3:E[JRSQ#
MG=M"[.0?4J3[C!H Z9[[XCZYX1M=:TZ]6&RMD69?G433A ^]GQU&1C;WX/7-
M=1\./B*OB31+LZQ+##>Z>A>>0D*&C'63'8#O70>!)(?^$"TB17B\L6V2R[0H
MP3G[JJ/7M]<]3X_\/=#U"_M/&]U:1>8D]C<6D2@\R2-DC'KT]: .Q\,ZMKOQ
M+CU2YM]8ET;3H)U2WAME'F< $;GZX.>0*?X?\:>(M-\<?\(GXN$+23;FMKJ.
M/;Y@XVX XVG#<GG.1VJE\!M1CDT#4=.:2/SH9]X0( VPCJ2!EN<]3FL[XD6$
M^M?&70+*T*/*MM"SC/"[978[L=.,?F/6@#=U;Q/?^(/B%/X/M]5.B6D$3&2X
M3 FG<88"-CT_J U;/AZ3Q%;^/[_3]6OWN[".R#VLGE!%8%AUQP6'3-9'BSPA
MH7Q$U^_MX+FZL=;TU(XG=US'(A.00I.6 ^897')YS6;\/]=\2:)XPE\$:^[7
M1*.\,TCEF7"EAACR5('0\C]* +D?BV[\7^(=1ALO$-OH^D6,OE1.K(TEQ)R
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M /X4 >YCK3J:.M.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'0:I>7_DQG<D$4BJBMC&1\I/ZUU=% '*S>![:?PVN@R:MJIL%01;/,CSY8
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M(QK=GJ=UIT[R;YQ$H.[@#Y"""AP#D\\FA?@WH9UFWU&;4-4N/)PVR>?<S,K
MCY\ @=1@>N<C%>D44 0VUO':6\<$((BC4*H+$D =.3DFICTHHH JWML]W:/
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M6/E(S89<,!(>F3SPO^-=1I_A;2M.\-#P^ML)M/V%'24 F0'J6P!D^_L*VZ*
M/.+;X73Z:TUII/BG4;+1YSF:S"*S'^]B3^'/L/SKK= \,:9X:TIM/TJ%H$;E
MWW9=WP 7)/&3@=L>U;5% '$)\,]/37GUU=7UE=3?[TXF0$C &,;,= *E\9_#
M^V\81VDC:A<VE]9C]Q<)AMIR"21QD_+V(Q7944 >8W?P7TF]L[".>_N7NH7W
M75XV6DN1_=Y.% [=<>]=4W@C1V\*R>'/+F^Q.JJ6:0NX(  8%LX/'88KI**
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MKT.B@#G/#G@O2/"Z7!L%G:YN 1-=32%Y9.2>3TZGTK(?X8:7)X@_MYM4U?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;.#@T =-?7]KIMM)<WEQ'! BEF>1L  <FJ^CZYIFO6SW&EWL-W"C;&>)L@'
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MHTTG%4-)UO3==M1<Z7?0W4)[QMR.2.0>1R#UJ2_U*RTJ!;B_NHK>)G6,/(<
MLQPH_.@"EJ/BG0M'N$@U#5;6VE?[J2. :V5/&/2OGCXG7VBZQXJT.ZT)+"\6
M7=YH7]VLK[_XR-I_$D<=Z^AQTH 6BBF2R)%$TDCJD: LS,<!0.22>PH 2>:.
M"(R2R+&@ZLQP*P+7QSX7OKN.WMM=LI)Y#A463DFO+=)NKCXL_$&[2^N)3X=L
MQO6S1S$'0'Y-P!.23UY^F*]3D\$>%Y=.^P-H-CY&P1\1 /@8_C&&STYSGWH
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M^A7>A)8WJ39\T >6LLGF<AR"IR?4D?6@#Z%%.IHZTZ@ HHHH **** "BBB@
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MO3K3+]AO(Y"\T8+ (QW*0!WW*!^- #OB]HME9^.=(DM+%Y#=H/,M;<;=^U@
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M].OI7MEM>07EK%<VTJ30RKN21""K#V- %BC%%5[N\M["VDNKNXC@MXQEY)&
M5?J: /'-!('[1>K9(Y$@'(!^XO3+ G\ Q]@,D9'QSL+>U\2Z8\,95KB)GE.\
MG)W=>>GX4OA;Q-8/\:]0UFYN%L[*X\T*\KE5.  ,D<8.W(SQ^.*C^-&JV&L:
MYI$NFW<5VD4+!VA;<%.[OCI0!L_%7P-H6@^#8=0T^V>*]BG1&GWDO+GJ7/=L
MC.>.<U>U[Q9J%A\#M.O8KE);N\"6GVF'>NS[V3\PR2!'M/N2<]*F^,.N:5J/
M@)(K+4+:XDFG22)8I Q9 6!88[ @BLV/3E\:_ ZTTW3FA?4M.Q,UI;X!!#.
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MBBMK9@TJY^;)3J,8Y%:?A*TT_P"'?@&U75+E+8OF:8N3\TC+G:H/.=J]/8T
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MGW;[X+:$,2GS'!)(&, XP,Y]1CGS_P %>/+CX="Y\,>);*Y40S$QE3GR\\D
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MCMXEC4L0!G  &< <^U6L<8I:* $"@4FP9R.*=10!0M]$TJT^U?9M,LX?M?\
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MA$1 %55 P  . !4E% $4=M#"TC11(AD;?(54#>V ,GU. !GVJ3:*6B@!K(K
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M(:1E4 N0  2>_  ^@%2T4 )CGJ:9-;Q7$$D,\:2Q2*4>-U#*ZG@@@]014E%
M%/3](TW28GCTW3[6S1SEEMX5C!/J<#FK>T4M% "8YS4,\OD6\DOE22;%+;(Q
MEFQV [FIZ:5]Z .*T/PM./&U[XEO["TLG>,);P6Y4L"1EW=E W%CG[P)]Z[>
MD"X-+0 48S110!1M]&TRTN+F>VT^TAFNB3<21PJK3$DD[R!EN2>OK5N.&.&)
M(HD5(T4(J*,*H'0 =J?10!GZCH6DZNR-J6EV5Z8P0AN;=)-H/7&X'%7@B@
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M0R75W)=BW0<0!\83\ *ZZDV\TM #617!##((P0>AJI)H^F3+;K-I]I(+92L
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MT7VE7 FAW%&!&UE8'^(=NQ^AKR[1 P_:,U8)N \MMVW=C&Q.N.V<=>,X[XH
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MZMIM_ID-T@,-S<Q80DD#'TP0<]* .\SSBDW>Q_&N&^(GCA_"NDR)9V\\EU+
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MC>6DJ0RP6S2(P+,5D ZA3\F/?&?PKNO@C#;OX1NK_(EO;F\<W,SMO<D8P"<
M]#G!+?>)SS@<KX'\'^+;5]5T&^T<6]A?XCN[J28 HA&3L )#$CIQP>I[5)X<
M_P"$Q^%]S>Z<OARZU:PNK@_9FC<*"5.W>0H<KN&S[V,8^M !I,26W[1MW%!]
MEABW.3&T:_-F($A.#AL\Y&#@-SR0=?XTZ5)9+IGBS34:.^L9U#S*JD*,Y1FR
M.<-M SD<]*R-,T#QG<?%P^(W\-K:MN\UXY[M?*4-&R#+J&)Z'[JG'&< YKV7
M5=)@UK1[G3KY/W-S$8Y G)7(QE21U'8XH X/5=<C\?67AW2K"X$,6JYN;V-)
M")(XD^\@.,-\V5((YQ6S\3(8X/ACK,42*D:0(J(HP%4.N  .U<[\'/"-]HEK
M?7FL6<T%X)#;PI*P(5 ?FV]<9;=SG!ZCUKJ/B)::AJ?A"]TG3=-N+RXO$V*8
MWC58\,IRQ9@>>>@/2@#EO!6C2:]\$IM,MYF@FN4D"/$0A+<$ D*.#C:V=Q()
MY].5T_QKJOA;3/\ A$O&NAN^E&'[-O4%'$1XQD'#?+TY!]ZWK#2O$EE\)K[P
M]=:/J-G?J5^SS6KQR;R94VCB7*DG.3PH7)]C-KVI:WK_ (/D\/:KX*O9=<"(
M@D79]G1R0%D63<>>^.<=SCF@#3\767A&7X;Z9'J&K7?]DVT42VLMK-^\F"J%
M V_=8X'<<>U<7\2-1U6_^'.EI_8_V'1X;B..&2XFW33 1GRVV@ !2NXGKSCI
MCG4\3_#;7+7P!X=T[3EAU&ZTJ226=%XW%SN.W=C< <CG!(QQV%;Q6/''CGP5
M:H/"J65K;R+*Z>;^]E(5ERD9 VJ,$;3R=RXS@T ;?B]I&^ (,NTN8;?)5W8?
MZU.[G<?Q-:?PU\/:+<_#VQ,^D6,C7$>9F> $R<Y&XDL3SSU&.P'2L^70_%OB
M#X3WFD7FFVUG<B*$6MN9B7?8P=LGD M@  G@]<56\(^(?$'A70$\-7WA+5)M
M5ARMLT,:&!]W*AY =JXZ$\^] &-\*A+IOQ6\0:59*8].5IT:/!8 1R$1C<<G
M@$]^?>K>C@']H[5"<<*Q&0#_ ,LTZ94D?@5/OC(/8^ O"-YX=M]2UC4L2:SJ
MSFXN;>$C9&<E@@)ZMECSG';) W'E+/1O%-K\6KGQ5_PC-XVGSY5HS- )0I0#
M@"7;G<!U)&/?% ">*7O]0^.VE6,-[:P?98EDMC<P+(BMM+$8."22  <Y'8@U
MJ>(OAOXF\46]G'JWB^"3[(69)%L!&2Q/WCM8#@8'&!QZ\TGQ*\":MJ]_8^)/
M#B!=6MBNZ(D!V((*L"3MROI]>O0Y>FZ_\1?&MM/HTNCP:>CC]_=7$4L"^6?X
M5ZG<>>1G\.M 'KFEPM;Z39P/<FY>.!$:<G/FD*!N[]>OXUR/Q=_Y)CK/_;#_
M -'QUVEM;Q6EK%;0($AA01QH/X5 P!^58/CK1IM?\%ZIIMO#YT\T0,49E\O<
MRL&'S8/<=^#TR,Y !SGP:ROPT@(/2:8^O\5<Q\#+QM0U?Q%=W+/)?W#++-+D
M!7W,Q.% X.23QQR.*W/A7:>*=+T^+1;_ $1+.PMY)C-<33 M*23A449Z'^+.
M".E8]OH&L?##QO=ZI8Z;<ZAX<NR0T5BH:2($DJNP\G;R,YP1@D@\4 0?&P/H
M?BKP[XBLY9%O=KIC=A0(V4CI@\^8P//3BO9[*5KFQMYV"AY(E<@=,D UYOJ&
MBZC\1_$VB:G/ILVGZ!I^7\N^ CN)G8G.%!;Y08X^&V\$UZ>BA1M"X & /04
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M;H5F_FRC4$$4\C9P0J@MV ^\!^-5OBUX9UWQ2^FV>BZ'.\5@9 9#)"D;!E3
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M673X_%5@FG7-DMN(X=,0!5(Y((/4C(/;G@ \U4/A*7P=\*/$VF2ZL+\>4[J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4=J** /&?B-IOB#Q'XMTNXTS0+UX].D*^8Q""
M4^8N"I[#W/;)Z"O5])O9M1TV"\GL9[*21=WV>XQO0'ID#H<=NU7Z*  =****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJL6VA<X&1VZY/2LWQ!XN^)/A*\@UO6+:U73IRL1M5="BG);;PQ._:I^;E>:
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M/E.X$;<Y&*RO#7B+Q#\09[W5-+UBUTRULIF2WLC&)&ERHP9L'A<]".^X<XY
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M%9:G9WEX]LKOIBVQ$>T_-N0DY9P,<<<9QDXSN> ?&:^,]'DN7@%M=V\OE3P
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M@XKTN@#Q+XC^5_PNSPYYPCV?9H<^9MVY\V7&=W'TKL_B[M/PPU8'&[,.W/\
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MR.>Q[B@#S3QI9/I^K>!+/4E0206,23^8RLH(;!R6.W'UKU;XFX/PYUK<HSY
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M"L@!ZMC!)QP#GBLR_P#@[_:\%FFJ>*]9O9(B#)]HF\Q1D?-L#9VY('KP.<T
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MNM>@> S_ ,4)H(/7[!$<=_NBH]8\&6^O^%SHFKW]Q=_.KI=O'&)4((Z$+C.
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M*N&WLKG^(;LC/?GCVH \K\!;?^%V>*-VT-]HN-N=N?\ 6-G&>?R_&CXBE/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT8XI:* $VC&*,<=:6B@!-N:6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6-G+*  >21@L<@<$#L<@ [^FMGJ*P?"OBW3?&&G27FFM*OE/LDBE7:R-[_\
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MDBB9B^ 3P,<?=/7 ]ZX^#XSZ1>6%S-9Z9J,]S&Y$=M''N++V9B/N@]#UQ[T
M>EFN*\6?$K2O"&N6FFW\$[&:/S9)4&1&O(!Q_%D@CVJUX-\>:9XVBNC9++#+
M;.0T4F,E"3M;TY Z=CD<]:K^/O#DOB2S73[72K.2>ZC*OJ<V UJJNI&/E)8G
M+8 ('!YYH Z^WF6X@CG0G9(H=<^A&:EK&O\ 4K3PKX9:\OYB+:RA4.RKRQ&%
M  ]2<#\:YK5/B/-HMI-<:IX8U*UB:39:N71EFST+$$^7GTP: .^HIH/./UIU
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4+U(]ZXA-9^)850?"VF$@<G[:!_6I?!VE^)_^$CU37/$ZP1/.BPVUO'('$2
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MD+JU?>;><J&BC);.=W1<X)VG^][UZ1X:T74/#>@W-Q<J=4UN[<37)5E4NQP
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MY=WFF.L7VBVN9'D56QD%L<;">.<=O6O9/!.IZ!JOAZ&;P_'##;JH1X$4*T;
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MYM$9K74YB6Q=%1%F20Y(Z-@ ]1D;UQC<U>PCG.1Q2[: ,=Z #''>C;SFEHH
M3:,8-&T4M% "$9HVCW_&EI,T &*-ON:-W)XXI: $VX[FC%+10 @ '3CZ4;12
MT4 )BC:*6B@!,4;1FEHH 3:,T;1FEHH 3:*-HI:* $Q2XHHH 3'K1C%+10 4
MF*6B@!,<T!0!@=/2C/%&:  CIR>*-HX]J6B@!,8HQGK2T4 )@4;><TM(3@4
M&/<_G1MHW"D# F@!<>]&/K2TA/MF@!:3%&:-W.* %HQFBB@!,48I:* $Q1M
MZ<?2EHH 3:*,4M% "%0:-HSD]:6B@!,#THQQ2T4 )M%&T4M% "8_/UHV^Y_.
MEHH 3 HVC&,<>E+10 F*Y/Q\FIW?AB[TO3-->\DO89(V8.%$?'4COGTKK:0K
MF@#SWX7:?K^@:2=#U73#%%"SR)<_:"P.6(VA3TY!;C PP.,DFO0AR*-M+0 F
M*,>YI:* $VBC%+10 A4&C')]Z6B@!, =*-H]*6B@!-HHVBEHH 3 I-OK3J*
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MS",$].<Y/O77/XONO$_C&ZTS3]=MM*TJPD17G5E,EQ(74*%S_#N(4^N2#UH
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MTP7H#3ZA( 2JMN 1/1B1U]2M 'I&X4M>>6T?B72/''A_3I=9N-1T66.7]ZZ
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M?4'/J>^*[@=P!!'0UYWJGPATV?4I-3T34;O1KZ202%H?FC'J N1C) /4CVH
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M0K!/%SMSV*]QGG''UK!N?@QH][ID4-WJ6HSWR 9O)9=Q)P,C:>BY!.,]3U-
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MF(]N?7J#7H'A[P!<3^&[6U/BG43HEQ:[9+%4CRVY><2 L .>@S]:[O1M#L=
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M+9[JUN$ "%20I3GAN=I( S@<$<YM:W\,]*\0ZPFJ:AJ&J/<QG]T5E0",!BP
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M2=9DRV1SD;,?I0!Y]X2U*VTGXXZZFH,(#<W4ZQO(% R7)')4D9SQ@@>N:O\
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MA'&.<^S@<8KEM'\%)8:Q%K>HZG=:KJZ6YM_/F1%4+NS\J@<$>N3U/K74XXH
M\%^%8T2WU;5]!\2:78?;EF+HUZB.01PR#<#]>M>ESR>%=&\1:59V.B::VH74
M[(KVL$8:WVCYF8@97J!VZFJ/C'X4Z1XKNVOHYGT_4&QNFC0,K^[+QD^^1^-:
M'A/X>:9X3-S/;W-S<7UU&%FN9B"V[G++QQDDGDGMUH \U@_Y.9/_ %W?_P!)
MS4OQU1'\1>'TEBEE1D<-'"<.P++D*<'D]N#7=+\+]+7Q!_;W]J:O_:FXG[3Y
ML><E=O39CIQTJ?7OAQIOB34(KW4=2U5IH/\ 4[)D7RNA^7"9'2@#C_C_ /\
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M2*5+*<$9XX]* /%=1^'<&O6K^+_ ^H7=I=2&27[,[;7WYPRJP.4/WN"3G('
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!5/5=.M]7TJZTZZ#&"YC,<@4X.#UP:N44 <=X4^'.A>$KN2ZLXGENF+ 2S')
M12Q("^G! SWQFNQHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY-8,8X[L?/;3NN?+<'/UP>A]C2^)/%]AX6BM8)DEN[^Y(2WLK8;I9.V0/3-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+XWN=/-I:V5NEFKC<]T27W[#TV<8*D5Z-HXO%TR%+ZVCMYT4(4CF\Q< 8SG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(2
M0:6B@#F]4\>>&]&U7^S=0U.*"Y RZMGY. 1N],@\507XJ>#V2)O[8B'F2&/!
M!RN,_,WHO'7W%::>$-*;7=3U>\M;>\GOGCQYT(;RU2-5VC.1U4G.!UQVKQW^
MSK/_ (:+^P_9(/LGG8\CREV8^SY^[C% 'JMO\2_"-P[(FM6X82>6H;.7/J..
M1S2Z1\1= USQ&VA6,D[W:[^6BPAV]<&EU?P!HFI7NF7UO;0V-WI]W%<1R6\2
MJ'"N&*,!C((&,]NO/0^3:'J=EH_QWUJ^U"X2WMHIKLO(YZ=?S^@H ^A**Y+0
M?B1X;\1ZF=/L+MOM&"4$B[0^&(X]3@!OHP[Y WM6UK3]"T]K_5+I+:V5@I=N
M<D]  .2?I0!?HKBK;XJ>&9M433YY;FRED52C7<!C4EC@+D]#[GCWKM,__KH
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MEM+M;\K,6"PM*A1)R03\A_#'./;-=-J&I6>E6$U]?3I!;0J6DD8\ ?U^@YH
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ME!'Y9WRG!(VCT." 3CGKBHM?\;> YK&UEU*ZMKX86YMX5C,CDCIQC@^S8]Z
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M@8EY%W%B,#."1C/91Z5YSX"\;'POX4\4:?<3>?+I!+VB["2V7\O)&<;0YCR
M0<,>M 'I^N^/M"T"Z-I<32SW2GYX+6,R.@[%@.@K:TS5[#6K-;S3;J*YMV)
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M&;' 'U.?:@#H**P]"\6Z1XDO+VVTN=YFL@AF8QE I8L-OS8.1L.>.XK<)Q0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\&/_)S'_;?_P!MZ]SN[D6EK).T<L@09*1(78_0#K7AMQ9:VGQF_P"$
MHA\.ZK+I_GJ<_9F5L>5L)P?2@#W?.:^?_#EC:W_[0.IQ7<"31K=W4@5QD;@2
M0:]VCOE?3?MWD7"KY9D\IHB)>.VWKGVKQ?P[IVKV'Q@OO$-QH6JKIT\UPR/]
ME8G#YVY';K0 GQ!C@T+XRZ#=6(MK)Y(HG=S&2A;>Z9(4=< #CVK2\>R:AJOQ
M>\/:+ MJ\<,7VF..Y!\MF.XG=C/:,8XX-5?B+9:[JGQ$TO5='TG53%8HD3S)
M;L.5E8MM/<$'J.N:T/B7X6U+6Y=+\7>'[6<ZA:E0]O)&1*0&RAV'T.<CN&]J
M '>*_ /C+Q?96T%]=Z#&89"YEA5PS=@/N] *]+TBWN[31[*"_G%Q>1PHL\H.
M0[@#<<X'>O)=/^(WC#Q=;W6BZ=H20ZD\;+]I#M&(5VD%LGHP.,5[!86,.FZ=
M;6-LI6"WC6*,,V2% P.3UH \*UJ9=)_:*CO+X20V[SQ,CLAPX:$(",#D;@1D
M=P?2O?0>/ZUYQ\4/ $WB5(M;TJ1TUBRC"HH;_6("6 'HP))!]_I6=H'Q2N=)
M@CTWQGIE]:WT<8;S_()\P=!E1SD\\^U 'JYY->*:_?\ V_\ :"T^QOF8VUF8
MDMT5 02R!_FR?5CSUZ5UYO=2\?1&UM[*:PT%V0R7$Y:.2ZCW D(!R%9<@YKG
MOB/X4U6T\767C30;5[B6(H;B-%WN"HP& /;: /PH VOC'I$.H> ;J\)"2V4L
M<P8)EF&=FW/4#Y\_A7)WVKR>(/V>Y[V\C5[FUDCMQ*W+,%E3G..,@XK;\0^*
M#\0_"4^B^&+"YGNK@QK<^=$T<<"\MRYXSN3'OS3_ !7X;?2OA,/"NE:==W5W
M*L;$V\&X,XD1F+$<9X_'% $/PK\)Z#J_P[LY]0TNWN93/*Q9UY)#$#]!BN<O
MM(T_4/V@[JPN8T%DPB+0AE59/W"';@D9'? R>.E=]\)H;O3?!\.DZAI]Y:74
M+2.WGPE5(9R1@GK7GNO:G<:3^T--<6T4\Q+PH\%N/GD4P)E<=_7'M0!?^-/A
M33-)TK3]:TV".SF^U"!UB7;ORA*MGL5\O _WJR?B)X@N=3\+^#HM0E*VUW +
MBY\A06)!"\ G!X/0GK73>,K]_B9+IN@:%9W;6T-Z)+^>2!H_L^ 5 YXY!?CU
M45?^)WP\.K>&;(Z+;J;G2T*1P+QOBQRJCIGO^E ':^)]%M]8\+WVGL$C5K=E
M1A&#Y?'\(_"O*OA5JSZCX!\1:-=QK+%I\+2P-)@[0Z/\H';!4MG_ &C7267Q
M%FU'P^^F'3KZ7Q.L#12VIMFVF4#:Q)' &>?:E\+^$Y?!/PZOH+FRFGU:_619
M5MHO-8$J51<K_".OL6- '(_!+P_I.N6>O#4["&Z ,* 2C/RY9L?FJG\*Z?QC
MH7AS0O$&@ZDU[<0S617[%I%I!YK3E3D*BCD9(QD\9[U3^"^FZIX=?4K35M(U
M"U>\:,QO);L$&U7SEN@ZBJGCR#4?#WQ3MO%LFBMJ&F1I& 0NX*P&W/LP/2@#
M)\9:K?W7Q2\/:A)I,FEEHHF@6XF2&1E)/+G)"')(P>>,<5H_M HJ'P\54 LU
MR6('4_NNO^>U4?&,WB?5/&6C>(?^$7OH(80D<$0R)&PS<$K]TDYQCMCUK8^+
M&C:UXC\*:-J;:3,MW;F9IH(3N$,;X(W#KG"+GL#GVH [?7[2V/PQU$_9XLKH
M\A7]V."(6P?K7"?#K49=+^#NN7]JT9N+<2NN=IPP'&0&S^8'X]:Z9]7U;5?A
MYJ<,WAZ_M_/L6M+2)8R\LC&)AN8#[JYQ@^]8_P --(O1X1O_  QKVCZC:K<[
MP&D1PA4CGGHISZ=: +/P+2"3P;>R@O)/)>N+AI%')VKP#DY&"#SW)^IYS6Y7
M\&?'BUFLCF+4A$LL*@(H60[,<=@55OK4_@V_OOA5?:AHWB.VN/[-FE\RVNH(
M"Z.X W$8YY&WCL0:W;/P_=>+_B;'XJOM/:'1[2$+9B9-K3,,%69&YQ\[$'U4
M4 <=XZT^TF^.>EV4EO$;::6U22(+A65F 8''J*U_CKI]E96^BWEO;1P3^<R&
M2) #M !'Y$FH/$^G:OJ/Q=T[7[;0]4?3[>:W,C_96SA&&X@=ZU/B[:ZKXEM-
M*BT?2-3EE@<S,PMF 7<H(Y]1W'8T >H:)/\ := TZ<R22F6UB?S)  S94')Q
MQDUR?Q?AB?X::M*T:F1/)VMMRR_OH\X[UT?A>[FNO#MG]J@NX;F&&.*<7491
MRX1=QYZC)Z_6N?\ BI'=7_@F]TFQL+R[NKKRS&+>$N!ME1CN(Z< T 0?#NWD
MO/A/;6UK=?9YI('C6:(JQC8]^&/(]\'U KSWPWXWO/ NG_\ "(^*]#N$M!YJ
MJX3#[68Y(!X==VX[@2/3-=CX8EU*S^%5YIUW;:CI-]:6<NV9XG^08.TJ?4=<
M#I6=/XF2_P# S:%XN\/ZBVK1VPVQM"Q,H7Y5EW?PG/7WS0!Z%X-M-/L/"5A;
MZ3>?;+ *S03#G<K,6P?<9P?<<XKG/BMHVC:GH-M-K>NR:9;6\V053S [$$8"
MCDGGMVS5OX5^&[[PQX-%KJ.!<3SM<&,?\LPRJ I]_ES^-<U\9=%U*XO=$UFT
MTP:A::>6>YB*[E(!#?./[N%()]Z .;^+&M7FL:7HMPV@W>G6PF8)+>A8Y78<
M8VY) [Y.*Z?XL2//\(].FE(,DDEL[D2B09*$GYQPWU'!ZUSGQ"U/7_&F@:=?
MVOAB\MM.MF,V]QEFRO4 ?PX[^M=7X@T[6O%_PJGBO-*N;2]MVC>UM=Q>:38H
M4[L\Y+%SZD8/>@#3T0$?!/#K A_LF?B!@4^Z_0@D9]>>N:Q_@;'YG@VZ21"4
M:<C#*=K<<CE<'\"??%8/A_Q/K4WPZNO#>F>'Y7FT^TE2]GN6VHJ'?G:.N_G@
M>QK6^"4&LV&E3PW.D/'9W#B2.Z8!"1@]CRXSQ[9H P/@+#'-JNM)-&KH(8R
MZY (8^M,U6TM[_\ :/-O=1++"\\>Y'&0<6ZD?J :D\"6FO\ @GQ3J]E#X<O;
MB2=52%GQM5%<@,S#@CW%6)M/U=_C6/$XT+5?[,$JMO\ LC;L"$*?EZ]: %^,
MEO;:-XI\,7]E';VDX=G:;RSM&QD(+!1R!DG@9J7XUZG(UYX?TZXF86$H^T3&
M%<LQR!P"0#QV-3?%RRUKQ!JNCRZ'I&IR26.YC*MNPVL2C*5/J,'Z&M'XD>%+
MOQEX<L]6TVTN1J5DI!@GC9))%[@*>^>?>@#N/%FBV^K^$K^P8)&OV=A&PC!\
MO SP.W3%>6_"_59-5^''B72;N-98]-@:2!I/FVATD. ,<8*DY_VC71VOQ%EU
M3PY)I0TV]E\4"W:&:V-LP4RCY7)(X SD^W2CPYX4D\%_#:_M9K*:?5=021)5
MMHO-;<5947*_PCK[%C0!RGP2\/Z5K>FZX-2L8;G#Q(/,7. <MC\U!_"M#XUZ
M78Z7H&@PV-G%!&EP458H^<!>!ZFK?P7TW5/#PU&SU72;^U>[D1HWDMV"856S
MEN@J7XRV&I:_;:?8Z7I-]=R6TQDD:.!BF"O9N] ';P:%8:SIFA7%]9MYME&D
MD22Q[&C8H 593G'N.>1[5Y7XIU%/B1XMM?!F@VR06%M.TEQ=K#RK*"K-@#Y5
M_AYZL5]JWO$NK>('\!6&C>'] UB"[,$<,^+=@(E5 "H8\G/3/M[TG@)9/!7A
MYK<^&]9N+^:4O/(MF5W#9E1G'0-\H!_O$]* (/BO%_PBGPST[0]-.RU>989"
M1\S*H+9S[D#/M6G?^$?&%_X;DT+=X<ALV@2%%1),Q8&&(^7O^GO3-8\.:GX_
M\!W8N[6>SU(7LEQ9P7C$&, \*?8C(';FN7\/_$7Q9H,5IX8N_#AFO((E@@5T
M97Z80$>F,<]30!=UVTU_X=?!^33I=1AEFEOO*22+)$<+J25&0,'<&_[ZKNO
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M[/,UM;RL1)&K.2=P_(#Z4 <M\+3_ ,7E\0''\%T/_(ZUT7Q\Y\(:=CG%^/\
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MI7E*"T8[@Q &WU/?'I6'\,-/U30_%>L7.H:'J5M!?8$!-I@+\Q/.T848].*
M*5]:K8?M&V8@BF@28HVTQ[$8>5@E,?>7Y>O]X,.U6$OO[3_:-2&^=B+3?%:H
MJ@KD1,W.3QU)R.X'U!J-KJ5S\8[/Q)#X?U4:=#M\R3[$0S$(1G &3U YYX]
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M*AE#8/TS5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_10 S#=12@>U.HH ;BC!IU% #>>^:3!Q[T^B@!N#1C%.HH :%.,48)^M.HH
M: :-O.:=10 S;TX!I<$$\4ZB@!N#CWHQ3LT4 (!CH*0Y["G9HH :H(SFE/2E
MHH : :,4ZC- #<'I_*C'/2G44 %-(IU% #<&C!_^N*=10 W;1MIU% #<$_6C
M!%.HH : <T[M110 W!)'%!!/':G49H ;BC!QS3J* &D&E'2EHH 0YR/3O28-
M.HH ;C%&/R^E.HH ;MHP33J* &D'M1@YIU%  *0CD<4M% #0N!THP<<"G44
M- ]>17->)M U+Q+"VF&\CL]+9D\YHPQFF4<L <A5';!#9_2NGS10!%##'!%'
M##&L<48"HB !54#   [8J6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:A\PN[2[40R!B"NX<_C\HH ]&U+4+32-.GO[^=(+6!=TDCG  _Q/3'K7"_\
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MIL-TV(S+RX4[0OL?FWY]BOOGM_$WB2Q\+:-)J-\6(!"11*/FE<]%7W./R!H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M';>(]#N]*N\B*=<;P 2C=B* ,GX<R+-\/=%=(8X5,& D>=H^8^I)]^O>O,O
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M<C(5@,!6[[2/3IUYQB@#<U?1M-\0Z6UAJ5N)[-]K%"Q4<<CH0:\\^)4>D?\
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MSCY0.G.:]MSTYKS*_P#"WB'QUKFE7/B+3;;2+&R!D,<,ZS3.^XC;N' & #W
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M_P L^C'@'W[56^+4H%UX)ANKRYMK1CNF=9<M'@Q@ON'!=06^;'<X'-=!\1?
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M%% !1110 4444 %%%% !BFE%+;B!G&,^U.I,T +28'I1G\Z6@ Q1BBB@! H
MQBC%!.!FC/.* # HP*6B@!,"C:/2EHH ,4=*** .#^)7A_7?%>GKI&GPVJVA
M*2M/))A]X+< >F,?G6IX%T_6M)T&/3=7@LXA:JL<!MC]\8R2PZ#DXXZD$]Q7
M3GKBD!Q0 N!C%! /6@F@&@ Q2TF><4M !1110 A4'J*6BB@ Q28HSS0"2.:
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M+#&>!GUZ9H ]AW"C/M7@WB'5_%D7Q>M]$@UXM*'C2)FCV1#>@SE!FMUHM?\
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ML+&68 ;1O&  .E8'ACPIK^O?"VWNH?$3V5O )9+6TB4A25=B2[=<[MW3/&*
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MD3W4LY'T,C$CZ"K%U:I=VLEO*9 D@VL8Y6C;\&4@C\#0!XI>/L_:1MGD:W"
M\&/ ('DM]_'\77KSC'M7LNH:MI^F6C75]>P6\"$;I)'  R0/ZBN:N?A7X.O;
MA[B[TJ6>=SEY9;ZX9FXQR3)D\<?A3KCX6^$+L 7.F33;22OF7UPV"<9/,G?
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MJ1]S:4+QQ;DX[@?,>0#][J!781:38VVFMI]K;):VK*5,=M^ZQGK@K@@^XYH
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MCL N%([\@T =CILT]SI=I/<P^1<20(\L6/N,5!*_@>*Y;XG^&Y?$W@FZM[6
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M,ER-[%I@R[3N;.[H3T(QGC%5O#WP_P##GA>YFNM,L2EQ)N'FO(SLBD_=4DG
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M&6-%0,Q8A5 Y)R3]2:EK-TW7M(UB1X],U2SO&C&7%O.LA4>IP>* -(=****
M"BBB@ HHHH **0]*S;[7M(TVZCM+[5+2UN)5!CBFF5&8$X& 3D\@B@#3HIH-
M.H **** "BJ6I:KIVD0+/J5];VD3-L5YY0@+8S@$GK@'\JGM;F"\M8[FVFCF
MAE4,DD;;E8'N#W% $U%%% !2'D4M% '.:_X(T'Q/=P76JV(FG@ 56W$90$G:
M<'IEB?6MNTM(+&UBM;:%8H(E")&HP% JQ10 4444 %%%% !14-S<0VEM)<7$
MJ10Q*6>21@%4#J23T%9UAXET+5;H6^G:Q874Y!;RX+A'; ZG - &O12"@^U
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M<PQ7$$BRPRH'21#D,I&001V(J:@ HHHH **** "BBB@ HHHH **** "BBB@
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M,SW'S"UN-K;]O.2#QQC->2? %8OMNLL$D\WRT!;C9MR>/7.:Z[PAX"TB[\#
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M_8NDSF.$0DB>Z'JS=1&>N  ><9[UZAINEV&CV:VFG6D-M N/DB4#)  R?4X
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M@?#7X5PVFD)Y-[<E+5[N,JLFXAF9BP7YN R@\$;L]16EX>^'^@ZE\.K&RO\
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M"BF_8[;.?L\7_? H \1^.NKZ==C2[2VNX9[B-F=UB<-L&.^&X// (Y]>QO\
MQ4M+J[@T?QEX?N1=QZ>-CR6C+(L8!SOR">_!X..]>PFUMR<F&,D]RHIPAC$9
MC"*$/5<<?E0!Y9%\<=%N=/B6&QO?[3F_=K %4JKD#!W%@"NXXSUX/ XK'^*]
MQ<Q_#72-/UF]MI-<6]2:XBCD!8 I+SCKM&0N>G'6O7+/P_H^GW-Q<V>FVT$U
MPV^9TC +G).3^)-7G@AD;<\2,>F64&@#RZSUG2A\"7MSJ5F)AI,D'EF==WF&
M-L)C/WO;K5/X+W<$G@R^TW^T+:2[D>0Q6FX+(B[>X.,\\Y&<9YQTKUO[+;XQ
MY$>.N-HI4MX8VW)$BMZA0#0!X!\(=;M?"NL:WINI+-_:%Q+#;Q6T,9D9W5G5
ML$#&%SDDGH.*^@QTJ!+"T2\>[2VB6X=0C2A1N(!) S]6;\S5CI0!XA\5=.O/
M#_CS3?&D5N]S9QO$91P%1T(P">2 ?7%=)X^\9Z'J7@J:PTN\74;S58O+MK>T
M'F2<X.60<KQV(!]N#7I,D:2H4D174]0PR*S-+\-:)HLCR:9I=K:.X 9HHPI.
M.E ',>!["Q\ > (/[6NX[4RDW,[3/M =E^Z 0#G:H^7DY!KB_@[XDT:QNO$4
M=YJ=M;&XN!-";A_+5T!;)!; S\PXZU[:\4<B[716'H1FF?9+;_GWB_[X% #L
MYZ'D]*X+QAXPL=%\8Z?H^M-:OH][:DR1O"6>-RQ4.Q/ 0\CC)!!X YKT#:*K
M7NFV6I6[V][:Q7$+KM9)%!!'I0!X=J.BZ;I7Q/\ #LW@;4H)#>RD36]I<(ZQ
M(F"_.>C)NX/]WC)J7XEQIHOQ?T'6[V9$L7D@D9@&8HL;C<2 /Q &<U[-INAZ
M7H\'DZ=I]O:Q[B^V*,*,GO\ H*DU'2M/U>U:VU&SANH&QE)4# X.: /"OBUX
MQT_Q';:4=+@O);.&=F2\>$QQ3' R$+<D@C!R/SK:\?6MSXI\!Z%K^C1W?GZ4
M SQ-;LC*&1"7&X+N"E1RH(.21P#7JS:#I+16<3:?;F.R(-LI08BP,?+Z5?V+
MMV[1MQC&.* /*--^-FDR:!$'M;J;6C%L6U1-WG2@JJ@,./FW9]>#QG ,7Q$N
MKN+X2M;Z[>P#6;N2.<VS,JLH+@E%4$DA>F1FO2+'PQH>FWKWEEI5I!<R AI8
MX@&()!//U K2>"*0@R1HY'3<H- 'E_PZUG2K?X01PSZE9Q2QQSB1)+A0R%G?
M:""<@GMZUA? /4+"#^V+222.*]F:$H))@#, 'X5.IV\DD9ZCIBO:Q:VX7:(8
M\'J-HYI5MH$8,L,:L.A"@&@"CK]E)JOAW5--A=%FNK26!"^=H9D*@G';)KQ3
MX;^-[;P/<:AX;\2YM5BF;]\J^8(G'#*VP$GGN,U[[@5G77A_2+V_AOKK3K::
MZAYCF>,%EYSP: /!QXHL;OX\+K6GW$DVGSO&N^*W=V<"%58!-N[[R]AGCTK5
M^-VK6;ZKX;D@G29[9I'EA1@)(\F-@&4@E"0.X_"O;$TZSCNVNDM8EN&0(9 @
M!*@D@9_$_G4C6T#L6>&-F/4E02: *>G7=EJ^DQR6\L%U;N@5MCK(N<<J<<<=
MQ7ANE^&[RS^(=[X"BNQ_8TMPMW*F\[C& & SCEBI /&.*^@4C2,81%4>@&!4
M7V.V^V&\\B/[24$9EV_-M!SC/I0 V>>UT^U:6>6&VM8E +R,$1!VY/ KP[X1
M:S96OCS78)[F&,7>XPR/,JK(?- 55S]XG=Q@]NAZCWAD5UVL 1W!Z&HUM;=6
M#+!&&'0A!0!\_>%]9E^%GCV_TO7T'V:X/SRQ#?L!.5D  R1CMU]LU#\1?%^E
MZYX\T34]"O?M$=O$B-((7&&\QCC#+SP>PKWS4]!TG651=2T^WN@AW+YL8;!J
M<Z;8M/'.;2$RQ9"/L&5SUQ^0H \>^*$=]::UHGC_ $E+E[>!1%,&A:(QA6.-
MP8;E#;G7)7 P/[PK7/QJTS4+2*UTFQO9-9O 8;>)XUV).<"/<2P&TL1WZ#G%
M>I,BNI5E# ]01FL_3_#^D:4\KV&FVUNTK!W,<8!9AT)H \;^,<TD?A3P_INH
M:A;W&L6[?Z6$D!;=L&6*]0">^!71:WK.ER? M($U&S:5M,AA$8G7<9%1-R 9
MSN'<=:]/:V@=BS0QLQ[E0:/LMOM"^1'@<XVB@#Q3PA:MXD^"VH^'+'4;*?59
M&,D=L7V.BJZ-@@@'MC=RN6 SZ-^&7Q-TO0=&?0_$,K6;6SMY4WE%U89^Z0@)
M!'KSGUKVY+>&-MR1(I]0H%46\/:.VJ#4VTVU-\%VB<QC?C&.OT)H \+\$>(K
M5?C)JU]#)-+87LMPZM#:R2,P+$J=H4L.OH,=ZZ^'Q)X9\5ZIK?A_Q=+IQFM;
MMUMKAE,*>4.  [X.]26SV/!&1S7I\-A:6\\L\-M%'+*07=5 +$ #G\ *IZGX
M;T76?+_M+2[6Z\LDIYL8.,]?Y"@#ROX5VLFB>+_$UO8WSWOAZSBSYL1$@9\@
MJ5522QVAQ\N<X]2*ZOPE\4])\5ZR^DQVUS;767,/F+\LBK].AQS@X^IKMX;:
M&V18X(DC10 %10  .E<)X:\,M)XI&O2:0FE6=O 8[&T&U75G^^S!?7G@\T =
M_P#C7A>NZQ8V'QSEG\5M<_V;;1C[&'C+1KE!SMP=RYWC(!^;'H<>Z*!CVJI?
MZ1IVJ",7UE#<"*02IYB [6'0CW&30!X!KWC#2Y?C!I>OQ+.NEQ>2!*\31[HP
M2"ZJ5)*@$\8R<8&*=\7M9M-9U[0KJW<#%L#+"Y D@8OG;(,_(P[@U] 2Z=93
M2122VL+O"<QED!V'!''X$C\:E:UMV)+0QDGN5&: /*_C-J^F7W@.&.TU&SN'
MEN8Y(UBF5RZC<I88/(!!&1W!K+UBPD\4_!#3H--U"SO[O2RMU<I&X5E0+(,8
M(&" >X&=IQGC/L_V6W/6",@< %1Q3EMX4!"1(H/!PH&: /)? OQ=T"'PU;V>
MNW36=W;*(\^2[+*!_$-BG'N#C\:Y_P"!.JBVU74K.3S2DZH8Q' S@-D@[F4$
M*/=B!7M<'A[1[6^FO8--M8[F?_6RK& S]^:MVUC:V:NMM;QPAW9VV*!EF))/
MXDDT 2D^]>"6VK7?PD^(6I+J5O=3Z3J&Z16C"CS.<AE!."025()& V?2O?<"
MJNH:98ZK:/:W]I#<P/C='*H8'!!_F!^5 '!67C\^--?M=.\+B6."UG6:_N;A
M0BM #T49W98\<KW[5Q=CX@TK2_B_X@N_&,EPICFEBM#-"71$#';\H4G!7:5(
M&._>O<[/3[/3[=+>SMHH(8U"JD:@  =JCN]'TZ^N8+FZLH)IK=BT3N@)0^HH
M \ MO%]C;?&NZUUX+L6D_P L:F(B1@8U"D)@D[BHP./O YZBM;Q!=ZA\/OB@
MGBIK:Z?2=4 :8; .&',9Y/S+@, <9(],FO;6T^S>ZCNFMHC/&I5)"@W*#C(!
M_P" K^0INH:98ZK9M9W]K%<V[$$QRKN4D'(X^M ' -\1/^$MO;?1O!ZW#2RR
M$75ZT6!:Q X+X.,DCD#^O%<-\7+^SN?B7HSP7=O*MO%$DS)(K"-EF;<&P>"/
M0U[MIVDZ?I%J+;3K.&U@!)"1(%'/)J<VEN6+&",DG))4<T >2_&_5M,OO!EA
M%::A:3RM?),J13*Q*;)!N !^[GC/3-=K\/+^PN_!.EI8R1XAMT5XEF$C1'T;
M'?\ "NE^R6YZP1G' RHZ4](8XP?+C5,]=HQ0!S'C[7[CPUX5EU*WDMT>.1!B
M9&<.I/*@#N1TSQZFO-?'EOX'\0>%&\2Z-?6=IJB!91 DBI+(>%*-'G((QV]"
M>0<U[B\22*5=0P/8C-9=KX7T*QOY+ZUTFSBNI-V^5(@&;)R<_4T >.?$6\F_
MX5-X<LM4NXVU@2QS2PF56EV%),,0#G&,<UTT>LZ7_P *)-O_ &E9^=_9)@\O
M[0N[S/+.$QG.[VZUZ>UM V-T,9P,#*@XH^RP8QY,>,YQM% 'A/P_U18/A-XA
MMM,F,>L!I)$C20-+)\J_.J=< <=^A.:;X-\6^&-,^'6H6&+F37[F.??$+=GD
ME++]Y6 QL &3DC[K'TS[PMM ARL,:\8X4"JUOHVFVEW<75O8V\=Q<D&:18P"
M^!@9^@)H \8^#'BW3=+L;K2[US"[R^89G($4:;3EG8@!!G:O).2PP*I_ V]M
M+;Q-JB374,33Q*D*R.%,C;^ H/4_2O=X=.LK<2^3:PIYK%Y-J ;F/<_D*E6U
M@5@RPQAAT(49H \D^+^FZGI^LZ3XQTU97%BHBF\L#]T Q()]CN(Z<8]ZMCXV
MZ1>V,4%A8WC:O=9ABA*)M28@!-Q+ %2QQZ\'(%>ILBLI5@&4]0>16?8>'](T
MN6>6QTVVMY)V#2M'& 7(S@G\S^= ":'%?V^B6<6JS)+?K&//=#D%^^.E8GQ'
MT"Y\2^"KVQM QN%(EC10,NR\[>2.M=;@48% 'D_PJ\::38>#&TG5KNWTZZTJ
M21'CN)-C,I8MG!QSDLNT9/RCU%5? NE?\))\3M5\:B"XAT]"6LFF0H969=FX
M9&"N W?J5KTV_P#"^A:G>QWM[I-I/<Q@!)7B!9<'(Y^I)K45%10JJ%4= * /
M#_B'XGT5_B?X7NHM1AEM]/D1KF6(EUC'F ]5!SQZ9KV>PU*QU.)I+"]M[N-&
MVLT$JN ?0X/!J7[);Y_U$7_? J1(XXAB-%0'G"C% %75;&/4])NK&4J$N(FB
M)9=V,C&<'TZ_A7A?AG5+SX/^+)](UZW)TR^8'[7&I/"\!QCJ!GE>HSTZ _0%
M075E:WL#P74$<T4B%&1U!!4C!'XT <]-\1/"4&G)?-KUFT,@4JJ,7D^;I^[
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MX)PH7(QP<UZGI?AG1-$D>33-+M;1Y,;VBC"DXZ?S-:+P12??C5O]X9H \O\
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M<5Z0;2W)R8(\_P"X*5K:!@ T,9P,#*C@4 >>^$M?TA?A-#&VK6*O#9-'(IG
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M>0QQ*3@RNQ7N.5!1SS@@M7NQ4'K4,-G;6\L\L,$<;SOOE95P7; &3Z\ #\*
M.*^+/AR[\2>"7CL5>2YM)EN4A0#,H *L!DC^%R>Y., <UF?#SQ]H<'@*WAU.
M_MK&?3(_)DAE<AR%Z$*1EB1V4'TKT[ K*G\+Z%<ZDFI3Z39R7J$%9VB!8$=.
M: /-OA?H<FH^+=;\9S6]Q;P75Q*UDDRE&9)&W[L=",$8(/K7+^&=3M_!GQ?U
MZ36O,B9Q.L<<:&5I'=U=% 7/++C&?QQ7T,%"J%   X ':H'L+26[2[>VB:XC
M5E20J"R@XR ??:OY"@#PW6K[4O GQ*A\72V%ZNF:H,SQ.$# ,.8S@D;A@,!D
M9Q]<=1+\3T\7/%H?A".X35+E583W"*L<*=7R<YRHST!YZ9KTRZM+>]MY+>ZA
M2:&12KHZY# C!'Y5!IVD:=I%NMOIUE!:Q*20D2!0,]: +8QG'>G4F!2T %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%(3SB@!:*3/%&[\Z %HI
M<TM !5.72=.GE>66PM9)'.YW>%26.%&22.3A$'_ 5]!5PG I-WM0 8I:\_\
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MUK.:RO[<>9Y,@Y*#"L?8ACC!]1[X[FO$M)\P?M':B(OM&PAA((B N/+4_/\
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M_%[AIC*! OEHI"C.3A !SQZUV=% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%(3@52N]8T^P5S>7MO#LQN#R
M#(SC''XB@"]15"/6M-FN9+:*_MGFC0.RB0$@'.#_ ..G\JB/B31@A?\ M.UV
MB40$^8/OD@8_,B@#4HJ**XBFC$D4B2(> RG(/XBI>HH **** "BBB@ HHHH
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M* +U%4=+UBPUJR%YIMU'<VQ8KYB'C(ZBKU !1110 44R25(HV>1E5%&69C@
M5S]OX]\+W=Q#!!K=H\DQQ&-Q&[Z9% '1T5#)=P11"62:)(VQM=G !_&J#>)-
M&"._]IVF$F6 GS1PY( 'YL/SH U:*J)J=E(X1+RW=V. JRJ2?UJSNH =16/>
M^*=%TW5(=-O=2@@O9MOEPN3N;<2!CZD8K8H **** "BBB@ HI"<'%)N&: '4
M4@.3BEH **** "BBB@ HHHH **** "BBB@ HK'G\4Z):ZRFCSZE!'J,A4+;D
MG<2W3\ZU\GTH 6BLS5O$.DZ%$LFJ7\%JK,%7S&Y).>W7L?RJU97]OJ-E#>6D
MJS6\R[XY$Z,/6@"S1110 4444 %%%% !1110 4444 %%%0SW4-K"TMQ*D4:]
M6<X% $U%9.C^)M&\0-,NDZA#=F$ R>6<[<YQ_(_E6L.10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 $9%<'\4]$TR?P-J]])86YNXHUD6<1@
M.&! !W#D\<8-=X3BN2^)A!^&^MX(_P!1_P"S"@#G_@[HFFGP+!=/80/<22R%
MI)$#,00%(!*@@8XQEAR>><#D=;T#2XOCW86,=C$MH[0S/"HPA;J>-K#&1R,
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MTC8S@9.!U)]AS7@_Q!US2KWQ1X9U70+:6W4-N%\UL8(Y@'7 4OM#;><G./F
M)]-[XZ6=M_PC^EZ@(U^TRW 1Y,]5V'L#C\J /3;SQ;X?L)[:&YU>TCDN2/*'
MF YR,@DC@ @@Y/%7KK5;"QL?MUU=PPVI7<)F<;6&,\'OQZ5Y%=^!=!'P735C
M9YU :<EU]H+$ON*@XS_=YQCT J[X EAU[X*WMK?+]I2S$\065!P0OF+@Y.<;
MNO'IC% &MX \>0^(]2UM[O4TC4W2)9VLI10J'(&QN"Y)&<$<<=<UZ+D"O"?@
M/I.GWLFJ7]S:Q2W5H\7V>5QDQ[@X./TKW8 $>M 'G'Q#^($&CW6FZ7I^I+%<
M2W(^U2P;9&@C!P05/&2<CD@C%=[;ZC97-L]U;WEO- A(:6.4,JX&3DC@8KP?
MXRZ=:0_$32O*MXT-U%&\^T8\P^85R??  KH/B]<+X;\,Z3X:T.&*QM;^63<4
MD$:@+M^4D\8)?))/\- 'HR^,_#;:@]B-;L?M"1^81YP"[>GWONY]LYK<!SCW
MKCKSP#H>M>#+?27M8;?;"IBG@4$QOC[P(^\.3WY!KE?@?XDFOK&]T*Y=Y7LV
M,L4K<Y1CT)SDG- 'KE9>J>(]&T1E74M1M[9VR0KO\V-K-G YQA3]3QUK3/2O
M)VLK+PK\2]0USQ)K%C=#4(A!;621-+<99EV?N0"0/D89'<^IH ]*TO6M.UNT
M6ZTV[ANH2 =T;=,],CJ/Q%7Z\)^&UXL?Q=U>"TMY+"TG$F+.90C*!R!M8@@C
M&> 3]!DCW:@#/O=<TS3KN"UO+^W@GG8+%&\@#-G../3@C/3BH[/Q%I&H:A+8
M6=_#/=1;M\<9R5VE0V>W5E_R#7AGQ9TJTA^*&E6T,9BCNX86E*,<EFGD!.3T
MKMO$?A31/A[H.L>*=&MY5U%+<0QDS';&9&6/>/<;L\]Z .WN_%N@6%Y]DNM6
MM(KC(!C:09!+;>?3D]^G7I6G;W=O>0+/;31S0MG;)&X93CW%>->&=)U&7P-&
MB^!HM3>^43O<7%[$/.8G(8DMN QSC'6K7@CPIXUT/PAX@TFXC%D98M]DXE60
MB0C#8V$XX [=30!Z._B_P]'JC:;)K%FETJ>8RM*  ,XY;H#GMG/M6E97]MJ-
ME'>6DJRVTHRDBYPPSBO!O!OBGPJ/#,_A+Q'8BQNI&D26\EBWYD)&"Q^\K ^N
M!\G)KI?'%S=^"/@_I^E6UPCRS%;0W,+[0$.YLCZ@8_&@#T&3QEX;BU".Q?6[
M$3R*74><"N!URW0?0G-:Q\B]M",K+;SIC*MD.K#L1V(-<3H'@K1M0^&VGZ9>
M6=L1-:HTDT+*Q\PC)=7&03GG()%<K\(M8ETSQ3K?@Z6:2XB@GE:WE8<CRVV-
MGG@8"X Z<T 5/#EE;V'[05_:VD"16\,16-$& H$:_P"RW\UZ_>_A;V"/7]'F
MG6"/5+%Y6;:L:W"%B>F ,YS7DND%1^T?J@8J"5;&2H_Y9KTR1G\ 3[8R15\2
M0I#^T#I*006JKOMF*RE47KR1DCYNX[DXP#0![//K6EVMP;>XU*SAG& 8Y)U5
MN>G!.:Q/'/BZT\*^'KN8SQ?;C'BWM_, =F;(! P>!@G)&.,5POQWBB2TT.41
MQJ[7+;GP!G '4_\ UZ=\8+*U?X:Z1?>5$UQ&\$<<JX.$,9) ()!!P#P2/0]Z
M .Y\#:]!K/AG3W;54O;YH-\V[8LN<\ED4G'8?E4?A73/"FF:EJ2>'9;=IW*-
M<1QR"39QV/7![\GGTK(^&OAS1W^'EC(UA%OOH0;E@"&DVN2,D<]A^5<E\#?W
M>HZ]ME^51Q%N3'7KC.[VZ8]\T >O:IK^DZ)"TNI:A!;!5WXD<;BOJ%ZG\!4F
MG:QIVK0^;I][!<KM5CY4@8J&Y&1U'X^E>1_"J<^+_%NO^(-5C@GD; ACDD60
MP*23M"]0H&!G'./7-5/B!8VWPY\:Z-XAT@O%'>RR/<6JCY/EVAL#('(D/!Z'
MZT >S:CK>F:0L;:C?06WF,%02. 6)(7@?4CGH.IXJK/XLT&VU1--GU:T2[<$
MB,R#C'4$] ?8D&O%/CA;V@O]%OK:$QM>P22N23DGY<9Y]ZV_B=X%T#1? (U"
MRM#'>0O$#/O)>3<0"7/<T >T;O:@FN6^'6HMJGP_T:ZDD9W\GRRSJ%)*,4]3
M_=Z]^IQTJ;QUK,WA_P %:IJ=M_KHHP$.[&UF8(&S[;L_A0!<U#Q7H&EW$5O>
MZM:0S22B%4,@)#GL<?=^IP*TK:[M[R 3VTT4T39P\;AE/XBO-?A/H5C?^!))
M]1M;:ZFOY9#.[%9&=3P Q!)!P3QP:YSPY*O@#XPS>&K>::;3;LK&BORR%QN7
MOT!/)[T :WQ<UZ)KSP]IUMJ4#VTMZ?ML*2J1\K)@/Z 9;@_TKI=5\%>$/&=Q
M93B:)UT_Y?+T^2,(RD@[7V@D#@XP1U-<1\6O#FCZ?KWAI[73X8GO[V3[45!_
M>Y:/.?\ OH_G7K^DZ%IFA6S6VEV4-K"S;F6,8R?4T )J.J:=H.GFXOKJ&U@C
M4X,C8S@=!W)QZ<UQ?P[\76_BW3+]M6O(7EN+V01V%P(_W<9P5C7O(,=R!SGC
MBMSXBV5M>> M:^T0I)Y5I)+'N&=KA201[YK@?@1I.GRZ/>ZI):1-?179BCG(
MRRKL4X'YT 8WPQFMK#XM^('EDBMK>..Y!9B$11YZ <]!V%>UZ1XDT?7E<Z7J
M$%T4)#*C888.#P><>_2O"? NA6'B#XMZW:ZE#YUNC7,IB)P'(E PP[CG/UQ6
MG/86WA#X]:9;:/;QQ6\X0-"TP1 ) RM@GK@<A>I( ')H ]PN[ZUL(&GNYXH(
M5ZR2N%7\S6?IWBK0M5<)8ZK:S2$J @D 8DJ&& >3P1TZ<CJ#7F7C6_O-<^+%
MAX>_LU]1L[*-9GLUG6,3';N+'=@<#MGFJ7BSPGXKUW5K/4M*\&V^FW,)61YX
M[R+=*VU1@@-C:"I ]1UQ0![B#FO/OB[I-O<> ]4NTM+9KQ/+;SV5 X4."<,>
M>F>,\]!7<V7GFQMS=@+=&-?.5>@?'S#CWS7)?%:,R?#C5@+66XVJC;8\Y7#
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M\+1Z8;6*V\J,>3+ HW1L!U]Q_.@#K]U8-[XU\-Z=<FWNM9M4F#HA4/NPS%@
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M!ZO_  UY=\0-3T&Y\!:5:Z5!]JNM/E2VEU*VMF6%'1 &42D ,6(!&,\#/<9
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MM^8C&#G.0<_0?AD?#SPSI.K_ !.UBPO EY9V\<TB(NX(Y$B@!@<$@;N_=0:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 AZ5Y]\6]9M[3P=>::)XC>72*%@()=E)Z@#_=ZGBO02,BD YZ<4 >9?
M";Q!I=KX,M]/NK^..[C:1C#(6#*H&XG#=@ 3QQU]ZXV^U^TN?CC:ZO\ :5&G
MQND7VF,.J;0,<D=1SSV]>*]_QBC'- '$>,/B-9^&]$MM2LH1J*7;M'$\;_(&
M7KG^5=AIUV-0TRTO51HQ<0I*$;JNY0<'\Z+NRMK^'R;NUAGBW!MDL8=<CH<'
MN*LT %%%% !1110 4444 %%%% !56^U*STRV-S?7,=O"&"EY#@9-6J:1STH
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M?3K5KEK?3[6)KK_CX,<*KYW7[^!\W4]?4U9MK6"SMTM[:"."",82.) JJ/0
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MR\ET8D+!/F3C/K\C<5Z[I6NZ9KD+2Z=>1W 0*7"'E<C@$=CP:OD$T8()ZXH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%!Z5RGCOQ7<^#]#.HP:5+>C>%9U8;(R2,%^X!Y&<=<#O0!U=%<
M]X.UR?Q'X:M=5N+9;=Y^1&H;&.WW@,_4<>E=#0 4444 %&:*R_$6H7&DZ#>Z
MA:6AN[BWB+I ,_/CMQS0!J45SW@[6=4U[P]'J6JZ:-/EF8F*(.3NCXPW/(SS
M^&#WK;%Q"+H6YE03E"XCW?,5! )QZ9(Y]Z )J*BN+B&W5#-*D8=PB[FQN8\
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MC:,$=U.XXZ CU% ':44@I: "BBB@ HHHH **BED2"-Y9'"QHI9F)P !U)-<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\;/$"V49BL()KE98X\*BC>0@VCMQQQQ0!T$?QEAFUN[L8]&N ;97'EN^))I
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M4T4_B7P\L.F.B![FTDWB)R<'=[>@ZUR/C>Z=?CSH"2J)XEEM0D4C-M1F?&X
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M=RZ^7/-PSISN8#Z&,@?[WMCG/C3_ ,E#T'_KA'_Z-:NI^.__ "(=M_V$(_\
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M$]I=1![>>W\N2/) *E>1D<BO%_@I<7G]D>);9B_V-8=Z_*-OF%2&YQUP!WH
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MCL^-DEFMM*>VMX6*.\DZE@V ?NXSCGK7G7@?Q8_@WPYXGT:^D$=[IY=[2"X
M*ESQL^7!)+$?XBJ/@J\/PP\87=CK;I#%<V$<LC2QD$2; X0$9'#,RD\CCM0!
MZC#X\=_$>K:7-HTT<.DIYEW=^<I1%*[EXQR2.WU]*QE^(^MZAH,_B'2?#\<N
MD6TV)2\W[TQK_K" /8@CTYS4_ARUL]/^'^KZWXGB4Q:M*][<I*N]EB; CC+9
MRV!C:>,;N@KG+.34M3^'&N/X?LK/0?#7V6=PCB2>XE(7+@%B JNH(S@XY^M
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MC/<_D*GO/#GB2Y^':>&/+TI9/LRV9F^TR8V*J@-CR^IP>.@]37=[11@9SWH
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M%QWYZ>]:$WA76O&FL:7JWB:"#3;6Q^==,27SR[[CDLP  R-O0GIVKT7%)M%
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M4 %%%(3B@!:*3/%&X4 +129YQ1F@!:*3=0&!Z4 +12;J-U "T4F[CGBC/M0
M$X(]Z <UR'Q(U#6-)\'WFI:1?16C6Z ON@\QVRZ@;3N 7&3G*MGVJ+X7:Q?Z
MWX,BO]4U!;VY>5\N%P5'&%(  R/;/7K0!VM%)FC/M0 M%)N%!;CUH 6BDS1G
MVH 6BDW4%@* %HI <T$XH 6BDW>U!8"@!:3/.*"V,UQFLV'C&Z\<V#Z;JJ6F
M@"-7N1L5B65N5P1GY@0 <\ ,?0$ [2F[N,\56U'4K/2;":^OIT@MH5+/(YX
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MXI,T +2$T9STKA_B'XON?#L.GZ9ID8_M75I?(MI9#B.'D N>I)^9<#'J>V"
M=ODTZO,]2TSXDZ1JMG-I&M1:O;RMLD@O(418,C&YBH!91UR,'IP:],H *0DB
MLK7/$>G>'H(9+^;89Y5ABC'+R,2!P/QY-<5\7M=\0>&](M;_ $K5$MHI;A83
M&MN&DR5<Y+$D8X'&W\: /2P<T5@^#;^YU+P9I%[>2F:YFM4>60@#<Q')XXK=
MW<&@!:*3- ;)([B@!:*#Q7/^+O%VG^#]'%_?I))O?9'#&5W.WXD<>I[9H W\
M\T$UYMI*^/?&.G0:HVMVGA^WE!>"*WLS+(RDG_6;R,8P,8Z[LUF^+M1^(?@G
M0)IO[3L-4LQA6OVMO+N(RW .T-MP#C'7GJ* /7**:&R!]*7=[4 +12;J,T +
M13=PHW>U #J*3-&: %I-HQ1NY]J,T -X/8=<TH/S5S?CFZUBP\)7]]HEQ;PW
M%O"\KM-&6R@4DE<'A@.1D$9&,=ZR/A1K>IZ_X3:^U6[>XN#.R[V ' ] $4#\
M"WU'0 '>8'I2T#I6?K>LV?A_1KK5=0=DM;==S%1DG)P !ZDD#\: +^[G%(&R
M.:\MTK6_&GQ%07VDW%MX=T=7*K-M%Q.Y YX.!C/T(]ZL:L_Q!\'Z?)=)?VOB
M.S4%Y2]N8;A.,?(%)4@<')R>3Q0!Z6#FEKG_  3JTFM^#-,U*:4RS3Q?._E[
M-S E3QD]QZ\]<#H-_=TX- "T4FX4;A[4 +12 Y'2C/M0 M(1FC<*-P- "CBB
MDW4;N.>* %HI,T;NM "T55O]1M-+L)[V]G2&V@4O)(QX ']?;O3-*U.#6-)M
M=1M@X@N8UECWC!VD9&: +F<TM<9X=T_QC'XNU:ZUG5%?1Q*XL[944[U8[E.0
M 1M!QSG)![ $]D&S0 M%)N%&X4 +129]J6@!"<4F[T%+CG->9?$?Q+XJ\%K:
MZE:WNG7%G)+(GD/;%"H.-NX^9ER/4!??K0!Z9NIV:YCP?_PD=SI-G?:WJ-E,
M+B'SA%!:LK+O.Y?G+X("G&-H^IQD]-]T>U "T4F?PHS0 M%)GD 49H 6BDW"
MC<* %HH'(I,\XH 6D;]>U&X>U97B37(?#GA^]U>>)Y8[9-Q13@L20 .>G)'-
M &GD=,<TX8ST[5Y3 GCWQ'X0'B+3/$(MKJXWS0Z<D*,C1Y&U0S#*M@-UR"<<
M@5WWAB;6Y]"@E\00V\.HMDR1P9VH.P/)YQUP2,T ;)Z4T-5'6-:L="TR;4-1
MF$-O$.2>I/8 =R:Y?Q]K6J6G@&37=$ODLU$,<I$EOOD(=DQ@[L*>3G(;.>W6
M@#M]U+7#_"O6]1\0>"H[[5+EKBY,\B%V4*<#&!P!7;@YH 6BD#9SQTHW4 +2
M$X-+6%XP\21>%?#5UJLBAVC&(HV) =ST&0#B@#;)YH !/08^E>::/8?$/7].
MCUR?Q+;Z:\^)H=.2R62,I@;=S%L@-UQDXSGV$O@3Q-XLU3QAJ^F^([>V@6U@
M!$<2[<-NP"N6)*D$Y//0=.A /1P,&EK)U3Q'IVCWEA9W<N+F^F6"")<%F).,
MX[*/6M7<* %HI-U,DGCAB>25UCC0%F=SA0!U)/84 245F:'KUCXBTT:AIS.]
MJTCQH[+C=M8J2!Z''%:6?:@!:*3<* <B@!:*0G%&[IQ0 $XI-W'UZ4N<UYM+
MXBU?Q9XWU#P_HEZVDVVEHXGN=JR222_=&%((V@]L@GU'2@#TD'-+7"^$(?'=
MEXAOK'Q!<6]]I466BOF0+)*3C:%"\  =01P3P2.:[J@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N=\<>(9/"_A.\U2&$S3( L:[&*AB<98@< >IP,X&>1715R/Q'\52>$?"C
MW\$"RSS2BWBW_=5B"=Q'?&T\>N* .'O]9\7V?@*R\<0Z\DF<22V3V^(\2,$
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M@DE?E8!5 !(/)(;I\M>B>#F7_A1D2Y&3IUUQZ\R5S_[/W_(-US' \V+\>&H
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ME[\YKCOBE;^(X_&7AL7%[8RA[L_V:RQ%3&=\?^L'?G;T[ U+)8SWW[2<TEJ
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MR0L-D\D[,O(19#N0GTSGI7NOA6_34O!^DWBW GWVD?F2;MVYPH#9/KN!S]*
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M?6](O)6@D=6Q:R'!,@;GY?4#- &ZWB_7? 7BJST#Q%>P:G979WQ7F&$J(SL
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MNP(B&<;V7KC/ ^AK(\1)XT\):8/$*^((+^.UB_TNTFAVJVYP?DQG)RQ&3C
MZUSGQH:ZL/'/A_4XS)!$D2JMPIP PD)(S]#^M>LZY-#/X1U*=)$>&2QD='!X
M92A((/XT 9F@>(;GQGX)&HZ1+#:7[ H!(A=(Y0>5.<$C'<>O?%>6>#[;Q?)\
M0_$\>FWNEQZFKL+N2:-C&QW_ ,  SU]:Z+X!V%S;Z#J=Y*NVWN)D6+GKM!SQ
MVZBG?#W_ )*]XV_ZZ/\ ^C* /4[)+I;&V%Z\;W8B43-$,*7P-Q7VSG%6*,T4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2&P">PZG&*])USPYIGB'0WTB_ME:U*@(%X,1 ^5D/8C_ !'0D5KT4 >2:?\
M NPM]0<7FKW=SI7F"1+-?D+$?WV'7C(RH4\]:]#UGPW8ZUX>ET2026]FZ","
MU?R]@'0 #C ]""/:MBB@#AO#7PWB\-6[B#6M2DN0C1V\K.K+;(7W'RT8%02
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MNZ5$;?S-0MP;A \(WCYP6501]2ZC\:L76H6=AL:[N8H [*B^8X&6)  _,@4
M6Z*J6>HV>H01SV=S%/$ZAU:-@05/0U;H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:H-3:SA-\(_*%QL&_9G.W/IFKE% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !12'D5P_Q E\1:1HMWK>E:O'%%:,LOV9X 05
MQ@@MU.2<XH [FC(KS#P/<^*/%_AEM2N/$BV[379(2"!'V!=IQG.5!QRI]?>N
M?B^)VL^%_'MUIOBBZM[NSW"-WM0,1=@P _\ 'EZT >WT57AGCN[1+BVF22*5
M-T<J$,K C((QU'>O.6D\5CX@W'AB7Q&JP3V8U".XCMAO4!E3;C. ,H>GK[T
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M'2B@ HHJKJ.H6NE6$U]>S)#;0J6DD<X"B@"UFC-9NB:M!KVB6NJ6RLL-PN]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNEMN1@GZ5]&Y/- 'C/Q&+K\:/#)0N&^SQX*%@?\ 62?W2#^M>S5XC\2YX?\
MA<GA_?+'B.")7RR_*=[G!RK =1U4]1TZU[:,YX- 'A/C7_DX'1?^N]G_ .A"
MO>:\%\:_\G :-_UWL_\ T(5[U0!YA\94BN;+0;*8.R7&HHA F*@J2 V5'7@]
M>WXUQ>H1:E\%_%\=Q92M<:+?9W0L?OJ/X3_M+G(;^F<]W\7)2L'AV+S)1NU6
M([ 4V-@CEL_-D9XQQR<]J[+7] T[Q+I$NF:G#YL$@SD</&W9E/8C_P#7D9%
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M*,("\[!B3ENPSQCH>]==\2I$;X.W<8=2ZP6NY0>1ETQD5)\(_P#DE<'^]/\
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MK_"/Q3K'B2\U=M6OFN2A7:F%55[9"@<9_+\:ZCX;2)_PK_0HRZB0VNX)N&2
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MTJ"+5KR.\OU#>;.D817^8D84=.,#\*\SA_Y.0N<G/^A#\?W2UZY0 #I7GOC
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MJTGN_P!F[3C!&7$-R\LF"/E432@G]1^= &A=:MJ]]X:.L2^/H;74P@O_ +%
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M//R>HKL,"EH ,"N<MO"&G6GC2X\2P+Y=Q-;"!HT&%)SEG/J2 H_X#WS71T@
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MAM64K)';2!!(,@_-P3V[>IIN@>'8?#T"6UM?7TUM'&(XX;APRH!Z84&MRD
MZ"@#(\0:!!XCL#875U=0V[ K(ENX7S >QR#6)HOPWTWP]'*FDZIK%HDQ!=4N
M%P2.AP5]Z[+:*6@#B]%^&FC^'M6;4].O-2CN7/[S,RD2#(8JPV]"1SBDN_AK
MI=[K,6L7.I:O)?PE3',;A<H1TQ\N*[4\TFT4 <CKWP_T[Q.L2:IJ.J311@;(
M_/4+D* 6QMZG&3[DUH-X3T^;PW)H5\T][9D!5-RP9D   VD 8QCC\:WL"C%
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M/?3\-PNT@ < 8[<_6NDQ2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M3U;3]&M6NM
M1NX;:%1DO(V.X']15VN$^+FG6=QX"U&^FMT>YMH0L,A&3&'DCW8^NT<_XF@#
MKM+U:RUFS%YI]PEQ;L2%D3."1]:NUYI\//$.DZ!\,[&XU74(;9,G&]LL>0.%
M#,3R1T ^@KT2UO+:]MUN+6>*>%NCQ.&!]>10!/169JGB'2-%9%U'4+>V:3[J
MR/ACUYQUQP>>E3:?J^GZM%YNGWD%RF 28I Q&>F0.GX^E %VBBLK5_$FCZ B
MOJFH06VX@*KMECDX!P.<>] &K6.GBG1)-=.B)J4!U,$C[,"=V0NX_H,U9LM:
MTW4;F:WLKV"YDA19)/)<.%5B0.1Q_">*PX--\)V_CQKV"2W&OSQ2;HQ)N9ON
M[FP?NL!@<8X+<&@#JP<T55O-1LM.C5[R[@MT;A6FD" GVS6?IOBWP_J\,<MC
MJ]I*LA(0&4*QQG/RG![>E &U169=^(='L;2*[N=2M8[>4XCD\T$/R%^7'7!(
MSCIWJ&Y\6Z!9ZC%I]QJ]I'<R@E4,@QP,G)Z+QZD9H V:*3=QD<_2L:X\7>'K
M2^-G/K%G'< A2AE'!)88)Z#[K?3OU% &U3'E6-&=R%51DDG 'U-,AN8+J!9[
M>6.:%QE9(V#*P]B*R]7\0Z!ILL=CJU_:Q-<L(A#*0<[NQ'8'U/% !9>+-"U'
M57TRSU2WGO4W;H4.2,=:V<FO!_AXEJWQKUM[6 O LESY,L##RHU+'&0 001T
MP0/K7O&/PH QIO%>AP:K'I;ZG;_;I" D ;+,2<=JVJ\+U[3[/2OCSH=O90I;
MPA8W(7C+,9,G.]<Y/J3]&^Z?6X/%>@W.J-ID&K6DEXH!\M9.N>  >A/L.: -
MFBJ=WJ^G6$BQWE_:VSL,A9IE0D>H!-.M]1LKJV:YM[NWE@3.Z6.4,JX&3DC@
M4 6J#5"VUS2KR=8+;4K.:5ONI'.K,?P!J:\O;6QMFN+RXCMX5ZR2.% _$T 3
MLP4$L0 .I/:L>'Q;H-QK(TB'5+:2_)($"MEB0-Q]NG-<?X-\>VOB/Q)XB6[U
M.)+(2I%96LQ0(T>"NY6."Q<C)4CC(Y.:XFSCMK#]HXI''%;V\4LAPH"(H^SD
MD^@% 'T!161IWBG0]6O)K2PU.VN+B%MKQH_).,_+_>'N,BM*:XBMX7FGD2*)
M!EG=@JJ/4D]* ):*Q+3QAX>O9C#;ZS9M(/X3*!D[F7 SUY4_H>A&=L<B@"&X
MNH+50T\T<2GH78+G\ZHQ^(]&E%N4U.U/VE/,B_>CYEP#GVX(ZU:O=.LM1C"7
MMI!<H.0LT8<#Z9KP[X=Z#IC?%?Q':/8QRVMG-/%#%("Z(HD( P5(. !R6!^O
M8 ]Y1@ZAE(*D9!!ZBG5EG6]'L[Y-,:^M(K@1LRVX< JJ 9X[8!!QQQ]#4>G^
M*=#U6^FLK'5+:>YA;:T:OR3C/R_WA@=1F@#8I,UQ/Q'\;0>%_#UPEO=1KJDN
M(XHU<%X\_P >W!Z#G!QFMWPUJUIJNBV3P:C'>S?9HGF8%0^2HY=%)VDG/';D
M4 ;5%8DOC#P[!??8Y=8LTGW!"IE& Q#'!/0?<;/IQZC.HMY;-:?:Q<1&VV[_
M #MXV;?7=TQ[T 3UDZSXETCP\(3JU_#:"8L(_,)^?&,X^F1^=1-XO\/+:_:C
MJ]IY'GFW\P2 C>.H_P#K].]9GBJV\(ZUING7^NSP"$;9K.9Y"IPQ0\*?O _+
MG(/![4 =7%*D\*2QL&1U#*P[@]*?5:2[M+2T$\DT,-JH&)&<*@!X'/3TQ6<_
MB[P_'I:ZD^K6@M60R*YD&64=<+U/TQF@#:HK,3Q!I3Z1'JPO[<6$BADG:0*I
M!Y[]_;KGC%+I6O:7KB2OIE[%<B(J)/+/W<J&&?P/\QU!H TJ#Q2 YKRSXO\
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MD9(<D9Z87IW(!ZGI/B'2==B:32[^"Z120?+;G(QVZ]Q6@\BQHSNP5%!+,QP
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MA@ ISR" 3[87%=#=:Q=W?P^\1:MK%RL$.L6T@TRSD;YD7RV 7C^(T <?\*?
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M;6QNQDP1JRJ4\LG'S#GYESD9';.<@-^#>I6=KXEU^2X86J7A5K=)%"%AN8X
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MK"S"JVINT+2EMI11CH>V<]>U>E5YE\:M O=5\.6VH63@'3':9USAB#CD?3%
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MW<$EO<PQS0R##1R*&5AZ$$<BH['3;'3(#!86=O:Q%MY2")8QNZ9PH'/%6Z*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV\>"S.QXX YQR,GH,C/6@#4HK+UWQ'I7AJP^VZO=I;0;@@)!9F)[!1DGUX'
MR:T]PH 6BDS1GF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS#X<^UK;W5S<+<R>8?M!4F/DG:I"@[?F. 20.W4Y -ZB@=** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRP2L-P"XW$,Q.<YZ<5[/5:VL+2S+&WMHHB[,[%% RQ.2?QJS0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_"G?!W_ #YW7_@7)_C0!WE%<'_PIWP=_P ^=U_X%R?XT?\ "G?!W_/G=?\
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MCW)QDGUJQ10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ5CN(FVR1C/8]#]"".3ZUT>** .:\+>!M"\'Q-_9=LWGR*$DN)6W22 $GD\
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MV&YSR-V"/KFNF'7FG8XQ10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 56OK^UTVTDNKVXC@MX\;Y9&"JN3@9)]R*
MLTT]>^/K0!R__"R/"0!/]N6G$OE$>8,YSC./[O?/3'-$OQ&\)Q+<$ZY:'R"
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M?$SPII<2O+JL4K,$81P?,VUAD'Z8-7M4\;>'M'L;>\O-3A6*Y4-!M.3(I(Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1L$G!V^M>_QDLBLR%"0"5/4>W% #Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0C-+1F@!,'Z4FWI3LT4
M -P:-N1BG44 ,V<T-&&/*@X.13Z* &XYSQ36B#'Y@&]R.E244 -Q2&-6.6 .
M.F1TI^129'/M0 FWG.!GIG%&WY<8R.^>].HH ;M.:"I/?I[TZB@!NW.00,']
M:,'%.HR* &[>,=O>D5 O"J ,]J?1D4 %-"FG9%% $;1(^"R*WU&:=MP,   =
M,4[-% "8YS0!CTI:* $YI NT<  >@IV1ZT9% #0N!]*7FC(S2YH 3G%)@XIU
M% #=OK^5!7K^=.HH 0"DV@L&QR*=10 W;U]?6C;[#CI3J* &[3VI<<YI:* $
M/(XIOEKNW;5W>N.:?10 W%&W%.HH ;MHVFG44 -V # _#VH"GBG44 )C]>M(
M4### $>A%.S29% "*,8P,#%.HHH ;@Y[4 8^E.S1F@!N*".OH:=D>M% #!&%
M^ZJC/7 IV#2T4 ,"8&  !2@$<8X[4ZB@!,9-(5W @@'ZTZB@!A3IP..GM2X.
M/_KTZB@!I7/!Y!ZCUI @VX('Y4^B@!I7^=&#FG44 (5S3=@)!(!([]Z?10 S
M;\V<"G <TM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3:VTFHZU>9$%I"1D<$AW_NKD=?3)[&@#JJH:SJ]CH6F3:AJ,XAMHAEF/4GL
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M\Z[N(K>+(&^5PBY/09-<C_PL"&'QE;^%[O2+ZWO)^4<;9%P02&.PD@<?AU.
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M\=LKXP R9)+ \]0.GKG%K1_B%87>JKHNK6TVCZWN"_9;G!5V.?N..&].<9)
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MIJVGS6-_;I/:S+MDC<<$?T/H1R#S7D-OX*\9_#W5;N\\)R0:CITC#%I<,=S
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M &YC"(<L ">"1N'!-;?Q-\ ZMXFM]-U"RDAGU.SC*RH,QQR#K\JG)!SZMTH
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MF1$XX/ );Z9'UKB/AWX8\6^";&XT^:TTJZMIIQ-N2[='0D -U0AA@# X[\T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !28&:6B@ Q28'I2T4 &*,444 )@4N!110 48HHH 3 ]*
M7%%% "8%+@444 )@4M%%  1GK28'I2T4 &*, 444 )@>E+@444 %)@>E+10
M8I,#%+10 8HP*** "BBB@ P*,"BB@ Q1BBB@ P*3 I:* #%&!110 F!2XHHH
M ,#-&!110 48HHH ,#THP#110 4444 &**** "C HHH 3 I<#THHH ,"C HH
MH 3 I<444 &,48HHH ,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>gtbp-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaiO6bP9z5Z8SekhvWB+bSm6vyctrwAtbivBrjSG4SEM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:GTBP="http://gtbiopharma.com/20221231" elementFormDefault="qualified" targetNamespace="http://gtbiopharma.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://gtbiopharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
	  <link:definition>00000005 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" id="OrganizationAndOperations">
	  <link:definition>00000008 - Disclosure - Organization and Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
	  <link:definition>00000010 - Disclosure - Fair Value of Financial Instruments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayable" id="AccountsPayable">
	  <link:definition>00000011 - Disclosure - Accounts Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayable" id="ConvertibleNotesPayable">
	  <link:definition>00000012 - Disclosure - Convertible Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/DerivativeLiability" id="DerivativeLiability">
	  <link:definition>00000013 - Disclosure - Derivative Liability</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000014 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/OperatingLeases" id="OperatingLeases">
	  <link:definition>00000015 - Disclosure - Operating Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000016 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/IncomeTax" id="IncomeTax">
	  <link:definition>00000017 - Disclosure - Income Tax</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000018 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
	  <link:definition>00000021 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableTables" id="AccountsPayableTables">
	  <link:definition>00000022 - Disclosure - Accounts Payable (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/DerivativeLiabilityTables" id="DerivativeLiabilityTables">
	  <link:definition>00000023 - Disclosure - Derivative Liability (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000024 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/OperatingLeasesTables" id="OperatingLeasesTables">
	  <link:definition>00000025 - Disclosure - Operating Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000026 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/IncomeTaxTables" id="IncomeTaxTables">
	  <link:definition>00000027 - Disclosure - Income Tax (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" id="ScheduleOfAnti-dilutiveSecuritiesDetails">
	  <link:definition>00000028 - Disclosure - Schedule of Anti-dilutive Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" id="ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails">
	  <link:definition>00000030 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" id="ScheduleOfFairValueHierarchyFinancialAssetsDetails">
	  <link:definition>00000031 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" id="ScheduleOfAccountsPayableDetails">
	  <link:definition>00000032 - Disclosure - Schedule of Accounts Payable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" id="AccountsPayableDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Accounts Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" id="ConvertibleNotesPayableDetailsNarrative">
	  <link:definition>00000034 - Disclosure - Convertible Notes Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" id="ScheduleOfDerivativeLiabilitiesAssumptionsDetails">
	  <link:definition>00000035 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" id="ScheduleOfDerivativeLiabilityTransactionsDetails">
	  <link:definition>00000036 - Disclosure - Schedule of Derivative Liability Transactions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" id="DerivativeLiabilityDetailsNarrative">
	  <link:definition>00000037 - Disclosure - Derivative Liability (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
	  <link:definition>00000038 - Disclosure - Schedule of Warrant Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" id="ScheduleOfOptionsActivityDetails">
	  <link:definition>00000039 - Disclosure - Schedule of Options Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails" id="ScheduleOfComponentsLeasesRentExpensesDetails">
	  <link:definition>00000041 - Disclosure - Schedule of Components Leases Rent Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails" id="ScheduleOfSupplementalLeasesDetails">
	  <link:definition>00000042 - Disclosure - Schedule of Supplemental Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails" id="ScheduleOfMaturityLeaseLiabilitiesDetails">
	  <link:definition>00000043 - Disclosure - Schedule of Maturity Lease Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" id="OperatingLeasesDetailsNarrative">
	  <link:definition>00000044 - Disclosure - Operating Leases (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails" id="ScheduleOfCompanysFutureFinancialCommitmentDetails">
	  <link:definition>00000045 - Disclosure - Schedule of Company&#8217;s Future Financial Commitment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000046 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails" id="ScheduleOfNetDeferredIncomeTaxAssetsDetails">
	  <link:definition>00000047 - Disclosure - Schedule of Net Deferred Income Tax Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" id="ScheduleOfIncomeTaxProvisionDetails">
	  <link:definition>00000048 - Disclosure - Schedule of Income Tax Provision (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/IncomeTaxDetailsNarrative" id="IncomeTaxDetailsNarrative">
	  <link:definition>00000049 - Disclosure - Income Tax (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000050 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="GTBP_OfficersEmployeesAndDirectorsMember" name="OfficersEmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonSharesIssuableMember" name="CommonSharesIssuableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CorporateNotesAndCommercialPaperMember" name="CorporateNotesAndCommercialPaperMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ServiceAgreementMember" name="ServiceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ThirdPartyManufacturerMember" name="ThirdPartyManufacturerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PaymentAgreementMember" name="PaymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableIssuedForCashMember" name="NotesPayableIssuedForCashMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableIssuedForSettlementAgreementsMember" name="NotesPayableIssuedForSettlementAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FiscalTwentyNinteenandTwentyTwentyMember" name="FiscalTwentyNinteenandTwentyTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableIssuedForForbearanceAgreementsMember" name="NotesPayableIssuedForForbearanceAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableIssuedForConsultingAgreementMember" name="NotesPayableIssuedForConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_JanuaryTwentyTwentyOneMember" name="JanuaryTwentyTwentyOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConvertibleNotePayableMember" name="ConvertibleNotePayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OwnersMember" name="OwnersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_InvestorsMember" name="InvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConvertibleNoteMember" name="ConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NoteHolderMember" name="NoteHolderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_EmploymentAgreementsMember" name="EmploymentAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OfficersAndDirectorsMember" name="OfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConsultantsMember" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesJOnePreferredStockMember" name="SeriesJOnePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesJPreferredStockMember" name="SeriesJPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesKPreferredStocksMember" name="SeriesKPreferredStocksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesKPreferredStockMember" name="SeriesKPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConsultantEmployeesOfficersAndDirectorsMember" name="ConsultantEmployeesOfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoEmployeesMember" name="TwoEmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SheffieldPropertiesMember" name="SheffieldPropertiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScientificResearchAgreementMember" name="ScientificResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" name="TwoThousandSixteenPatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" name="TwoThousandAndTwentyOnePatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_InstitutionalInvestorMember" name="InstitutionalInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonWarrantsMember" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ResearchAndDevelopmentAgreementMember" name="ResearchAndDevelopmentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockIssuable" name="CommonStockIssuable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockIssuableShares" name="CommonStockIssuableShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" name="StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" name="StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" name="StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" name="StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" name="StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants" name="IssuanceOfCommonStockAsEquityCompensationToConsultants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants" name="StockIssuedDuringPeriodSharesEquityCompensationToConsultants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCancellation" name="StockIssuedDuringPeriodValueCancellation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCancellation" name="StockIssuedDuringPeriodSharesCancellation" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" name="StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" name="StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants" name="StockIssuedDuringPeriodValueEquityCompensationToConsultants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" name="StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" name="StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" name="StockBasedCompensationConsultantsAndResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" name="StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockBasedCompensationVestedStockOptions" name="StockBasedCompensationVestedStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement" name="FairValueOfCommonStockIssuedToNoteholderAsSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConvertibleNotesPayableIssuedForConsultingServices" name="ConvertibleNotesPayableIssuedForConsultingServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UnrealizedLossOnMarketableSecurities" name="UnrealizedLossOnMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" name="IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IncreaseDecreaseInDeposit" name="IncreaseDecreaseInDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer" name="CancellationOfCommonStockUponSettlementWithFormerOfficer" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CashPaidDuringYearFor" name="CashPaidDuringYearFor" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RightofuseAssetsExchangedForLeaseLiabilities" name="RightofuseAssetsExchangedForLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" name="ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockIssuedUponSettlementOfVendorPayable" name="CommonStockIssuedUponSettlementOfVendorPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AccountsPayableReclassifiedToConvertibleNotes" name="AccountsPayableReclassifiedToConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExtinguishmentOfDerivativeLiability" name="ExtinguishmentOfDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureDerivativeLiabilityAbstract" name="DisclosureDerivativeLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureOperatingLeasesAbstract" name="DisclosureOperatingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock" name="UnusualRisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" name="ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfSupplementalLeaseTableTextBlock" name="ScheduleOfSupplementalLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock" name="ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CashOnHandAndShortTermInvestment" name="CashOnHandAndShortTermInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableForUnpaidConsultingFee" name="NotesPayableForUnpaidConsultingFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SharesIssuedDuringPeriodValueAccruedInterest" name="SharesIssuedDuringPeriodValueAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SharesIssuedDuringPeriodSharesAccruedInterest" name="SharesIssuedDuringPeriodSharesAccruedInterest" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" name="DerivativeLiabilityFairValueAssumptionsExpectedTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExtinguishmentOfWarrants" name="ExtinguishmentOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ClassOfWarrantExpireTerm" name="ClassOfWarrantExpireTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockConsultantToFairValue" name="CommonStockConsultantToFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LongtermRightofuseAssetsNet" name="LongtermRightofuseAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AdditionalOperatingLeaseAssets" name="AdditionalOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ProjectFee" name="ProjectFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ProjectFeeIncurred" name="ProjectFeeIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ProceedsFromUpfrontAmount" name="ProceedsFromUpfrontAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyFeePercentage" name="RoyaltyFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PerformanceMilestonePayments" name="PerformanceMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesMilestonePayments" name="SalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GrossSales" name="GrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesRevenue" name="SalesRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CummulativeGrossSales" name="CummulativeGrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UpfrontLicenseFee" name="UpfrontLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LicenseMaintenanceFeeReceivable" name="LicenseMaintenanceFeeReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockBasedCompensationServices" name="StockBasedCompensationServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" name="StockBasedCompensationToOfficersAndBoardOfDirectors" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableIssuedExchangeForConsultingService" name="NotesPayableIssuedExchangeForConsultingService" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" name="AdoptionofAsuTwentyTwentyZeroSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DuringTwentyTwentyMember" name="DuringTwentyTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_InterestExpenseDueAmortizationOfDebtDiscount" name="InterestExpenseDueAmortizationOfDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockSharesGrantedForConsultants" name="CommonStockSharesGrantedForConsultants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfStockOptionsGrantedForConsultants" name="FairValueOfStockOptionsGrantedForConsultants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_MasterServicesAgreementMember" name="MasterServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_MasterServiceAgreementMember" name="MasterServiceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NetSalesPercentage" name="NetSalesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DeferredTaxAssetsPatentAmortization" name="DeferredTaxAssetsPatentAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AimmuneTherapeuticsIncMember" name="AimmuneTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NovemberTwoThousandAndTwentyTwoMember" name="NovemberTwoThousandAndTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_VendorMember" name="VendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OfficersMember" name="OfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymenAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymenAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommitmentAndContegenciesTableTextBlock" name="CommitmentAndContegenciesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PreFundedMember" name="PreFundedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PreFundedExercisePriceMember" name="PreFundedExercisePriceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_HCWainwrightCoLLCMember" name="HCWainwrightCoLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AccountsPayableAndLineOfCreditCurrent" name="AccountsPayableAndLineOfCreditCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OfficeSpaceAndEquipmentMember" name="OfficeSpaceAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesJIPreferredStockMember" name="SeriesJIPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OfficeLeaseAgreementsMember" name="OfficeLeaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OptionsWarrantsAndConvertibleNotesMember" name="OptionsWarrantsAndConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OtherConsultantsMember" name="OtherConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IssuanceOfCommonStockForServicesShares" name="IssuanceOfCommonStockForServicesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultantsShares" name="IssuanceOfCommonStockAsEquityCompensationToConsultantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>gtbp-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20221231.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:href="gtbp-20221231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:href="gtbp-20221231.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:href="gtbp-20221231.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayable" xlink:href="gtbp-20221231.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:href="gtbp-20221231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiability" xlink:href="gtbp-20221231.xsd#DerivativeLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquity" xlink:href="gtbp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeases" xlink:href="gtbp-20221231.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/IncomeTax" xlink:href="gtbp-20221231.xsd#IncomeTax" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvents" xlink:href="gtbp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="gtbp-20221231.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableTables" xlink:href="gtbp-20221231.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:href="gtbp-20221231.xsd#DerivativeLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:href="gtbp-20221231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:href="gtbp-20221231.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:href="gtbp-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/IncomeTaxTables" xlink:href="gtbp-20221231.xsd#IncomeTaxTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:href="gtbp-20221231.xsd#AccountsPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="gtbp-20221231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:href="gtbp-20221231.xsd#DerivativeLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="gtbp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfComponentsLeasesRentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfSupplementalLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfMaturityLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:href="gtbp-20221231.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfCompanysFutureFinancialCommitmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfIncomeTaxProvisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/IncomeTaxDetailsNarrative" xlink:href="gtbp-20221231.xsd#IncomeTaxDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="gtbp-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockIssuable" xlink:label="loc_GTBPCommonStockIssuable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_GTBPCommonStockIssuable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" xlink:label="loc_GTBPStockBasedCompensationConsultantsAndResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPStockBasedCompensationConsultantsAndResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:label="loc_GTBPStockBasedCompensationOfficersEmployeesAndBoardOfDirectors" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPStockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationVestedStockOptions" xlink:label="loc_GTBPStockBasedCompensationVestedStockOptions" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPStockBasedCompensationVestedStockOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement" xlink:label="loc_GTBPFairValueOfCommonStockIssuedToNoteholderAsSettlement" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPFairValueOfCommonStockIssuedToNoteholderAsSettlement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConvertibleNotesPayableIssuedForConsultingServices" xlink:label="loc_GTBPConvertibleNotesPayableIssuedForConsultingServices" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPConvertibleNotesPayableIssuedForConsultingServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_UnrealizedLossOnMarketableSecurities" xlink:label="loc_GTBPUnrealizedLossOnMarketableSecurities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPUnrealizedLossOnMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" xlink:label="loc_GTBPIncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPIncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IncreaseDecreaseInDeposit" xlink:label="loc_GTBPIncreaseDecreaseInDeposit" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPIncreaseDecreaseInDeposit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer" xlink:label="loc_GTBPCancellationOfCommonStockUponSettlementWithFormerOfficer" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_GTBPCancellationOfCommonStockUponSettlementWithFormerOfficer" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:title="00000010 - Disclosure - Fair Value of Financial Instruments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayable" xlink:title="00000011 - Disclosure - Accounts Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:title="00000012 - Disclosure - Convertible Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiability" xlink:title="00000013 - Disclosure - Derivative Liability" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeases" xlink:title="00000015 - Disclosure - Operating Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/IncomeTax" xlink:title="00000017 - Disclosure - Income Tax" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000021 - Disclosure - Fair Value of Financial Instruments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableTables" xlink:title="00000022 - Disclosure - Accounts Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:title="00000023 - Disclosure - Derivative Liability (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:title="00000024 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:title="00000025 - Disclosure - Operating Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/IncomeTaxTables" xlink:title="00000027 - Disclosure - Income Tax (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000028 - Disclosure - Schedule of Anti-dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:title="00000030 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:title="00000031 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="00000032 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableCurrent" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableCurrent" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:title="00000033 - Disclosure - Accounts Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - Convertible Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:title="00000035 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:title="00000036 - Disclosure - Schedule of Derivative Liability Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:title="00000037 - Disclosure - Derivative Liability (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000038 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000039 - Disclosure - Schedule of Options Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails" xlink:title="00000041 - Disclosure - Schedule of Components Leases Rent Expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails" xlink:title="00000042 - Disclosure - Schedule of Supplemental Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails" xlink:title="00000043 - Disclosure - Schedule of Maturity Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000044 - Disclosure - Operating Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails" xlink:title="00000045 - Disclosure - Schedule of Company&#8217;s Future Financial Commitment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="loc_us-gaapOtherCommitmentDueInNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherCommitment" xlink:to="loc_us-gaapOtherCommitmentDueInNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaapOtherCommitmentDueInSecondYear" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherCommitment" xlink:to="loc_us-gaapOtherCommitmentDueInSecondYear" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000046 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:title="00000047 - Disclosure - Schedule of Net Deferred Income Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:title="00000048 - Disclosure - Schedule of Income Tax Provision (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/IncomeTaxDetailsNarrative" xlink:title="00000049 - Disclosure - Income Tax (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000050 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>gtbp-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20221231.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:href="gtbp-20221231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:href="gtbp-20221231.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:href="gtbp-20221231.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayable" xlink:href="gtbp-20221231.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:href="gtbp-20221231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiability" xlink:href="gtbp-20221231.xsd#DerivativeLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquity" xlink:href="gtbp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeases" xlink:href="gtbp-20221231.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/IncomeTax" xlink:href="gtbp-20221231.xsd#IncomeTax" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvents" xlink:href="gtbp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="gtbp-20221231.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableTables" xlink:href="gtbp-20221231.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:href="gtbp-20221231.xsd#DerivativeLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:href="gtbp-20221231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:href="gtbp-20221231.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:href="gtbp-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/IncomeTaxTables" xlink:href="gtbp-20221231.xsd#IncomeTaxTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:href="gtbp-20221231.xsd#AccountsPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="gtbp-20221231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:href="gtbp-20221231.xsd#DerivativeLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="gtbp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfComponentsLeasesRentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfSupplementalLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfMaturityLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:href="gtbp-20221231.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfCompanysFutureFinancialCommitmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfIncomeTaxProvisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/IncomeTaxDetailsNarrative" xlink:href="gtbp-20221231.xsd#IncomeTaxDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="gtbp-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple" />
    <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd#eedm1" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockIssuableShares" xlink:label="loc_GTBPCommonStockIssuableShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPCommonStockIssuableShares_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndDirectorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndDirectorsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonSharesIssuableMember" xlink:label="loc_GTBPCommonSharesIssuableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonSharesIssuableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants" xlink:label="loc_GTBPIssuanceOfCommonStockAsEquityCompensationToConsultants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPIssuanceOfCommonStockAsEquityCompensationToConsultants_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesEquityCompensationToConsultants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesEquityCompensationToConsultants_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCancellation" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCancellation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCancellation_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCancellation" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCancellation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCancellation_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants" xlink:label="loc_GTBPStockIssuedDuringPeriodValueEquityCompensationToConsultants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueEquityCompensationToConsultants_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_70" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:title="00000010 - Disclosure - Fair Value of Financial Instruments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayable" xlink:title="00000011 - Disclosure - Accounts Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:title="00000012 - Disclosure - Convertible Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiability" xlink:title="00000013 - Disclosure - Derivative Liability" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeases" xlink:title="00000015 - Disclosure - Operating Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/IncomeTax" xlink:title="00000017 - Disclosure - Income Tax" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000021 - Disclosure - Fair Value of Financial Instruments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableTables" xlink:title="00000022 - Disclosure - Accounts Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:title="00000023 - Disclosure - Derivative Liability (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:title="00000024 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:title="00000025 - Disclosure - Operating Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/IncomeTaxTables" xlink:title="00000027 - Disclosure - Income Tax (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000028 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_WarrantsToPurchaseCommonStockMember" xlink:label="loc_GTBPWarrantsToPurchaseCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPWarrantsToPurchaseCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OptionsToPurchaseCommonStockMember" xlink:label="loc_GTBPOptionsToPurchaseCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPOptionsToPurchaseCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CashOnHandAndShortTermInvestment" xlink:label="loc_GTBPCashOnHandAndShortTermInvestment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPCashOnHandAndShortTermInvestment_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash" xlink:label="loc_us-gaapInvestmentsAndCash_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInvestmentsAndCash_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShortTermInvestments_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_50" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:title="00000030 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaapShortTermInvestmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapShortTermInvestmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:title="00000031 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapMoneyMarketFundsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CorporateNotesAndCommercialPaperMember" xlink:label="loc_GTBPCorporateNotesAndCommercialPaperMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_GTBPCorporateNotesAndCommercialPaperMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability_250" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="00000032 - Disclosure - Schedule of Accounts Payable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:title="00000033 - Disclosure - Accounts Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ServiceAgreementMember" xlink:label="loc_GTBPServiceAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPServiceAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PaymentAgreementMember" xlink:label="loc_GTBPPaymentAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPaymentAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ThirdPartyManufacturerMember" xlink:label="loc_GTBPThirdPartyManufacturerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPThirdPartyManufacturerMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesCurrentAndNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNotesPayableRelatedPartiesCurrentAndNoncurrent_110" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForCashMember" xlink:label="loc_GTBPNotesPayableIssuedForCashMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForCashMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForSettlementAgreementsMember" xlink:label="loc_GTBPNotesPayableIssuedForSettlementAgreementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForSettlementAgreementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForForbearanceAgreementsMember" xlink:label="loc_GTBPNotesPayableIssuedForForbearanceAgreementsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForForbearanceAgreementsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForConsultingAgreementMember" xlink:label="loc_GTBPNotesPayableIssuedForConsultingAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForConsultingAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConvertibleNotePayableMember" xlink:label="loc_GTBPConvertibleNotePayableMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPConvertibleNotePayableMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_FiscalTwentyNinteenandTwentyTwentyMember" xlink:label="loc_GTBPFiscalTwentyNinteenandTwentyTwentyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPFiscalTwentyNinteenandTwentyTwentyMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_JanuaryTwentyTwentyOneMember" xlink:label="loc_GTBPJanuaryTwentyTwentyOneMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPJanuaryTwentyTwentyOneMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="loc_us-gaapAccountingStandardsUpdate202006Member_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate202006Member_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayableCurrent_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableForUnpaidConsultingFee" xlink:label="loc_GTBPNotesPayableForUnpaidConsultingFee_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPNotesPayableForUnpaidConsultingFee_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SharesIssuedDuringPeriodValueAccruedInterest" xlink:label="loc_GTBPSharesIssuedDuringPeriodValueAccruedInterest_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPSharesIssuedDuringPeriodValueAccruedInterest_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SharesIssuedDuringPeriodSharesAccruedInterest" xlink:label="loc_GTBPSharesIssuedDuringPeriodSharesAccruedInterest_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPSharesIssuedDuringPeriodSharesAccruedInterest_260" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaapCommonStockSharesSubscribedButUnissued_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscribedButUnissued_260" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_260" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_260" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_260" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:title="00000035 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:label="loc_GTBPDerivativeLiabilityFairValueAssumptionsExpectedTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_GTBPDerivativeLiabilityFairValueAssumptionsExpectedTerm1_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:title="00000036 - Disclosure - Schedule of Derivative Liability Transactions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:title="00000037 - Disclosure - Derivative Liability (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000038 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000039 - Disclosure - Schedule of Options Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OwnersMember" xlink:label="loc_GTBPOwnersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOwnersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_InvestorsMember" xlink:label="loc_GTBPInvestorsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPInvestorsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NoteHolderMember" xlink:label="loc_GTBPNoteHolderMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPNoteHolderMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OfficersAndDirectorsMember" xlink:label="loc_GTBPOfficersAndDirectorsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersAndDirectorsMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConsultantsMember" xlink:label="loc_GTBPConsultantsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPConsultantsMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConsultantEmployeesOfficersAndDirectorsMember" xlink:label="loc_GTBPConsultantEmployeesOfficersAndDirectorsMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPConsultantEmployeesOfficersAndDirectorsMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_EmployeesMember" xlink:label="loc_GTBPEmployeesMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPEmployeesMember_490" xlink:type="arc" order="491" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_TwoEmployeesMember" xlink:label="loc_GTBPTwoEmployeesMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPTwoEmployeesMember_510" xlink:type="arc" order="511" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConvertibleNoteMember" xlink:label="loc_GTBPConvertibleNoteMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPConvertibleNoteMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_EmploymentAgreementsMember" xlink:label="loc_GTBPEmploymentAgreementsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPEmploymentAgreementsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesJOnePreferredStockMember" xlink:label="loc_GTBPSeriesJOnePreferredStockMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesJOnePreferredStockMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesJPreferredStockMember" xlink:label="loc_GTBPSeriesJPreferredStockMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesJPreferredStockMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesKPreferredStocksMember" xlink:label="loc_GTBPSeriesKPreferredStocksMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesKPreferredStocksMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesKPreferredStockMember" xlink:label="loc_GTBPSeriesKPreferredStockMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesKPreferredStockMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_470" xlink:type="arc" order="472" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_480" xlink:type="arc" order="482" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_550" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_550" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_550" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_550" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_550" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_550" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_550" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ClassOfWarrantExpireTerm" xlink:label="loc_GTBPClassOfWarrantExpireTerm_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPClassOfWarrantExpireTerm_550" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_550" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_550" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_550" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_550" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_550" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_550" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaapStockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_550" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_550" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaapStockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_550" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock_550" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_550" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_550" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation_550" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_550" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_550" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_550" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_550" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesIssued_550" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockConsultantToFairValue" xlink:label="loc_GTBPCommonStockConsultantToFairValue_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPCommonStockConsultantToFairValue_550" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_550" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProfessionalFees_550" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_550" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_550" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_550" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_550" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_550" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaapPreferredStockConvertibleSharesIssuable_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleSharesIssuable_550" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_550" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_550" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_550" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_550" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_550" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_550" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_550" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_550" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_550" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_550" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_550" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_550" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_550" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_550" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_550" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_550" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_550" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_550" xlink:type="arc" order="52" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails" xlink:title="00000041 - Disclosure - Schedule of Components Leases Rent Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails" xlink:title="00000042 - Disclosure - Schedule of Supplemental Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails" xlink:title="00000043 - Disclosure - Schedule of Maturity Lease Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000044 - Disclosure - Operating Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapLeaseAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingSubleaseOptionToExtend_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingSubleaseOptionToExtend_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_AdditionalOperatingLeaseAssets" xlink:label="loc_GTBPAdditionalOperatingLeaseAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_GTBPAdditionalOperatingLeaseAssets_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails" xlink:title="00000045 - Disclosure - Schedule of Company&#8217;s Future Financial Commitment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000046 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SheffieldPropertiesMember" xlink:label="loc_GTBPSheffieldPropertiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPSheffieldPropertiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ScientificResearchAgreementMember" xlink:label="loc_GTBPScientificResearchAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPScientificResearchAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ProjectFee" xlink:label="loc_GTBPProjectFee_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProjectFee_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ProjectFeeIncurred" xlink:label="loc_GTBPProjectFeeIncurred_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProjectFeeIncurred_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostMaintenance_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_LicenseMaintenanceFeeReceivable" xlink:label="loc_GTBPLicenseMaintenanceFeeReceivable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPLicenseMaintenanceFeeReceivable_160" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:title="00000047 - Disclosure - Schedule of Net Deferred Income Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:title="00000048 - Disclosure - Schedule of Income Tax Provision (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/IncomeTaxDetailsNarrative" xlink:title="00000049 - Disclosure - Income Tax (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000050 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PurchaseAgreementMember" xlink:label="loc_GTBPPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ResearchAndDevelopmentAgreementMember" xlink:label="loc_GTBPResearchAndDevelopmentAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPResearchAndDevelopmentAgreementMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_InstitutionalInvestorMember" xlink:label="loc_GTBPInstitutionalInvestorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_GTBPInstitutionalInvestorMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PreFundedWarrantsMember" xlink:label="loc_GTBPPreFundedWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPPreFundedWarrantsMember_20" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1000" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>gtbp-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember_lbl" xml:lang="en-US">Officers Employees and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonSharesIssuableMember" xlink:label="GTBP_CommonSharesIssuableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonSharesIssuableMember" xlink:to="GTBP_CommonSharesIssuableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonSharesIssuableMember_lbl" xml:lang="en-US">Common Shares Issuable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_WarrantsToPurchaseCommonStockMember" xlink:label="GTBP_WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsToPurchaseCommonStockMember" xlink:to="GTBP_WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OptionsToPurchaseCommonStockMember" xlink:label="GTBP_OptionsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OptionsToPurchaseCommonStockMember" xlink:to="GTBP_OptionsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OptionsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Options to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US">Short-Term Investments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CorporateNotesAndCommercialPaperMember" xlink:label="GTBP_CorporateNotesAndCommercialPaperMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CorporateNotesAndCommercialPaperMember" xlink:to="GTBP_CorporateNotesAndCommercialPaperMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CorporateNotesAndCommercialPaperMember_lbl" xml:lang="en-US">Corporate Notes and Commercial Paper [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ServiceAgreementMember" xlink:label="GTBP_ServiceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ServiceAgreementMember" xlink:to="GTBP_ServiceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ServiceAgreementMember_lbl" xml:lang="en-US">Service Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ThirdPartyManufacturerMember" xlink:label="GTBP_ThirdPartyManufacturerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ThirdPartyManufacturerMember" xlink:to="GTBP_ThirdPartyManufacturerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ThirdPartyManufacturerMember_lbl" xml:lang="en-US">Third Party Manufacturer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PaymentAgreementMember" xlink:label="GTBP_PaymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PaymentAgreementMember" xlink:to="GTBP_PaymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PaymentAgreementMember_lbl" xml:lang="en-US">Payment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForCashMember" xlink:label="GTBP_NotesPayableIssuedForCashMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForCashMember" xlink:to="GTBP_NotesPayableIssuedForCashMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NotesPayableIssuedForCashMember_lbl" xml:lang="en-US">Notes Payables Issued For Cash [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForSettlementAgreementsMember" xlink:label="GTBP_NotesPayableIssuedForSettlementAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForSettlementAgreementsMember" xlink:to="GTBP_NotesPayableIssuedForSettlementAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NotesPayableIssuedForSettlementAgreementsMember_lbl" xml:lang="en-US">Notes Payable Issued For Settlement Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_FiscalTwentyNinteenandTwentyTwentyMember" xlink:label="GTBP_FiscalTwentyNinteenandTwentyTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FiscalTwentyNinteenandTwentyTwentyMember" xlink:to="GTBP_FiscalTwentyNinteenandTwentyTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FiscalTwentyNinteenandTwentyTwentyMember_lbl" xml:lang="en-US">Fiscal 2019 and 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForForbearanceAgreementsMember" xlink:label="GTBP_NotesPayableIssuedForForbearanceAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForForbearanceAgreementsMember" xlink:to="GTBP_NotesPayableIssuedForForbearanceAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NotesPayableIssuedForForbearanceAgreementsMember_lbl" xml:lang="en-US">Notes Payable Issued For Forbearance Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForConsultingAgreementMember" xlink:label="GTBP_NotesPayableIssuedForConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForConsultingAgreementMember" xlink:to="GTBP_NotesPayableIssuedForConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NotesPayableIssuedForConsultingAgreementMember_lbl" xml:lang="en-US">Notes Payable Issued For Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_JanuaryTwentyTwentyOneMember" xlink:label="GTBP_JanuaryTwentyTwentyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_JanuaryTwentyTwentyOneMember" xlink:to="GTBP_JanuaryTwentyTwentyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_JanuaryTwentyTwentyOneMember_lbl" xml:lang="en-US">January 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConvertibleNotePayableMember" xlink:label="GTBP_ConvertibleNotePayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertibleNotePayableMember" xlink:to="GTBP_ConvertibleNotePayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConvertibleNotePayableMember_lbl" xml:lang="en-US">Convertible Note Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OwnersMember" xlink:label="GTBP_OwnersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OwnersMember" xlink:to="GTBP_OwnersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OwnersMember_lbl" xml:lang="en-US">Owners [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_InvestorsMember" xlink:label="GTBP_InvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InvestorsMember" xlink:to="GTBP_InvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_InvestorsMember_lbl" xml:lang="en-US">Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConvertibleNoteMember" xlink:label="GTBP_ConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertibleNoteMember" xlink:to="GTBP_ConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NoteHolderMember" xlink:label="GTBP_NoteHolderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NoteHolderMember" xlink:to="GTBP_NoteHolderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NoteHolderMember_lbl" xml:lang="en-US">Note Holder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_EmploymentAgreementsMember" xlink:label="GTBP_EmploymentAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_EmploymentAgreementsMember" xlink:to="GTBP_EmploymentAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_EmploymentAgreementsMember_lbl" xml:lang="en-US">Employment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OfficersAndDirectorsMember" xlink:label="GTBP_OfficersAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersAndDirectorsMember" xlink:to="GTBP_OfficersAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConsultantsMember" xlink:label="GTBP_ConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConsultantsMember" xlink:to="GTBP_ConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesJOnePreferredStockMember" xlink:label="GTBP_SeriesJOnePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesJOnePreferredStockMember" xlink:to="GTBP_SeriesJOnePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesJOnePreferredStockMember_lbl" xml:lang="en-US">Series J One Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesJPreferredStockMember" xlink:label="GTBP_SeriesJPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesJPreferredStockMember" xlink:to="GTBP_SeriesJPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesJPreferredStockMember_lbl" xml:lang="en-US">Series J Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesKPreferredStocksMember" xlink:label="GTBP_SeriesKPreferredStocksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesKPreferredStocksMember" xlink:to="GTBP_SeriesKPreferredStocksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesKPreferredStocksMember_lbl" xml:lang="en-US">Series K Preferred Stocks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesKPreferredStockMember" xlink:label="GTBP_SeriesKPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesKPreferredStockMember" xlink:to="GTBP_SeriesKPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesKPreferredStockMember_lbl" xml:lang="en-US">Series K Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConsultantEmployeesOfficersAndDirectorsMember" xlink:label="GTBP_ConsultantEmployeesOfficersAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConsultantEmployeesOfficersAndDirectorsMember" xlink:to="GTBP_ConsultantEmployeesOfficersAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConsultantEmployeesOfficersAndDirectorsMember_lbl" xml:lang="en-US">Consultant Employees Officers And Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_EmployeesMember" xlink:label="GTBP_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_EmployeesMember" xlink:to="GTBP_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_TwoEmployeesMember" xlink:label="GTBP_TwoEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoEmployeesMember" xlink:to="GTBP_TwoEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoEmployeesMember_lbl" xml:lang="en-US">Two Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xml:lang="en-US">Lease Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SheffieldPropertiesMember" xlink:label="GTBP_SheffieldPropertiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SheffieldPropertiesMember" xlink:to="GTBP_SheffieldPropertiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SheffieldPropertiesMember_lbl" xml:lang="en-US">Sheffield Properties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ScientificResearchAgreementMember" xlink:label="GTBP_ScientificResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScientificResearchAgreementMember" xlink:to="GTBP_ScientificResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScientificResearchAgreementMember_lbl" xml:lang="en-US">Scientific Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xml:lang="en-US">2016 Patent Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xml:lang="en-US">2021 Patent License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PurchaseAgreementMember" xlink:label="GTBP_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseAgreementMember" xlink:to="GTBP_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_InstitutionalInvestorMember" xlink:label="GTBP_InstitutionalInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InstitutionalInvestorMember" xlink:to="GTBP_InstitutionalInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_InstitutionalInvestorMember_lbl" xml:lang="en-US">Institutional Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PreFundedWarrantsMember" xlink:label="GTBP_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreFundedWarrantsMember" xlink:to="GTBP_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonWarrantsMember" xlink:label="GTBP_CommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantsMember" xlink:to="GTBP_CommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonWarrantsMember_lbl" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ResearchAndDevelopmentAgreementMember" xlink:label="GTBP_ResearchAndDevelopmentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ResearchAndDevelopmentAgreementMember" xlink:to="GTBP_ResearchAndDevelopmentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ResearchAndDevelopmentAgreementMember_lbl" xml:lang="en-US">Research And Development Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at December 31, 2022 and 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001, 250,000,000 shares authorized, 32,722,452 shares and 32,061,989 shares issued and outstanding as of December 31, 2022 and 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockIssuable" xlink:label="GTBP_CommonStockIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuable" xlink:to="GTBP_CommonStockIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockIssuable_lbl" xml:lang="en-US">Common stock issuable, 0 shares and 327,298 shares at December 31, 2022 and 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockIssuableShares" xlink:label="GTBP_CommonStockIssuableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuableShares" xlink:to="GTBP_CommonStockIssuableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockIssuableShares_lbl" xml:lang="en-US">Common stock issuable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development (including $718 and $0 of stock compensation to officers, directors and employees during the years ended December 31, 2022 and 2021, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative (including $3,903 and $17,234 of stock compensation to officers, directors and employees during the years ended December 31, 2022 and 2021, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (Income) Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other (Income) Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Share - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Extinguishment of debt discount upon adoption of ASU 2020-06</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Conversion of Preferred Series J-1 to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Conversion of Preferred Series J-1 to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_lbl" xml:lang="en-US">Common shares issued upon mandatory conversion of notes payable and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_lbl" xml:lang="en-US">Common shares issued upon mandatory conversion of notes payable and accrued interest, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_lbl" xml:lang="en-US">Common shares issued upon exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_lbl" xml:lang="en-US">Common shares issued upon exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_lbl" xml:lang="en-US">Issuance of common stock in public offering, net of cost</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:to="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_lbl" xml:lang="en-US">Issuance of common stock in public offering, net of cost, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_lbl" xml:lang="en-US">Issuance of common stock for research and development agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:to="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_lbl" xml:lang="en-US">Issuance of common stock for research and development agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants" xlink:label="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants" xlink:to="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants_lbl" xml:lang="en-US">Issuance of common stock as equity compensation to consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants" xlink:label="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants" xlink:to="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants_lbl" xml:lang="en-US">Equity compensation to consultants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xml:lang="en-US">Issuance of common stock as equity compensation to officers, employees, and board of directors</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Equity compensation to officers, employees, and board of directors, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xml:lang="en-US">Fair value of vested stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Extinguishment of derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCancellation" xlink:label="GTBP_StockIssuedDuringPeriodValueCancellation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCancellation" xlink:to="GTBP_StockIssuedDuringPeriodValueCancellation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCancellation_lbl" xml:lang="en-US">Cancellation of common stock previously issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCancellation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCancellation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCancellation" xlink:to="GTBP_StockIssuedDuringPeriodSharesCancellation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCancellation_lbl" xml:lang="en-US">Cancellation of common stock previously issued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" xlink:label="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" xlink:to="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued_lbl" xml:lang="en-US">Cancellation of common stock previously issued to prior CEO</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" xlink:label="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" xlink:to="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued_lbl" xml:lang="en-US">Cancellation of common stock previously issued to prior CEO, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued upon conversion of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued upon conversion of notes payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants" xlink:label="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants" xlink:to="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants_lbl" xml:lang="en-US">Issuance of common stock as equity compensation to consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_lbl" xml:lang="en-US">Issuance of common stock in settlement of vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_lbl" xml:lang="en-US">Issuance of common shares in settlement of vendors payable, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" xlink:label="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" xlink:to="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment_lbl" xml:lang="en-US">Stock based compensation &#8211; consultants and research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:label="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:to="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors_lbl" xml:lang="en-US">Stock based compensation - officers, employees and board of directors</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationVestedStockOptions" xlink:label="GTBP_StockBasedCompensationVestedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationVestedStockOptions" xlink:to="GTBP_StockBasedCompensationVestedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockBasedCompensationVestedStockOptions_lbl" xml:lang="en-US">Stock based compensation - vested stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement" xlink:label="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement" xlink:to="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement_lbl" xml:lang="en-US">Fair value of common stock issued to a noteholder as settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConvertibleNotesPayableIssuedForConsultingServices" xlink:label="GTBP_ConvertibleNotesPayableIssuedForConsultingServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertibleNotesPayableIssuedForConsultingServices" xlink:to="GTBP_ConvertibleNotesPayableIssuedForConsultingServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConvertibleNotesPayableIssuedForConsultingServices_lbl" xml:lang="en-US">Convertible notes payable issued for consulting services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Change in operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain from extinguishment of line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_UnrealizedLossOnMarketableSecurities" xlink:label="GTBP_UnrealizedLossOnMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UnrealizedLossOnMarketableSecurities" xlink:to="GTBP_UnrealizedLossOnMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_UnrealizedLossOnMarketableSecurities_lbl" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" xlink:label="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" xlink:to="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets_lbl" xml:lang="en-US">Decrease in prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IncreaseDecreaseInDeposit" xlink:label="GTBP_IncreaseDecreaseInDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInDeposit" xlink:to="GTBP_IncreaseDecreaseInDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_IncreaseDecreaseInDeposit_lbl" xml:lang="en-US">(Increase) in deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">(Decrease) increase in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Decrease in operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Increase in accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Sales (purchases) of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer" xlink:label="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer" xlink:to="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer_lbl" xml:lang="en-US">Cancellation of common stock upon settlement with former officer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_ProceedsFromIssuanceOfMediumTermNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes_lbl" xml:lang="en-US">Proceeds from issuance of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash (Used in) Provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (Decrease) Increase in Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CashPaidDuringYearFor" xlink:label="GTBP_CashPaidDuringYearFor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CashPaidDuringYearFor_lbl" xml:lang="en-US">Cash paid during the year for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_RightofuseAssetsExchangedForLeaseLiabilities" xlink:label="GTBP_RightofuseAssetsExchangedForLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RightofuseAssetsExchangedForLeaseLiabilities" xlink:to="GTBP_RightofuseAssetsExchangedForLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RightofuseAssetsExchangedForLeaseLiabilities_lbl" xml:lang="en-US">Right-of-use assets exchanged for lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" xlink:label="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" xlink:to="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption_lbl" xml:lang="en-US">Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Common stock issued upon conversion of notes payable and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockIssuedUponSettlementOfVendorPayable" xlink:label="GTBP_CommonStockIssuedUponSettlementOfVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuedUponSettlementOfVendorPayable" xlink:to="GTBP_CommonStockIssuedUponSettlementOfVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockIssuedUponSettlementOfVendorPayable_lbl" xml:lang="en-US">Common stock issued upon settlement of vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_AccountsPayableReclassifiedToConvertibleNotes" xlink:label="GTBP_AccountsPayableReclassifiedToConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AccountsPayableReclassifiedToConvertibleNotes" xlink:to="GTBP_AccountsPayableReclassifiedToConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AccountsPayableReclassifiedToConvertibleNotes_lbl" xml:lang="en-US">Accounts payable reclassified to convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ExtinguishmentOfDerivativeLiability" xlink:label="GTBP_ExtinguishmentOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfDerivativeLiability" xlink:to="GTBP_ExtinguishmentOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExtinguishmentOfDerivativeLiability_lbl" xml:lang="en-US">Extinguishment of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Series J Preferred Stock to Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="GTBP_DisclosureDerivativeLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureDerivativeLiabilityAbstract" xlink:to="GTBP_DisclosureDerivativeLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureDerivativeLiabilityAbstract_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="GTBP_DisclosureOperatingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureOperatingLeasesAbstract" xlink:to="GTBP_DisclosureOperatingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureOperatingLeasesAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_LiquidityPolicyTextBlock" xlink:label="GTBP_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiquidityPolicyTextBlock" xlink:to="GTBP_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock" xlink:label="GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock" xlink:to="GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">COVID-19</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents and Short-Term Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Fair Value of Financial Instrument</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy Financial Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Liabilities Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Liability Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:label="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:to="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_lbl" xml:lang="en-US">Schedule of Components Leases Rent Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ScheduleOfSupplementalLeaseTableTextBlock" xlink:label="GTBP_ScheduleOfSupplementalLeaseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfSupplementalLeaseTableTextBlock" xlink:to="GTBP_ScheduleOfSupplementalLeaseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfSupplementalLeaseTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturity Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock" xlink:label="GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock" xlink:to="GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Future Financial Commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Deferred Income Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Non-cash stock compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash in Operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CashOnHandAndShortTermInvestment" xlink:label="GTBP_CashOnHandAndShortTermInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashOnHandAndShortTermInvestment" xlink:to="GTBP_CashOnHandAndShortTermInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CashOnHandAndShortTermInvestment_lbl" xml:lang="en-US">Cash and short term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Cash on equity issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCash_lbl" xml:lang="en-US">Investments and cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Decrease to additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Schedule of Fair Value, off-Balance-Sheet Risks [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xml:lang="en-US">Unrealized gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Unrealized losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_lbl" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_lbl" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total financial assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Accounts payable to a third-party manufacturer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrent_2_lbl" xml:lang="en-US">Total accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Reserach and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xml:lang="en-US">Adjustment to additional paid in capital, stock issued, issuance cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock issued during period, value, new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share issued price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Notes payable, related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Converted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Total, notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableForUnpaidConsultingFee" xlink:label="GTBP_NotesPayableForUnpaidConsultingFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableForUnpaidConsultingFee" xlink:to="GTBP_NotesPayableForUnpaidConsultingFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NotesPayableForUnpaidConsultingFee_lbl" xml:lang="en-US">Notes payable for unpaid consulting fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SharesIssuedDuringPeriodValueAccruedInterest" xlink:label="GTBP_SharesIssuedDuringPeriodValueAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SharesIssuedDuringPeriodValueAccruedInterest" xlink:to="GTBP_SharesIssuedDuringPeriodValueAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SharesIssuedDuringPeriodValueAccruedInterest_lbl" xml:lang="en-US">Total accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SharesIssuedDuringPeriodSharesAccruedInterest" xlink:label="GTBP_SharesIssuedDuringPeriodSharesAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SharesIssuedDuringPeriodSharesAccruedInterest" xlink:to="GTBP_SharesIssuedDuringPeriodSharesAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SharesIssuedDuringPeriodSharesAccruedInterest_lbl" xml:lang="en-US">Number of shares issued for accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US">Common stock shares, unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Debt instrument, convertible, beneficial conversion feature</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense due to amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:label="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:to="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureDerivativeLiabilityAbstract" xlink:to="GTBP_DisclosureDerivativeLiabilityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_DisclosureDerivativeLiabilityAbstract_2_lbl" xml:lang="en-US">Schedule Of Derivative Liability Transactions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Addition</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ExtinguishmentOfWarrants" xlink:label="GTBP_ExtinguishmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfWarrants" xlink:to="GTBP_ExtinguishmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExtinguishmentOfWarrants_lbl" xml:lang="en-US">Extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_lbl" xml:lang="en-US">Warrant exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainOnDerivative_lbl" xml:lang="en-US">Net gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US">Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of warrants, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of warrants, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of warrants, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Warrants exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of options outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Number of options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of options outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2_lbl" xml:lang="en-US">Number of options outstanding, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding outstanding, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options outstanding, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' equity, reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock, capital shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Common stock exercise warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ClassOfWarrantExpireTerm" xlink:label="GTBP_ClassOfWarrantExpireTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ClassOfWarrantExpireTerm" xlink:to="GTBP_ClassOfWarrantExpireTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ClassOfWarrantExpireTerm_lbl" xml:lang="en-US">Class of warrant expire term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debt face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Debt instrument, increase, accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt conversion converted instrument amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xml:lang="en-US">Debt instrument, convertible, conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2_lbl" xml:lang="en-US">Debt conversion, converted instrument, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US">Remaining number of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xml:lang="en-US">Stock repurchase program, remaining authorized repurchase amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital, common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_2_lbl" xml:lang="en-US">Adjustments to additional paid in capital, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Number of shares issued for service</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share based compensation cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockConsultantToFairValue" xlink:label="GTBP_CommonStockConsultantToFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockConsultantToFairValue" xlink:to="GTBP_CommonStockConsultantToFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockConsultantToFairValue_lbl" xml:lang="en-US">[custom:CommonStockConsultantToFairValue]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Number of shares received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Legal and professional expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Common shares issued upon conversion of notes payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Convertible shares issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Warrants cash proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock option granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Stock options exercisable price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_3_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, vested in period, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Non- vested number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Share based compensation unvested intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Stock option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Options expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Fair value of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value of stock option, per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureOperatingLeasesAbstract" xlink:to="GTBP_DisclosureOperatingLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_DisclosureOperatingLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Components Leases Rent Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureOperatingLeasesAbstract" xlink:to="GTBP_DisclosureOperatingLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="GTBP_DisclosureOperatingLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Supplemental Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_LongtermRightofuseAssetsNet" xlink:label="GTBP_LongtermRightofuseAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LongtermRightofuseAssetsNet" xlink:to="GTBP_LongtermRightofuseAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LongtermRightofuseAssetsNet_lbl" xml:lang="en-US">Long-term right-of-use assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Non-current portion of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest/present value discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xml:lang="en-US">Commencement date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease, right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_AdditionalOperatingLeaseAssets" xlink:label="GTBP_AdditionalOperatingLeaseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AdditionalOperatingLeaseAssets" xlink:to="GTBP_AdditionalOperatingLeaseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AdditionalOperatingLeaseAssets_lbl" xml:lang="en-US">Additional Operating lease assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="us-gaap_OtherCommitmentDueInSecondYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInSecondYear" xlink:to="us-gaap_OtherCommitmentDueInSecondYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCommitmentDueInSecondYear_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US">Litigation settlement expense</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ProjectFee" xlink:label="GTBP_ProjectFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProjectFee" xlink:to="GTBP_ProjectFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ProjectFee_lbl" xml:lang="en-US">Project fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ProjectFeeIncurred" xlink:label="GTBP_ProjectFeeIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProjectFeeIncurred" xlink:to="GTBP_ProjectFeeIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ProjectFeeIncurred_lbl" xml:lang="en-US">Project fee incurred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="GTBP_ProceedsFromUpfrontAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ProceedsFromUpfrontAmount_lbl" xml:lang="en-US">Proceeds from upfront amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Maintenance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_RoyaltyFeePercentage" xlink:label="GTBP_RoyaltyFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyFeePercentage_lbl" xml:lang="en-US">Net sales percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Annual royalty payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PerformanceMilestonePayments" xlink:label="GTBP_PerformanceMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PerformanceMilestonePayments_lbl" xml:lang="en-US">Performance milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SalesMilestonePayments" xlink:label="GTBP_SalesMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesMilestonePayments_lbl" xml:lang="en-US">Sales milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_GrossSales" xlink:label="GTBP_GrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GrossSales_lbl" xml:lang="en-US">Gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SalesRevenue" xlink:label="GTBP_SalesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesRevenue_lbl" xml:lang="en-US">Sales revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CummulativeGrossSales" xlink:label="GTBP_CummulativeGrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CummulativeGrossSales_lbl" xml:lang="en-US">Cumulative gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_UpfrontLicenseFee" xlink:label="GTBP_UpfrontLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UpfrontLicenseFee_lbl" xml:lang="en-US">Upfront license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_LicenseMaintenanceFeeReceivable" xlink:label="GTBP_LicenseMaintenanceFeeReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LicenseMaintenanceFeeReceivable" xlink:to="GTBP_LicenseMaintenanceFeeReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LicenseMaintenanceFeeReceivable_lbl" xml:lang="en-US">License maintenance fee, receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock based compensation and other items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intellectual property</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets before valuation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred income tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance on net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Gross proceeds from common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Placement agent fees and other offering expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants purchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrants exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Shares and warrants sold price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Common stock value issued during the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuable" xlink:to="GTBP_CommonStockIssuable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockIssuable_doc" xml:lang="en-US">Common Stock Issuable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuableShares" xlink:to="GTBP_CommonStockIssuableShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockIssuableShares_doc" xml:lang="en-US">Common Stock Issuable Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember_doc" xml:lang="en-US">Officers Employees and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonSharesIssuableMember" xlink:to="GTBP_CommonSharesIssuableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonSharesIssuableMember_doc" xml:lang="en-US">Common Shares Issuable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_doc" xml:lang="en-US">Common shares issued upon mandatory conversion of notes payable and accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_doc" xml:lang="en-US">Common shares issued upon exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_doc" xml:lang="en-US">Issuance of common stock in public offering, net of cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_doc" xml:lang="en-US">Issuance of common stock for research and development agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCancellation" xlink:to="GTBP_StockIssuedDuringPeriodValueCancellation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCancellation_doc" xml:lang="en-US">Stock issued during period value cancellation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" xlink:to="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued_doc" xml:lang="en-US">Stock issued during period value cancellation of common stock previously issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_doc" xml:lang="en-US">Stock Issued During Period Value Common Shares In Settlement Of Vendors Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_doc" xml:lang="en-US">Common shares issued upon mandatory conversion of notes payable and accrued interest, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_doc" xml:lang="en-US">Common shares issued upon exercise of warrants, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:to="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_doc" xml:lang="en-US">Issuance of common stock in public offering, net of cost, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:to="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_doc" xml:lang="en-US">Issuance of common stock for research and development agreement, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCancellation" xlink:to="GTBP_StockIssuedDuringPeriodSharesCancellation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCancellation_doc" xml:lang="en-US">Stock issued during period shares cancellation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" xlink:to="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued_doc" xml:lang="en-US">Stock issued during period shares cancellation of common stock previously issued.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationServices" xlink:label="GTBP_StockBasedCompensationServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationServices" xlink:to="GTBP_StockBasedCompensationServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockBasedCompensationServices_doc" xml:lang="en-US">Stock based compensation services.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" xlink:label="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" xlink:to="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors_doc" xml:lang="en-US">Stock based compensation to officers and board of directors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertibleNotesPayableIssuedForConsultingServices" xlink:to="GTBP_ConvertibleNotesPayableIssuedForConsultingServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConvertibleNotesPayableIssuedForConsultingServices_doc" xml:lang="en-US">Convertible notes payable issued for consulting services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UnrealizedLossOnMarketableSecurities" xlink:to="GTBP_UnrealizedLossOnMarketableSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UnrealizedLossOnMarketableSecurities_doc" xml:lang="en-US">Unrealized loss on marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInDeposit" xlink:to="GTBP_IncreaseDecreaseInDeposit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IncreaseDecreaseInDeposit_doc" xml:lang="en-US">Increase decrease in deposit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer" xlink:to="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer_doc" xml:lang="en-US">Cancellation of common stock upon settlement with former officer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CashPaidDuringYearFor_doc" xml:lang="en-US">Cash paid during the year for [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RightofuseAssetsExchangedForLeaseLiabilities" xlink:to="GTBP_RightofuseAssetsExchangedForLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RightofuseAssetsExchangedForLeaseLiabilities_doc" xml:lang="en-US">Right of use assets exchanged for lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" xlink:to="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption_doc" xml:lang="en-US">Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuedUponSettlementOfVendorPayable" xlink:to="GTBP_CommonStockIssuedUponSettlementOfVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockIssuedUponSettlementOfVendorPayable_doc" xml:lang="en-US">Common stock issued upon settlement of vendor payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AccountsPayableReclassifiedToConvertibleNotes" xlink:to="GTBP_AccountsPayableReclassifiedToConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AccountsPayableReclassifiedToConvertibleNotes_doc" xml:lang="en-US">Accounts payable reclassified to convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfDerivativeLiability" xlink:to="GTBP_ExtinguishmentOfDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ExtinguishmentOfDerivativeLiability_doc" xml:lang="en-US">Extinguishment of derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForCashMember" xlink:to="GTBP_NotesPayableIssuedForCashMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableIssuedForCashMember_doc" xml:lang="en-US">Notes Payables Issued For Cash [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_JanuaryTwentyTwentyOneMember" xlink:to="GTBP_JanuaryTwentyTwentyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_JanuaryTwentyTwentyOneMember_doc" xml:lang="en-US">January twenty twenty one member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForSettlementAgreementsMember" xlink:to="GTBP_NotesPayableIssuedForSettlementAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableIssuedForSettlementAgreementsMember_doc" xml:lang="en-US">Notes Payable Issued For Settlement Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FiscalTwentyNinteenandTwentyTwentyMember" xlink:to="GTBP_FiscalTwentyNinteenandTwentyTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FiscalTwentyNinteenandTwentyTwentyMember_doc" xml:lang="en-US">Fiscal Twenty Ninteen And Twenty Twenty [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForForbearanceAgreementsMember" xlink:to="GTBP_NotesPayableIssuedForForbearanceAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableIssuedForForbearanceAgreementsMember_doc" xml:lang="en-US">Notes Payable Issued For Forbearance Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedExchangeForConsultingService" xlink:label="GTBP_NotesPayableIssuedExchangeForConsultingService" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedExchangeForConsultingService" xlink:to="GTBP_NotesPayableIssuedExchangeForConsultingService_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableIssuedExchangeForConsultingService_doc" xml:lang="en-US">Notes payable issued exchange for consulting service.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForConsultingAgreementMember" xlink:to="GTBP_NotesPayableIssuedForConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableIssuedForConsultingAgreementMember_doc" xml:lang="en-US">Notes payables issued for consulting agreement member.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" xlink:label="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" xlink:to="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember_doc" xml:lang="en-US">Adoption of ASU 2020-06 [Member].</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DuringTwentyTwentyMember" xlink:label="GTBP_DuringTwentyTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DuringTwentyTwentyMember" xlink:to="GTBP_DuringTwentyTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_DuringTwentyTwentyMember_doc" xml:lang="en-US">During 2020 [Member].</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_InterestExpenseDueAmortizationOfDebtDiscount" xlink:label="GTBP_InterestExpenseDueAmortizationOfDebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InterestExpenseDueAmortizationOfDebtDiscount" xlink:to="GTBP_InterestExpenseDueAmortizationOfDebtDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_InterestExpenseDueAmortizationOfDebtDiscount_doc" xml:lang="en-US">Interest expense due amortization of debt discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:to="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1_doc" xml:lang="en-US">Derivative liability fair value assumptions expected term 1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_doc" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_EmploymentAgreementsMember" xlink:to="GTBP_EmploymentAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_EmploymentAgreementsMember_doc" xml:lang="en-US">Employment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockSharesGrantedForConsultants" xlink:label="GTBP_CommonStockSharesGrantedForConsultants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockSharesGrantedForConsultants" xlink:to="GTBP_CommonStockSharesGrantedForConsultants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockSharesGrantedForConsultants_doc" xml:lang="en-US">Common stock shares granted for consultants.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_FairValueOfStockOptionsGrantedForConsultants" xlink:label="GTBP_FairValueOfStockOptionsGrantedForConsultants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfStockOptionsGrantedForConsultants" xlink:to="GTBP_FairValueOfStockOptionsGrantedForConsultants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FairValueOfStockOptionsGrantedForConsultants_doc" xml:lang="en-US">Fair value of stock options granted for consultants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options vested and expected to unvest outstanding aggregate intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConsultantsMember" xlink:to="GTBP_ConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConsultantsMember_doc" xml:lang="en-US">Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockConsultantToFairValue" xlink:to="GTBP_CommonStockConsultantToFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockConsultantToFairValue_doc" xml:lang="en-US">Common stock consultant to fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ResearchAndDevelopmentAgreementMember" xlink:to="GTBP_ResearchAndDevelopmentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ResearchAndDevelopmentAgreementMember_doc" xml:lang="en-US">Research And Development Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesKPreferredStocksMember" xlink:to="GTBP_SeriesKPreferredStocksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesKPreferredStocksMember_doc" xml:lang="en-US">Series K Preferred Stocks [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Paymen tAward Non Options Exercises In Period Weighted Average Exercise Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoEmployeesMember" xlink:to="GTBP_TwoEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoEmployeesMember_doc" xml:lang="en-US">Two Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SheffieldPropertiesMember" xlink:to="GTBP_SheffieldPropertiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SheffieldPropertiesMember_doc" xml:lang="en-US">Sheffield Properties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProjectFee" xlink:to="GTBP_ProjectFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ProjectFee_doc" xml:lang="en-US">Project fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProjectFeeIncurred" xlink:to="GTBP_ProjectFeeIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ProjectFeeIncurred_doc" xml:lang="en-US">Project fee incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScientificResearchAgreementMember" xlink:to="GTBP_ScientificResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScientificResearchAgreementMember_doc" xml:lang="en-US">Scientific Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" xlink:label="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" xlink:to="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_doc" xml:lang="en-US">Research and development arrangement contract to perform for others costs incurred.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_MasterServicesAgreementMember" xlink:label="GTBP_MasterServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MasterServicesAgreementMember" xlink:to="GTBP_MasterServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_MasterServicesAgreementMember_doc" xml:lang="en-US">Master Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_MasterServiceAgreementMember" xlink:label="GTBP_MasterServiceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MasterServiceAgreementMember" xlink:to="GTBP_MasterServiceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_MasterServiceAgreementMember_doc" xml:lang="en-US">Master Service Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ProceedsFromUpfrontAmount_doc" xml:lang="en-US">Received upfront payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xml:lang="en-US">2016  Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyFeePercentage_doc" xml:lang="en-US">Royalty fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PerformanceMilestonePayments_doc" xml:lang="en-US">Performance milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesMilestonePayments_doc" xml:lang="en-US">Sales milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_GrossSales_doc" xml:lang="en-US">Gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesRevenue_doc" xml:lang="en-US">Sales revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CummulativeGrossSales_doc" xml:lang="en-US">Cummulative gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UpfrontLicenseFee_doc" xml:lang="en-US">Upfront license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xml:lang="en-US">2021 Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LicenseMaintenanceFeeReceivable" xlink:to="GTBP_LicenseMaintenanceFeeReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LicenseMaintenanceFeeReceivable_doc" xml:lang="en-US">License maintenance fee, receivable.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NetSalesPercentage" xlink:label="GTBP_NetSalesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NetSalesPercentage" xlink:to="GTBP_NetSalesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NetSalesPercentage_doc" xml:lang="en-US">Net sales percentage.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DeferredTaxAssetsPatentAmortization" xlink:label="GTBP_DeferredTaxAssetsPatentAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DeferredTaxAssetsPatentAmortization" xlink:to="GTBP_DeferredTaxAssetsPatentAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_DeferredTaxAssetsPatentAmortization_doc" xml:lang="en-US">Deferred tax assets patent amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiquidityPolicyTextBlock" xlink:to="GTBP_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_doc" xml:lang="en-US">Stock issued during period shares common sharesIn settlement of vendors payable.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_AimmuneTherapeuticsIncMember" xlink:label="GTBP_AimmuneTherapeuticsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AimmuneTherapeuticsIncMember" xlink:to="GTBP_AimmuneTherapeuticsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AimmuneTherapeuticsIncMember_doc" xml:lang="en-US">Aimmune Therapeutics Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ThirdPartyManufacturerMember" xlink:to="GTBP_ThirdPartyManufacturerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ThirdPartyManufacturerMember_doc" xml:lang="en-US">Third Party Manufacturer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PaymentAgreementMember" xlink:to="GTBP_PaymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PaymentAgreementMember_doc" xml:lang="en-US">Payment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NovemberTwoThousandAndTwentyTwoMember" xlink:label="GTBP_NovemberTwoThousandAndTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NovemberTwoThousandAndTwentyTwoMember" xlink:to="GTBP_NovemberTwoThousandAndTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NovemberTwoThousandAndTwentyTwoMember_doc" xml:lang="en-US">November 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_VendorMember" xlink:label="GTBP_VendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_VendorMember" xlink:to="GTBP_VendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_VendorMember_doc" xml:lang="en-US">Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OfficersMember" xlink:label="GTBP_OfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersMember" xlink:to="GTBP_OfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficersMember_doc" xml:lang="en-US">Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockOptionsMember" xlink:label="GTBP_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockOptionsMember" xlink:to="GTBP_StockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockOptionsMember_doc" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesJPreferredStockMember" xlink:to="GTBP_SeriesJPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesJPreferredStockMember_doc" xml:lang="en-US">Series J Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConsultantEmployeesOfficersAndDirectorsMember" xlink:to="GTBP_ConsultantEmployeesOfficersAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConsultantEmployeesOfficersAndDirectorsMember_doc" xml:lang="en-US">Consultant Employees Officers And Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymenAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymenAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymenAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymenAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymenAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based paymen award equity instrument other than options vested in period.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equit iInstruments forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:to="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_doc" xml:lang="en-US">Schedule Of Other Information Related Leases UnderN On Cancellable [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommitmentAndContegenciesTableTextBlock" xlink:label="GTBP_CommitmentAndContegenciesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommitmentAndContegenciesTableTextBlock" xlink:to="GTBP_CommitmentAndContegenciesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommitmentAndContegenciesTableTextBlock_doc" xml:lang="en-US">Commitment And Contegencies [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InstitutionalInvestorMember" xlink:to="GTBP_InstitutionalInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_InstitutionalInvestorMember_doc" xml:lang="en-US">Institutional Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreFundedWarrantsMember" xlink:to="GTBP_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockWarrantsMember" xlink:label="GTBP_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockWarrantsMember" xlink:to="GTBP_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PreFundedMember" xlink:label="GTBP_PreFundedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreFundedMember" xlink:to="GTBP_PreFundedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PreFundedMember_doc" xml:lang="en-US">Pre Funded [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PreFundedExercisePriceMember" xlink:label="GTBP_PreFundedExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreFundedExercisePriceMember" xlink:to="GTBP_PreFundedExercisePriceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PreFundedExercisePriceMember_doc" xml:lang="en-US">Pre Funded Exercise Price [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseAgreementMember" xlink:to="GTBP_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantsMember" xlink:to="GTBP_CommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonWarrantsMember_doc" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_HCWainwrightCoLLCMember" xlink:label="GTBP_HCWainwrightCoLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_HCWainwrightCoLLCMember" xlink:to="GTBP_HCWainwrightCoLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_HCWainwrightCoLLCMember_doc" xml:lang="en-US">HC Wainwright Co LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_AccountsPayableAndLineOfCreditCurrent" xlink:label="GTBP_AccountsPayableAndLineOfCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AccountsPayableAndLineOfCreditCurrent" xlink:to="GTBP_AccountsPayableAndLineOfCreditCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AccountsPayableAndLineOfCreditCurrent_doc" xml:lang="en-US">Accounts Payable And Line Of Credi tCurrent.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OfficeSpaceAndEquipmentMember" xlink:label="GTBP_OfficeSpaceAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficeSpaceAndEquipmentMember" xlink:to="GTBP_OfficeSpaceAndEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficeSpaceAndEquipmentMember_doc" xml:lang="en-US">Office Space and Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashOnHandAndShortTermInvestment" xlink:to="GTBP_CashOnHandAndShortTermInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CashOnHandAndShortTermInvestment_doc" xml:lang="en-US">Cash on hand and short term investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CorporateNotesAndCommercialPaperMember" xlink:to="GTBP_CorporateNotesAndCommercialPaperMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CorporateNotesAndCommercialPaperMember_doc" xml:lang="en-US">Corporate Notes and Commercial Paper [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesJIPreferredStockMember" xlink:label="GTBP_SeriesJIPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesJIPreferredStockMember" xlink:to="GTBP_SeriesJIPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesJIPreferredStockMember_doc" xml:lang="en-US">Series J-I Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesKPreferredStockMember" xlink:to="GTBP_SeriesKPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesKPreferredStockMember_doc" xml:lang="en-US">Series K Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OfficeLeaseAgreementsMember" xlink:label="GTBP_OfficeLeaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficeLeaseAgreementsMember" xlink:to="GTBP_OfficeLeaseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficeLeaseAgreementsMember_doc" xml:lang="en-US">Office Lease Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants" xlink:to="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants_doc" xml:lang="en-US">Equity compensation to consultants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants" xlink:to="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants_doc" xml:lang="en-US">Equity compensation to consultants, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock" xlink:to="GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock_doc" xml:lang="en-US">Unusual Risks and Uncertainties [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsToPurchaseCommonStockMember" xlink:to="GTBP_WarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OptionsToPurchaseCommonStockMember" xlink:to="GTBP_OptionsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OptionsToPurchaseCommonStockMember_doc" xml:lang="en-US">Options to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableForUnpaidConsultingFee" xlink:to="GTBP_NotesPayableForUnpaidConsultingFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableForUnpaidConsultingFee_doc" xml:lang="en-US">Notes payable for unpaid consulting fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SharesIssuedDuringPeriodValueAccruedInterest" xlink:to="GTBP_SharesIssuedDuringPeriodValueAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SharesIssuedDuringPeriodValueAccruedInterest_doc" xml:lang="en-US">Shares issued during period value accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SharesIssuedDuringPeriodSharesAccruedInterest" xlink:to="GTBP_SharesIssuedDuringPeriodSharesAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SharesIssuedDuringPeriodSharesAccruedInterest_doc" xml:lang="en-US">Number of shares issued for accrued interest.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OptionsWarrantsAndConvertibleNotesMember" xlink:label="GTBP_OptionsWarrantsAndConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OptionsWarrantsAndConvertibleNotesMember" xlink:to="GTBP_OptionsWarrantsAndConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OptionsWarrantsAndConvertibleNotesMember_doc" xml:lang="en-US">Options Warrants and Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OtherConsultantsMember" xlink:label="GTBP_OtherConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OtherConsultantsMember" xlink:to="GTBP_OtherConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OtherConsultantsMember_doc" xml:lang="en-US">Other Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock" xlink:to="GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock_doc" xml:lang="en-US">Schedule of Company&#8217;s Future Financial Commitment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants" xlink:to="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants_doc" xml:lang="en-US">Issuance of common stock as equity compensation to consultants.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IssuanceOfCommonStockForServicesShares" xlink:label="GTBP_IssuanceOfCommonStockForServicesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfCommonStockForServicesShares" xlink:to="GTBP_IssuanceOfCommonStockForServicesShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IssuanceOfCommonStockForServicesShares_doc" xml:lang="en-US">Issuance of common stock for services shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultantsShares" xlink:label="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultantsShares" xlink:to="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultantsShares_doc" xml:lang="en-US">Issuance of common stock as equity compensation to consultants shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:to="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors_doc" xml:lang="en-US">Stock based compensation officers employees and board of directors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" xlink:to="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment_doc" xml:lang="en-US">Stock based compensation consultants and research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationVestedStockOptions" xlink:to="GTBP_StockBasedCompensationVestedStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockBasedCompensationVestedStockOptions_doc" xml:lang="en-US">Stock based compensation vested stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement" xlink:to="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement_doc" xml:lang="en-US">Fair value of common stock issued to note holder as settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ServiceAgreementMember" xlink:to="GTBP_ServiceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ServiceAgreementMember_doc" xml:lang="en-US">Service Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertibleNotePayableMember" xlink:to="GTBP_ConvertibleNotePayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConvertibleNotePayableMember_doc" xml:lang="en-US">Convertible Note Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ClassOfWarrantExpireTerm" xlink:to="GTBP_ClassOfWarrantExpireTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ClassOfWarrantExpireTerm_doc" xml:lang="en-US">Class of warrant expire term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InvestorsMember" xlink:to="GTBP_InvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_InvestorsMember_doc" xml:lang="en-US">Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertibleNoteMember" xlink:to="GTBP_ConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConvertibleNoteMember_doc" xml:lang="en-US">Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NoteHolderMember" xlink:to="GTBP_NoteHolderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NoteHolderMember_doc" xml:lang="en-US">Note Holder [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesJOnePreferredStockMember" xlink:to="GTBP_SeriesJOnePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesJOnePreferredStockMember_doc" xml:lang="en-US">Series J One Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AdditionalOperatingLeaseAssets" xlink:to="GTBP_AdditionalOperatingLeaseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AdditionalOperatingLeaseAssets_doc" xml:lang="en-US">Additional operating lease assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OwnersMember" xlink:to="GTBP_OwnersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OwnersMember_doc" xml:lang="en-US">Owners [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfSupplementalLeaseTableTextBlock" xlink:to="GTBP_ScheduleOfSupplementalLeaseTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfSupplementalLeaseTableTextBlock_doc" xml:lang="en-US">Schedule of Supplemental Lease [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LongtermRightofuseAssetsNet" xlink:to="GTBP_LongtermRightofuseAssetsNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LongtermRightofuseAssetsNet_doc" xml:lang="en-US">Long term right of use assets net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" xlink:to="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets_doc" xml:lang="en-US">Increase decrease in prepaid expense and other current assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfWarrants" xlink:to="GTBP_ExtinguishmentOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ExtinguishmentOfWarrants_doc" xml:lang="en-US">Extinguishment of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersAndDirectorsMember" xlink:to="GTBP_OfficersAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficersAndDirectorsMember_doc" xml:lang="en-US">Officers and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_2_lbl" xml:lang="en-US">Interest Income, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants" xlink:to="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueEquityCompensationToConsultants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement" xlink:to="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement_3_lbl" xml:lang="en-US">FairValueOfCommonStockIssuedToNoteholderAsSettlement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UnrealizedLossOnMarketableSecurities" xlink:to="GTBP_UnrealizedLossOnMarketableSecurities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UnrealizedLossOnMarketableSecurities_3_lbl" xml:lang="en-US">UnrealizedLossOnMarketableSecurities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" xlink:to="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets_3_lbl" xml:lang="en-US">IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInDeposit" xlink:to="GTBP_IncreaseDecreaseInDeposit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IncreaseDecreaseInDeposit_3_lbl" xml:lang="en-US">IncreaseDecreaseInDeposit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer" xlink:to="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer_3_lbl" xml:lang="en-US">CancellationOfCommonStockUponSettlementWithFormerOfficer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_2_lbl" xml:lang="en-US">Derivatives and Fair Value [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_2_lbl" xml:lang="en-US">Notes Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_2_lbl" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_2_lbl" xml:lang="en-US">Other Commitment, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInSecondYear" xlink:to="us-gaap_OtherCommitmentDueInSecondYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentDueInSecondYear_2_lbl" xml:lang="en-US">Other Commitment, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_2_lbl" xml:lang="en-US">Other Commitment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>gtbp-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20221231.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:href="gtbp-20221231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:href="gtbp-20221231.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:href="gtbp-20221231.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayable" xlink:href="gtbp-20221231.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:href="gtbp-20221231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiability" xlink:href="gtbp-20221231.xsd#DerivativeLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquity" xlink:href="gtbp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeases" xlink:href="gtbp-20221231.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/IncomeTax" xlink:href="gtbp-20221231.xsd#IncomeTax" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvents" xlink:href="gtbp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="gtbp-20221231.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableTables" xlink:href="gtbp-20221231.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:href="gtbp-20221231.xsd#DerivativeLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:href="gtbp-20221231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:href="gtbp-20221231.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:href="gtbp-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/IncomeTaxTables" xlink:href="gtbp-20221231.xsd#IncomeTaxTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:href="gtbp-20221231.xsd#AccountsPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="gtbp-20221231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:href="gtbp-20221231.xsd#DerivativeLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="gtbp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfComponentsLeasesRentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfSupplementalLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfMaturityLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:href="gtbp-20221231.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfCompanysFutureFinancialCommitmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:href="gtbp-20221231.xsd#ScheduleOfIncomeTaxProvisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/IncomeTaxDetailsNarrative" xlink:href="gtbp-20221231.xsd#IncomeTaxDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="gtbp-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockIssuable" xlink:label="loc_GTBPCommonStockIssuable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_GTBPCommonStockIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockIssuableShares" xlink:label="loc_GTBPCommonStockIssuableShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPCommonStockIssuableShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndDirectorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonSharesIssuableMember" xlink:label="loc_GTBPCommonSharesIssuableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_GTBPCommonSharesIssuableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants" xlink:label="loc_GTBPIssuanceOfCommonStockAsEquityCompensationToConsultants" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPIssuanceOfCommonStockAsEquityCompensationToConsultants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesEquityCompensationToConsultants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesEquityCompensationToConsultants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCancellation" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCancellation" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCancellation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCancellation" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCancellation" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCancellation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants" xlink:label="loc_GTBPStockIssuedDuringPeriodValueEquityCompensationToConsultants" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueEquityCompensationToConsultants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" xlink:label="loc_GTBPStockBasedCompensationConsultantsAndResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPStockBasedCompensationConsultantsAndResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:label="loc_GTBPStockBasedCompensationOfficersEmployeesAndBoardOfDirectors" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPStockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_StockBasedCompensationVestedStockOptions" xlink:label="loc_GTBPStockBasedCompensationVestedStockOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPStockBasedCompensationVestedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement" xlink:label="loc_GTBPFairValueOfCommonStockIssuedToNoteholderAsSettlement" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPFairValueOfCommonStockIssuedToNoteholderAsSettlement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConvertibleNotesPayableIssuedForConsultingServices" xlink:label="loc_GTBPConvertibleNotesPayableIssuedForConsultingServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPConvertibleNotesPayableIssuedForConsultingServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_UnrealizedLossOnMarketableSecurities" xlink:label="loc_GTBPUnrealizedLossOnMarketableSecurities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPUnrealizedLossOnMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" xlink:label="loc_GTBPIncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_GTBPIncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_IncreaseDecreaseInDeposit" xlink:label="loc_GTBPIncreaseDecreaseInDeposit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_GTBPIncreaseDecreaseInDeposit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer" xlink:label="loc_GTBPCancellationOfCommonStockUponSettlementWithFormerOfficer" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_GTBPCancellationOfCommonStockUponSettlementWithFormerOfficer" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CashPaidDuringYearFor" xlink:label="loc_GTBPCashPaidDuringYearFor" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_GTBPCashPaidDuringYearFor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_RightofuseAssetsExchangedForLeaseLiabilities" xlink:label="loc_GTBPRightofuseAssetsExchangedForLeaseLiabilities" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPRightofuseAssetsExchangedForLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" xlink:label="loc_GTBPExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockIssuedUponSettlementOfVendorPayable" xlink:label="loc_GTBPCommonStockIssuedUponSettlementOfVendorPayable" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPCommonStockIssuedUponSettlementOfVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_AccountsPayableReclassifiedToConvertibleNotes" xlink:label="loc_GTBPAccountsPayableReclassifiedToConvertibleNotes" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPAccountsPayableReclassifiedToConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ExtinguishmentOfDerivativeLiability" xlink:label="loc_GTBPExtinguishmentOfDerivativeLiability" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPExtinguishmentOfDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:title="00000010 - Disclosure - Fair Value of Financial Instruments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayable" xlink:title="00000011 - Disclosure - Accounts Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:title="00000012 - Disclosure - Convertible Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiability" xlink:title="00000013 - Disclosure - Derivative Liability">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_GTBPDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="loc_us-gaapDerivativesAndFairValueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapDerivativesAndFairValueTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeases" xlink:title="00000015 - Disclosure - Operating Leases">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/IncomeTax" xlink:title="00000017 - Disclosure - Income Tax">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_LiquidityPolicyTextBlock" xlink:label="loc_GTBPLiquidityPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_GTBPUnusualRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPUnusualRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000021 - Disclosure - Fair Value of Financial Instruments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableTables" xlink:title="00000022 - Disclosure - Accounts Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:title="00000023 - Disclosure - Derivative Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_GTBPDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:title="00000024 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:title="00000025 - Disclosure - Operating Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:label="loc_GTBPScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_GTBPScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ScheduleOfSupplementalLeaseTableTextBlock" xlink:label="loc_GTBPScheduleOfSupplementalLeaseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_GTBPScheduleOfSupplementalLeaseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock" xlink:label="loc_GTBPScheduleOfCompanysFutureFinancialCommitmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_GTBPScheduleOfCompanysFutureFinancialCommitmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/IncomeTaxTables" xlink:title="00000027 - Disclosure - Income Tax (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000028 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_WarrantsToPurchaseCommonStockMember" xlink:label="loc_GTBPWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OptionsToPurchaseCommonStockMember" xlink:label="loc_GTBPOptionsToPurchaseCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPOptionsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CashOnHandAndShortTermInvestment" xlink:label="loc_GTBPCashOnHandAndShortTermInvestment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPCashOnHandAndShortTermInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash" xlink:label="loc_us-gaapInvestmentsAndCash" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInvestmentsAndCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:title="00000030 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaapShortTermInvestmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapShortTermInvestmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:title="00000031 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CorporateNotesAndCommercialPaperMember" xlink:label="loc_GTBPCorporateNotesAndCommercialPaperMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_GTBPCorporateNotesAndCommercialPaperMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="00000032 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:title="00000033 - Disclosure - Accounts Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ServiceAgreementMember" xlink:label="loc_GTBPServiceAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPServiceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PaymentAgreementMember" xlink:label="loc_GTBPPaymentAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPaymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ThirdPartyManufacturerMember" xlink:label="loc_GTBPThirdPartyManufacturerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPThirdPartyManufacturerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesCurrentAndNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForCashMember" xlink:label="loc_GTBPNotesPayableIssuedForCashMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForCashMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForSettlementAgreementsMember" xlink:label="loc_GTBPNotesPayableIssuedForSettlementAgreementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForSettlementAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForForbearanceAgreementsMember" xlink:label="loc_GTBPNotesPayableIssuedForForbearanceAgreementsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForForbearanceAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableIssuedForConsultingAgreementMember" xlink:label="loc_GTBPNotesPayableIssuedForConsultingAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConvertibleNotePayableMember" xlink:label="loc_GTBPConvertibleNotePayableMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPConvertibleNotePayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_FiscalTwentyNinteenandTwentyTwentyMember" xlink:label="loc_GTBPFiscalTwentyNinteenandTwentyTwentyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPFiscalTwentyNinteenandTwentyTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_JanuaryTwentyTwentyOneMember" xlink:label="loc_GTBPJanuaryTwentyTwentyOneMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPJanuaryTwentyTwentyOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="loc_us-gaapAccountingStandardsUpdate202006Member" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate202006Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NotesPayableForUnpaidConsultingFee" xlink:label="loc_GTBPNotesPayableForUnpaidConsultingFee" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPNotesPayableForUnpaidConsultingFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SharesIssuedDuringPeriodValueAccruedInterest" xlink:label="loc_GTBPSharesIssuedDuringPeriodValueAccruedInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPSharesIssuedDuringPeriodValueAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SharesIssuedDuringPeriodSharesAccruedInterest" xlink:label="loc_GTBPSharesIssuedDuringPeriodSharesAccruedInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPSharesIssuedDuringPeriodSharesAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaapCommonStockSharesSubscribedButUnissued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscribedButUnissued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:title="00000035 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_GTBPDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:label="loc_GTBPDerivativeLiabilityFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_GTBPDerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:title="00000036 - Disclosure - Schedule of Derivative Liability Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_GTBPDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ExtinguishmentOfWarrants" xlink:label="loc_GTBPExtinguishmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_GTBPExtinguishmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:title="00000037 - Disclosure - Derivative Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_GTBPDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaapDerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapDerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000038 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000039 - Disclosure - Schedule of Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OwnersMember" xlink:label="loc_GTBPOwnersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOwnersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_InvestorsMember" xlink:label="loc_GTBPInvestorsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_NoteHolderMember" xlink:label="loc_GTBPNoteHolderMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPNoteHolderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_OfficersAndDirectorsMember" xlink:label="loc_GTBPOfficersAndDirectorsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConsultantsMember" xlink:label="loc_GTBPConsultantsMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConsultantEmployeesOfficersAndDirectorsMember" xlink:label="loc_GTBPConsultantEmployeesOfficersAndDirectorsMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPConsultantEmployeesOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_EmployeesMember" xlink:label="loc_GTBPEmployeesMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_TwoEmployeesMember" xlink:label="loc_GTBPTwoEmployeesMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPTwoEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ConvertibleNoteMember" xlink:label="loc_GTBPConvertibleNoteMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_EmploymentAgreementsMember" xlink:label="loc_GTBPEmploymentAgreementsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPEmploymentAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesJOnePreferredStockMember" xlink:label="loc_GTBPSeriesJOnePreferredStockMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesJOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesJPreferredStockMember" xlink:label="loc_GTBPSeriesJPreferredStockMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesJPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesKPreferredStocksMember" xlink:label="loc_GTBPSeriesKPreferredStocksMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesKPreferredStocksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SeriesKPreferredStockMember" xlink:label="loc_GTBPSeriesKPreferredStockMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesKPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ClassOfWarrantExpireTerm" xlink:label="loc_GTBPClassOfWarrantExpireTerm" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPClassOfWarrantExpireTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaapStockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaapStockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonStockConsultantToFairValue" xlink:label="loc_GTBPCommonStockConsultantToFairValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPCommonStockConsultantToFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaapPreferredStockConvertibleSharesIssuable" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleSharesIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails" xlink:title="00000041 - Disclosure - Schedule of Components Leases Rent Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails" xlink:title="00000042 - Disclosure - Schedule of Supplemental Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_LongtermRightofuseAssetsNet" xlink:label="loc_GTBPLongtermRightofuseAssetsNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_GTBPLongtermRightofuseAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails" xlink:title="00000043 - Disclosure - Schedule of Maturity Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000044 - Disclosure - Operating Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapLeaseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingSubleaseOptionToExtend" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingSubleaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_AdditionalOperatingLeaseAssets" xlink:label="loc_GTBPAdditionalOperatingLeaseAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_GTBPAdditionalOperatingLeaseAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails" xlink:title="00000045 - Disclosure - Schedule of Company&#8217;s Future Financial Commitment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="loc_us-gaapOtherCommitmentDueInNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentDueInNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaapOtherCommitmentDueInSecondYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentDueInSecondYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000046 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SheffieldPropertiesMember" xlink:label="loc_GTBPSheffieldPropertiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPSheffieldPropertiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ScientificResearchAgreementMember" xlink:label="loc_GTBPScientificResearchAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPScientificResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ProjectFee" xlink:label="loc_GTBPProjectFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProjectFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ProjectFeeIncurred" xlink:label="loc_GTBPProjectFeeIncurred" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProjectFeeIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_LicenseMaintenanceFeeReceivable" xlink:label="loc_GTBPLicenseMaintenanceFeeReceivable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPLicenseMaintenanceFeeReceivable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:title="00000047 - Disclosure - Schedule of Net Deferred Income Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:title="00000048 - Disclosure - Schedule of Income Tax Provision (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/IncomeTaxDetailsNarrative" xlink:title="00000049 - Disclosure - Income Tax (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaapOperatingLossCarryforwardsExpirationDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000050 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PurchaseAgreementMember" xlink:label="loc_GTBPPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_ResearchAndDevelopmentAgreementMember" xlink:label="loc_GTBPResearchAndDevelopmentAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPResearchAndDevelopmentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_InstitutionalInvestorMember" xlink:label="loc_GTBPInstitutionalInvestorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_GTBPInstitutionalInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_PreFundedWarrantsMember" xlink:label="loc_GTBPPreFundedWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20221231.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219804251008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GT
BIOPHARMA, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000109657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-1620407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8000
Marina Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">919-4040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GTBP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,809,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">In
Part III, portions of the registrant&#8217;s 2023 Proxy Statement to be filed with the Securities and Exchange Commission within 120
days of the Registrant&#8217;s fiscal year end.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Weinberg
    & Company, P.A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Los
    Angeles, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219802378432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,672,000<span></span>
</td>
<td class="nump">$ 8,968,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">10,836,000<span></span>
</td>
<td class="nump">23,011,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">16,562,000<span></span>
</td>
<td class="nump">32,169,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">16,736,000<span></span>
</td>
<td class="nump">32,169,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,140,000<span></span>
</td>
<td class="nump">8,189,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,669,000<span></span>
</td>
<td class="nump">1,901,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of credit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">4,938,000<span></span>
</td>
<td class="nump">10,259,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">5,002,000<span></span>
</td>
<td class="nump">10,259,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001, 250,000,000 shares authorized, 32,722,452 shares and 32,061,989 shares issued and outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CommonStockIssuable', window );">Common stock issuable, 0 shares and 327,298 shares at December 31, 2022 and 2021, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">686,168,000<span></span>
</td>
<td class="nump">674,348,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(674,468,000)<span></span>
</td>
<td class="num">(653,584,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">11,734,000<span></span>
</td>
<td class="nump">21,910,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 16,736,000<span></span>
</td>
<td class="nump">$ 32,169,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219804160240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">32,722,452<span></span>
</td>
<td class="nump">32,061,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">32,722,452<span></span>
</td>
<td class="nump">32,061,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CommonStockIssuableShares', window );">Common stock issuable, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">327,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuable Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219803214928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including $718 and $0 of stock compensation to officers, directors and employees during the years ended December 31, 2022 and 2021, respectively)</a></td>
<td class="nump">8,811<span></span>
</td>
<td class="nump">9,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including $3,903 and $17,234 of stock compensation to officers, directors and employees during the years ended December 31, 2022 and 2021, respectively)</a></td>
<td class="nump">12,446<span></span>
</td>
<td class="nump">47,924<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">21,257<span></span>
</td>
<td class="nump">57,515<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(21,257)<span></span>
</td>
<td class="num">(57,515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (Income) Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">(292)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other (Income) Expense</a></td>
<td class="num">(373)<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (20,884)<span></span>
</td>
<td class="num">$ (58,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Share - Basic and Diluted</a></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (2.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">31,868,024<span></span>
</td>
<td class="nump">28,155,624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219804243776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical) - Officers Employees and Directors [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 718<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 3,903<span></span>
</td>
<td class="nump">$ 17,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219805494752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Common Shares Issuable [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 566,356<span></span>
</td>
<td class="num">$ (595,797)<span></span>
</td>
<td class="num">$ (29,433)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">2,450<span></span>
</td>
<td class="nump">5,218<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Extinguishment of debt discount upon adoption of ASU 2020-06</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,745)<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="num">(4,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Conversion of Preferred Series J-1 to common stock</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Conversion of Preferred Series J-1 to common stock, shares</a></td>
<td class="num">(2,354)<span></span>
</td>
<td class="nump">692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest', window );">Common shares issued upon mandatory conversion of notes payable and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 1,113<span></span>
</td>
<td class="nump">37,675<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">38,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest', window );">Common shares issued upon mandatory conversion of notes payable and accrued interest, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,086<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants', window );">Common shares issued upon exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,430<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants', window );">Common shares issued upon exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost', window );">Issuance of common stock in public offering, net of cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,674<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost', window );">Issuance of common stock in public offering, net of cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement', window );">Issuance of common stock for research and development agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement', window );">Issuance of common stock for research and development agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants', window );">Issuance of common stock as equity compensation to consultants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,337<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants', window );">Equity compensation to consultants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock as equity compensation to officers, employees, and board of directors</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,979<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Equity compensation to officers, employees, and board of directors, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Extinguishment of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(58,013)<span></span>
</td>
<td class="num">(58,013)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 1,113<span></span>
</td>
<td class="nump">674,348<span></span>
</td>
<td class="num">(653,584)<span></span>
</td>
<td class="nump">21,910<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">32,062<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants', window );">Equity compensation to consultants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock as equity compensation to officers, employees, and board of directors</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,521<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Equity compensation to officers, employees, and board of directors, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,032<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,884)<span></span>
</td>
<td class="num">(20,884)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCancellation', window );">Cancellation of common stock previously issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCancellation', window );">Cancellation of common stock previously issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued', window );">Cancellation of common stock previously issued to prior CEO</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued', window );">Cancellation of common stock previously issued to prior CEO, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,113)<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of notes payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants', window );">Issuance of common stock as equity compensation to consultants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,091<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable', window );">Issuance of common stock in settlement of vendor payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable', window );">Issuance of common shares in settlement of vendors payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 686,168<span></span>
</td>
<td class="num">$ (674,468)<span></span>
</td>
<td class="nump">$ 11,734<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">32,723<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock as equity compensation to consultants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for research and development agreement, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares cancellation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares cancellation of common stock previously issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common sharesIn settlement of vendors payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares issued upon exercise of warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares issued upon mandatory conversion of notes payable and accrued interest, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity compensation to consultants, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in public offering, net of cost, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value cancellation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value cancellation of common stock previously issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Common Shares In Settlement Of Vendors Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares issued upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares issued upon mandatory conversion of notes payable and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity compensation to consultants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for research and development agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in public offering, net of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219804320512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,884)<span></span>
</td>
<td class="num">$ (58,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment', window );">Stock based compensation &#8211; consultants and research and development</a></td>
<td class="nump">2,522<span></span>
</td>
<td class="nump">16,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors', window );">Stock based compensation - officers, employees and board of directors</a></td>
<td class="nump">2,092<span></span>
</td>
<td class="nump">16,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockBasedCompensationVestedStockOptions', window );">Stock based compensation - vested stock options</a></td>
<td class="nump">3,032<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement', window );">Fair value of common stock issued to a noteholder as settlement</a></td>
<td class="nump">35<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertibleNotesPayableIssuedForConsultingServices', window );">Convertible notes payable issued for consulting services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Change in operating lease right-of-use assets</a></td>
<td class="nump">95<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain from extinguishment of line of credit</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_UnrealizedLossOnMarketableSecurities', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets', window );">Decrease in prepaid expenses and other current assets</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_IncreaseDecreaseInDeposit', window );">(Increase) in deposits</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">(Decrease) increase in accounts payable and accrued expenses</a></td>
<td class="num">(2,030)<span></span>
</td>
<td class="nump">7,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liability</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Increase in accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(15,217)<span></span>
</td>
<td class="num">(15,606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Sales (purchases) of investments</a></td>
<td class="nump">12,145<span></span>
</td>
<td class="num">(23,040)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by (Used in) Investing Activities</a></td>
<td class="nump">12,145<span></span>
</td>
<td class="num">(23,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">24,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer', window );">Cancellation of common stock upon settlement with former officer</a></td>
<td class="num">(224)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes', window );">Proceeds from issuance of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash (Used in) Provided by Financing Activities</a></td>
<td class="num">(224)<span></span>
</td>
<td class="nump">42,317<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (Decrease) Increase in Cash</a></td>
<td class="num">(3,296)<span></span>
</td>
<td class="nump">3,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at Beginning of Period</a></td>
<td class="nump">8,968<span></span>
</td>
<td class="nump">5,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at End of Period</a></td>
<td class="nump">5,672<span></span>
</td>
<td class="nump">8,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RightofuseAssetsExchangedForLeaseLiabilities', window );">Right-of-use assets exchanged for lease liabilities</a></td>
<td class="nump">260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption', window );">Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued upon conversion of notes payable and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">38,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CommonStockIssuedUponSettlementOfVendorPayable', window );">Common stock issued upon settlement of vendor payable</a></td>
<td class="nump">3,251<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AccountsPayableReclassifiedToConvertibleNotes', window );">Accounts payable reclassified to convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ExtinguishmentOfDerivativeLiability', window );">Extinguishment of derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series J Preferred Stock to Common Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_AccountsPayableReclassifiedToConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable reclassified to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_AccountsPayableReclassifiedToConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cancellation of common stock upon settlement with former officer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockIssuedUponSettlementOfVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued upon settlement of vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockIssuedUponSettlementOfVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ConvertibleNotesPayableIssuedForConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes payable issued for consulting services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ConvertibleNotesPayableIssuedForConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ExtinguishmentOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ExtinguishmentOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock issued to note holder as settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IncreaseDecreaseInDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IncreaseDecreaseInDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in prepaid expense and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RightofuseAssetsExchangedForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use assets exchanged for lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RightofuseAssetsExchangedForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation consultants and research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation officers employees and board of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockBasedCompensationVestedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation vested stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockBasedCompensationVestedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_UnrealizedLossOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized loss on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_UnrealizedLossOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219807481056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Operations</a></td>
<td class="text"><p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zlcg3HbkuYg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_825_zi81Nk93I8U3">Organization and Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
1965, the corporate predecessor of GT Biopharma Inc. (the &#8220;Company&#8221;), Diagnostic Data, Inc., was incorporated in the State of California.
Diagnostic Data changed its incorporation to the State of Delaware in 1972, and changed its name to DDI Pharmaceuticals, Inc. in 1985.
In 1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International,
Inc. In July 2017, the Company changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products
based off our proprietary Tri-specific Killer Engager (TriKE<sup>&#174;</sup>), and Tetra-specific Killer Engager (Dual Targeting TriKE<sup>&#174;</sup>Dual
Targeting TriKE<sup>&#174;</sup>) platforms. The Company&#8217;s TriKE<sup>&#174; </sup>and Dual Targeting TriKE<sup>&#174;</sup> platforms
generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer
cells (NK cells).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219808874992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zL8l5PbY0r2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82C_zqg1YR3oXhrb">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z19k8I4c2dmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zqob9Y9qTHU5">Basis
of Presentation and Principles of Consolidation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America. The consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries,
Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated
in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--LiquidityPolicyTextBlock_zDg78qWfj2Jg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zMWPnp1TEuY9">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared under the assumption that the Company will continue as a going
concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The Company recorded a net loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_zoYFhP1AV3l" title="Net loss">20.9</span>
million of which $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231_zQYfgsiL4tW1" title="Non-cash stock compensation">7.7</span>
million resulted from non-cash stock compensation, and used cash in operations of $<span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_z0jLxMO5fjSe" title="Cash in Operating activities">15.2</span>
million for the year ended December 31, 2022. The Company had a cash and short-term investments balance of $<span id="xdx_908_ecustom--CashOnHandAndShortTermInvestment_iI_pn5n6_c20221231_z6Kl1tjczTUc" title="Cash and short term investments">16.5</span>
million at December 31, 2022. On January 4, 2023, the Company raised an additional $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUJmTJm8h05b" title="Cash on equity issuance">6.5</span>
million of cash through an equity issuance (see Note 11). Management anticipates that the $<span id="xdx_90C_eus-gaap--InvestmentsAndCash_iI_pn5n6_c20221231_z7HvOH39bIM3" title="Investments and cash">23.0</span>
million of cash and cash equivalents and short-term investments available following the stock issuance are adequate to satisfy the
liquidity needs of the Company for at least one year from the date the Company&#8217;s 2022 consolidated financial statements are
issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has financed its operations through public and private sales of common stock, issuance of preferred stock, issuance of
convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to secure
additional financing on acceptable terms. <span style="background-color: white">In the event that the Company does not generate
sufficient cash flows from investing and financing activities, the Company will be forced to delay, reduce, or eliminate some or all
of its discretionary spending, which could adversely affect the Company&#8217;s business prospects, ability to meet long-term
liquidity needs or ability to continue operations.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--UnusualRisksAndUncertaintiesPolicyTextBlock_zCnh8KI6YFS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86F_zbPGhi2mNm84" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">COVID-19</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global COVID-19 pandemic continues to present uncertainty and unforeseeable risks to GT Biopharma&#8217;s operations and business plan.
The Company has closely monitored recent developments, including the lifting of COVID-19 safety measures, the spread of new strains or
variants of the coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. Thus, the full impact of
the COVID-19 pandemic on the business and operations remains uncertain and will vary depending on the pandemic&#8217;s future impact
on the third parties with whom the Company does business, as well as any legal or regulatory consequences resulting therefrom. The Company
has been following the recommendations of health authorities to minimize exposure risk for its team members and may take further actions
that alter our operations, including any required by federal, state or local authorities, or that it determines are in the best interests
of its employees and other third parties with whom GT Biopharma does business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p id="xdx_847_eus-gaap--UseOfEstimates_zmffGgDs1vt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zFLvBtEPfeKk">Accounting
Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates. Significant estimates include accruals for potential liabilities,
assumptions used in deriving the fair value of derivative liabilities, share-based compensation and valuation of deferred tax assets.
Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjR4PL06PRr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Cash
Equivalents and Short-Term Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying consolidated financial statements. As of December 31, 2022, total cash and cash equivalents which consist
of cash and money market funds, amounted to approximately $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zI0liZ1AxHj5" title="Cash and cash equivalents">5.7</span>&#160;million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our businesses. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
consolidated statements of operations. As of December 31, 2022, total short-term investments amounted to approximately $<span id="xdx_901_eus-gaap--ShortTermInvestments_iI_pn5n6_c20221231_z9WB8Ry3wHBh" title="Short-term investments">10.8</span> million.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zuyF6MoVXLOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_zB5YeCD5rWh2">Fair
Value of Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 820-10 requires entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10
defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s derivative liability of $<span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231_zoupMEcwRSUa" title="Derivative liability">18,700</span>
at December 31, 2022 and $<span id="xdx_903_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231_zvdjwnOhtTn7" title="Derivative liability">138,000</span> at December 31, 2021 was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and notes payable, approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_z81iMwHLqIv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_zodClfERMec">Derivative
Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception and on
subsequent valuation dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zvj8Qg36B8f5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically issues stock-based compensation
to officers, directors, employees and consultants for services rendered. Such issuances vest and expire according to terms established
at the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="background-color: white">Stock-based payments to officers,
directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options,
are recognized in the financial statements based on their grant date fair values in accordance with ASC 718,&#160;<i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVuOyqmgqzxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zrP9tkQS7247">Research
and Development Costs</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products comprise research and development expenses. Purchased materials that do not have an alternative
future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--LesseeLeasesPolicyTextBlock_z5zpoPyrzbi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_864_zdZH1dcAPH6g">Leases</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
accounts for its lease<span style="background-color: white">s</span> in accordance with the guidance of ASC 842,&#160;<i>Leases</i>. The Company determines whether a contract is, or
contains, a lease at inception. Right-of-use assets represent the Company&#8217;s right to use an underlying asset during the lease term,
and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and
lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease
term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present
value of unpaid lease payments</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z4bd0h0IYdrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zWDNiQlHPtI5">Net
Loss Per Share</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEgi1z1Rmswe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following shares were excluded in the computation of the diluted net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zipYmU8WkIGg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zU9UWDlsIkZb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231_zQlvrHZC1fVc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zpx6zK8cGit3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,337,274</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,337,274</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zTAusukgtt6b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,630,452</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zoUC5MvZbyd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,967,726</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,639,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zCRXDR4bUjNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zF7y24q5FnX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zUUmErhmJpd2">Concentration</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal
Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20221231_z0tzcbSMKFH7" title="FDIC amount">250,000</span>.<span style="background-color: white">
Management believes that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly,
minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zl2eOgoSa2K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zODc3uUH0vU4">Segments</span>
</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined its reporting units in accordance with  &#8220;<i>Segment Reporting</i>&#8221; (&#8220;ASC 280&#8221;). Management
evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that the Company has one consolidated operating segment. The Company&#8217;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#8217;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zS2DXMm4M17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zs67VLMvEI7e">Recently
Issued Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <i>Credit Losses &#8211; Measurement of Credit Losses on Financial
Instruments</i> (&#8220;ASC 326&#8221;). ASU 2016-13 requires entities to use a forward-looking approach based on current expected
credit losses (&#8220;CECL&#8221;) to estimate credit losses on certain types of financial instruments, including trade receivables.
This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1,
2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related
codification improvements will be material to its financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt&#8212;Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity&#8217;s Own Equity</i>. Effective January 1, 2021, the Company adopted ASU 2020-06 using
the modified retrospective approach. Adoption of the new standard resulted in a decrease to additional paid-in capital of $<span id="xdx_90A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_pn5n6_c20220101__20221231_zgHlZwJegvjl" title="Decrease to additional paid-in capital">4.5</span> million
(see Note 5).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>. ASU 2021-04 provides clarification
and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options
(such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange
as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification
or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting
treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and
debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including
interim periods within those fiscal years. Effective January 1, 2022, the Company adopted ASU 2021-04 using a prospective approach. The
adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission (the &#8220;SEC&#8221;) did not or are not believed by management to have a material
impact on the Company&#8217;s present or future consolidated financial statements.</span></p>

<p id="xdx_854_zMZMDLpExu42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219808551280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_807_eus-gaap--FairValueDisclosuresTextBlock_zAlOFwgznSlf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 <span>&#8211;</span> <span id="xdx_823_zLJ52zke3p65">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_z5P3ACjZbzje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of financial instruments outstanding were (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z8O7MHPLJB85" style="display: none">Schedule
of Estimated Fair Value of Financial Instrument</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z0Nwf4vaguHj" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost">10,866</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zxzqvnjslD7b" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z7w5n6zTDhad" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses">(30</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zO2MI49T56p" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value">10,836</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total</p></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231_zuPQFV0NnH08" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">10,866</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20221231_z4YJRJdvNVdk" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0658">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20220101__20221231_zNlzXae6QJc2" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses">(30</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20220101__20221231_zEQ272R0XVh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">10,836</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztAYkzKBPsRg" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost">23,040</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zNPPfyPvHdHd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0666">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z0c3DddLu0Df" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses">(29</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zfz99ky0Pkdb" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value">23,011</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231_zxAaYty20ae7" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">23,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231_zp3R7zxneRl6" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0674">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20210101__20211231_z2JoDP36MTr1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses">(29</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20210101__20211231_z72PrVxMotCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">23,011</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AF_zEVvL7rYm0z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zRV5XjC21Sf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&#8217;s fair value hierarchy for its financial assets (cash equivalents and investments, in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zhYv3SDQBCra" style="display: none">Schedule of Fair Value Hierarchy Financial Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zVlB2J6BDbHb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zs3pIkHwJCA2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZBVLWVooYVg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgy53sOf7B63" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zCD2990X8Uig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,505</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,505</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_z2iq57rzLLBd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,836</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,836</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zVqoiyls41Tk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total financial assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,341</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,341</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0695">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_49A_20211231_z6u3KPsgWw72" style="border-bottom: Black 1.5pt solid; text-align: center">1</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1xzZplSugg5" style="border-bottom: Black 1.5pt solid; text-align: center">2</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjIAwY1kW568" style="border-bottom: Black 1.5pt solid; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkP0MsVY8XPj" style="border-bottom: Black 1.5pt solid; text-align: center">4</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zLzr2WdwxdJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,484</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,484</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0700">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zLGxsofpk1Fj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0704">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zKl8cYu3bI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AC_zJ9Et4xwZfB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219808771136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zorO4p4t9P9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_822_z76ZlGsHNg9d">Accounts Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUhfGv2y8k07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z6lDKgLhjGB7" style="display: none">Schedule of Accounts Payable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20221231_zILvVLffkSD2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31, </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20211231_zqGmjJ5QkVJd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31, </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maAPCz7ta_zHlh7QCLZok7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable to a third-party manufacturer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,283</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,335</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz7ta_zW4zfHTwGGR" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    accounts payable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">857</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,854</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz7ta_zJC8oa4mKaJ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accounts payable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,140</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,189</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p id="xdx_8A2_zMiltEy7cZyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 5, 2020, the Company entered into a Master
Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the
Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products
for use in clinical trials. The Company&#8217;s commitments in relation to these Statements of Work and any related Change Orders totaled
approximately $<span id="xdx_904_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20201005__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8MzGIZgAOz6" title="Accounts payable">13.0</span> million. There was no outstanding liability with this third-party product manufacturer as of December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2021, the
Company recorded research and development expenses of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWm6L3XfJMR3" title="Reserach and development expenses">6.5</span>
million  related to the services rendered by this third-party product manufacturer and paid $<span id="xdx_904_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zh1jpKpeSJHj" title="Adjustment to additional paid in capital, stock issued, issuance cost">142,500</span>.
In addition, the Company also issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ0sgs6hSn1c" title="Number of shares issued">189,753</span>
shares of common stock with a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmxZZWRJ6w3a" title="Number of shares issued, value">1.4</span>
million  pursuant to this Master Services Agreement. As of December 31, 2021, the outstanding balance due to this third-party
product manufacturer amounted to $<span id="xdx_908_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwwAov8Im7xa" title="Accounts Payable">6.3</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 24, 2022, the Company entered into an agreement
with this third-party manufacturer and issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220823__20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zK7KCvopDJj6" title="Number of shares issued">1,222,281</span> shares of common stock with a fair value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220823__20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z08TNV9ctPQa" title="Stock issued during period, value, new issues">3.2</span> million as part of a payment
agreement. The shares were valued at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbiphK4SHLvl" title="Share issued price per share">2.66</span> per share based on the closing price of the Company&#8217;s common stock on the date of the
agreement. As part of the agreement, the Company also paid this third-party manufacturer $<span id="xdx_906_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pn5n6_c20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxD7t3wchJB" title="Notes payable, related parties">1.3</span> million on September 1, 2022, $<span id="xdx_901_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pn5n6_c20220901__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0soNdamtB7h" title="Notes payable, related parties">1.0</span> million
on October 3, 2022, and $<span id="xdx_908_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pn5n6_c20221003__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzJ8LCCdbeO7" title="Notes payable, related parties">1.0</span> million in November 2022. In addition, the Company and the third-party manufacturer agreed that services
to be rendered in future periods, as specified in the agreement, will be paid or settled at the Company&#8217;s discretion, in a combination
of cash and issuance of the Company&#8217;s common stock. The agreement also amended certain agreements executed in prior years which
eliminated future financial commitments of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2022, the Company
recorded research and development expenses in the aggregate of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMn66qh5sDv1" title="Reserach and development expenses">3.6</span> million for services rendered by this third-party product manufacturer
and made additional payments of $<span id="xdx_902_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember_zS10UbSEA673" title="Accounts Payable">900,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022, the Company was indebted
$<span id="xdx_907_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCrqFFf2AuHd" title="Accounts Payable">2.3</span> million to this third-party product manufacturer and was reported as part of accounts payable in the accompanying balance sheet.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219807341824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zoh1YnyNyoxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_828_z8FeedWbIsv1">Convertible Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following activity occurred during the year
ended December 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
    Payable Issued for Cash</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Company&#8217;s financing activities, the Company issued convertible notes payable in exchange for cash. As of December 31,
2020, the outstanding balance of these notes amounted to $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zqFozVAyc7wb" title="Outstanding balance">24.1</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company issued similar notes payable in
exchange for cash of $<span id="xdx_901_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20210101__20210101__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zrxr5S17gs4a" title="Proceeds from notes payable in cash">1.2</span> million. On February 16, 2021, in accordance with the note agreements upon completion of an equity offering,
these notes were mandatorily converted at a conversion rate of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zT636pS5Rkg4" title="Conversion rate">3.40</span> per share into <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zA6NRtTulYNi" title="Shares">7,438,235</span> shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
    Payable Issued for Settlement Agreements</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2019 and 2020, the Company issued its convertible notes payable to resolve claims and disputes pertaining to certain debt and
equity instruments issued by the Company in prior years. As of December 31, 2020, the outstanding balance of these notes payable for
settlement agreements amounted to $<span id="xdx_90B_eus-gaap--NotesPayableCurrent_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember__us-gaap--AwardDateAxis__custom--FiscalTwentyNinteenandTwentyTwentyMember_zD3ukr0MbFji" title="Outstanding balance">2.5</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2021 in accordance with the note agreements upon completion of an equity
offering, these notes were mandatorily converted at a conversion rate of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember_zO8m1AKV5d6l" title="Conversion rate">3.40</span> per share into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember_zo8INDS91pM8" title="Shares">743,529</span> shares of the Company&#8217;s common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
    Payable Issued for Forbearance Agreements</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2020, the Company entered into Standstill and Forbearance Agreements (collectively, the &#8220;Forbearance Agreements&#8221;)
with the holders of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200623__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_ztxRkPxDaCGc" title="Forbearance Agreements">13.2</span> million aggregate principal amount of the Convertible Notes (the &#8220;Default Notes&#8221;), which were in
default. As of December 31, 2020, the outstanding balance of the notes payable amounted to $<span id="xdx_90A_eus-gaap--NotesPayableCurrent_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_zpqi52SKuFW2" title="Outstanding balance">3.8</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2021 in accordance
with the note agreements upon completion of an equity offering, these notes were mandatorily converted at a conversion rate of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_z5K5NdFbsLqf" title="Conversion rate">3.40</span>
per share into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_zOZWiA8aWItc" title="Shares">1,132,059</span> shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
    Payable issued for Consulting Agreements</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the outstanding balance of convertible notes payable issued in exchange for consulting services amounted to $<span id="xdx_909_eus-gaap--NotesPayable_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zq9MBgYR9oIl" title="Outstanding balance">0.4</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, the Company issued additional notes payable of $<span id="xdx_903_eus-gaap--NotesPayable_iI_pn5n6_c20210131__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zy4rzf83RuFg" title="Notes payable, issued">0.7</span>
million in exchange for consulting services as well as a note payable of $<span id="xdx_900_ecustom--NotesPayableForUnpaidConsultingFee_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zINSXAywSok2" title="Notes payable for unpaid consulting fee">0.5</span>
million in exchange for cancellation of an unpaid consulting fee recorded and incurred in fiscal  2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2021 in accordance with the note agreements upon completion of an equity offering, these notes were mandatorily
converted at a conversion rate of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zHudqM3IXHn9" title="Conversion rate">3.40</span> per share into <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_z4fNr0nX4Z3h" title="Shares">472,059</span> shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company accrued interest of $<span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zc3yQkwrfuZe" title="Accrued interes">4.8</span>
million related to all outstanding convertible notes payable. In addition, during the period ended December 31, 2021, the Company
accrued interest of $<span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zm5MPJUQHOj8" title="Accrued interest">0.7</span>
million. As a result of the mandatory conversion of the Company&#8217;s notes payable, on February 16, 2021, total accrued interest
amounting to $<span id="xdx_908_ecustom--SharesIssuedDuringPeriodValueAccruedInterest_pn5n6_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_z9DsTt501rZ9" title="Total accrued interest">5.5</span>
million was converted to <span id="xdx_900_ecustom--SharesIssuedDuringPeriodSharesAccruedInterest_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zpxJMiVeDF1d" title="Number of shares issued for accrued interest">1,627,440</span>
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
total, notes payable of $<span id="xdx_905_eus-gaap--NotesPayable_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zuvlxiLtgQ1k" title="Total, notes payable">38.8</span> million ($<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_z6tLet9u7uMf" title="Principal amount">33.3</span> million principal and accrued interest of $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zOCE8oJXlEOf" title="Accrued interest">5.5</span> million) were mandatorily converted to <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zjE0u6UwQwM8" title="Converted shares">11,413,322</span>
shares of common stock of which, <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zi3VDxa8rXA" title="Converted shares">11,086,024</span> shares of common stock were issued in fiscal 2021 and the
remaining <span id="xdx_90F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zR11M47JQKRg" title="Common stock shares, unissued">327,298</span> shares were issued in fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Adoption
of ASU 2020-06</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="background-color: white">In fiscal 2020, the Company recorded
a note/debt discount of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn5n6_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotePayableMember_zAJhhwRvtzC4" title="Debt instrument, convertible, beneficial conversion feature">4.7</span>&#160;million to account for the beneficial conversion feature that existed on the date of issuance of certain
convertible notes payable. The debt discount was </span><span>being</span> <span style="background-color: white">amortized
to interest expense over the term of the corresponding convertible notes payable.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2021, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, <i>Debt-Debt with Conversion and
Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for
Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>. As a result of the adoption of ASU 2020-06, the Company extinguished
its previously recorded debt discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20221231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member_z4OBmMoB3scl" title="Debt discount">4.7</span> million by charging the opening additional paid in capital at January 1, 2021. In addition,
the Company also adjusted accumulated deficit to account for the derecognition of the $<span id="xdx_906_eus-gaap--InterestExpenseDebt_pn5n6_c20200101__20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member_z2WiKHnPFFLa" title="Interest expense due to amortization of debt discount">0.2</span> million interest expense due to the amortization
of the debt discount that was recorded in fiscal 2020. As a result of these adjustments, the unamortized debt discount of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20211231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member_zsyBEA73pR42" title="Debt instrument, unamortized discount">4.5</span> million
was extinguished during the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219803375904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureDerivativeLiabilityAbstract', window );"><strong>Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Derivative Liability</a></td>
<td class="text"><p id="xdx_806_eus-gaap--DerivativesAndFairValueTextBlock_zFpbva4V1Woi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_829_zVr2Srjfp9i5">Derivative Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">During the year
ended December 31, 2020, the Company issued certain warrants that contained a fundamental transaction provision that could give rise to
an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with ASC 480,
the fair value of these warrants is classified as a liability in the Consolidated Balance Sheets and will be re-measured at
the end of every reporting period with the change in value reported in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuG0syJwcwxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liabilities were valued using a Binomial pricing model with the following average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_z0UziVqcKBw3" style="display: none">Schedule
of Derivative Liabilities Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zIpdXiETvf6d" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231_zRCfpTGncpsl" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5cUR9Ao3Je2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: justify">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">4.22</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1.26</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zASm9Vf2dB6j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0NcfDqHMfvh" title="Expected life (in years)">2.6</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_pid_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zwRU9ZyZICi7" title="Expected life (in years)">3.6</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlDsQEUAjxIf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Fair value of warrants (in thousands)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231_zR5pR86lfrsk" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210101__20211231_zZ2N533ilBTl" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">138</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zM9qaQARkQXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.65pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its
common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by
the remaining contractual life of the derivative instrument. The expected dividend yield was based on the fact that the Company has not
paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2021, <span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_c20210101__20211231_zscbCzIe5ZR8" title="Warrant exercised">2,826</span> warrants were exercised which resulted in an extinguishment of derivative liability charge of $<span id="xdx_908_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_pn4n6_c20211231_zniRJAbzohsk" title="Derivative liability">0.03</span> million. The Company
recognized a net gain of $<span id="xdx_905_eus-gaap--DerivativeGainOnDerivative_pn4n6_c20220101__20221231_zK5JdbpGRtIg" title="Net gain">0.12</span> million and $<span id="xdx_90E_eus-gaap--DerivativeGainOnDerivative_pn4n6_c20210101__20211231_zsF1F9OMwKDk" title="Net gain">0.21</span> million for the years ended December 31, 2022 and 2021, respectively, to account for
the <span id="xdx_907_eus-gaap--DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_iP3us-gaap--DerivativeGainOnDerivative_dxL_c20220101__20221231_zY5P46e6jWDg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23DerivativeGainLossOnDerivativeNet"><span id="xdx_90B_eus-gaap--DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_iP3us-gaap--DerivativeGainOnDerivative_dxL_c20210101__20211231_zo8iUfYNmmJi" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23DerivativeGainLossOnDerivativeNet"><span style="-sec-ix-hidden: xdx2ixbrl0845"><span style="-sec-ix-hidden: xdx2ixbrl0846">change in fair value of the derivative liability</span></span></span></span>.</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zLPhfjCHTdL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zEdDNLvpQEi" style="display: none">Schedule
of Derivative Liability Transactions</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20220101__20221231_zwhqCDktytb2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022<br/>
                                            (in thousands)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20210101__20211231_zuvS276Z3CY9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021<br/>
                                            (in thousands)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zeO1NaGtY4Q8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
    Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">384</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3n3_zomiiUQtoG6d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0854">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--ExtinguishmentOfWarrants_pn3n3_zZBctFgLebVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(35</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3n3_z7PNVM0M82Ic" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(119</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(211</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zUPudqAzKVg5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending
    Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AA_zl2aaIOQzpXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureDerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureDerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219803947248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zKQUBuy02gBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82A_z0QFMO2rDW23">Stockholders&#8217; Equity </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zd8CeVvLZQR2" title="Common stock, shares authorized">250,000,000</span> shares
of common stock , par value of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zKyJSga7VWla" title="Common stock, par value">0.001</span> as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 10, 2021, the Company effectuated a 1:17
<span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20210208__20210210_zKbiWGmEmDxf" title="Stockholders' equity, reverse stock split">reverse stock split</span> of the Company&#8217;s issued and outstanding shares of common stock and all fractional shares were rounded up. All
share and per share amounts in the accompanying consolidated financial statements have been adjusted retroactively to reflect the reverse
stock split as if it had occurred at the beginning of the earliest period presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On October 10,
2022, at a special meeting of the stockholders of the Company, the stockholders ratified and approved the inclusion of discretionary votes
by brokers and other nominees holding shares for beneficial owners in the tabulation of votes on the proposal presented at the Company&#8217;s
annual meeting of stockholders to reduce the authorized number of shares of the Company&#8217;s common stock from <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20221010__srt--TitleOfIndividualAxis__custom--OwnersMember_zyWBx5RfAoEb" title="Common stock, shares authorized">750,000,000</span> shares to
<span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20221010_zdisYheuoLDh" title="Common stock, shares authorized">250,000,000</span> shares</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Common
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Issuance of common stock in public offering</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 16, 2021, the Company completed a public
offering of <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpwAkNUmmyhh" title="Common stock, capital shares reserved for future issuance">4,945,000</span> shares of common stock for net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zcfc3cdXCT45" title="Proceeds from issuance of common stock">24.7</span> million, after deducting underwriting discounts, commissions and
other direct offering expenses. As part of the offering, the Company also granted these investors, warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zLiIQyznE9c5" title="Number of warrant purchase shares">5,192,250</span> shares
of common stock. The warrants are fully vested, exercisable at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zDTAoHt2jvn5" title="Warrant exercise price per share">5.50</span> per share and will expire in <span id="xdx_901_ecustom--ClassOfWarrantExpireTerm_dc_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zv3UVhc6cmz3" title="Class of warrant expire term">five years</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the completion of the public offering
and the successful listing of its shares of common stock on the Nasdaq Capital Market, convertible notes with an aggregate principal amount
of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_ztv1nvRA7o96" title="Debt face amount">33.3</span> million and accrued interest of $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zE52rCbki8I5" title="Debt instrument, increase, accrued interest">5.5</span> million, for a total of $<span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zwYC8ECGuS52" title="Debt conversion converted instrument amount">38.8</span> million, were mandatorily converted at its stated conversion
rate of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zosnijamzma1" title="Debt instrument, convertible, conversion price">3.40</span> per share into <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zR1jxSRohmXj" title="Debt conversion, converted instrument, shares issued">11,413,322</span> shares of the Company&#8217;s common stock. The Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zspqLc9PbJUe" title="Number of shares issued">11,086,024</span> shares of common stock
to these note holders while the remaining <span id="xdx_906_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zuhaSe9BwRwe" title="Remaining number of common shares">327,298</span> common shares, valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zRWEMXTjQ15b" title="Stock issued during period, value, new issues">1.1</span> million, were issuable at December 31, 2021. For financial
reporting purposes, as of December 31, 2021, the Company reported the $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMEexKEpKDY5" title="Stock issued during period, value, new issues">1.1</span> million as common stock issuable to account for the estimated
balance of the converted notes payable and accrued interest that the Company had not yet issued the corresponding common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2022, the Company
issued the remaining <span id="xdx_90C_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zAHkBFRuhr23" title="Remaining number of common shares">327,298</span> common shares issuable at December 31, 2021 valued at $<span id="xdx_90F_eus-gaap--StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_iI_pn5n6_c20221010__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zy4y5tBK1eia" title="Stock repurchase program, remaining authorized repurchase amount">1.1</span> million. In addition, the Company also issued
an additional <span id="xdx_907_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zHtM7NuXL5Ng" title="Additional paid in capital, common stock">10,404</span> shares of commons stock with a fair value of $<span id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_z1vVp6xrKmV9" title="Adjustments to additional paid in capital, fair value">35,000</span> as settlement with a noteholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<i><span style="text-decoration: underline">Cancellation of common stock previously
issued for services</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company cancelled <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpC8K3TQjYY3" title="Number of shares issued for service">290,999</span> previously issued shares
of common stock during the year ended December 31, 2022.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Issuance of common stock as equity compensation
to officers, employees and board of directors</span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Company completed its equity offering and listed its shares of common stock on the Nasdaq Capital Market. As such,
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210213__20210216__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zOKBpO2B0xaa">4,379,407</span> shares of its common stock were granted to these officers, employees and directors, which had a fair value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210213__20210216__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zAC0TiTiNdra">18.6</span> million
at the date of Grant. Since the grant of the common stock is subject to milestone or performance conditions, such awards will be recorded
as compensation expense as the milestone or performance condition are met and in accordance with its vesting terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zxO8nyZd41wi">4,040,524</span> shares of common stock and recognized stock compensation expense of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zy4PJYkb0Blc">16.9</span>
million to account the fair value of common stock that vested under this award. Also in 2021, the Company cancelled&#160;<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zhTAG1wePlW9" title="Share based compensation cancelled">278,058</span>&#160;shares
of common stock granted to a Board member in February 2021 and issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210201__20210228__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zh5XtqwoJh8">12,500</span> shares of common stock with a fair value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210201__20210228__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zY5IUBNIkUzj">38,000</span> to an
employee for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_z99BZu1zXgM9">312,815</span> shares of common stock and recognized stock compensation expense of $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zz3DnPpubcpl">1.5</span>
million to account the fair value of common stock that vested. &#160;Also in 2022, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zRjWoyEuNrGh">396,708</span> shares of common stock
with a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zXwoPxTK32Jl">994,000</span> to certain officers of the Company for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there were <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zXF14PWgLZZj">44,818 </span>unvested shares of common stock issued to officers, employees and directors with a fair value
of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zpVWvUpmm1yh">206,035</span> that will be recognized as stock compensation expense in future periods pursuant to its vesting term.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Equity
compensation to consultants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Company completed its equity offering and listed its shares of common stock on the Nasdaq Capital Market. As such,
<span id="xdx_90F_eus-gaap--SharesIssued_iI_pid_c20210216__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zlm91lZmPGnh">2,850,090</span> shares of its common stock were granted to consultants, which had a fair value of $<span id="xdx_90D_ecustom--CommonStockConsultantToFairValue_pn5n6_c20210215__20210216__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zNGMxFvPC2H1">10.7</span> million at the date of Grant. Since
the grant of the common stock is subject to milestone or performance conditions, such awards will be recorded as compensation expense
as the milestone or performance condition are met and in accordance with its vesting terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zd0kZoKGb8B1">2,432,895</span> shares of common stock and recognized stock compensation expense of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z8oK4XzitrA2">9.2</span>
million to account the fair value of common stock that vested under this award. Also in 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_znKGIDHPI4G3">649,511</span> shares of common
stock with a fair value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zWIanw0JMO2e">6.1</span> million to consultants for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z6TjmqnNKap">370,744</span> shares of common stock and recognized stock compensation expense of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zVSyDib7z3pi">1.3</span>
million to account the fair value of common stock that vested under this award. Also in 2022, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zX7y68c43hp8">156,113</span> shares of fully
vested common stock with a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zB77YaHajyGf">791,000</span> to consultants for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zrvgZZ8x25Ee">46,343</span> unvested shares of common stock issued to consultants with a fair value of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zAwDwiLanqf">162,664</span> that will
be recognized as stock compensation expense in future periods pursuant to its vesting term.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span style="text-decoration: underline">Cancellation of common stock upon settlement
with a former Officer</span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2022, the Company entered into a settlement agreement with its former Chief Executive Officer (&#8220;Officer&#8221;) and
received <span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20220428__20220429__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ztrphrX4wcU3" title="Number of shares received">1,845,000</span>
shares of its previously issued common stock in full and final settlement of all its claims against the Officer. The common stock
was subsequently cancelled and returned to treasury. In addition, the Company incurred legal and professional expenses of $<span id="xdx_908_eus-gaap--ProfessionalFees_c20220428__20220429__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zU1TVmgUCzub" title="Legal and professional expenses">224,243</span>.
The legal and professional fees incurred were accounted as costs of the acquisition of the common stock and recorded as
a reduction to additional paid in capital. Both the Company and the Officer released each other from claims under the settlement
agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Preferred
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">A.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Series
    C Preferred Stock</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2022 and 2021, there were <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zOzKHR6Yl3e9">96,230
</span>shares of Series C Preferred Stock, par value $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zmMwkpPgloja">0.01
</span>per share (the &#8220;Series C Preferred Stock&#8221;) issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of stock splits in previous years, the <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zXGkBLjfg6y7" title="Preferred stock, shares issued">96,230</span> shares of Series C Preferred Stock are not convertible. Shares of Series C Preferred
Stock have no voting rights. Similarly, as there are no conversion rights, in the event of liquidation, the holders of the Series C Preferred
Stock shall not participate in any distribution of the assets or surplus funds of the Company. The holders of Series C Preferred Stock
also are not entitled to any dividends if and when declared by the Company&#8217;s board of directors. No dividends
to holders of the Series C Preferred Stock were issued or unpaid through December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Series
    J-1 Preferred Stock</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -34.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue its
Series J-1 Preferred Stock with a par value of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zoRxDOmjT7a4" title="Preferred stock, par value">0.01</span> per share. Shares of the Series J Preferred Stock were convertible at any time,
at the option of the holders, into shares of the Company&#8217;s common stock at an effective conversion price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_z56X6v6U2Lk8">3.40</span>&#160;per
share, subject to adjustment for, among other things, stock dividends, stock splits, combinations, reclassifications of our capital
stock and mergers or consolidations, and subject to a beneficial ownership limitation which prohibits conversion if such conversion
would result in the holder (together with its affiliates) being the beneficial owner of in excess of&#160;<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zWLsw9PYqd5j">9.99</span>%
of the Company&#8217;s common stock. Shares of the Series J Preferred Stock had the same voting rights as shares of the
Company&#8217;s common stock, with the holders of the Series J Preferred Stock entitled to vote on an as-converted-to-common stock
basis, subject to the beneficial ownership limitation described above, together with the holders of the Company&#8217;s common stock
on all matters presented to the Company&#8217;s stockholders. The Series J Preferred Stock are not entitled to any dividends (unless
specifically declared by the Board), but would participate on an as-converted-to-common-stock basis in any dividends to the holders
of the Company&#8217;s common stock. In the event of the Company&#8217;s dissolution, liquidation or winding up, the holders of the
Series J Preferred Stock would be on parity with the holders of the Company&#8217;s common stock and would participate, on a on an
as-converted-to-common stock basis, in any distribution to holders of the Company&#8217;s common stock. As of December 31, 2020,
total Series J-1 Preferred stock issued and outstanding totaled 2,353,548 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the completion of the public offering and
the successful listing of the Company&#8217;s shares of common stock on the Nasdaq Capital Market, in February 2021, all outstanding Series
J Preferred Stock totaling <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20210201__20210228__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_z1SZHqcgqMc8" title="Common shares issued upon conversion of notes payable, shares">2,353,548</span> shares were mandatorily converted to <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zunYhvIJZWp4" title="Common shares issued upon conversion of notes payable, shares">692,220</span> shares of common stock pursuant to the terms
of the conversion agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022 and 2021, there were <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zHWqyNlzDfh4" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zVL0F4id9Gii" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zYj5xapsZj3h" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zZkQlC2yv5wf" title="Preferred stock, shares outstanding">no</span></span></span></span> Series J-1 Preferred Stock
issued and outstanding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Series
    K Preferred Stock</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Board designated <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210215__20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_z7ejRTICysig" title="Preferred stock shares designated">115,000</span> shares of Series K preferred stock, par value $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zEhcGRbMnKbk" title="Preferred stock, par value">.01</span>. (the &#8220;Series K Preferred Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company&#8217;s common
stock at an effective conversion rate of <span id="xdx_90B_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zP97wDRlj8qc" title="Convertible shares issuable">100</span> shares of common stock for each share of Series K Preferred Stock. Shares of the Series
K Preferred Stock have the same voting rights a shares of the Company&#8217;s common stock, with the holders of the Series K Preferred
Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders
of the Company&#8217;s common stock on all matters presented to the Company&#8217;s stockholders. The Series K Preferred Stock are not
entitled to any dividends (unless specifically declared by the Board), but will participate on an as-converted-to-common-stock basis
in any dividends to the holders of the Company&#8217;s common stock. In the event of the Company&#8217;s dissolution, liquidation or
winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company&#8217;s common stock and will
participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021, there were
<span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zgEZZNVaC3T4" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zFCEqqMKnhUe" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_z3CzNQbAehxl" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zQKKxUv9kecg" title="Preferred stock, shares outstanding">no</span></span></span></span> Series K Preferred stock, issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Warrants
and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVmuTixxFRaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the years ended December 31, 2022 and 2021, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zPL1qDLeTdUk" style="display: none">Schedule of Warrant Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants outstanding at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zAidrt5agsmk" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance">221,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zcGY9iwCNPcb" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance">3.40</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_z3EuXatLSHOl" style="text-align: right" title="Number of warrants, granted">5,192,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20210101__20211231_z2d46zBA1gvb" style="text-align: right" title="Weighted average exercise price, granted">5.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231_z3FOuNgqLgG" style="text-align: right" title="Number of warrants, forfeited">(2,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20210101__20211231_zROGhViFSt42" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0991">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231_zOAQSpW12wJk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised">(3,074,017</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zjSQy4fHZey7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">5.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_z1ALWcmxMJB4" style="text-align: right" title="Warrants outstanding, beginning balance">2,337,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zHJbdLrHCZa" style="text-align: right" title="Weighted average exercise price, beginning balance">5.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_z4oyI7zEEEc6" style="text-align: right" title="Number of warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20220101__20221231_zdzHJQmsyOFl" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231_zB3JqQ7hdXn6" style="text-align: right" title="Number of warrants, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20220101__20221231_zyy8ERkDL5i2" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231_zr1rAal3cNe8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zb1oj5ephd23" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231_zs8TjyYL8tD9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, beginning balance">2,337,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_z8OFkijsZDT8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, beginning balance">5.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20221231_zhXYdJr1oDH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance">2,337,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zZaOUhMxFGYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, ending balance">5.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zEGw13l4zTt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, as part of the Company&#8217;s public offering, the Company issued warrants to investors to purchase up to an aggregate
of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210216__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_znaZytMyyWj9" title="Issued warrants">5,192,250</span> shares of common stock. The warrants have an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210216__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zfJcAWBtWWsd" title="Exercise price per share">5.50</span> per share, subject to adjustment in certain circumstances
and has a term of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dc_c20210216__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zcFDSKBm74uj" title="Warrant term">five years</span> from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfqLj6XNRulh" title="Common stock  exercise  warrants">3,074,017</span> shares of common stock upon exercise of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4xnxFEAG49e" title="Common stock  exercise  warrants">3,074,017</span> warrants, which resulted cash proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN8q6pmoTz46" title="Warrants  cash proceeds">16.4</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, all issued and outstanding
warrants are fully vested. <span style="background-color: white">There was <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20221231_z5b8mH6RebPd" title="Options outstanding intrinsic value">no</span> intrinsic
value of the outstanding warrants as of December 31, 2022, as the exercise price of these warrants was equal to or greater than the market
price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9N3xVDZw8b3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option transactions for the years ended December 31, 2022 and 2021 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BF_zkmuoVUXWQr" style="display: none">Schedule
of Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zvSot9rnVhHk" style="text-align: right" title="Number of options outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1037">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zWwJMd2Jqvg8" style="text-align: right" title="Weighted-Average Exercise Price, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20210101__20211231_zPtEn2lmMNve" style="width: 16%; text-align: right" title="Number of options, Granted">302,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zOA5w1sNPSxk" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Granted">3.05</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20210101__20211231_zq2iQDVImP56" style="text-align: right" title="Number of options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_znWJP9XBSWu1" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20210101__20211231_z5Ra0jdk0ouj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zQsqX1NCgGZa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_z32vbvCsSZPh" style="text-align: right" title="Number of options outstanding, beginning">302,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z2mT1cvUOU9b" style="text-align: right" title="Weighted-Average Exercise Price, Beginning">3.05</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231_zOfZ1vfUgNp1" style="text-align: right" title="Number of options outstanding, Granted">1,532,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zH5JUeKQI1Q9" style="text-align: right" title="Weighted-Average Exercise Price, Granted">2.48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231_zZcvKcdMJeX1" style="text-align: right" title="Number of options outstanding, Forfeited">(205,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zIEx8nBiVGS" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited">2.48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20220101__20221231_z9CTyUEVT7j8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zA1BPoS8srYj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zNJkXaRTv711" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding outstanding, Ending">1,630,452</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zq7QYxtAaMzb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Ending">2.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zrF4X1nmq76b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, exercisable">1,440,404</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zk9HfEbEkYnd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Ending">2.55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zG8DHITmGgD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Year Ended December 31, 2022</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2022, the Company granted certain consultants, employees, officers and directors stock options to purchase an aggregate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zc9y8XUDc3f5" title="Common stock, stock option shares">1,532,952</span>
shares of common stock. The stock options are exercisable at $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_z9vRzXx3AYS3" title="Stock options  exercisable">2.48</span> per share and will expire in 10 years. A portion of the options vested
immediately with the remaining portion vesting over a period of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_zNrFdJzh91Nk" title="Vesting period">5 months</span> up to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zqpLi5KI9466" title="Vesting period">36 months</span>. The fair value of the options amounted to $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zWVtr8KphqE5" title="Fair value">3.4</span>
million or an average of $2.22 per share and were calculated using the Black Scholes Option pricing model. Assumptions used in the model
were: expected term &#8211; <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zvLguMBScbva" title="Expected term">6.27</span> years; expected volatility &#8211; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zr2bHm3hY3Eg" title="Expected volatility">125.53</span>%; risk free interest rate &#8211; <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zuTk8M89qP71" title="Risk free interest rate">3.03</span>% and dividend yield
of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zKeVIbTIa5ji" title="Dividend yield">0</span>%. The Company  recognized the corresponding stock compensation expense of these options based upon the vesting term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded forfeitures of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_znwTXK4ACZbd" title="Forfeited">205,000</span> options to purchase common stock during 2022 due to the resignation of employees. The forfeitures
were related to shares that had not yet been vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2022, the Company
recorded total stock compensation of $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231_z5Ly2DokQ6I6" title="Share-based compensation arrangement by share-based payment award, options, vested in period, fair value">3,032,000</span> to account the fair value of stock options that vested in fiscal 2022.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022, there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20221231_z6YmLoqjlCkl" title="Non- vested number of shares issued">275,101</span> unvested
options with a grant date fair value of $<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_iI_c20221231_zySlCthYJeUe" title="Share based compensation unvested intrinsic value">645,172</span> which will be recognized as stock compensation expense in future periods based upon the
remaining vesting term of the applicable grants. There was no intrinsic value of the outstanding options at December 31, 2022, as the
exercise price of these options is greater than or equal to the market price.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Year Ended December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 31, 2021, the Company granted two employees
a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zY3LVkNpUmlf" title="Stock option granted">302,500</span> stock options. The stock options are exercisable at $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zdvNobShe0v8" title="Stock options exercisable price">3.05</span> per share and will expire in <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zQ3Ky9PxCoui" title="Options expiration period">10 years</span>. A portion of the options
vested immediately, with the remaining portion vesting over a two-year period from the date of grant. The fair value of the options amounted
to $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zH8Dsliw3qh7" title="Fair value of options">808,280</span> or an average of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zGJgEH7dlNhk" title="Fair value of stock option, per share">2.67</span> per share and were calculated using a Black-Scholes option pricing model. Assumptions used in the model
were: expected term &#8211; <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220714__20220715__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zHLsFeZaFhBb" title="Expected term">5.5</span> years; expected volatility &#8211; <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zalQQh5QohYf" title="Expected volatility">129.0</span>%; risk free interest rate &#8211; <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zWMiPsVOjATe" title="Risk free interest rate">1.26</span>% and dividend yield of
<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zULcgE4KZAwd" title="Dividend yield">0</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2021, the Company
recorded stock compensation of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zD3tRNlc3qSb" title="Stock option granted">251,000</span> to account the fair value of stock options that vested in fiscal 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219807351408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_zbPCxLmqGDIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note
8 &#8211; <span id="xdx_821_zBt9qWb7Y5G2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Leases</span></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 19, 2021, the Company entered into a sublease
with a third party for <span id="xdx_908_eus-gaap--AreaOfLand_iI_uSqft_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdwpnFY5S88" title="Area of land">4,500</span> square feet of office space located in Brisbane, California, with a <span id="xdx_906_eus-gaap--LesseeOperatingSubleaseOptionToExtend_c20211118__20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zCgCyzaaWIEk" title="Commencement date">commencement date of January 1, 2022
and maturing on June 30, 2024.</span> <span style="background-color: white">Leases with an initial term of 12 months or less are not recorded
on the balance sheet. The Company accounts for the lease and non-lease components of its leases as a single lease component. Rent expense
is recognized on a straight-line basis over the lease term. As a result of this agreement, the Company recognized</span> right-of-use
(&#8220;ROU&#8221;) asset and liability of $<span id="xdx_90B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zTxl9URnVjtc" title="Operating lease, right-of-use asset">247,294</span> <span style="background-color: white">pursuant to ASC 842<i>, Lease.</i></span> Operating
lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease
term. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the
Company&#8217;s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is
not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The
Company&#8217;s incremental borrowing rate is a hypothetical collateralized borrowing rate based on its understanding of what its credit
rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 8, 2022, the Company entered another lease
which will end on February 7, 2025. As a result, the Company <span style="background-color: white">recognized</span> additional ROU asset
and liability of $<span id="xdx_908_ecustom--AdditionalOperatingLeaseAssets_c20220207__20220208__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0EB4mXgz551" title="Additional Operating lease assets">12,861</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">As a result of these lease agreements,
the Company recognized ROU asset and liability in the aggregate of $<span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20220208_zm332CEMNLxk" title="Operating lease, right-of-use asset">260,155</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_899_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_z92Vm6MA67r1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">The components of rent expense and
supplemental cash flow information related to leases for the period are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">&#160;<span id="xdx_8B1_zFWXrBDT8D1h" style="display: none">Schedule of Components
Leases Rent Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Lease Costs (in thousands):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 76%; text-align: justify; padding-bottom: 1.5pt">Operating cash flows from operating leases</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeasePayments_c20220101__20221231_zDf2DayfmIDe" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Operating cash flows from operating leases">109</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: justify">Other Information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Weighted-average remaining lease term (in years):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zHOIuaDSkMm4" title="Weighted average remaining lease term operating leases">1.75</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Weighted-average discount rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20221231_zlh5gotrxAuk" title="Weighted average discount rate operating leases">10</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_zs2c3Go7FO58" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89D_ecustom--ScheduleOfSupplementalLeaseTableTextBlock_zQqKkypmcrnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
supplemental balance sheet information related to leases for the period is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_8BB_zL5YJSkPcp3a" style="display: none"><span>Schedule of
Supplemental Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zI2kWyxqLMk6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Operating leases (in thousands)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LongtermRightofuseAssetsNet_iI_pn3n3_zSbacztJBaqg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 76%; text-align: justify; padding-bottom: 1.5pt">Long-term right-of-use assets, net</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right">165</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLz4mp_zItWNdkXQIkf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Current portion of operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLz4mp_zoy3sdcm63Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Non-current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLz4mp_zlvj2TidPRDj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Total operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">174</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zCsp7DHArpk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhWalD4vG3Ti" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Maturities of the Company&#8217;s
lease liabilities are as follows (in thousands):</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zpkYAqAVHDL6" style="display: none">Schedule of Maturity Lease Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">Year ending</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_z5ARj7VPtFO7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzt3J_zGKx2PUnKdj5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">122</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzt3J_zk5pIjkIgFQb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLLzt3J_z7Na7aLyZ1p1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzt3J_zH17zc4DhhA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Total lease payments</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">214</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_za5mS08gj6hi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Less: Imputed interest/present value
    discount</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_zfYygSXv4mdj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Present value of lease liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">174</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p id="xdx_8A1_zFcbcSxu2lrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219803974432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zL5cb7TZwcS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_827_z7DFQ6mEV838">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, the Company records accruals for contingencies to the extent that our management concludes that the occurrence is
probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed
as incurred. There is no current or pending litigation of any significance with the exception of the matters that have arisen under,
and are being handled in, the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 13, 2022, the Company filed a demand for arbitration with the American Arbitration Association (AAA) against Michael Handelman, its
former Chief Financial Officer, on claims of breach of fiduciary duty and failure to comply with federal securities reporting law. The
claims are pending before an arbitrator in Los Angeles and the hearing is scheduled to begin on May 15, 2023. Mr. Handelman has not asserted
counterclaims against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28, 2019, a complaint was filed in the Superior Court of California, County of Los Angeles, West Judicial District, Santa Monica
Courthouse, Unlimited Civil Division by Jeffrey Lion and by Daniel Vallera, as individuals. The complaint was filed against GT Biopharma,
Inc. and its subsidiary Oxis Biotech, Inc. The Plaintiffs allege breach of a license agreement between the Plaintiffs and the Company
entered into on or about September 3, 2015. The Company filed an answer to the complaint denying many allegations and asserting affirmative
defenses. The Company reached a settlement of the case and paid on March 4, 2022, $<span id="xdx_905_eus-gaap--LitigationSettlementExpense_c20220301__20220304_zIxuh5yPGAW5" title="Litigation settlement expense">425,000</span> in full and final settlement of the claims.
This amount was fully accrued at December 31, 2021 and was paid during fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 3, 2021, a complaint was filed by Sheffield Properties in the superior Court of California, County of Ventura. The litigation arose
from a commercial lease entered into by GT Biopharma, Inc. for office space in Westlake Village in California. In July, 2021 the Company
entered into settlement agreement with Sheffield Properties and the payment in the settlement amount of $<span id="xdx_90E_eus-gaap--LitigationSettlementExpense_pn5n6_c20210805__20210806__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SheffieldPropertiesMember_zi3UALQO0la6" title="Litigation settlement expense">0.1</span> million was made on August
6, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Significant
Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a Scientific Research Agreement (&#8220;SRA&#8221;) with the Regents of the University of Minnesota, effective
June 16, 2021. This SRA has three major goals: (1) support the Company&#8217;s TriKE<sup>&#174;</sup>
product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans; and, (3)
investigation of the patient&#8217;s native NK cell population based on insights obtained from the analysis of the human data
generated during our GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for
TriKE<sup>&#174;</sup> constructs in support of our product development and GMP manufacturing efforts; (2) TriKE<sup>&#174; </sup>platform
drug delivery changes to allow transition to alternative drug delivery means and extended PK in humans; and, (3) gain an increased
understanding of changes in the patient&#8217;s native NK cell population as a result of TriKE<sup>&#174;</sup> therapy. Most studies
will use TriKE<sup>&#174;</sup> DNA/amino acid sequences created by us under current UMN/GTB licensing terms. The term of this
agreement shall expire on June 30, 2023. The University of Minnesota shall use reasonable efforts to complete the project for a
fixed sum of $<span id="xdx_901_ecustom--ProjectFee_pn5n6_c20220101__20221231_znX8N0UnZ7Wk" title="Project fee">2.1</span> million,
of which $<span id="xdx_90C_ecustom--ProjectFeeIncurred_pn5n6_c20220101__20221231_z3FC3sDrYsDk" title="Project fee incurred">1.7</span>
million has been incurred and recorded as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recorded an expense of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zpxaZ9XbI0b1" title="Research and development expense">766,000</span>
and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zskFIsaiqs9f" title="Research and development expense">964,000</span>
relating to the scientific research agreement for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2016
Exclusive Patent License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (&#8220;UofMN&#8221;),
to further develop and commercialize cancer therapies using TriKE<sup>&#174;</sup> technology developed by researchers at the UofMN to
target NK cells to cancer. Under the terms of the 2016 agreement, the Company receives exclusive rights to conduct research and to develop,
make, use, sell, and import TriKE<sup>&#174;</sup> technology worldwide for the treatment of any disease, state, or condition in humans.
The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted
by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE<sup>&#174;</sup>
technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union.
Under the agreement, the UofMN received an upfront payment of $<span id="xdx_908_ecustom--ProceedsFromUpfrontAmount_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zIY1O6U800xa" title="Proceeds from upfront amount">0.2</span> million, and an annual License Maintenance fee of $<span id="xdx_900_eus-gaap--CostMaintenance_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpevlTGwQbjl" title="Maintenance fee">0.1</span> million beginning
in 2021. The agreement also includes <span id="xdx_907_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zw5GAdAFkCJ3" title="Royalty fee percentage">4%</span> royalty fees, (not to exceed <span id="xdx_909_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zyR5a3A0Pjlj" title="Royalty fee percentage">6</span>% under subsequence license agreements or amendments to this agreement
or minimum annual royalty payments ranging from $<span id="xdx_904_eus-gaap--RoyaltyExpense_pn4n6_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zKIFkbspZKPk" title="Annual royalty payments">0.25</span> million to $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn5n6_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zPPEhNCer4Yd" title="Annual royalty payments">5.0</span> million. The agreement also includes certain performance milestone
payments totaling $<span id="xdx_90E_ecustom--PerformanceMilestonePayments_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zv7YOjA5Lo4k" title="Milestone payments">3.1</span> million, and one-time sales milestone payments of $<span id="xdx_907_ecustom--SalesMilestonePayments_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zT8dcmHnEfKc" title="Sales milestone payments">1.0</span> million upon reaching $<span id="xdx_902_ecustom--GrossSales_pn6n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zHAvE3einS8g" title="Sales">250</span> million in gross sales, and
$<span id="xdx_907_ecustom--SalesRevenue_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpaIWXZr1Gmg" title="Sales revenue">5.0</span> million upon reaching $<span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zgwWRPoGlIIl" title="Cumulative gross sales">500</span> million dollars in cumulative gross sales of Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did <span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zMDxqCnMbczh" title="Research and development expense">no</span>t incur any research and development expense relating to the 2016 Exclusive Patent
License Agreement for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021
Patent License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE<sup>&#174;</sup>. Under the agreement, the UofMN received
an upfront license fee of $<span id="xdx_901_ecustom--UpfrontLicenseFee_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zabHXXf0dU61" title="Upfront license fee">20,000</span>, and will receive an annual License Maintenance fee of $<span id="xdx_901_ecustom--LicenseMaintenanceFeeReceivable_iI_c20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zZcbJzB6K9S8" title="License maintenance fee, receivable">5,000</span> beginning in 2022, <span id="xdx_906_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zTi64CfuvDfe" title="Net sales percentage">2.5%</span> to <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zTccv5LX3Ojh" title="Net sales percentage">5%</span> royalty
fees, or minimum annual royalty payments of $<span id="xdx_90B_eus-gaap--RoyaltyExpense_pn4n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zTDWdC6uL0O" title="Annual royalty payments">0.25</span> million beginning in the year after the first commercial sales of Licensed Product,
and $<span id="xdx_901_eus-gaap--CostMaintenance_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zUG4R1ersv34" title="Maintenance fee">2.0</span> million beginning in the fifth year after the first commercial sale of such Licensed Product. The agreement also includes certain
performance milestone payments totaling $<span id="xdx_905_ecustom--PerformanceMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zhSqJdWZ4rA5" title="Performance milestone payments">3.1</span> million, and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z9vFpZJlPwI8" title="Sales milestone payments">1.0</span> million upon reaching $<span id="xdx_90E_ecustom--GrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8J1nnEfFa1k" title="Gross sales">250</span> million
in gross sales, and $<span id="xdx_909_ecustom--SalesRevenue_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zi9U1CfAyz2" title="Sales revenue">5.0</span> million upon reaching $<span id="xdx_901_ecustom--CummulativeGrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zNjYVUv7Knd8" title="Cumulative gross sales">500</span> million dollars in cumulative gross sales of Licensed Products. There is no double
payment intended; if one of the milestone payments has been paid under the 2016 agreement no further payment is due for the corresponding
milestone above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did <span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdOEvssQX5aa" title="Research and development expense"><span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zHz5gzbRA6k6" title="Research and development expense">no</span></span>t incur any research and development expense relating to the 2021 Patent License
Agreement for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p id="xdx_8AA_zSlMIiHsedS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Employee Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock_zJjSbKygK2t4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s future financial commitment to certain employees pursuant to their respective employment
agreements (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zasXu0L8RLFa" style="display: none">Schedule
of Company&#8217;s Future Financial Commitment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year ending</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zQONIIjZE8B5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherCommitmentDueInNextTwelveMonths_iI_pn3n3_maOCzdEO_zB66ZJtMVo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">432</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherCommitmentDueInSecondYear_iI_pn3n3_maOCzdEO_zWNNXeI8fjTi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherCommitment_iTI_pn3n3_mtOCzdEO_zchEAYQARl88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">486</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_z5EnAi48fsQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219808551280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zdbUCYALItXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_826_zGs4BOHfW4g9">Income Tax</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any income tax provision for the years ended December 31, 2022 and 2021, respectively, due to the Company&#8217;s net losses.
The Company files income tax returns in the United States (&#8220;Federal&#8221;) and California, Minnesota and Massachusetts (&#8220;State&#8221;)
jurisdictions. The Company is subject to Federal and State income tax examinations by tax authorities for all years since its inception.
At December 31, 2022, the Company had Federal and State net operating loss carry forwards available to offset future taxable income of
approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20221231_zgRke5BEOZr9" title="Operating loss carry forwards">238</span> million. These carry forwards will begin to expire in the year ending <span id="xdx_903_eus-gaap--OperatingLossCarryforwardsExpirationDate_c20220101__20221231_zpnmav7XqAQ4">December 31, 2030</span>, subject to IRS limitations,
including change in ownership. The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts
the carrying amount of the deferred tax assets by a valuation allowance to the extent the future realization of the deferred tax assets
is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of our
deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or
loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the weight of available evidence,
including cumulative losses in recent years and expectations of future taxable income, the Company has determined that it was more
likely than not that its deferred tax assets would not be realized at December 31, 2022 and 2021, respectively. Accordingly, the Company has recorded a valuation allowance for <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20220101__20221231_zGJ0K1PR39J2"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20210101__20211231_zRpN296xz6cc">100</span></span>%
of its cumulative deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes, and operating losses and tax credit carryforwards. The significant components
of net deferred income tax assets are (in thousands):</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zpsMRDz6YbBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zgUdxd1Q2Lnd" style="display: none">Schedule
of Net Deferred Income Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_496_20221231_zJFoI1d9QIrl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_491_20211231_zGGctYHlTdvl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn3n3_maDTAGzPo9_zjG3tRmkgLZ4" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Federal net operating loss carryforward</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">66,741</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">58,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTAGzPo9_zCJGaYqDJxe6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation and other items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,622</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzPo9_zQDTJK1tT7yc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Intellectual property</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,572</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzPo9_maDTANzU5L_z2A16JeZ213e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets before valuation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,848</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzU5L_zwiCOrrHX0Kh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(112,987</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(127,848</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzU5L_zdxbcBSgYsF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zDM9xO4w7Lff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z7lxuxZ2xD3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income tax
provision is as follows for the year ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zC4cXtFI7ON3" style="display: none">Schedule
of Income Tax Provision</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zKRygQgZKjLg" title="Federal statutory income tax rate">21</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zNVbotp5Aolj" title="Federal statutory income tax rate">21</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zmZUT8NLhfdi" title="State tax, net of federal benefit">8</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231_zXTK0f8UVrQk" title="State tax, net of federal benefit">9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance on net operating loss carryforwards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20220101__20221231_zEtbWqxdas7b" title="Change in valuation allowance on net operating loss carryforwards">(29</span></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20210101__20211231_zvArZUvdEWe6" title="Change in valuation allowance on net operating loss carryforwards">(30</span></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zg1lOq9En3wc" title="Effective income tax rate">0</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zZMABh2k79r7" title="Effective income tax rate">0</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A5_zaJjnrNAQQ3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219807394864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zev4qmpX8GH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; <span id="xdx_82F_zDvMeHszkSlc">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock
Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, GT Biopharma received gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember_zb2HwkUEJlm" title="Gross proceeds from common stock">6.5</span> million, before deducting placement agent fees and other offering expenses
of approximately $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ziWlbS8dWKSh" title="Placement agent fees and other offering expenses">450,000</span>, in relation to a purchase agreement (the &#8220;Purchase Agreement&#8221;) signed on December 30, 2022, <span style="background-color: white">between
the Company</span> and an institutional investor (the &#8220;Purchaser&#8221;) for the issuance and sale, in a registered direct offering
(the &#8220;Offering&#8221;), of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjrAIizOUfUg" title="Common stock shares issued during the period">3,600,000</span> shares of the Company&#8217;s common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBotL1Cvaqi3" title="Common stock par value">0.001</span> per share (the &#8220;Shares&#8221;),
pre-funded warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__srt--RangeAxis__srt--MaximumMember_zrNvqD7rtCJ" title="Warrants purchase of common stock">2,900,000</span> shares of the Company&#8217;s common stock (the &#8220;Pre-Funded Warrants&#8221;), and
warrants to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_ziwF1AC09GB2" title="Warrants purchase of common stock">6,500,000</span> shares of the Company&#8217;s common stock (the &#8220;Common Warrants&#8221;).
The Common Warrants have an exercise price equal to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zrHSRH5EBhli" title="Warrants exercise price per share">1.00</span>, will be exercisable commencing six months following issuance, and will have
a term of exercise equal to five years following the initial exercise date. The Pre-Funded Warrants have an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zdzuJqF92Ftg" title="Warrants exercise price per share">0.0001</span>
per Share, are immediately exercisable and can be exercised at any time after their original issuance until such Pre-Funded Warrants
are exercised in full. The Shares and Common Warrants were sold at an offering price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zoiHWhKkxnE8" title="Shares and warrants sold price per share">1.00</span> per Share and accompanying Common Warrant
and the Pre-Funded Warrants and Common Warrants were sold at an offering price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pip0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zUSxHzPBDTW7" title="Shares and warrants sold price per share">0.9999</span> per Pre-Funded Warrant and accompanying Common
Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Issuance
of Common Stock for research and development agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 14, 2023, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230313__20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentAgreementMember_ztTj4Qn3KKye" title="Common stock shares issued during the period">486,819</span> </span> shares of common stock with a fair value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230313__20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentAgreementMember_z0liH6L68MV" title="Common stock value issued during the period">820,341</span> pursuant to a payment agreement
with a third-party manufacturer (see Note 4). The shares were valued at the respective month-end closing prices of the Company&#8217;s common stock when the payment was due to the vendor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Demand
Letter</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company received a demand letter from an attorney representing an alleged holder of a convertible note which alleges
that the Company did not deliver shares of common stock that were due on conversion in 2022. The demand letter contends that the Company
is liable for per diem liquidated damages. The Company has denied liability and will defend any such claim vigorously if asserted.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219805355952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z19k8I4c2dmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zqob9Y9qTHU5">Basis
of Presentation and Principles of Consolidation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America. The consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries,
Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated
in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_84F_ecustom--LiquidityPolicyTextBlock_zDg78qWfj2Jg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zMWPnp1TEuY9">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared under the assumption that the Company will continue as a going
concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The Company recorded a net loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_zoYFhP1AV3l" title="Net loss">20.9</span>
million of which $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231_zQYfgsiL4tW1" title="Non-cash stock compensation">7.7</span>
million resulted from non-cash stock compensation, and used cash in operations of $<span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_z0jLxMO5fjSe" title="Cash in Operating activities">15.2</span>
million for the year ended December 31, 2022. The Company had a cash and short-term investments balance of $<span id="xdx_908_ecustom--CashOnHandAndShortTermInvestment_iI_pn5n6_c20221231_z6Kl1tjczTUc" title="Cash and short term investments">16.5</span>
million at December 31, 2022. On January 4, 2023, the Company raised an additional $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUJmTJm8h05b" title="Cash on equity issuance">6.5</span>
million of cash through an equity issuance (see Note 11). Management anticipates that the $<span id="xdx_90C_eus-gaap--InvestmentsAndCash_iI_pn5n6_c20221231_z7HvOH39bIM3" title="Investments and cash">23.0</span>
million of cash and cash equivalents and short-term investments available following the stock issuance are adequate to satisfy the
liquidity needs of the Company for at least one year from the date the Company&#8217;s 2022 consolidated financial statements are
issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has financed its operations through public and private sales of common stock, issuance of preferred stock, issuance of
convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to secure
additional financing on acceptable terms. <span style="background-color: white">In the event that the Company does not generate
sufficient cash flows from investing and financing activities, the Company will be forced to delay, reduce, or eliminate some or all
of its discretionary spending, which could adversely affect the Company&#8217;s business prospects, ability to meet long-term
liquidity needs or ability to continue operations.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock', window );">COVID-19</a></td>
<td class="text"><p id="xdx_84E_ecustom--UnusualRisksAndUncertaintiesPolicyTextBlock_zCnh8KI6YFS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86F_zbPGhi2mNm84" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">COVID-19</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global COVID-19 pandemic continues to present uncertainty and unforeseeable risks to GT Biopharma&#8217;s operations and business plan.
The Company has closely monitored recent developments, including the lifting of COVID-19 safety measures, the spread of new strains or
variants of the coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. Thus, the full impact of
the COVID-19 pandemic on the business and operations remains uncertain and will vary depending on the pandemic&#8217;s future impact
on the third parties with whom the Company does business, as well as any legal or regulatory consequences resulting therefrom. The Company
has been following the recommendations of health authorities to minimize exposure risk for its team members and may take further actions
that alter our operations, including any required by federal, state or local authorities, or that it determines are in the best interests
of its employees and other third parties with whom GT Biopharma does business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_847_eus-gaap--UseOfEstimates_zmffGgDs1vt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zFLvBtEPfeKk">Accounting
Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates. Significant estimates include accruals for potential liabilities,
assumptions used in deriving the fair value of derivative liabilities, share-based compensation and valuation of deferred tax assets.
Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents and Short-Term Investments</a></td>
<td class="text"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjR4PL06PRr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Cash
Equivalents and Short-Term Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying consolidated financial statements. As of December 31, 2022, total cash and cash equivalents which consist
of cash and money market funds, amounted to approximately $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zI0liZ1AxHj5" title="Cash and cash equivalents">5.7</span>&#160;million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our businesses. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
consolidated statements of operations. As of December 31, 2022, total short-term investments amounted to approximately $<span id="xdx_901_eus-gaap--ShortTermInvestments_iI_pn5n6_c20221231_z9WB8Ry3wHBh" title="Short-term investments">10.8</span> million.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zuyF6MoVXLOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_zB5YeCD5rWh2">Fair
Value of Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 820-10 requires entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10
defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s derivative liability of $<span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231_zoupMEcwRSUa" title="Derivative liability">18,700</span>
at December 31, 2022 and $<span id="xdx_903_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231_zvdjwnOhtTn7" title="Derivative liability">138,000</span> at December 31, 2021 was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and notes payable, approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_z81iMwHLqIv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_zodClfERMec">Derivative
Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception and on
subsequent valuation dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zvj8Qg36B8f5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically issues stock-based compensation
to officers, directors, employees and consultants for services rendered. Such issuances vest and expire according to terms established
at the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="background-color: white">Stock-based payments to officers,
directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options,
are recognized in the financial statements based on their grant date fair values in accordance with ASC 718,&#160;<i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVuOyqmgqzxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zrP9tkQS7247">Research
and Development Costs</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products comprise research and development expenses. Purchased materials that do not have an alternative
future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_845_eus-gaap--LesseeLeasesPolicyTextBlock_z5zpoPyrzbi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_864_zdZH1dcAPH6g">Leases</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
accounts for its lease<span style="background-color: white">s</span> in accordance with the guidance of ASC 842,&#160;<i>Leases</i>. The Company determines whether a contract is, or
contains, a lease at inception. Right-of-use assets represent the Company&#8217;s right to use an underlying asset during the lease term,
and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and
lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease
term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present
value of unpaid lease payments</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z4bd0h0IYdrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zWDNiQlHPtI5">Net
Loss Per Share</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEgi1z1Rmswe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following shares were excluded in the computation of the diluted net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zipYmU8WkIGg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zU9UWDlsIkZb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231_zQlvrHZC1fVc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zpx6zK8cGit3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,337,274</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,337,274</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zTAusukgtt6b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,630,452</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zoUC5MvZbyd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,967,726</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,639,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zCRXDR4bUjNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zF7y24q5FnX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zUUmErhmJpd2">Concentration</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal
Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20221231_z0tzcbSMKFH7" title="FDIC amount">250,000</span>.<span style="background-color: white">
Management believes that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly,
minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_845_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zl2eOgoSa2K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zODc3uUH0vU4">Segments</span>
</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined its reporting units in accordance with  &#8220;<i>Segment Reporting</i>&#8221; (&#8220;ASC 280&#8221;). Management
evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that the Company has one consolidated operating segment. The Company&#8217;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#8217;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zS2DXMm4M17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zs67VLMvEI7e">Recently
Issued Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <i>Credit Losses &#8211; Measurement of Credit Losses on Financial
Instruments</i> (&#8220;ASC 326&#8221;). ASU 2016-13 requires entities to use a forward-looking approach based on current expected
credit losses (&#8220;CECL&#8221;) to estimate credit losses on certain types of financial instruments, including trade receivables.
This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1,
2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related
codification improvements will be material to its financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt&#8212;Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity&#8217;s Own Equity</i>. Effective January 1, 2021, the Company adopted ASU 2020-06 using
the modified retrospective approach. Adoption of the new standard resulted in a decrease to additional paid-in capital of $<span id="xdx_90A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_pn5n6_c20220101__20221231_zgHlZwJegvjl" title="Decrease to additional paid-in capital">4.5</span> million
(see Note 5).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>. ASU 2021-04 provides clarification
and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options
(such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange
as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification
or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting
treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and
debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including
interim periods within those fiscal years. Effective January 1, 2022, the Company adopted ASU 2021-04 using a prospective approach. The
adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission (the &#8220;SEC&#8221;) did not or are not believed by management to have a material
impact on the Company&#8217;s present or future consolidated financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unusual Risks and Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219803947248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEgi1z1Rmswe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following shares were excluded in the computation of the diluted net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zipYmU8WkIGg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zU9UWDlsIkZb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231_zQlvrHZC1fVc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zpx6zK8cGit3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,337,274</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,337,274</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zTAusukgtt6b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,630,452</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zoUC5MvZbyd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,967,726</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,639,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219804250048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Estimated Fair Value of Financial Instrument</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_z5P3ACjZbzje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of financial instruments outstanding were (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z8O7MHPLJB85" style="display: none">Schedule
of Estimated Fair Value of Financial Instrument</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z0Nwf4vaguHj" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost">10,866</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zxzqvnjslD7b" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z7w5n6zTDhad" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses">(30</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zO2MI49T56p" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value">10,836</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total</p></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231_zuPQFV0NnH08" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">10,866</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20221231_z4YJRJdvNVdk" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0658">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20220101__20221231_zNlzXae6QJc2" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses">(30</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20220101__20221231_zEQ272R0XVh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">10,836</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztAYkzKBPsRg" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost">23,040</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zNPPfyPvHdHd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0666">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z0c3DddLu0Df" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses">(29</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zfz99ky0Pkdb" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value">23,011</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231_zxAaYty20ae7" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">23,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231_zp3R7zxneRl6" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0674">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20210101__20211231_z2JoDP36MTr1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses">(29</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20210101__20211231_z72PrVxMotCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">23,011</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy Financial Assets</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zRV5XjC21Sf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&#8217;s fair value hierarchy for its financial assets (cash equivalents and investments, in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zhYv3SDQBCra" style="display: none">Schedule of Fair Value Hierarchy Financial Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zVlB2J6BDbHb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zs3pIkHwJCA2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZBVLWVooYVg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgy53sOf7B63" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zCD2990X8Uig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,505</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,505</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_z2iq57rzLLBd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,836</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,836</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zVqoiyls41Tk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total financial assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,341</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,341</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0695">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_49A_20211231_z6u3KPsgWw72" style="border-bottom: Black 1.5pt solid; text-align: center">1</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1xzZplSugg5" style="border-bottom: Black 1.5pt solid; text-align: center">2</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjIAwY1kW568" style="border-bottom: Black 1.5pt solid; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkP0MsVY8XPj" style="border-bottom: Black 1.5pt solid; text-align: center">4</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zLzr2WdwxdJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,484</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,484</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0700">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zLGxsofpk1Fj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0704">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zKl8cYu3bI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219807341824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUhfGv2y8k07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z6lDKgLhjGB7" style="display: none">Schedule of Accounts Payable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20221231_zILvVLffkSD2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31, </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20211231_zqGmjJ5QkVJd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31, </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maAPCz7ta_zHlh7QCLZok7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable to a third-party manufacturer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,283</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,335</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz7ta_zW4zfHTwGGR" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    accounts payable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">857</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,854</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz7ta_zJC8oa4mKaJ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accounts payable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,140</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,189</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219805676704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureDerivativeLiabilityAbstract', window );"><strong>Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Derivative Liabilities Assumptions</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuG0syJwcwxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liabilities were valued using a Binomial pricing model with the following average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_z0UziVqcKBw3" style="display: none">Schedule
of Derivative Liabilities Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zIpdXiETvf6d" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231_zRCfpTGncpsl" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5cUR9Ao3Je2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: justify">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">4.22</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1.26</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zASm9Vf2dB6j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0NcfDqHMfvh" title="Expected life (in years)">2.6</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_pid_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zwRU9ZyZICi7" title="Expected life (in years)">3.6</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlDsQEUAjxIf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Fair value of warrants (in thousands)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231_zR5pR86lfrsk" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210101__20211231_zZ2N533ilBTl" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">138</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liability Transactions</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zLPhfjCHTdL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zEdDNLvpQEi" style="display: none">Schedule
of Derivative Liability Transactions</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20220101__20221231_zwhqCDktytb2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022<br/>
                                            (in thousands)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20210101__20211231_zuvS276Z3CY9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021<br/>
                                            (in thousands)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zeO1NaGtY4Q8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
    Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">384</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3n3_zomiiUQtoG6d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0854">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--ExtinguishmentOfWarrants_pn3n3_zZBctFgLebVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(35</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3n3_z7PNVM0M82Ic" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(119</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(211</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zUPudqAzKVg5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending
    Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureDerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureDerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219807328288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVmuTixxFRaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the years ended December 31, 2022 and 2021, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zPL1qDLeTdUk" style="display: none">Schedule of Warrant Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants outstanding at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zAidrt5agsmk" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance">221,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zcGY9iwCNPcb" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance">3.40</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_z3EuXatLSHOl" style="text-align: right" title="Number of warrants, granted">5,192,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20210101__20211231_z2d46zBA1gvb" style="text-align: right" title="Weighted average exercise price, granted">5.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231_z3FOuNgqLgG" style="text-align: right" title="Number of warrants, forfeited">(2,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20210101__20211231_zROGhViFSt42" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0991">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231_zOAQSpW12wJk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised">(3,074,017</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zjSQy4fHZey7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">5.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_z1ALWcmxMJB4" style="text-align: right" title="Warrants outstanding, beginning balance">2,337,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zHJbdLrHCZa" style="text-align: right" title="Weighted average exercise price, beginning balance">5.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_z4oyI7zEEEc6" style="text-align: right" title="Number of warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20220101__20221231_zdzHJQmsyOFl" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231_zB3JqQ7hdXn6" style="text-align: right" title="Number of warrants, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20220101__20221231_zyy8ERkDL5i2" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231_zr1rAal3cNe8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zb1oj5ephd23" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231_zs8TjyYL8tD9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, beginning balance">2,337,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_z8OFkijsZDT8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, beginning balance">5.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20221231_zhXYdJr1oDH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance">2,337,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zZaOUhMxFGYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, ending balance">5.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options Activity</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9N3xVDZw8b3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option transactions for the years ended December 31, 2022 and 2021 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BF_zkmuoVUXWQr" style="display: none">Schedule
of Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zvSot9rnVhHk" style="text-align: right" title="Number of options outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1037">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zWwJMd2Jqvg8" style="text-align: right" title="Weighted-Average Exercise Price, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20210101__20211231_zPtEn2lmMNve" style="width: 16%; text-align: right" title="Number of options, Granted">302,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zOA5w1sNPSxk" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Granted">3.05</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20210101__20211231_zq2iQDVImP56" style="text-align: right" title="Number of options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_znWJP9XBSWu1" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20210101__20211231_z5Ra0jdk0ouj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zQsqX1NCgGZa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_z32vbvCsSZPh" style="text-align: right" title="Number of options outstanding, beginning">302,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z2mT1cvUOU9b" style="text-align: right" title="Weighted-Average Exercise Price, Beginning">3.05</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231_zOfZ1vfUgNp1" style="text-align: right" title="Number of options outstanding, Granted">1,532,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zH5JUeKQI1Q9" style="text-align: right" title="Weighted-Average Exercise Price, Granted">2.48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231_zZcvKcdMJeX1" style="text-align: right" title="Number of options outstanding, Forfeited">(205,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zIEx8nBiVGS" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited">2.48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20220101__20221231_z9CTyUEVT7j8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zA1BPoS8srYj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zNJkXaRTv711" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding outstanding, Ending">1,630,452</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zq7QYxtAaMzb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Ending">2.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zrF4X1nmq76b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, exercisable">1,440,404</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zk9HfEbEkYnd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Ending">2.55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219803382928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock', window );">Schedule of Components Leases Rent Expenses</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_z92Vm6MA67r1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">The components of rent expense and
supplemental cash flow information related to leases for the period are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">&#160;<span id="xdx_8B1_zFWXrBDT8D1h" style="display: none">Schedule of Components
Leases Rent Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Lease Costs (in thousands):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 76%; text-align: justify; padding-bottom: 1.5pt">Operating cash flows from operating leases</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeasePayments_c20220101__20221231_zDf2DayfmIDe" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Operating cash flows from operating leases">109</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: justify">Other Information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Weighted-average remaining lease term (in years):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zHOIuaDSkMm4" title="Weighted average remaining lease term operating leases">1.75</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Weighted-average discount rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20221231_zlh5gotrxAuk" title="Weighted average discount rate operating leases">10</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfSupplementalLeaseTableTextBlock', window );">Schedule of Supplemental Leases</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfSupplementalLeaseTableTextBlock_zQqKkypmcrnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
supplemental balance sheet information related to leases for the period is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_8BB_zL5YJSkPcp3a" style="display: none"><span>Schedule of
Supplemental Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zI2kWyxqLMk6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Operating leases (in thousands)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LongtermRightofuseAssetsNet_iI_pn3n3_zSbacztJBaqg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 76%; text-align: justify; padding-bottom: 1.5pt">Long-term right-of-use assets, net</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right">165</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLz4mp_zItWNdkXQIkf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Current portion of operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLz4mp_zoy3sdcm63Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Non-current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLz4mp_zlvj2TidPRDj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Total operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">174</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity Lease Liabilities</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhWalD4vG3Ti" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Maturities of the Company&#8217;s
lease liabilities are as follows (in thousands):</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zpkYAqAVHDL6" style="display: none">Schedule of Maturity Lease Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">Year ending</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_z5ARj7VPtFO7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzt3J_zGKx2PUnKdj5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">122</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzt3J_zk5pIjkIgFQb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLLzt3J_z7Na7aLyZ1p1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzt3J_zH17zc4DhhA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Total lease payments</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">214</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_za5mS08gj6hi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Less: Imputed interest/present value
    discount</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_zfYygSXv4mdj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Present value of lease liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">174</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Other Information Related Leases UnderN On Cancellable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfSupplementalLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Supplemental Lease [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfSupplementalLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219807399584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock', window );">Schedule of Company&#8217;s Future Financial Commitment</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock_zJjSbKygK2t4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s future financial commitment to certain employees pursuant to their respective employment
agreements (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zasXu0L8RLFa" style="display: none">Schedule
of Company&#8217;s Future Financial Commitment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year ending</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zQONIIjZE8B5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherCommitmentDueInNextTwelveMonths_iI_pn3n3_maOCzdEO_zB66ZJtMVo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">432</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherCommitmentDueInSecondYear_iI_pn3n3_maOCzdEO_zWNNXeI8fjTi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherCommitment_iTI_pn3n3_mtOCzdEO_zchEAYQARl88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">486</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Company&#8217;s Future Financial Commitment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219807331808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Income Tax Assets</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zpsMRDz6YbBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zgUdxd1Q2Lnd" style="display: none">Schedule
of Net Deferred Income Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_496_20221231_zJFoI1d9QIrl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_491_20211231_zGGctYHlTdvl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn3n3_maDTAGzPo9_zjG3tRmkgLZ4" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Federal net operating loss carryforward</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">66,741</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">58,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTAGzPo9_zCJGaYqDJxe6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation and other items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,622</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzPo9_zQDTJK1tT7yc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Intellectual property</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,572</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzPo9_maDTANzU5L_z2A16JeZ213e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets before valuation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,848</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzU5L_zwiCOrrHX0Kh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(112,987</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(127,848</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzU5L_zdxbcBSgYsF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Provision</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z7lxuxZ2xD3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income tax
provision is as follows for the year ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zC4cXtFI7ON3" style="display: none">Schedule
of Income Tax Provision</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zKRygQgZKjLg" title="Federal statutory income tax rate">21</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zNVbotp5Aolj" title="Federal statutory income tax rate">21</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zmZUT8NLhfdi" title="State tax, net of federal benefit">8</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231_zXTK0f8UVrQk" title="State tax, net of federal benefit">9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance on net operating loss carryforwards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20220101__20221231_zEtbWqxdas7b" title="Change in valuation allowance on net operating loss carryforwards">(29</span></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20210101__20211231_zvArZUvdEWe6" title="Change in valuation allowance on net operating loss carryforwards">(30</span></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zg1lOq9En3wc" title="Effective income tax rate">0</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zZMABh2k79r7" title="Effective income tax rate">0</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219804351792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">3,967,726<span></span>
</td>
<td class="nump">2,639,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">2,337,274<span></span>
</td>
<td class="nump">2,337,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">1,630,452<span></span>
</td>
<td class="nump">302,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219805538896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 04, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,884,000<span></span>
</td>
<td class="nump">$ 58,013,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash in Operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,217,000<span></span>
</td>
<td class="nump">15,606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CashOnHandAndShortTermInvestment', window );">Cash and short term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Investments and cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,672,000<span></span>
</td>
<td class="nump">8,968,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,836,000<span></span>
</td>
<td class="nump">23,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">$ 138,000<span></span>
</td>
<td class="nump">$ 384,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Decrease to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Cash on equity issuance</a></td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CashOnHandAndShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash on hand and short term investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CashOnHandAndShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219803196480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Estimated Fair Value of Financial Instrument (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 10,866<span></span>
</td>
<td class="nump">$ 23,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Fair value</a></td>
<td class="nump">10,836<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">10,866<span></span>
</td>
<td class="nump">23,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Fair value</a></td>
<td class="nump">$ 10,836<span></span>
</td>
<td class="nump">$ 23,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219804508160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value Hierarchy Financial Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">$ 16,341<span></span>
</td>
<td class="nump">$ 28,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">16,341<span></span>
</td>
<td class="nump">28,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">5,505<span></span>
</td>
<td class="nump">5,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">5,505<span></span>
</td>
<td class="nump">5,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">10,836<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">10,836<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219806256416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable to a third-party manufacturer</a></td>
<td class="nump">$ 2,283<span></span>
</td>
<td class="nump">$ 6,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total accounts payable</a></td>
<td class="nump">$ 3,140<span></span>
</td>
<td class="nump">$ 8,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219802288096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 03, 2022</div></th>
<th class="th"><div>Sep. 01, 2022</div></th>
<th class="th"><div>Oct. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Reserach and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,811,000<span></span>
</td>
<td class="nump">$ 9,591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustment to additional paid in capital, stock issued, issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_ServiceAgreementMember', window );">Service Agreement [Member] | Third Party Manufacturer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_ServiceAgreementMember', window );">Service Agreement [Member] | Third Party Manufacturer [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Reserach and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustment to additional paid in capital, stock issued, issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PaymentAgreementMember', window );">Payment Agreement [Member] | Third Party Manufacturer [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">1,222,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per share</a></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes payable, related parties</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_ServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_ServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_ThirdPartyManufacturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_ThirdPartyManufacturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_PaymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_PaymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219801092464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,669<span></span>
</td>
<td class="nump">$ 1,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense due to amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock shares, unissued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForCashMember', window );">Notes Payables Issued For Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion rate</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted shares</a></td>
<td class="nump">7,438,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForSettlementAgreementsMember', window );">Notes Payable Issued For Settlement Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion rate</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted shares</a></td>
<td class="nump">743,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForSettlementAgreementsMember', window );">Notes Payable Issued For Settlement Agreements [Member] | Fiscal 2019 and 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForForbearanceAgreementsMember', window );">Notes Payable Issued For Forbearance Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion rate</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted shares</a></td>
<td class="nump">1,132,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForConsultingAgreementMember', window );">Notes Payable Issued For Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion rate</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted shares</a></td>
<td class="nump">472,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total, notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_NotesPayableForUnpaidConsultingFee', window );">Notes payable for unpaid consulting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SharesIssuedDuringPeriodValueAccruedInterest', window );">Total accrued interest</a></td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SharesIssuedDuringPeriodSharesAccruedInterest', window );">Number of shares issued for accrued interest</a></td>
<td class="nump">1,627,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForConsultingAgreementMember', window );">Notes Payable Issued For Consulting Agreement [Member] | January 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,413,322<span></span>
</td>
<td class="nump">11,086,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_ConvertibleNotePayableMember', window );">Convertible Note Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt instrument, convertible, beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_NotesPayableForUnpaidConsultingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes payable for unpaid consulting fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_NotesPayableForUnpaidConsultingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SharesIssuedDuringPeriodSharesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SharesIssuedDuringPeriodSharesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SharesIssuedDuringPeriodValueAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued during period value accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SharesIssuedDuringPeriodValueAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForSettlementAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForSettlementAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_FiscalTwentyNinteenandTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_FiscalTwentyNinteenandTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForForbearanceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForForbearanceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_JanuaryTwentyTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_JanuaryTwentyTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_ConvertibleNotePayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_ConvertibleNotePayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219805406768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Liabilities Assumptions (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">4.22<span></span>
</td>
<td class="nump">1.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability fair value assumptions expected term 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219805820880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Liability Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureDerivativeLiabilityAbstract', window );"><strong>Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Beginning Balance</a></td>
<td class="nump">$ 138,000<span></span>
</td>
<td class="nump">$ 384,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Addition</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ExtinguishmentOfWarrants', window );">Extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value</a></td>
<td class="num">(119,000)<span></span>
</td>
<td class="num">(211,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Ending Balance</a></td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="nump">$ 138,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureDerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureDerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ExtinguishmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ExtinguishmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219806254512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureDerivativeLiabilityAbstract', window );"><strong>Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Derivative, Gain (Loss) on Derivative, Net<span></span>
</td>
<td class="text">Derivative, Gain (Loss) on Derivative, Net<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureDerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureDerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219801789952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">2,337,274<span></span>
</td>
<td class="nump">221,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance</a></td>
<td class="nump">$ 5.30<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,192,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Weighted average exercise price, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of warrants, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Weighted average exercise price, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,074,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">2,337,274<span></span>
</td>
<td class="nump">2,337,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance</a></td>
<td class="nump">$ 5.30<span></span>
</td>
<td class="nump">$ 5.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants exercisable, ending balance</a></td>
<td class="nump">2,337,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, ending balance</a></td>
<td class="nump">$ 5.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Paymen tAward Non Options Exercises In Period Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219802438544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning</a></td>
<td class="nump">302,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Beginning</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options outstanding, Granted</a></td>
<td class="nump">1,532,952<span></span>
</td>
<td class="nump">302,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted</a></td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of options, Forfeited</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised', window );">Number of options outstanding, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of options outstanding, Forfeited</a></td>
<td class="num">(205,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding outstanding, Ending</a></td>
<td class="nump">1,630,452<span></span>
</td>
<td class="nump">302,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Ending</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options outstanding, exercisable</a></td>
<td class="nump">1,440,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Ending</a></td>
<td class="nump">$ 2.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219792466016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 15, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 24,679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Adjustments to additional paid in capital, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,032,000<span></span>
</td>
<td class="nump">$ 251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based compensation arrangement by share-based payment award, options, vested in period, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,032,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non- vested number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue', window );">Share based compensation unvested intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 645,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,952<span></span>
</td>
<td class="nump">302,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock exercise warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,074,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesJOnePreferredStockMember', window );">Series J One Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesJPreferredStockMember', window );">Series J Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common shares issued upon conversion of notes payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,353,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStocksMember', window );">Series K Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStockMember', window );">Series K Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_EmploymentAgreementsMember', window );">Employment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,379,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,815<span></span>
</td>
<td class="nump">4,040,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock exercise warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,192,250<span></span>
</td>
<td class="nump">5,192,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock exercise warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,074,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Adjustments to additional paid in capital, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common shares issued upon conversion of notes payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series J Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common shares issued upon conversion of notes payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,300,000<span></span>
</td>
<td class="nump">$ 33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Debt instrument, increase, accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion converted instrument amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,413,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,945,000<span></span>
</td>
<td class="nump">4,945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_OwnersMember', window );">Owners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_InvestorsMember', window );">Investors [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock exercise warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,192,250<span></span>
</td>
<td class="nump">5,192,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ClassOfWarrantExpireTerm', window );">Class of warrant expire term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_NoteHolderMember', window );">Note Holder [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,086,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Remaining number of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,298<span></span>
</td>
<td class="nump">327,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital, common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Adjustments to additional paid in capital, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_OfficersAndDirectorsMember', window );">Officers and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">396,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share based compensation cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="nump">$ 994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,744<span></span>
</td>
<td class="nump">2,432,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,113<span></span>
</td>
<td class="nump">649,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 791,000<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,850,090<span></span>
</td>
<td class="nump">2,850,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CommonStockConsultantToFairValue', window );">[custom:CommonStockConsultantToFairValue]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Number of shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Legal and professional expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_ConsultantEmployeesOfficersAndDirectorsMember', window );">Consultant Employees Officers And Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Fair value</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option granted</a></td>
<td class="nump">1,532,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable price</a></td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">125.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_ConsultantEmployeesOfficersAndDirectorsMember', window );">Consultant Employees Officers And Directors [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_ConsultantEmployeesOfficersAndDirectorsMember', window );">Consultant Employees Officers And Directors [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_TwoEmployeesMember', window );">Two Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Fair value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 808,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of stock option, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ClassOfWarrantExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant expire term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ClassOfWarrantExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockConsultantToFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock consultant to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockConsultantToFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to unvest outstanding aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesJOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesJOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesJPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesJPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_EmploymentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_EmploymentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_OwnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_OwnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_NoteHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_NoteHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_ConsultantEmployeesOfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_ConsultantEmployeesOfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_TwoEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_TwoEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219807317424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Components Leases Rent Expenses (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term operating leases</a></td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate operating leases</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219806165696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Supplemental Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_LongtermRightofuseAssetsNet', window );">Long-term right-of-use assets, net</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">110<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liabilities</a></td>
<td class="nump">64<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LongtermRightofuseAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term right of use assets net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LongtermRightofuseAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219804347712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturity Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest/present value discount</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219801875808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Feb. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="nump">$ 260,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AdditionalOperatingLeaseAssets', window );">Additional Operating lease assets</a></td>
<td class="nump">$ 12,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseOptionToExtend', window );">Commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">commencement date of January 1, 2022
and maturing on June 30, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_AdditionalOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_AdditionalOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend operating sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219804249920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Company&#8217;s Future Financial Commitment (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">2024</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Total</a></td>
<td class="nump">$ 486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219802113488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2022</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ProjectFee', window );">Project fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ProjectFeeIncurred', window );">Project fee incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,811,000<span></span>
</td>
<td class="nump">$ 9,591,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_ScientificResearchAgreementMember', window );">Scientific Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
<td class="nump">964,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ProceedsFromUpfrontAmount', window );">Proceeds from upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cumulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cumulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_LicenseMaintenanceFeeReceivable', window );">License maintenance fee, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_SheffieldPropertiesMember', window );">Sheffield Properties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CummulativeGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cummulative gross sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CummulativeGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_GrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_GrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LicenseMaintenanceFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License maintenance fee, receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LicenseMaintenanceFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_PerformanceMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_PerformanceMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ProceedsFromUpfrontAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Received upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ProceedsFromUpfrontAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ProjectFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Project fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ProjectFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ProjectFeeIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Project fee incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ProjectFeeIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_ScientificResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_ScientificResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_SheffieldPropertiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_SheffieldPropertiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219803315392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Net Deferred Income Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforward</a></td>
<td class="nump">$ 66,741<span></span>
</td>
<td class="nump">$ 58,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock based compensation and other items</a></td>
<td class="nump">4,674<span></span>
</td>
<td class="nump">7,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intellectual property</a></td>
<td class="nump">41,572<span></span>
</td>
<td class="nump">62,055<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation</a></td>
<td class="nump">112,987<span></span>
</td>
<td class="nump">127,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(112,987)<span></span>
</td>
<td class="num">(127,848)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219804234416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Income Tax Provision (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance on net operating loss carryforwards</a></td>
<td class="num">(29.00%)<span></span>
</td>
<td class="num">(30.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219805840272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating Loss Carryforwards, Expiration Date</a></td>
<td class="text">Dec. 31,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140219801896736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2023</div></th>
<th class="th"><div>Jan. 04, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 24,679,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock value issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member] | Institutional Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent fees and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Conversion of Preferred Series J-1 to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member] | Institutional Investor [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares and warrants sold price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member] | Institutional Investor [Member] | Pre Funded Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member] | Institutional Investor [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares and warrants sold price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Research And Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Conversion of Preferred Series J-1 to common stock, shares</a></td>
<td class="nump">486,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock value issued during the period</a></td>
<td class="nump">$ 820,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=GTBP_InstitutionalInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=GTBP_InstitutionalInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_ResearchAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_ResearchAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:GTBP="http://gtbiopharma.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gtbp-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2023-03-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-032023-01-04_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-10-05_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-05</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-08-232022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PaymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-23</startDate>
            <endDate>2022-08-24</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PaymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-24</instant>
        </period>
    </context>
    <context id="AsOf2022-09-01_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PaymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-01</instant>
        </period>
    </context>
    <context id="AsOf2022-10-03_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PaymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ThirdPartyManufacturerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NotesPayableIssuedForCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-01-01_custom_NotesPayableIssuedForCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_NotesPayableIssuedForCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:FiscalTwentyNinteenandTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForSettlementAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForSettlementAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForSettlementAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-23_custom_NotesPayableIssuedForForbearanceAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForForbearanceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-23</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NotesPayableIssuedForForbearanceAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForForbearanceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_NotesPayableIssuedForForbearanceAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForForbearanceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForForbearanceAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForForbearanceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NotesPayableIssuedForConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-01-31_custom_NotesPayableIssuedForConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_NotesPayableIssuedForConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:JanuaryTwentyTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:JanuaryTwentyTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:JanuaryTwentyTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember15065312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ConvertibleNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:ConvertibleNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccountingStandardsUpdate202006Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AccountingStandardsUpdate202006Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccountingStandardsUpdate202006Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-02-082021-02-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2021-02-08</startDate>
            <endDate>2021-02-10</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-10_custom_OwnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OwnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="AsOf2022-10-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="AsOf2021-02-16_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-16_us-gaap_CommonStockMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:NoteHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:NoteHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:NoteHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-10-10_us-gaap_CommonStockMember_custom_NoteHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:NoteHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:NoteHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-02-132021-02-16_custom_EmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-13</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_EmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-02-012021-02-28_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-282022-04-29_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesJOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesJPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesJPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-02-012021-02-28_custom_SeriesJPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesJPreferredStockMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesJOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_SeriesKPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesKPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesKPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-02-16_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantEmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-14</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantEmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-15</instant>
        </period>
    </context>
    <context id="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantEmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-14</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultantEmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-14</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwoEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:TwoEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:TwoEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-07-142022-07-15_custom_TwoEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:TwoEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-14</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-19_us-gaap_LeaseAgreementsMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="From2021-11-182021-11-19_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-18</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-19_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="From2022-02-072022-02-08_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-07</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="From2022-03-012022-03-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-04</endDate>
        </period>
    </context>
    <context id="From2021-08-052021-08-06_custom_SheffieldPropertiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:SheffieldPropertiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ScientificResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ScientificResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ScientificResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ScientificResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="From2021-03-252021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2021-03-252021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-032023-01-04_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_InstitutionalInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GTBP:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GTBP:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GTBP:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GTBP:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GTBP:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="From2023-03-132023-03-14_us-gaap_SubsequentEventMember_custom_ResearchAndDevelopmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-13</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0000109657</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">GTBP</dei:TradingSymbol>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0067"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0090"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0100"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:CommonStockIssuable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0146"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0165"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0166"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0229"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued
      contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants
      contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0433"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0446"
      unitRef="Shares"
      xsi:nil="true"/>
    <GTBP:FairValueOfCommonStockIssuedToNoteholderAsSettlement
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ConvertibleNotesPayableIssuedForConsultingServices
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:IncreaseDecreaseInDeposit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:CancellationOfCommonStockUponSettlementWithFormerOfficer
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:RightofuseAssetsExchangedForLeaseLiabilities
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:CommonStockIssuedUponSettlementOfVendorPayable
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:AccountsPayableReclassifiedToConvertibleNotes
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfDerivativeLiability
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2021-01-012021-12-31_us-gaap_ShortTermInvestmentsMember"
      id="xdx2ixbrl0666"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0685"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0694"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0695"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0699"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0700"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0704"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0705"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl0831"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl0832"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0845">http://fasb.org/us-gaap/2022#DerivativeGainLossOnDerivativeNet</us-gaap:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0846">http://fasb.org/us-gaap/2022#DerivativeGainLossOnDerivativeNet</us-gaap:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0853"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0854"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfWarrants
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0856"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0991"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1001"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1003"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1005"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1007"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1009"
      unitRef="Shares"
      xsi:nil="true"/>
    <GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1011"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1037"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1039"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1045"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1047"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1049"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1051"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1065"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1067"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1264"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-40023</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">GT BIOPHARMA, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">94-1620407</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">8000 Marina Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">919-4040</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common     Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="-5" unitRef="USD">89800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-30" decimals="INF" unitRef="Shares">36809271</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2022-01-01to2022-12-31">In
Part III, portions of the registrant&#x2019;s 2023 Proxy Statement to be filed with the Securities and Exchange Commission within 120
days of the Registrant&#x2019;s fiscal year end.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">572</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">Weinberg &amp; Company, P.A</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Los Angeles, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">5672000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">8968000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">10836000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">23011000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">54000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">190000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">16562000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">32169000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">165000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">9000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">16736000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">32169000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3140000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">8189000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1669000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1901000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">110000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">31000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">19000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">138000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">4938000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">10259000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">64000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">5002000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">10259000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">32722452</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">32722452</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">32061989</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">32061989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">33000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">32000</us-gaap:CommonStockValue>
    <GTBP:CommonStockIssuableShares contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</GTBP:CommonStockIssuableShares>
    <GTBP:CommonStockIssuableShares contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">327298</GTBP:CommonStockIssuableShares>
    <GTBP:CommonStockIssuable contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1113000</GTBP:CommonStockIssuable>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">686168000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">674348000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-674468000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-653584000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">11734000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">21910000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">16736000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">32169000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="-3"
      unitRef="USD">718000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="-3"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">8811000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">9591000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="-3"
      unitRef="USD">3903000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="-3"
      unitRef="USD">17234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">12446000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">47924000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">21257000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">57515000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-21257000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-57515000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">292000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">38000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">8000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">718000</us-gaap:InterestExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">119000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">211000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-30000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-29000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">373000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-498000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-20884000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-58013000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-2.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">31868024</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">28155624</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">2450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">5218000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">566356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-595797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-29433000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">-4745000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">226000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-4519000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">-2354000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">692000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">11086000</GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">11000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="Shares">327000</GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-12-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="USD">1113000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">37675000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">38799000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">3074000</GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">3000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">16430000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">16433000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants>
    <GTBP:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">4945000</GTBP:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">5000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">24674000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">24679000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost>
    <GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">190000</GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1355000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1355000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement>
    <GTBP:StockIssuedDuringPeriodSharesEquityCompensationToConsultants
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">3082000</GTBP:StockIssuedDuringPeriodSharesEquityCompensationToConsultants>
    <GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">3000</GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants>
    <GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">15337000</GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants>
    <GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">15340000</GTBP:IssuanceOfCommonStockAsEquityCompensationToConsultants>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">3775000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">16979000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">16983000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">35000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">35000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-58013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-58013000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">32062000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">32000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="Shares">327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="USD">1113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">674348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-653584000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">21910000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">32062000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">32000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="Shares">327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="USD">1113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">674348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-653584000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">21910000</us-gaap:StockholdersEquity>
    <GTBP:StockIssuedDuringPeriodSharesCancellation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">-291000</GTBP:StockIssuedDuringPeriodSharesCancellation>
    <GTBP:StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">-1845000</GTBP:StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued>
    <GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">-2000</GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued>
    <GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">-222000</GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued>
    <GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-224000</GTBP:StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">338000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="Shares">-327000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="USD">-1113000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1148000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">35000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">710000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">2521000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2522000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <GTBP:StockIssuedDuringPeriodSharesEquityCompensationToConsultants
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">527000</GTBP:StockIssuedDuringPeriodSharesEquityCompensationToConsultants>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">2091000</GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2092000</GTBP:StockIssuedDuringPeriodValueEquityCompensationToConsultants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">3032000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3032000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">1222000</GTBP:StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">3250000</GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3251000</GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-20884000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-20884000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">32723000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">686168000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-674468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">11734000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">32723000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">686168000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-674468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">11734000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-20884000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-58013000</us-gaap:NetIncomeLoss>
    <GTBP:StockBasedCompensationConsultantsAndResearchAndDevelopment
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2522000</GTBP:StockBasedCompensationConsultantsAndResearchAndDevelopment>
    <GTBP:StockBasedCompensationConsultantsAndResearchAndDevelopment
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">16695000</GTBP:StockBasedCompensationConsultantsAndResearchAndDevelopment>
    <GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2092000</GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors>
    <GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">16983000</GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors>
    <GTBP:StockBasedCompensationVestedStockOptions
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3032000</GTBP:StockBasedCompensationVestedStockOptions>
    <GTBP:StockBasedCompensationVestedStockOptions
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">251000</GTBP:StockBasedCompensationVestedStockOptions>
    <GTBP:FairValueOfCommonStockIssuedToNoteholderAsSettlement
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-35000</GTBP:FairValueOfCommonStockIssuedToNoteholderAsSettlement>
    <GTBP:ConvertibleNotesPayableIssuedForConsultingServices
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">720000</GTBP:ConvertibleNotesPayableIssuedForConsultingServices>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">119000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">211000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">95000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">31000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <GTBP:UnrealizedLossOnMarketableSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-30000</GTBP:UnrealizedLossOnMarketableSecurities>
    <GTBP:UnrealizedLossOnMarketableSecurities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-29000</GTBP:UnrealizedLossOnMarketableSecurities>
    <GTBP:IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-136000</GTBP:IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets>
    <GTBP:IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-174000</GTBP:IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets>
    <GTBP:IncreaseDecreaseInDeposit
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">9000</GTBP:IncreaseDecreaseInDeposit>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-2030000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">7077000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-86000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">689000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-15217000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-15606000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-12145000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">23040000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">12145000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-23040000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">24679000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <GTBP:CancellationOfCommonStockUponSettlementWithFormerOfficer
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">224000</GTBP:CancellationOfCommonStockUponSettlementWithFormerOfficer>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">16433000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1205000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-224000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">42317000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-3296000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">3671000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">8968000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">5297000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">5672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">8968000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <GTBP:RightofuseAssetsExchangedForLeaseLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">260000</GTBP:RightofuseAssetsExchangedForLeaseLiabilities>
    <GTBP:ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">4745000</GTBP:ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption>
    <us-gaap:StockIssued1
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">38799000</us-gaap:StockIssued1>
    <GTBP:CommonStockIssuedUponSettlementOfVendorPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3251000</GTBP:CommonStockIssuedUponSettlementOfVendorPayable>
    <GTBP:AccountsPayableReclassifiedToConvertibleNotes
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">525000</GTBP:AccountsPayableReclassifiedToConvertibleNotes>
    <GTBP:ExtinguishmentOfDerivativeLiability
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">35000</GTBP:ExtinguishmentOfDerivativeLiability>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">2000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zlcg3HbkuYg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_825_zi81Nk93I8U3"&gt;Organization and Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
1965, the corporate predecessor of GT Biopharma Inc. (the &#x201c;Company&#x201d;), Diagnostic Data, Inc., was incorporated in the State of California.
Diagnostic Data changed its incorporation to the State of Delaware in 1972, and changed its name to DDI Pharmaceuticals, Inc. in 1985.
In 1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International,
Inc. In July 2017, the Company changed its name to GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products
based off our proprietary Tri-specific Killer Engager (TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;), and Tetra-specific Killer Engager (Dual Targeting TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;Dual
Targeting TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;) platforms. The Company&#x2019;s TriKE&lt;sup&gt;&#xae; &lt;/sup&gt;and Dual Targeting TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platforms
generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient&#x2019;s own natural killer
cells (NK cells).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zL8l5PbY0r2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_82C_zqg1YR3oXhrb"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z19k8I4c2dmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zqob9Y9qTHU5"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America. The consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries,
Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated
in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--LiquidityPolicyTextBlock_zDg78qWfj2Jg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zMWPnp1TEuY9"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared under the assumption that the Company will continue as a going
concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The Company recorded a net loss of $&lt;span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_zoYFhP1AV3l" title="Net loss"&gt;20.9&lt;/span&gt;
million of which $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231_zQYfgsiL4tW1" title="Non-cash stock compensation"&gt;7.7&lt;/span&gt;
million resulted from non-cash stock compensation, and used cash in operations of $&lt;span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_z0jLxMO5fjSe" title="Cash in Operating activities"&gt;15.2&lt;/span&gt;
million for the year ended December 31, 2022. The Company had a cash and short-term investments balance of $&lt;span id="xdx_908_ecustom--CashOnHandAndShortTermInvestment_iI_pn5n6_c20221231_z6Kl1tjczTUc" title="Cash and short term investments"&gt;16.5&lt;/span&gt;
million at December 31, 2022. On January 4, 2023, the Company raised an additional $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUJmTJm8h05b" title="Cash on equity issuance"&gt;6.5&lt;/span&gt;
million of cash through an equity issuance (see Note 11). Management anticipates that the $&lt;span id="xdx_90C_eus-gaap--InvestmentsAndCash_iI_pn5n6_c20221231_z7HvOH39bIM3" title="Investments and cash"&gt;23.0&lt;/span&gt;
million of cash and cash equivalents and short-term investments available following the stock issuance are adequate to satisfy the
liquidity needs of the Company for at least one year from the date the Company&#x2019;s 2022 consolidated financial statements are
issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historically,
the Company has financed its operations through public and private sales of common stock, issuance of preferred stock, issuance of
convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to secure
additional financing on acceptable terms. &lt;span style="background-color: white"&gt;In the event that the Company does not generate
sufficient cash flows from investing and financing activities, the Company will be forced to delay, reduce, or eliminate some or all
of its discretionary spending, which could adversely affect the Company&#x2019;s business prospects, ability to meet long-term
liquidity needs or ability to continue operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--UnusualRisksAndUncertaintiesPolicyTextBlock_zCnh8KI6YFS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86F_zbPGhi2mNm84" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;COVID-19&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
global COVID-19 pandemic continues to present uncertainty and unforeseeable risks to GT Biopharma&#x2019;s operations and business plan.
The Company has closely monitored recent developments, including the lifting of COVID-19 safety measures, the spread of new strains or
variants of the coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. Thus, the full impact of
the COVID-19 pandemic on the business and operations remains uncertain and will vary depending on the pandemic&#x2019;s future impact
on the third parties with whom the Company does business, as well as any legal or regulatory consequences resulting therefrom. The Company
has been following the recommendations of health authorities to minimize exposure risk for its team members and may take further actions
that alter our operations, including any required by federal, state or local authorities, or that it determines are in the best interests
of its employees and other third parties with whom GT Biopharma does business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zmffGgDs1vt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zFLvBtEPfeKk"&gt;Accounting
Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates. Significant estimates include accruals for potential liabilities,
assumptions used in deriving the fair value of derivative liabilities, share-based compensation and valuation of deferred tax assets.
Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjR4PL06PRr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Cash
Equivalents and Short-Term Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying consolidated financial statements. As of December 31, 2022, total cash and cash equivalents which consist
of cash and money market funds, amounted to approximately $&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zI0liZ1AxHj5" title="Cash and cash equivalents"&gt;5.7&lt;/span&gt;&#160;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our businesses. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
consolidated statements of operations. As of December 31, 2022, total short-term investments amounted to approximately $&lt;span id="xdx_901_eus-gaap--ShortTermInvestments_iI_pn5n6_c20221231_z9WB8Ry3wHBh" title="Short-term investments"&gt;10.8&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zuyF6MoVXLOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zB5YeCD5rWh2"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 820-10 requires entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10
defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s derivative liability of $&lt;span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231_zoupMEcwRSUa" title="Derivative liability"&gt;18,700&lt;/span&gt;
at December 31, 2022 and $&lt;span id="xdx_903_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231_zvdjwnOhtTn7" title="Derivative liability"&gt;138,000&lt;/span&gt; at December 31, 2021 was based on Level 3 measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and notes payable, approximate their fair values because of the short maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_z81iMwHLqIv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zodClfERMec"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception and on
subsequent valuation dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zvj8Qg36B8f5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company periodically issues stock-based compensation
to officers, directors, employees and consultants for services rendered. Such issuances vest and expire according to terms established
at the issuance date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="background-color: white"&gt;Stock-based payments to officers,
directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options,
are recognized in the financial statements based on their grant date fair values in accordance with ASC 718,&#160;&lt;i&gt;Compensation-Stock
Compensation&lt;/i&gt;. Stock based payments to officers, directors, employees and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVuOyqmgqzxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zrP9tkQS7247"&gt;Research
and Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products comprise research and development expenses. Purchased materials that do not have an alternative
future use are also expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--LesseeLeasesPolicyTextBlock_z5zpoPyrzbi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zdZH1dcAPH6g"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
accounts for its lease&lt;span style="background-color: white"&gt;s&lt;/span&gt; in accordance with the guidance of ASC 842,&#160;&lt;i&gt;Leases&lt;/i&gt;. The Company determines whether a contract is, or
contains, a lease at inception. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset during the lease term,
and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Right-of-use assets and
lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease
term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present
value of unpaid lease payments&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z4bd0h0IYdrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zWDNiQlHPtI5"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEgi1z1Rmswe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following shares were excluded in the computation of the diluted net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zipYmU8WkIGg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Anti-dilutive Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20221231_zU9UWDlsIkZb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231_zQlvrHZC1fVc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zpx6zK8cGit3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,337,274&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,337,274&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zTAusukgtt6b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,630,452&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zoUC5MvZbyd1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,967,726&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,639,774&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zCRXDR4bUjNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zF7y24q5FnX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zUUmErhmJpd2"&gt;Concentration&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal
Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20221231_z0tzcbSMKFH7" title="FDIC amount"&gt;250,000&lt;/span&gt;.&lt;span style="background-color: white"&gt;
Management believes that the financial institutions that hold the Company&#x2019;s cash are financially sound and, accordingly,
minimal credit risk exists.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further
information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zl2eOgoSa2K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zODc3uUH0vU4"&gt;Segments&lt;/span&gt;
&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined its reporting units in accordance with  &#x201c;&lt;i&gt;Segment Reporting&lt;/i&gt;&#x201d; (&#x201c;ASC 280&#x201d;). Management
evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has determined that the Company has one consolidated operating segment. The Company&#x2019;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#x2019;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zS2DXMm4M17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zs67VLMvEI7e"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;i&gt;Credit Losses &#x2013; Measurement of Credit Losses on Financial
Instruments&lt;/i&gt; (&#x201c;ASC 326&#x201d;). ASU 2016-13 requires entities to use a forward-looking approach based on current expected
credit losses (&#x201c;CECL&#x201d;) to estimate credit losses on certain types of financial instruments, including trade receivables.
This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1,
2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related
codification improvements will be material to its financial position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, &lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;. Effective January 1, 2021, the Company adopted ASU 2020-06 using
the modified retrospective approach. Adoption of the new standard resulted in a decrease to additional paid-in capital of $&lt;span id="xdx_90A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_pn5n6_c20220101__20221231_zgHlZwJegvjl" title="Decrease to additional paid-in capital"&gt;4.5&lt;/span&gt; million
(see Note 5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/i&gt;. ASU 2021-04 provides clarification
and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options
(such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange
as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification
or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting
treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and
debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including
interim periods within those fiscal years. Effective January 1, 2022, the Company adopted ASU 2021-04 using a prospective approach. The
adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) did not or are not believed by management to have a material
impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_854_zMZMDLpExu42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z19k8I4c2dmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zqob9Y9qTHU5"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America. The consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries,
Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated
in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <GTBP:LiquidityPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_ecustom--LiquidityPolicyTextBlock_zDg78qWfj2Jg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zMWPnp1TEuY9"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared under the assumption that the Company will continue as a going
concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The Company recorded a net loss of $&lt;span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_zoYFhP1AV3l" title="Net loss"&gt;20.9&lt;/span&gt;
million of which $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231_zQYfgsiL4tW1" title="Non-cash stock compensation"&gt;7.7&lt;/span&gt;
million resulted from non-cash stock compensation, and used cash in operations of $&lt;span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_z0jLxMO5fjSe" title="Cash in Operating activities"&gt;15.2&lt;/span&gt;
million for the year ended December 31, 2022. The Company had a cash and short-term investments balance of $&lt;span id="xdx_908_ecustom--CashOnHandAndShortTermInvestment_iI_pn5n6_c20221231_z6Kl1tjczTUc" title="Cash and short term investments"&gt;16.5&lt;/span&gt;
million at December 31, 2022. On January 4, 2023, the Company raised an additional $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUJmTJm8h05b" title="Cash on equity issuance"&gt;6.5&lt;/span&gt;
million of cash through an equity issuance (see Note 11). Management anticipates that the $&lt;span id="xdx_90C_eus-gaap--InvestmentsAndCash_iI_pn5n6_c20221231_z7HvOH39bIM3" title="Investments and cash"&gt;23.0&lt;/span&gt;
million of cash and cash equivalents and short-term investments available following the stock issuance are adequate to satisfy the
liquidity needs of the Company for at least one year from the date the Company&#x2019;s 2022 consolidated financial statements are
issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historically,
the Company has financed its operations through public and private sales of common stock, issuance of preferred stock, issuance of
convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to secure
additional financing on acceptable terms. &lt;span style="background-color: white"&gt;In the event that the Company does not generate
sufficient cash flows from investing and financing activities, the Company will be forced to delay, reduce, or eliminate some or all
of its discretionary spending, which could adversely affect the Company&#x2019;s business prospects, ability to meet long-term
liquidity needs or ability to continue operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:LiquidityPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">-20900000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">7700000</us-gaap:ShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">-15200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <GTBP:CashOnHandAndShortTermInvestment contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">16500000</GTBP:CashOnHandAndShortTermInvestment>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-032023-01-04_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">6500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:InvestmentsAndCash contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">23000000.0</us-gaap:InvestmentsAndCash>
    <GTBP:UnusualRisksAndUncertaintiesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_ecustom--UnusualRisksAndUncertaintiesPolicyTextBlock_zCnh8KI6YFS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86F_zbPGhi2mNm84" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;COVID-19&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
global COVID-19 pandemic continues to present uncertainty and unforeseeable risks to GT Biopharma&#x2019;s operations and business plan.
The Company has closely monitored recent developments, including the lifting of COVID-19 safety measures, the spread of new strains or
variants of the coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. Thus, the full impact of
the COVID-19 pandemic on the business and operations remains uncertain and will vary depending on the pandemic&#x2019;s future impact
on the third parties with whom the Company does business, as well as any legal or regulatory consequences resulting therefrom. The Company
has been following the recommendations of health authorities to minimize exposure risk for its team members and may take further actions
that alter our operations, including any required by federal, state or local authorities, or that it determines are in the best interests
of its employees and other third parties with whom GT Biopharma does business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:UnusualRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zmffGgDs1vt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zFLvBtEPfeKk"&gt;Accounting
Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates. Significant estimates include accruals for potential liabilities,
assumptions used in deriving the fair value of derivative liabilities, share-based compensation and valuation of deferred tax assets.
Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjR4PL06PRr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Cash
Equivalents and Short-Term Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying consolidated financial statements. As of December 31, 2022, total cash and cash equivalents which consist
of cash and money market funds, amounted to approximately $&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zI0liZ1AxHj5" title="Cash and cash equivalents"&gt;5.7&lt;/span&gt;&#160;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our businesses. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
consolidated statements of operations. As of December 31, 2022, total short-term investments amounted to approximately $&lt;span id="xdx_901_eus-gaap--ShortTermInvestments_iI_pn5n6_c20221231_z9WB8Ry3wHBh" title="Short-term investments"&gt;10.8&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">5700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">10800000</us-gaap:ShortTermInvestments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zuyF6MoVXLOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zB5YeCD5rWh2"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 820-10 requires entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10
defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s derivative liability of $&lt;span id="xdx_901_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231_zoupMEcwRSUa" title="Derivative liability"&gt;18,700&lt;/span&gt;
at December 31, 2022 and $&lt;span id="xdx_903_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231_zvdjwnOhtTn7" title="Derivative liability"&gt;138,000&lt;/span&gt; at December 31, 2021 was based on Level 3 measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and notes payable, approximate their fair values because of the short maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">18700</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">138000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_z81iMwHLqIv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zodClfERMec"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception and on
subsequent valuation dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zvj8Qg36B8f5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company periodically issues stock-based compensation
to officers, directors, employees and consultants for services rendered. Such issuances vest and expire according to terms established
at the issuance date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="background-color: white"&gt;Stock-based payments to officers,
directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options,
are recognized in the financial statements based on their grant date fair values in accordance with ASC 718,&#160;&lt;i&gt;Compensation-Stock
Compensation&lt;/i&gt;. Stock based payments to officers, directors, employees and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVuOyqmgqzxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zrP9tkQS7247"&gt;Research
and Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products comprise research and development expenses. Purchased materials that do not have an alternative
future use are also expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_eus-gaap--LesseeLeasesPolicyTextBlock_z5zpoPyrzbi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zdZH1dcAPH6g"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
accounts for its lease&lt;span style="background-color: white"&gt;s&lt;/span&gt; in accordance with the guidance of ASC 842,&#160;&lt;i&gt;Leases&lt;/i&gt;. The Company determines whether a contract is, or
contains, a lease at inception. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset during the lease term,
and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Right-of-use assets and
lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease
term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present
value of unpaid lease payments&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z4bd0h0IYdrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zWDNiQlHPtI5"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEgi1z1Rmswe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following shares were excluded in the computation of the diluted net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zipYmU8WkIGg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Anti-dilutive Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20221231_zU9UWDlsIkZb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231_zQlvrHZC1fVc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zpx6zK8cGit3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,337,274&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,337,274&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zTAusukgtt6b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,630,452&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zoUC5MvZbyd1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,967,726&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,639,774&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zCRXDR4bUjNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEgi1z1Rmswe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following shares were excluded in the computation of the diluted net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zipYmU8WkIGg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Anti-dilutive Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20221231_zU9UWDlsIkZb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231_zQlvrHZC1fVc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zpx6zK8cGit3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,337,274&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,337,274&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zTAusukgtt6b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,630,452&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zoUC5MvZbyd1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,967,726&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,639,774&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">2337274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">2337274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_OptionsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">1630452</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_custom_OptionsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">302500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">3967726</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">2639774</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zF7y24q5FnX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zUUmErhmJpd2"&gt;Concentration&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal
Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20221231_z0tzcbSMKFH7" title="FDIC amount"&gt;250,000&lt;/span&gt;.&lt;span style="background-color: white"&gt;
Management believes that the financial institutions that hold the Company&#x2019;s cash are financially sound and, accordingly,
minimal credit risk exists.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further
information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zl2eOgoSa2K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zODc3uUH0vU4"&gt;Segments&lt;/span&gt;
&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined its reporting units in accordance with  &#x201c;&lt;i&gt;Segment Reporting&lt;/i&gt;&#x201d; (&#x201c;ASC 280&#x201d;). Management
evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has determined that the Company has one consolidated operating segment. The Company&#x2019;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#x2019;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zS2DXMm4M17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zs67VLMvEI7e"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;i&gt;Credit Losses &#x2013; Measurement of Credit Losses on Financial
Instruments&lt;/i&gt; (&#x201c;ASC 326&#x201d;). ASU 2016-13 requires entities to use a forward-looking approach based on current expected
credit losses (&#x201c;CECL&#x201d;) to estimate credit losses on certain types of financial instruments, including trade receivables.
This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1,
2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related
codification improvements will be material to its financial position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, &lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;. Effective January 1, 2021, the Company adopted ASU 2020-06 using
the modified retrospective approach. Adoption of the new standard resulted in a decrease to additional paid-in capital of $&lt;span id="xdx_90A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_pn5n6_c20220101__20221231_zgHlZwJegvjl" title="Decrease to additional paid-in capital"&gt;4.5&lt;/span&gt; million
(see Note 5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/i&gt;. ASU 2021-04 provides clarification
and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options
(such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange
as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification
or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting
treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and
debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including
interim periods within those fiscal years. Effective January 1, 2022, the Company adopted ASU 2021-04 using a prospective approach. The
adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) did not or are not believed by management to have a material
impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">4500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--FairValueDisclosuresTextBlock_zAlOFwgznSlf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &lt;span&gt;&#x2013;&lt;/span&gt; &lt;span id="xdx_823_zLJ52zke3p65"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_z5P3ACjZbzje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of financial instruments outstanding were (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_z8O7MHPLJB85" style="display: none"&gt;Schedule
of Estimated Fair Value of Financial Instrument&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z0Nwf4vaguHj" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost"&gt;10,866&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zxzqvnjslD7b" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z7w5n6zTDhad" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses"&gt;(30&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zO2MI49T56p" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value"&gt;10,836&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231_zuPQFV0NnH08" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;10,866&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20221231_z4YJRJdvNVdk" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0658"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20220101__20221231_zNlzXae6QJc2" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"&gt;(30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20220101__20221231_zEQ272R0XVh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;10,836&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztAYkzKBPsRg" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost"&gt;23,040&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zNPPfyPvHdHd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z0c3DddLu0Df" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses"&gt;(29&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zfz99ky0Pkdb" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value"&gt;23,011&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231_zxAaYty20ae7" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;23,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231_zp3R7zxneRl6" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20210101__20211231_z2JoDP36MTr1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"&gt;(29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20210101__20211231_z72PrVxMotCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AF_zEVvL7rYm0z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zRV5XjC21Sf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the Company&#x2019;s fair value hierarchy for its financial assets (cash equivalents and investments, in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zhYv3SDQBCra" style="display: none"&gt;Schedule of Fair Value Hierarchy Financial Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zVlB2J6BDbHb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zs3pIkHwJCA2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZBVLWVooYVg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgy53sOf7B63" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zCD2990X8Uig" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0685"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_z2iq57rzLLBd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zVqoiyls41Tk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,341&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,341&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0694"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0695"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20211231_z6u3KPsgWw72" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1xzZplSugg5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjIAwY1kW568" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkP0MsVY8XPj" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zLzr2WdwxdJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,484&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,484&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0700"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zLGxsofpk1Fj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0704"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zKl8cYu3bI5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0709"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AC_zJ9Et4xwZfB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_z5P3ACjZbzje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of financial instruments outstanding were (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_z8O7MHPLJB85" style="display: none"&gt;Schedule
of Estimated Fair Value of Financial Instrument&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z0Nwf4vaguHj" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost"&gt;10,866&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zxzqvnjslD7b" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z7w5n6zTDhad" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses"&gt;(30&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zO2MI49T56p" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value"&gt;10,836&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20221231_zuPQFV0NnH08" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;10,866&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20221231_z4YJRJdvNVdk" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0658"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20220101__20221231_zNlzXae6QJc2" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"&gt;(30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20220101__20221231_zEQ272R0XVh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;10,836&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztAYkzKBPsRg" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost"&gt;23,040&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zNPPfyPvHdHd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z0c3DddLu0Df" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses"&gt;(29&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zfz99ky0Pkdb" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value"&gt;23,011&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231_zxAaYty20ae7" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;23,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231_zp3R7zxneRl6" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20210101__20211231_z2JoDP36MTr1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"&gt;(29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20210101__20211231_z72PrVxMotCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2022-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      unitRef="USD">10866000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      unitRef="USD">30000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2022-01-012022-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      unitRef="USD">10836000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">10866000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">30000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">10836000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      unitRef="USD">23040000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2021-01-012021-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      unitRef="USD">29000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2021-01-012021-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      unitRef="USD">23011000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">23040000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">29000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">23011000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zRV5XjC21Sf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the Company&#x2019;s fair value hierarchy for its financial assets (cash equivalents and investments, in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zhYv3SDQBCra" style="display: none"&gt;Schedule of Fair Value Hierarchy Financial Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zVlB2J6BDbHb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zs3pIkHwJCA2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZBVLWVooYVg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgy53sOf7B63" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zCD2990X8Uig" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0685"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_z2iq57rzLLBd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zVqoiyls41Tk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,341&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,341&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0694"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0695"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20211231_z6u3KPsgWw72" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1xzZplSugg5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjIAwY1kW568" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkP0MsVY8XPj" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zLzr2WdwxdJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,484&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,484&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0700"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zLGxsofpk1Fj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0704"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zKl8cYu3bI5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0709"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      unitRef="USD">5505000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      unitRef="USD">5505000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      unitRef="USD">10836000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      unitRef="USD">10836000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">16341000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      unitRef="USD">16341000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      unitRef="USD">5484000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      unitRef="USD">5484000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      unitRef="USD">23011000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      unitRef="USD">23011000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">28495000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      unitRef="USD">28495000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zorO4p4t9P9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_822_z76ZlGsHNg9d"&gt;Accounts Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUhfGv2y8k07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z6lDKgLhjGB7" style="display: none"&gt;Schedule of Accounts Payable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_zILvVLffkSD2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
    31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231_zqGmjJ5QkVJd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
    31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maAPCz7ta_zHlh7QCLZok7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
    payable to a third-party manufacturer&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,283&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,335&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz7ta_zW4zfHTwGGR" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    accounts payable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;857&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,854&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz7ta_zJC8oa4mKaJ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    accounts payable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,140&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,189&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zMiltEy7cZyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 5, 2020, the Company entered into a Master
Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the
Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products
for use in clinical trials. The Company&#x2019;s commitments in relation to these Statements of Work and any related Change Orders totaled
approximately $&lt;span id="xdx_904_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20201005__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8MzGIZgAOz6" title="Accounts payable"&gt;13.0&lt;/span&gt; million. There was no outstanding liability with this third-party product manufacturer as of December 31, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2021, the
Company recorded research and development expenses of $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWm6L3XfJMR3" title="Reserach and development expenses"&gt;6.5&lt;/span&gt;
million  related to the services rendered by this third-party product manufacturer and paid $&lt;span id="xdx_904_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zh1jpKpeSJHj" title="Adjustment to additional paid in capital, stock issued, issuance cost"&gt;142,500&lt;/span&gt;.
In addition, the Company also issued &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ0sgs6hSn1c" title="Number of shares issued"&gt;189,753&lt;/span&gt;
shares of common stock with a fair value of $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmxZZWRJ6w3a" title="Number of shares issued, value"&gt;1.4&lt;/span&gt;
million  pursuant to this Master Services Agreement. As of December 31, 2021, the outstanding balance due to this third-party
product manufacturer amounted to $&lt;span id="xdx_908_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwwAov8Im7xa" title="Accounts Payable"&gt;6.3&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 24, 2022, the Company entered into an agreement
with this third-party manufacturer and issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220823__20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zK7KCvopDJj6" title="Number of shares issued"&gt;1,222,281&lt;/span&gt; shares of common stock with a fair value of $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220823__20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z08TNV9ctPQa" title="Stock issued during period, value, new issues"&gt;3.2&lt;/span&gt; million as part of a payment
agreement. The shares were valued at $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbiphK4SHLvl" title="Share issued price per share"&gt;2.66&lt;/span&gt; per share based on the closing price of the Company&#x2019;s common stock on the date of the
agreement. As part of the agreement, the Company also paid this third-party manufacturer $&lt;span id="xdx_906_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pn5n6_c20220824__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxD7t3wchJB" title="Notes payable, related parties"&gt;1.3&lt;/span&gt; million on September 1, 2022, $&lt;span id="xdx_901_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pn5n6_c20220901__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0soNdamtB7h" title="Notes payable, related parties"&gt;1.0&lt;/span&gt; million
on October 3, 2022, and $&lt;span id="xdx_908_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pn5n6_c20221003__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--TypeOfArrangementAxis__custom--PaymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzJ8LCCdbeO7" title="Notes payable, related parties"&gt;1.0&lt;/span&gt; million in November 2022. In addition, the Company and the third-party manufacturer agreed that services
to be rendered in future periods, as specified in the agreement, will be paid or settled at the Company&#x2019;s discretion, in a combination
of cash and issuance of the Company&#x2019;s common stock. The agreement also amended certain agreements executed in prior years which
eliminated future financial commitments of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company
recorded research and development expenses in the aggregate of $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMn66qh5sDv1" title="Reserach and development expenses"&gt;3.6&lt;/span&gt; million for services rendered by this third-party product manufacturer
and made additional payments of $&lt;span id="xdx_902_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember_zS10UbSEA673" title="Accounts Payable"&gt;900,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2022, the Company was indebted
$&lt;span id="xdx_907_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyManufacturerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCrqFFf2AuHd" title="Accounts Payable"&gt;2.3&lt;/span&gt; million to this third-party product manufacturer and was reported as part of accounts payable in the accompanying balance sheet.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zUhfGv2y8k07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z6lDKgLhjGB7" style="display: none"&gt;Schedule of Accounts Payable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_zILvVLffkSD2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
    31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231_zqGmjJ5QkVJd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
    31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maAPCz7ta_zHlh7QCLZok7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
    payable to a third-party manufacturer&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,283&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,335&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz7ta_zW4zfHTwGGR" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    accounts payable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;857&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,854&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz7ta_zJC8oa4mKaJ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    accounts payable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,140&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,189&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2283000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6335000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">857000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1854000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3140000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">8189000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2020-10-05_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">13000000.0</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">6500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">142500</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">189753</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">1400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">6300000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-08-232022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1222281</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-08-232022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">3200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">2.66</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-08-24_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">1300000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-09-01_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">1000000.0</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-10-03_custom_ThirdPartyManufacturerMember_custom_PaymentAgreementMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">1000000.0</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">3600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember"
      decimals="0"
      unitRef="USD">900000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">2300000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zoh1YnyNyoxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_828_z8FeedWbIsv1"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following activity occurred during the year
ended December 31, 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Notes
    Payable Issued for Cash&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the Company&#x2019;s financing activities, the Company issued convertible notes payable in exchange for cash. As of December 31,
2020, the outstanding balance of these notes amounted to $&lt;span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zqFozVAyc7wb" title="Outstanding balance"&gt;24.1&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In January 2021, the Company issued similar notes payable in
exchange for cash of $&lt;span id="xdx_901_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20210101__20210101__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zrxr5S17gs4a" title="Proceeds from notes payable in cash"&gt;1.2&lt;/span&gt; million. On February 16, 2021, in accordance with the note agreements upon completion of an equity offering,
these notes were mandatorily converted at a conversion rate of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zT636pS5Rkg4" title="Conversion rate"&gt;3.40&lt;/span&gt; per share into &lt;span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForCashMember_zA6NRtTulYNi" title="Shares"&gt;7,438,235&lt;/span&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;B.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Notes
    Payable Issued for Settlement Agreements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
fiscal 2019 and 2020, the Company issued its convertible notes payable to resolve claims and disputes pertaining to certain debt and
equity instruments issued by the Company in prior years. As of December 31, 2020, the outstanding balance of these notes payable for
settlement agreements amounted to $&lt;span id="xdx_90B_eus-gaap--NotesPayableCurrent_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember__us-gaap--AwardDateAxis__custom--FiscalTwentyNinteenandTwentyTwentyMember_zD3ukr0MbFji" title="Outstanding balance"&gt;2.5&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 16, 2021 in accordance with the note agreements upon completion of an equity
offering, these notes were mandatorily converted at a conversion rate of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember_zO8m1AKV5d6l" title="Conversion rate"&gt;3.40&lt;/span&gt; per share into &lt;span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember_zo8INDS91pM8" title="Shares"&gt;743,529&lt;/span&gt; shares of the Company&#x2019;s common
stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;C.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Notes
    Payable Issued for Forbearance Agreements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 23, 2020, the Company entered into Standstill and Forbearance Agreements (collectively, the &#x201c;Forbearance Agreements&#x201d;)
with the holders of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200623__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_ztxRkPxDaCGc" title="Forbearance Agreements"&gt;13.2&lt;/span&gt; million aggregate principal amount of the Convertible Notes (the &#x201c;Default Notes&#x201d;), which were in
default. As of December 31, 2020, the outstanding balance of the notes payable amounted to $&lt;span id="xdx_90A_eus-gaap--NotesPayableCurrent_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_zpqi52SKuFW2" title="Outstanding balance"&gt;3.8&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 16, 2021 in accordance
with the note agreements upon completion of an equity offering, these notes were mandatorily converted at a conversion rate of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_z5K5NdFbsLqf" title="Conversion rate"&gt;3.40&lt;/span&gt;
per share into &lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementsMember_zOZWiA8aWItc" title="Shares"&gt;1,132,059&lt;/span&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;D.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Notes
    Payable issued for Consulting Agreements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2020, the outstanding balance of convertible notes payable issued in exchange for consulting services amounted to $&lt;span id="xdx_909_eus-gaap--NotesPayable_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zq9MBgYR9oIl" title="Outstanding balance"&gt;0.4&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2021, the Company issued additional notes payable of $&lt;span id="xdx_903_eus-gaap--NotesPayable_iI_pn5n6_c20210131__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zy4rzf83RuFg" title="Notes payable, issued"&gt;0.7&lt;/span&gt;
million in exchange for consulting services as well as a note payable of $&lt;span id="xdx_900_ecustom--NotesPayableForUnpaidConsultingFee_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zINSXAywSok2" title="Notes payable for unpaid consulting fee"&gt;0.5&lt;/span&gt;
million in exchange for cancellation of an unpaid consulting fee recorded and incurred in fiscal  2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 16, 2021 in accordance with the note agreements upon completion of an equity offering, these notes were mandatorily
converted at a conversion rate of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zHudqM3IXHn9" title="Conversion rate"&gt;3.40&lt;/span&gt; per share into &lt;span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_z4fNr0nX4Z3h" title="Shares"&gt;472,059&lt;/span&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2020, the Company accrued interest of $&lt;span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zc3yQkwrfuZe" title="Accrued interes"&gt;4.8&lt;/span&gt;
million related to all outstanding convertible notes payable. In addition, during the period ended December 31, 2021, the Company
accrued interest of $&lt;span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zm5MPJUQHOj8" title="Accrued interest"&gt;0.7&lt;/span&gt;
million. As a result of the mandatory conversion of the Company&#x2019;s notes payable, on February 16, 2021, total accrued interest
amounting to $&lt;span id="xdx_908_ecustom--SharesIssuedDuringPeriodValueAccruedInterest_pn5n6_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_z9DsTt501rZ9" title="Total accrued interest"&gt;5.5&lt;/span&gt;
million was converted to &lt;span id="xdx_900_ecustom--SharesIssuedDuringPeriodSharesAccruedInterest_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zpxJMiVeDF1d" title="Number of shares issued for accrued interest"&gt;1,627,440&lt;/span&gt;
shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
total, notes payable of $&lt;span id="xdx_905_eus-gaap--NotesPayable_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_zuvlxiLtgQ1k" title="Total, notes payable"&gt;38.8&lt;/span&gt; million ($&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember_z6tLet9u7uMf" title="Principal amount"&gt;33.3&lt;/span&gt; million principal and accrued interest of $&lt;span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zOCE8oJXlEOf" title="Accrued interest"&gt;5.5&lt;/span&gt; million) were mandatorily converted to &lt;span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zjE0u6UwQwM8" title="Converted shares"&gt;11,413,322&lt;/span&gt;
shares of common stock of which, &lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForConsultingAgreementMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zi3VDxa8rXA" title="Converted shares"&gt;11,086,024&lt;/span&gt; shares of common stock were issued in fiscal 2021 and the
remaining &lt;span id="xdx_90F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zR11M47JQKRg" title="Common stock shares, unissued"&gt;327,298&lt;/span&gt; shares were issued in fiscal year 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Adoption
of ASU 2020-06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="background-color: white"&gt;In fiscal 2020, the Company recorded
a note/debt discount of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn5n6_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotePayableMember_zAJhhwRvtzC4" title="Debt instrument, convertible, beneficial conversion feature"&gt;4.7&lt;/span&gt;&#160;million to account for the beneficial conversion feature that existed on the date of issuance of certain
convertible notes payable. The debt discount was &lt;/span&gt;&lt;span&gt;being&lt;/span&gt; &lt;span style="background-color: white"&gt;amortized
to interest expense over the term of the corresponding convertible notes payable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 1, 2021, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, &lt;i&gt;Debt-Debt with Conversion and
Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for
Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;. As a result of the adoption of ASU 2020-06, the Company extinguished
its previously recorded debt discount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20221231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member_z4OBmMoB3scl" title="Debt discount"&gt;4.7&lt;/span&gt; million by charging the opening additional paid in capital at January 1, 2021. In addition,
the Company also adjusted accumulated deficit to account for the derecognition of the $&lt;span id="xdx_906_eus-gaap--InterestExpenseDebt_pn5n6_c20200101__20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member_z2WiKHnPFFLa" title="Interest expense due to amortization of debt discount"&gt;0.2&lt;/span&gt; million interest expense due to the amortization
of the debt discount that was recorded in fiscal 2020. As a result of these adjustments, the unamortized debt discount of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20211231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member_zsyBEA73pR42" title="Debt instrument, unamortized discount"&gt;4.5&lt;/span&gt; million
was extinguished during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForCashMember"
      decimals="-5"
      unitRef="USD">24100000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-01-012021-01-01_custom_NotesPayableIssuedForCashMember"
      decimals="-5"
      unitRef="USD">1200000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-02-16_custom_NotesPayableIssuedForCashMember"
      decimals="INF"
      unitRef="USDPShares">3.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForCashMember"
      decimals="INF"
      unitRef="Shares">7438235</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember"
      decimals="-5"
      unitRef="USD">2500000</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">3.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember"
      decimals="INF"
      unitRef="Shares">743529</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-06-23_custom_NotesPayableIssuedForForbearanceAgreementsMember"
      decimals="-5"
      unitRef="USD">13200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForForbearanceAgreementsMember"
      decimals="-5"
      unitRef="USD">3800000</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-02-16_custom_NotesPayableIssuedForForbearanceAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">3.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForForbearanceAgreementsMember"
      decimals="INF"
      unitRef="Shares">1132059</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:NotesPayable
      contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="-5"
      unitRef="USD">400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-01-31_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="-5"
      unitRef="USD">700000</us-gaap:NotesPayable>
    <GTBP:NotesPayableForUnpaidConsultingFee
      contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="-5"
      unitRef="USD">500000</GTBP:NotesPayableForUnpaidConsultingFee>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="INF"
      unitRef="USDPShares">3.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="INF"
      unitRef="Shares">472059</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="-5"
      unitRef="USD">4800000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="-5"
      unitRef="USD">700000</us-gaap:AccruedLiabilitiesCurrent>
    <GTBP:SharesIssuedDuringPeriodValueAccruedInterest
      contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="-5"
      unitRef="USD">5500000</GTBP:SharesIssuedDuringPeriodValueAccruedInterest>
    <GTBP:SharesIssuedDuringPeriodSharesAccruedInterest
      contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="INF"
      unitRef="Shares">1627440</GTBP:SharesIssuedDuringPeriodSharesAccruedInterest>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="-5"
      unitRef="USD">38800000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember"
      decimals="-5"
      unitRef="USD">33300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember"
      decimals="-5"
      unitRef="USD">5500000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2022-01-012022-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember"
      decimals="INF"
      unitRef="Shares">11413322</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-012021-12-31_custom_NotesPayableIssuedForConsultingAgreementMember_custom_JanuaryTwentyTwentyOneMember"
      decimals="INF"
      unitRef="Shares">11086024</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember15065312"
      decimals="INF"
      unitRef="Shares">327298</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_custom_ConvertibleNotePayableMember"
      decimals="-5"
      unitRef="USD">4700000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-12-31_us-gaap_AccountingStandardsUpdate202006Member"
      decimals="-5"
      unitRef="USD">4700000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpenseDebt
      contextRef="From2020-01-012020-12-31_us-gaap_AccountingStandardsUpdate202006Member"
      decimals="-5"
      unitRef="USD">200000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-12-31_us-gaap_AccountingStandardsUpdate202006Member"
      decimals="-5"
      unitRef="USD">4500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--DerivativesAndFairValueTextBlock_zFpbva4V1Woi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_829_zVr2Srjfp9i5"&gt;Derivative Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;During the year
ended December 31, 2020, the Company issued certain warrants that contained a fundamental transaction provision that could give rise to
an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with ASC 480,
the fair value of these warrants is classified as a liability in the Consolidated Balance Sheets and will be re-measured at
the end of every reporting period with the change in value reported in the statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuG0syJwcwxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
derivative liabilities were valued using a Binomial pricing model with the following average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_z0UziVqcKBw3" style="display: none"&gt;Schedule
of Derivative Liabilities Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zIpdXiETvf6d" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231_zRCfpTGncpsl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5cUR9Ao3Je2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1.26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zASm9Vf2dB6j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0NcfDqHMfvh" title="Expected life (in years)"&gt;2.6&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_pid_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zwRU9ZyZICi7" title="Expected life (in years)"&gt;3.6&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlDsQEUAjxIf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Fair value of warrants (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231_zR5pR86lfrsk" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210101__20211231_zZ2N533ilBTl" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zM9qaQARkQXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.65pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its
common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by
the remaining contractual life of the derivative instrument. The expected dividend yield was based on the fact that the Company has not
paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2021, &lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_c20210101__20211231_zscbCzIe5ZR8" title="Warrant exercised"&gt;2,826&lt;/span&gt; warrants were exercised which resulted in an extinguishment of derivative liability charge of $&lt;span id="xdx_908_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_pn4n6_c20211231_zniRJAbzohsk" title="Derivative liability"&gt;0.03&lt;/span&gt; million. The Company
recognized a net gain of $&lt;span id="xdx_905_eus-gaap--DerivativeGainOnDerivative_pn4n6_c20220101__20221231_zK5JdbpGRtIg" title="Net gain"&gt;0.12&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--DerivativeGainOnDerivative_pn4n6_c20210101__20211231_zsF1F9OMwKDk" title="Net gain"&gt;0.21&lt;/span&gt; million for the years ended December 31, 2022 and 2021, respectively, to account for
the &lt;span id="xdx_907_eus-gaap--DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_iP3us-gaap--DerivativeGainOnDerivative_dxL_c20220101__20221231_zY5P46e6jWDg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23DerivativeGainLossOnDerivativeNet"&gt;&lt;span id="xdx_90B_eus-gaap--DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_iP3us-gaap--DerivativeGainOnDerivative_dxL_c20210101__20211231_zo8iUfYNmmJi" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23DerivativeGainLossOnDerivativeNet"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0845"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;change in fair value of the derivative liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zLPhfjCHTdL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zEdDNLvpQEi" style="display: none"&gt;Schedule
of Derivative Liability Transactions&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zwhqCDktytb2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;br/&gt;
                                            (in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231_zuvS276Z3CY9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;br/&gt;
                                            (in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zeO1NaGtY4Q8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning
    Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;138&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;384&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3n3_zomiiUQtoG6d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Addition&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ExtinguishmentOfWarrants_pn3n3_zZBctFgLebVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0856"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(35&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3n3_z7PNVM0M82Ic" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(119&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(211&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zUPudqAzKVg5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending
    Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;138&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zl2aaIOQzpXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuG0syJwcwxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
derivative liabilities were valued using a Binomial pricing model with the following average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_z0UziVqcKBw3" style="display: none"&gt;Schedule
of Derivative Liabilities Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zIpdXiETvf6d" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231_zRCfpTGncpsl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5cUR9Ao3Je2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1.26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zASm9Vf2dB6j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0NcfDqHMfvh" title="Expected life (in years)"&gt;2.6&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_pid_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zwRU9ZyZICi7" title="Expected life (in years)"&gt;3.6&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlDsQEUAjxIf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Fair value of warrants (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231_zR5pR86lfrsk" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210101__20211231_zZ2N533ilBTl" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      unitRef="Pure">4.22</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      unitRef="Pure">1.26</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Pure">109</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Pure">129</us-gaap:DerivativeLiabilityMeasurementInput>
    <GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember">P2Y7M6D</GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1>
    <GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember">P3Y7M6D</GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">19000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">138000</us-gaap:FairValueAdjustmentOfWarrants>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">2826</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2021-12-31" decimals="-4" unitRef="USD">30000.00</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="From2022-01-01to2022-12-31"
      decimals="-4"
      unitRef="USD">120000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="From2021-01-012021-12-31"
      decimals="-4"
      unitRef="USD">210000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zLPhfjCHTdL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zEdDNLvpQEi" style="display: none"&gt;Schedule
of Derivative Liability Transactions&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zwhqCDktytb2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;br/&gt;
                                            (in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231_zuvS276Z3CY9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;br/&gt;
                                            (in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zeO1NaGtY4Q8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning
    Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;138&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;384&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3n3_zomiiUQtoG6d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Addition&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ExtinguishmentOfWarrants_pn3n3_zZBctFgLebVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0856"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(35&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3n3_z7PNVM0M82Ic" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(119&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(211&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zUPudqAzKVg5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending
    Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;138&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">138000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">384000</us-gaap:DerivativeLiabilitiesCurrent>
    <GTBP:ExtinguishmentOfWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-35000</GTBP:ExtinguishmentOfWarrants>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-119000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-211000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">19000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">138000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zKQUBuy02gBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_82A_z0QFMO2rDW23"&gt;Stockholders&#x2019; Equity &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is authorized to issue &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zd8CeVvLZQR2" title="Common stock, shares authorized"&gt;250,000,000&lt;/span&gt; shares
of common stock , par value of $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zKyJSga7VWla" title="Common stock, par value"&gt;0.001&lt;/span&gt; as of December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 10, 2021, the Company effectuated a 1:17
&lt;span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20210208__20210210_zKbiWGmEmDxf" title="Stockholders' equity, reverse stock split"&gt;reverse stock split&lt;/span&gt; of the Company&#x2019;s issued and outstanding shares of common stock and all fractional shares were rounded up. All
share and per share amounts in the accompanying consolidated financial statements have been adjusted retroactively to reflect the reverse
stock split as if it had occurred at the beginning of the earliest period presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On October 10,
2022, at a special meeting of the stockholders of the Company, the stockholders ratified and approved the inclusion of discretionary votes
by brokers and other nominees holding shares for beneficial owners in the tabulation of votes on the proposal presented at the Company&#x2019;s
annual meeting of stockholders to reduce the authorized number of shares of the Company&#x2019;s common stock from &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20221010__srt--TitleOfIndividualAxis__custom--OwnersMember_zyWBx5RfAoEb" title="Common stock, shares authorized"&gt;750,000,000&lt;/span&gt; shares to
&lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20221010_zdisYheuoLDh" title="Common stock, shares authorized"&gt;250,000,000&lt;/span&gt; shares&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuance of common stock in public offering&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 16, 2021, the Company completed a public
offering of &lt;span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpwAkNUmmyhh" title="Common stock, capital shares reserved for future issuance"&gt;4,945,000&lt;/span&gt; shares of common stock for net proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zcfc3cdXCT45" title="Proceeds from issuance of common stock"&gt;24.7&lt;/span&gt; million, after deducting underwriting discounts, commissions and
other direct offering expenses. As part of the offering, the Company also granted these investors, warrants to purchase &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zLiIQyznE9c5" title="Number of warrant purchase shares"&gt;5,192,250&lt;/span&gt; shares
of common stock. The warrants are fully vested, exercisable at $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zDTAoHt2jvn5" title="Warrant exercise price per share"&gt;5.50&lt;/span&gt; per share and will expire in &lt;span id="xdx_901_ecustom--ClassOfWarrantExpireTerm_dc_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zv3UVhc6cmz3" title="Class of warrant expire term"&gt;five years&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a result of the completion of the public offering
and the successful listing of its shares of common stock on the Nasdaq Capital Market, convertible notes with an aggregate principal amount
of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_ztv1nvRA7o96" title="Debt face amount"&gt;33.3&lt;/span&gt; million and accrued interest of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zE52rCbki8I5" title="Debt instrument, increase, accrued interest"&gt;5.5&lt;/span&gt; million, for a total of $&lt;span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zwYC8ECGuS52" title="Debt conversion converted instrument amount"&gt;38.8&lt;/span&gt; million, were mandatorily converted at its stated conversion
rate of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zosnijamzma1" title="Debt instrument, convertible, conversion price"&gt;3.40&lt;/span&gt; per share into &lt;span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210215__20210216__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zR1jxSRohmXj" title="Debt conversion, converted instrument, shares issued"&gt;11,413,322&lt;/span&gt; shares of the Company&#x2019;s common stock. The Company issued &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zspqLc9PbJUe" title="Number of shares issued"&gt;11,086,024&lt;/span&gt; shares of common stock
to these note holders while the remaining &lt;span id="xdx_906_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zuhaSe9BwRwe" title="Remaining number of common shares"&gt;327,298&lt;/span&gt; common shares, valued at $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zRWEMXTjQ15b" title="Stock issued during period, value, new issues"&gt;1.1&lt;/span&gt; million, were issuable at December 31, 2021. For financial
reporting purposes, as of December 31, 2021, the Company reported the $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMEexKEpKDY5" title="Stock issued during period, value, new issues"&gt;1.1&lt;/span&gt; million as common stock issuable to account for the estimated
balance of the converted notes payable and accrued interest that the Company had not yet issued the corresponding common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company
issued the remaining &lt;span id="xdx_90C_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zAHkBFRuhr23" title="Remaining number of common shares"&gt;327,298&lt;/span&gt; common shares issuable at December 31, 2021 valued at $&lt;span id="xdx_90F_eus-gaap--StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_iI_pn5n6_c20221010__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zy4y5tBK1eia" title="Stock repurchase program, remaining authorized repurchase amount"&gt;1.1&lt;/span&gt; million. In addition, the Company also issued
an additional &lt;span id="xdx_907_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zHtM7NuXL5Ng" title="Additional paid in capital, common stock"&gt;10,404&lt;/span&gt; shares of commons stock with a fair value of $&lt;span id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--NoteHolderMember_z1vVp6xrKmV9" title="Adjustments to additional paid in capital, fair value"&gt;35,000&lt;/span&gt; as settlement with a noteholder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Cancellation of common stock previously
issued for services&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company cancelled &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpC8K3TQjYY3" title="Number of shares issued for service"&gt;290,999&lt;/span&gt; previously issued shares
of common stock during the year ended December 31, 2022.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuance of common stock as equity compensation
to officers, employees and board of directors&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2021, the Company completed its equity offering and listed its shares of common stock on the Nasdaq Capital Market. As such,
&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210213__20210216__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zOKBpO2B0xaa"&gt;4,379,407&lt;/span&gt; shares of its common stock were granted to these officers, employees and directors, which had a fair value of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210213__20210216__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zAC0TiTiNdra"&gt;18.6&lt;/span&gt; million
at the date of Grant. Since the grant of the common stock is subject to milestone or performance conditions, such awards will be recorded
as compensation expense as the milestone or performance condition are met and in accordance with its vesting terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2021, the Company issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zxO8nyZd41wi"&gt;4,040,524&lt;/span&gt; shares of common stock and recognized stock compensation expense of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zy4PJYkb0Blc"&gt;16.9&lt;/span&gt;
million to account the fair value of common stock that vested under this award. Also in 2021, the Company cancelled&#160;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zhTAG1wePlW9" title="Share based compensation cancelled"&gt;278,058&lt;/span&gt;&#160;shares
of common stock granted to a Board member in February 2021 and issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210201__20210228__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zh5XtqwoJh8"&gt;12,500&lt;/span&gt; shares of common stock with a fair value of $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210201__20210228__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zY5IUBNIkUzj"&gt;38,000&lt;/span&gt; to an
employee for services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_z99BZu1zXgM9"&gt;312,815&lt;/span&gt; shares of common stock and recognized stock compensation expense of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zz3DnPpubcpl"&gt;1.5&lt;/span&gt;
million to account the fair value of common stock that vested. &#160;Also in 2022, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zRjWoyEuNrGh"&gt;396,708&lt;/span&gt; shares of common stock
with a fair value of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zXwoPxTK32Jl"&gt;994,000&lt;/span&gt; to certain officers of the Company for services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, there were &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zXF14PWgLZZj"&gt;44,818 &lt;/span&gt;unvested shares of common stock issued to officers, employees and directors with a fair value
of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zpVWvUpmm1yh"&gt;206,035&lt;/span&gt; that will be recognized as stock compensation expense in future periods pursuant to its vesting term.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Equity
compensation to consultants&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2021, the Company completed its equity offering and listed its shares of common stock on the Nasdaq Capital Market. As such,
&lt;span id="xdx_90F_eus-gaap--SharesIssued_iI_pid_c20210216__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zlm91lZmPGnh"&gt;2,850,090&lt;/span&gt; shares of its common stock were granted to consultants, which had a fair value of $&lt;span id="xdx_90D_ecustom--CommonStockConsultantToFairValue_pn5n6_c20210215__20210216__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zNGMxFvPC2H1"&gt;10.7&lt;/span&gt; million at the date of Grant. Since
the grant of the common stock is subject to milestone or performance conditions, such awards will be recorded as compensation expense
as the milestone or performance condition are met and in accordance with its vesting terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2021, the Company issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zd0kZoKGb8B1"&gt;2,432,895&lt;/span&gt; shares of common stock and recognized stock compensation expense of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z8oK4XzitrA2"&gt;9.2&lt;/span&gt;
million to account the fair value of common stock that vested under this award. Also in 2021, the Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_znKGIDHPI4G3"&gt;649,511&lt;/span&gt; shares of common
stock with a fair value of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zWIanw0JMO2e"&gt;6.1&lt;/span&gt; million to consultants for services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z6TjmqnNKap"&gt;370,744&lt;/span&gt; shares of common stock and recognized stock compensation expense of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zVSyDib7z3pi"&gt;1.3&lt;/span&gt;
million to account the fair value of common stock that vested under this award. Also in 2022, the Company issued &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zX7y68c43hp8"&gt;156,113&lt;/span&gt; shares of fully
vested common stock with a fair value of $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zB77YaHajyGf"&gt;791,000&lt;/span&gt; to consultants for services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, there were &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zrvgZZ8x25Ee"&gt;46,343&lt;/span&gt; unvested shares of common stock issued to consultants with a fair value of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zAwDwiLanqf"&gt;162,664&lt;/span&gt; that will
be recognized as stock compensation expense in future periods pursuant to its vesting term.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Cancellation of common stock upon settlement
with a former Officer&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 29, 2022, the Company entered into a settlement agreement with its former Chief Executive Officer (&#x201c;Officer&#x201d;) and
received &lt;span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20220428__20220429__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ztrphrX4wcU3" title="Number of shares received"&gt;1,845,000&lt;/span&gt;
shares of its previously issued common stock in full and final settlement of all its claims against the Officer. The common stock
was subsequently cancelled and returned to treasury. In addition, the Company incurred legal and professional expenses of $&lt;span id="xdx_908_eus-gaap--ProfessionalFees_c20220428__20220429__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zU1TVmgUCzub" title="Legal and professional expenses"&gt;224,243&lt;/span&gt;.
The legal and professional fees incurred were accounted as costs of the acquisition of the common stock and recorded as
a reduction to additional paid in capital. Both the Company and the Officer released each other from claims under the settlement
agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Preferred
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;A.&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Series
    C Preferred Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2022 and 2021, there were &lt;span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zOzKHR6Yl3e9"&gt;96,230
&lt;/span&gt;shares of Series C Preferred Stock, par value $&lt;span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zmMwkpPgloja"&gt;0.01
&lt;/span&gt;per share (the &#x201c;Series C Preferred Stock&#x201d;) issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of stock splits in previous years, the &lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zXGkBLjfg6y7" title="Preferred stock, shares issued"&gt;96,230&lt;/span&gt; shares of Series C Preferred Stock are not convertible. Shares of Series C Preferred
Stock have no voting rights. Similarly, as there are no conversion rights, in the event of liquidation, the holders of the Series C Preferred
Stock shall not participate in any distribution of the assets or surplus funds of the Company. The holders of Series C Preferred Stock
also are not entitled to any dividends if and when declared by the Company&#x2019;s board of directors. No dividends
to holders of the Series C Preferred Stock were issued or unpaid through December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;B.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Series
    J-1 Preferred Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -34.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is authorized to issue its
Series J-1 Preferred Stock with a par value of $&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zoRxDOmjT7a4" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share. Shares of the Series J Preferred Stock were convertible at any time,
at the option of the holders, into shares of the Company&#x2019;s common stock at an effective conversion price of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_z56X6v6U2Lk8"&gt;3.40&lt;/span&gt;&#160;per
share, subject to adjustment for, among other things, stock dividends, stock splits, combinations, reclassifications of our capital
stock and mergers or consolidations, and subject to a beneficial ownership limitation which prohibits conversion if such conversion
would result in the holder (together with its affiliates) being the beneficial owner of in excess of&#160;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zWLsw9PYqd5j"&gt;9.99&lt;/span&gt;%
of the Company&#x2019;s common stock. Shares of the Series J Preferred Stock had the same voting rights as shares of the
Company&#x2019;s common stock, with the holders of the Series J Preferred Stock entitled to vote on an as-converted-to-common stock
basis, subject to the beneficial ownership limitation described above, together with the holders of the Company&#x2019;s common stock
on all matters presented to the Company&#x2019;s stockholders. The Series J Preferred Stock are not entitled to any dividends (unless
specifically declared by the Board), but would participate on an as-converted-to-common-stock basis in any dividends to the holders
of the Company&#x2019;s common stock. In the event of the Company&#x2019;s dissolution, liquidation or winding up, the holders of the
Series J Preferred Stock would be on parity with the holders of the Company&#x2019;s common stock and would participate, on a on an
as-converted-to-common stock basis, in any distribution to holders of the Company&#x2019;s common stock. As of December 31, 2020,
total Series J-1 Preferred stock issued and outstanding totaled 2,353,548 shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the completion of the public offering and
the successful listing of the Company&#x2019;s shares of common stock on the Nasdaq Capital Market, in February 2021, all outstanding Series
J Preferred Stock totaling &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20210201__20210228__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_z1SZHqcgqMc8" title="Common shares issued upon conversion of notes payable, shares"&gt;2,353,548&lt;/span&gt; shares were mandatorily converted to &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zunYhvIJZWp4" title="Common shares issued upon conversion of notes payable, shares"&gt;692,220&lt;/span&gt; shares of common stock pursuant to the terms
of the conversion agreement.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2022 and 2021, there were &lt;span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zHWqyNlzDfh4" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zVL0F4id9Gii" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zYj5xapsZj3h" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesJOnePreferredStockMember_zZkQlC2yv5wf" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; Series J-1 Preferred Stock
issued and outstanding.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;C.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Series
    K Preferred Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2021, the Board designated &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210215__20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_z7ejRTICysig" title="Preferred stock shares designated"&gt;115,000&lt;/span&gt; shares of Series K preferred stock, par value $&lt;span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zEhcGRbMnKbk" title="Preferred stock, par value"&gt;.01&lt;/span&gt;. (the &#x201c;Series K Preferred Stock&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company&#x2019;s common
stock at an effective conversion rate of &lt;span id="xdx_90B_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zP97wDRlj8qc" title="Convertible shares issuable"&gt;100&lt;/span&gt; shares of common stock for each share of Series K Preferred Stock. Shares of the Series
K Preferred Stock have the same voting rights a shares of the Company&#x2019;s common stock, with the holders of the Series K Preferred
Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders
of the Company&#x2019;s common stock on all matters presented to the Company&#x2019;s stockholders. The Series K Preferred Stock are not
entitled to any dividends (unless specifically declared by the Board), but will participate on an as-converted-to-common-stock basis
in any dividends to the holders of the Company&#x2019;s common stock. In the event of the Company&#x2019;s dissolution, liquidation or
winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company&#x2019;s common stock and will
participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022 and 2021, there were
&lt;span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zgEZZNVaC3T4" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zFCEqqMKnhUe" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_z3CzNQbAehxl" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zQKKxUv9kecg" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; Series K Preferred stock, issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Warrants
and Options&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVmuTixxFRaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the years ended December 31, 2022 and 2021, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BA_zPL1qDLeTdUk" style="display: none"&gt;Schedule of Warrant Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Warrants outstanding at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zAidrt5agsmk" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"&gt;221,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zcGY9iwCNPcb" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;3.40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_z3EuXatLSHOl" style="text-align: right" title="Number of warrants, granted"&gt;5,192,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20210101__20211231_z2d46zBA1gvb" style="text-align: right" title="Weighted average exercise price, granted"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231_z3FOuNgqLgG" style="text-align: right" title="Number of warrants, forfeited"&gt;(2,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20210101__20211231_zROGhViFSt42" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0991"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231_zOAQSpW12wJk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised"&gt;(3,074,017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zjSQy4fHZey7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants outstanding at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_z1ALWcmxMJB4" style="text-align: right" title="Warrants outstanding, beginning balance"&gt;2,337,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zHJbdLrHCZa" style="text-align: right" title="Weighted average exercise price, beginning balance"&gt;5.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_z4oyI7zEEEc6" style="text-align: right" title="Number of warrants, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20220101__20221231_zdzHJQmsyOFl" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231_zB3JqQ7hdXn6" style="text-align: right" title="Number of warrants, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1005"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20220101__20221231_zyy8ERkDL5i2" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231_zr1rAal3cNe8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zb1oj5ephd23" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1011"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231_zs8TjyYL8tD9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, beginning balance"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_z8OFkijsZDT8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, beginning balance"&gt;5.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20221231_zhXYdJr1oDH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zZaOUhMxFGYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, ending balance"&gt;5.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zEGw13l4zTt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2021, as part of the Company&#x2019;s public offering, the Company issued warrants to investors to purchase up to an aggregate
of &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210216__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_znaZytMyyWj9" title="Issued warrants"&gt;5,192,250&lt;/span&gt; shares of common stock. The warrants have an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210216__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zfJcAWBtWWsd" title="Exercise price per share"&gt;5.50&lt;/span&gt; per share, subject to adjustment in certain circumstances
and has a term of &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dc_c20210216__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zcFDSKBm74uj" title="Warrant term"&gt;five years&lt;/span&gt; from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2021, the Company issued &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfqLj6XNRulh" title="Common stock  exercise  warrants"&gt;3,074,017&lt;/span&gt; shares of common stock upon exercise of &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4xnxFEAG49e" title="Common stock  exercise  warrants"&gt;3,074,017&lt;/span&gt; warrants, which resulted cash proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN8q6pmoTz46" title="Warrants  cash proceeds"&gt;16.4&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, all issued and outstanding
warrants are fully vested. &lt;span style="background-color: white"&gt;There was &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20221231_z5b8mH6RebPd" title="Options outstanding intrinsic value"&gt;no&lt;/span&gt; intrinsic
value of the outstanding warrants as of December 31, 2022, as the exercise price of these warrants was equal to or greater than the market
price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9N3xVDZw8b3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
option transactions for the years ended December 31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BF_zkmuoVUXWQr" style="display: none"&gt;Schedule
of Options Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zvSot9rnVhHk" style="text-align: right" title="Number of options outstanding, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1037"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zWwJMd2Jqvg8" style="text-align: right" title="Weighted-Average Exercise Price, Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1039"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20210101__20211231_zPtEn2lmMNve" style="width: 16%; text-align: right" title="Number of options, Granted"&gt;302,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zOA5w1sNPSxk" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Granted"&gt;3.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20210101__20211231_zq2iQDVImP56" style="text-align: right" title="Number of options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_znWJP9XBSWu1" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20210101__20211231_z5Ra0jdk0ouj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zQsqX1NCgGZa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1051"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_z32vbvCsSZPh" style="text-align: right" title="Number of options outstanding, beginning"&gt;302,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z2mT1cvUOU9b" style="text-align: right" title="Weighted-Average Exercise Price, Beginning"&gt;3.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231_zOfZ1vfUgNp1" style="text-align: right" title="Number of options outstanding, Granted"&gt;1,532,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zH5JUeKQI1Q9" style="text-align: right" title="Weighted-Average Exercise Price, Granted"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231_zZcvKcdMJeX1" style="text-align: right" title="Number of options outstanding, Forfeited"&gt;(205,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zIEx8nBiVGS" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20220101__20221231_z9CTyUEVT7j8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zA1BPoS8srYj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1067"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zNJkXaRTv711" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding outstanding, Ending"&gt;1,630,452&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zq7QYxtAaMzb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Ending"&gt;2.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zrF4X1nmq76b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, exercisable"&gt;1,440,404&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zk9HfEbEkYnd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Ending"&gt;2.55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zG8DHITmGgD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 15, 2022, the Company granted certain consultants, employees, officers and directors stock options to purchase an aggregate of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zc9y8XUDc3f5" title="Common stock, stock option shares"&gt;1,532,952&lt;/span&gt;
shares of common stock. The stock options are exercisable at $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_z9vRzXx3AYS3" title="Stock options  exercisable"&gt;2.48&lt;/span&gt; per share and will expire in 10 years. A portion of the options vested
immediately with the remaining portion vesting over a period of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_zNrFdJzh91Nk" title="Vesting period"&gt;5 months&lt;/span&gt; up to &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zqpLi5KI9466" title="Vesting period"&gt;36 months&lt;/span&gt;. The fair value of the options amounted to $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zWVtr8KphqE5" title="Fair value"&gt;3.4&lt;/span&gt;
million or an average of $2.22 per share and were calculated using the Black Scholes Option pricing model. Assumptions used in the model
were: expected term &#x2013; &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zvLguMBScbva" title="Expected term"&gt;6.27&lt;/span&gt; years; expected volatility &#x2013; &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zr2bHm3hY3Eg" title="Expected volatility"&gt;125.53&lt;/span&gt;%; risk free interest rate &#x2013; &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zuTk8M89qP71" title="Risk free interest rate"&gt;3.03&lt;/span&gt;% and dividend yield
of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220714__20220715__srt--TitleOfIndividualAxis__custom--ConsultantEmployeesOfficersAndDirectorsMember_zKeVIbTIa5ji" title="Dividend yield"&gt;0&lt;/span&gt;%. The Company  recognized the corresponding stock compensation expense of these options based upon the vesting term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded forfeitures of &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_znwTXK4ACZbd" title="Forfeited"&gt;205,000&lt;/span&gt; options to purchase common stock during 2022 due to the resignation of employees. The forfeitures
were related to shares that had not yet been vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company
recorded total stock compensation of $&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231_z5Ly2DokQ6I6" title="Share-based compensation arrangement by share-based payment award, options, vested in period, fair value"&gt;3,032,000&lt;/span&gt; to account the fair value of stock options that vested in fiscal 2022.&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2022, there were &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20221231_z6YmLoqjlCkl" title="Non- vested number of shares issued"&gt;275,101&lt;/span&gt; unvested
options with a grant date fair value of $&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_iI_c20221231_zySlCthYJeUe" title="Share based compensation unvested intrinsic value"&gt;645,172&lt;/span&gt; which will be recognized as stock compensation expense in future periods based upon the
remaining vesting term of the applicable grants. There was no intrinsic value of the outstanding options at December 31, 2022, as the
exercise price of these options is greater than or equal to the market price.&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 31, 2021, the Company granted two employees
a total of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zY3LVkNpUmlf" title="Stock option granted"&gt;302,500&lt;/span&gt; stock options. The stock options are exercisable at $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zdvNobShe0v8" title="Stock options exercisable price"&gt;3.05&lt;/span&gt; per share and will expire in &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zQ3Ky9PxCoui" title="Options expiration period"&gt;10 years&lt;/span&gt;. A portion of the options
vested immediately, with the remaining portion vesting over a two-year period from the date of grant. The fair value of the options amounted
to $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zH8Dsliw3qh7" title="Fair value of options"&gt;808,280&lt;/span&gt; or an average of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zGJgEH7dlNhk" title="Fair value of stock option, per share"&gt;2.67&lt;/span&gt; per share and were calculated using a Black-Scholes option pricing model. Assumptions used in the model
were: expected term &#x2013; &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220714__20220715__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zHLsFeZaFhBb" title="Expected term"&gt;5.5&lt;/span&gt; years; expected volatility &#x2013; &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zalQQh5QohYf" title="Expected volatility"&gt;129.0&lt;/span&gt;%; risk free interest rate &#x2013; &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zWMiPsVOjATe" title="Risk free interest rate"&gt;1.26&lt;/span&gt;% and dividend yield of
&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zULcgE4KZAwd" title="Dividend yield"&gt;0&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2021, the Company
recorded stock compensation of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__srt--TitleOfIndividualAxis__custom--TwoEmployeesMember_zD3tRNlc3qSb" title="Stock option granted"&gt;251,000&lt;/span&gt; to account the fair value of stock options that vested in fiscal 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2021-02-082021-02-10">reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-10-10_custom_OwnersMember"
      decimals="INF"
      unitRef="Shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-10-10" decimals="INF" unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-02-16_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">4945000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-02-152021-02-16_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="-5"
      unitRef="USD">24700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-02-16_us-gaap_CommonStockMember_custom_InvestorsMember"
      decimals="INF"
      unitRef="Shares">5192250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-02-16_us-gaap_CommonStockMember_custom_InvestorsMember"
      decimals="INF"
      unitRef="USDPShares">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <GTBP:ClassOfWarrantExpireTerm contextRef="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_InvestorsMember">P5Y</GTBP:ClassOfWarrantExpireTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember"
      decimals="-5"
      unitRef="USD">33300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember"
      decimals="-5"
      unitRef="USD">5500000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember"
      decimals="-5"
      unitRef="USD">38800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember"
      decimals="INF"
      unitRef="USDPShares">3.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-02-152021-02-16_us-gaap_CommonStockMember_custom_ConvertibleNoteMember"
      decimals="INF"
      unitRef="Shares">11413322</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember"
      decimals="INF"
      unitRef="Shares">11086024</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember"
      decimals="INF"
      unitRef="Shares">327298</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember"
      decimals="INF"
      unitRef="Shares">327298</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="AsOf2022-10-10_us-gaap_CommonStockMember_custom_NoteHolderMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember"
      decimals="0"
      unitRef="USD">10404</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_NoteHolderMember"
      decimals="0"
      unitRef="USD">35000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">290999</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-02-132021-02-16_custom_EmploymentAgreementsMember"
      decimals="INF"
      unitRef="Shares">4379407</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-02-132021-02-16_custom_EmploymentAgreementsMember"
      decimals="-5"
      unitRef="USD">18600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_EmploymentAgreementsMember"
      decimals="INF"
      unitRef="Shares">4040524</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_OfficersAndDirectorsMember"
      decimals="-5"
      unitRef="USD">16900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-12-31_custom_OfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Shares">278058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-02-012021-02-28_custom_OfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-02-012021-02-28_custom_OfficersAndDirectorsMember"
      decimals="0"
      unitRef="USD">38000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementsMember"
      decimals="INF"
      unitRef="Shares">312815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_OfficersAndDirectorsMember"
      decimals="-5"
      unitRef="USD">1500000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-12-31_custom_OfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Shares">396708</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_custom_OfficersAndDirectorsMember"
      decimals="0"
      unitRef="USD">994000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-12-31_custom_OfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Shares">44818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2022-12-31_custom_OfficersAndDirectorsMember"
      decimals="0"
      unitRef="USD">206035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-02-16_custom_ConsultantsMember"
      decimals="INF"
      unitRef="Shares">2850090</us-gaap:SharesIssued>
    <GTBP:CommonStockConsultantToFairValue
      contextRef="From2021-02-152021-02-16_custom_ConsultantsMember"
      decimals="-5"
      unitRef="USD">10700000</GTBP:CommonStockConsultantToFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_ConsultantsMember"
      decimals="INF"
      unitRef="Shares">2432895</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_ConsultantsMember"
      decimals="-5"
      unitRef="USD">9200000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-12-31_custom_ConsultantsMember"
      decimals="INF"
      unitRef="Shares">649511</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_custom_ConsultantsMember"
      decimals="-5"
      unitRef="USD">6100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_ConsultantsMember"
      decimals="INF"
      unitRef="Shares">370744</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_ConsultantsMember"
      decimals="-5"
      unitRef="USD">1300000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-12-31_custom_ConsultantsMember"
      decimals="INF"
      unitRef="Shares">156113</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_custom_ConsultantsMember"
      decimals="0"
      unitRef="USD">791000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-12-31_custom_ConsultantsMember"
      decimals="INF"
      unitRef="Shares">46343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2022-12-31_custom_ConsultantsMember"
      decimals="0"
      unitRef="USD">162664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-04-282022-04-29_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="Shares">1845000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ProfessionalFees
      contextRef="From2022-04-282022-04-29_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">224243</us-gaap:ProfessionalFees>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesJOnePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-12-31_custom_SeriesJPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">3.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2022-01-012022-12-31_custom_SeriesJPreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.0999</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-02-012021-02-28_custom_SeriesJPreferredStockMember"
      decimals="INF"
      unitRef="Shares">2353548</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_custom_SeriesJPreferredStockMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">692220</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesJOnePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_custom_SeriesJOnePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesJOnePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesJOnePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">115000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">100</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesKPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_custom_SeriesKPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesKPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesKPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVmuTixxFRaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the years ended December 31, 2022 and 2021, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BA_zPL1qDLeTdUk" style="display: none"&gt;Schedule of Warrant Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Warrants outstanding at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zAidrt5agsmk" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"&gt;221,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zcGY9iwCNPcb" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;3.40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_z3EuXatLSHOl" style="text-align: right" title="Number of warrants, granted"&gt;5,192,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20210101__20211231_z2d46zBA1gvb" style="text-align: right" title="Weighted average exercise price, granted"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231_z3FOuNgqLgG" style="text-align: right" title="Number of warrants, forfeited"&gt;(2,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20210101__20211231_zROGhViFSt42" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0991"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231_zOAQSpW12wJk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised"&gt;(3,074,017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zjSQy4fHZey7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants outstanding at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_z1ALWcmxMJB4" style="text-align: right" title="Warrants outstanding, beginning balance"&gt;2,337,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zHJbdLrHCZa" style="text-align: right" title="Weighted average exercise price, beginning balance"&gt;5.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_z4oyI7zEEEc6" style="text-align: right" title="Number of warrants, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20220101__20221231_zdzHJQmsyOFl" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231_zB3JqQ7hdXn6" style="text-align: right" title="Number of warrants, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1005"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20220101__20221231_zyy8ERkDL5i2" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231_zr1rAal3cNe8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zb1oj5ephd23" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1011"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231_zs8TjyYL8tD9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, beginning balance"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_z8OFkijsZDT8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, beginning balance"&gt;5.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20221231_zhXYdJr1oDH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zZaOUhMxFGYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, ending balance"&gt;5.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">221041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">3.40</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">5192250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">3074017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.50</GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">2337274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.30</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">2337274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">5.30</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">2337274</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">5.30</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-02-16_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">5192250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-02-16_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-02-16_us-gaap_IPOMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3074017</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3074017</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="-5"
      unitRef="USD">16400000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9N3xVDZw8b3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
option transactions for the years ended December 31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BF_zkmuoVUXWQr" style="display: none"&gt;Schedule
of Options Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zvSot9rnVhHk" style="text-align: right" title="Number of options outstanding, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1037"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zWwJMd2Jqvg8" style="text-align: right" title="Weighted-Average Exercise Price, Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1039"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20210101__20211231_zPtEn2lmMNve" style="width: 16%; text-align: right" title="Number of options, Granted"&gt;302,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zOA5w1sNPSxk" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Granted"&gt;3.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20210101__20211231_zq2iQDVImP56" style="text-align: right" title="Number of options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_znWJP9XBSWu1" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20210101__20211231_z5Ra0jdk0ouj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zQsqX1NCgGZa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1051"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_z32vbvCsSZPh" style="text-align: right" title="Number of options outstanding, beginning"&gt;302,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z2mT1cvUOU9b" style="text-align: right" title="Weighted-Average Exercise Price, Beginning"&gt;3.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231_zOfZ1vfUgNp1" style="text-align: right" title="Number of options outstanding, Granted"&gt;1,532,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zH5JUeKQI1Q9" style="text-align: right" title="Weighted-Average Exercise Price, Granted"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231_zZcvKcdMJeX1" style="text-align: right" title="Number of options outstanding, Forfeited"&gt;(205,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zIEx8nBiVGS" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20220101__20221231_z9CTyUEVT7j8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zA1BPoS8srYj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1067"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zNJkXaRTv711" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding outstanding, Ending"&gt;1,630,452&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zq7QYxtAaMzb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Ending"&gt;2.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zrF4X1nmq76b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, exercisable"&gt;1,440,404&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zk9HfEbEkYnd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Ending"&gt;2.55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">302500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">3.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">302500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">1532952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">205000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1630452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1440404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Shares">1532952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember"
      decimals="INF"
      unitRef="USDPShares">2.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember_srt_MinimumMember">P5M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember_srt_MaximumMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember"
      decimals="-5"
      unitRef="Shares">3400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember">P6Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Pure">1.2553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Pure">0.0303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-07-142022-07-15_custom_ConsultantEmployeesOfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2022-01-012022-12-31_custom_EmployeesMember"
      decimals="INF"
      unitRef="Shares">205000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">3032000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">275101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">645172</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember"
      decimals="INF"
      unitRef="Shares">302500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_TwoEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember"
      decimals="0"
      unitRef="USD">808280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">2.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-07-142022-07-15_custom_TwoEmployeesMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember"
      decimals="INF"
      unitRef="Pure">1.290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember"
      decimals="INF"
      unitRef="Pure">0.0126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31_custom_TwoEmployeesMember"
      decimals="INF"
      unitRef="Shares">251000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_zbPCxLmqGDIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_821_zBt9qWb7Y5G2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 19, 2021, the Company entered into a sublease
with a third party for &lt;span id="xdx_908_eus-gaap--AreaOfLand_iI_uSqft_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdwpnFY5S88" title="Area of land"&gt;4,500&lt;/span&gt; square feet of office space located in Brisbane, California, with a &lt;span id="xdx_906_eus-gaap--LesseeOperatingSubleaseOptionToExtend_c20211118__20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zCgCyzaaWIEk" title="Commencement date"&gt;commencement date of January 1, 2022
and maturing on June 30, 2024.&lt;/span&gt; &lt;span style="background-color: white"&gt;Leases with an initial term of 12 months or less are not recorded
on the balance sheet. The Company accounts for the lease and non-lease components of its leases as a single lease component. Rent expense
is recognized on a straight-line basis over the lease term. As a result of this agreement, the Company recognized&lt;/span&gt; right-of-use
(&#x201c;ROU&#x201d;) asset and liability of $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zTxl9URnVjtc" title="Operating lease, right-of-use asset"&gt;247,294&lt;/span&gt; &lt;span style="background-color: white"&gt;pursuant to ASC 842&lt;i&gt;, Lease.&lt;/i&gt;&lt;/span&gt; Operating
lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease
term. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the
Company&#x2019;s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is
not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The
Company&#x2019;s incremental borrowing rate is a hypothetical collateralized borrowing rate based on its understanding of what its credit
rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 8, 2022, the Company entered another lease
which will end on February 7, 2025. As a result, the Company &lt;span style="background-color: white"&gt;recognized&lt;/span&gt; additional ROU asset
and liability of $&lt;span id="xdx_908_ecustom--AdditionalOperatingLeaseAssets_c20220207__20220208__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0EB4mXgz551" title="Additional Operating lease assets"&gt;12,861&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;As a result of these lease agreements,
the Company recognized ROU asset and liability in the aggregate of $&lt;span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20220208_zm332CEMNLxk" title="Operating lease, right-of-use asset"&gt;260,155&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_z92Vm6MA67r1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="background-color: white"&gt;The components of rent expense and
supplemental cash flow information related to leases for the period are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;span id="xdx_8B1_zFWXrBDT8D1h" style="display: none"&gt;Schedule of Components
Leases Rent Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Lease Costs (in thousands):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 76%; text-align: justify; padding-bottom: 1.5pt"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeasePayments_c20220101__20221231_zDf2DayfmIDe" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Operating cash flows from operating leases"&gt;109&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Other Information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Weighted-average remaining lease term (in years):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zHOIuaDSkMm4" title="Weighted average remaining lease term operating leases"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Weighted-average discount rate:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20221231_zlh5gotrxAuk" title="Weighted average discount rate operating leases"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zs2c3Go7FO58" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfSupplementalLeaseTableTextBlock_zQqKkypmcrnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
supplemental balance sheet information related to leases for the period is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8BB_zL5YJSkPcp3a" style="display: none"&gt;&lt;span&gt;Schedule of
Supplemental Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231_zI2kWyxqLMk6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Operating leases (in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--LongtermRightofuseAssetsNet_iI_pn3n3_zSbacztJBaqg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 76%; text-align: justify; padding-bottom: 1.5pt"&gt;Long-term right-of-use assets, net&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right"&gt;165&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLz4mp_zItWNdkXQIkf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Current portion of operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLz4mp_zoy3sdcm63Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Non-current portion of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLz4mp_zlvj2TidPRDj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;174&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zCsp7DHArpk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhWalD4vG3Ti" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Maturities of the Company&#x2019;s
lease liabilities are as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zpkYAqAVHDL6" style="display: none"&gt;Schedule of Maturity Lease Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;Year ending&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_z5ARj7VPtFO7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzt3J_zGKx2PUnKdj5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;122&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzt3J_zk5pIjkIgFQb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLLzt3J_z7Na7aLyZ1p1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzt3J_zH17zc4DhhA2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_za5mS08gj6hi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Less: Imputed interest/present value
    discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_zfYygSXv4mdj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;174&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p id="xdx_8A1_zFcbcSxu2lrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2021-11-19_us-gaap_LeaseAgreementsMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Sqft">4500</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingSubleaseOptionToExtend contextRef="From2021-11-182021-11-19_us-gaap_LeaseAgreementsMember">commencement date of January 1, 2022
and maturing on June 30, 2024.</us-gaap:LesseeOperatingSubleaseOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-11-19_us-gaap_LeaseAgreementsMember"
      decimals="0"
      unitRef="USD">247294</us-gaap:OperatingLeaseRightOfUseAsset>
    <GTBP:AdditionalOperatingLeaseAssets
      contextRef="From2022-02-072022-02-08_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">12861</GTBP:AdditionalOperatingLeaseAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-02-08" decimals="0" unitRef="USD">260155</us-gaap:OperatingLeaseRightOfUseAsset>
    <GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_z92Vm6MA67r1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="background-color: white"&gt;The components of rent expense and
supplemental cash flow information related to leases for the period are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;span id="xdx_8B1_zFWXrBDT8D1h" style="display: none"&gt;Schedule of Components
Leases Rent Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Lease Costs (in thousands):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 76%; text-align: justify; padding-bottom: 1.5pt"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeasePayments_c20220101__20221231_zDf2DayfmIDe" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Operating cash flows from operating leases"&gt;109&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Other Information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Weighted-average remaining lease term (in years):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zHOIuaDSkMm4" title="Weighted average remaining lease term operating leases"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Weighted-average discount rate:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20221231_zlh5gotrxAuk" title="Weighted average discount rate operating leases"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">109000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31">P1Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <GTBP:ScheduleOfSupplementalLeaseTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_ecustom--ScheduleOfSupplementalLeaseTableTextBlock_zQqKkypmcrnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
supplemental balance sheet information related to leases for the period is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8BB_zL5YJSkPcp3a" style="display: none"&gt;&lt;span&gt;Schedule of
Supplemental Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231_zI2kWyxqLMk6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Operating leases (in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--LongtermRightofuseAssetsNet_iI_pn3n3_zSbacztJBaqg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 76%; text-align: justify; padding-bottom: 1.5pt"&gt;Long-term right-of-use assets, net&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right"&gt;165&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLz4mp_zItWNdkXQIkf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Current portion of operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLz4mp_zoy3sdcm63Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Non-current portion of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLz4mp_zlvj2TidPRDj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;174&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfSupplementalLeaseTableTextBlock>
    <GTBP:LongtermRightofuseAssetsNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">165000</GTBP:LongtermRightofuseAssetsNet>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">110000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">64000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">174000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhWalD4vG3Ti" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Maturities of the Company&#x2019;s
lease liabilities are as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zpkYAqAVHDL6" style="display: none"&gt;Schedule of Maturity Lease Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;Year ending&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_z5ARj7VPtFO7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzt3J_zGKx2PUnKdj5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;122&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzt3J_zk5pIjkIgFQb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLLzt3J_z7Na7aLyZ1p1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzt3J_zH17zc4DhhA2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_za5mS08gj6hi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Less: Imputed interest/present value
    discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_zfYygSXv4mdj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;174&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">122000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">91000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">214000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">40000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">174000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zL5cb7TZwcS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_827_z7DFQ6mEV838"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, the Company records accruals for contingencies to the extent that our management concludes that the occurrence is
probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed
as incurred. There is no current or pending litigation of any significance with the exception of the matters that have arisen under,
and are being handled in, the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 13, 2022, the Company filed a demand for arbitration with the American Arbitration Association (AAA) against Michael Handelman, its
former Chief Financial Officer, on claims of breach of fiduciary duty and failure to comply with federal securities reporting law. The
claims are pending before an arbitrator in Los Angeles and the hearing is scheduled to begin on May 15, 2023. Mr. Handelman has not asserted
counterclaims against the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 28, 2019, a complaint was filed in the Superior Court of California, County of Los Angeles, West Judicial District, Santa Monica
Courthouse, Unlimited Civil Division by Jeffrey Lion and by Daniel Vallera, as individuals. The complaint was filed against GT Biopharma,
Inc. and its subsidiary Oxis Biotech, Inc. The Plaintiffs allege breach of a license agreement between the Plaintiffs and the Company
entered into on or about September 3, 2015. The Company filed an answer to the complaint denying many allegations and asserting affirmative
defenses. The Company reached a settlement of the case and paid on March 4, 2022, $&lt;span id="xdx_905_eus-gaap--LitigationSettlementExpense_c20220301__20220304_zIxuh5yPGAW5" title="Litigation settlement expense"&gt;425,000&lt;/span&gt; in full and final settlement of the claims.
This amount was fully accrued at December 31, 2021 and was paid during fiscal year 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 3, 2021, a complaint was filed by Sheffield Properties in the superior Court of California, County of Ventura. The litigation arose
from a commercial lease entered into by GT Biopharma, Inc. for office space in Westlake Village in California. In July, 2021 the Company
entered into settlement agreement with Sheffield Properties and the payment in the settlement amount of $&lt;span id="xdx_90E_eus-gaap--LitigationSettlementExpense_pn5n6_c20210805__20210806__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SheffieldPropertiesMember_zi3UALQO0la6" title="Litigation settlement expense"&gt;0.1&lt;/span&gt; million was made on August
6, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Significant
Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a Scientific Research Agreement (&#x201c;SRA&#x201d;) with the Regents of the University of Minnesota, effective
June 16, 2021. This SRA has three major goals: (1) support the Company&#x2019;s TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;
product development and GMP manufacturing efforts; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; pharmacokinetics optimization in humans; and, (3)
investigation of the patient&#x2019;s native NK cell population based on insights obtained from the analysis of the human data
generated during our GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for
TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; constructs in support of our product development and GMP manufacturing efforts; (2) TriKE&lt;sup&gt;&#xae; &lt;/sup&gt;platform
drug delivery changes to allow transition to alternative drug delivery means and extended PK in humans; and, (3) gain an increased
understanding of changes in the patient&#x2019;s native NK cell population as a result of TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; therapy. Most studies
will use TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; DNA/amino acid sequences created by us under current UMN/GTB licensing terms. The term of this
agreement shall expire on June 30, 2023. The University of Minnesota shall use reasonable efforts to complete the project for a
fixed sum of $&lt;span id="xdx_901_ecustom--ProjectFee_pn5n6_c20220101__20221231_znX8N0UnZ7Wk" title="Project fee"&gt;2.1&lt;/span&gt; million,
of which $&lt;span id="xdx_90C_ecustom--ProjectFeeIncurred_pn5n6_c20220101__20221231_z3FC3sDrYsDk" title="Project fee incurred"&gt;1.7&lt;/span&gt;
million has been incurred and recorded as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has recorded an expense of $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zpxaZ9XbI0b1" title="Research and development expense"&gt;766,000&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zskFIsaiqs9f" title="Research and development expense"&gt;964,000&lt;/span&gt;
relating to the scientific research agreement for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Patent
and License Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2016
Exclusive Patent License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (&#x201c;UofMN&#x201d;),
to further develop and commercialize cancer therapies using TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology developed by researchers at the UofMN to
target NK cells to cancer. Under the terms of the 2016 agreement, the Company receives exclusive rights to conduct research and to develop,
make, use, sell, and import TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology worldwide for the treatment of any disease, state, or condition in humans.
The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted
by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;
technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union.
Under the agreement, the UofMN received an upfront payment of $&lt;span id="xdx_908_ecustom--ProceedsFromUpfrontAmount_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zIY1O6U800xa" title="Proceeds from upfront amount"&gt;0.2&lt;/span&gt; million, and an annual License Maintenance fee of $&lt;span id="xdx_900_eus-gaap--CostMaintenance_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpevlTGwQbjl" title="Maintenance fee"&gt;0.1&lt;/span&gt; million beginning
in 2021. The agreement also includes &lt;span id="xdx_907_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zw5GAdAFkCJ3" title="Royalty fee percentage"&gt;4%&lt;/span&gt; royalty fees, (not to exceed &lt;span id="xdx_909_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zyR5a3A0Pjlj" title="Royalty fee percentage"&gt;6&lt;/span&gt;% under subsequence license agreements or amendments to this agreement
or minimum annual royalty payments ranging from $&lt;span id="xdx_904_eus-gaap--RoyaltyExpense_pn4n6_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zKIFkbspZKPk" title="Annual royalty payments"&gt;0.25&lt;/span&gt; million to $&lt;span id="xdx_909_eus-gaap--RoyaltyExpense_pn5n6_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zPPEhNCer4Yd" title="Annual royalty payments"&gt;5.0&lt;/span&gt; million. The agreement also includes certain performance milestone
payments totaling $&lt;span id="xdx_90E_ecustom--PerformanceMilestonePayments_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zv7YOjA5Lo4k" title="Milestone payments"&gt;3.1&lt;/span&gt; million, and one-time sales milestone payments of $&lt;span id="xdx_907_ecustom--SalesMilestonePayments_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zT8dcmHnEfKc" title="Sales milestone payments"&gt;1.0&lt;/span&gt; million upon reaching $&lt;span id="xdx_902_ecustom--GrossSales_pn6n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zHAvE3einS8g" title="Sales"&gt;250&lt;/span&gt; million in gross sales, and
$&lt;span id="xdx_907_ecustom--SalesRevenue_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpaIWXZr1Gmg" title="Sales revenue"&gt;5.0&lt;/span&gt; million upon reaching $&lt;span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zgwWRPoGlIIl" title="Cumulative gross sales"&gt;500&lt;/span&gt; million dollars in cumulative gross sales of Licensed Products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company did &lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zMDxqCnMbczh" title="Research and development expense"&gt;no&lt;/span&gt;t incur any research and development expense relating to the 2016 Exclusive Patent
License Agreement for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021
Patent License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;. Under the agreement, the UofMN received
an upfront license fee of $&lt;span id="xdx_901_ecustom--UpfrontLicenseFee_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zabHXXf0dU61" title="Upfront license fee"&gt;20,000&lt;/span&gt;, and will receive an annual License Maintenance fee of $&lt;span id="xdx_901_ecustom--LicenseMaintenanceFeeReceivable_iI_c20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zZcbJzB6K9S8" title="License maintenance fee, receivable"&gt;5,000&lt;/span&gt; beginning in 2022, &lt;span id="xdx_906_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zTi64CfuvDfe" title="Net sales percentage"&gt;2.5%&lt;/span&gt; to &lt;span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zTccv5LX3Ojh" title="Net sales percentage"&gt;5%&lt;/span&gt; royalty
fees, or minimum annual royalty payments of $&lt;span id="xdx_90B_eus-gaap--RoyaltyExpense_pn4n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zTDWdC6uL0O" title="Annual royalty payments"&gt;0.25&lt;/span&gt; million beginning in the year after the first commercial sales of Licensed Product,
and $&lt;span id="xdx_901_eus-gaap--CostMaintenance_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zUG4R1ersv34" title="Maintenance fee"&gt;2.0&lt;/span&gt; million beginning in the fifth year after the first commercial sale of such Licensed Product. The agreement also includes certain
performance milestone payments totaling $&lt;span id="xdx_905_ecustom--PerformanceMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zhSqJdWZ4rA5" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million, and one-time sales milestone payments of $&lt;span id="xdx_90E_ecustom--SalesMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z9vFpZJlPwI8" title="Sales milestone payments"&gt;1.0&lt;/span&gt; million upon reaching $&lt;span id="xdx_90E_ecustom--GrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8J1nnEfFa1k" title="Gross sales"&gt;250&lt;/span&gt; million
in gross sales, and $&lt;span id="xdx_909_ecustom--SalesRevenue_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zi9U1CfAyz2" title="Sales revenue"&gt;5.0&lt;/span&gt; million upon reaching $&lt;span id="xdx_901_ecustom--CummulativeGrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zNjYVUv7Knd8" title="Cumulative gross sales"&gt;500&lt;/span&gt; million dollars in cumulative gross sales of Licensed Products. There is no double
payment intended; if one of the milestone payments has been paid under the 2016 agreement no further payment is due for the corresponding
milestone above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company did &lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdOEvssQX5aa" title="Research and development expense"&gt;&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zHz5gzbRA6k6" title="Research and development expense"&gt;no&lt;/span&gt;&lt;/span&gt;t incur any research and development expense relating to the 2021 Patent License
Agreement for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p id="xdx_8AA_zSlMIiHsedS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
Employee Compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock_zJjSbKygK2t4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s future financial commitment to certain employees pursuant to their respective employment
agreements (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zasXu0L8RLFa" style="display: none"&gt;Schedule
of Company&#x2019;s Future Financial Commitment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Year ending&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zQONIIjZE8B5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherCommitmentDueInNextTwelveMonths_iI_pn3n3_maOCzdEO_zB66ZJtMVo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;432&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherCommitmentDueInSecondYear_iI_pn3n3_maOCzdEO_zWNNXeI8fjTi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherCommitment_iTI_pn3n3_mtOCzdEO_zchEAYQARl88" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;486&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z5EnAi48fsQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2022-03-012022-03-04"
      decimals="0"
      unitRef="USD">425000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2021-08-052021-08-06_custom_SheffieldPropertiesMember"
      decimals="-5"
      unitRef="USD">100000</us-gaap:LitigationSettlementExpense>
    <GTBP:ProjectFee
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">2100000</GTBP:ProjectFee>
    <GTBP:ProjectFeeIncurred
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">1700000</GTBP:ProjectFeeIncurred>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_ScientificResearchAgreementMember"
      decimals="0"
      unitRef="USD">766000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_ScientificResearchAgreementMember"
      decimals="0"
      unitRef="USD">964000</us-gaap:ResearchAndDevelopmentExpense>
    <GTBP:ProceedsFromUpfrontAmount
      contextRef="AsOf2022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">200000</GTBP:ProceedsFromUpfrontAmount>
    <us-gaap:CostMaintenance
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">100000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.04</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.06</GTBP:RoyaltyFeePercentage>
    <us-gaap:RoyaltyExpense
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember"
      decimals="-4"
      unitRef="USD">250000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember"
      decimals="-5"
      unitRef="USD">5000000.0</us-gaap:RoyaltyExpense>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">1000000.0</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">5000000.0</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <GTBP:UpfrontLicenseFee
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      unitRef="USD">20000</GTBP:UpfrontLicenseFee>
    <GTBP:LicenseMaintenanceFeeReceivable
      contextRef="AsOf2021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      unitRef="USD">5000</GTBP:LicenseMaintenanceFeeReceivable>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2021-03-252021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.025</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2021-03-252021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.05</GTBP:RoyaltyFeePercentage>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-4"
      unitRef="USD">250000</us-gaap:RoyaltyExpense>
    <us-gaap:CostMaintenance
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">2000000.0</us-gaap:CostMaintenance>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">1000000.0</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">5000000.0</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <GTBP:ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_897_ecustom--ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock_zJjSbKygK2t4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s future financial commitment to certain employees pursuant to their respective employment
agreements (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zasXu0L8RLFa" style="display: none"&gt;Schedule
of Company&#x2019;s Future Financial Commitment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Year ending&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zQONIIjZE8B5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherCommitmentDueInNextTwelveMonths_iI_pn3n3_maOCzdEO_zB66ZJtMVo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;432&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherCommitmentDueInSecondYear_iI_pn3n3_maOCzdEO_zWNNXeI8fjTi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherCommitment_iTI_pn3n3_mtOCzdEO_zchEAYQARl88" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;486&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock>
    <us-gaap:OtherCommitmentDueInNextTwelveMonths contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">432000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
    <us-gaap:OtherCommitmentDueInSecondYear contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">54000</us-gaap:OtherCommitmentDueInSecondYear>
    <us-gaap:OtherCommitment contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">486000</us-gaap:OtherCommitment>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zdbUCYALItXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &#x2013; &lt;span id="xdx_826_zGs4BOHfW4g9"&gt;Income Tax&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not record any income tax provision for the years ended December 31, 2022 and 2021, respectively, due to the Company&#x2019;s net losses.
The Company files income tax returns in the United States (&#x201c;Federal&#x201d;) and California, Minnesota and Massachusetts (&#x201c;State&#x201d;)
jurisdictions. The Company is subject to Federal and State income tax examinations by tax authorities for all years since its inception.
At December 31, 2022, the Company had Federal and State net operating loss carry forwards available to offset future taxable income of
approximately $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20221231_zgRke5BEOZr9" title="Operating loss carry forwards"&gt;238&lt;/span&gt; million. These carry forwards will begin to expire in the year ending &lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwardsExpirationDate_c20220101__20221231_zpnmav7XqAQ4"&gt;December 31, 2030&lt;/span&gt;, subject to IRS limitations,
including change in ownership. The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts
the carrying amount of the deferred tax assets by a valuation allowance to the extent the future realization of the deferred tax assets
is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of our
deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or
loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Based on the weight of available evidence,
including cumulative losses in recent years and expectations of future taxable income, the Company has determined that it was more
likely than not that its deferred tax assets would not be realized at December 31, 2022 and 2021, respectively. Accordingly, the Company has recorded a valuation allowance for &lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20220101__20221231_zGJ0K1PR39J2"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20210101__20211231_zRpN296xz6cc"&gt;100&lt;/span&gt;&lt;/span&gt;%
of its cumulative deferred tax assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes, and operating losses and tax credit carryforwards. The significant components
of net deferred income tax assets are (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zpsMRDz6YbBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zgUdxd1Q2Lnd" style="display: none"&gt;Schedule
of Net Deferred Income Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20221231_zJFoI1d9QIrl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20211231_zGGctYHlTdvl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn3n3_maDTAGzPo9_zjG3tRmkgLZ4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Federal net operating loss carryforward&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;66,741&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;58,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTAGzPo9_zCJGaYqDJxe6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation and other items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzPo9_zQDTJK1tT7yc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Intellectual property&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41,572&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzPo9_maDTANzU5L_z2A16JeZ213e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets before valuation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzU5L_zwiCOrrHX0Kh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(112,987&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(127,848&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzU5L_zdxbcBSgYsF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred income tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1263"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1264"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zDM9xO4w7Lff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z7lxuxZ2xD3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income tax
provision is as follows for the year ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zC4cXtFI7ON3" style="display: none"&gt;Schedule
of Income Tax Provision&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Federal statutory income tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zKRygQgZKjLg" title="Federal statutory income tax rate"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zNVbotp5Aolj" title="Federal statutory income tax rate"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zmZUT8NLhfdi" title="State tax, net of federal benefit"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231_zXTK0f8UVrQk" title="State tax, net of federal benefit"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance on net operating loss carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20220101__20221231_zEtbWqxdas7b" title="Change in valuation allowance on net operating loss carryforwards"&gt;(29&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20210101__20211231_zvArZUvdEWe6" title="Change in valuation allowance on net operating loss carryforwards"&gt;(30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zg1lOq9En3wc" title="Effective income tax rate"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zZMABh2k79r7" title="Effective income tax rate"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zaJjnrNAQQ3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="-6" unitRef="USD">238000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="From2022-01-01to2022-12-31">2030-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zpsMRDz6YbBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zgUdxd1Q2Lnd" style="display: none"&gt;Schedule
of Net Deferred Income Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20221231_zJFoI1d9QIrl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20211231_zGGctYHlTdvl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn3n3_maDTAGzPo9_zjG3tRmkgLZ4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Federal net operating loss carryforward&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;66,741&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;58,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTAGzPo9_zCJGaYqDJxe6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation and other items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzPo9_zQDTJK1tT7yc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Intellectual property&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41,572&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzPo9_maDTANzU5L_z2A16JeZ213e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets before valuation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzU5L_zwiCOrrHX0Kh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(112,987&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(127,848&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzU5L_zdxbcBSgYsF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred income tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1263"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1264"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">66741000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">58171000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">4674000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">7622000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">41572000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">62055000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">112987000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">127848000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">112987000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">127848000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z7lxuxZ2xD3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income tax
provision is as follows for the year ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zC4cXtFI7ON3" style="display: none"&gt;Schedule
of Income Tax Provision&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Federal statutory income tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zKRygQgZKjLg" title="Federal statutory income tax rate"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zNVbotp5Aolj" title="Federal statutory income tax rate"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zmZUT8NLhfdi" title="State tax, net of federal benefit"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231_zXTK0f8UVrQk" title="State tax, net of federal benefit"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance on net operating loss carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20220101__20221231_zEtbWqxdas7b" title="Change in valuation allowance on net operating loss carryforwards"&gt;(29&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20210101__20211231_zvArZUvdEWe6" title="Change in valuation allowance on net operating loss carryforwards"&gt;(30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zg1lOq9En3wc" title="Effective income tax rate"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zZMABh2k79r7" title="Effective income tax rate"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.09</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.30</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zev4qmpX8GH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11 &#x2013; &lt;span id="xdx_82F_zDvMeHszkSlc"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Offering&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 4, 2023, GT Biopharma received gross proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember_zb2HwkUEJlm" title="Gross proceeds from common stock"&gt;6.5&lt;/span&gt; million, before deducting placement agent fees and other offering expenses
of approximately $&lt;span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ziWlbS8dWKSh" title="Placement agent fees and other offering expenses"&gt;450,000&lt;/span&gt;, in relation to a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) signed on December 30, 2022, &lt;span style="background-color: white"&gt;between
the Company&lt;/span&gt; and an institutional investor (the &#x201c;Purchaser&#x201d;) for the issuance and sale, in a registered direct offering
(the &#x201c;Offering&#x201d;), of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230103__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjrAIizOUfUg" title="Common stock shares issued during the period"&gt;3,600,000&lt;/span&gt; shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBotL1Cvaqi3" title="Common stock par value"&gt;0.001&lt;/span&gt; per share (the &#x201c;Shares&#x201d;),
pre-funded warrants to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__srt--RangeAxis__srt--MaximumMember_zrNvqD7rtCJ" title="Warrants purchase of common stock"&gt;2,900,000&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;Pre-Funded Warrants&#x201d;), and
warrants to purchase up to an aggregate of &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_ziwF1AC09GB2" title="Warrants purchase of common stock"&gt;6,500,000&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;Common Warrants&#x201d;).
The Common Warrants have an exercise price equal to $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zrHSRH5EBhli" title="Warrants exercise price per share"&gt;1.00&lt;/span&gt;, will be exercisable commencing six months following issuance, and will have
a term of exercise equal to five years following the initial exercise date. The Pre-Funded Warrants have an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zdzuJqF92Ftg" title="Warrants exercise price per share"&gt;0.0001&lt;/span&gt;
per Share, are immediately exercisable and can be exercised at any time after their original issuance until such Pre-Funded Warrants
are exercised in full. The Shares and Common Warrants were sold at an offering price of $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pp0p0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zoiHWhKkxnE8" title="Shares and warrants sold price per share"&gt;1.00&lt;/span&gt; per Share and accompanying Common Warrant
and the Pre-Funded Warrants and Common Warrants were sold at an offering price of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pip0_c20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zUSxHzPBDTW7" title="Shares and warrants sold price per share"&gt;0.9999&lt;/span&gt; per Pre-Funded Warrant and accompanying Common
Warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuance
of Common Stock for research and development agreement&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 14, 2023, the Company issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230313__20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentAgreementMember_ztTj4Qn3KKye" title="Common stock shares issued during the period"&gt;486,819&lt;/span&gt; &lt;/span&gt; shares of common stock with a fair value of $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230313__20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentAgreementMember_z0liH6L68MV" title="Common stock value issued during the period"&gt;820,341&lt;/span&gt; pursuant to a payment agreement
with a third-party manufacturer (see Note 4). The shares were valued at the respective month-end closing prices of the Company&#x2019;s common stock when the payment was due to the vendor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Demand
Letter&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2023, the Company received a demand letter from an attorney representing an alleged holder of a convertible note which alleges
that the Company did not deliver shares of common stock that were due on conversion in 2022. The demand letter contends that the Company
is liable for per diem liquidated damages. The Company has denied liability and will defend any such claim vigorously if asserted.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-032023-01-04_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_InstitutionalInvestorMember"
      decimals="-5"
      unitRef="USD">6500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-01-032023-01-04_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_InstitutionalInvestorMember"
      decimals="0"
      unitRef="USD">450000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-032023-01-04_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_InstitutionalInvestorMember"
      decimals="INF"
      unitRef="Shares">3600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember_srt_MaximumMember"
      decimals="0"
      unitRef="Shares">2900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_CommonWarrantsMember"
      decimals="0"
      unitRef="Shares">6500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_CommonWarrantsMember"
      decimals="0"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_CommonWarrantsMember"
      decimals="0"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-01-04_us-gaap_SubsequentEventMember_custom_InstitutionalInvestorMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.9999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-03-132023-03-14_us-gaap_SubsequentEventMember_custom_ResearchAndDevelopmentAgreementMember"
      decimals="INF"
      unitRef="Shares">486819</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-03-132023-03-14_us-gaap_SubsequentEventMember_custom_ResearchAndDevelopmentAgreementMember"
      decimals="0"
      unitRef="USD">820341</us-gaap:StockIssuedDuringPeriodValueNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M3*@-X/LYYW+[1OU \5C*X']02P,$%     @ (8A^5E:UAZ:7!0  2A<  !@
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MA#& ]PLA].[&'*=6Q^?C_P!02P,$%     @ (8A^5MT^5<P' P  9@L  !@
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M(8.S'LJNZM%1;XRL7/>=2H.]W"T+G+:@K %^SZ4TJXV]H)W?R6]02P,$%
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MD!, ,84+-:8\ATA;_0B(+=:S#1QPD-T)$S:@XTSSU4PT=L*V:+VY:/O2JAZ
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MEZ"  BB@\!H@0W*'$J( @/I?X>G$*G*APNWZT#'M LRL8W<!1-5SIG@A;_-
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M@=NB=<:/HFO(1,,F1L& LZX@&[8=#I!H\J'B%!8Z:*0DPMU\HK/9"/D/JHR
M%^6Y 4'/<;(#;H420#\1>Y*E*N^\@&YX.RILB-&UM@WR3]FQ7OB5IMY]1 9)
M$9X^I8Z\((Q#T@Y=!NWN';"(,*?5M\& L^Q_+_DYT$)V <<"\=X65Y2:IY\1
M?  BA![$3!0&,=.146U!>6)K-UMXM)3?@#9D/?L\SNE" F)_:(RA4D8--"4
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M^:MR^0&WXR^Y5ZYM7<5_4O]G&EJ ]VN'"AQ^T ']I_UO_@=02P,$%     @
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M+S>"8]2B!7B^DM)T-Z2@_RGFXG]02P,$%     @ (8A^5AQ("D#8!   H@L
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M2CYGK737>OD[[^P9$UZAI?6_L QWT]T8BM8Z77?"R* 6*GS97>>'-8%)\H)
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M< L>-86^TP^QR!O@F0#0;1QH38^<J#!^4!U';B_Z]OA<%$J3ZW.QY!M;\5+
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MC7L5=2MZ<6E05#\N1?*36'[<L74^9 _E^' ,UN.CLIXV"G&:BDZ6I(;KY]C
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MJW]V,7%!M<.B/1A9-0VZD8;:O=GF-%]160-ZGTEI^H,-,$SL^"]02P,$%
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M[W/L9\&C<BG]#_II!@<4T6\5T7^S(FZ8K36WR^8PX7H3;Y<P#N+N%L8J@$N
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M&HUWH/-<:[?=^ 3=Y$]^ U!+ P04    "  AB'Y6^+2IK(8#  !Z"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R-5DMOVS@0ONM7#+3M(@'4Z&'Y
M$=<VX"0--H<N@J:/PV(/M#2RB$BDEZ3B^-_OD+(5%76<'FR1XLPWW[PXFFVE
M>M0EHH'GNA)Z[I?&;*9AJ+,2:Z8OY 8%G112U<S05JU#O5'(<J=45V$21:.P
M9ESXBYE[=Z\6,]F8B@N\5Z";NF9J=X65W,[]V#^\^,+7I;$OPL5LP];X@.;;
MYE[1+NQ0<EZCT%P*4%C,_64\O1I:>2?PG>-6]]9@/5E)^6@W=_G<CRPAK# S
M%H'1XPFOL:HL$-'X;X_I=R:M8G]]0+]UOI,O*Z;Q6E8_>&[*N3_Q(<>"-97Y
M(K=_X=X?1S"3E7;_L&UETX$/6:.-K/?*Q*#FHGVRYWT<>@J3Z!6%9*^0.-ZM
M(<?RAAFVF"FY!66E"<TNG*M.F\AQ89/R8!2=<M(SBSN1R1KA*WN&LZ]L5:$^
MGX6&@.UQF.U!KEJ0Y!60.('/4IA2PR>18_XS0$B,.EK)@=95<A+Q!K,+&,0!
M)%&2G, ;=&X.'-[@;3=ON,XJJ1N%\,]RI8VBPOCWF,\M8GH<T3;+5&]8AG.?
MND&C>D)_\><?\2CZ>()OVO%-3Z$O'JCY\J9"D 7\3:UY@P4JA3GT'%EJC48?
M8WX2^SAS.%CTWK3H47*P7J&R"?)L@FR68J_3,"3*G.C4N\4<%:M $"3=)(H9
M+M9 \=>0,:5V=*ULF<KA'8Q&P3B-:3&<!/$X]AZ,S!Y=Q^5 #.@6TJQM9)&#
M-"79YP9K#6DP&J<P#D9)XMT)0PU.'=^0S8VR%LT.TC@8CA,8)4$T'![C"2LD
M(@A/K&I:(W&<!)>3,<3).)BD$^][=\(JNLB8R!#.#D+GM&SEX-RSP<L/)G@;
MO)ZE=_#!_4X4R; KDN%O%TDO2_=*/G%[:1XKC=.(2T]A)D7&*]XZ2\@4:2CV
M6=2&F<9(M>L[1CE%EQ0KB46![J+]54(# \I'AL+0=6^A]R+[X+\H>)N#"\"U
M52RD#;I]*F=EATP!VKMF^E/A'HO":^5Z^Z9/20SOW1_5HMW30= 6<M%%9(4"
M"VY@0J*7)'E=,K&VOO1JZ:5B:/-&(V@X2R[A_#V<#2)Z>)]>C6=$%NEWK(["
MWCRH4:W=U",[LA&F'0W=VVZP+MMY\B+>3N7/3*VYT%!A0:K1Q9@*2+63KMT8
MN7'3924-S2JW+.GC )45H/-"2G/86 /=Y\;B?U!+ P04    "  AB'Y6)_H:
M-Q<#  # "P  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6S-5EUOVC 4
M_2M6)DV;M#9?D)0.(A7::956#95M?:CV8)(+L>K$F>U ]^]G.R$E%-@ZY:$O
M8#OW'I][[DUTAFO&'T0*(-%C1G,QLE(IBW/;%G$*&1:GK(!</5DPGF&IMGQI
MBX(#3DQ21FW/<0([PR2WHJ$YF_)HR$I)20Y3CD2999C_'@-EZY'E6IN#6[),
MI3ZPHV&!ES #^;V8<K6S&Y2$9) +PG+$83&R+MSSB>OH!!/Q@\!:;*V1+F7.
MV(/>7"<CR]&,@$(L-016?RN8 *4:2?'X58-:S9TZ<7N]0?]DBE?%S+& ":-W
M))'IR#JS4 (+7%)YR]:?H2ZHK_%B1H7Y1>LZUK%07 K)LCI9,<A(7OWCQUJ(
MK00W.)#@U0G>;D+O0()?)_BFT(J9*>L22QP-.5LCKJ,5FEX8;4RVJH;DNHTS
MR=53HO)D-%-SD904$%N@BUR2DX304BN+9A"7G$@" KV[!(D)%>_1"1(IYB"&
MME27:P@[KB\:5Q=Y!RYR/73#<ID*=)4GD+0!;,6ZH>YMJ(^]HXB7$)\BW_V
M/,?S]A":_'NZ>X2.WRCI&SS_ )Y6;Y]X5X\Q+57%:,%9AB8L*TJ)S0@KR:\P
MSTF^%&@*',VTM.C^BP)&UQ(R\7.?S!6+WGX6^JT_%P6.862IUUH 7X$5O7WC
M!L['?1)U!-82K-<(UCN&'GUC$E.$6T,G&MWVE5[A!09/?Y]6D3\(PM +AO9J
MNZKG<5[@#\*PU\2U"/<;POVCA.\PYXJN0)*A:<GC5'T^=$,SU<N99/$#NK^!
M; Y\;]^.8K^T;QV!M60(&AF"5S'H09>"=036$BQL! L['O3P^0#[?NAM#7!5
MU=_C6H3/&L)G1PE_+73;_G/.CT*_M&T=@;54&#0J#%[%G ^Z%*PCL)9@KO-D
M)IR.)[T&W!YA-_"=7M_;&?4]@;[C]1UG9]3M+2^4 5\:BRA0S,I<5MZB.6UL
MZ(4Q7SOG8VU/C<=Z@JF\[0WF2Z)>#PH+!>F<ANIKS"N[6&TD*XSCFC.I_)M9
MILIB ]<!ZOF",;G9Z L:TQ[] 5!+ P04    "  AB'Y6Y^L[WHP$  "%&
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M<)MJL56UQ)9:=U9.91L<VSV"@%9+-ZMJL56UQ)9:=V9.-1Z\H,BC9;5U$R^
M<+Y'98JU<Q+V$HJVB%B870[&;5,ML:56XW;/CEL+S#;5.3<'U8EI?5K9OFW/
MTN^J$^2?WB_@;5R?B)]DZ@/Z1\0VI.0@QVLIZ5U',EY8?>9=/PBZJPYU5U0(
M6E2W6XPRS%0#^7U-J7A]4 [:?Q[F_P%02P,$%     @ (8A^5F)94.1L P
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M7JZ +H 7 ]3O2Z8$5]T4[VG5[^6-_P=02P,$%     @ (8A^5GTW02-Z @
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M+BXUBVP;6QN@J&UO6 G4G<8."_TO &D2]'HN!+X$IMWT?Y?D'U!+ P04
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M&J]0F@>E^2B:+I#&>*7FW^[>%B/$HT#6HK#\E3ZJ@:-5#Q5NNFMGG8['3\4
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M5ENXN?KC<!V24-T'K -A?CKRO@S,K__.WLS@XQ#4_X?2*)3&H#2.HIEBTB&
M:T\!FDN)RFG 8;;9J::V93X+_+GG3\X5!77SH;0(2J-0&H/2.(IF*DIG!*X]
M)# O2#N98SY(I1)994WDW6,NZU>%?=()S0F@M!!*BZ T"J4Q*(VC:*8Z=:[@
M7F$GG="  4H+H;0(2J-0&H/2.(IF7MRJ8P;/ZB'W&;\U!/OXS=[,4#%!:1&4
M1J$T!J5Q%,T4DPX,O-<"@]?';U[;AR_';Q/OZEQ04/<?2HN@- JE,2B-HVBF
MH'1&X W("/H/W\B?A,;%4B3$<]PK(M)5?2&E=7AG[\G0<RN4%D)I$91&H30&
MI7$4S52OSA0\;*;@03,%*"V$TB(HC4)I#$KC*)HI09TI>)!,P4X9K#QHI@"E
M15 :]3HRA=;UFPS:)D?13$7I2,&S1PHOGI++/PLI\DIB?2T5>U.#90>]=P%*
MBZ T"J4Q*(VC:*8\=1[A86]A\*#W,$!I(90606D42F-0&D?13 GJ%,/KDV+8
M+959'TL%&F! :1&41J$T!J5Q%,T4DPXP/'N T<M2F;=&(:[K>\ZDY:E 0P<H
M+8+2*)3&H#2.HIF*TJ&#9[^;H>^4 )HU0&DAE!9!:;2A&=<9S]M3 FB&@**9
MRRKH#,&W9PCW>9PNXYU(JGNO7KC)RHX8*B<H+832(BB-0FD,2N,-S;BPRS^]
MLLO4DXX1?'N,\.(4LSP9%ONDOE/^.,.T3C#M#0U6'322@-(B*(U":0Q*XRB:
M*4X=2?@>=(+I0W,%*"V$TB(HC4)I#$KC*)HIP9-UC*RF<9\)9D.P3S#MS0P6
M$W95(NRR1-AUB; +$_T5"8&O$P+?GA#TF6#Z;9L[F'7,+^U-#184U/B'TBB4
MQJ TCJ*9@M(!@?_:/0<]9@-0XQ]*"_WV[0J^[[=6[H V2J$T!J5Q%,W4DW;T
M??L=!I\S)9(+\^:53DU!G7PH+6QHAJ;F+5<@@C9*&YIQU&X9$1T]:ZU2PU']
M,A6@#77?;JA_,NY;6I<3P7VZ$_&*+/5\<"V[10%='PA*"Z&T"$JC?OLNBW:N
M#6V2HVBFR+31[MN-]CYK--H1@]4$=>.AM,AO+_#3.BQ0OYT[!&VK$]HQCJ*9
M*M'FN6\WS^N3$1%]M'+5^@U.6O^%[NS-#=8 U!>'TBB4QJ TCJ*9B\-J_SRP
M^^>?]I6!6:U5]F,][(/E69WI^DBMP1OYW]2;!<&YVNS]&*HV*"V"TBB4QJ T
MCJ*9:M/N>O!7N.OD3_*K2/<B_UZOYFUUW>T=&'J:A-)"*"V"TBB4QJ TCJ*9
MHM6N>X!UW0.HZPZEA5!:!*51*(U!:1Q%,R6H7?>@C^MN-TKMB,&R@_KS#<V\
M2BAP?;]ZL(2YEGO7ELY\ZGC!^8+N4%\=2N,HFBF7DR7_[;YZKS7_D;[O'906
M-C3[_"6"MDFA- :E<13-E)-VU0.[JW[^E)WC ,XZ$(/:[%!:"*5%4!J%TAB4
MQE$T4X?:C0^PU]<'4%<>2@NAM A*HU :@](XBF9*4,<!P<!G!2SUL?&"+&0J
MU_$R%DGS>7V=Q%H*M<\[(P)[:X,5"HT(H+0(2J-!GP<<,&B;'$4[*&]\\M"[
MK<P?ZP<@%J1^4,#A 7''3X\/67Q7/UKP[//0?4L/CTK4F,.3&S^*_+&4*DGD
MND0ZE[/RZ)T?'H9X>*.R7?UHO46F5+:M7VZD6,F\VJ#\^3HK3_;-FZJ!XR,I
M;_\/4$L#!!0    ( "&(?E:&PS+9S@,  -,1   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;,5886_:/!#^*Z>\TZM.FDAB*)0.D JL>BNM4M5VW8=I
M'TQR@-4DSFP'RK]_;0<"Z=*T;)'Z!>+$]]S=<X^3LP=K+A[E$E'!4QPE<N@L
ME4K/75<&2XRI;/$4$_UDSD5,E1Z*A2M3@32T1G'D$L_KNC%EB3,:V'LW8C3@
MF8I8@C<"9!;'5&S&&/'UT/&=W8U;ME@J<\,=#5*ZP#M4W](;H4=N@1*R&!/)
M> ("YT/GPC^?^%UC8&<\,%S+@VLPJ<PX?S2#JW#H>"8BC#!0!H+JOQ5.,(H,
MDH[CUQ;4*7P:P\/K'?JE35XG,Z,2)SSZSD*U'#IG#H0XIUFD;OGZ/]PF=&KP
M AY)^POK?&Z/.!!D4O%X:ZPCB%F2_].G+1$'!J3S@@'9&I"W&K2W!FV;:!Z9
M36M*%1T-!%^#,+,UFKFPW%AKG0U+3!GOE-!/F;93HSNMBS"+$/@<IBC8BAI:
MX2NC,Q8QQ5#"A=0U3@WI$DZFJ"B+Y$?X "R!^R7/)$U".7"5#L9 NL'6\3AW
M3%YP[!.XYHE:2OB2A!B6 5R=19$*V:4R)K6(4PQ:T/8_ ?$(@6]W4SCY\+$B
ML,G;8?QJF%)X[8+IML5MOX![29F !QIE"-=(9290KP8%5TF:*0F:1/N06G'?
M8[!,V*],L__CJ\:!*X6Q_%G%<NZT4^W4O 3.94H#'#IZE4L4*W1&__[C=[W/
M5<PT!%;BIU/PTZE#S_E967ZT%M=4")JH2F'E.#V+8UY3JY'?'[BKPT0JIK3/
MBCFE^$Z+^$YKX_NM:)_@ELE'N!2HZY,HU)0HN*4*X<<UQC,4E?6J=7)LO1H"
M*_'1+?CHOH>>NTWRTQ!8B9]>P4^O5B]?GE+]J<(00K9B(6H^-@RCL"KG',CW
M#N3::1'R3-,5L_P6Z5:K^JR(\NQ85=\(%B \\$C73G\"-K5RKD4_MEP-@96(
MZ!=$]-]#SOTF^6D(K,2/[^T[!:\I06^1NH=2]9Z_HZLFD7ZUG/V#?L8_5M!%
MX/<HXEHUUV,?6ZZFT,I,D#T3Y#T4O?7:%$<-H94YVO=D?FU+L]=TQ.8()[JE
MW2 5LJIM'+\"17)3Z$&<][5=".FFJH&9O(+4?@M2.>%]D^77=UEURV.Z6]>O
M-C'U3H[60$-H94KV?9U_^B[KI-%.KRFT,D?[7L^O;96.>O?_0=,%E2G_/5">
MK7NP/8Y1+.RI@82 9XG*MY?%W>)DXL+NQY_='YL3"[OMWL/DQQW75"R8WA]'
M.->07JNGRR7R$X1\H'AJ-^$SKO26WEXND88HS 3]?,ZYV@V,@^(<9_0_4$L#
M!!0    ( "&(?E913!KRRP(  (8(   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;*U6:V_3,!3]*U9 :)/8\FK3,-I(:[L))"9-*X//;G+36'/L8COM
M]N^QG32T:QI \"6QG7N.S[E^W(RW7#S) D"AYY(R.7$*I=97KBO3 DHL+_D:
MF/Z2<U%BI;MBY<JU )Q94$G=P/,BM\2$.<G8CMV+9,PK10F#>X%D5998O$R!
M\NW$\9W=P -9%<H,N,EXC5>P /6XOA>ZY[8L&2F!2<(9$I!/G&O_:A:;>!OP
MC<!6[K61<;+D_,ET/F<3QS."@$*J# /6KPW,@%)#I&7\:#B==DH#W&_OV&^M
M=^UEB27,./U.,E5,G-A!&>2XHNJ!;S]!XV=H^%).I7VB;1T;10Y**ZEXV8"U
M@I*P^HV?FSSL ?Q3@* !!*\!@Q. L &$UFBMS-J:8X63L>!;)$RT9C,-FQN+
MUFX(,ZNX4$)_)1JGDH7>%EE% ?$<S4&0#39I15\(7A)*U OZ*C"3V.9<HK,Y
M*$RH/$<7Z'$Q1V=OS\>NTC(,F9LV4T[K*8,34_H!NN-,%1+=L RR0P)7ZV]-
M!#L3TZ"7<0[I)0K]]RCP@J!#T.S/X7Z/G+#-:6CYPI-\QWGL2E/-,NAF,<?W
M2JYQ"A-'GT\)8@-.\NZ-'WD?NRS^)[(#PX/6\*"//9G"BC!&V I-,<4LA2ZW
M-<7(4IB[99/X8>QYWMC=[/LX#@OCP7[8@<)AJW#8J_ ZRXC9PEW">I'=F4-=
M*_#O/ ?6HM9:U&OMYEGIS%=$%OIR55T&>_%_8;#FB?:6YB(<GER:4:M_U*M_
M5F"V D08RC$1:(-IU;E_1L>S^_Z'XPW4$1?X_DF9<2LS[D\SRWZSP>/C#1Z/
MCN1U1!T>@UJ=NW>EER!6MM))E/**J?IB;$?;8GIM:\BK\:DNLG5-_$535^@[
M+/2QE8A"KBF]RY'>P**N>G5'\;4M'$NN=!FRS4+_*( P ?I[SKG:=<P$[:]'
M\A-02P,$%     @ (8A^5G)3AAO1 @  =0@  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&ULM59M3]LP$/XKIPQ-(#'R5EK$VDC0[@4)$*)C?)CVP4VN
MC85C=[;[PK^?[:2A0(BHM'UI[+/ON>>Y:^[27PGYH')$#>N"<37P<JWGI[ZO
MTAP+HH[$'+DYF0I9$&VV<N:KN422.:>"^5$0=/V"4.XE?6>[D4E?+#2C'&\D
MJ$51$/EXCDRL!E[H;0RW=)9K:_"3_IS,<(SZ;GXCS<ZO43):(%=4<) X'7AG
MX>FP9^^["S\IKM36&JR2B1 /=G.1#;S $D*&J;8(Q#R6.$3&+)"A\:?"].J0
MUG%[O4'_ZK0;+1.B<"C8/<UT/O!./,AP2A9,WXK5=ZST'%N\5##E?F%5W0T\
M2!=*BZ)R-@P*RLLG65=YV'+HQ&\X1)5#]%Z'N'*(G="2F9,U(IHD?2E6(.UM
M@V87+C?.VZBAW%9QK*4YI<9/)R.4=$EL*N&2D@EE5#_"_@@UH4S!-9'2'1[
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MTDXPWZ="Z$W'.JA+UN0/4$L#!!0    ( "&(?E;,1!WMIP,  .$/   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;*U7;6_:.A3^*U;N-.U*+4F<%V@O
M1(*V>_FPK5JUVP]7]X-)#A MB9EMH/OWLYT0( EN*1,2L1V?Q\]SCAV?,]Q0
M]H,O  1ZRK."CZR%$,MKV^;Q G+">W0)A7PSHRPG0G;9W.9+!B311GEF8\<)
M[9RDA14-]=@]BX9T);*T@'N&^"K/"?LU@8QN1I9K;0>^I?.%4 -V-%R2.3R
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MJ0GR_8Q2L>VH!>JJ/OH-4$L#!!0    ( "&(?E:2D$0F51T  ">_ 0 9
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M_/WM=IN??U,.\&F;_7S\<5[_#U!+ P04    "  AB'Y6OR$X%GT"   8!@
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M:%/$7;,TURQ*.\%\+X30]QU;R?N+._T#4$L#!!0    ( "&(?E::XTB]@@(
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M/=V(<"GR<@'U_U66R;<790?[.SK/_P]02P,$%     @ (8A^5J45NML, P
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M&VZP*X.R ?@]E=+L)W:#NL]'?P%02P,$%     @ (8A^5J]KGG#$ @  I@<
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M-.#0;]O?:<H6>=+,NH-$V%EM^QLL+XR;8[^.Q41*ES0=VZZ<3>JFIQLZJOT
M81>YK3]N!.,8S(T AL7!'& <P\+B_$_KZ:/K,1CFK>]$^BBGCW(,RX6,ZR\6
MQ\U)],>]TB2)HCC&,CH>.QV,L;S%,?RXU3!OP,#B0*27Y1K?;;Q"]M<!MJ?[
M*@1;*5Z)V$KQ7 /BSALPDL2]VU@<8&"[@-4.Q'?'@9IR<Z((=A7SAMW!.)(D
M& *UZ*[1.$:R$\/7O3_871)%2>)& ',[B"(,@;L11S 'X %#HJA^#^Z\CX+U
M>RIH_X\[^@M02P,$%     @ (8A^5I>*NQS     $P(   L   !?<F5L<R\N
M<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9
M>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:
M+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU
M1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*
MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  AB'Y6T,U!?48$  "%(0  #P
M 'AL+W=O<FMB;V]K+GAM;,6:36_;.!! _PJA4_:P:^LC:1O4!;IQL@V0)D8=
M9(\!+=$V$8I42<II\NN7I.)VE*B#O= ZV2)E\6DD\<U0_OBH],-*J0?RHQ;2
MS)*MM<WI9&+*+:NI^4LU3+J>M=(UM6Y3;R:FT8Q69LN8K<4DFTY/)C7E,OGT
M<7^LA9[ #659:;F2KM$WW''V:'[U^TVRXX:ON.#V:9:$[X(EI.:2U_R95;-D
MFA"S58]?E.;/2EHJEJ560LR2M.NX8]KR\DWSTD/>TI4)+9:NOE$',DM.INZ
M:ZZ-#7N$XU/'N&-NYVZKM>J""\OTG%KVCU9MP^7&'\:=Q02<1HC#_K,+XJG^
M/V%4ZS4OV5R5;<VD[>*HF?" TFQY8Q(B:<UFR9G:,>W/QPUP677G9AT4B)0^
MY:Y#7U8!+R:*-$KPRHU>D;^IH+)D)(30 , , <Q& R1'"PH@<P0R/R#DTD/X
M'QBBUN2FZ5WJ H$L1H2\SP#D,0)Y/!KDTJH20)X@D">C09Y1LP60[Q#(=W$A
M;_2&2OX<.@B55;@3N]T X'L$\'U<P&5;UU0_A4O+-Y*[GU%IR>>R5*VT'$!^
M0" _Q(6\H%R3.RI:YCDON'3S#Z>"7$IC=5O#27R*S>+3N)@O03-D09]H&/H7
M%VJ7^'K9>9&[4<FURQH& 3&[I)'U,F>:[ZC/$\@5IUW" MDPJ:21K>(GO(>M
M$A73YIZ<?V]?L6$N22/+Y&4RD1MRQ:AA<$I),7VDT?U1U]QVT[&?]-P-Z"F9
M>VK[D)@^TLC^N)2EJAFYI3\@$>:*-+(LENW*L.^MVXF<[WSP(!CFB'1,2?22
MEA2S1!I9$SAF#E-I3!-99$V@-NM%,\.LD46VQFN;D:-;_V'^@(!H33*"-08A
M,7UD(^AC$!+S2'9@CPP"8D+)QA0*.8*8F%*R@REE,(*86[+8;G''J%H1IIS/
M+GA_5ERTX=E9LK*%Q7&&F28;U30%Q,1,D\4V#8CFN;&\#D7HSXD=KH=@ILDC
MFP9B NM\X>YQUR4LD7/,-'EDT_3NS3?6F4-,S#=Y9-\,H#%+N3#DFFK=6P1#
M5\'B+X,-5WL=+\3$G)-'=@Z\Z ,FAYB8>?+(YD$Q>\E:CIDGCVR>X5SHY_T)
M,3$+Y0>TT+_^H0ESN\/N<"$F9J$\MH4 YDT3NG^'B5DHCVVAP=QRZ*(7F(6*
M UK()7*-DB&/>TDUOT%,S$+% 2VT;)M&A/5D5Y>]65LI, L5D2T$,;]2VVI_
MT0-B>/(A)F:A(K*%WI84OY-E@;Z-.:"%_+U)Y=.](1>MBRMSI3G$Q"Q4C%G_
M]"Q48!8J(EL(1O/:C3%G:Z:URXR[P@AB8A8J#F@A4+(MM/(L"F)B%BHB6PA6
MD[V'QVL>%I8%)J$B^J+;JT7+/BQ\H8E)Z#A(:+)_[5^Q-9>LNG9#&-=>4E$N
M-/$?W<N*XMBO-*Y;(<Y<VXV\4K3:_XM@_P^(3_\!4$L#!!0    ( "&(?E8X
M@V\FQ $   T>   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V3MN
MPD 4A>&M("\@PWV8A BHTM!&V8!%AH=BL.69*+#[(%*0@U*D07,J:VSY^J\^
M6^/9:VR;O.L.:;OKT^BX;P]I7FUS[I]#2*MMW#?IH>OCX7QEW0W[)I^7PR;T
MS>JCV<2@X_$D#+]G5(O9[YFCMU,?_S.Q6Z]WJ_C2K3[W\9#_&!R^NN$C;6/,
MU>BM&38QSZMP;*^G4[@<Y.$\N1HMW^?5L'R7*I0.4@C2\D$&058^R"'(RP?5
M$%27#YI T*1\T",$/98/>H*@I_)!4PB:E@^2,<HX)DBZP9I :T&NA<!K0;"%
M0&Q!LH7 ;$&TA4!M0;:%P&U!N(5 ;D&ZA<!N0;R%0&]%O95 ;T6]E4!OO?G8
M)M!;46\ET%M1;R706U%O)=!;46\ET%M1;R706U%O)=!;46\ET-M0;R/0VU!O
M(]#;4&\CT-MN-DL(]#;4VPCT-M3;"/0VU-L(]#;4VPCT-M3;"/0VU-L(]';4
MVPGT=M3;"?1VU-L)]';4VPGT]IO-;@*]'?5V KT=]78"O1WU=@*]'?5V KT=
M]78"O6O4N[ZGWBF?VIBN/3]K?/X]J<[G>^/U\9?ESTE\7]07G /\_5U\ U!+
M P04    "  AB'Y6@(3XG< !    '@  $P   %M#;VYT96YT7U1Y<&5S72YX
M;6S-V<ENPC 4!=!?0=E6Q'B #@(V;;<MB_Z FSP@(HDMVU#X^SIAD%K1J(A*
MO9M$B>UW7VSI;#)^VUGRO6U5UGZ2+$.P#XSY;$F5]JFQ5,>1N7&5#O'1+9C5
MV4HOB(G!8,0R4P>J0S\T-9+I^(GF>EV&WO,VOO:%J2>)H](GO<?]Q"9KDFAK
MRR+3(8ZS39U_2^D?$M*XLIWCEX7U-W%"PLXF-",_!QS6O6[(N2*GWDR[\**K
M.(MM2^;#KB2?=I<XTZ.9SXN,<I.MJ[@D]=:1SOV2*%1ENB]ZTYT<X@[3_LJO
MSF_+= 7&F3-GK(\GYNCRN..1-*O[-A8B%XKN3SPEQM)7?Q\UIYU3_LOLN+T?
MQJW:\_"LO5V_QU_/^%3_PCX$2!\2I \%TL<0I(\12!^W('W<@?1Q#](''Z T
M@B(J1R&5HYC*45#E**IR%%8YBJL<!5:.(JM D56@R"I09!4HL@H4606*K )%
M5H$BJT"15:#(*E%DE2BR2A19)8JL$D56B2*K1)%5HL@J4625*+(J%%D5BJP*
M15:%(JM"D56AR*I09%4HLBH4616*K,/_E/7=F-5?_Y-L[FFEB_J8S]H?O]-/
M4$L! A0#%     @ (8A^5@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  AB'Y6$C+M0>T    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  AB'Y6F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( "&(?E8Z%J&1^P<  *(R   8
M      " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  AB'Y65K6'II<%  !*%P  &               @($]$   >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ (8A^5MT^5<P' P  9@L  !@
M             ("!"A8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( "&(?E9$\0L"U 0  "(1   8              " @4<9  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  AB'Y6C,POX=@"  #+
M!P  &               @(%1'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ (8A^5LO!4.6L"0  MTT  !@              ("!7R$
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "&(?E8@##*>
MP @  &8H   8              " @4$K  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    "  AB'Y6)YUG*8$#  #O!P  &
M@($W-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ (8A^
M5A04DV< $@  YB\  !@              ("![C<  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( "&(?E9NTG48D@,  *<)   9
M      " @21*  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ (8A^5@U>KXIB!    @H  !D              ("![4T  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  AB'Y6/_78H'@%  "!#@
M&0              @(&&4@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( "&(?E9*%\&=]00  '@+   9              " @358  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ (8A^5KC]4GW*
M"   EAD  !D              ("!85T  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    "  AB'Y6'$@*0-@$  "B"P  &0
M@(%B9@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "&(
M?E9++E03W <  /<1   9              " @7%K  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ (8A^5J5(G'B*!0  Z@P  !D
M         ("!A',  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    "  AB'Y6L/YX2GP#  !O!P  &0              @(%%>0  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "&(?E9#$M"*(1,  .8W
M   9              " @?A\  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ (8A^5G=F6(G3 @  .@8  !D              ("!4)
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  AB'Y6WMQ7
MQ:(#  !-"@  &0              @(%:DP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( "&(?E8ZF'A3BP(  +T%   9
M  " @3.7  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M(8A^5J]<TK4R P  P <  !D              ("!]9D  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    "  AB'Y6RC[I[F #  !T"0  &0
M            @(%>G0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( "&(?E;<>Q\.LP,  /$)   9              " @?6@  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ (8A^5G%.2 .L @
M!08  !D              ("!WZ0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    "  AB'Y6^+2IK(8#  !Z"   &0              @('"
MIP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "&(?E8G
M^AHW%P,  , +   9              " @7^K  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ (8A^5N?K.]Z,!   A1@  !D
M     ("!S:X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "&(?E:"=[)*Z0D  )YR   9              "
M@:G%  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ (8A^
M5H;#,MG. P  TQ$  !D              ("!R<\  'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    "  AB'Y644P:\LL"  "&"   &0
M        @('.TP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( "&(?E9R4X8;T0(  '4(   9              " @=#6  !X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ (8A^5K9(X]!\ P  O@X
M !D              ("!V-D  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    "  AB'Y6S$0=[:<#  #A#P  &0              @(&+W0
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( "&(?E:2D$0F
M51T  ">_ 0 9              " @6GA  !X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ (8A^5K\A.!9] @  & 8  !D
M ("!]?X  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  A
MB'Y6KL8/@8T"  #$!P  &0              @(&I 0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "&(?E::XTB]@@(  'D&   9
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M970T-RYX;6Q02P$"% ,4    "  AB'Y69*A'%-<"  #S!P  &0
M    @('*&0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M "&(?E:O:YYPQ (  *8'   9              " @=@< 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ (8A^5F%FW$+K!0  ("X  !D
M             ("!TQ\! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    "  AB'Y6ACX(OE0#  #4%0  #0              @ 'U)0$ >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "&(?E:7BKL<P    !,"   +
M      "  70I 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "&(?E;0S4%]1@0
M (4A   /              "  5TJ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  AB'Y6.(-O)L0!   -'@  &@              @ '0+@$ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  AB'Y6@(3XG< !
M'@  $P              @ ',, $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    .@ Z ,T/  "],@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>186</ContextCount>
  <ElementCount>322</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayable</Role>
      <ShortName>Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://gtbiopharma.com/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/DerivativeLiability</Role>
      <ShortName>Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableTables</Role>
      <ShortName>Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayable</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/DerivativeLiabilityTables</Role>
      <ShortName>Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/DerivativeLiability</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/OperatingLeases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/IncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/IncomeTax</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Schedule of Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails</Role>
      <ShortName>Schedule of Estimated Fair Value of Financial Instrument (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails</Role>
      <ShortName>Schedule of Fair Value Hierarchy Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails</Role>
      <ShortName>Schedule of Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Accounts Payable (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableDetailsNarrative</Role>
      <ShortName>Accounts Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayableTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Convertible Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative</Role>
      <ShortName>Convertible Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails</Role>
      <ShortName>Schedule of Derivative Liabilities Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Derivative Liability Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails</Role>
      <ShortName>Schedule of Derivative Liability Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Derivative Liability (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative</Role>
      <ShortName>Derivative Liability (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/DerivativeLiabilityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails</Role>
      <ShortName>Schedule of Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of Components Leases Rent Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails</Role>
      <ShortName>Schedule of Components Leases Rent Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Supplemental Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails</Role>
      <ShortName>Schedule of Supplemental Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Maturity Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of Maturity Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Operating Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative</Role>
      <ShortName>Operating Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/OperatingLeasesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of Company???s Future Financial Commitment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails</Role>
      <ShortName>Schedule of Company???s Future Financial Commitment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of Net Deferred Income Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails</Role>
      <ShortName>Schedule of Net Deferred Income Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Schedule of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails</Role>
      <ShortName>Schedule of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Income Tax (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/IncomeTaxDetailsNarrative</Role>
      <ShortName>Income Tax (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/IncomeTaxTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SubsequentEvents</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 10321, 10325</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 10380, 10381</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:TradingSymbol -  form10-k.htm 27</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>ex23-1.htm</File>
    <File>ex3-5.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>ex4-3.htm</File>
    <File>gtbp-20221231.xsd</File>
    <File>gtbp-20221231_cal.xml</File>
    <File>gtbp-20221231_def.xml</File>
    <File>gtbp-20221231_lab.xml</File>
    <File>gtbp-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="596">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 596,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 186,
   "dts": {
    "calculationLink": {
     "local": [
      "gtbp-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gtbp-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gtbp-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gtbp-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gtbp-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 498,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 97,
    "http://gtbiopharma.com/20221231": 43,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 144
   },
   "keyCustom": 66,
   "keyStandard": 256,
   "memberCustom": 38,
   "memberStandard": 25,
   "nsprefix": "GTBP",
   "nsuri": "http://gtbiopharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://gtbiopharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://gtbiopharma.com/role/FairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Accounts Payable",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://gtbiopharma.com/role/AccountsPayable",
     "shortName": "Accounts Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Convertible Notes Payable",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://gtbiopharma.com/role/ConvertibleNotesPayable",
     "shortName": "Convertible Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Derivative Liability",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://gtbiopharma.com/role/DerivativeLiability",
     "shortName": "Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://gtbiopharma.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Operating Leases",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://gtbiopharma.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Income Tax",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://gtbiopharma.com/role/IncomeTax",
     "shortName": "Income Tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://gtbiopharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://gtbiopharma.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Accounts Payable (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://gtbiopharma.com/role/AccountsPayableTables",
     "shortName": "Accounts Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Derivative Liability (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://gtbiopharma.com/role/DerivativeLiabilityTables",
     "shortName": "Derivative Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://gtbiopharma.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Operating Leases (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://gtbiopharma.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "GTBP:ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "GTBP:ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Income Tax (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://gtbiopharma.com/role/IncomeTaxTables",
     "shortName": "Income Tax (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Schedule of Anti-dilutive Securities (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
     "shortName": "Schedule of Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:LiquidityPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "GTBP:CashOnHandAndShortTermInvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails",
     "shortName": "Schedule of Estimated Fair Value of Financial Instrument (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails",
     "shortName": "Schedule of Fair Value Hierarchy Financial Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Schedule of Accounts Payable (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
     "shortName": "Schedule of Accounts Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Accounts Payable (Details Narrative)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
     "shortName": "Accounts Payable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_ServiceAgreementMember_custom_ThirdPartyManufacturerMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Convertible Notes Payable (Details Narrative)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
     "shortName": "Convertible Notes Payable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_AccountingStandardsUpdate202006Member",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails",
     "shortName": "Schedule of Derivative Liabilities Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Schedule of Derivative Liability Transactions (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails",
     "shortName": "Schedule of Derivative Liability Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "GTBP:ExtinguishmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Derivative Liability (Details Narrative)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative",
     "shortName": "Derivative Liability (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Schedule of Warrant Activity (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
     "shortName": "Schedule of Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Schedule of Options Activity (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
     "shortName": "Schedule of Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://gtbiopharma.com/role/StatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-10-10",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Schedule of Components Leases Rent Expenses (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails",
     "shortName": "Schedule of Components Leases Rent Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfSupplementalLeaseTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "GTBP:LongtermRightofuseAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Schedule of Supplemental Leases (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails",
     "shortName": "Schedule of Supplemental Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfSupplementalLeaseTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "GTBP:LongtermRightofuseAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Schedule of Maturity Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails",
     "shortName": "Schedule of Maturity Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-02-08",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Operating Leases (Details Narrative)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative",
     "shortName": "Operating Leases (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-02-08",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Schedule of Company\u2019s Future Financial Commitment (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails",
     "shortName": "Schedule of Company\u2019s Future Financial Commitment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-03-012022-03-04",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-03-012022-03-04",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Schedule of Net Deferred Income Tax Assets (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails",
     "shortName": "Schedule of Net Deferred Income Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Schedule of Income Tax Provision (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails",
     "shortName": "Schedule of Income Tax Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Income Tax (Details Narrative)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://gtbiopharma.com/role/IncomeTaxDetailsNarrative",
     "shortName": "Income Tax (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_OfficersEmployeesAndDirectorsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Operations (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
     "shortName": "Consolidated Statements of Operations (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_OfficersEmployeesAndDirectorsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Subsequent Events (Details Narrative)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2023-01-032023-01-04_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember_custom_InstitutionalInvestorMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://gtbiopharma.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "GTBP:StockBasedCompensationConsultantsAndResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Organization and Operations",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://gtbiopharma.com/role/OrganizationAndOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "GTBP_AccountsPayableReclassifiedToConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payable reclassified to convertible notes.",
        "label": "Accounts payable reclassified to convertible notes"
       }
      }
     },
     "localname": "AccountsPayableReclassifiedToConvertibleNotes",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_AdditionalOperatingLeaseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional operating lease assets.",
        "label": "Additional Operating lease assets"
       }
      }
     },
     "localname": "AdditionalOperatingLeaseAssets",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CancellationOfCommonStockUponSettlementWithFormerOfficer": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancellation of common stock upon settlement with former officer.",
        "label": "CancellationOfCommonStockUponSettlementWithFormerOfficer",
        "negatedLabel": "Cancellation of common stock upon settlement with former officer"
       }
      }
     },
     "localname": "CancellationOfCommonStockUponSettlementWithFormerOfficer",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CashOnHandAndShortTermInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash on hand and short term investment.",
        "label": "Cash and short term investments"
       }
      }
     },
     "localname": "CashOnHandAndShortTermInvestment",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CashPaidDuringYearFor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid during the year for [Abstract]",
        "label": "Cash paid during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringYearFor",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "GTBP_ClassOfWarrantExpireTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant expire term.",
        "label": "Class of warrant expire term"
       }
      }
     },
     "localname": "ClassOfWarrantExpireTerm",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "GTBP_CommonSharesIssuableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Shares Issuable [Member]",
        "label": "Common Shares Issuable [Member]"
       }
      }
     },
     "localname": "CommonSharesIssuableMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_CommonStockConsultantToFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock consultant to fair value.",
        "label": "[custom:CommonStockConsultantToFairValue]"
       }
      }
     },
     "localname": "CommonStockConsultantToFairValue",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CommonStockIssuable": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issuable.",
        "label": "Common stock issuable, 0 shares and 327,298 shares at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockIssuable",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CommonStockIssuableShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issuable Shares.",
        "label": "Common stock issuable, shares"
       }
      }
     },
     "localname": "CommonStockIssuableShares",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_CommonStockIssuedUponSettlementOfVendorPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued upon settlement of vendor payable.",
        "label": "Common stock issued upon settlement of vendor payable"
       }
      }
     },
     "localname": "CommonStockIssuedUponSettlementOfVendorPayable",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CommonWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Warrants [Member]",
        "label": "Common Warrants [Member]"
       }
      }
     },
     "localname": "CommonWarrantsMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ConsultantEmployeesOfficersAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultant Employees Officers And Directors [Member]",
        "label": "Consultant Employees Officers And Directors [Member]"
       }
      }
     },
     "localname": "ConsultantEmployeesOfficersAndDirectorsMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants [Member]",
        "label": "Consultants [Member]"
       }
      }
     },
     "localname": "ConsultantsMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Note [Member]",
        "label": "Convertible Note [Member]"
       }
      }
     },
     "localname": "ConvertibleNoteMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ConvertibleNotePayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Note Payable [Member]",
        "label": "Convertible Note Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotePayableMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ConvertibleNotesPayableIssuedForConsultingServices": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes payable issued for consulting services.",
        "label": "Convertible notes payable issued for consulting services"
       }
      }
     },
     "localname": "ConvertibleNotesPayableIssuedForConsultingServices",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CorporateNotesAndCommercialPaperMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Notes and Commercial Paper [Member]",
        "label": "Corporate Notes and Commercial Paper [Member]"
       }
      }
     },
     "localname": "CorporateNotesAndCommercialPaperMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_CummulativeGrossSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cummulative gross sales.",
        "label": "Cumulative gross sales"
       }
      }
     },
     "localname": "CummulativeGrossSales",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability fair value assumptions expected term 1.",
        "label": "Expected life (in years)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "GTBP_DisclosureDerivativeLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "verboseLabel": "Schedule Of Derivative Liability Transactions"
       }
      }
     },
     "localname": "DisclosureDerivativeLiabilityAbstract",
     "nsuri": "http://gtbiopharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "GTBP_DisclosureOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases",
        "terseLabel": "Schedule Of Supplemental Leases",
        "verboseLabel": "Schedule Of Components Leases Rent Expenses"
       }
      }
     },
     "localname": "DisclosureOperatingLeasesAbstract",
     "nsuri": "http://gtbiopharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "GTBP_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_EmploymentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Agreements [Member]",
        "label": "Employment Agreements [Member]"
       }
      }
     },
     "localname": "EmploymentAgreementsMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ExtinguishmentOfDerivativeLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment of derivative liability.",
        "label": "Extinguishment of derivative liabilities"
       }
      }
     },
     "localname": "ExtinguishmentOfDerivativeLiability",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06.",
        "label": "Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06"
       }
      }
     },
     "localname": "ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ExtinguishmentOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment of warrants.",
        "label": "Extinguishment"
       }
      }
     },
     "localname": "ExtinguishmentOfWarrants",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_FairValueOfCommonStockIssuedToNoteholderAsSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock issued to note holder as settlement.",
        "label": "FairValueOfCommonStockIssuedToNoteholderAsSettlement",
        "negatedLabel": "Fair value of common stock issued to a noteholder as settlement"
       }
      }
     },
     "localname": "FairValueOfCommonStockIssuedToNoteholderAsSettlement",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_FiscalTwentyNinteenandTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal Twenty Ninteen And Twenty Twenty [Member]",
        "label": "Fiscal 2019 and 2020 [Member]"
       }
      }
     },
     "localname": "FiscalTwentyNinteenandTwentyTwentyMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_GrossSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross sales.",
        "label": "Gross sales"
       }
      }
     },
     "localname": "GrossSales",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_IncreaseDecreaseInDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in deposit.",
        "label": "IncreaseDecreaseInDeposit",
        "negatedLabel": "(Increase) in deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeposit",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in prepaid expense and other current assets.",
        "label": "IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets",
        "negatedLabel": "Decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_InstitutionalInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Institutional Investor [Member]",
        "label": "Institutional Investor [Member]"
       }
      }
     },
     "localname": "InstitutionalInvestorMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_InvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors [Member]",
        "label": "Investors [Member]"
       }
      }
     },
     "localname": "InvestorsMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_IssuanceOfCommonStockAsEquityCompensationToConsultants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock as equity compensation to consultants.",
        "label": "Issuance of common stock as equity compensation to consultants"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAsEquityCompensationToConsultants",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_JanuaryTwentyTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January twenty twenty one member.",
        "label": "January 2021 [Member]"
       }
      }
     },
     "localname": "JanuaryTwentyTwentyOneMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_LicenseMaintenanceFeeReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fee, receivable.",
        "label": "License maintenance fee, receivable"
       }
      }
     },
     "localname": "LicenseMaintenanceFeeReceivable",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity [Policy Text Block]",
        "label": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "GTBP_LongtermRightofuseAssetsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term right of use assets net.",
        "label": "Long-term right-of-use assets, net"
       }
      }
     },
     "localname": "LongtermRightofuseAssetsNet",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_NoteHolderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Holder [Member]",
        "label": "Note Holder [Member]"
       }
      }
     },
     "localname": "NoteHolderMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_NotesPayableForUnpaidConsultingFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes payable for unpaid consulting fee.",
        "label": "Notes payable for unpaid consulting fee"
       }
      }
     },
     "localname": "NotesPayableForUnpaidConsultingFee",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_NotesPayableIssuedForCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payables Issued For Cash [Member]",
        "label": "Notes Payables Issued For Cash [Member]"
       }
      }
     },
     "localname": "NotesPayableIssuedForCashMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_NotesPayableIssuedForConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes payables issued for consulting agreement member.",
        "label": "Notes Payable Issued For Consulting Agreement [Member]"
       }
      }
     },
     "localname": "NotesPayableIssuedForConsultingAgreementMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_NotesPayableIssuedForForbearanceAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable Issued For Forbearance Agreements [Member]",
        "label": "Notes Payable Issued For Forbearance Agreements [Member]"
       }
      }
     },
     "localname": "NotesPayableIssuedForForbearanceAgreementsMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_NotesPayableIssuedForSettlementAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable Issued For Settlement Agreements [Member]",
        "label": "Notes Payable Issued For Settlement Agreements [Member]"
       }
      }
     },
     "localname": "NotesPayableIssuedForSettlementAgreementsMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_OfficersAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers and Directors [Member]",
        "label": "Officers and Directors [Member]"
       }
      }
     },
     "localname": "OfficersAndDirectorsMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_OfficersEmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers Employees and Directors [Member]",
        "label": "Officers Employees and Directors [Member]"
       }
      }
     },
     "localname": "OfficersEmployeesAndDirectorsMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to Purchase Common Stock [Member]",
        "label": "Options to Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_OwnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Owners [Member]",
        "label": "Owners [Member]"
       }
      }
     },
     "localname": "OwnersMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_PaymentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Agreement [Member]",
        "label": "Payment Agreement [Member]"
       }
      }
     },
     "localname": "PaymentAgreementMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_PerformanceMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance milestone payments.",
        "label": "Performance milestone payments"
       }
      }
     },
     "localname": "PerformanceMilestonePayments",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrants [Member]",
        "label": "Pre Funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ProceedsFromUpfrontAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Received upfront payment.",
        "label": "Proceeds from upfront amount"
       }
      }
     },
     "localname": "ProceedsFromUpfrontAmount",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ProjectFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Project fee.",
        "label": "Project fee"
       }
      }
     },
     "localname": "ProjectFee",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ProjectFeeIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Project fee incurred.",
        "label": "Project fee incurred"
       }
      }
     },
     "localname": "ProjectFeeIncurred",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement [Member]",
        "label": "Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ResearchAndDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Agreement [Member]",
        "label": "Research And Development Agreement [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAgreementMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_RightofuseAssetsExchangedForLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use assets exchanged for lease liabilities.",
        "label": "Right-of-use assets exchanged for lease liabilities"
       }
      }
     },
     "localname": "RightofuseAssetsExchangedForLeaseLiabilities",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_RoyaltyFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty fee percentage.",
        "label": "Net sales percentage"
       }
      }
     },
     "localname": "RoyaltyFeePercentage",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "GTBP_SalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone payments.",
        "label": "Sales milestone payments"
       }
      }
     },
     "localname": "SalesMilestonePayments",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_SalesRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales revenue.",
        "label": "Sales revenue"
       }
      }
     },
     "localname": "SalesRevenue",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Company\u2019s Future Financial Commitment [Table Text Block]",
        "label": "Schedule of Company\u2019s Future Financial Commitment"
       }
      }
     },
     "localname": "ScheduleOfCompanysFutureFinancialCommitmentTableTextBlock",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Information Related Leases UnderN On Cancellable [Table Text Block]",
        "label": "Schedule of Components Leases Rent Expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "GTBP_ScheduleOfSupplementalLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Supplemental Lease [Table Text Block]",
        "label": "Schedule of Supplemental Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalLeaseTableTextBlock",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "GTBP_ScientificResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific Research Agreement [Member]",
        "label": "Scientific Research Agreement [Member]"
       }
      }
     },
     "localname": "ScientificResearchAgreementMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_SeriesJOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series J One Preferred Stock [Member]",
        "label": "Series J One Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesJOnePreferredStockMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_SeriesJPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series J Preferred Stock [Member]",
        "label": "Series J Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesJPreferredStockMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_SeriesKPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series K Preferred Stock [Member]",
        "label": "Series K Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesKPreferredStockMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_SeriesKPreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series K Preferred Stocks [Member]",
        "label": "Series K Preferred Stocks [Member]"
       }
      }
     },
     "localname": "SeriesKPreferredStocksMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Agreement [Member]",
        "label": "Service Agreement [Member]"
       }
      }
     },
     "localname": "ServiceAgreementMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised.",
        "label": "Warrant exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.",
        "label": "Warrants exercisable, ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.",
        "label": "Exercisable, ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, beginning balance",
        "periodStartLabel": "Weighted average exercise price, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised",
        "label": "Number of options outstanding, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to unvest outstanding aggregate intrinsic value.",
        "label": "Share based compensation unvested intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangements By Share Based Paymen tAward Non Options Exercises In Period Weighted Average Exercise Price.",
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "GTBP_SharesIssuedDuringPeriodSharesAccruedInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for accrued interest.",
        "label": "Number of shares issued for accrued interest"
       }
      }
     },
     "localname": "SharesIssuedDuringPeriodSharesAccruedInterest",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_SharesIssuedDuringPeriodValueAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued during period value accrued interest.",
        "label": "Total accrued interest"
       }
      }
     },
     "localname": "SharesIssuedDuringPeriodValueAccruedInterest",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_SheffieldPropertiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sheffield Properties [Member]",
        "label": "Sheffield Properties [Member]"
       }
      }
     },
     "localname": "SheffieldPropertiesMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation consultants and research and development.",
        "label": "Stock based compensation \u2013 consultants and research and development"
       }
      }
     },
     "localname": "StockBasedCompensationConsultantsAndResearchAndDevelopment",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation officers employees and board of directors.",
        "label": "Stock based compensation - officers, employees and board of directors"
       }
      }
     },
     "localname": "StockBasedCompensationOfficersEmployeesAndBoardOfDirectors",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockBasedCompensationVestedStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation vested stock options.",
        "label": "Stock based compensation - vested stock options"
       }
      }
     },
     "localname": "StockBasedCompensationVestedStockOptions",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for research and development agreement, shares.",
        "label": "Issuance of common stock for research and development agreement, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesCancellation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares cancellation",
        "label": "Cancellation of common stock previously issued for services, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCancellation",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares cancellation of common stock previously issued.",
        "label": "Cancellation of common stock previously issued to prior CEO, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares common sharesIn settlement of vendors payable.",
        "label": "Issuance of common shares in settlement of vendors payable, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares issued upon exercise of warrants, shares.",
        "label": "Common shares issued upon exercise of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares issued upon mandatory conversion of notes payable and accrued interest, shares.",
        "label": "Common shares issued upon mandatory conversion of notes payable and accrued interest, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesEquityCompensationToConsultants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity compensation to consultants, shares.",
        "label": "Equity compensation to consultants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEquityCompensationToConsultants",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in public offering, net of cost, shares.",
        "label": "Issuance of common stock in public offering, net of cost, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueCancellation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value cancellation",
        "label": "Cancellation of common stock previously issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCancellation",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value cancellation of common stock previously issued.",
        "label": "Cancellation of common stock previously issued to prior CEO"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Common Shares In Settlement Of Vendors Payable",
        "label": "Issuance of common stock in settlement of vendor payable"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares issued upon exercise of warrants.",
        "label": "Common shares issued upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares issued upon mandatory conversion of notes payable and accrued interest.",
        "label": "Common shares issued upon mandatory conversion of notes payable and accrued interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueEquityCompensationToConsultants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity compensation to consultants.",
        "label": "StockIssuedDuringPeriodValueEquityCompensationToConsultants",
        "verboseLabel": "Issuance of common stock as equity compensation to consultants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEquityCompensationToConsultants",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for research and development agreement.",
        "label": "Issuance of common stock for research and development agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in public offering, net of cost.",
        "label": "Issuance of common stock in public offering, net of cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ThirdPartyManufacturerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Party Manufacturer [Member]",
        "label": "Third Party Manufacturer [Member]"
       }
      }
     },
     "localname": "ThirdPartyManufacturerMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_TwoEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Employees [Member]",
        "label": "Two Employees [Member]"
       }
      }
     },
     "localname": "TwoEmployeesMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Patent License Agreement [Member]",
        "label": "2021 Patent License Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOnePatentLicenseAgreementMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_TwoThousandSixteenPatentLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016  Patent License Agreement [Member]",
        "label": "2016 Patent Exclusive License Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandSixteenPatentLicenseAgreementMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_UnrealizedLossOnMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized loss on marketable securities.",
        "label": "UnrealizedLossOnMarketableSecurities",
        "negatedLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "UnrealizedLossOnMarketableSecurities",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_UnusualRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unusual Risks and Uncertainties [Policy Text Block]",
        "label": "COVID-19"
       }
      }
     },
     "localname": "UnusualRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "GTBP_UpfrontLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fee.",
        "label": "Upfront license fee"
       }
      }
     },
     "localname": "UpfrontLicenseFee",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock [Member]",
        "label": "Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://gtbiopharma.com/20221231",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r553",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r553",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r553",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r553",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r319",
      "r468",
      "r488",
      "r517",
      "r518",
      "r531",
      "r535",
      "r540",
      "r593",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r319",
      "r468",
      "r488",
      "r517",
      "r518",
      "r531",
      "r535",
      "r540",
      "r593",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r311",
      "r319",
      "r342",
      "r343",
      "r344",
      "r444",
      "r468",
      "r488",
      "r517",
      "r518",
      "r531",
      "r535",
      "r540",
      "r587",
      "r593",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r311",
      "r319",
      "r342",
      "r343",
      "r344",
      "r444",
      "r468",
      "r488",
      "r517",
      "r518",
      "r531",
      "r535",
      "r540",
      "r587",
      "r593",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r581",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r539"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable",
        "totalLabel": "Total accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r120",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable [Default Label]",
        "verboseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Other accounts payable"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r11",
      "r111",
      "r112",
      "r576"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable to a third-party manufacturer"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses",
        "verboseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r157",
      "r158",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r539"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid in capital, common stock"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r577",
      "r578",
      "r579",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r174",
      "r175",
      "r176",
      "r177",
      "r186",
      "r225",
      "r226",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r347",
      "r348",
      "r349",
      "r357",
      "r358",
      "r359",
      "r360",
      "r367",
      "r368",
      "r369",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r409",
      "r410",
      "r413",
      "r414",
      "r415",
      "r416",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r470",
      "r471",
      "r472",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r61",
      "r64",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Extinguishment of debt discount upon adoption of ASU 2020-06"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": {
     "auth_ref": [
      "r61",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.",
        "label": "Fair value of vested stock options",
        "verboseLabel": "Adjustments to additional paid in capital, fair value"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Extinguishment of derivative liability"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r61",
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Decrease to additional paid-in capital",
        "verboseLabel": "Adjustment to additional paid in capital, stock issued, issuance cost"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based payment arrangement, expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r114",
      "r126",
      "r148",
      "r167",
      "r207",
      "r216",
      "r220",
      "r231",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r370",
      "r372",
      "r393",
      "r539",
      "r591",
      "r592",
      "r637"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r145",
      "r152",
      "r167",
      "r231",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r370",
      "r372",
      "r393",
      "r539",
      "r591",
      "r592",
      "r637"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r227",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "negatedLabel": "Unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37",
      "r147",
      "r520"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash Equivalents and Short-Term Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r32",
      "r37",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash at End of Period",
        "periodStartLabel": "Cash at Beginning of Period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r32",
      "r105"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (Decrease) Increase in Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "FDIC amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r167",
      "r188",
      "r189",
      "r191",
      "r193",
      "r197",
      "r198",
      "r231",
      "r256",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r293",
      "r294",
      "r297",
      "r301",
      "r308",
      "r393",
      "r519",
      "r562",
      "r573",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price per share",
        "verboseLabel": "Warrants exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Common stock exercise warrants",
        "verboseLabel": "Warrants purchase of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r53",
      "r249",
      "r250",
      "r516",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock, capital shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r577",
      "r578",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value",
        "verboseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common stock shares, unissued"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r539"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, par value $0.001, 250,000,000 shares authorized, 32,722,452 shares and 32,061,989 shares issued and outstanding as of December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r123",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Series J Preferred Stock to Common Stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r3",
      "r116",
      "r127",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Outstanding balance"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostMaintenance": {
     "auth_ref": [
      "r568"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered.",
        "label": "Maintenance fee"
       }
      }
     },
     "localname": "CostMaintenance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt conversion converted instrument amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Converted shares",
        "verboseLabel": "Debt conversion, converted instrument, shares issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r165",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r281",
      "r288",
      "r289",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Convertible Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r115",
      "r116",
      "r124",
      "r170",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r412",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "Debt instrument, convertible, beneficial conversion feature"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r56",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Conversion rate",
        "verboseLabel": "Debt instrument, convertible, conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r107",
      "r109",
      "r265",
      "r412",
      "r527",
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Principal amount",
        "verboseLabel": "Debt face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Debt instrument, increase, accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r18",
      "r170",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r412",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r106",
      "r109",
      "r594"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Unrealized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Schedule of Estimated Fair Value of Financial Instrument"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Intellectual property"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets before valuation"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r83",
      "r625"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Federal net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r83",
      "r625"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Stock based compensation and other items"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r563"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r22",
      "r90",
      "r113",
      "r153",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "verboseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r628"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "Net gain"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain from derivative.",
        "label": "Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative liability",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DerivativesAndFairValueTextBlock": {
     "auth_ref": [
      "r92",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.",
        "label": "Derivatives and Fair Value [Text Block]",
        "verboseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativesAndFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/DerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r89",
      "r91",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r162",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r187",
      "r188",
      "r191",
      "r192",
      "r193",
      "r195",
      "r386",
      "r387",
      "r485",
      "r487",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net Loss Per Share - Basic and Diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r168",
      "r350",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r623",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance on net operating loss carryforwards"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/IncomeTaxDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r623",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r61",
      "r141",
      "r157",
      "r158",
      "r159",
      "r171",
      "r172",
      "r173",
      "r175",
      "r183",
      "r185",
      "r196",
      "r235",
      "r310",
      "r347",
      "r348",
      "r349",
      "r359",
      "r360",
      "r385",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r432",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r35",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Schedule of Fair Value Hierarchy Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Schedule of Derivative Liabilities Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/DerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r279",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r389",
      "r441",
      "r442",
      "r443",
      "r527",
      "r528",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r279",
      "r312",
      "r317",
      "r389",
      "r441",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r279",
      "r312",
      "r317",
      "r389",
      "r442",
      "r527",
      "r528",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r279",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r389",
      "r443",
      "r527",
      "r528",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis.",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r279",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r441",
      "r442",
      "r443",
      "r527",
      "r528",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Total financial assets"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]"
       }
      }
     },
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r290",
      "r306",
      "r375",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r525",
      "r583",
      "r584",
      "r585",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r35",
      "r57",
      "r58"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain from extinguishment of line of credit"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r351",
      "r352",
      "r355",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/IncomeTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r570"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Change in fair value"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase in accrued interest"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r570",
      "r633"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Decrease in operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "(Decrease) increase in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r108",
      "r122",
      "r160",
      "r206",
      "r411"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r28",
      "r285",
      "r292",
      "r529",
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest expense due to amortization of debt discount"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and cash"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Addition"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Maturity Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest/present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingSubleaseOptionToExtend": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend operating sublease.",
        "label": "Commencement date"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r167",
      "r231",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r371",
      "r372",
      "r373",
      "r393",
      "r523",
      "r591",
      "r637",
      "r638"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r117",
      "r130",
      "r539",
      "r575",
      "r586",
      "r632"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r146",
      "r167",
      "r231",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r371",
      "r372",
      "r373",
      "r393",
      "r539",
      "r591",
      "r637",
      "r638"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r1",
      "r115"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of credit"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation settlement expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r54",
      "r55",
      "r251",
      "r252",
      "r253",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash (Used in) Provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Provided by (Used in) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r32",
      "r33",
      "r36"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Cash in Operating activities",
        "totalLabel": "Net Cash Used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r36",
      "r121",
      "r134",
      "r144",
      "r155",
      "r156",
      "r159",
      "r167",
      "r174",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r190",
      "r207",
      "r215",
      "r219",
      "r221",
      "r231",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r387",
      "r393",
      "r524",
      "r591"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total Other (Income) Expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (Income) Expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r3",
      "r116",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Total, notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "verboseLabel": "Outstanding balance"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r110",
      "r133",
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties.",
        "label": "Notes payable, related parties"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r207",
      "r215",
      "r219",
      "r221",
      "r524"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfMaturityLeaseLiabilitiesDetails",
      "http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liability, current",
        "verboseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Non-current operating lease liability",
        "verboseLabel": "Non-current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfSupplementalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r419",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease, right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Change in operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r424",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r423",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfComponentsLeasesRentExpensesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/IncomeTaxDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.",
        "label": "Operating Loss Carryforwards, Expiration Date"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/IncomeTaxDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r44",
      "r50",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization and Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherCommitment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "OtherCommitmentDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherCommitment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "OtherCommitmentDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfCompanysFutureFinancialCommitmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.",
        "label": "Payments for (Proceeds from) Investments",
        "negatedLabel": "Sales (purchases) of investments"
       }
      }
     },
     "localname": "PaymentsForProceedsFromInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Placement agent fees and other offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of preferred stock.",
        "label": "Convertible shares issuable"
       }
      }
     },
     "localname": "PreferredStockConvertibleSharesIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r539"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r567"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock",
        "verboseLabel": "Gross proceeds from common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfMediumTermNotes": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.",
        "label": "Proceeds from issuance of notes payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Warrants cash proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Cash on equity issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from notes payable in cash"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Legal and professional expenses"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r318",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r318",
      "r433",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r79",
      "r138",
      "r645"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development (including $718 and $0 of stock compensation to officers, directors and employees during the years ended December 31, 2022 and 2021, respectively)",
        "terseLabel": "Research and development expense",
        "verboseLabel": "Reserach and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r64",
      "r129",
      "r495",
      "r500",
      "r539"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r141",
      "r171",
      "r172",
      "r173",
      "r175",
      "r183",
      "r185",
      "r235",
      "r347",
      "r348",
      "r349",
      "r359",
      "r360",
      "r385",
      "r491",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r161",
      "r167",
      "r204",
      "r205",
      "r214",
      "r217",
      "r218",
      "r222",
      "r223",
      "r224",
      "r231",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r393",
      "r486",
      "r591"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Annual royalty payments"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Shares and warrants sold price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Anti-dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Net Deferred Income Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liability Transactions"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/DerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Income Tax Provision"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "auth_ref": [
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.",
        "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r70",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative (including $3,903 and $17,234 of stock compensation to officers, directors and employees during the years ended December 31, 2022 and 2021, respectively)"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r564",
      "r565",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Non-cash stock compensation",
        "verboseLabel": "Share-Based Payment Arrangement, Noncash Expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.",
        "label": "Weighted average exercise price, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Non- vested number of shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Number of warrants, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "negatedLabel": "Number of warrants, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of warrants, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Warrants outstanding, beginning balance",
        "periodStartLabel": "Warrants outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of options outstanding, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted-Average Exercise Price, Ending",
        "verboseLabel": "Stock options exercisable price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Fair value of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share based compensation cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Number of options outstanding, Granted",
        "verboseLabel": "Stock option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Stock option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Fair value of stock option, per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Options outstanding intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options outstanding outstanding, Ending",
        "periodStartLabel": "Number of options outstanding, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Ending",
        "periodStartLabel": "Weighted-Average Exercise Price, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted-Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted-Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted-Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Number of options, Forfeited",
        "negatedLabel": "Number of options outstanding, Forfeited",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based compensation arrangement by share-based payment award, options, vested in period, fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Share issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r118",
      "r119",
      "r125",
      "r566"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r44",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r167",
      "r188",
      "r189",
      "r191",
      "r193",
      "r197",
      "r198",
      "r231",
      "r256",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r293",
      "r294",
      "r297",
      "r301",
      "r308",
      "r393",
      "r519",
      "r562",
      "r573",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r61",
      "r141",
      "r157",
      "r158",
      "r159",
      "r171",
      "r172",
      "r173",
      "r175",
      "r183",
      "r185",
      "r196",
      "r235",
      "r310",
      "r347",
      "r348",
      "r349",
      "r359",
      "r360",
      "r385",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r432",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r196",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Common stock issued upon conversion of notes payable and accrued interest"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r20",
      "r61",
      "r62",
      "r64",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Common stock issued upon conversion of notes payable, shares",
        "verboseLabel": "Common shares issued upon conversion of notes payable, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Equity compensation to officers, employees, and board of directors, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Number of shares issued for service"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r61",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Conversion of Preferred Series J-1 to common stock, shares",
        "terseLabel": "Fair value",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r21",
      "r61",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Common stock issued upon conversion of notes payable"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Issuance of common stock as equity compensation to officers, employees, and board of directors"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r61",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Conversion of Preferred Series J-1 to common stock",
        "terseLabel": "Common stock value issued during the period",
        "verboseLabel": "Stock issued during period, value, new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock repurchase program, remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Remaining number of common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r4",
      "r5",
      "r61",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Number of shares received"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r51",
      "r539",
      "r575",
      "r586",
      "r632"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r166",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r310",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' equity, reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r408",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r408",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r408",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r408",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r435",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r290",
      "r306",
      "r375",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r583",
      "r584",
      "r585",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r174",
      "r175",
      "r176",
      "r177",
      "r186",
      "r225",
      "r226",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r347",
      "r348",
      "r349",
      "r357",
      "r358",
      "r359",
      "r360",
      "r367",
      "r368",
      "r369",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r409",
      "r410",
      "r413",
      "r414",
      "r415",
      "r416",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r470",
      "r471",
      "r472",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r199",
      "r200",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Accounting Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r187",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e34017-109320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r543": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r544": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r545": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r546": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r547": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r548": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r549": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r551": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r552": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r553": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r554": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r555": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r556": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r557": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r558": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r559": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r561": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001493152-23-009812-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-009812-xbrl.zip
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M%!&QO7'(..$!(Q&D!VQ?G8MD PX-:+RB$BPSFZ"=@<<*-G4M%#)3<D=)5N%
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MV _3 (P(-EYC1 ]T+E6X8%.0*04#"A)AN&1[AR,C6KU1/Z)*(*ETCU*D(1*
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MM<ZL4F^Z'BO^&["J]/(O]S8P>FG8?P%02P,$%     @ (8A^5CK#;$ ]!
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MY\VZ<6?FL>_^AM1<$YOKX>R^V%PK_P502P,$%     @ (8A^5E5<<]= !
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MAEG2BEZV0K%]LL@&?.5]83+8XIU_(CF+F885EC-=/\>[/)>F[(D_BHJ& WX
M17+*O#1*TN1 Q7R>PLK&J0+&%=?:PIJ(;\<*R,0WX0>OYHMLX)6)YT"QSH6:
M3$ ZQ,04F2A!3G?*8@=_OA"WK[S;@1?A*VV X%(#)Y<@U2;<^$39V.@Y3?K%
MS6\+<N_PY<E6]VQ*]QR]ZU?EK##P6=+M#.1<ES+=:O_-D7U>&3C?]1Z(F+=
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MT#$ *E 0<8XC=@KPU]JE. 67PAWB<&LD+/M/ "ME[=:%W&F6QNL)CPII+'@
MV(&X!KZH2G1N!$QAJJQ6B27X&U;66G%<69W#ZGGC&\7'7G&;%/@.J9@7"UB8
M4;"C%D,I\%K)/F:F%#V!&T@NF9\=G!HKIBI7ADZK47"N#--= A^%HX<]Z@<X
M6EO M#G ]#N[JG:+E39'-H6N&*D*SW_0C1@;05V8H%(*(E(3#(K@Z7"*@55U
M\STK&CQU\\K$,VD5 :P:4MU4F"5&48R.@0PXLQ@@*\3?]WO@+ 6^3X@Q$N0"
MF5U4H=K&%2A7IT(C"J]IT.=.2>R_W86!>EDO(I[\49A/8H *!X,D$6(TTO1Z
M4H(JR7.-YDB:)=E?_";QZ@&8(<'N]03:0]+""U!<J%,?F6NWH-B:;:+AVIO>
M3S_N/Q;;0$J^S#=Q*]L"F%(S#.VO^JQ,K*UB];[P7Z$.]L8PEG:6@@%QQ@P0
MK 2GFC&N"X A#&9^.@5.84!:K0MR-O!MH8%F,"SS (85,(HA=!#""W<LR'\#
M8 F_UM1BI)4H=HLAP$H?$&)E"".G4R *69%7V1CMSN06SY\9A=1I-XQ?=, @
MLKSC8,.??W[1[1"[]<3A,OB^7"C B,_U"Q<"<%OR &+0D/N I_(K1$:.%?+(
M4P3"(_&_Z.-2I%$A9$-C#=(@I\K)YUKQ1?##,L>'A:0)3DF52D!T)?X.N^29
MX4G (_1<P\H(*ZQ=7;?S]9?'GHC?!UX5 ?$Z !LY3P=1@WB^=-MRYRNL258>
M(;QX;UE9%<EP/72ZX*@H=_*9S0AZ)/[4)JXR1'TQ&@<.@U/J8L7MDFY.[\A%
M,!^<,?" 05O >:\=/'8@P)/D^)?^E_0.1F&F,O=_=SN9,E-<'GD;X,XY[X?9
MT5(-8Q7N!4+U%/7,DNF"0^VDJ^: #WDWHK["WN> PZN,,#QX13>/&&A>F!5V
MB;QZ9-FCZAA2[7<JF9;XO\"1*HN'!P<&\,J;VM9#ZQ1M4A!]Y Z&OI4)/#@B
MYE87#I$[.%L.G[OW*[!F*0X8J''.*]0S<U*&XQ3KQ1G\J]J?]N:":+E%^N\4
M^H@C.,Z>+K13F/<(]ZR$=SAX ]+*T1N7&L,7Z3N0QE;<YLG!OK5H%0C_V\Z.
M>*^!%V_%!:CP QC@KPH-"[PH=G9<_<WA\<EOG@RF>V=<E&61O15OYN6!& ,+
ME:D_.THE;-RKWCXLC4X\K&34/SH=BL'P]/2B?WQ\<O;A'\]VG]'?5Q?]@?_;
MS>'&BXLTE7,+M/C?#F"/DW*&J]K];IU3,;KT8URCOQ?+U#.U+.9M+J=J0F\<
M^S>"H1N&C8ZQZN@2_X,K@)_ BS5L&1LE/^V,%8@94#,G7CI6P<S$)YCLHLU%
MVOUFKHOVZ,'>O,3-X?WX"M+V1(N4'L<)O6ABD]O _7\BF4;19\JNUUFUB PJ
M!J)=& ?T+ZK]4 ='J*/71?.J.7YS=^;,(ZN<[$,!5&0%1BTIME@'H^?2EH1E
MF<09A_!XPL0'(E-5LE/7AW=,44UGXI\--8F?G8!689LYSO.T%>YU",$!,C=X
M,-V S;D?C@>GH',8'3ZOJ8T!R$ST9S3Z,O4&]WZ!70K -EQCJ\D$>6" OAZ8
M>_1,.*B&T4H,TF> !DLN=S!4G@% S'W9H,Z5-$%T,Q =.>C1[?B_ZSJ:)H0=
MW19.KY'A#6Q=!S+)\15Q"@@1*?6[,@I0R;I<*PQ0I2"?'%>\!5[#1%5:-M(E
M2+@<=&G*AEPPW,%-^_;)'=_U6J>Q]*%E7[7\#UY:R_#?"A">D?$,8,#])U@#
M&)YY4]R A <3O-O;V]?Y([)]=/QM4OD_/[_Y\>>O0^;7I"M1,4 U2[H%R>&T
MA/FDRMOC%^$B" U^(T+VC4K5_P<QJDV;EZ,F*U_D-P3H8"M!6PE:540ZK<J6
M&FIE0]>HH:T4;:5HE2Z=S:4V+3$*07%357%#F "8;N5I*T\WX%$JE[4X4<28
MD@/.7^*. G1YX$534 U496MW?5(9*H%JW'8J%E\;.FW)G(NN/5VOYYLG.XBU
M4)P\HRJ9?%DGYEAAE(4+HW"+!WO-=6(,??X_JV3J\\H88,?:0@!#U%:"J*CQ
MOE<^]JT#_WV!]&^?[,.3=U<4XNAV!J(.>0H7\=PV<&R*[/<8:Y2^'B-HMVFU
MB?%6B1L[%0FKE#C#=-:/_NS)*M$8'YS "<YC3:T(+D\)=."^!^?-=7^*(2"$
M<HD;'V'(T9?"^=R\QA1B7-$I'V-QG0NL;8_K!OM\PI+0;F==3:BX1TGH-IVQ
M.;('' [N=O[/37]D5%WC'X7?P=8VY<UU3<D+@F$8@0YFI&IG"E-W.W4%@.L;
MQ/)_!_ B^ UUBZN11HU$O8P$]'*N9,=NQR4W&\H8"VSQRQ;RHXBY#=L<(U^H
M:WP_*?>JN<(S+/181U4X?5Q@MA^?\171<X.(TD?V0=,E6!15!D^,=;*&&*)"
MIM9GBE1"^HX61@FDNH,3R^@LO@$:]A,2@35TM&:U@G7ABXDV@&QR-06'':F@
M\H\Z4=03OR/V2;6B9<)N,!C*U40S#((-QQ@DL@5H+9N.$AQC#A]P-P6W$2QQ
MQI6Y)%8V3\!(Y F6NQOX"Q/M,5D"1S:6/9=4H\4E>MK*Y%J"N+@L3\ARM$E
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M",]?B0!_7P[=.GA&NK64W<X/RH>+DW!?]H)G!.C#9Z3'(_=[X7JWPA>Z9W2
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MIZDI^#U@":HJOML5"3Y%L(ZF1.2)*?R$@[)M,HTGQXHP'6A-CB(YBLPGZ$D
M0]@V+9/ZV".H&7H(T(?:B6]YI$"CQT :\,D@3/S0)8-U+VJ6(4U"TJ@.V$"F
M<YDK#\]:WB@LD%R-^0-*F[$QB=5O6[HCY!N :K;>%"#_N9[T':#8E_1 .:+-
MCB#$8.G+1\. ;;L/B,YLSB;$5HL C)5DP\GU_!R/YF,UL3N& D'@U1#H="!E
MHH0TB%R#<8Y5^A&"3A(7"9L4,A2Q:;70_N8ZA:H5MNFBEI0THP&>V 'FH@9B
M8"4^5GWK1TR/\%2ABO0#&4,B&ADNT!<H;6BFZ.*\RLHF5YVC3(XR<Z&,AQ!'
MY@7+,\F_*M$#G;V(!L W(FV"Q*\!Y2DM,B6P9E>KMZ0'-#TXHPHZB5&Q(6>X
M1%_=0ZMSJ)B4LDZ@5]X,V>SA,2*P_9FD/=U$KW%LI\.Q08@D=@G[F"+VN5[:
M:2)EQ9$[HOVG+'N,NTT2<'TTO+ GMZ-[W=S]DN/BC(L][X%4U[4,"7L8YN#0
M%X@+%,OG<TB%[FNGU[_7SXKE8VW;<#W7T>\M+_1W"AJPF=!#/+%\W<=,6F0O
M@@1#EX,92)@$8.TC"F/8@690&<<"")BACSCV('1\02*C"O9 +4AXGNM9?H#6
M04:#GHN<%.D !Z44E+QI^5X()QJA"-MDE'38 9Z(+)#LAX-F&,0N7,"#15$3
M%*VB:(,N@U;@O3@@!>1=*FL&8F6.;#FRS;38!@8'*3G-!]HM0%"+3(J]L&D#
MWG7C!AJ#(39:0;DO)1_#T* 8UQRA/:!]('+9DZ!YCVH;AC3I)JA!B'NV]7=H
MF>C,Y+5<A!X.@'%N%, $2,&Q;!SK,VHE!153AJ*F07J6>DFN7RZ"+?3 I>Y=
MM+?8[(!-\BXTIO Z8+T/N-B6'2+C9:\!("Z@6M'OH"V'P[QR=,O1;9;%?A#$
M=V*Q*H5+$BXQ> Z03U>!FSWA.'T5L2EA?53@:7HPB0U-$856PI@=J]TI8M@=
MPCRO(F&,9#Q16A:P*6!%G+\_!L 7D&V1P5#HMZGP_0EI'-4\C6/A:1R9/(6E
MI)O$,+KHS)7%X><"47)9:\Q8\@L/9IF_;G'_M')T"YAWOKE17Q"I'-Y(GK;T
M<S=W6OO:J%]?4>;2U76C?GJNW9Y_K-V>U:\^:A?7M]_@8_'+]?5G_/NN46N<
M7YY?-3*4V/1R][D4Q<SR-S=JG(1S.YR$4\#P4CLTV0^,241&R/DO<7 #R'[P
MD"H&2<8.3[0$Y])8#DA\E.F3FJ1 =D;= CU'BI\PY8/NF<4OKON#\GGBKBU*
M*)5A4)3;(G2'3!HMV!H)CUKEL*92=N(6B5K-H$"H\G&U6D!3CM[%@E!F01;4
MD:^6ST>\>O[(MAHXGVB0O>0@NUH-E$X_[B[#/L&@0Y<3?]N2P;UD=T&/!+GG
M1^];&]XVJJ&]T,,@+K@K5]EW2</UV5847Q(946W=26<4%>CRX(V_9,5N_#4*
M.T$UEU8>&WE +^_Z_%9Z)^3VP/$W-\AT1%*]=<_!<=VXY!PN6CI-DGE- P,"
M$!C"<UCEEF%J#@!OY/O'& %9]6CHY43NEYQ)P'ANET/LI!V-+'NQQ8KO?7A;
MNN^'W5XB,-7N*Y"7FT9YL.W"EWSKXZ]M<X-O [9"P&KY$=9P5IT.FKX>'28:
MN34TCY";UZ1'FCH>A(O*5]1!0-/O=<M6!O;0ET.0B1+'V-6^"=Z&T!PW$6F[
MN8'/]V@>W,_8E7,6&49D&# _G/?X/:J@$=#W**B1L1ZW@[YSW)GPNA9%Z/:5
M%75S0T(\T(R"@FWY%5IO!K]C;X,_^#4!W^"7<2C*T$] @# .6'T=K:(I;(ST
M&GH>H]JZHP;JN8$@7T/T X"6_$W%XR=_PM.(?/&!O&&%:IB.UNWI'%^0."P$
MK@!4ZG8'C5URC1Q:0+F(=";20 1$UF9_C"2*D^Z+J2WJYK 0;"'D822-[KL.
M+H$S!CVA[A4 "$')HSA8FIVS"Y/38Z) C!X3YB;3' 4O(.22I<##"GT2%]G5
M)/,@59H>1O8(+YFH)V/C9&307[QQ7 .!_ QGL*M=,)48D5N9,)@C5@&53=(L
MV (H=D3X)^'/4$RCY>"9JJ1@FB-$>H<WP>&1:>8JB3"'!C,/]81)^"M-+SU*
MW/6$+725%\*9L[Z&H2(FL<A!/H9/*5Y&?8@MZFLIN5?8Y""18.+&@L"SFB'I
MC+0>&:K2HV43A?4ITME@1P-0K@#-O!W=;G%^YR,M'>[Q;^PL2!2#;\SR-$0K
M#X,LF8;X"(84.DWQEXD+K,5)G?*4$&X!.E$,D7DT)E5_A+EU3RZ%$@^BE!IU
MRSJY\U4Z*B<C3$AAIOA/VQ</A":*L*=D&H":9/IR1B3$3(F[H+_4,7X>A0O7
MZV]N(#H ;&6H1D&F[JO1\9 7NF& B#Z(< .:"CEP@)5&*L7'AO;!<GL8&* /
M<O./C0\W0U*(&/PF')("@)@,B1()8I@D%_$;@[\2:4<.D5HAB%_&+K ;[4S8
M^@/2)Z54(8="01#%4ID5#\SH[*RNW="K!@518<SYY@8/<F;I;<?U,;0*&USR
MV+2JZT<XQKK#05)$2]7$@=MF?QHQ$:H6 ,S!,BV@I,GXVO4&J87AQXAU/KMM
M:80EK1)9TNJ-\\O-C?*N]N'K7?WJ_&Y1-IA5V'BFJ!R&A5'AC#@Z@Q/4FXHV
M* 2/9*X6:)121R0E<B"-/1E=Q>0#Q'0')' ;RV6$CEL$Q9NULTC5)J639!B5
M-09H3RUR&YY5Q,(CE+WV&:1YH!'G3AM6Z&G;\./G\_=^V,,[.=S#.X'/.Z#\
M4_-T&"= ?8.F98\)R'O\;I3%V4>30H 4CE-S!L>$JZ51U5-1ZHR?6F<BH-27
MB3^"\N/@#*.P&.%TI%9#V@Z(X]H/V!+)X%&D*NKB&JB35K(E/)#=S0T5\O.#
MCX$\/A2,??69_X =X/!-K$](&46.^JE !]MU8;4RT2^UR.3"HC<HZL?#<C<8
M,BAE6RL@&1S#'C T#VODJ.LA50D. R@Y9_SAX?M*_&: T:.GM:#?(W5='@3=
M#@Q)\4UH?& MBY?"@C-7XF%>*Z<!G0T>B([)Q("FW:$[Y!N,+ ?)G?- I (Y
M8;>)$1V@5(9=TC #"RZ;DGP[ M1!2OK%6!'$1E3CV'Y%'DLX%7PI&1NL4LC4
M9<9P#/@#""[1(V=N*[@9118QJ(T-FZ-A*B(>L?9+1A_2P9ND!491!^/)7U31
M(_ $E@K1/-*7T7@;P]WF1A+P&#T)]!A<92FI:#U8?0M0DBPL*H")HGG"() V
M3XS&%1SL8V-V$UM(E)E/A<MS$(8TZ&%))322FE[8UK;K5V<[:,DQ^S%I0?L.
M97$!,8"3!EJIZ:T _QFC_IBS)(MLCZ-_"45WM3OU"DV8B,R%CV0W(H36S7LD
M(J:R^ O)S"(-'(16LHJ11*]%UC1VAC==57")[A"CEF'5E$% ' \%4#1P*HO8
M>&CP\8ZD-8#2MSG.!'-<XAR:5E36":8HR$,GAHK1:2ZLH.LZ+O,3SHF#(X65
M-"T6FJ6(3-(RAB";:#=Q6T4L-";94"XRK^9F(F$+"X'-3EHHE7BH()"/0-,*
M[2@CA(B'RKYG!FJYP$M-8. @7T41Q? \%VE+O2"95(+U2JLZIU S[3*IUX]P
MC+[DT]N?ZK_O[&(E;ULD;?#(.XN>"-!/1%'*@+X^QE]N;J0CYZVN1 N:2N@V
MP#;#O($F8OF#[0(]O,>0+=J::=U;9H@AQ-%B"2E@,05IQ>,)!^4<3,1!861S
M@Y?OB9X-@@NA%<IJPNX!]IF8.$"FWC8^+'_4#>+FYO!1^'W']-!WL5VKG]WM
M<!ZK*Q/K6ASGB9&:CB_-G])P+5>Q"TJWW[."Z0=8B/>;/ 1XC#,>T%WE6A[)
MD+@%N%DXDF)*F&)N4]#"'KIG*--<">FCYI00!S0,^1-<"7K<V)V#]M\BL 9@
M&);?202EPIP1_ $-OT!9"E.U8G<$#KBY86+X76@$\8G WN-U:P/K[@)"@KSV
M0S"[8GZ'^QO/3MC+2Z28A3E0:QRR>;<\O8V@O[FQ?:$W=]C$KP/+=G73QBI%
M(5P8:#!L'P^LIFLJX9:8NISZW+F/U S:IOJ#6#I.EH#1T[.]?VL-):I/6;WE
MCY)3X87-C0?"-@!%$LEQ.5)FC[2)M$CNRHNQ^S' PT/#1SQ]49@B!$]??6;!
M&[=K6RWIKV#95P#[@GLE=WR""2(7 PSV7%S/ !SALM.0VBC&"_+);8*WYA/8
M&_3:YD;,QF$1(B*#$Y=/3T2SJS4+1%5'3P"B!$,D4&I)>%P1BDF0;/:QZB8I
M> HJY%5$*DDJH\^T=(GF"J:*?(GR!H#PP-#]P W<1Z N\-IV[>ST="?3W'QR
M!.G>.^V:G>-O<2(9-O%.^UVW0QSWM068CHHJ2X5;)@]3'>,[K0':]ENMY@$X
M&N^T*[TK^*BO7#S <BK^4KV%OV2F!GEN.5Q&+0/0LH@"/[C>CSB]1J:2"JFZ
M)'2L6$V^1/\_J&BG;/XY)5#69*S!5\?"9# I\%U:H$;Z;J!+5ZG.HIG>U6P2
M4S<WSKQ=[3?1:GFB#T^C=8Q=,F<"U-U^U)4/)"WX/S_ !;+A>[?M8.U,JNWF
M]F!#L$HL;H6/,+]H(0CB0A2;19Y1_U(L[Z.5E%1YRC5@CW(JM5RQ*%(@22\4
MCX8=<CF4J*P<3C)-"5#Q.=+\2'))[))&HX.-$1DA:NBR,D2?ZYPH%5JIZ)EF
M)NM*&M";8IW4V4)T+2U$FQLW\OK?O[%.<A?*:FZ&KR[IJ-C<2'LJ_'&N"G\G
MO]C5)3 -5-$5O675P.C *QX04Z5/ @,1/6 MY(<YK=T6E+\#";34]5BY1*N>
M81.UEL(_FDN19X)2QG7G!:5V6ET,,,!R.GX@>DC#,30*>:WRE4@56FE'D=%/
MM84@AH(+1QXD'#@WP09-V(%:$U7FXI@N60 ?5L_N)'XDVIK\\O26C<YLPHIT
M4[(J14&"7=@5!5BI:=AJ()FL5!!!.W3[2;^/KRQ(NM8F"[@IX)3(U -" 3PO
MC\E@E0QE#&!R: 0PR8XQ_EJTAKJ88J,0VS(L'E'&P[&E1MJ D662%2!A)M9[
MI#5+3:[)&8XX"%FAE9N'$A:558;MO;HZ&\L?+!P8%SEC\[S*C$P6$,1Y^^PV
MLU'_)XN^V(W\?3'D8$1T G#81)641)2?BZPA?9(D)+!P,!QYO-A16O1#[UX
M >.@9;Q!I;G&6JML;AS00HKR=W3'#2NO4;P]>A.+%((,PIN#O>6DQ9UBI"W6
MQ?&G?_IP/A^BXF]PO,8/K)PN#$\$N/"6K6/G!:KY"!/^X'H@'.1H6S\ ;2,P
MQ]T.^.,4D/0\*U5DCLP0_)J4_/2FK[IR=/6_L/P6!M.36P .@L$!_[+%H[9]
M^>ET1W60D-'/TJB&7L1=$&IQ:=34I&@#5I*E4Q&"P@2G"%O)V)J)LU&H.KF)
MD<K8HFAT\'0'O-ZQ!8JMO:=GY8,8+V)IUI>N75LYI.A()/33V=@Z5]N,[C:R
M,\%F>UCIJ\"8:HL0KD(#N7B;Q.,=Z4?JPEBQS2@VOA0H>!..E Z9_<T)>Y(,
MTDUYB&,3'(FS&+3L) 7A)O6C)XOVX(%J?** :+)5"NDJE@PQE;9+$.A-R^>(
M4UX"J@F)<F;20 2"OM_5B<DCRU"UG5*5TC%(/49)9\A(O[F1]M\E>II(K<"7
MOBV,R!@/(@.F0HJA=HI, P#T+*,@ U1['+% I4! Q>$0Z[B,7('S*J277/&-
MM)]<N\>(+-;+TF[R7*U8P<V@QRF.Y*?P80G/E#. ]+(+UXKT&T-\X+YEA3$5
MQC'HLXYEC<AI';D[8X;)4&@2H2*'L J!: 'P.";6>''#0'X)=#U@7ZB$O# .
M%D'_)AP/AILT=: 4@(\AV>W9R\OEWT:(5NF ')(!U,!DDG#^"AV#:32Q( ID
MH6(:DHX,2EHS^7^3Q%J>"AQW0H[@%D$>]Y9ZD!8!%5!D2OSCK)'!5@OJ*0S2
M[%D]@36PR&\W7+5*^O$7XQ27!T3RAY?PB&=$85ET?805V=/'QH=B=7^_!(+0
M:$A%0+OIH%NXK-6,$#C"95_8+G"C+\#$1=?2W] 79M_O$?\WM+O8S7GYY<TE
M>CK5"*<J=K"!&3,9.LI,,8,8*"QVBI[&H>'DJVI9GA\4$QKO.*/D(,V1T@_W
M'$S(I 4L]17'O:$B2'$LF*1)TBK9*DE<C4AG2L3%5:+$07X93[15_JB,%KCG
M !D;+:D:S>A'CFR2=SGCDOZJ5I-Z-TN62EW=W" ;*[Q*<FN!VL_!BIPH$H*$
M/1!7>P$62P)P_R%4R)4ZU@@;TG7.F)^.#+4@RHHK*\9&@P)5L*&T+:T[@($J
MT$ FP (?X5X._3>>(,\3IK0A+G<E+ML2ES$'R9&L77%=X8"L;:OB.G>P,T'Q
MCY52^5@%\H)B@_L?\^CF1J54*?,A#.SY0?<37H#)5OT(_$:[!&!&>E3'"G0
MW8/>  JDD*YP-M*@D?\<,YZU;[H'BCN5 F+3O^[]T'X+C1\@<>3RZ@K26[:E
M?HBZK#.@WPET;6A7H-5$G 932W+CZ>J"91VCBV(Y.T[LB?K41"V7?LXI6%#9
MR;8;VVEC,X$R.Y!8/*R^HJG'DK%HB<0&SE=H)GB7#+J7^0.L4GP [DB%,,<P
M+-3]%<>*><_F1CJ.B!F5-(J04479:)S81H-H0#P,A2_Z"P2P=Z ZH7NRC:G%
MU-5TIZ!]./P$3R4M"Y0-5BZ_T]!%[P<%S0Z!S^#UV*JU*R:ZPKN?A%?1MC_(
MQS[J5!YMATVH9^7C-Z=G%?R=33%VO]OK "SX.RH5A T";-%=V\)&D\-1]O/(
MDX5&GE2R'WF2U^>:1P"PNFW-]PP<QNN62\4?6*%K]Z]>>PO+Z_^Z%2%!1Z#4
M_U:KE/=ZCQ$D[NU5>H];VIN\@-?JB01W4;T'&\-_];1R.#:;+]8,R>2((:SD
M^:,P35+$0(^SL0D],L'@ :WZ$5_UC8M[97=C!DK?D,21U/\XG$>-$[FL*%38
MUATJ2A%U-"F0?A/;[7@"X0=8EPD%TRA.U8]=H[2<1QDW],AK8:,;19EB8"UI
MPXEX6DH PI!X=&$YB40_8-HN:(M->),<IJKR$_L:99!N$YN5H0, DP"D7AOK
MZ>C9BKP2*,C$>9";&PUE_C6%;5';,RG:\.J5S7!"W!*E.'#:'MM<HWL&24UW
M$E'PL8R#EX+- &@#5%M)>J(3KSBX\Z!(T?18CB>(]%E?1W4U=T.LXF:^=82C
MR@Y)?U*,$80)"(&%L7@RWO%%<$:=7KA;4811&#;@4M"#<E;B4^B6)K?L(!3%
M@G8;K4C!H%E&^_2E>%"2>H6LB.]974S]18&\B1::*%Q=U7D9&PL/!]"2BI%.
MW3 21>PPCH WKUS;L04_A:=LP\+]#\W#U('G2FE#*04H<IU''F#*[8WQ4>49
ML$_8;;6*T@VH&E(IPJIW05D/TF.B+XGO6G;DX%A)F92 =83NV0[(YY#C[0IN
MAB*@DOJE-/$:E)>*OB2,0B"HC+GT-BQY1QI8I_G)M&W>SHYB31V.4(D#B1@5
MF,^C+W,V_DXJN4.5FW)!<"UD_,HD&;]<J29D_&KE()?Q5Y=B,!H68Z8SW5F.
MXC3+SXK_8LR2)P3(W%BI,%!IJ+&%2:,F4!3&>*_;U&)#B9C ]=[2(OXMN?8V
MQB"A2\3 %C:15V1'"=/X;$&[U?^RM.T/H??#"J+*&YL;RLRU4XB,<$7M4Z-"
M'7EL%QDGNO9-D+,-W0-.B<\.UZ"0T4?:MG(7[:C.VWW:ONM0A!LV)Y$2B*)H
M<A?*C)G03'3M2VC(*GQ<U$G'3HODYJ%TNWM7 QFE+4,_(Q,=*C#"D_$0F!;;
M0<HN7U"=AO$-HNS;Y8-JE0GZN.(HR4W)U4<,/GEQ2GS:IAT5[=#8T=Q[-/$Z
MW"<6)88>@);+QE2 -78O^7T CB[W>2 PH>!0*TA54B25 4/UL($*IU=C1 ?K
M4MN5_5*Q<@A2U<<^7"7WI&0MR7+^$LDLU*0=4]NN[_Z^2R<:K1E#, @ZBZ:.
M"IC[@$&,Z/PKQ&/12GCOL=8FBR8*G96B@6DY9SD1]EK@"QAU\@J:&$M0GJ3<
M6L)6'6Y7_  8K//=;VZ0.T[W/&2HJ&&!EG@&2S\L:.4]7E6ES/^.;D%7$MRN
M%NOM0")"<I\2^$C9.QXVB8Q<H("6[2=BHI/&;QWKI2EXD?6+TY57MLF8C>OZ
M='Y;D7"-04&&>,TYD0>Y$7JA1NAJ]HW0N7]SZ:H1<E%?)IBS_K_-Y*P9 J9P
M='L7HX%1+=_!#F(.AD@F\O?1G(&ACJA!84] 8>\48KV?G)_(R1";\2V.L29&
M$\6@;'<MTT37([[]3D-E&X@S<?!"I">-9B:%Q"A\DFH4JK,3#57>1W$@BI#'
MVLK$YV0)+%3=L$ETQ"XIL)D-?9357R11!X@_[.W!)<:AZIPC#R/N3?P%6WTB
M?T9652E++S&^P4]CF@+(3Q@*CJ]T=/H<M9M7RU&GC^:8GI6L;,+BFTDBDN#X
M:^Y BIP7PWWB]<!N!29SR*FGL67B;+P^8*!8&#.*["XD) RY-'F4H\<J4N@0
MK)+/!;:1:+B-C8\Q@X>,OPE;;NJE0L(^Q!RX(^*Z*Y&X1TE*$2#.OJ87X<-9
M:JWQ3 IV=:(3[>@@J6 ?E1:F8*_ <62*[WR(2F4&25MS(>ZFZC.)J5^=D< <
M$76D'5RI'9#[-ZR(62F5#Q4Q'!-=P^K7Q5F-LJ=812<O4YQS@UZKN&4T)0A1
MKD AG:">Z"9!7:5UCXB8#)!QL%A<W#*]D&X]G:PQ2DT8>%GQDI*KF3(5L98X
MME$6FXI;R$3&=CQ I/NG#3I(&)'2 /@(U0/4CD5%1JI#/9)YDH[CAA2"CY$\
M0&TIOA(4+7RD$'L&\70Q[8V6HWI5*X<;SJ',F[( *UZD'@8=UZ/"!52B'U5A
M]!W(&%X 2M8]*29U<Z-,FEN?>6@$$;#DVN67 H82R7J"<,[4)@2SW/H!""?R
MI,>$MN)*U-SFN#!26Z:!;&XD?ZV4LY)"D,$ S(;2T>'.*)"L$1<WO29%_4:E
MBX (4HO3YTX[.GX4V#O:,OP\0'-U&<E7F2D[9SZJY3\I!S7VV$Q,0:4(B($<
M5 8RRM :D92J4E!9P$_X09M]+<F7I.5J7+ZHR5E6I%=P7N?F!I[6J$32^"1D
MW61S,&WT*=F@VMAD4-7UQ$^FV#UC7JA*D$;W6S(M5.5ESY8>FDRADZFMLK,+
MS-#%LG[P;9>RZ"G]?Z#Z>.3UIO*5ZAP"*D;'2>C<N2J9^J[6/CI#$0W/!N8S
M4=\I5?<M40H OJ+" 2H+,!:QHC1#[EV45UQ=U<V</W)4$!E),/I<8$8(5\[%
M>@HQRB6")$:D5&+J?2(\G!U&'PZ+GZH<-%V@^&CXYY?STW*EAG]6*LIA5*Y6
M01@DR\YP.=\1>#&<13H N1+;5.!V(0KLEA'=+D6@PP<*WN)E=(0NLRD<8?R0
M^:U4>Q0K.<AV1631X5YO4? (50'%PJEVOT YJT 64C(G"YJQ9"B8,+?(A<(%
M-N3A)XY;$?K4*<.3(!A6<\%P!3?#@N%YBZO>!IL;-<XO5MPK$@A5J[,;>;^G
M\?VJ/ 3YDU+0[K"JB?:UETN+JTM(EU(0OXM-'8 \SUL9GWVKXUHR3"Z,+SOE
MC2J-+\L)@$2#Y0QQJ3),..A8GEG$PO#1TA+F"D%U$*,B^3*KQ^T%%BQ+^WAY
MH]Y!>%>>4/@H?=I()Z=&2.3"Q0IN)EE<8US+$6I ^0P- 4!;66HO@)4EJ),]
MY8>YIWRAGO*]W%.^5J+#*FQF7&G3(?DPE_]6=S-\B<ISD-_4ZDHE<947"BL%
M29U<0C/7<MG5ZD&BOW<TP"QU8:).>O5@1#&8S8U4PA\%Z@^7A-$2%6'^"MMD
ME%QL11@T@TPM":.E*L*0E89-R"97]8I&+-(#Q7C(,9&_EJ-R_GR+?"4J#)GJ
M[K$$Z*6[Y27C4+&,6ES;16;UJ2$H0Y]<>>-*QM 3EV=WN[P(+$M&Z4L6AN*H
M>C%81P5[G[-IE=5S+I5)BI!P3/0*8EWSV#:L.J:D%AZG1.&IQMF*!;:URF4;
M&@?U<@586A<L\LX"B#&*U<V-;1^;2!JP;\N,&K?4VT4JHVE3ZQ.M"HA0__CE
M_#3YH=T[.(1)#PYW& JY]X[H-N'?(G9 I);,IXS1PZIVCN4($"4P>H> .?1#
M<D10#+))!G#Y: 32!:V)Z8NLL5)T;!/-AMB-$?4]VCI%DUNIABM#T-B/VM.P
M'J Z-OD*!CEB'A9AD0+A47MZH5V6C_?9'$>.X7A<0+7?I25<ENA7I? B%7S
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M&&+ F: 4@Q3)8*HL@QX7;FJ!6 4X+%U'BCNJ8B^4F!K+O;U.WY=1XE%&J_S
M<4X6>1!%#XMCN_="5J># ;!.!9;XC@/M^FB(QP?0?Z_J0(-,>>.)XF T>KK
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MCB/+U["XOO>+YKE]W0:TQ\<W-[;1JHEQ.H\&5EPX^$46'O;#)DMTP3!1\1$
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M$\EX<%GW%/'K<9THC0<*?0&B5;Q!&5:?.*-$>#GN$0OWD:@M'=ZR9ITRIR7
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MNCJDE#/YSZDR&J>S+A]99E&:S)H_M_',7#"#Q,\PU36S 4&BM2'MHCW,S:S
M7[6VH>RS-YY<43DV.A8QI<LY+RS7(WG<Y%%G!9@H$\QY XK4XOWYF[*\Z=IR
M!P.(QR&673PX:GC%3*B+T.C$,@WV_@%*7E,GYVDU)D#T2"&[<7UHK-'+3(3%
M+N,;R5MSIL"9;BIJLW%VQ9:+0653)S'3XA3\ET)74W34%Z/D,/18O)+ \NN-
M?H&3D=C\5\R=I%;J(T*9M[!_P_,)-JAW\4\@O=%E44M;KDJ^$B.&;%I>G/I%
MKX'T2YU,5B!>G-*PGC2=RDI<X2:2)0 (]+R_YZDP1%EPOE?"P_#VW./D,HT"
M"JH!M@ZX/2.C,?D3OBK,!$IT*3#3%+)Y*M("D8X^GUZ-[-^6/E#!SZ+UT"SG
MSR?95@!MNB'SC,3^T3QOE9L2SDZ!Y]N.M*H*!B]C"ZLNEOSRS?$*[XOV'^?+
MX\#9XXM%VW2O/98<(&'6$S[I,C0^D'S$1YG8/O*(/]&..%9S=MB5K>.;4)=N
M'VCL.UJ8/P6IJ9CS81'J AQ7FFH=2; $]8,P3Z'X;@-NI/ISO?7G'AB#11B%
M2.M\"$P\\?FI>=$2Y*HZ.W,Y=?7F9\-1RDY,:ZU*=>QGF6'BV_J,PD-W28R-
M%.W@@ T'5.)Y<&?'3R13X$E([!P\I])SXX0?8E5L#'0]9T78(W3GS(JYJ=OM
M6Q\)8B\A#P4)6/F,;C!)@^4ATD5B77,Z-E'_Q".:2AV>GB=)"3",M8\\<AV!
M[FCX]0 '"=$2:5_'2&4QZ6Z"A0_Q>1XU?"%*_T7=8%_#9>@#*TH.2,]*AAV;
M?2*4).>0I*L?V*GMPEW9[6H%;(HF)QFN &UAN]G<>X\%KZ7& ->B0AFEJ/[1
M854SSP?VMJ:HS6UVG7PCS879VQ.Z"DS0@XQX&NYFU%H&F16=@#ZB(Z1& H&#
M8S:!7;DGWP*^L9PTKZGTS/5V6V=Z _1$0PZ?0,S@H:UV>CSMKF9^C6@Q8 !=
M>RRE0%"[<'9!"A+5YXNW_+S.4#6AQ$:=A2)2D@ '>!]15/Q\CH>@S&@&Q[^G
M2?-E[9A/3DC('H/D\#G>E?21+DU^<XL^M?R(TSY>,B7.Y936N8)EUVO</<H&
MH KO\3XTW*=.(A2,"# 5S)7.L9+JA"!.$E'M5N[B;<SK>%BTR)^%Y,T5&%4T
MM#<G6T!/\YF=,%G-Q=-/<#DG?NN_ "#L&3C!YRN<X,/""3Y=X00KG.!O"K!8
MQVE<8?#%Q&UEDY$K]?7*2+5U\5[E</HY2[9];"PIFEV\4L!&-UU\C-X9UU>>
M%_39*\#= &MXYG(G\P9.I@F %#QPU.),I#<5(JHC;;9%;-4-RZB##00!R'B>
MSJ#?(\%DNJ.+1/2T+9G/12U>6"#.9CFQDSC-G&;#L42U%I3XC9DHVFYO%>YJ
MA9B=($50NS9(NBSZPHP"G9A(3P7#O:%EEJ*GRJV/T1S3FN&YZ%:*JEI0'BLL
MI2B6T'CD*-<TK/8.OCH>Q;B5J0Y@IX!50,G+GS(,HH)FS%18_HSAF-MD15W,
M-)$'A#4^0F>:O\?<ADYW)K'7B0)T;YYC+\[MUG?76#RRJG'@$S06X%)('6_:
M&I9)EC0>]/O0=)D%6LQ2H2JQRDJ!>K&3D0N:47^GT!X.D0J]]OZIF*AE@&.]
M)VN:[$Y&*MO$V]<;N*Q>F67KUQOW<B?#!<>LR82F,&H^+H2^"TWHQ E5Y,N=
M>>>LMZ54O!8@('<[\4"I/DG='#9.+YSF551B*?2BL068A<IDGL+H"/> &T+C
M !&UXG%V/D0NV8$S\MZ%O4)#4 =<(^Q_(]D^&57;2;#:D:$:CREI68V1RU?%
M#A'R=7ES%X:3Y4H+=;)([NKW]@=6:AJ!V4>$;"JPF#F#4S5P+NIB,0Y?2B$5
M>PZGR;8XW>!6@1X&M[,^OIU_P>+<,WUE1;P&! 7I]:-.3\LN\D0<QSO9Y&&-
M,PM.7,OG+GLRN0<IB8=8C0JTS5CEQ4A@AE<0F\<G6][._GF;G]>< >;&ZN[I
MDF(NV/"*<5N)$W9L4I!YO:LN>#)?39%H*7G^K'0XI7UHAV )C:CB?Q:*C_V!
ME71/\\S3#)P;2\QF"&44W.B"M:DZ@E%89T*_$46JCF232:80=63"*?B2"GU6
MMH-CP>#K*/;.86V9$C/D':$Z<.P&=5VV(%A4#C$#$?"(I/>*.S>174/!F3$G
M6/5Y6K"0##M<EMM1W"U>+ZRZP@MQ>>MU/O9VM76A#@_,>I(N:O5C[[I6FYQ8
M2EMW3Z$+*<'O?DM*PZI.IEA!KE 18BN!%"0(J.(%"[%GM^1Y=W5B,7+7G?MJ
M+$5X4.'2U8A$R9/-5>JIV.J"&\14]VV[X\&HNHDE)5[.&&4;.*:1]K@2YBGV
M@G\9NZK?58:#;:(SEW ")P]UB3MV#36#F-X5<QWC\(3PPA\%#37^+"4HKO"D
MF"D[*2(E'1D8N+.E9*4^:KJ$JSCYG?$E.1;"O9 #('T_)OI8XZ&-N3G?L?Y7
M(?"?&C1TH#JZ6>JC,U  )T'Z<'.:=_*+O3J]ESB9[R!='$G;3B0:<-'V[4Q4
MF6/6W$QIL"J@_W[]T^O-CS__8"Y&%BF,> DUT"NZ H:C)*(-+2Z8)#J"!P;U
M&[H[74ESTLW*I$UX&G<=O0&1)NL;"6^/ U/JF6;Q_$)TU)A*UJE9@>M&32D8
M\NR"FR14+38_I!0O7()2"F-8G;_>_'":I8SL 5I:=O*K30Q>MC#+^9@Y"-I[
M)&XW_S=38I7;]XW?]E@]R-3!0<O>DH6'7IQ'CZKR67)I#Y!=O#D%E0MGQD*
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M%T^F98Q3/07E.#]"=B7BQ$*VE-7;]1JXZ[BTKD<^1E+A0R^Y&2OKO[ZRNGY
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MQA<.,JQEH5H*?(P'3L9:&$=9,Z@A%9M*<H6-A"&T,8'A+4#.QNA8?K4!(/5
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MDP)A(I0I4Y4)^.C*FO(2E>@_9>+,P3&VJ&),+'V/;MQZ9.]/. E*A&BK@TR
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M''ED^TEA,+%=L$CF!*[SAMS 8EH,M<= =!1ZY"4[LM>V'H5QW0J&H+TM<J8
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M":QT@"LT_E4M@F?077]8T5T?%MWU^8KN6M%=[SF9'[M@<&?E_YH!/P.T/G(
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ME"7!C&SQ)($5DMY*&^3+.IE3H*=/[DPX/0T-:!+-Q/4PJXYWU46$VB05GX#
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M?I01JT+X(++/="KF;?UC&DK7RT3(EG(KE.NTNMUNJ[OGW$&[Y;S7:Y!KZ+\
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M[.<<!%GBRH .\M0N"O1G8"QY:',EY[J:V^C_O=IX#"9#K<?R[;3"O)F3.=:
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M9$PN&R0%II0/3@D>;(R OJ,R6PPR-*Z.I4*@Y@PKROS@<D+=RO2*.\>!?JX
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M;/-</DR]0]>8)\M01Y0@"A<C;KAMU]/ R=1PBEZ%4^RUQ8?CD_[)P7'_H[@
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MU-G?HQ$MZJ76^EHAMMKU)T?50RW :Z[_-=A;6AGI\\??@T"!*IA.RV26P)[
M;2%B:E'_[G%TPVVKM?.PQ?OMAV,&B2;D9K<P*Q'G7/OF2"$HR+9%!2?N .@A
M2V6KH&+5AP+))=+H$88J8 Z.=(Z)3/,NU]S\@D='.%[5&R898BL8EC"VW,CC
M0/ T5L6XVQFC"X*F!FN3JT2HY(1RY*>Z1Q!'JNC! Z9P!*B5JO,W>D;9D/=C
M[C'>%N_ET,UR>(WZU4.?86!$YLS=D"4$K'P(YF+K=:VJG<8S52151TO3O._1
M*'8SV%E_)*B4")4V3L0H"I$*.$;F*=(C((N8"A);0C+4+OHJU;CI.M!C0ZXM
M&ICY57<0B3%\TAU5"T'J,%RC]):49-7**D=@77B*Q(N=SV5G+XR&.Y= UU+-
M*+7RWS)P8?)PL#\1!V-?CL11'F@X-5(A^;<B%J=_4UWG5"^M/&^'!O+-\?$[
M0SZ(.\@Q!C\QWDBQ;H+",X/G6+;SBM%SBESGX?/U-2-^+AX4/K\U)W+A0>X7
MH]*7'OC2+=#K<"']GKL@"AP+4;!8B(*]U8<HL$RFD0NTY*K.SX._]U/,UW.Y
M N@;DXBLJOI*PV>XA3ORS?-NQ$431>$6.ZYT+%UIXX>>1(<YFB:QO,+.B&@8
MJJ9&AN=]Y"/0H6K?SB8LPAJC:\3%'B>EG)_?HD%"23X$C(H8$',($ MM/?0*
MA^CYRE1><A8'E(^5H&_E=<M1[/%_8/4=^H#(_Q26_ WZ5)K)\V SP88E.L<=
M+<T![&E+\!JP-^F&  .%2LQ3Y2P/-BN5)XP 69%OS&$&PA.NB:-H6)8[.!<]
M"@$,M6L6@X J&8]0@2DS4CE>9B+POZ U2'CZ^GI@1G1#ZW'3:(M^D(ZI1;>N
MRW,#YH1)-(%% GM7Q!$8]V",FTSPX/2/X\,-9Q^T1V!^$W_8XB(=7LY$KR?=
M+XN"'=./ #L6I>H5)M*;<EPB)S?6@P$<5=K]??8T1G?S=/30*QZHX""-]:WU
M+N@D1%IB3C@U^^4M[2%:<AY04YF_4ZW,?]\6IY>_'IV+XY,/I^>?^I?'IR>6
M;[_>\!<%<V$7?S$'9K=Z8 [:!EJ,.#_ZI7]^B( R<'J.CG\Y$;]]/C^^.#P^
MP(-T(2Y_[5^*L_.C/XY.+N&(79P=\0_VB-DC]ETN?LT1V\N/V%G__')][?CX
MV!Z/1NW0?H4).AUD@N? RT[/+UKBZ)]'!Y\)F//TPX?C@Z-S!ODY.#T_.SWO
M7QZ)7T[_.#I'K*TCN[&O-_SC OTR+QS3(7T?>W)( D0!BR.*IQ%7Y:/I!\K\
M@'+N,;1/20T1PX]@M9=/<<QI''V=&<'KJL6)EW<[W9ZVZCY)J>N J;',. JP
MT:R*IX_\ %Z=%XICY;&*W#O=CO#<&5@<HY3-6XE0"44SL@1[81""PL/M22L+
M&L-INITJIW':!GLY./UT=G1R88V4YG 2=!U\,RL1"^,DE WQ!%8B+"=99H*L
MX21.E9-TV[C]8)U=_DN<_GD"6LJOQV>@L0A06"[[QR?B_=')$:@OB ?*OY,6
M\ZE_TO^%,$7IS_.CCZ#1'(J+R].#WW\]_7AX= Z77%["Y98C-8(C6=W&<J37
M'WX-1ZJV.7!Z[9SW$%M!QQ#PI(L2H[D\[X/&PUZCEL(Y9LM+')\<'H$^='AD
M#2O+?"SSL7'[^WE0M8&"L]469^?')P?'9Z#V&/CH'XZ.5!N%H_,_C@\6!M1L
M&8QE,(UB,'5IITT B+DG4;AK$X47FRB\O_J)PDTE]>5AQ#42M>A+HJ)7?[Q6
M\TS>4KM;=^U6M3.%LXW^Y5^/WQ^KKE$U[:3$Q<&O1X>?/RY8![([NYB>\GD6
MVOTX(@J4ERX((\3OI]Q&T%VP5C; I&9/&"AU'H-IS^D@9ONI]37=?XH;H(\B
MS'+&W[QHF*GW$KIJ'%*+<RPXDU_'_@#K;K4*]Q)&E"6XI[5#838!'/[D\.B?
MJ\X*+#PA/J^A<")V6$T<%E O?OVW'W:K!I(^S8-Y(^PIVON"&=RQX3[@68$%
M?JZ=!U5<F:=  =6<R$6N5*U)F8-U[F[[X:)% XMSGM1)AG7D"X3AN7LZ3A5Z
M]-DE1-ULGG/[^*&FX;Q0;>%%)"HM5Q/Q?JK4>RB38>Q/T=5847$L&2^"C(TI
M,Q^R1/TRXP="1YO*$K4EZI4BZD-0URQ1/R]1=RU5OS!5URC1EJZ_<V:-$ASC
MRW.NMV4C[E_!HL:P>!UY-PEA]SOWY]AA/>.P&L!J[0K:%;0KV.!AK:HL[+6=
M)5C]1@SK9U>,8SGZVP_C-)TF/VUNWMS<M!,Y;%]%UYO]>#A&1.U-Z5VY\:;G
MINZFT]G?V=[=['0Z3J?7[3J=3A<^;_<ZFY[\VG/;Z=<TC\YLP(,V@ /$[A F
MIF+R/_S]G"#0I"<.D((0.#8E@.LB/J)@8SG;T0_%H0S<&PSR7V C$H*1=3HM
MX>SO[W!/795HP*5FJHDA?!43DM G%^8A"':VT_UYTUU,W*"AQ/'</!=3)B[>
MVQ7\]J%VMC8[SB;3HEW%;^?Q_55>/BOXOXTH5OI,-47P;SL]F),#LA^E_R;(
M_6Y[G$[ND_L5<=]',4TU$0K#[V%Z 7SQRZ5X[T?3L1M/W!;^W&X)SDK\( =Q
MALW0]E':.XZ5]D^7]G;]GB#K>YL]E/6.HX9HU](R=ROQ%TD4O258_48,ZRD2
M?V=[:W][R]D#>;^]O[-YE0ZF_P:Q[[RZV"]:0W&;F=^R8"8<EOZ[5OH_;:A[
M&[]OKK25]0+BW]E&\;]GQ;]UZEKQ_PSB?VL)5K\1PWJZ^$=GO[.UN]]@\9_;
M_Q@>Z':ZU@'P=!7 +M\3%(#NIH/V?W>E99<5_0T>UNJ*_NTE6/T%G2F%T;)X
M90"D^,8VB?&7$M2_9:$43H^;P%KQW)BA-G18=@7M"K[VL)Y[!?_97'G=:^\\
M=4OU1BR!-/P&TWAKO^=L=[O=3L]Q>OL8"]]XD%G<5TEJF+Z62];WL\"]2>Z7
MH2?1M6JFOG QNOC=TN>%3,FF#@ZLM,[^)J]E4\=(9E!3!V<\N5D<;'%L8LN:
MH2_ 43O[O?W=_3UG'S\[NYN*8Z;P/(F-Q1[O<CR4"5!2;IZ<Y7BM,(%S_VJL
M@,L^^A.?6S,3!\:IP9Q_VW#4'0B92I"L=Z<@]:>Q'S!C=O:M?6/=CZ_I?MS:
MA/\R(=I5M.Y'ZWY<H#)@L]%>-/*XU=W?UI''K6_)-WZ2&O"[50)L$O*2KA^H
M ,Z.#4):AF^U #73^0X!N+^]IV/@+,;#<LL(C:#=UD:/@W8&G*!N]7$NK_P$
M9&&8YLC=%W*8Q7Z*@HQ_I?X?TRQ.,I<#?!?H68RPC8A^C''/T=?AV VOI.@/
M4_S9V>]MM3#C1CDQ6< U8^WN]4[9\:W@^/[91"ZS0 7(6J O9VPXNYW.;F]W
M=S/ZZB=@;#B=WD.L#6"2049MHS[Z0)8)<,NK6%)C!&T5<''"'ED%.RTQD.F-
ME*%FVM3)0#'?SR$\*$[\=(;??/+#4"91ZI*!<@K#0KLCE<,Q6QW6P'BR@?$/
MNWY/,##V.,L1*V[L*CZ!R]M:ME6Q,!9)%=;N?$79O_40V7^KQ"_PBM@7N UF
MTR0*K\2A&_HR$/TV=AD,9.RVQ&]R-(KE#-0'1#^R@MX*^L:MGQ7T"V+IMFK-
M"GJK_KUF1!%!"^&CCB@ZG=T'A10#/T3R$9<QMCZ\0]YCX.^;3?SYP**5_%;R
MO^;Z;3.00;=C%_%)+'ZE%2<K^*TZV'3!#Q:^T]EQM@O!K^H?[Y'\)V"&BX,H
M))D-!OJ<Z&< @GYVE26IZ"H$(FWNSPMTDO.H!XRCP(-G:K5@2*](?>P.RRV4
M\4)/#N!560Q_ANZ$L(UE+/W0J@56+7C5]7,VG2WK$'BZ!%CI6G:K%UBJ6$*]
M8._!=9P$DY!K!"*6 :D$:23N51M.AVFD^QE8C6$9>+75&*S&\.JKV&GOK?+Z
M68WA&ZEB9PF6OQ'#>A:-8><A&L.?;HS)V>+HJXR'?EW6P..="#?JF5HUL"+?
MBOSFK)\5^9:Y6Y'_7")_I4]5XT7^_@*<!/=K!-_@); J@54)FKM^5B58#/-?
M:6 7JQ)8W] 2J@0/RB2LPHD4-=;/D%@PS5^6T,NL+F!U@>:LG]4%K"%H=8'G
MT@6LAOB:N@!LP-/] P_7%9Z636#5!*LF-'?]K)JP&('@K'0-A]43+%DT5U'0
MX.:[^+G3W4QRD+5I!C>ZB711I#]$9S#PV<[4O36(0VZ883O$BM?@])_'%Z %
M &\)781]<X.*4J!'8^,&%L^\0<O7 1V@9W6 !3#[55X_JP)\*U58LGAY%2!/
MU'^(T/\0Q1-"8.W\!<86^E&LB@LX_?]0/TN\,=P'WZ(IO+62WDIZ*^F7?!4M
M>-QB)/UFZ@)[A<\%+O?#MSA'\(9+\W_/./(IC!/_\_/_V=@0'WP9>#^),_=*
MOH,'_#?#AA<_B:W>.P2>R_ 98F-#[X#G7^L1#:+8D_'&($K3:/*3>!^XPR_"
M:6_#X),H\#T]K_R*'9*+M%! R4$P=3W/#Z_^]D/G!_H;1C?4?Y??,8R"P)TF
M,!;]Z9VX\;UTC!/L_*5._!:J5XU"5=LLLB"N^2-7>AU<:RR<7K)WXG(VA??W
M8W?@#]^)$["*>5E/(ES K8YYUZ:^#7\J:$G3T<^;L-!U:QY+]\O&0(ZB&!X^
MI3U3JPS3TDL\#PUO$L&T_'1S4#A:WNQE(F2#I$P2JI+8HV=3HK!;*?&'IJCZ
M^8 [[=UM/URTYK\8,6$,TEGL&!LJ-!9H!ZA\W<=8 0?19!*%*BB8J_8ZF[@Y
M)L!2D(4Q2#A?RV(>V*5];M-AV5:X^P)+O#"LRF5;W 5+WN_+NVCA35\N$VD/
M/N]L[1292 ]J2O\H-:';)3UA[P$Y1H-L9D.)#=4@OM/E RVA2UK"2M=*V%!B
MDX>URL+>0IJ^HK!_4'MDW2>2^CZJ!LA6V#>3SUIA;X7]JZ^BC29:85\O["U.
MZ2L*^P=U)]4A@YJD(8(H_>9@@58,;,*0%?%6Q"_[*MHF5%;$UXMXBSWWBB+^
M04U(M8C7\7\L'-;BNY0I8&7]:[-9*^NMK'_U5;1]IZRLKY?U*YUSWSQ9O[?5
M>99 O88,>[#GWE;]6G'?P.7K[&UVK+BWH7HK[I]'W*_TL6JPN)=?M_[](&G_
M?%6_917!VO56T%M!O^RKN&7EO)7S=7+>(H&^J)S?=[JF6?\@(%!5RA? LQ]@
MT ]F9+;3Y5'5:(=IQ9R/)T,Y\E-4('Z)LV3\)1+_XTZF[\0G/TUI.<[:!VTK
M^I]ZP"R\YQ-E/\-[6MG_1#9O<1RM]*_)W+1D\;+2?W]W^]N<^K,[[/4+.4WE
M!!&^=ZU7WQK[R[Q\G?W-SJX5^-:K;^7]L\A[2Q:O)N^W7MFK/Z<E6,>^E?56
MUB_[*EK'OA7UM:+>5F6^I*AW.CN]W><T[;M;UK:W\GZ9EP_D?7?/RGMKVUN!
M_RP"W]9HOIK ;XYMK]4$:]Q;86^%_;*OHC7NK:ROE?6V1O/E9/T^?'2ZW><H
MQOL@!W&&1?0LM?>M<6_E_7(N7Z>[V=E!>;_2^<36N&_RL%99X%LPO5<4^ \"
MTWL0<JX5^(WAM5;@6X'_ZJMHH?6LP*\7^!9:[]4$_N.\^63H@UA^.GIN53FP
M/GPKXJV(7_95M#Y\*^%K);P%U'M%D_Y!S7#R!+VGVO'] +X2!^[43]U ],,$
M_@^>Y2;<4AHX#GSM7L$+K,BW(M^*_"5?1=L3Q\K\>JI8Z6R8ALC\SGYO?W=_
M#V5^I]/=W53B/)5A%,J%A>X_N3GTO?7B6WF_I,O7V=[L;EEY;\/V5MX_B[Q?
MZ6/5>'F?WD0+B]Q;>=\(5FOEO97WK[Z*UKZW\KX^E\/BZ;V&O!]%6?Q VUY'
M[9\>K3<5 ANIMV+=BO5E7T4;J;=2O5:J6[)XT4C]_O[NLU3;::3\CK7BK;A?
MYN7K8&6]%??6:V_E_;/(>^O<>45YO[AB.ROOF\)JK;RW\O[55]%Z[:V\KY?W
MM@3SU>3]XVKMGNZUK^@$UG%O);N5[,N^BM9Q;P5[K6"W,'DO)MB[\'$;/CZ'
MX_XW-\RPV*Y'4AME]\,M>6O(+_90V8:V3Y+WVYO.]B;2L%U%Z[FW G_1 M_"
MY+VBP']03?V#//=6X#>'U5J!;P7^:Z^B==U;@5\O\"U,WBL*_ >%ZA?GNZ]J
M!=9Y;X6[%>Y+OXH6 ]<*]WJJL AYKRC<MQXLW.\4WM]LN8LW\BL\& 4__-&?
MQGZP235W5O);R?_:ZV<E_X)XO(W06LE?(_DM3MXK2O[MQYCU=_KSK?!O)MNU
MPM\*_]=>16#S-EIKA7^-\%_I7-BF"_^=E_'I"RO?K7QOZ/I9^;X@3FZ#LU:^
MU[A\5OI8-4^^[V[M[S]+5GX6S,2N3=![739K"_">)NOAM.Q;6?]TKFX3\A<@
MZS=3%TPI^/SS]/%;/''C*Q^V%R_-_SWCR*<P3OS/S_]G8T-\\&7@_23.W"OY
M#A[PWTR&0[AQ:^N=^,,-,GR&V-C0.^#YUWI$@RCV9+PQB-(TFOPDW@?N\(MP
MVMLP^"0*?$_/*[]BAR0C+110<A!,7<_SPZN__=#Y@?Z&T0WUW^5W4*^U:0)C
MT9_>B1O?2\<XP<Y?Z@1PH7S5J%3E4Q7($=V1$]?\D2N]#JXU%DXOV3MQ.9O"
M^_NQ._"'[\0)R$I>UI,(%W#+,>_:U+?A3P4M:3KZ>1,6NF[-8^E^V1C(413#
MPZ>T9VJ585IZB7,2- BK(()I^>GFH'"TO-G+1,@&29DD5"6Q1\^F1&&W4N(/
M35'V\P%WVKO;?KAHW7\Q8L(8I+/8,394:#R'); XH*V&60)+01W&(.&8+8N5
M8)?VN2V(95OA[@LL\<(RA)=M<1<L@+\O-Z.M&'LUY>*E4;U,!<2&#QNB*WRG
MRV<]BHL8JH7TLE*]5JK;4K$7E>H[^YW>(X.'6JQ?I&#P)ZD?!&3YP]<#Z<8N
M>BMK!'@H1;>G70@#F=Y(&9*WX"":P)+,Z!E#($W7#\4X"CP$Z8:W# WE(03E
M(:$+/3F IV>Q3*PV8+6!U]0&=C:[/:L-V/BB50>>11VP]6,OJP[L]1Z?2Y2F
M >?\UHM][,QQ=^2@)8XF4QG/1#])9"H^N0GP%_$Q]8I?+MVOXF@T\H<^/?[C
M&:D!=3^*XV/\O27Z83J.0+$X@-D&7D0WG+E9('Z721+(N&U5!ZLZO*[JX%A'
M@E4=K.KP/*J#K3Y[1=7A05BAMP4(:M6'2M3@@4J'C198(6^%_+*OHA7R5LC7
M"WE;@O:*0OY1^*!GL=SXD(4>2.@_W3AV072#(,]C_@?19!*%XB*-AE^L_&\.
MZ[7RW\K_5U]%*_^M_*^7_Q9"],7DO[,''W>W]QXI_\&X3[(@=>M$]0<YB#.$
M_':VJ%_GWETQ@E]D%%_)-+H)Q26H#PDH WX4NH$XH\N&,B,Z38QJ!!T"^*VM
MHP!6';#JP"LN7W>SZV [T)7&/UR:<H&&KI_5!KY5&UCI8]4L;0"] ?O.OID\
M^*!T@:/)-(AF#!Z:@X7=^.FX&J__W_^ULOJI)\+BA#U)U]ETMJSIO@#3W=KN
M5EK72&N+ _J2TAK,]>ZK%?!=R&DJ)P,9"V?'.N:M)?[ZR[>_V>U:X?[$H=HJ
M/BO:ZT3[]DJ?JF:+]D5"@,Z+[<? _R06"=0*_,8LGQ7X-A!O)?ZS27Q+%B\K
M\?>V.X^4^*JL#L9U[0]E#<S?Z3"-4-9O5\OT;Q'V![,TNJ9Z?_@UB*[\H8J]
M6TEO)?VK"JG-'2OIK:2WDOY9)+W%W7M12>_L;76_$:'G@Q\GJ>B#C/<XX(XE
M\U]3&2:(]OM "!\KS*TP?TTYY&S:(+P5YE:8/X\PMXF4+RK,@9'M?%L,GOSU
M8*178_%6/%OQ_+KBV9:WV3"ZE<[/(ITM^MVK2>=%A-&M;+:RV<KF)5]$:SI;
MX5PKG"V^W,L*Y][.EB&<]Y^*3>L2O/Q)=,T);CE([8"AZ#G-K>^Y$_&[FT0W
M,FZ)(S=)Q1\*>%Z7I??%>U0 DK'XP\>^EN(X"="K+H8,; _K\H=X'T7I&&Z
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MF[&?RA_^/O83X"-&6;!(QFX0D.8P "U"PJIYI'ET.^]0L?#HLX,OI=+@:93
MT**1R N"]W2I[]'7X=@-K^3Z6G^8MG#!(_@ZOO%!TTBRP7_@!BP2QDL#WQWX
M@9_.^%XWU8]KP4AB-2;?'!+<.$#=9QC!$&(7*X\',Q'+D8PE5D2!5A0)-YRA
M-N2'5P*;:8.*127(<IC%?NK#N/M,".9H\;N"#E: '-Z)6W?_KW\%77)][5Q>
M^4F*;83%V(7-G/@I57)',6Y!PGL"A*+Z>_$&H6((DQ@3J4Q@ V(L&G=#CU8S
MG4TEWN>'0"<3IBRZ#7\TWI?&TDU!RP2]<QK[U_ 8/ICAR/?@N,(C5^5,+HRA
MUHSS03-<*+S 0#W,]_[V@_22?W>Z.S_HXW)\>?1I?<W9:8L/I^>?!'8I$Q>?
M/WWJG__KY\W!_\_>ES:GS36)?G>5_X/&,^^MI K[85^2YTT5QM@FL<$!'"?Y
M0@ET,+*%1+1@PZ^_W>=H!0$"2R <[IV9Q[%!ZM/[=KK#$*HXH"!D [E;YJPK
M,GG7@@;'^9_34XAVB21\HD'V9WC 'P-MQ2<NF__,_> E Y_!G9Y:[J4@CFT#
MJJA@/^QSG$N@4KG460Y0HBF2*,R=-$^YC7J!8& E:<0+ MBA_YXD3^B_ ;J>
M]6_O.T!%2_Q( UBLGSY#X"WH SQ@\C]^TN@DCGS205Z$2Z1/OV%[SO,1A>=U
M\%D7XBR4?>;:H. _<645[';O,U?GAX2AM:X@ K,9][?^L;Z&?W(<9<M)_O<?
M0+0?SL$V/)]V"5@0>/B(TLS-8 S%-I>Z'$V'"4;>I[N!HID62NP0'=OWH6'"
MCRS!8+1J5_5R^[Y9;45@!2S.W5<C$ >+=F=.[@$OF7GE*HBMJ-*XR>OB9]!)
M2^4^"!_ML3Z.3^UVI/'/J5(FFS"?Y_$S!4.:<#3Q*##_4B7H<IJN/6[:(<+Q
M$;Q/A-=W"<0 ??3Q\4G4FV>?H(]6B8'^/GTB;^@#185S"6%8M#@0QI_+'-OB
MMB6SMF;M WM,S4*3=/(>*Q;+\DQP</SU?T_2:^,T9#UZU690S2U3=BG5F)65
M;*[*48<BCHE!&\1,["',%B(&,4ZL$^9)+S!-](F!<LNKO0&722:X=#*=B5UN
M^7SRB='%A&89?#.Q27<^-MF)IA*__*/]8R%;-KC&0!7__4>,K9**J=C_!6 A
M>S! D$<27&4@DO[\),H(*BWO*838,,I;DAYV4GS.!DT3SC =FKO&0[5Y?-2X
MY,KM=J-9KX:5)HP*(S$D>Y#ZFOE+4<;,.GSA+"?*6SGKMWKCX?BH?'/#W56;
MK4:]Q9W_XMK7U5:5NVO"_ZVW6PE6'2 \&.41A'80];T,%(VX%JZR1A:,!"7E
M!4L$<"C=P/(>%AW@KXJ(<>JM".$GD;ASE1"9_LFV/@G\Y_$1?0F+6X=T="W&
MGKIJ$/IIB7_I&Q+'F^M?-< 7'!Q"6?J61XR%$[01AH./2=P(E\;BTS2CRP#"
M"!F+8P-Q2%^(K3?X!ID?8EF*%J4H'%C3ZO$8NV'<G,"X%T]K?8##O\-W9($%
MX#0HA^>49=D I=ADP3*\[%)1AS3+SEX'GZ,=0!@G:_!]$UJS>*.Q<)D6QP16
MD#L^LAIX-(0/,"N;@3[]*'[;?,9,I(]/L*/]BC(<BII&:W:/&..SJAL>BA>%
M%?CTH8L+N_23+*K7)W@^@4$/C(+5)<8U^ L"'@'@SGPX]BH]LB2&!AQ-?P<G
M(YK&JQ,SRR H,G$?$PM1^&;Z=UIT!(V B*'OL\J=R#.T4*7!?X;BX\ L)QN2
M@+ !$AD/)SA\,M8E>11 ! >?0\M;ZI#^$UY!.=\?2< D7BQ1YC!QQ%$FTQS.
M8R#9_X)O#/F)R=!P(H ,H:2=7J[3 WAC4=6!_1%8I1]>'6#;1?\][UE8F7\+
MF&AS,FF89>NB&F2I,E-UFCFTOB+!OY )&;-JJ$O,-!M[V?&1*V-G:C+\IJ.T
MF!)AOQ5HJX5H-EV$DGR+$QN][W1;>#&DDZ;(AIJF $<1JTRS::ZWIU/2VT[X
M1(#K3.BXOE,T.FKB@&]?<2V&C6_,3<4YA?L7I"$.8+U+L+8A17N0@G6'Q;-I
MV)A2+A9@V2ON&#25 0^A&SS;],?/%5[%J$R('> QQ:>G\)+^&\R=*7IFU9;)
M7\R($BZOQ+&9BEY\$X?'1ZRX,+^X\L.2K98?7<'@>R7:GEO@>)ST -8!K#A*
M4<09GUD190_=>C?!&W(3ODHFEDP6.:S40#+PYI=![L<1]@G=?Z$_[&GWV /-
M&PNP/OCM:,7R2[G74PQ6;IUS5^,"?$QQ>G!5#V =P-I/*8I_RO5<-7J$>R"R
M0*1#QC4X6#_ ABU)ML8.WIBB\>]S+*G ,4@LJ8L936+**@>PXF_OXG'2 U@'
ML/99BN+O-3;Y)Z(-N-9 5715G/ 'SS$X6!>B2GJZHL8.L)CBZ^]S$9ET,5!L
M$4MPMV<7[WIXZ0&L^(#U7D5K;PAP .L=@'5P%A'8L@0/O9>[_*&E\^ F;L=-
MS/P-M@SEB@%RKU+ABAE%8LHH![#",FHAS _?]F3"%2,V"X<1F^&.V,R^_Q&;
M[VD\R^9G">L"=<@W%MF8Y^(9=UFKE^N56OF&:[7+\$N<Y\&5ZQ=<Z_[N[H;^
MN]S\Q5V4V^50![M\\KL/'OE2C#V!&@E4OZC^/#YJ-WPI]'Y(L:\W\^<G[ZB/
MW0_I9#:1SA03Z5SNXYM&+JZT4Q&,3@"NLYL3S22KSNO.!(NK]JJQE2$>F&E1
M9QY!<?2Z_04Z;XN0YEGD@0UGV@Y?\-Q )?W_GOQO7Y3-^5_A9>+-^45]8 .!
MC B=2F6NAB J$;@[HRN)/7=[ZZ6H#KD/=Y5RXYS]7+OXQ#E#REZ%UTXI6>T0
M@8BGIV5#$"'&Q\_5A$X/"QS)5#+5Z>!/J70FU9D.^D^%=OFK\4JRF%9Y_20K
M<MT8 L ]NB<&<-+$XU^JRA"_=9I,P?_H"OTYE3[-I$[H5*?_GL ;/WE>>/(E
M5TC_^X_GF1:?.^VY?&0\'RV;7YZ&6"R*CQJ<8?=TJ+<J%)E&,713S3DO\>BK
MMP:$T.TG* 87I(>+]E0NDV+U.-K=/?O;U#M@GA!32/%2D)G(.,9K1ALC@A/%
M<&93WUQ?-,$ECZA$YUF&,=([X9WL7Z!XLEMBHY:N])X'BH2S].ERT<)GKOK'
MP"%[?QM;Y=ZK2LIMB9<JO#;@+B7EY>]32?F_0"7EPT197<%)@>:00P]/.3?;
M'.YZ!QQ2B#K)'\M\U]LSGLOJ"<7/X 91'^@3@F#NICD4&186&2Y/-RDSI+96
M9=@#''OP:<G)4BP<JB%O3!MC8L?)/D4P?;Y9O6LTVW3\/";,[ZKP?^IMKEF]
MJK7:U6;U@KN[/[^I5;ARI=*XK[=K]2ONLM:\W6+^?+_3\^%"'4'2FN[ =<="
MU#EE@]TP+V-V"RU,8._9<<]54>OR,DD<'U7*>P?]=GDLC.>'6E]Q/XF"+)">
MPG)!G]A6/$F4(=9LC$09?D?7YZ&7O=2Q#@^7>TC^R$%^ .TRX,>$X[% 0-A^
M;+Z'R^=YF>X$Z+E#H*Z9&]98;MA7YW ?\!GF5O8*>Y"YE_WCLFSR\1&&W/:2
M;I5(])6>]VN>L%ZQ,XT)CDV;ISLB-)_,$:&9([:EH(?9@/Y<-H NGP"FI$F!
MQ!P<,HT+/Z KA][\F$CF1G>5+7SGZ?>=;?062SL@6T@X S1QBJ$"_%0.V/Y)
MSSG[3IW2=>212C2L0_5Y497@,+BO0Y*<_>;PYQ' IK$'.B",S''9UDUUDRA+
M4_M("QL).&M?,R2&=5S3X6">C=Z'7RW%*F<BE6WPP+T8F,>C:SMXIX0V8D-D
M),#S(Y'A#;@8 OY.1H@3$6B#3[V713O#0P$JTP(6'ZJQ.^B*-^CW<UX3<54)
ML(&IZ@_:?"L@@[.H@;#Z*1^.5XFIS[01R*W8%2640:]*,-6E!C#+$!#B-\^X
M!JBJF6^)-$-&7E$CH0JP5)FU;F/F<0M ZO*X75=ARI :H#/N@5!(>6[$*NPN
M]8!K:<PUO;0&;V_],8OQEEISSYP:TTV\ YUYS,=''SS:XR/WP=37M&[O6"G<
M9:/:.TX$<R.-Z.H%H"\W%:Z3+60 H%X&&%2!VDH;S/NSUAG7)P(J-M#KSJX4
MB7_1;'O#CT9P&)IN4 U4A?@'.+4AF0IW?M?*@E5']B/IX0[J<0NN%!@WP>@A
M@]DLK2UB!Q $60"FM"G*R,2UV6HQ^Z\F$[)-3"^$&^&U&O>&*<HU^"KD0Z6K
M\V@I5<)KBDS9B-<T0Z7OYKN* <\8$%PJ->,DS*B*ODH( F8[%\A4UD<2]C,$
M@ZYK B\(E#W\3U\%2/ ,MC0<'^%Z,47W"!.ZG GXK0H'@I?!J8C\" J'_M$\
M%WH?YKE,KP/77:DRP(+]+ZHB<0J(M^L(;+$0R/T95P9OB6<=/#8ECH]>R)Q8
M,WSAJ]C:;D0[:@Y\9=#7<5W *A[1<GS,75SX$%-'LNU:EIJT(Q_2[S-G4D8]
MND 7KW-LRF?P([J'B%530\L*IQFXP(R]_Z +(@893.;QD2W^/<G .J/)U\S3
M57I$,%16:0(!12)1ZRQJS]I"N;,XQ$]J_642.,T4RH1;9\S"@*J%F7B!&3/D
M7@K+&=="QG%]V#X/>07LR/"H!-IP'G"JZ6C318"%C$6!YN+!<O&4(YGSS@_1
M-#.3)8A:3U(T\Z$+#\8<$!.9O*0I+@C&O&3P5 2MN'4^E##0R<#WX9XQL0^V
M%;>8 :SBD$800UZ@>^8<EX?N77PA$%K!?V?>@;*'09<9B_'NN,H?>O!HND02
MR=A4X8YE.#X"M"*B 'DN?4U12'6)*T@,563_<ND,',A4T,'JH;=&^R>Y6UX'
MJ82(6>NIXD@_!#9;#&S N3*I83H%0T:,'OB[ALS6^ID[!$%Z>.O//&@Q&CRH
M"O.4P&M6496")A05P7$P%GI#S.\"3>!^$]6K,^&!!Q(S)&"/Q[^(  XQ77)X
MX(?41S.UQ$P 4UT:^E!NO4@_BSZ+;0_,!_MGB/#Q'](?04..%6F,&A(#%)$F
M4B ^D"1PLZC"UHSN$_,\$FP[Z!!TY2N03G@TU59[X#Z1J>5\2:!Q@D) F:$'
MQ$N(='.1[ L_<:LP*SCTSW1Y3)G./^-^7*3CRT"1"#->IOL&[TF@PG9!9RKG
MGBVO'A:A7)'@F++%SVH$G$,>5Y(RR#0;-%\60TTLNRW,/)D47$S<HX[]Q*3K
MW^YDS>ZOCD*1BU]N1)!!H!7$&67J1B$'>>8-[,=1]A+_99!Z@1K#+DW0TB0Y
ME[9T5!!!]XEW5GZ-AH]L=RRX82#*+(O$'Q\]*F;)H@<1D^6+\NYTEN6+F:K5
MG;9Y$<&OZV*4+%$'&EPR"0Y+0T]TT5UNZP"0S/X@B3S-B8FV$XN*4!W2<,U0
M61#H3I=K3$=TP>,8$NJKHZ?'6_8(/@W!FL3B 2!3*LT- >T#S;%@ M5<$)]J
MN)&W1TSKI7D1[I]S.\.%W"L;(#UT07?;H%4.GI.)SH'.HQ'*_Z639R4(3R3)
MRC7A7VD9@+K<HFR=&YU_'HT-0Q/:TO]+Y<[2UI?/<&N&11_3WR::+V](EKC3
M3=L$M#.$($")/MN3S5D;IW'%-QQ<4(RN;J8]?/.2O)G0A*=A="W*N&@=S8Z'
MDVC%AK$:,S6B&Q+>UCL)-Z/11!X<PQ5VV/85D6-&(!0[?8-ND;=K*+[;E2UZ
MV&G3+CS-XDIL7X*OLS@0+9$9)(%Q!FZ7T- ]TDS0D/6EV74M./D'\:,-#4U.
M],TXC;DKXM!,B%#P )6LRF.7TD29_N(S\SY$>)A%&/S>"XJ9>3[RBNE34:<V
M$TVYY1BQ (U^E"TJ[[)DF@;!$7(>RIQ*$#I>G83<U;"'JGT[_O;(WNE@48)W
MKG6@7V>1F;F'5)_ZYQ<HKU')88;!3W:8U^[K@(&8FL4+/UGRB^"]\L4<YK>*
M&"UH,1FS]HV[1,M=*G:)&?K1(K,,!E@DR:P5<P/Q<0!??S2SK#R[GF>?R>6@
M4RS!ZTB_CU<2,;?KCV3Z(2=9P1#HRL/8XNZ@R4>MN@ABE0_,4UH)*+<2L3(Q
MQT=F L=*JPAS^-;^=G]X>[T<&E''E U]3:C%:Q 6 U_8MA_L?M)+HGWMM]K7
M*_?A3IRR <XE[77@SD7DI/<B,C96^U]#+O/#K_+OY_.B-#@)*68+YRHS@HP\
M+\K O8\,3?^/'XX^6PR?X.[.R@MN.8?'@N%,9O4C5ARO_$<S%&TA6]XH+/7D
MSYJU\R3_\.WNQ_=N*5ZL:8%]\N5&T<Q9B/(CD?#=%< <&&]9Y!>QYEZ, (L/
M\X1QTL4S!&,!7J!9;/MKK^-^<^#?KLK]$_IUBE AG(%MV=6TTN$66LBWT-*'
M6VB'6VBQN(66CN86VE7[^.B\UKB[+C=ORPFN5J^<F2/TSENUBUJY6:ONY<0V
M.%K%DS'WCK[9TR-]J,G'1^V!8FB\+,!'JZ_80 _Z2F6*G^9U6@-,J5WP.O\Q
MI&/&5O2"*4TK!LDDSSNI5*HSDC-RIC,=?R.-]&_EHMG.@&(UAG" "?W@)^>N
M$G?*+1F@M$&F(9CFGLLT+%IT;ONP'GWL=6E/7PBV2>.7),&CN!T/&*! S/[W
M).V@*ULJNB(R_3+7'J@/H[;1/UGX='\1<->@U@,PM)-4\"0I=A)M.AP-?[:;
MR5IJBR?Q":]"(^IGSF1_6_JH3Q< 0X']PH (8NM\O.#ZPN;SQ,"4C]5Q4^$<
MU\T>-MLF4QUB:*>//#\Z/2W3,G6YJ^DJW],[XGEG*OP4E=%YNV>0W,ERIGK#
MA)< :"BW6E4<[,H0X4\&'S^=.9C^1'=_3L7W!_F@WP/C!(T_D;-S1*ZP/C:'
MULD44%N_N7EZ5)ZOVM(&Q%XT"FH>8//E9EM$'-$8+VC\B5IR$15'5)5E ?^#
M4\[&O(1UR;)>X545[^%2UPV(G*YUAGRY,KU2M,[TX:)8U+_]_E:M9**1;=/=
MR&.<Z,,%6-NSVP"( _8L<LS'I/^S0/W.Q(Z^+_N_!0]-Y6<^;I+)3.9>HG!@
M>9IE:4U\?PJ$[A-/"KBL-?KNM"^68'G]OR?BJ_Y)-H:"H@ND)PYYD#SS!^V_
M)Z=(&* &O!I^,F21/>N^=7'R)9?(.V-8+3B_+#JF+U+\>?$]H3L5&KJ+B5*^
M&!ZZ_44Z[1+IUD!1]391AS5Y3#2=-AK,2K!>_E-2?H &_\E'JK I+*?8KH&]
MP18T4:O*Y4SAAY^(12Z53!0S^95,L"O3$A*^PI.9=":13*7>B"]_22FZ).4.
M6^M$H8KM81H!1=' ;CZ/GS-G^L1F\ZF95DG]*1K3-W\F$TK6Q::9'3<*O7+5
M\_6'EGK[RW7SZN@C*)NM]Z1 C!B 7%&;SNQ*GEP08@5%VX%F8>N25"D9#='\
M]4ME4<2$FJ0-JD0W50GHE*EZ70"5,DWUK^3JL][JAFB+K2,AW"S]YW>>MJ+S
M$F>%5>6MA%7+&6:;XIS*)W+YU:YP/,WR-F4HDTZD\J40[7&8EC/&\7>\H/%7
M6!<NA=6P+D[<$%XC37Q5HW\/>AMY#5,]-4=MO5Z\5H?78D8=]2(-(6R8X-\\
MO1X.4)TJ_5-#(\SQV:T<+L59Y HL%U_MY:ZOG6JD=RJ^G@Y$02#P&6"]M/C:
M5:5D,E\X^7+J:3(*+V5Y0>@,,HWIRKHB]VQ;[&;EGIR7K^^ZWU]NA7"=^B\6
M ._=S5N$Z(CY?[5)^OO<\8!B5T@N%KL0W>'Y*A'*'O.#F? -TN*P>5%]%K]'
M[?ZNJ!B9'G&C7;[AO%6C17A);\@-]'OTDJ!$ B5!UWS*&OYC]!YV(4#BRQ>Q
MFTOI>Z7+UAWZC>AR\/-CZ>>[$Q,WSNWQLBRXQWRS54>N2GZ(.CE@Q?ZF5CZO
MW=3:M:JY,;?=J'R[;MQ<5)LM>R/3]_M:^Q<71^S'"YK5,9^+%_QK^[]J/RXR
MU6[[/+E)<7^CE+>5D')-.8@C<N,%C3^I,VX'S!PC<\=/L#EQIL1Q4YD.RZG.
M]/%5_?KPF$ZKU]$&]A8TW(B!LR%.YXSR^A;7%RT1>T:91"J[.C$=,O]M%5=A
MEM!3Q3"SCXYTY+W2H1I$F->'LP*BO+P6TXI<R.6VIA!-V.P:X(Y3SXLP%74T
MD<B_.0N]'S@+L?R5*"6CJ:07%B:.K4-.%@C0??U^_+-X_3NGA1GRKTX=6^[$
M)&%5SN.4.I[%6M3"E-JZ^0D]=UPLAIL[OO3XQ3(!G%=4(HCZ D9^N&L:^>'-
M<+11&]5&E@#!8B,1$:ZX$**T))L83WWL1]ZHDR[1Z.&*I^"ABF,>YVNN=F.&
MW<%35>2S>7X0J19V8'(4\#O(LZ^HARRF0]1Z_5 4B9I8(7IGF=6MP2%68_)+
M\SY6AQ)_,]6>IIVA;FD*:?#SY?&[H?\D$04\FS0KW6PO-[3*DFQ9PK.)4@"V
MB:O9W;:$)8'I=MJZ-&LI8YQ"C!<TZ_8KV0'4?*,'TVC3R:]?(KFXK=QWT]OR
MUP&64ZM-6UD4C[YW"[N23A%KS/RA;WO3T"Z5W$ZC2-;?-;&[14R?A+\IMZK3
M1D;L3-/\M$$>1O*KD(U%XPCU3GR\DCUFD:"F//(;B\GDZC;MOT^"WT2>K;M8
M;U86AV:2V#AAGONF2]I'DJDP&TCF(6WY[%QF,!QZ0S8D;=9[09)MFJ9X]LP"
M "O\8OSI3 NY"Z4LU.NC_"991'\)7=X;HLCT^3A=R8:/H\NW$[A\D1O3:5/_
M-SOC-;7P7'>\VE#I6"6!'O&.J'1.54>L=4:BP*; LOD\TQ_)KZ5:^D?K:^F$
MTT4=05P,Q/R@V>J;@#"'!-V6"_G!^9^KM)X/!L2J&WH!P C!PM?JEU[+<4>?
MK$4(X'HV;C& R3/?&NK<+]Q+V1+<+/&+"XG/WE,V](&BBE,B^'#>SYR4R]U.
M'N[^\(N)KM'G<+S](-]1QQL 87)>K7Y3>KG\I@NY]6!8@[ZS4(3.>)LP72"@
MWL)L%E I='63^+_KLML\WNE8-_A-A3M=FQ5KFF;XL6''9?7-,705B=<  ?3+
MY5=1<W^& E#QON"63BGK3.OIT5W^(5TA#ZL96J3@S#/S^8IC- S=VJP;Z5FN
M?XH#O3ZY$_MDY5D4!Z;Y U76IDLJ[+-\^UGY36XFN1LMLS%=5K'7 KJ$?I;O
M:E-_O6BVM-O!FG196SDPRBS35A;,G24@;UFCN>BP9Y O07<JMD"O0O>V("_E
MP>$.9&'6LT&^%@D=>J8GV. 2!P<<K\_O@*,?0EPDZ&9HMBQ4FM@!DQ-#S412
M <*>8-_P1E1T"/OQT3K$WL80KP6M)"L1\3[P&&+N:D,\^B#"C*<7M]]7E.%0
MD1>'TNUO=]<_A[GDY23UMJ0)TI:]+$!<7/2'<(V@6+Z5M$FAVGCI%VTKN^#U
MR^.1-5]O!B7GEP-R??/SH3(M!7C]\GEQJP'882"\*70A1L%AA,$I?XH'B(&?
MQGEM./XVN3+R"R@=( !.K_]ZD]&D9*&<JS5ZRG-AC=<')6E, M]U(0HCZDWG
MDN&%O<OS+G/'6Q3I3E_$LE)O/C_]F$C+J1TD.)U[[=+(=-IJC!O=QK?>:,PO
M?_<:0<N"D\>%S0*&(F\"*9-.%-+I1#;G5TP,QF;@G*Y%YT4!^_3I\;[2_FW(
MV>SS9NRU5(\M#;"G1N/YJ3\4=>TINQ/V"D-GA,Q>88 $[)7,IQ(EW[MJ@=AK
M49Q$@RBE_Y9H*3+_/C AMA$693+A^?,QC9$"833,21$11TC9#ND9H':&'C6&
MV@,OF+(8B6U%<2*EIZ_C;\JS4:VC\MS2E727?J1RBM#-^QJEI:=AFL+'X%\G
M[U]R+[_*R4G:5R.[WJ@M58!7[?.[3PO?')EE]?/;5AK.BS5Q95JOW_U</5]Z
MN/R:%;:.JW#,1"&1+ODU<'LQMF9R;/>WP%+9_+[< EM$^L@OXZ92"RS4&[LV
MW#L=RH(@XH-YZ8X7A9I<X4>BSDNSZ:;ZD)0NZG]>A'+$<QYL<#@ZQUJ4N1Z#
M:,<WLOW1%'4K<C&?2 58"! O>=D$9^&)3;Z0362R;\79ZBM13:+SHDR$*J_*
MX'=KY5[/&!H29MDN2%_LB?JL#/TN)*?U_@M)JH];' 5A 07HHU#M?ROKA^5L
MMYHPH4NM!N#![_Q8,1M ? ,WNWX\$"_\*V"+B)?+)'+%$.^"?%RF60I+>V3M
M<?"F*G'?;/AM9![Z1J.G5\3XW&QX:ZMMK)OEY^D3^?2-1"&SFA/?Y 6\!XR'
MN%,FE2B]>>3)EJXCO,$61'$+QI>\&W\_Y$LX^WC@M6[G^T[H=.[%V5;CO)4L
M]XO\^/EWF#N]WCA(>8-AGHLPN]=3?5?1\S"'^5U0;,\F-/]#EY1_"67%?/0;
MU=\*H?^XX?"@_E?\TAZ0XR.^UU.&\%#<,,G)BH[)7)5PF/N&5SZJ-!&FZEC0
MTP=$(\A(SAKWOBCS<D^$#VE6^[-V!GSP)6QTA'KTKDVS[BR@ .K_G)YRER*1
MA$_<'?\(TM@B?PPB]^#[.2 +K6/!H[C34TM#".(XN//)CF5_(D\AHJP-5)8D
M4T;^>Y(\H?\&Z'K6O[WOL!;>?^*LGSYSUF;.)"ZCG3_X8D=05T9^@KC UV3L
MZ'G=R9?+4S?J+*1]YMJ3$4!05D%#]3YS==!;#+%U!5&8<7_I'^M;^!='_"W1
M__<?P+0?TE7"/Y]V">@Q>/:($LU$,YQKCW#LP>>L$O3%@AMYB%3&E9L)G!^%
MW6BD[M0,^[(S;T4T(U6IZ-B",NLDDYD3^\5A'NNJ?7QT7FO<79>;M^4$5ZM7
MSIB/>7_>JEW4RDUP.K=]Z)".5G%9A.,C^QZ,AC;#'*8"G^#V]'0?:O+Q47N@
M&!HO"_#1ZFN/P*MI@92[X'7^8U@GBX'\^?LRP32G%1MFDI5.*I4Q^R"FD^N?
M]Y-!^;;X@/NJC"$<8$(_"#;"8A7NE',S$;>(AT[61VHP17XRFR@11&TD\8!!
M\&?AH_ZAZ>J<B$_PN4[6 &!%2OSW).V@-ULJ=##<2J:2J4['Z<H8YNJC[P.C
M_?!5G+5B2[R1@&LN\#4!DPES3UP4@$6"FS1B)&7CQNS"4%_J?UK:ZWVFEHX$
M-ZEP<.-T'"W-B&S =JMPF#]90A6_0U\J*L8#W"_"JUQ5%HBP'@S!DY/;$[)\
M^+SA;HH)DT=BA;=H9"K.^B;N*F398KLF&1/9(+C3N5&[F=Y,\IUIJ?ZS)3<J
MY]^U?C2= 3Y06W#LJ*0<+"T7UERZ?"[DN73O'5]+FO.V/YKK,!0UU*%-*;^A
MJ%5S68QKFUMGFFYER>A[F^>KN2WI)3\^<C9S6$!^BB.RXP5-D 8V#9S'WJ L
M"Q=@"R1EA!&?B6(L&:*%JDZ'U5)G^OC-&#;*=[<WN:<0RX5F )C/_L>/[!9\
MM(]9<"#D/HAR3S+H99>Y"\KN@61E25)Z&,_27,$YKQ&AH@SQ>#2:M4[:\XGF
MG)$A-;FG#(D=$-_@$^'+,X-%EN+2'##2T53]]+2-/>B-?DT6Q+$H&+S$GF3U
MMC?Z?;&'9:/A2%(FA):3+D25]'1%U:Q))7_XJ_OI[XG.9_MV4SL]XVD7#XD[
MTBBB>%7EY4<*=\+:!K6R:3,0TKSUK$M5&=(*9#(%_^,S"B0(>A@&.@$0$$+!
MK)!:W%*/[#;'5YG-^&HV$HXW7U65.JG^F!A7XU2<^"IE\]7LS)/8\=7BJRU*
MGV,73GJN4W.Z G]@@"4XP0*'LB"Q .4$0T5=A^'^!(ZK<03C_< 7/N::1DVU
MF_[/<B_52L_Y*F=_DV1]95:A!ZJA+R7F,H6C*Z&V/Q03Q=3JY3N;8V?_\3XG
MD"%@O93(E4+$^F$4<"S]3\\H8"))H->NB SNO03<5Q:&HBQB^(&*R]\1S8G\
MX%OVQW/RN1CMK& &7()[9.!1W<I[ %SJA^9VXX<&PZD6NN?0TNIYK?JU>-,:
MQ,ES6.R1KH>HK?H0F02XF^MYIZ7=>*>[XK;!0U_6?]6?FST2)VY;[*?&F-M2
M!3!S?G<+8N>V[M]=IQ67&@(QQ18=WU0ZD<VNW_<;SWSY/I Q"C\Z6TB4TA%M
M,%KMT\VEDSMBNS/43>]MJ-D5KYN"E+O^^7K]_%/886:975:;SR^_=YZ=(],6
MM0SH^72N<- R45 L"H62*R1RJ5P,%_8<JH*AAN;G?FJ<Q0$WBF8I<E-_#_DZ
M_'1Y*W6F_<?LZ[50;N7K$:TU#Z3)$42N#U+@ZE8,A/MX7X?W(42DJGK!7?B
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MJ9ZB4;_8H02=E\"S81*/ _T4E3]Z60 6>C9='$7/*6-S_JWU"LL!;++G.+<
M7>\RDY"4O="G<S GVGZSAJN V,, (72 @2P3ZN2+W@EE."F2)D;9X"1STJ3%
MHGX>FH<#&9H)]?.M#B7+.\,'T1S=::LW4"2\4<B^=8KU:/S$4!&(9!'8P,2J
M/:O"=<=-92X"L@Y.:3CM8WN+-?> P_(S\L\K3DB"3XT5G'TN4<_;_B7$383-
MX6!#+5""<1XH[?-N>P80.W?JYN W#\UYP#==8#RXRD(B\Q*D+]'LD &C.Q,4
M1B<MQ [8[1K0@ZN\R%5N$HU@JU59%BZ<0355Q@N^K;KNZ8X!OMV9_C :DS_#
MQS_3U^Z[SI E.U/UKJ0_?V\5TMG"R1<+.4R]N?##T5#BD"#;%=@4_;@@@N8:
M6&Y)-8EEFE_7:C.56*J19E&L;S&EK/$26WO!=<'P]T5KFB&:S0%.;$*S2]TC
M4*&: A:.#HK'[6>HGE4/B[A?NZ#<:&U.HZJ;WEQ9"+A5"3SC[LP[/(X),%-L
M@D)3*G3N/<[VE<S%?IC4-4<KT<LWZ(KCU24+#X=,1%#U>H-7B<@->'ZKZ@WN
M/5]+OM69YJ8CY6ZB3KOB^RXX9#M3X?=U2NB5[Z[SC]CRA>@X:,V=T7++Z9.%
MP:]GS)K="6$-1L-!QB38@RQF\@LH:7QFB((UWI9>8\BFG0#38D<,(]V9%-?M
M2RMSS5-5@EU $(,D:.[=+)^@M6 0>Y+!$%W1B$SIGU+]RWI*5&*--?2S#"I^
MP[DN:4H6:V'![YMC0MC80?I&A#/!+ _[A?=VR+*7*5V@'&\MN:5C5]@C[" :
MKU7BZ^Q!TO3O_@<#"(Z/YD&8R1N80ZH)NR0+J!HZ90)Z@Y3FY>T SP+?#@H-
MF0:1,W#:\2W]_?$1(L5+4!KTF<M]62L6+W%=;"RF0_WHQ5QWW@(^Q]K&:%;?
M'N#M#SZ=B\(8QB*."3A.=EP&^9[%-WNG[G;E,51Y%5E!NR,JW>"RW&MP;UQ<
M\<W.--L5DH-D[9>@[L%:T#=X#H7.].&B+GZ7KN_T6N[D2YV -.%.(0Y0PU'<
M'-R(78&-&RY[QT?$9%;N ]Z,_XCA$1OWA&DZ#&X,;Y;NA:#A(,(IQ"HJ-CK)
M!NV?=<VDQV^#0C=TO,Y!DZ<NDV?7K46)/MEZ__%1V !8 [P$?!/6H@E+MGEF
MAOE >WSD ^Z=-6 +YSI8#YQ[C)6?A(@0B"E*$VL&BY,,I342M$/45))7G#*A
M^21+J2U^X566UG=M5F3]9()K,X2)2;I$S,%>CY=Z!MOM:+>4LFR^B0=<.@[P
MGUK'>2_!9 3[HGL#(ABX9J8,"+/PU<*5!M1#JIHTP>=7*,=2M#?ZLY9@@?4H
MN5-YX;^L,ZT^BJEIJCG47DCL#0[MFG)F-9OR^4)H^L?D?;NOQSZ^W7IB"H.]
M5<\1B$!"L-V;K38'G!<[4W'T:WA??'BN73E+.@51&TD\8!%+?R:R-D6LQ5BT
M[:GL/C3G<)=U_)!EU%]2U^H$#H[_8#W#)[1UU]4F/(/KV:YAUBA^8C7\+FO(
M]O8,+V_=I@AC-@W?(0F?.1,9=FLZ;5OW/-.! 8Z&./WO2?K$YJ9LJ=SQVY=W
M7[I_N)"TVO/O[FQ_]9(^>1\ _4Z,KPER7M_#^;QEYSA,(^92-@[-JU#?I;%Z
M_;N2ZO_H18+#5'0XQ-YU%+J%??%S'+Z !&&A.Q\^!MW7N6;!?@O6/(IBUWA+
M;T=ZWRJI\3[NG*"]G3ULW>'9>/I&+ZY,K[UU1J+0&83US/.)_P/81D=K =&#
M&7RT%:MN5:'Q%>W5L=8[CE[STV_%WI6H.X-A_>7#;S"A^MC]D$YF$^E,,9'.
MY3[Z6%?38N?QDL_\G1T+1KIKQH32LQMMELKFX]+_6<!U,Q> ?%_JS^[65_(S
MWZ'YX%4W8T-ADF5;:9U0QZ1O)P!Y ]Z[K=4O73=O*4 :R%@BDRDDTH6LS_5;
M?\RMC^R_AXPIFXRIO2>CO\Y,O@>=V6#9FZ4JLUTV-./Y4=?SW0U4Y@,KF2V-
M0A#E"XUMPQK"'U!CKF.S ]OIH-*XWI/BJFI7<\6;1#25R&>2B6S.;SUX(!\G
M*#4.K/!F=1TQ*V22Z43.=^)%"(S@K[?3D>CMJ7)?R=V.?W<G0BH:QW(6!6G&
MS&TZNM>3$V3+:\WTV'(\IC>4"/H]3E",KD3>*!*+'Q4/]>A-N[^%UQ.E?"%1
M2.?7YO;TV]3>@<AK*+XW.I_Y3"E1".!\;D1B6Z&9$QU\.PM<=9IRJ3.M-']>
M-+/=^Z=Z_$LIN[OV*6.FA74(X +CBDH$("W\--,V4?1<]5SXK<[TLC!)9__D
M+N6?^=BC_2TM$^7.]/Y^6%4'PZ\C(8TMTBZD')HE=M:I3E<"T7OE(T43S=D"
MBCP[.$'4#=8WV'9NL6O<@$CF;7YQ=O2#^07Z5PH3KD+HTKVMYDH*'"W.=L >
M'UVPM^-X#T.E'9$5<R<%/L,>9GU1J]C#K$7[H[B)GK7 &R.,_I9.A\,#XW/H
MFXA@>F;>>7I)?=KKMFZ_75X[8^'P.^:HKB![6^9>$<7\O'0NN6P,W%FP)M7C
M(]>2CRZ11#)VC\KU):OY=]Q"X=N^R8:0J:YO2Q.(9@R9C@)/./=NI4GB^(AN
M(L:]/U0OLC7$Y%74W / ]DRNWCH'+'^8 Q;R'+#280[8WS4';$N[G,(&VS-<
M"0>4\Y[)P#VWWT1OQ5OS&.W;9G2-T<S\1M95AX\"G8MWK65!4<^X.];RK1'"
MU16=<%EZR\%<\(X7V.Q&\_?21!=]D- BCVA*F]9$(]8E'?QN5J#O=Z92FC0>
ME1:?_O:^;VE!X-"XZ&6,^^OD^#Y[\L5$C]70A20]1 V[' #GFD@EZIIKDA<Z
MJ[ZS-#C3GP>V,*G)V=R.9#1]?-OOQZM1Z6+2<OW=6^F.CYSY<_S,NW'\>E]4
M<2H%W0O1IW>5:*C 9J-A%Z;)38P#.?--WOLY=':;\QHZK\Q^PO&1^8BY(7>B
M;LTPT6A !8IUJ*BLN1/^;8^APTYJZE<3.(&U'>Z,J]&^3Y5=CG5]QYPM!I2<
M.X6YK&"(L\78N+*^Z S0<!Z>\$R_<$[&EA6[X9LY$GQMP@V!GS"2XQ\?5?+(
MLY 11YHX9SP^FN$">AQ^-)+8+A]L)R?>BTDFPC3W-D&Z2,YZB[E6F5Y=GB.?
M]T3.#3DP8>:P88O.]+8UH%P9FK.([.T1&)?@;$*%/<R'1^@U9?O4[\4BQAYL
MM[2C0^12.':4ZG:8D!$]DQ'G2.F1;^>"H\VSEDBKI"^1GLZ6Q)CC8W#GK;6B
M"@+=@4CZKA=@M*[1"7S\,\%+_V.1O&CV@G!SPZ32H_(&OU4,U1XQLQH>E&QM
M1K1IU[.?-F#W]15X#U[!M\8IT>D])@^;BF$(H(DCR8_EWPN/1^_U 83..K8[
M%12,85[!U((X@)<N!W#=1W6FK?3%S]MA]C95>->NX&5GJN4+/VYNQ]5:@>#\
M$PR%I,GQ40T'R@F<:R&>%V^'!/.NP*Z!@OIJ@$9.)U-Y9EEQ)R$; >BAF+/"
M\'Y$1Y8Y[M^]G?6M*V?T2:>I3(+#*6PL97C#EM]2U0F.XZVSU0(5G/=#H/1<
M.Q0] Z7%+QZ?,Y/..SXG0&&]V7][(KUOCO$SSD8[E13EF5Z-1W<&/4;[!K<U
M?]8:S'5\9.8]S0V^%@25:N7&/K=[^:'WX_A$<V"8/AD1;<FV1F>PKXX3V/#N
M.Q'ITB+M[/BHC4E\S-(S8V7=12(\2",U99YQ;&C%7E@5 %,&#!@OEG <&KV,
M1.<PFU/5+$/=)<"$U//[:H 7EDH<'X&JS;#A-OC."<<+YJPQD=YV&HJZ;DW%
ML3T]R[R9>6MVM=&ZTLB)\*F>/>I&!J:U)R[@:\RA:C@L07 F(\.75&5LS@O$
M)8[H[%IS;9 0WCG7M' !WTO81MXS?-E9Q=''!8/OQ:#&'FS4.V7C$6,5X*ND
MC^:AG)I.GB;S5)-<D*Y.]4?Z,_[((M6*(H^)JEGCDQMTVH;9ZG1\]*%E='5E
M!!Y$MI \32<_<FP.ES.P&?]]300X]Z/Y[(HYJ(,&QE6ZAM!V^!HO\"LZ,)MS
M'EU,Y4ZSR8^?W*H2A8F!IHM=O/A6<\]2AW=ZWL(O>1$;+U*UQ?0K+QNXX-Q<
M&N2-JZA >E''[B^SX=9#*D4$Y4I7%6UD/M+2@* <+(%V":1F:GU3>JS-JN 1
MJ&R&"(2  IM,27?6B\(IKK'G1R*V,_DMT2J[^[;H]DB*E[92MI]S!X^IR17V
M$-JBQAR(FCGGE<[O<B\@G[UQ]G@M_7[Y2A['3Y)K<500D%=VL+P!XI"[DY:M
M,\^>Y59M,P?YL//*N8\'Q;=%Q7<+5MP17Q^M!QR1I5KO_[/WILV)*\VZZ'='
M^#]H]WU71'<$]D)B[EZG(S!XGO#<]A>'D 3(%A+68 R__E96:9X!B<'M$_NL
MUVV#5)65E7,^:55 .< 5U/=;+'>8:O%'@0)1N'/N4H]$ONQ_@!PR1&U 9(Y7
M$E;@FTGXN-9[:G3]1R%.<.[,+S+Q'5'M#SL2%!JQD0@U[2;O_M ?]C^L&0Q0
MI* *@@WX0-ZUTW+&#CRH8)?(5 M91)9J(%+516N U0.L50T&%JCVRP@V$C+G
M#+"C>!'K&K05(K1%[^I9K_P?^A<MN!?=<R^:#&'8<<U*&)N+AA"8A<P ]]6<
M(6;!,_P@ 19D20.9R&/<(Q?8'K**/"MQ+P11P-J$!4U,@A<.7@4;^64\/8(T
MOI.P'R=8H[5#IGM[U(_K*;RU%1LTP_\]&/EM?D0<#I%AC0P]"<Q3R/%Z5K>]
MY=V;ZW1%Q* *.4368R@3=%PSS$OP%,%>-F!^K"[T%54DQ^4:(.[@>\!L64$;
M*>0061?SZDC18!V!.0$'I,WGH6M@'I.%65Y $KT+PR]$=)E88JGBW[CW1BZ@
MEZ4,V04Z['LH0?'P/YCRL>4/'Y7\_@ PG^U!X<2C"/J&FB#[7W-Y"(3-[!98
MNF(9)[9# ZE*,-"')JZ)'28G(6WW<Z.M'2;6VL%;L$9NC$+M&YP683U&CJ@Y
M%@XO\BXT3,>EL+P4.;R4QAW)#,4TAX$W:(/(!8,;MGF*=N,6O&AQ3^VKN"?C
MXAZZ^%7=\U7=LP&BXY(4UJ@X<NTVZ4:>>+5EKG<GM@7O#M]!!&I_*,#"^\3(
MU:A;5GN%X6>@\>$[39S;0,L^MM/+$ H%9L)64L?H2H"39AK%9,R$97HXO1.F
MN4^L'E!.0[0T;+[#Y\Q0Y<V^4Y=K:3G0[\B"<@7G\':&3JTI,BM\JA"I\5A=
M:$%NXAHEC!Z=J!T#ZC"F#:)2?IZ>/YVWST;['T:96?M<RJIR70?(AL8*K.V8
M'1&)K6+-%8V)_=[SM"E='HS[4_E&ZJT]Z?_K_H; QO96B<(/_6VF'JP8B"]U
MQ92>IV<G%6;Z*I1&U0I2<^"&W%MN2/Q\R^XGL9!R&;;:U5TMZQ86+A*#-ZPD
MW,+/4=!T^Y[QJ^D?\SRM=$K-ULM3=_JR_IU2V"5Q,(O=0XZB\D0>@$L,3_>=
M.%*&AGZI_<@<22[3>^F#GVL]3^N7M?.CSMG)7KT2#C_G0Y#;MZF5?$E-4FP"
M"MRJP9WH<KZH6%1V4$\90&,E0C_%?#Z.^.DQI5*2\$Y&7H\$^.>SO?MKD?Y%
M@K28<7E_!P8;Y*;^(@RV0QB[\!?MEY35_$4;QA;!DC7-8B!SY7"0N9N!HNH[
M4$R+[#\8OVCZ'1&09+.=0&JJQ\)K_<]>C9W@K[LM=[^M[K/DAU! .R6CE0$7
M7H-.WY%<DDNN?M]GQT&U3#S'PB,P6$YS#I#L%E'LV"&8A7]5O!CWRN]LWSAZ
ML8L"X,4S<*!%"S\QTH%?S$B+N)9D:\?/T1M.6T50LJL(2OXJ KI8J%>384Y<
M'+(@T-/:\7(KM1=Z;5I H%[<+.PK3<F*F3^F;^_RBR:U:UV;F1TSC.J#DLN0
ML=T.X(XF<#OBQ\Y Y'D!?091BA$_NJI4K%:*WWZ;A52VM_77\$HEM=P[5)%.
M=DX+-/2S>&%R#2_FRCBU<46N3F_; Y8/8QQ2*)H=YWQ?1":&T"DE -Y2Q&,I
M&>]L'G;_L?:<7DHM%9W# [F(&3U_V7C)G!^7&[>5ZLB!![$#:\O2]K/299T8
M&_1^*7^]OY!U[<<C_;U0G-/$WX/8X*I0V,(N6CMC4WIJ=*X.[HL7\E&Q/H,-
MO"CJ6X:&[_*LV@T![PMCFV;65NNT_'AR?<*_7]SSKW.:F\D\E-;&K"?9F!M\
M<K5<;<CIA33]PPK5JQ..F=?X2SS'95I\\U3-+V;0I>:M@!6W2K8ZR,=@F^Y?
M,37FNOCG?C"SI;6@3LG2O,J8BU):3YDAAZY9BO<KV;H>R=8<!LU\)5O7((^Y
M$8O\2K9^)5N_DJU_P8:_DJVK#<4>9!8AHC.-P>K-Q]?IZ5Y'N^YO;K*57F;0
ME2D5BN5\,@H;DD!+GU:("%OYIZ9FQ<P7G4YOTGD_XH]"<V8K2K96JW]QLI7)
M-%"6%^,4N5*;Y\^,8KOW:9*MP1%3RQ&/C;\TV5K/)G:7%XOWIHW&ZZ38>>6[
MFYYM715G(\5/TQN6;373I>L3XBYF; A//YKLHSYABJQ0V[!4Z6P3L#*P23<X
MX;:7M<TY'96N:],/6;B6JJM.E=;*GSA56L[5 IPR)TJ[4ZJ>WZKT9J=*YYV,
MMZ QMIF)TO1=IS,96],:TU'O/\X5O=7?R$QI+DR4SN[),D\:-V/QX'FZ?_]^
M5E,?A\4I/4<N<AU:N->^\SS_GG,;Q:"))+2N-67^3&2[HH39WT0>YB_E:[@2
M*F(L]($+!=T"\Y_8K(KM3&^&029D]K+GZ?5]Y<]+BZ%OUA]F ;>O]Q3 &L:P
MQ3C)KPHF#H@6"A+B0G@;B(+*JMQ@@M'%O+B]+"8H]1UC\P*\&?J*C9_JBM 7
MJ'R[WV-IZ#2R[SU/!X_OI9OVU5Y+99,:V7&_NM.]?F33P6EB)PQE[>:OJL[P
M$.T7M0998'OJ>*/AJGZZE_:8D^I>NWO4S3ZQYK#'&F<3';I40LOX+>FX-[%_
MM'G]3'@7)%^@R?[4L3PR= U_A+8B35II=/QZ-#YI-?-(W,*KJ(QJ9G*F=2LW
M6C,6K9_V[L\>[A7E\;Z?%ZTS H/(F=;-W&A=LFC=GU1*VF6OME<MY47K4I89
M^C4JT/F[0$LVH!QD([36WZ<[_CX)O@%RE,@"6]44ZV%^Y86@8T_ <BLG3JYB
M8'_:R4H!#*M/]YPC(WIRSJJO@GY@(!?)4CNM-M-H%/_4[T1'Q2^QW@HO"UPM
MM"ZJ!PN+S,3&Q_Y2)E1]GYXKRQA]*JFP&L)/(H-(6J50*8;->XA,(,Y<]O%9
MCB#.P?@ZIIF.*64.JIZ8@_IL&ZYDMN%P/5')5$]PAH9$_,Y.2U%',.1/ -Q4
M"&0"EK"@0BRJPXX$U5(;C/A6J:G3L[,]?@ZUX:\CL)X0I(.]'H H-G&..7M)
MR"Y :TJEC1<MV$G+D[,]*4]A1X[T.=V)KJ[A;<82Q*_#3:W)OAA@31@@K<IH
MS%JG\44ZDW2-1,2IA8OEYM>\T_LW19Q(6IF^?<W6Q\HRAP>5?('$VRSU0KG6
M9N18&3&?!,Y"7E8+I7).E0]?9S6CMOPZSYS.,ZT$_WQ%BLNA6Z*?F5GEU/J7
M%7V:LH9YG69K6%>RI;?P Q8T%:V(NF])OI2K63=9-4JG':W_,*[-$M,/>UW:
M]$R*I:XU]2JA+3Z9%F+0'].GD71C]/N5!0\E;09ITP^%SNU0[(J-E^/F^)%^
M?:A4ZPL>2MHDUZ8?2CVW0[%+.UX[Q7/M_K'^I_.RX*&4,SJ4O[*$8WV@D#8@
MT_U5PO$7[?BKA&.32SC.IBKSP(\_^!/AJX0CESB2OQ$\Q]J <KW\:6H#\CR"
M%9=P?*9C2AMI2DQ/?:X-UXJSC#'9O!*.L\,/3>F-7NF#EQQ+."(5_U=EQ]PR
M<-F)_3E;=#]_=GI5"NZ+ =:$ =)JDIF36U^DLT@W<WYKF94=IU*=>S1*W>-*
M/IY7LC8UTYA1Y1N;G0/-0;YF(0WKA7(CN8+[+\M7KT@7?IWG2NL/:L69BQ:_
MZ 9THV>N6,P+\:;U/#UI[.OEC_%3;Z^:$]B(M4:S),._GNSQ7YH<AW2MKG78
M"1 "&<?H-^AS;F26MJAQD@+@+!$@+T4/KO9\3WR>*NIE>536&YV&D!-U,P3F
MZ?X&9V)[JTQA[J1_43Z,$X9YGM:J3]*A=G31;_#??EMTH4S"V.S<#<#\;&@!
M4?;<:2' 7/;2<%4L#E'#Q:*+//9Y>C?H';XSD_IKL;8HGV9Y)M96MK=&9#-P
M IJHZ0(/ #H +N1@#WW/%P8H/U[S 0DAWZ(JM4_[9X.7PSWG.&* A"*O8: *
MSEWUYJ^*FYD\KE*WF)*X0!5<^A<DYM9G?62.\B+,&%FW984#G-1=@$;'9^_W
M9[W>ZTT[,OW:#4^_IMQGMFK 2NQFJ@2MVA%"-R@@">@S3- -V H!+_$L?C,X
M=4V7%8,09):KOAT.7TXJ5Z_W)_S7!?H4%XC>H L4$=LL1[LRUX+$(FNJPZI@
M%K8,545D=**<0[;9:4UK.OL\/9(&M:O6V9/R.H^)F#XT^O^U6OO[!P<+:'G;
M,JE";CD/:Q069EFDND*QR.X457YGA*@(Y3"RT6,Y'7F":B;2S34R8DWE;TXK
M_%_&BZNF* I83&+$HWFGN'HY]QTR!:9>"@EWKB\/K#^7KO\*O^Y1UGF@:J%4
M"DL;K"\/I#86]J*-A4M](*AQ-L)#>=H[NAT?'E[G:B*,(PJ05F&$89J0E;!6
M&&;D"\.LK\&8E#]9S%?9S(6ODVQSW[B<38-ZI9:/0%M37;NQ_+FQ"]^HBY6=
MK4 7ZI6PBO&UY^$( Z$5;2#8ML&M;1SHMG%PTJHK;'EXRI[4USR D.F #*C.
M^N3V ;/+N$LC5K'T>!<GRU6ODQ1;CF50*M"A(P WCWO7=%E?EVI3+E5V5D&]
M0-?#9NBM/?>&U)G%UI@QS]-S4=+W)S7N:?*Z]E50&SI5#<_A,@=M4:H@B>C;
MB-&]F0E@:. T5XH""F>4D:"R^%[H"C52%=[@!.C)^E=1T;(UG5(,%?JS1F!E
M:92A"3!_"_]VI.CHJN"F+?P]G>+0%T6>1=_;W3@B;NC99[G@B,5>RM0EIRN
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M"TG0$1=@\SO,$.)%C5,%LGP1R@*19=0595Q,A"XC\E%9;6!'2W#$,X5)19P
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MMYQ>];"R;K)"S1Y$&U>W[9X0Z-+ [LR9OPO:&V$!<^58UI#M$PRON)]"N/U
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MW) ;A P"-N+VS+[Z&YC%3=R7,:#O=:&K;V<HL#!<%1JYR,O1@<!;T6+5B3D
M'$[,K"6WV\J</9*%VJ/"S25H5GH-'H9,5A+\U#9/YF[<@L.51/9*P9;E34U#
MC(6DNZMLY]QDJTOY6H K FEJF;]09-7ZYQZKB1I\'S/&K< -9/'-$+1;B/I$
M:):&NPYN*>]_GAJ'16UR,N;&']VU5T^WD$#G'84C.00A^5E\5WG*T+ #2>V)
MLC*$J.,(,07\:JCP@N1<<M<(720.(&.$!(\Q)(&9GTN]&38/[.T_3XMW4_'^
MC3O=&Y?L,X$1%A*+B(;8'"F:&PY9@H8DF/U3 1T,)&DZFW%'0)<"SI0BK9B>
MC.D2D '<)G_.D>2978!,GK2BDWDTUV[GI7'.VI.#=*"(T$J !/_O&_)CK#,L
M-UI.Z=GT>,3_$?=OWWM5WI]1C4F-!U/,6%1DR8'V8[,T'SV6CL\ I#9A W!P
MOG7/SA^9,E/#*2Z;7K=ZH]M#F1MITA<SK?\&X. 69R8;[@N)-ILMBJU0+]3V
MP4P+ 4S48WEDZ%:MF-&!W.K _JK_<U"BXHOI^#]R+6JO!ZH@6!&_:V0*V_"<
MW-UUHZF43@3F6[P<1F(]X$6I_>YWIE@N,#"QKU+Y$0*>9]$+ZD4(I6TE4(4B
ME% ="RO>Z:$E.W$]P#SPGX7Y'.:?B/OIJTSY)ZR")5P*6%^I^KZCBOU!BIA6
MXNFFBOJG/\>Y"NHZ. U>W@VMT TG1R@%__GDQ^(/-B[E6.A=IIK)L80+H^;*
MA!$&';E7 ..'O,DL[[@9-NY[#+]7?9E##CV0:$XJX1,J<" )PD&XX-U>F47L
M6!Y.R[AK(T-"R;\(GQ;# #RB-^\3&9M%W"1)D#EQ0\<,I22N^^(O2[''WRU)
M[ G4=U$F,QA_Y,X#&=?C.7F[EM,U'L)*[D"0Y<];-+@5U"']S.N/"6U/<PA6
M]RLLJ5J\X'KMMZ/SWKN#,11U'-_29VI2R)G@:CSW8$<3N)^\H<*KO[D;TN>A
M)TQ6K ;23F9:#F_.@\:;GKDVCS/+"W(F*'F+.Z,[I3+BSO'U7>-I\G3<$FN9
M<&>P86D]N+.4!W>&VW5[*[/KK#VWQ7>1%V3>[61*;>UJ_Z[Y\G'<6ZEQQYMK
MHR;0=;#46PXLM2-^[ Q$'JW@)X6.BQ$_NJI4K)<0B^RLLX2*6SLS[]KS,D^6
M1*#D#R[SN.99S4('L."=_$7YPV@,":,=>%+-=I+Y.\[B*H8&L]I^^/<9\:PX
M6H?&8/'W*%XQNI(0YE'_SWZQK7#K=&@&T"[&NNP]F'MX'LDEN11J]DVO*Z/K
M>E7JJ9H#-Q).B?@@<O0&4KE%L>N/:T;W)FG355F5["JK4F (6[+7$WKDZ>-(
MJ^28UAP<XS?%ID_,1:54$J6]6VFS."9@HV7!+Z6P;N ,&"8XMR.DO,U5#]"L
M/T_/&V_L5?/Z]>K/HN5C=&6W"J?SU1^25&*@AJ<+<$%OE]5(FQ+\1J/0W]!1
MDKK,[@17%1P(Z%ZP$G4M ""]0.VQ\BOI3++JO0Q-T,@,3U$#1!2H"G8"A;CO
M2=>@S\G5=Z\K\"[$O;I :A<,W#SE^AJ4KD,/A0>0#+]7\#A!=L&R732@0=&(
M64:!ML@+T,B$2\ZZ$U(UY: 6<&9KB('6'/$XIX;7]WJOO>PE)RD,X\S2:7=U
MW(#%D(W;6[@-P'J&!A3Q;]>:B6H6:8U8=')0$,8K GZ&N12K_&V69Q%Z;UY]
MUX;>0U)(N;U%&K1"YMM[8!;W@(N 7P19P_5.35 9?>Q-[DV<CW38">X3!1"5
M"T4F+5BDD\DI&M__$%1.1)\.5Y4:UVU-CX7*T[6#VV.J*,1>YE>301+S67*F
M.C(<+X,IU$-3220 89O8N![+IH<YC);T.Y J2D#EMZO:K4K*D.(NLSTH#>J^
M]5W;C+CLA00M2.-#V=/X,)7%ZY-F=ZH,7"9S.V0QZ5,!\8N(RP>D-6'*<2TN
MQ41$-X]. F :W.\TQ87&LJ!3?:CU3<)3=+9VB#Y^*3O_=M$XX*"<5D[X[NCP
M6C]VS;0Q7YF>POXW9NU2Q-*73C'7&6F> /'V9R5>4  =T >-R_/Q:?LU;^+-
M;5W'D@YJ8A)(9[7AX7AF1(,+@PE,% 2T6KO&J7OZ^8@%$P_]Y::*C9QTV3N6
MD44@7*IP251A@$0U^@SYY?Z'#O]$9OR^#*8[EN'/8J>4YG3YC[/PB_%8Z92K
M0O7EH>U<C)\__[3__/PYT/71/Z7F/\P!^K\>JW5W%;6/?C3?AWZ"Q_S#E+SO
M/5,TS?UNQ"G!,']XF'?)Q @PNE(7[WJ/%\/AB9@_,9)CD^7*#)^M?OOMM! $
M&AY"]9P?"<#]/P&[,_MZ=ZNB.$Q=(<^@J3O-37$E[&Y6FO>1S].SSJ#WTCJZ
MY<_HM:]*]Q=P-YZG^WS[XNQ]=+4OSEN_/:%NG?X>*Z.SH;;\>E>)SS_=-U!/
M/NLC\YWHNW8+2BITKCR'J<3QX*W5?M4G>I>9H>1YOMG &15'+[$TFM T[?_+
MH8YZ627Y797Z]_=LN_5G>6+KL-?CBJS=@I+N+/,<9KD9[S=,K?I4:CTVON[L
MWWIGZ;_ESH:7SH2C!(3AW]^8F;FI<$E?L(?Z8_FJ/H?]DVDU9OK71C5?F(">
MF1%^3T#L*^.@,*S5;/M>4'C:RX?F@N7(T7E7&%Z5G]V:_Y<5*2.[*;*3+S-6
M8Z<;>I9;YC@CLN9\_ID8(U_WZ>L^6;A>&=RG4CT2@W\3[U-RC>VQB7=JX?7+
MO%7]<J"H-^9\^TNU);'BT"KHF2I#4;R[TI5#5X=Y'F9#5)'>*LRPIHGUMR'.
MT\RGL@&2?@F-",F!]DK)73"<X8[6DNA?[+KI[%K>7':-[/RU2G'V/>4<@<+3
MZ=,>IQ_TSX3N_6!3W-LL2>HESY<D^,LE075S)<$7NWX:=OT>4Z<8)<]S+,37
MT"[1[P)^8"1,[GK>F1\SQH>/94X56 #-)O][+(<ZW98BK74N[L^+YW7FF%MK
MAR]?(K=P?0U9G*?(9K-D55YYL:5*L[PVL2QYYX#8I[J(N3:O1<A .K2-;6.$
MX-<]_+J'R[F'N5HB#!U9O+P)MS#<%&%2IZKW+1/DKF/P;\WIZ7V_\E?Z\GBL
M5Y:9Z'60=M[NW?7@WZ@T6FX;6/?L6LY]\6LLRC8Q$O%USS;UGJUY5<BJ@O]I
MH0N:SU.)8=GCRZOIZ(^T]DT<JQH]=.-J-2==O3" !X9520K@847-('*/^DK]
MC.?IZ=7=GC$I,OV]>4H%5C2,J!8YC @Q6?'JX/R24=L/3.G;;S<ES&F5UD3,
MY<\D6N<>_H@EWWJ&$E&LH0\4%;<$ T "3"D*]%&ZFX%;&#X!'P+I%F_:#X"F
M:V?>YI2OMX3[][.GJVMG_EO+!;Y0H#3\ -<2D@1\S,LSL*,B>N$KQ4*QB/]_
M9$LKV0CN\_( >A2H$>OJ"@PT"A^$$[;#JI<J[LKD<>=<1U#Q:GP$/IV<W/39
MVOV#Q$80V'[[#(2->GGF!$9ZLV,1N;A;+$9W#+,:A3OH?+W!NWE>D_RGC5W*
MU('050T\XK08-J=8Z/4$0&'!,TTI^B==0ROQL5"\DKB&&5B:0&[,"!E$9A<N
M4ZR37@[X/\1)7?'A<+@_;'_T;$[RR%EVI&B_* $_$SJQ\5--)M?@N2FQ-I'N
MK%L_T<5D11E8_[??(2^/0LHT&W%-<MJCC<U1;-!9KABZ!M,? ?7&E$;^.PP?
M8R6)ZIE<R4K6)S'\!8YDP#RBT2[5E*3M+?Q'_*T1XE7S7T-H5+=Q9J!Q'2_)
M!-MQ!IWU1)F5\1!U>_B81@W8=YBO+LC.A%M5T%6%-9OA07"K0D_"J#<8R =3
M""W%(1'<(1$PA]#3>&OF&TQ,,X>WFW7W%LD$5I5$P$0R9Z:-T'ZAA83?\#N7
M;L(?NIF7G*Z K$$7$P/4, 6@%4L!! $<SU 0=!>]/&A"7K8K!#\ O?-D]!WP
MU@@F^X'Z'4 C.2<9FC6:%UEWZ*"!YY"(>(>1\MM;W0G55957> QF8#QG'$9@
MR0(B#+S!Q<L L= 59#P"&2U:&<LNM"-DY,.,9/-E^/$62!-:$;KP>*B6>>Z4
M%[#)NDLP<U VO/3P;!6S)F]P!-#*96P@)0'TA<_;]R[LLGKN8@\)DH!UTI[5
M.BDBD?>LJ?K.SBV(.D ]P"A1:!\$L-8J=KK$]+(0:2</>Q^5ZUY3V>^NT)XI
MHO\S%_CL7M]"-DXMM8V#YTSZ3Z YSPE,$7L_#@1#.6L/5DS/)=F'#LY#C@)N
M8QP>Y/I9\C[@KA'P"^$#"4->^/W?_^WL4 < )_>3ZK!]X1=ZYIL!$TNA)>T7
MA<U4]%AJ9\<*SJ'[G#Y=1O9M?Z**5S<3@$$Z6((P(D0#Z>K**#0"%([52QH\
M?2@(!SMNTEE$^T4!-/=/JJFR79'[15V@*T0(>Z$ ">F2^UO_6E^#/SEQ(BM&
M]-^_B-1A5%<%]G6G*Z"+A1X^PJ=FTAEM;(.(["&H'^@SE INX@%5">%<_)S)
M_5S65=P(0>)Y&'X=DMH*@2CZ28&!CLQ9@&0A"F)["ZN(KW#1RF%BUE4#1CU;
M3,]J5IM7P*%$YO?(Z$K(1U:0?P\0F#95Q%Q7O^201C4LI &.KR20@ :A D3-
M"!F 4G[3LA%N6K;8D:BS$K'!3!!>_D!1#S""JT5ZR^"$*$?5-8?"!CPC0098
MFR*#J^V;5^%ZH>D$N)YA=#61%]%.;UC)[N7S?O^X<VDY#Z-Q\_7B;CB<#**,
M78YLR3)Z57-3V(<S@8!%<U\SF,'I"!61'(,@3=4>B!*DAO47>Y\+&=+E0J-<
M2>."^"\44 C +)'7R@D"KX6&6LLN1NJ8'X2XE-.-Z=K?\TBNV-",#%VQ8V4K
MYB*NQY4X_D_KMERQN<C:#'&.Q0BID\0RB22)*L-"+%+)E5EV*M$XDTQYMY:$
M,UF@V!XRC=$3>8/#,0HLI,< AHW^ 4$6')PK8'HA^@$8&\16D&#"P15>5"&R
M9DLIP)>6-4';I9H:1-AU*W1A?<(K\= F%*H/1?4DQJ-!E.== %!P]$X;2Q?@
MJ@V5&[!:/(YE2V(US:[3OU2O(<5^@8,IB'ULD.\6*TD"OS>QZOG-#VHYB,0T
MD91C:\<6)Y^)QU>3J;S?X!Q.OK!#0B95'(IHIHQ(D'N+T69.*6@&8WQ;7$@4
M5@IT@RDPE9DS3@3OUV8JB#WW#$F:4+ V@2]8:,W8[V+UH)BDDUC-@J'&<PN=
M?A&+AO2Z,%C[MJD<Z<S+NUR)A/!&&@-MPHG3S\5?2019/5>Y$VV5W1BF<B4L
M9!XYU9($PDY4,<!I"*=8Q/?291]_!>:8/?-<?CIT+JYX+]W=#[@J-YR6'#,,
M5N^6.N:>84!"ZK162B68XE2M07)C1>4U0?;,DHLB]+??/0 6-2?#A2;#-CQQ
M@U0M:T++6^K6="7,_ 5.6WC=*DA.D+2*9G"<H&E(%%*2J%F)"I@&$6%2FGF0
M"U;CV3?*-**I<U9]%70P%&0<2 (A*N.\R5C4!X!VS_;[JM"'^1U(M,B<.$+?
M(LD_+*H#XM9;E=W5';C_ Y83FOB;!,O>;8]F;85ZW^R]0BUGKU"I8UTD_9V6
MWZ^;-:51=6'I=W68[V'E.Y/+]<(WO)C$#%UP!K9FJ;2;"+=/$GH<IQIX_H$Y
M5R;LX)N1!V^U133)8ZP)X4MS2>9@AOT*H[:ZKV+]N.)E!F=*3 %2FWA?A0"!
M9N.3"/HL[)_DS#Y(\29[*N#)LL@5 &$3QC4E']>0Q8+'8BX;Z&$?';Y,]#HS
MSOBQ5=]O'1HW%<;+.)R],4O88GZQ'CZ#@$E#HG7GG5)]-[*ZV&$>7(Z"5"O/
MPKPI:>*B'++TL;+#55TNXFYOX9E78:Q6C110KETZQ,76;Q[&_R+LI6BR^,(.
MIT.6CI9++F5></,=]@UF$TTQE%F=3HOV!4J[Y32^ !+32ICUGUX2D1<>X[(K
M>CTET37]\G%SK0R&?UZB)%$A5!3950JDJFQAD>2AU3H(IO (!4T7RG2I4&*B
M1^2DK^OQ3LXSR_/B:F7Q%@F-R!"Q#BY3(XM#/@;^DY8PD3QGWQ,(?82KH"P>
MTT9O9URCTSVY$T)B7C.Q43H"I&N=368?_U86Y9QBO5HH,I&PCQ%.V?86DD,D
M@ I.%V65F(T'HB10W@F&<=H,;_!:L&*+'57IJ^SPVOJN'2_T%1#=*GN"\RV[
MF&GE7&4,V!NAL3>^'CM<96_&569GD3)5)#4;&L7U7"V9ZTI,K< THJTH#W4*
MI&B>3XR01EQ#7)#DB"&W ;XVPNCZ8?_\S^W+%5WI>DN^+?G+XPV9!< F10J4
M+(S)!]*Q4!)M5BRAXHQN>C=QA)EI<^.<FQE0]S<IT+O4 21PK;INF,$W4E0<
M@D+W9*1HP&[A#0Z^U#GYHEDH'!M06 NVG#?'>;XO?)SNCT[;CY5-9LP\TITI
M6!)8R5MM8C&G=V >J?(WAPWSVUM= G#@Q%8M2Y?$-T?LA'!X6'PK9)HO_AXU
M$73KT,A#59CAIY!V"X\!N-G!:<)&]C##J%F&GNN\O>6B3+3ATLK-<&%6K8&:
M1Z][!]?&0&5*&V&X,.MON,2KHCBK)N!=1=/0H9KS&2O6Z$E5F)T6J^.P27E2
MT?=.:4%D?:I$M5<.54.PO8+K$KK:5%P?3!=SG)]XL1T?:VH![5+'T)5&<-I#
MZEZ(C(-$G/TI5HJM;VG:'^NP(G\LF[DW=W'6N@BP(_V\=F'\.:M<.(-<G>53
M>)2]*%N%?869ZK&2R; 2&54,\$BQ4"ZF]^0UTRHA^5+?T-2 4&IY^ +4+6Z(
MO%4BJ /YV5N%9&E#9^^ND%GH]_M1]4,]'=XW7,QB[PF;9S&\XU JF7-F(U0<
MSN$J.*H47P.*[%M-T!'Y<![(Y",P4DDX:,,M2?,-,Y29M\!LEYP^3H_Q/U*%
M=U$Q-,DQ-\'VU\PA(Y^F[MP=/N8(04(BR/6T$63R>]<TEMR$R734JI^6;J]>
M'A]+23%A]]$M%!\.;&]1$;!8_V2C6&@T(F'*7#QLT2$*;8-/YX;M+NT:KWLG
M"I*E!-(!UU()LH:_B^/L2J^'. ,JE(7A2%(FT%P.SG]7856>-*=#5;2B!H5(
MIH,K-Z1U*M]NW-Q)<HD./77C#E02F&QCU\0#:T!EG?GG.:KJ<#6]9G"#0K"_
M/! $24[]C43>3C270A/-T 1[V6M")65?".:)]S';X]_W58$@<5A"^_)T;W3)
M[!4_6#;?1!V2O"57GM>TM**7MF#_3:G60-9\=$>%<ZQPR)ZCQ8%PN\O!RM-%
M21%;>!0@>\<-<,0PT1T(0-W,%.+.@0^:K>*M>"M>\.J\?) NZ)P3&\3Z_O7=
M:I+SC]QZ$O?ES2*B0SC_7>I&E$V\#\P0KGI==U@:7?;N"X:L4>"!4 \MHZ>H
M$-C'RX>'<! LAG<C3@'A0+%CI'\T4IO>A< I!UWA$&'0/$K,ZM(!'0<O3WX#
M;I88"CIF4.1Z0;!<Y?%GL)<!+ ]5V]C$$-2AMKL<%;*1>B^S19/+@DR2>*/.
MIZPB2DCV%]$C42FR!>3'QV5=GCSQ97HL+K7@(V\]4BP7"Y69ZSOPQ8,+W9=Q
MZ)7\,O12AVD'-PP07LH>1/);KJ_'93Q3P0&9VJPI\VU+@3FAYL[)XVNWN"=Q
MB4<9NKC9CBYZ*5G(_NINI#NVO64E&EWY1+AZ7MWM.5><'R0-:,0M0;\!Y$D0
MY0":!G%B.<SDM#QY4W+%]$Z$T]1U*?<FSD<Z+&%Z>/_E"&L7Y SW!!%:HK5C
MF5RMZ*N_**\,;IN']%CH2 ].*!"OCNK"\KPL;Q-A/K9:B 1+YLF(^$"M7BA6
M(A-@A#>B0@(NBY2E]K#O.B2*0W1!%>#D&%;[X7JC-G_@R.6'6$Q49)AZ!DQ4
M^:._C96307T)L2""W$A;/Z'UYWOF-%.HS(X#D"ZIL)?2BP@/ F9^CH^5X[N]
MB^/7N^G+(C[$JL\Q&,:OQX;QX4(B!\)R"SUA:60$@); 8),;9:Q^9@N;265A
M,_-;V-'A]04L[$9C[\F@IW_ZYXT<+>Q@J#Q?"[N$Y&.=CNXGR\6^/IC%O@X<
MYJ)B<EIJRYV1T>5&4H;V=>3!Y6M?1[<"+FA>[U)$!+ELZG3W-D51<Y*%D_F1
M7[\\*)-]XT(]'*PDW96OB5-J5 NU8G1=5U0/1#HCI[*0D9/Y4?X9*YV/V],2
M<Y)\>Q<V<O([R8"1TVB4DZP<]$*=%64[%.[KA_HR?"(GWICK].PDRT4WB;\8
M;N@@9QRG-.(ZL!?UN.^QS$;<N(_4+J=#%2K\ZM+!I">5 +BJTI*R&5W( [K<
M>>B?/3TE>QU+VF5L/5N^LKA<1N944!1;\V0,V0Q>1=A55B%W=-;<SG<%?=1D
M7)#\#Z!IH98<RSH2N9K(87'K*[1<E.=&]P_O=Z/AD)XDZ_-5;7DI3!A0(TRQ
M6BA&SS\G%IX[Y65:\*P69\3#O&R"&TE:931H.()*$)QR\Z>SO"HG'X7C+8N9
M >2;_@+YSAKDN_P%\OUW@7QO*F+T#(5NI/QR>\LC#L$&1RK!D'2 Y?-4J_V=
M-O97V=J2RM8"$3,S%.&VY\UJI#2V5<OA8LNDDH8-6GH:=@[E=":5N8!8,!H'
M,L3[ML62>(4ZC$EII,GI)-:6N:[S3/5C;1=BI0LAVW[:K7* 'D!,WQC0K#G/
MZN+P_./@O=-BCNBHLR(8CPE+2XD)L^ QQL8OB\FHRU1,:1C)-2RM-HR** W#
M-6-?M6&?/G.5KC:LE&%MV)P2@B^^/BFGA]WZ7J2$R+,<+&N)7RXAJ=]8<I8J
M.3ZW:!58R,'5E=/RGZFHJTUF&<5?><CTQFXDD-<R2[XB+N<"G5M97U+Y]/"X
M?=0Y+A^6EE-XLXS+6BTW"A4ZNMO;?U6MT:+IDE$I3B\B&97]57TX9N5Q\>3\
MDIFWAVZV<IOEW>!J"G 8K_'\E7M:=],E7?*^D6'1S9S7JGK[,GR3+T[9T2K*
M;+(5AJ5:L5 K+[EZO9E[=4W(J=W?3-IBMS8MC9+[#S(HJLG%%XT&9<_5;DEW
M,U/4FN925A-RUG]JDVJ=*Y<&HV44#"_IJM*5:H&FHV'YG:N*I^!L;YE'.T?9
M<(K*QJPK:D).<:]6>V2/V)?)86^%A33S'F(@\5EKT(GU,U_VRJ;6RB1W9*U-
MK4S(55/?^T]/]0^FLI_L*:Q1B4RV K9<+93*T?(U?66,^QJG$[C5#2V!"6&E
MYK@]%L]8^2U9:*]SX4MF8I^N,H5J-=K"MNM=MK<VN^!E#;7&,A?M6^X,!3_,
M5\%/U@4_E:^"GW4O^-E4@9$57)TQ@A]M=#^GV0%I&61TFH672P*<RA##ZU,4
MVC1'JBA13",L,(G%%($$AT9K%T C:_6].8ER\S1; U'H4?L? F?H,+S2/%WJ
M.XR(88J_S'_C?]&_?I")S,@6$,3WD$A+ /[>A>8<#&*XHBME:.(U?VK$6WCX
M;WC9]JK-1=I3$=710/U3'G-W,6A^UAYF1!(.V4:4UU[>8>KV3PU8]W/,LA>+
MP!3J\4/;M[>\E3U!.#^OQR#C4 V.IL+0!,G-3.@1+/H;+A"26'&H(?9B8103
M9D9S4V28D*]IBL4E)1I6>KKD!HDD85MD-<HF<!4,%S3420RRL2ASA@KL+B%#
MFBQUI"H] 8\.9R5[0'AB,JSC^M:!8(>*,F7)._KV?MB_:TT-9\['6?RZ4\R*
M]RQ[J6P8+)YGR@4FVD?=W=X"?H@XJAYT:-CGB:,89J38JAO2=+MEB^7>#%$3
M+=45J%NR,@!FT='V%DRLQ4/GS1AT)+[O+K6G(.GH@<\V1]=:8E$5) &C@P@L
M-Z#(9/H>(K5U$ZQHM>!1H+;XS3A*MHS"WTU;\*866'?36V\=5>@)<%6VM[!V
MLC?;_2S'Y?@N;E_%[\O,O#6/OP$>A<M[2?^4$#_GF^6?.+[-S*MBRJ./J+';
MN]@M6N =:\2]\ P "8*]M"B;EZE(5K8<0GQ@IE.XN:R=T[*;P4DC#-9>=G57
M5'Z@Z#&%S-/ AT&L2U?4,B2L'T3?;DFLIH7/ER)'W_*^Q89SG9X>75<?I9*0
M"!*2L,Q4,QEBUK*0*=ZH%IA2T Y')T\8P;'#R0J"=Z" [!(K)!^+ONI=>X=5
M+U5\"B2[B%P4O*;$01WS'MCP?/PZZO0EY241=S7=2E=R;NY1O,7=8K!ZRSXY
M9Q;O=S#P3 <YZA1MC]GTK^ N*@Z/9C,AX?/)L6R3I6#Z0[($^_W8.]!&$CBN
MHFR[P+CR2R.^Y:RRT>DDRN6&_3E\W3M[Z?6KDYKM-3ILIA%A,=/$VNA-K*/0
M#!:01-TVW!H"P^Y<<\1WJ9N8[YFV,S5@W^&;U+N"<U*JV!_H&K3((*YC56E2
M,+&+P2?%[W!/)R>?+@ [X4E^[V9\1!*1C\JS3M#"FI)K.JS1RT%;E22\$Z0$
MD)DICJ!U!YI=D#?*BYJNBEW#[?LBSA+ .4:RR5!'$N+G'C*V_  G)!SC6D44
M(=&=@?(JBYQH/\!V!+H1K^!=Y 5XOMC#(FT\$&0X7D0K]*GN)'3*='!<P2YU
MH3@/P[,.$DEDGK0][!/]!NW:D+$7KP]4Q>@/8HR@S?.]OWPCMV^4)67W=MW>
MQ>?SJTYVZ!5Z5N2_NQ51CBB/PK\4T=+A\3NE\BZS_EFWZ/N>\_-O/06N[JF(
MNCG9#T+Q2'\0@1ER]%:IC^-6)-4^Y^996.4Y9+$GE[(0;ODHUQ_MR^'+;8TM
M1UL^]GZ6X'Z8Q3?QZ\[' ;%',%G^A]NP<:G*DW!5Z;*(H!T8V$A'3%BPYT8H
M([<]8:KA LDB:IX7^?6Z-^X.SZ:$7@]I>,@DNLRDD2IRX4SGQG1N"UW]6$86
MCH%YQUEVRWY2!QY$+\YWX4Q7J?ZIOE?OF+/7Q.+LU&N=@:ERX:C2;CG2KB9B
M$K&5F1TLN!N^67N (2RA '-7D7E,,A[Z )D9T.]-!GY99ES!XV/A29M=46;-
MYG 5C$1-$WO(/L"_ H90#-7*OEC=;&"O#06UCVU!%9<L0BF1]1CXLWN95%>0
M!?1,D94H92RC;PW$$3+ A^B9^. (-,%(509BEX :V'R);%C<LN[\:GMKK!@2
M;[F-IEU/[@1R^Y6^@ E@9]'97D^41,1VV@^T$&ONF7])..L*%7*<H,&VPY'T
M:_Y2RVYR!6+77X'8L2?>(NZ[[+E@#)"8@T(F',#C1VEGZ<UYE1[.M'&C\_C&
M5](AV^6RU=G*Z3.ZA6:+S [CNI!HI0(T]T;/U_L'%W8GR=C4@A^ .' 2$E':
MZ]GBXDWW0[:WXMY8(*P>[<(&W^UV&=&K!0!N@<'#VHX]SGY'5W:\I0'H<$7-
M(W_"[I'_:O."QB%_&*)K7>4=R2_O!0U9==Q>T1'(N+(!G;0.WQDA*@FN45J!
M;^.OF6\@'G8D59(=ZN^&+"'Q@,3@"'$42$E)F@1<:SP]X4>!ZAHZ1425.TX0
M1^H=(EXQI9V @O5V<X?F9E)RX[$O[!'V#1Z9J(IDD%"(*RX"LGTLXE@H98S"
MHB2.21LT;/#.NWC#:/^ )C3/B9,(AI^*!4Q&0DM )XGF6\IDV[#P3#"B$4_+
M)OZ</WQ1+$!L!(".0LU[3WV_+\),X>^AWS.%4J54J)3KYL7/<3CO+T01[K6O
M*L@OA6)21?T)^E<7,B[DBTZ#(0'GBOF:Q2& />4R<4=&5Q(Y#_X4Z0%&Q@!H
MZ)XA83PJ^%O$V<V!454(##LI8&GC/C++AP]R/#Y,^$@LO%5<RZ!CF8*NM W6
M&X%#']7%N"DIF9D%],W3T1O7?SOGZK9;US()Z!FRBVM0798:(C1,ET8RF9U
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MYH\.;5Q$*"M&<\L[9K=<_WO1S .("DL(!"6 OCQQ[Z<<?WXB_$DM)%.%'])
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M1LMHA:XKHS#>B(AND:X;7X/5P8Z;=!;1?E$ +/"3:JIL5^1^41?H-A+"7BA
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MP&AJ\(&AP@L2TI6(7$.3K0S$NZ!),78:_'E["Q[^$Y0LH@#P&\ X8U!X^E=
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M$-3]72^"Y/:6!VE;P1.!V:YBZ.@\1[K9O(1/K>+%T#7W!M31QH#FJ9CFK44
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M8A$9M0*G+)_V&6,/$Y1ME#=E&[,NVZANRC8V91MK8#I(2]%<>7NK@80U,;1
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MX*<.=W]?/-=*IWK1-0[.Q!)%A!Y#8I:TXDYK(44A!SF3P))VR-5^4\22KGZ
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M%<*PRW/K<%_NW[]:NO1.?NA9?15^^!]02P,$%     @ (HA^5I20>P ^*P
MVRT  !    !F;W)M,3 M:U\P,#$N:G!GG7IU5%Q/E^UMW-($@KN[NTL('MPE
M$"PX!-<$M\8A2""XNP3WX!)<@SO!W0)T/WZ?S,R:]<U\[[WJM?^Y=5>MM:OK
M['W./05;@*T#+Q5DY&4 $ @$O'_^ ; E0 I 0T9&149"0T5!14='P\ D?(D)
M!F.2X>%C$])0T-%24U!3,; *<C P\3%347.]X>(3%I60D*#CD%&4%E,0%)<0
M_6L1$#HZ.N8+3-*7+TE%&:D91?^?!ZP+P$(!YD M\" J  X+!(\%@O4"Y
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MNR@::ITN7!6&#E6YH4?>]N#:#JA\R<S?(\'<T9!VR:V[E!3+*3901%G>-!B
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M':5[0F]I>%O*,/_PQOAR5OPT1S5#O4_^A9<=R@%&&93W^0RA6(;!@-]8UC#
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M&?05V:^"PPX7'B2,5KEU%/_N@@/LU_\!4$L#!!0    ( "*(?E9!!)RU$1X
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M,^\A[/"#39%15\J'9": X<Q0ZQOK0!:[ZZ\T[+K7 O!<]?X&2SN>JGCIE.\
MYT6"GS>/]*T9GN'N)C_7XEZ/_*WR>%)<D_J1P[XEG-K<X"U,[O0&?;QU<#XN
M.18T86;6T[G[_-RW6%/\T%%=\%F'Z5%TE5M_Z[#WY( 0L>=IZ=/,8P5!UMT
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MW?=371'ZZ-MIU(:QVN/9/"4JVK7G<>@6]N@<-<N<5G<DJK#)L/=R5M%U9-_
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MY79? ZSGSB=P0]_@!"30.:7$P_[W$X!?M\OPC?_35/YWN74]\V]02P,$%
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MA,^E<#WHG$$J?P7EGZRX%=L:+% :XF9KYD6;M/N*YQ+[.^$:A6NF:@;R&5V
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MS.I2)2L(ULWRFYG&Q+!IAB$0@PML4A[PI[(F73<ZXS._H5R;&^WX17N#NR@
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MFL^L\8GR_"H9D,TT38M5Q"5B:KC!G[G2&E?,\.X;C5Y\?-:#]DP@MO#L!X;
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M59ZMH%28,57;S#CP!&)*.X]H)'@Z&C^]&J]ZU%9^+*U$>Q@5;"76_@S3JR\
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M' &(V!_C?]9T(U%RJI[C?'6<?(=+Q;5!#?D+VM^0_?> !?Y?(?LO8/\+UR(
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M*Q]J+R+9K[O/P7^;B\RE^5F$"LQ"71.Q:DEC/?_]CX=]*PS^?N_6#JF>^IS
M3'#6A?8$)U45U$1R'[RC&',4M&LFM$<?P$)%N]IZT:4O<TZ6,VS#11H=BQ+^
MFPVA#$+62 S_8,E .-=LMHRQQ[;S*D**'272.R*VCQ_0I.TYW$5"_+E+*N @
MR3&S-?JV;1<FTO%:"PJW6+9[E';O>-$\-2\$!B/VNY-"Q(D1<^'R(NA@:/M(
M+^BM1:^W1%_\+<X;GR($6)_=N]^<Y9V0RBN (KGV%6# ^0K8AX]%]AO,SWL%
MS$61/@ J17?6)JZX7P$IAJ)_9HL4&+IA$SI<\Y+Y\-=1YG@W14GV#0B-X?JZ
MFSJ$F+.JU\B% V"*M_3FP4^66]6&*DUVZ!:_S'%KT*_"/SSG+SU!%+DR]*8F
MT;!UW[X]7K(&O/D@MDFE1SH[2;7#9FV=R3=DDW%"%63;-_PG!HD&^N?@;E<=
MQ<Z*M1XG^PNME9$O$8_V@]#$ S @[D-NK1A#R].4B.T;4**-*%E>!"-,ZC_.
M>J1A\Z&BXOL]@8%WR6L&YX49^H</;CVI..$7>2\3S$S%D^HHB09774GDBFA\
M(DF;Y]ZD$&<2\D3]5\#WX5D?A18]?2VD--&551G#WRDJ5P*BWT,-FL"LK"XY
MJ ?I3$ZI8RT+BY%N/[YLM\1X19E/S^4#>3>$&7L?OK2\O2"V%]-J5Z%#.L6J
M^MY]W--E@C3).>GSCW\3,IX*'O4Y3YE2A:^ +["O@,ER&?."2<F_:=3_9%#]
M=[.O@%[/S\F- @8_S8DK^WIY.M1G^Q;TEVQ/EIJ)^?J<'[X!_QQ :/*=</KF
M$4:3Z9[J:853:(F .=X:$/WL)):T(@78,X;E;K]FP%(-%3]1=IM&JEV;+ 0>
M<$-XQ8H^S&9+"'^XX74\@"C\"LAR;K$!1WJR[.D6TLIQ6%*O/2POSCTYF!:L
M^)EI2="45HHB&=L,(1#K7:D\S)KXOGNKXLG;()5KF6WW.OH%47$?A0=W,E9;
M;!!Z=( A)Z@=:58UMKNRZ*,7I)K&0Y7&4[4W$0(29T>O ,#$(IVETE^_8!ZF
M-SJP#W@T25 "3Q>)$U=JZTZ:LOKTDSROUH%.>CG_G)P*M1M5@:=,$K85H&5I
MEVC\E<"RJ&1: +K.AC.QN7SBIFC8 C<CCVY8Q=1[6K7=:DU85J%L:;E3?=Q/
M)BXH46S#4N(D21GH(5>,'OGIQ(1*,3+S' *Z9 S2]F+KDTB2-#DJ:C^^%N2H
MJ4;058P&1M#E0O^SE5I#/^W/Y<O1<:.3OXR:/':8B>@]FN.XEE@[RN(&^U$!
M)^<'&TXU3S7@C/A$^1$"$724C"HG^&.W.%C2&S@M@%/N[7K=-+'8TB)?7ICG
M-]#U+ORR7 U0WEPG6X%"-P<GTOVL.',P^=QGGK)K,>U4"MUIKM)][*3\D&"G
MJ)ZW[QG6RC7H&Y!=G,BN\;&R+KIG?J\4].4<9V9F-Y@IQ9>F#H(2N.'?6A^M
MHO[%.]6 0^"%6[Z9:;CNSH[!X"CAD&"^(U)7^_V92ZZV*T=<R2];00WWK@&K
MN?-70-#7J41E&[FS1TVON\T0LW0X=8M\_9(,?F*DB5)N\*2L!>>H+Y'.TH*W
MQ%V C26LLCCQ6+5,GEA9OK$S3(!!EH'=.ND]?0ZFZ-'ATBM S.KJ?\9BX,W2
M2?('G@YCR;U/D_?A,XZ(@[?X53QV"$H"VK]6+34/L,L<;"PP;($?V=S,'2[.
M?=LA^H7#*?5IG[Y^5/'_N.3F !:N/3)PX VY!KX7(C#N^S8E]T<'V_\X/H$M
M>$[P(W14:\I>]X1:.F"QYMPF.<?+V@'E)IRY.,[$)(R1.)+LJZ+[2IOY\ZJ3
MCN= *'PE\W2@16@:<9.Z,[5;'WF<;3>^YB"L)U"8-O0L1:4YC6LH>Z'*=](-
M)1KYN>"^U3_J7&X]L?X9VP6^OHW1TL74B[FMO%K:_-VP_S951@%#\[Y<OS*1
M*[(8;#9ZTI5&G;ZB>I:],1D6BB@_%056'$\MV5ZAH.2Y_^09LSF6!%\PS?<T
MBONG(CH*9:<G) )0)VW$(5TNFO+=1PF2-,SLZ4CU<)VMX[5.-<*SYZ6]'=0_
M0=F<1YHL;?P>PBM!+$4ZA#R7E DF:P*=_#TFT(AD&.+K#G,Q,1& '810N\J*
MXJ3"F,U=^3L[';P/(U)T0%<8K!& DIXYCDC61FLKJM1,\!V/I@UY.+9 :_GI
M/>GNO!CSG*VOREEV0@1@\QH=9L2MZ" YT$M69,B:N19_TQ'MHE,@V&APZ<_#
MG$JQ%O=W:H*+W8,,?,MY(@SV?@22IO(??PFO(5.9KQZF+C*3\ISL7<H"B6)$
M2GV&&,MW?K^EC\_[:)>R*JDN.2_**4VB2-J U!O\3[I;*^\(!7T442FE?VG4
MQ9\$7!8NYG>XK\=L0<H)4E,V\6>NFX/0T0YXP)&($_)I@3PFPN=\E.>W(/%S
ME\+ZXN_.^39VV"(V!1RR.[GZQRJ. \1*[:X\I:KU[4?/:U."R_E2T95GAJ?@
MRQKT4"'TG^Y&;@LZ""VBGH=^V9JB:N#S/EL#G<J3'[.55#5,)<IM+"ISPCUH
M(<5YS7J%M*[7?(7\LI>\I2/[+W#@*X5/!HMKAZ,[HS$)JYQ445)(IB^4UU<X
MTRJ2[Q,36Y$4U=P2FU0D<:B"L57$X/XRC]#>M;!;$ORFNFKPS\Z8';LO6&,W
MPA!9+&AMS%BX%GO^(X,< T.(=&\R^ZK._L6=YRM RXL2MYB\(6=(BZU/N:9[
M7-&]< ;51? 973O4<"I_FJRQM3%ZX8>T&U*$>%",^E6%OF%_C>4J]U2;($YC
MIJUWCY/(,;(]I;D*.)E<=J!8^* #!>+S"HA@<9&QJZ/G"F<BIK0P2Q4*3L7=
M!K"Q1Y'<BR2I/F[T?B"AKYW-G;';5&]+/MV$3_TU.$$RRGKKWB7LCE=T^YYT
M0XEX9!/U(QW+,65=Q$7O(8\JT]+(1U(C]#B>1HE^*70#1F3)::9ZT=B'Z+[@
MG?9ETGF9#I/W"'KAP*@83MT.G'.B=+@K)_U#) _4PG!P1;Z6*XY_QV7;]JEM
M$"4,3#'W^)V3)-B9-%8G.CG)%#6K\>9]9]+[=5N.*@5>6W_/=FP5&>A_XUV8
MW#&GR*VU=T*;.'/?1H,;X-:F]_"J8MJ.CP3@,R"4.LVM[341B'5WXM0IH4"?
M+K3"4"(T:SE[U>9*.OK5@X/Y*[GM^D["PG;(Y!6R6OF1=!"*]*V]U^ SX.9%
M(W6N@PQR8PS^M,@:FKH!(K)I:M9[*T[8GP"7$Z^ LI85])X'\]!O<-EI5G'2
M,V$[F0\UAPHB6CV;,S>O -$+QF2N%V%#N\M7 .6H-W#=P^17S8R0;(F\3]F*
M%8;N((5-C016QSLI=C!"I6=54I'N_J)&0Y9EY_'-_GOAD\2 0^LT2%7.IH*F
MO*X-1W^_KA8+><M[>4>52$IS2T)/$OXQ%P+K-7DCK$-E";@%A-$8?.2RRWXD
M&"'C>@W9866@J48I/3AZS4=T';=<4!M,/?-M%M%%<$PX*.32!E^"U#C.O9*
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M5R,"47F(*LH>1VR(]KQB!:&WQ3QL,^WJGGH%2H7*Z=.D0 CACZ0O:'B.Z)Z
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M4XT89+VV3@&=_@KF?DC[?I8".;<KKL:_>KT+7STC#<AHNPI_-3/3N?#^/!V
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M9\>XD([N Y#J'P3&5@[?&/,!!ZK+P7$3E%. FQ ZVLDL>YFM9;YNX_8,9T2
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M8/\128_ EN;[LSY_ 8,XY [CE/,^"E 8"Z.?03^F*.)B.(<10&&W-1KB&3@
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ME56+QR4F%_C75'E?1Y77$Y37$Y2]/4')<XQ*+8L*,O(S%"F1VZ<H&OHZ%/<
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MK_N\NE47W:0/8>"-)A/,VU_CA/^^UB+#[ .]1+ZNGK*D@,[Z>YL.4.<+O?2
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MW3N <*\ X1Y[R.YV<7"#LQ+W/*7\L31, ^)GJ2_Q-7[.?B7=Z>C0[[-3F%C
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M*);WQ0D2'#W9:M<3$P-R@^9M>.=8?+>R=&<BW&(/!T] 3C@G4U#UQ/1:6H!
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M=LB?2%M;<5.FZ).8:D=TK!2UP%)2"=6 C[4N8C?%P9/QE#Y_@=/(>JC7&8!
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MJ#-B^=S,X^^3WY99^.OM4T *<+DM"SJ"$F#J77"MDN/C!0,'!H<,&@U U#.
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MTQ4DX]B+@S9LJQ5\,ZT/?(QE7!HTPWH03=G%M^=!,DN=U-=8RS?'%&E]#55
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M1ITTCCP[P&8P!MRP6[?@.IANWR0@FF8)N,MXKH =XJK[9J"%R,N<M V%[]H
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MNCG<[7:S2=B</TBJ6=R>SC,OL_21]GHL TNVVA8T: ^7Q14>=B/CXL[. PU
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MFY/I2HT<)F$[R"64_?>#H>R.90&3H+OP$M9$UA*U?&;+Y[/5W1W@D]G[M-Y
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M"7KJINP.HX?41;* JI^'XQ,RX\*1:#H;7>Q<T1-54#L 8JHP&Q.13IR+^EE
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M<J( D8Z^I,[)5AQ1DX*DFSCR=:M+W@.MYK4)6W0$HW.DF)A.NR&6N#8_5K\
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M:P4,X$UL3.T+.//#\1ICW3M0S6 T 3%'[N5M$Y<T\B)_G&U".98[M18&;Q,
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MBW#6I?<LTJ)HH(OV:+6%PC^^^\\<?AFEZ$RXB2.?4W*\0(J"@X&:ERH"7*W
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M@):%KB?6^C  7;)68)B,_,8EROM;LO?PZNOMVY:'H]+QCW_XX>V;[_\Z*P=
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MJ!NL[R/T\D>GS%' OUOMT-SJNU5IAY?#41F%Z'>N2^9%R8HPX;FX)^R)^MP
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M>5%0_+WXMU+QP+MC'[DD,E-5/:986-+__^5%F<=VU>\N(K7^5W>!;L76SDX
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MGS>37!LM/D7\!"%]04>TJ3=!BW?H@UG[YJ:+7DLW<E>Y<S/6H-MJA78#,0[
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M?K=HM .RP-K;?.;;0R>AM@Y&A*UBMA%KZ0,-29+&D>K]@5P?*KN@V:O]=#N
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M\2>U9Q[4&?O>9 1FRS&9="'O%IW=[]O)4#%YV\[:7<P(W.U^U6Z2^:Y'F^F
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M>#,M-2YH=&U02P$"% ,4    "  AB'Y6'8_^VR@(  "Y3   "@
M    @ $E!0  97@S,2TQ+FAT;5!+ 0(4 Q0    ( "&(?E:"2W&@&0@  #M,
M   *              "  74-  !E>#,Q+3(N:'1M4$L! A0#%     @ (8A^
M5CK#;$ ]!   718   H              ( !MA4  &5X,S(M,2YH=&U02P$"
M% ,4    "  AB'Y655QSUT $  !R%@  "@              @ $;&@  97@S
M,BTR+FAT;5!+ 0(4 Q0    ( "&(?E9T_.CMKA,  +9L   )
M  "  8,>  !E>#0M,RYH=&U02P$"% ,4    "  BB'Y6=FX6H<U' @  $!<
M#               @ %8,@  9F]R;3$P+6LN:'1M4$L! A0#%     @ (HA^
M5I20>P ^*P  VRT  !               ( !3WH" &9O<FTQ,"UK7S P,2YJ
M<&=02P$"% ,4    "  BB'Y6002<M1$>   N'P  $               @ &[
MI0( 9F]R;3$P+6M?,# R+FIP9U!+ 0(4 Q0    ( "*(?E:DN[QIRDX  #)0
M   0              "  ?K# @!F;W)M,3 M:U\P,#,N:G!G4$L! A0#%
M  @ (HA^5GM7U8%Y-0  _#H  !               ( !\A(# &9O<FTQ,"UK
M7S P-"YJ<&=02P$"% ,4    "  BB'Y6[P KP%A0   #5   $
M    @ &92 , 9F]R;3$P+6M?,# U+FIP9U!+ 0(4 Q0    ( "*(?E:P;\2L
M$!,  /_;   1              "  1^9 P!G=&)P+3(P,C(Q,C,Q+GAS9%!+
M 0(4 Q0    ( "*(?E8HE&$E%1   ##*   5              "  5ZL P!G
M=&)P+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  BB'Y6WD(CGG(M   A
MV0( %0              @ &FO , 9W1B<"TR,#(R,3(S,5]D968N>&UL4$L!
M A0#%     @ (HA^5E3:ACI =   Q9<& !4              ( !2^H# &=T
M8G M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( "*(?E92NY<WI$4  $N5
M!  5              "  ;Y>! !G=&)P+3(P,C(Q,C,Q7W!R92YX;6Q02P4&
2     !( $@!!!   E:0$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
